<SEC-DOCUMENT>0001628280-23-002413.txt : 20230206
<SEC-HEADER>0001628280-23-002413.hdr.sgml : 20230206
<ACCEPTANCE-DATETIME>20230206160224
ACCESSION NUMBER:		0001628280-23-002413
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230206
DATE AS OF CHANGE:		20230206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		23590648

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arwr-20221231.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:e8083e98-eeaa-4076-9e59-e239858f4776,g:e1942b16-5fc3-435c-8ded-c247fb91952b,d:9e436183b5b546b1bf8bde17c7a99c90--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:arwr="http://www.arrowheadresearch.com/20221231" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF8yLTEtMS0xLTI4OTA0_95fa2075-5148-4f50-b516-4e5070bd9e7d">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF8zLTEtMS0xLTI4OTA0_40e3692a-f9c1-4c61-867d-24bb597dd325">09-30</ix:nonNumeric><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF80LTEtMS0xLTI4OTA0_93f548a7-ba8f-4200-bacf-9acde9a1ac14">2023</ix:nonNumeric><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF81LTEtMS0xLTI4OTA0_9c9f3e8e-d27a-44b8-b55b-09782d0d46bf">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF82LTEtMS0xLTI4OTA0_d8c5248b-1aac-4229-8248-a362522a1a3a">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ac05044f5a45a9b425ea6471db9c99_I20230201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i06abac4e1f98416b8ae5ab270600de1a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0973239be0154868a5c0a6b435b415ac_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if88ea1264d34418cb7275044ad1fb1df_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a0de3cc32924634a9ccf0a2bd93a727_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f153e0382f4ac28b7528ad3646cac2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie444a272a1eb4b079631b5b5db9909fd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee0675bb73de4fd3ab4bc406773f8cb4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3787aa308494e6fabfa34270e2a98a3_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8f3fe7a23d4d658eabff5f9122ad89_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ec8a43fe2b4ac39a998e248193d6bc_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2884a29569d49d4b0c8e85c4112ecd9_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ca39c8d80949cf9a8b1394e754badd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i631979769d5c467191f41a0d5fc63ad8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e350ee9f64142d9bf9f4aed07b098ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96cd0d22a1684bd7aae80feb5bceb816_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9edc90c95f0b450b9cf755c9e4f7bf63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i496886d6abed4f999c1ace5f866fcb6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a39646f95b4f89b1694a9939f5327a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35381f0ea5a44e383a735802d46673f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0af42ecb0f284f94b06b37a27ff07368_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6449ff00713d4e21976744c273cccae8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b117b978284cd6a85fd88b72346e47_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90a5c8c8db52479c96374a3a0f3d318b_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e8e9723fb342fc9b33826fac8e4171_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d21df7082f14f328f24834628e5a4f9_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6ee791b62f4538b6bfc8ec3f396205_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c40ddf690448b0bb93935296f8f5d6_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aba4e2426de4a28acd5d29a6320c9bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f94331985a400f846c766bf11f5925_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced398649a794c4e8e8d86a2846c3ae1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c4dcde64e0e45438fe394fa33f8e503_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i381adb6a0c044161942d6a4204364b39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cea4208cdeb42c9a22cc59d648953a0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db3274cc4d14160ae2d5f647d651c24_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65665136f1d40fd862086f2dd922e9f_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied9e360396f44e37a5fa2c12b7d58208_I20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6d16e113b834a97a9fcbf8e0681786c_I20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief93fea769094d7eb5fb5948a8f0d52b_D20211122-20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342c597acfec441dab0f3b37209a55ba_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c306c538924e74a11b388564ca6b80_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i038818ff5b9843f1b9d17f64430e188b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378c508c95df484ba3e6ef6a5454bc94_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8cc0f14c60475299147a3dd0c03daa_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7372fb791af34e0d8dd8edb75dff1a73_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="bundle"><xbrli:measure>arwr:bundle</xbrli:measure></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>arwr:obligation</xbrli:measure></xbrli:unit><xbrli:context id="i2a500b1709164996b845bbac989d7b84_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida93008e93a8494783ed240b674e7a64_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i988f7cda978749b1b3f5337961e8742e_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09940e4ffb194a128c45cb16ba228ade_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia939243a8ac74e65952dd91c16f544b4_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icda38447f5614cebb8ef1552acb61332_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9284be9df69d4141bedb600f69d1042c_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c44558d7e484eb2a6b9cae263a65437_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ec1fea81bb4a3f85a50d428952c2a4_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca13f49c2ac4338bd38897981c0e87b_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05fdd27fe28461a9e78cc9c9d4e69d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf0f351abeb4ff9920e8f448a4b04d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b9fa1ae2884a8d985db088de873bf2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad13da460ff45d888e1281a60477acd_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dbada01124d4560be0e826511f8dce1_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a989d7ce0a44ccf9bf1022c8f7f9b2a_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92f82a268c774e9bb9992a060a63740b_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba27b7bdc69548378fef58b5f42961ff_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i328d3ff81ad3491a99bdf175a0d11762_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if317166287bb4b13944a83a251e50077_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadbb1a93d51d4301be4fa1d4b852337c_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2766009a08bc437580f4294c351f7cd6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c684d870f3a4136a5f54739f8a8b3a0_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7883a42e42404293d06a18e9cd891e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2364b30800c9442ab7f8d6ccf86939e9_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c624b66e784ad1baf3e3fb6bea568e_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db0b5443200492482544d7c90204e4a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if64321b9c6e247da8443d05133b342ff_I20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>arwr:agreement</xbrli:measure></xbrli:unit><xbrli:context id="iae284bdb5fea480a9e15773836d59063_D20160928-20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-28</xbrli:startDate><xbrli:endDate>2016-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc17c83235054c9298c89a26c8fb35e1_I20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f7402c90cf488f944efc5f47b5caeb_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c6d551c455a4169899e5d3a186b7638_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2933262b7b1411284a2bb299c20d306_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f61a8d393224431a507b3f200215db7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cfe482a057d4dca8df5560f98cef3e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ee8ab30ad3445958f3b561928b95608_D20220425-20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-25</xbrli:startDate><xbrli:endDate>2022-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c7506b5d91485d9801a47dca99e510_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e51d9c60c54ce1a159fc24a37a7ae1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2a387c1c2504379a168792bc1c3e50b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917462b04ff841eaac0e3339bd0cb7bf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f7584f587e4681907eb42f27510096_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea276053053c4bb59f85d31ebab93a3e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0889a0226de945a0aaa5c52879fb13f4_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i714564a42c4645a4aa8fec5fbfae6cf1_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0223aca615484a88a1f963d53db983b5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a3b5deb088e42a4b098ad5687964c9e_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d52a26129d84983ad9bb9f0ee488966_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i449ded4307a74763bf247ab23aa3b5f9_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f581ef502d44a597740c97e5d034bf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03c5e2040b97478685482edb1a081bb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2aeef9c8ccd4d24a3762ad0cae17f16_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953cacdb283b4570974e198523332adc_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if602610bd9274f15ab350c697c16fbcd_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75f84a2f705547a9a7be5905324c37e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8614ef1e09dc4ad7b48305618623004c_D20211220-20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="acre"><xbrli:measure>utr:acre</xbrli:measure></xbrli:unit><xbrli:context id="i7b3dac9a5a774156b890ac8ed0751a6a_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i0f1aae662bc6418db9f0619cc2642795_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62abdefe617a488691c724830dcd72c9_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie59ded034230456484b32676c5f7bea0_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i475551cf88cb4dccacdf1b2a61c7583d_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0154bab3efba4f2b94e2b7c59316083b_D20211220-20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic881a18f95ea4f17a15cc3756a39574f_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i349f57ec0207498e87e4c69e2bce507c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5126eab2e8c467bbb24c03e16becfd7_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib156f4f74fcf40dab1e99dda624e5df7_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide63f19f872342da8608f446fb18d4de_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>arwr:option</xbrli:measure></xbrli:unit><xbrli:context id="ic35d28a67b834f6484c8d5ee20d55588_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2811668ed19749b68707a9ed9f6d8253_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea10d5800b11488baca5f307e6d73957_I20221223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SorrentoValleyOwnerDELLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ce5e7d49bd492c9e566ef7247a28c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8040ef89c2154b74b3e460ed12cd081a_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5a7a96684442d296082eb9d52b8bcd_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35831effd60d42e480dad85b0cf9984c_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4bfba6d666f497ab7f1a694161b0c89_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc2a8a0b4a714ac7bf244c847af32ed7_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af89e8de2144f908cdf6eed480d28b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba8a5ebb90254f6f8963f5d5f42509a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90cda53c17144e44900529474c8dade0_I20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eda0cf364544def8987efed665491a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47739b2328c247bab0fc929214a7ba52_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5eaa8a48bce4fa6b14d1cc81a3b2f78_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d653e654b143c2b0c47570e75b7f38_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6801c6b77c1f498681559c7a2dce2274_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5982379dbbec4d4c87792e3a1fcdf6b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed10835a1c94a47a82efe00a8e128c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3a67532b13e4f299f83c7328786c6b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d4a7405e154645aec245988ba1db1e_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieded460c29c84a3bae41035d3b604b0a_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7371c7b684f24f2ea135c09ba65d9460_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia962a8cd9cbf48eab5243a5e151c89a3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ad8857cb6d490a9939df3c07ff4518_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic12f642c28fd43bb8bf90642994bc4ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7c02af510c4a37adf92b11b0e43eaf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia208947dbdb34f48ac070a4eaf8f6ab8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04b788dc055c47f289db232c658f93a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4024a6c45e8b453eb06624488de7893b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39044bf341fe482cbbdce983d914bbec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8310bcf25814821b30b9f25902a564d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b8edd077cc145338ae4844a504c6d15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e5f5182517047a2857c3e4a25738d82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia323910ecf904687b25c3160e49c81a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida69711b30dc4c71b1277eaf63e7bdd5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7481b819e6694390ada33ee48dd204bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cba61c40f15431a97004a8eed248d67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f8630cb003e4706a57151bdfa8dc88c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5851c535fb2c4a6ab422410bef2bbd02_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied344ba18ef64e3d9de729f6de914532_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452920e837684080b738d48ba1b27ff2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7cd572b180c415db97822ca50b32ac9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fefec5d13e145909fc3b74408e1e444_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c9ae1d799ee4d03923270e5ee1d6d21_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ce3b6dcc92d46758613038bc30d2d06_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb6ea8e37eb3434eb30ea1ab2ceca664_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39634f9fa175451b8ba8d5d58bf3740c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c4faae844d34e619c9019b81d17f07e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb683bdc076a49628834f62824ed68f4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a05dee7c43b439f82b54c288eea3838_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0c9e1d3a53545b2ad24da42f70a1040_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic813502c9a304662b9dfbd3942bd3230_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id85626261eb446dcaddc667f6dabc5cc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i406ec781c5d644bdb1d8414e80314cc6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039e74dffa1f49d9a35ad0d64a55d837_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f10fb8f48cc4003b37f0dce7bcf8710_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad0de95aea0445adaf44a4746fbc4967_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aa3981837334860a25583d48dd904d9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42efed8b98314bbfbbb3748a5f769fa7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a183941914437b8b3a7e507c345f29_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a7f0c6944640a18b75bccffab1cb19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782e0824540f448daa350332d8e73bac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i582fc5eed03a4994b06179429d92df7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i462d644c71d546a9af599d5543f3d5c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2e69018bdb4a98bb2a58ba8c80e25a_D20221109-20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645dd71143994cfd81a4843c13790bbb_D20221109-20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4193086f2a4fc198c05eae2aa999c6_I20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4521874a9864ab3bed52ad5aa487856_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba7f05878cb48c783c8d12cf1ff5540_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjM4_9dbd034f-dec1-49b7-b4f6-020b633ba1c9">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.796%"><tr><td style="width:1.0%"></td><td style="width:3.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6OTBkZGYyZTQyNzgxNGQzNGJiYjQzOTliMzlkNDQ5NzUvdGFibGVyYW5nZTo5MGRkZjJlNDI3ODE0ZDM0YmJiNDM5OWIzOWQ0NDk3NV8wLTAtMS0xLTI4OTA0_9a6aa884-d76f-456b-9729-38b46fe9ab6c">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMDc_1640f9a4-b71a-4a51-b862-9fe9ade8e717">December 31, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6ZWVlNmQ0ZjllZTU3NGFjMDhkOWJmZGY3ZTY5MDQyY2UvdGFibGVyYW5nZTplZWU2ZDRmOWVlNTc0YWMwOGQ5YmZkZjdlNjkwNDJjZV8wLTAtMS0xLTI4OTA0_c86a1d24-7dbc-4c7e-8ae5-bc18de68c238">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQz_f2f134f2-7e72-4c1e-bb25-2de17ecfa798">001-38042</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQ0_a81e043b-2c69-4e4c-a19c-9ec9cdbcba09">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MDJiZDUyM2M2ZDI0NDVlNjgzNDYwZWNiNGVmOGFhNmQvdGFibGVyYW5nZTowMmJkNTIzYzZkMjQ0NWU2ODM0NjBlY2I0ZWY4YWE2ZF8wLTAtMS0xLTI4OTA0_ab394b59-dfb4-43bc-b087-ed033228bf33">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MDJiZDUyM2M2ZDI0NDVlNjgzNDYwZWNiNGVmOGFhNmQvdGFibGVyYW5nZTowMmJkNTIzYzZkMjQ0NWU2ODM0NjBlY2I0ZWY4YWE2ZF8wLTItMS0xLTI4OTA0_7e32e2be-a23b-43f2-b433-5e7a2cddb06c">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80NjU_e0317a43-ac47-4ab9-b825-084b459ed023">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80Njk_f5f11cdb-9924-4119-b8da-ce486beff2f9">Suite 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80NzI_7fc296a2-e27e-4c22-8d05-b98c40b7af34">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80NzY_a7154408-15a2-422f-8715-70bef3d27776">California</ix:nonNumeric> <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80Nzk_21f519b9-f441-48c2-b52a-5edc1fe44397">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80ODM_422a24f4-102d-4f13-bffa-8ecdab8403d5">626</ix:nonNumeric>) <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80ODc_40e35636-a152-4c2a-be71-9df291e00fb2">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address and telephone number of principal executive offices) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Former name, former address, and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:37.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.78pt;text-align:center;text-indent:-0.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MmI1ZTExMDcwMDU1NDFiMWI3OTFmNTM5ZDE1MWNiNGMvdGFibGVyYW5nZToyYjVlMTEwNzAwNTU0MWIxYjc5MWY1MzlkMTUxY2I0Y18xLTAtMS0xLTI4OTA0_0953d03d-1708-40cd-a171-14e6e1c6a15f">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.38pt;padding-right:1.38pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MmI1ZTExMDcwMDU1NDFiMWI3OTFmNTM5ZDE1MWNiNGMvdGFibGVyYW5nZToyYjVlMTEwNzAwNTU0MWIxYjc5MWY1MzlkMTUxY2I0Y18xLTItMS0xLTI4OTA0L3RleHRyZWdpb246ZDBiYTI2MWZhZDhhNGFiMDk3Mzk2ODYyYmI0MzVmYTZfNA_48c54a1f-2af3-4c2a-a4f6-fa972bf2f1d7">ARWR</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MmI1ZTExMDcwMDU1NDFiMWI3OTFmNTM5ZDE1MWNiNGMvdGFibGVyYW5nZToyYjVlMTEwNzAwNTU0MWIxYjc5MWY1MzlkMTUxY2I0Y18xLTQtMS0xLTI4OTA0_2372c431-e404-4746-bcc2-ab074d4a34de">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQw_0bda6ae2-74db-4aa2-826f-4d675db2b2c7">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQx_6376a4b5-eb1d-4876-a5d4-d056639071e9">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MTAyOTYxNWJjODk5NGQ4MmIxMmZhNmJjOTdjMWMzMWUvdGFibGVyYW5nZToxMDI5NjE1YmM4OTk0ZDgyYjEyZmE2YmM5N2MxYzMxZV8wLTAtMS0xLTI4OTA0L3RleHRyZWdpb246MDcyZTQ0YzBjZmFkNGQ2ZmJiMTFmMmU5MmU2MDk1MzlfNA_18c4dec7-4afa-4780-aa56-07c22a41e809">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MTAyOTYxNWJjODk5NGQ4MmIxMmZhNmJjOTdjMWMzMWUvdGFibGVyYW5nZToxMDI5NjE1YmM4OTk0ZDgyYjEyZmE2YmM5N2MxYzMxZV8yLTMtMS0xLTI4OTA0_675b9530-fde9-4b3f-80fd-45bab442330d">o</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MTAyOTYxNWJjODk5NGQ4MmIxMmZhNmJjOTdjMWMzMWUvdGFibGVyYW5nZToxMDI5NjE1YmM4OTk0ZDgyYjEyZmE2YmM5N2MxYzMxZV80LTEtMS0xLTI4OTA0_07bdac8d-8381-4455-9e9b-fc8fafe0e186">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQy_5fc9a46d-7c62-49a4-87c1-4c4c23fdc4e8">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant&#8217;s common stock outstanding as of February&#160;1, 2023 was <ix:nonFraction unitRef="shares" contextRef="ib6ac05044f5a45a9b425ea6471db9c99_I20230201" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjMz_f8768db3-1e7b-4c89-be4f-0c2666d11e32">108,310,163</ix:nonFraction>. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"></td><td style="width:91.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Page(s)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_10">PART I &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_13">ITEM 1. FINANCIAL STATEMENTS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_16">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_16">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_19">Consolidated Statements of Operations and Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_19">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_19"> </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_19">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_22">Consolidated Statements of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_22">Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_22">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_25">Consolidated Statements of Cash Flows</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_25">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_28">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_28">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_64">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_64">21</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_85">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_85">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_88">ITEM 4. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_88">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_91">PART II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_91">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_94">ITEM 1. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_94">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_97">ITEM 1A. RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_97">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_100">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_100">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_103">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_103">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_106">ITEM 4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_106">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_109">ITEM 5. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_109">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_112">ITEM 6. EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_112">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9e436183b5b546b1bf8bde17c7a99c90_115">SIGNATURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9e436183b5b546b1bf8bde17c7a99c90_115">31</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION </span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_13"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS </span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.083%"><tr><td style="width:1.0%"></td><td style="width:68.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.923%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMy0xLTEtMS0yODkwNA_63878d57-ef86-4c5d-93f2-fd8b748f540b">202,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMy0zLTEtMS0yODkwNA_e1698ece-9d7a-43b5-b8c3-4686f71313cd">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNC0xLTEtMS0yODkwNA_78205377-0e4c-4748-9af2-683581ad5bc2">39,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNC0zLTEtMS0yODkwNA_b93b4b7d-fb01-4504-adcc-df60e4571a91">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Short term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNi0xLTEtMS0zNzYwNw_d4b566f7-b2a2-4004-ac96-ca74fbb6a000">299,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNi0zLTEtMS0zNzYwNw_ec47a4dc-d5b2-4c06-812a-01ba6d5d418d">268,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNy0xLTEtMS0zNzY2MQ_e3f434b0-bb40-4f57-a102-521c10e89ba2">8,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNy0zLTEtMS0zNzY2MQ_0deaae0e-f74b-4092-b08f-00cc50001463">7,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOC0xLTEtMS0zNzY3MQ_f001ced0-fba3-4994-9d13-f6c4d6e7e9c9">25,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOC0zLTEtMS0zNzY3MQ_42eb09b6-3c9d-460b-b61f-f8f1a2c425e5">20,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOS0xLTEtMS0zNzcxMg_0496aef7-2d4e-493f-a65a-2e131419bc7b">574,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOS0zLTEtMS0zNzcxMg_ca6dc7bf-2f8c-4097-a411-8c9adb0fbf6d">405,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNi0xLTEtMS0yODkwNA_d26aa808-db31-461b-aad7-bd7cbca9e7d4">147,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNi0zLTEtMS0yODkwNA_b2a13470-c323-41ce-9e67-6227f6b4dbb8">110,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOS0xLTEtMS0yODkwNA_4d416f4e-5b4b-4f3f-be28-d3f079f53596">11,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOS0zLTEtMS0yODkwNA_8d7310bd-26ba-4a0e-94d0-a5032fc1fb3e">11,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTAtMS0xLTEtMjg5MDQ_69b74367-464f-4ffe-b4fb-ab8103b9d2f4">115,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTAtMy0xLTEtMjg5MDQ_fc1eb6bc-e850-474d-94bf-f4e90d3d7c66">105,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTEtMS0xLTEtMjg5MDQ_8679106e-faaa-4cdb-ac27-01db55b64e62">41,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTEtMy0xLTEtMjg5MDQ_0d428836-a817-45d3-a989-78ed5a2b4765">58,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTItMS0xLTEtMjg5MDQ_e8cb0a8e-2b39-4273-b901-208946c51a97">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTItMy0xLTEtMjg5MDQ_ab381dda-dc52-4a80-ae67-5131c8dfedf6">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTMtMS0xLTEtMjg5MDQ_8e57ed22-b48a-4084-98ab-4b51d9cc15fa">891,489</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTMtMy0xLTEtMjg5MDQ_8e9b4d6b-aeb6-4bc4-8604-f7c18362271c">691,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTktMS0xLTEtMzc4MTk_c6da9df9-e514-46a5-b87a-99b6f8c5edce">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTktMy0xLTEtMzc4MTk_cf098efb-20fd-4ff4-8818-95b971793867">2,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjAtMS0xLTEtMzc4MTk_83367a35-69fe-46a2-be4e-79f76b81121c">48,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjAtMy0xLTEtMzc4MTk_1ae417a3-028d-49dc-ba65-d6b341a4a00d">46,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTgtMS0xLTEtMjg5MDQ_810ec3d2-dead-48b2-a4f2-9cc114c8fe7a">4,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTgtMy0xLTEtMjg5MDQ_73dfef19-b0ce-4885-83cf-647ba4c810e1">12,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTktMS0xLTEtMjg5MDQ_22dcb1bb-4f00-4572-8e19-ef85c681ead3">2,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTktMy0xLTEtMjg5MDQ_7d919b0f-b09a-4792-9468-f4c73199314e">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjAtMS0xLTEtMjg5MDQ_d24b11df-eac4-4035-8e65-72b72be2b266">66,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjAtMy0xLTEtMjg5MDQ_6388824f-c7f5-4e47-ba09-85bd80508981">74,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjItMS0xLTEtMjg5MDQ_b28196e4-1580-4d50-8911-56d731273513">122,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjItMy0xLTEtMjg5MDQ_77878290-dbae-44fb-9462-5cc80cc9d983">138,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjMtMS0xLTEtMjg5MDQ_1438baa3-d5b2-44fb-8176-53cadc92b303">79,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjMtMy0xLTEtMjg5MDQ_b0c1ca87-6e7b-4cf3-8360-b9eada556ce3">78,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjctMS0xLTEtMzc4NTk_6aa7ee46-0980-4bc9-95a0-653cee8ef4c1">40,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjctMy0xLTEtMzc4NTk_ccb64e36-98b8-4e0b-9b71-bf4e26d37a23">55,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjUtMS0xLTEtMjg5MDQ_97ba8cd1-f25d-4c6d-8473-78ce7d18bc23">252,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjUtMy0xLTEtMjg5MDQ_7ebeb1f1-9c7a-4ee4-91ca-c831bb9a863d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjYtMS0xLTEtMjg5MDQ_c08698c7-999a-48b2-bcdc-62df822aa02f">373,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjYtMy0xLTEtMjg5MDQ_090a802a-545b-4dd2-b1c3-c6ba0b6b7c47">134,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjgtMS0xLTEtMzQzMDI_cb8a5089-8df6-4f83-b961-06260491f16f"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjgtMy0xLTEtMzQzMDI_e5a7565b-4373-42e2-820a-443c8948bff6"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling interest and stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTI3_5961f3ba-f1b9-463f-a55f-83e94170cd83"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTI3_edd585fe-af5c-4274-80f1-8ba6d487dc68">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Authorized <ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTE3_3ea92019-92e1-49ab-9cee-b0feec3583fa"><ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTE3_bccc6362-b5d2-4c43-9a7f-d16bc9cdde16">145,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3ODk1_c4e740b8-d2d0-43cf-8d1e-25a14a49cc02"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3ODk1_d9a87b6f-3b21-42f4-acc9-54cc5bdba0bc">106,140</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTA2_dc91fb59-d0d5-4425-a522-1ff932a6a6f4"><ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTA2_e8191071-1565-4622-acfe-860d4393d642">105,960</ix:nonFraction></ix:nonFraction> shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzItMS0xLTEtMzc5NjM_d71f1b23-7cec-476e-8343-5149c3fb7b7a">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzItMy0xLTEtMzc5NjM_d8d79656-af11-489d-843e-70438a3ad811">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzMtMS0xLTEtMzc5NjM_73c40bcf-9c43-4bcf-88ae-d8aa1d65325b">1,239,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzMtMy0xLTEtMzc5NjM_ed7d6959-99ff-4534-b78a-55b0b2ec8a40">1,219,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzQtMS0xLTEtMzc5NjM_3c80236a-c6e2-4b10-a12b-74c2d75d4d87">258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzQtMy0xLTEtMzc5NjM_44d8d567-3472-423e-8f59-4f88a691ad69">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzItMS0xLTEtMjg5MDQ_1531301a-7011-4fce-911f-8abb90b426e0">862,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzItMy0xLTEtMjg5MDQ_48c8f8f0-ea2a-4f65-b597-04dfa6602c82">820,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzMtMS0xLTEtMjg5MDQ_7fb6c163-97d5-4415-a094-824c38ece7cf">377,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzMtMy0xLTEtMjg5MDQ_16c6e579-5d2e-467f-a265-874c3792a63a">398,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzQtMS0xLTEtMjg5MDQ_1c4f3cae-3aef-4dda-b0fb-e9d85752c42a">19,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzQtMy0xLTEtMjg5MDQ_c4f798e1-ddaa-44bd-a359-e033203f8c76">19,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total noncontrolling interest and stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzctMS0xLTEtMjg5MDQ_cb339966-c17f-4cea-aa4a-4846b8011198">396,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzctMy0xLTEtMjg5MDQ_78bd3ca1-54d0-4f8d-b6b8-9ecb5439fec6">418,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzgtMS0xLTEtMjg5MDQ_72d84e09-945e-48bf-ac42-24e8ac8be888">891,489</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzgtMy0xLTEtMjg5MDQ_3b8ea548-a598-45d6-9654-70d64349c0a9">691,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:65.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMi0xLTEtMS0yODkwNA_bdf0417d-38f3-49dc-89ab-f3b8c1a763cf">62,546</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMi0zLTEtMS0yODkwNA_3011601b-adc2-4bf1-8431-52f12740266c">27,439</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNC0xLTEtMS0yODkwNA_06650c54-a2e7-4150-adc5-76368925fcd0">83,695</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNC0zLTEtMS0yODkwNA_bd295fa4-e396-4f86-a156-2e91b3e5bb9f">65,765</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNS0xLTEtMS0yODkwNA_f658c388-0dc3-4809-868e-0f05fa694736">20,985</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNS0zLTEtMS0yODkwNA_19113029-08c3-4a28-b21c-212327e76b17">24,995</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNi0xLTEtMS0yODkwNA_8de060bc-2dda-4ed9-9a05-147954b17eb5">104,680</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNi0zLTEtMS0yODkwNA_1b9c8597-fe72-42f5-b301-01f663341692">90,760</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating loss</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNy0xLTEtMS0yODkwNA_9839a639-5aa5-4582-a91d-df356460f48f">42,134</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNy0zLTEtMS0yODkwNA_df29e70c-bb5f-4745-adbf-81d712724b1f">63,321</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other income (expense):</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest (expense) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfOS0xLTEtMS0yODkwNA_a77e2711-b4b9-47b2-8364-22aa9eb3f5ec">167</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfOS0zLTEtMS0yODkwNA_7bac3d93-a6b6-4b5e-87a9-12fd13a19df7">1,156</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other income (expense), net</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTAtMS0xLTEtMjg5MDQ_68747162-864d-4134-a70a-cbeb3b575edb">507</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTAtMy0xLTEtMjg5MDQ_1c12926b-3bd6-4e9a-83ab-02a23e647814">707</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total other income</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTEtMS0xLTEtMjg5MDQ_242e9b62-7408-42bd-877c-4e31747b8628">340</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTEtMy0xLTEtMjg5MDQ_550381a8-a211-4908-83aa-ec4efaafa24a">449</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Loss before income tax expense and noncontrolling interest</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTItMS0xLTEtMjg5MDQ_44055727-48bc-41e8-a6cd-916d609fb15d">41,794</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTItMy0xLTEtMjg5MDQ_50f04b8b-088e-4c0a-a6e7-7894966d9a38">62,872</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTMtMS0xLTEtMjg5MDQ_de64d088-f7ab-488f-9279-7073fc984cc5">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTMtMy0xLTEtMjg5MDQ_1ef7627b-67ba-4463-8e27-bdb54058b358">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss including noncontrolling interest</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTQtMS0xLTEtMjg5MDQ_c257f571-2207-4c93-bde5-59766b7b66a8">41,811</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTQtMy0xLTEtMjg5MDQ_f4c422cb-c2f6-47b8-b6c5-89d0435afdf2">62,872</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interest, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTctMS0xLTEtMzQ0NjI_abf01612-d8b6-4e40-a8e2-4aa35446c273">486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTctMy0xLTEtMzQ0NjI_e9eeba75-5e32-4849-8ad7-ef192ab633f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTgtMS0xLTEtMzQ0NjI_c592c263-704d-49fd-ab39-a0f6b693ed46">41,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTgtMy0xLTEtMzQ0NjI_8f2f8b6f-e423-4c63-afcf-4339bb3f65cb">62,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTUtMS0xLTEtMjg5MDQ_b750dd56-3d6a-4d84-a558-6c68ac7ff687">0.39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTUtMy0xLTEtMjg5MDQ_04ce401a-97f7-41e0-bf35-31ed4df23fe9">0.60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTYtMS0xLTEtMjg5MDQ_674a9cf5-c5f9-4030-b0f3-a7bdd3aef8c5">0.39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTYtMy0xLTEtMjg5MDQ_823d0472-2929-4706-a67c-f9fa9f3fb577">0.60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average shares used in calculating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTctMS0xLTEtMjg5MDQ_46dbd57b-9f20-405f-a292-ce162f190f31">106,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTctMy0xLTEtMjg5MDQ_7a378556-d265-468f-8025-8797fe57e1e2">104,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTgtMS0xLTEtMjg5MDQ_b8b14665-968f-42b8-a1e6-a6a1eaff13ac">106,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTgtMy0xLTEtMjg5MDQ_def4d230-e264-405f-9318-ab6c7b5148bc">104,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other comprehensive loss, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMjAtMS0xLTEtMjg5MDQ_f3a17311-2714-4fd1-9d64-901a71cadc1a">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMjAtMy0xLTEtMjg5MDQ_a88ca69a-fb29-4f7f-b432-b5111e274fe5">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMjEtMS0xLTEtMjg5MDQ_4c76efe3-b5b5-4c74-8fad-a51402b45169">41,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMjEtMy0xLTEtMjg5MDQ_f83690bd-470c-482c-ac36-6424a4f930d1">62,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"></td><td style="width:35.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Other </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Non-<br/>controllling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0973239be0154868a5c0a6b435b415ac_I20210930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS0xLTEtMS0yODkwNA_33b361ef-c6da-4d84-9f94-f3bdf0f5d771">104,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0973239be0154868a5c0a6b435b415ac_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS0zLTEtMS0yODkwNA_95f4d279-97cd-404c-acca-d8c29d842d51">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if88ea1264d34418cb7275044ad1fb1df_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS01LTEtMS0yODkwNA_eb90de6a-6658-45e9-bd57-a111d31ce69b">1,053,386</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0a0de3cc32924634a9ccf0a2bd93a727_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS03LTEtMS0yODkwNA_7d8146da-6141-4c27-888c-a308bfadbdf6">69</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i51f153e0382f4ac28b7528ad3646cac2_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS05LTEtMS0yODkwNA_17389b5f-cc75-4418-9809-a29fd690f5b3">644,692</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie444a272a1eb4b079631b5b5db9909fd_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS0xMS0xLTEtMjg5MDQ_caa42fbf-7b99-45e4-882f-a594d229cbb3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iee0675bb73de4fd3ab4bc406773f8cb4_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS0xMy0xLTEtMjg5MDQ_68a92d0b-c647-4e7c-8ca6-9b34500e3993">408,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib3787aa308494e6fabfa34270e2a98a3_D20211001-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMi01LTEtMS0yODkwNA_03377828-8145-4dbc-ae6d-cfa547ce9181">24,504</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMi0xMy0xLTEtMjg5MDQ_f1208b2a-4166-4560-95e0-8db0bccff248">24,504</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i3a8f3fe7a23d4d658eabff5f9122ad89_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMy0xLTEtMS0yODkwNA_3b8743d9-9944-45d8-963b-bc3d50e36b26">208</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib3787aa308494e6fabfa34270e2a98a3_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMy01LTEtMS0yODkwNA_532d253f-b11a-41a5-be8e-8d3ec82d8bdd">2,145</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMy0xMy0xLTEtMjg5MDQ_f5c5b416-32bd-49cf-84fd-aacd78692d63">2,145</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i3a8f3fe7a23d4d658eabff5f9122ad89_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNC0xLTEtMS0yODkwNA_cec95e06-0069-4515-9755-eb335755a6b4">263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if7ec8a43fe2b4ac39a998e248193d6bc_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNS03LTEtMS0yODkwNA_671c06c0-ebdb-4123-a86f-8f65cd8fe5d5">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNS0xMy0xLTEtMjg5MDQ_20e2dbbb-d812-4aed-bb75-500008d38d6f">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net loss for the three months ended December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie2884a29569d49d4b0c8e85c4112ecd9_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNi05LTEtMS0yODkwNA_ae91f4fd-78ec-42cf-995b-4813c54e2800">62,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNi0xMy0xLTEtMjg5MDQ_e42d496c-9f42-4d4e-90bd-ca6c4f9fd882">62,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia0ca39c8d80949cf9a8b1394e754badd_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy0xLTEtMS0yODkwNA_b59a1be2-4f3e-401e-ad15-deee98f82049">104,798</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia0ca39c8d80949cf9a8b1394e754badd_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy0zLTEtMS0yODkwNA_910a9aba-fc50-41d9-8c3c-1ae9e26311be">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i631979769d5c467191f41a0d5fc63ad8_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy01LTEtMS0yODkwNA_be0489ba-6a50-4f6b-81b4-07c5a450f6fb">1,080,035</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0e350ee9f64142d9bf9f4aed07b098ed_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy03LTEtMS0yODkwNA_a1d0f869-2896-4f0c-92c7-dd9ff9fdb551">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i96cd0d22a1684bd7aae80feb5bceb816_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy05LTEtMS0yODkwNA_9fe4485d-13d3-42eb-b610-bb5ee6ea3777">707,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9edc90c95f0b450b9cf755c9e4f7bf63_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy0xMS0xLTEtMjg5MDQ_12be9c0b-8985-4dce-8c39-6b058d2c9a6b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i496886d6abed4f999c1ace5f866fcb6c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy0xMy0xLTEtMjg5MDQ_6c8c53e8-2cbb-4c34-aa52-0c640d5d084d">372,560</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:34.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.149%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Other </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Non-<br/>controllling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i74a39646f95b4f89b1694a9939f5327a_I20220930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS0xLTEtMS0yODkwNA_296e4528-2954-4310-bf3e-17f080af5ba5">105,960</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i74a39646f95b4f89b1694a9939f5327a_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS0zLTEtMS0yODkwNA_3ae4ebbe-2917-4973-a21f-ce091b55d133">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie35381f0ea5a44e383a735802d46673f_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS01LTEtMS0yODkwNA_9e979dff-e220-4e07-a806-efccb86692a3">1,219,213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i0af42ecb0f284f94b06b37a27ff07368_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS03LTEtMS0yODkwNA_18b1f8f9-cd8b-44e5-8fbc-49164849ed45">136</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6449ff00713d4e21976744c273cccae8_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS05LTEtMS0yODkwNA_9973b93a-9e88-4d8a-898d-1e2b1996a15f">820,755</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id5b117b978284cd6a85fd88b72346e47_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS0xMS0xLTEtMjg5MDQ_9857cacf-cd4a-4fbc-a054-0eaebac6aafd">19,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS0xMy0xLTEtMjg5MDQ_e07b43c6-d330-4888-8bb9-0f447bf7033c">418,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i90a5c8c8db52479c96374a3a0f3d318b_D20221001-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMi01LTEtMS0yODkwNA_b36bf85a-2440-4443-8278-ed5792045489">19,390</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMi0xMy0xLTEtMjg5MDQ_01de59a2-f980-4a30-8a62-2f5bfee2df5e">19,390</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i66e8e9723fb342fc9b33826fac8e4171_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMy0xLTEtMS0yODkwNA_e5f99698-1187-448a-8dc7-e4f806a258ff">82</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i90a5c8c8db52479c96374a3a0f3d318b_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMy01LTEtMS0yODkwNA_8b646d67-6b37-4eec-bad2-60fdb0bcb453">576</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMy0xMy0xLTEtMjg5MDQ_606b3c95-7751-4a3a-b028-c9e71d23bba9">576</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i66e8e9723fb342fc9b33826fac8e4171_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNC0xLTEtMS0yODkwNA_f353938b-e323-4b94-9f56-451e7969cbfe">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i66e8e9723fb342fc9b33826fac8e4171_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNC0zLTEtMS0yODkwNA_bc1b0f3e-d876-41e7-96a8-f03ee9f2fc27">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i90a5c8c8db52479c96374a3a0f3d318b_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNC01LTEtMS0yODkwNA_2586982a-2864-4e4b-ad48-18bb2c43a7c8">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNC0xMy0xLTEtMjg5MDQ_cd905b29-b3d6-4ea5-a839-53d6a5a54ec4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8d21df7082f14f328f24834628e5a4f9_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNS03LTEtMS0yODkwNA_d49ba82e-e370-4eec-b7ed-d9431c1ff768">122</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNS0xMy0xLTEtMjg5MDQ_a92e3e3b-2409-4981-a4e8-dceb323e7664">122</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Interest in joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="ibf6ee791b62f4538b6bfc8ec3f396205_D20221001-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNi0xMS0xLTEtMjg5MDQ_6c3e20a7-96a6-4482-b394-ad60041ec04e">486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNi0xMy0xLTEtMjg5MDQ_cc3e69dc-2e0b-4035-a695-2ad2ef47ce00">486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net loss for the three months ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie1c40ddf690448b0bb93935296f8f5d6_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNy05LTEtMS0yODkwNA_11e2727e-c4a6-4d8e-aa7c-0d71020f56fd">41,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNy0xMy0xLTEtMjg5MDQ_6fc00d4b-8aee-49dc-a3eb-bd08bb72525c">41,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i3aba4e2426de4a28acd5d29a6320c9bd_I20221231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC0xLTEtMS0yODkwNA_840898af-1c50-46f5-8a7d-7c174c01a982">106,140</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3aba4e2426de4a28acd5d29a6320c9bd_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC0zLTEtMS0yODkwNA_9f2868e8-6584-45c2-a9ab-3862b67e90ab">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i18f94331985a400f846c766bf11f5925_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC01LTEtMS0yODkwNA_4eb1480d-840e-48f5-966e-fb0e1d92807e">1,239,178</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iced398649a794c4e8e8d86a2846c3ae1_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC03LTEtMS0yODkwNA_01b2e890-5869-446c-bc5d-db70bdcff4af">258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i3c4dcde64e0e45438fe394fa33f8e503_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC05LTEtMS0yODkwNA_8ab3795c-abff-45aa-a53a-eaa9fac9aaf2">862,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i381adb6a0c044161942d6a4204364b39_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC0xMS0xLTEtMjg5MDQ_b662d3b8-6321-4121-ba79-68d5252fc161">19,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC0xMy0xLTEtMjg5MDQ_dbd6e159-8af7-40c2-b336-9ed63251cf65">396,372</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMy0xLTEtMS0yODkwNA_d227de26-a8cc-4811-b2dc-d6b4031f1657">41,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMy0zLTEtMS0yODkwNA_ee283d04-f3eb-460f-a3c4-5e3d0ac02a71">62,872</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Adjustments to reconcile net loss to net cash flow from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNC0xLTEtMS0yODkwNA_cc1e060f-8694-4016-8669-5eef42c4d74f">19,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNC0zLTEtMS0yODkwNA_09cf4c84-e79f-45e5-897a-a1622a2423f8">24,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNS0xLTEtMS0yODkwNA_79fd2a01-4e79-47f8-b5da-4a7b133a175a">2,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNS0zLTEtMS0yODkwNA_5b942b68-5797-45ff-be55-7ae11666d842">2,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Amortization (accretion) of note premiums/discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNy0xLTEtMS0yODkwNA_331dc219-6222-46df-a83d-303bf68a9732">690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNy0zLTEtMS0yODkwNA_fb356eef-da66-4aeb-82b9-f728bacce13b">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash interest expense on liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfOC0xLTEtMS00MTcwNg_6507eb71-f2f6-4998-9190-5c8a2cb01ed8">2,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfOC0zLTEtMS00MTUwMg_b042e20c-0c28-4c27-a21c-f95a03f75f66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfOS0xLTEtMS0yODkwNA_376ae63f-0f27-4f87-8f3e-da22532f89f3">38,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfOS0zLTEtMS0yODkwNA_7b535ebd-2c21-4623-894c-446a4430a76a">10,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTAtMS0xLTEtMjg5MDQ_9360862f-45a9-4d56-8d02-eb3602a1c597">10,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTAtMy0xLTEtMjg5MDQ_9910199c-b5b0-4694-a0fc-385d3931f746">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTItMS0xLTEtMjg5MDQ_77829db7-ae69-4d47-b697-a69156bb60ca">2,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTItMy0xLTEtMjg5MDQ_6bef847a-480a-4f93-ab29-5a896588b2e5">5,389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTMtMS0xLTEtMjg5MDQ_ab0252cf-0ab9-4954-948f-eb71cc397435">7,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTMtMy0xLTEtMjg5MDQ_e69c3824-32e5-4fd7-bc26-3c0cc07a0e45">2,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMS0xLTEtNDEyOTg_c98939c3-0213-41bc-95f1-239b6c3cd0ff">22,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMy0xLTEtNDEyOTg_7ddc0841-befb-4279-8bec-b6d107ae9bb8">27,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMS0xLTEtNDE3MTU_a3c492e2-a371-454d-a985-88707b201206">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMy0xLTEtNDE1MjE_a0bfb1dd-c2f1-4546-a4a9-d702e9aec1a2">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMS0xLTEtMjg5MDQ_28e37e5d-8339-4932-a875-199748246b61">75,516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMy0xLTEtMjg5MDQ_61c10096-c7f0-4f73-8028-3a2ecb5094bd">61,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTctMS0xLTEtMjg5MDQ_990264d3-e0e6-4360-9c19-12ce19c5bf14">38,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTctMy0xLTEtMjg5MDQ_9282896e-5cfb-4a06-9487-2be936d410d7">5,778</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTgtMS0xLTEtMjg5MDQ_932148e2-a23d-4f83-bb9a-9d821498e6de">111,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTgtMy0xLTEtMjg5MDQ_a5c493b4-4f25-4094-b08f-8e37c46fffb9">65,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTktMS0xLTEtMjg5MDQ_72fd5267-a346-4223-9e56-4679db4a90f7">69,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTktMy0xLTEtMjg5MDQ_dd4e0803-ab6c-4230-b3b4-4b70c551fb99">38,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjAtMS0xLTEtMjg5MDQ_8be82c63-41cb-4084-9091-6d15ff542c6b">80,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjAtMy0xLTEtMjg5MDQ_01d227eb-0b24-462f-a932-bb38e50f3cd7">33,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjItMS0xLTEtMjg5MDQ_0d8eddac-2792-479e-a37d-b9f4bcdbc66f">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjItMy0xLTEtMjg5MDQ_76405186-ebbc-4322-ad7b-2a17608f8cbf">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjMtMS0xLTEtMjg5MDQ_25533600-0fcd-4d1b-8844-0a45d47adf9d">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt 0 8.5pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjMtMy0xLTEtMjg5MDQ_5d3a619a-769a-43e8-94e4-50409d7a999b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjQtMS0xLTEtMjg5MDQ_681ab7bd-4f57-42b6-ad43-d15dd4094583">250,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjQtMy0xLTEtMjg5MDQ_b4b1e467-7003-490c-9c99-31463e47676f">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjUtMS0xLTEtMjg5MDQ_d97f0fab-76d3-4b8e-bc5c-39ea0757c1ae">94,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjUtMy0xLTEtMjg5MDQ_bfd38335-b637-4d91-a32d-c4615b6e1d2d">92,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of exchange rate on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzEtMS0xLTEtNDE3Njg_7eae304d-eeab-4dec-a99b-4619abc7171f">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzItMy0xLTEtNDE1NjQ_948e3c6d-d856-47c2-9754-6973b9d6c6cd">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">BEGINNING OF PERIOD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjYtMS0xLTEtMjg5MDQ_91116525-39fa-4d78-a772-0e88b895461d">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iee0675bb73de4fd3ab4bc406773f8cb4_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjYtMy0xLTEtMjg5MDQ_7dd92bed-b3ad-4eb9-aedd-6b32b4c1923c">184,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">END OF PERIOD</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjctMS0xLTEtMjg5MDQ_f28e4c9d-bc30-401a-acc5-3305747ae7b1">202,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i496886d6abed4f999c1ace5f866fcb6c_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjctMy0xLTEtMjg5MDQ_4ffefd31-ad42-45df-8e7e-07b7946df91a">91,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplementary disclosures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt 0 8.5pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzctMS0xLTEtNDE4MTI_f21cdd8c-ac0a-4a6f-acbb-607b56997425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzctMy0xLTEtNDE4MTI_54c494e0-4e61-4215-b025-ac8e65227c48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes (paid) refunded</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzgtMS0xLTEtNDE4MTI_95dc6579-4263-4472-bef7-66d8581bd8ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzgtMy0xLTEtNDE4MTI_f79678d1-343a-4168-939d-d43c1780db0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMTE0MjY_5c260033-9646-445d-b372-36d696598e21" continuedAt="i39603bbb4418440ebbae39def9b2820c" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i39603bbb4418440ebbae39def9b2820c" continuedAt="i8600ed2247224e99906774520fbb617b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="arwr:ScheduleOfCurrentProductsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMwMjkxNA_6899360e-8cf7-40b2-9290-170103979896" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:20.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-APOC3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Two Phase 2b and one Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ANG3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Two Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ENAC2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-HSD</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fazirsiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HZN-457 (formerly ARO-XDH)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-75220795</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Muscle</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DUX4</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2023, the Company continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety tolerability, pharmacokinetics and pharmacodynamics of a development-stage medicine, HZN-457 (formerly ARO-XDH), which is out-licensed to Horizon, triggering a $<ix:nonFraction unitRef="usd" contextRef="i5cea4208cdeb42c9a22cc59d648953a0_D20230101-20230331" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMxMzg3MA_c77da3d2-db44-4040-b45b-6916a9bb9dc0">15.0</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in Amgen&#8217;s Phase 3 trial of Olpasiran, triggering a $<ix:nonFraction unitRef="usd" contextRef="i5db3274cc4d14160ae2d5f647d651c24_D20230101-20230331" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMxMzg4NQ_16168c3a-b730-4b55-bf56-315c3bce99f4">25.0</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;) with Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) on November 9, 2022, pursuant to which Royalty Pharma paid $<ix:nonFraction unitRef="usd" contextRef="ia65665136f1d40fd862086f2dd922e9f_D20221001-20221231" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMxMzg1MA_2ef64cd0-d7e7-444b-a20c-19502bd102ac">250.0</ix:nonFraction>&#160;million upfront (See Note 11 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced Topline Results from SEQUOIA Phase 2 Study of Fazirsiran (formerly ARO-AAT) in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease in which;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Fibrosis regression was observed in 50% of patients receiving Fazirsiran;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Median reductions of 94% of Z-AAT accumulation in the liver and mean reductions of 68% in histologic globule burden were observed;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8600ed2247224e99906774520fbb617b"><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Treatment emergent adverse events were generally well balanced between Fazirsiran and placebo groups;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Results were consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#8217;s financial position at December&#160;31, 2022 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#8217;s Annual Report on Form 10-K for the year ended September&#160;30, 2022 for more complete descriptions and discussions. Operating results and cash flows for the three months ended December&#160;31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMzc2MA_6990d077-d865-470a-ab92-c312781ce98a">202.2</ix:nonFraction> million in cash and cash equivalents (including $<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMTY3Ng_b0532963-9da9-4083-af7e-cccc0d96f803">7.3</ix:nonFraction> million in restricted cash), $<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-5" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMzc2NA_6c0c1cac-62ab-46c3-8e58-6dd1a2207ad7">299.6</ix:nonFraction> million in short-term investments and $<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-5" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMTA5OTUxMTY4NjkwNw_9116a637-674f-4cb6-acce-15ecbbfcc720">115.8</ix:nonFraction>&#160;million in long-term investments to fund operations. During the three months ended December&#160;31, 2022, the Company&#8217;s cash and cash equivalents and investments balance increased by $<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-5" name="arwr:IncreaseDecreaseInCashAndInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMzc4MA_ea2043b4-77de-47ba-8c4b-245610545655">135.3</ix:nonFraction> million which was primarily due to the $<ix:nonFraction unitRef="usd" contextRef="ia65665136f1d40fd862086f2dd922e9f_D20221001-20221231" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMxMzg2Nw_2ef64cd0-d7e7-444b-a20c-19502bd102ac">250.0</ix:nonFraction>&#160;million upfront payment received from Royalty Pharma. See Note 11.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-8" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMzQ3Mg_aa42b282-d14e-4c66-8ea8-bc182144a035">4.1</ix:nonFraction> billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMTE0Mjk_1130cc84-0263-4d6d-af7e-38cc2e07c82f" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div></ix:nonNumeric></ix:continuation><div id="i9e436183b5b546b1bf8bde17c7a99c90_34"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTk3NzQ_1017b446-61e7-4514-bf86-c53a78fd7b71" continuedAt="if986a2fe23a44efab8d6b6723f0b0ea5" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="if986a2fe23a44efab8d6b6723f0b0ea5" continuedAt="ic15b040ea6db42f492b4bfeb256040ac">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic15b040ea6db42f492b4bfeb256040ac" continuedAt="id6d706d0a3c7491187491f83e984b9c1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for ARO-HSD. The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize ARO-HSD. The Company has completed its Phase 1/2 study of ARO-HSD, and GSK is now wholly responsible for all clinical development and commercialization of ARO-HSD in its territory. Under the terms of the agreement, the Company has received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ied9e360396f44e37a5fa2c12b7d58208_I20211122" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTM2OA_ac2f3c21-cfbe-43ea-8161-1b4358cf6a44">120.0</ix:nonFraction>&#160;million and is eligible for additional payments of $<ix:nonFraction unitRef="usd" contextRef="ied9e360396f44e37a5fa2c12b7d58208_I20211122" decimals="-5" name="arwr:MilestonePaymentReceivableAtStartOfPhaseTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTM4NA_2e163aff-c3b9-42bd-9908-e24bf8ec72ec">30.0</ix:nonFraction>&#160;million at the start of a Phase 2 trial and $<ix:nonFraction unitRef="usd" contextRef="ied9e360396f44e37a5fa2c12b7d58208_I20211122" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTM5OQ_d33644fc-3be2-4603-9893-00aa726b8d4a">100.0</ix:nonFraction>&#160;million upon achieving (i) a successful Phase 2 trial readout and (ii) the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="if6d16e113b834a97a9fcbf8e0681786c_I20211122" decimals="-5" name="arwr:CommercialMilestonePaymentsAtFirstCommercialSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQxNQ_3730472e-b457-45bb-a4f8-677a435781f2">190.0</ix:nonFraction>&#160;million at first commercial sale, and up to $<ix:nonFraction unitRef="usd" contextRef="if6d16e113b834a97a9fcbf8e0681786c_I20211122" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQzMQ_7f7f6b85-86ac-40a1-9834-d42ad3e740bf">590.0</ix:nonFraction>&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="ief93fea769094d7eb5fb5948a8f0d52b_D20211122-20211122" decimals="INF" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQ0Nw_e40a68eb-028b-46de-be13-a482cd36f863">120.0</ix:nonFraction>&#160;million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="ief93fea769094d7eb5fb5948a8f0d52b_D20211122-20211122" decimals="INF" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQ3Nw_e40a68eb-028b-46de-be13-a482cd36f863">120.0</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ief93fea769094d7eb5fb5948a8f0d52b_D20211122-20211122" decimals="INF" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQ5NA_e40a68eb-028b-46de-be13-a482cd36f863">120.0</ix:nonFraction>&#160;million was fully recognized as of September&#160;30, 2022. There were <ix:nonFraction unitRef="usd" contextRef="i342c597acfec441dab0f3b37209a55ba_D20221001-20221231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4MzA0MA_568dc879-65df-4399-aeca-f96ff40ee744"><ix:nonFraction unitRef="usd" contextRef="i00c306c538924e74a11b388564ca6b80_D20211001-20211231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4MzA0MA_e1c94088-488b-444e-8e96-bb5697587192">no</ix:nonFraction></ix:nonFraction> revenue recorded associated with the GSK License Agreement for the three months ended December&#160;31, 2022 and 2021. There were <ix:nonFraction unitRef="usd" contextRef="i038818ff5b9843f1b9d17f64430e188b_I20221231" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4MzE3Mg_510557a9-1a0e-4f8a-b3fc-ad0a1d73b5f1"><ix:nonFraction unitRef="usd" contextRef="i038818ff5b9843f1b9d17f64430e188b_I20221231" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4MzE3Mg_8cafda81-dd15-4f42-b254-bbd453d924d2">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of December&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. The Company conducted all activities through the preclinical stages of development of, and Horizon is now wholly responsible for clinical development and commercialization of HZN-457. In July 2021, the Company received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i378c508c95df484ba3e6ef6a5454bc94_I20210731" decimals="-5" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQ5Nw_5b7606a6-bf6b-4f8a-a32a-1407e39f1297">40.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an upfront payment and is eligible to receive up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ide8cc0f14c60475299147a3dd0c03daa_I20210618" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTUxMg_117b5c87-90cd-43c9-b762-54cc95387225">660.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented <ix:nonFraction unitRef="bundle" contextRef="i7372fb791af34e0d8dd8edb75dff1a73_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTYzMA_fbd5d5dc-9dc2-4c31-9464-dc488a37b861">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="i7372fb791af34e0d8dd8edb75dff1a73_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTYzMQ_b673ac1b-9851-41cd-80f8-5ada3385487b">one</ix:nonFraction> performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon is responsible for managing future clinical development and commercialization of HZN-457. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="i2a500b1709164996b845bbac989d7b84_D20210618-20210618" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTUyOA_30515ad1-2a59-406d-973b-ff89333a3652">40.0</ix:nonFraction>&#160;million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocates the total $<ix:nonFraction unitRef="usd" contextRef="i2a500b1709164996b845bbac989d7b84_D20210618-20210618" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU1Ng_30515ad1-2a59-406d-973b-ff89333a3652">40.0</ix:nonFraction>&#160;million initial transaction price to its <ix:nonFraction unitRef="obligation" contextRef="i2a500b1709164996b845bbac989d7b84_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU1OA_50c62331-a738-4016-b858-127410e137e6">one</ix:nonFraction> distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;D Services. Revenue is recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $<ix:nonFraction unitRef="usd" contextRef="i5cea4208cdeb42c9a22cc59d648953a0_D20230101-20230331" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU4MA_c77da3d2-db44-4040-b45b-6916a9bb9dc0">15.0</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended December&#160;31, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="ida93008e93a8494783ed240b674e7a64_D20221001-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU4Mw_eec3097f-fcfc-4597-871d-26086231e710">21.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i988f7cda978749b1b3f5337961e8742e_D20211001-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU5OA_56cde5d1-363d-4443-a8b9-30a7d2e22466">6.7</ix:nonFraction>&#160;million, respectively. There were $<ix:nonFraction unitRef="usd" contextRef="i09940e4ffb194a128c45cb16ba228ade_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTYxMg_117c1d16-8c8d-4679-9b99-ad248134c988">15.0</ix:nonFraction>&#160;million in contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="i09940e4ffb194a128c45cb16ba228ade_I20221231" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTYyNw_07cca7ae-2382-4d8f-8fb7-6d23770aeec3">0</ix:nonFraction> in contract liabilities recorded as deferred revenue as of December&#160;31, 2022. </span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id6d706d0a3c7491187491f83e984b9c1" continuedAt="i186bab6696664726928d23e437189599"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop its Fazirsiran program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, Fazirsiran, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize Fazirsiran, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia939243a8ac74e65952dd91c16f544b4_D20201007-20201007" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY0Nw_d5b75edc-8b4b-4f50-b35f-a7f582ef3bdc">20</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icda38447f5614cebb8ef1552acb61332_D20201007-20201007" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY1Mg_2aa9351f-1a55-4647-b020-f14877e4f1f5">25</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9284be9df69d4141bedb600f69d1042c_I20210131" decimals="-5" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY1Nw_800897c5-c522-46d2-946b-22071b88d0c5">300.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i3c44558d7e484eb2a6b9cae263a65437_I20210131" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY3Mw_20e02e6a-44fd-40fc-a55a-3373a3413107">595.0</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of Fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="bundle" contextRef="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY4OA_f81f8fdd-f612-4785-8bae-2bf768a1d254">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY5NQ_bf16c4b1-dcd0-4fab-ba32-6d76b7433d67">one</ix:nonFraction> performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTcwNQ_9d62eded-943a-40a4-be08-2cee75652f41">300.0</ix:nonFraction>&#160;million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTczNQ_9d62eded-943a-40a4-be08-2cee75652f41">300.0</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the Fazirsiran license and the associated Takeda R&amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i09ec1fea81bb4a3f85a50d428952c2a4_D20221001-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTczOA_8920ea92-1e2e-488e-bae0-53894e0d0012">16.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idca13f49c2ac4338bd38897981c0e87b_D20211001-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTc1Mw_bc94f364-4209-4cab-88c6-ee1f7e72d571">20.8</ix:nonFraction>&#160;million in connection with these efforts for the three months ended December&#160;31, 2022 and 2021, respectively. There were $<ix:nonFraction unitRef="usd" contextRef="if05fdd27fe28461a9e78cc9c9d4e69d0_I20221231" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTc2OA_6e9820ea-5b3c-494d-8eee-703a0d3300db">0</ix:nonFraction> of contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="i0cf0f351abeb4ff9920e8f448a4b04d1_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4Mzg4OA_d350d019-8830-4759-8758-a7db80d12f5d">107.1</ix:nonFraction> million of contract liabilities recorded as deferred revenue, of which $<ix:nonFraction unitRef="usd" contextRef="i0cf0f351abeb4ff9920e8f448a4b04d1_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTgwMA_810097f6-e8db-4b56-a79b-8acecf03d1fb">66.3</ix:nonFraction>&#160;million was classified as current deferred revenue, as of December&#160;31, 2022. The Company also recorded $<ix:nonFraction unitRef="usd" contextRef="ib3b9fa1ae2884a8d985db088de873bf2_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTc3Mg_554ded45-4e03-4718-9ee7-f57c6bd1244f">9.8</ix:nonFraction>&#160;million as accrued expenses as of December&#160;31, 2022 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson's venture capital arm (the &#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which the Company would develop clinical candidates. These candidates were subject to certain restrictions and did not include candidates that already were in the Company&#8217;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $<ix:nonFraction unitRef="usd" contextRef="idad13da460ff45d888e1281a60477acd_D20181003-20181003" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTgxNQ_7ee849f2-19a5-477a-9d51-d1187b46b14e">175.0</ix:nonFraction>&#160;million as an upfront payment, $<ix:nonFraction unitRef="usd" contextRef="i1dbada01124d4560be0e826511f8dce1_D20181003-20181003" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTgzMQ_dc64e39c-e940-47d4-945d-bd8e69b139a7">75.0</ix:nonFraction>&#160;million in the form of an equity investment by JJDC in the Company&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $<ix:nonFraction unitRef="usd" contextRef="i2a989d7ce0a44ccf9bf1022c8f7f9b2a_I20181003" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg0Ng_0163bc28-3410-4ac1-a8fc-5f3f94722730">73.0</ix:nonFraction>&#160;million, and the Company may receive up to $<ix:nonFraction unitRef="usd" contextRef="i92f82a268c774e9bb9992a060a63740b_I20181003" decimals="INF" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg2MQ_4c21a42e-f412-46a7-b1c2-2a77b775a62f">0.8</ix:nonFraction>&#160;billion in development and sales milestone payments for the Janssen License Agreement, and up to $<ix:nonFraction unitRef="usd" contextRef="iba27b7bdc69548378fef58b5f42961ff_I20181003" decimals="INF" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg3NQ_5138cd1f-b560-40d6-897b-e2eced81ad6e">0.6</ix:nonFraction>&#160;billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i186bab6696664726928d23e437189599" continuedAt="ibc97933b1123427ba912e92fdfe38114"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement and up to low teens under the Janssen Collaboration Agreement. During 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Janssen License Agreement and Janssen Collaboration Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="i328d3ff81ad3491a99bdf175a0d11762_D20181003-20181003" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg4OA_e87f1d8b-fa62-4eee-ab98-19d5b431ef9a">one</ix:nonFraction> distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price totaled approximately $<ix:nonFraction unitRef="usd" contextRef="if317166287bb4b13944a83a251e50077_D20181003-20181003" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg5Nw_79e75add-ad2c-4a7c-a57f-16bc510c0aaf">252.7</ix:nonFraction>&#160;million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $<ix:nonFraction unitRef="usd" contextRef="iadbb1a93d51d4301be4fa1d4b852337c_I20181003" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTkxMw_35765347-e6f8-4364-8543-2923c8a24a57">25.0</ix:nonFraction>&#160;million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="if317166287bb4b13944a83a251e50077_D20181003-20181003" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTkyOA_6593be39-f8f3-4e35-b06b-272d0860a037">252.7</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were <ix:nonFraction unitRef="usd" contextRef="i2766009a08bc437580f4294c351f7cd6_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk0Mw_844bec78-dfc3-486d-9e06-19418d4bf3dd"><ix:nonFraction unitRef="usd" contextRef="i2766009a08bc437580f4294c351f7cd6_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk0Mw_e7412e04-d4ac-4edd-a77d-264b2ed56843">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement during 2022. In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $<ix:nonFraction unitRef="usd" contextRef="i5c684d870f3a4136a5f54739f8a8b3a0_I20210531" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk1Mg_c2f423f4-aca2-41f7-9d72-17606db8a757">10.0</ix:nonFraction>&#160;million milestone payment to the Company. This $<ix:nonFraction unitRef="usd" contextRef="i2b7883a42e42404293d06a18e9cd891e_I20210930" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk2Nw_a5313577-420d-46e9-be92-56138f6a7cc8">10.0</ix:nonFraction>&#160;million milestone payment was recognized entirely as of September 30, 2021. There were <ix:nonFraction unitRef="usd" contextRef="i2364b30800c9442ab7f8d6ccf86939e9_D20211001-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjE1MA_3fe0a415-bad3-4fc2-8a1c-a8eb2f907f9c"><ix:nonFraction unitRef="usd" contextRef="i23c624b66e784ad1baf3e3fb6bea568e_D20221001-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjE1MA_4ac6d9f5-1033-47d4-8227-89962c59e951">no</ix:nonFraction></ix:nonFraction> revenue recorded associated with the Company&#8217;s agreement with Janssen for the three months ended December&#160;31, 2022 and 2021. There were <ix:nonFraction unitRef="usd" contextRef="i9db0b5443200492482544d7c90204e4a_I20221231" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjExNA_734c7869-7588-401b-b757-17060828325a"><ix:nonFraction unitRef="usd" contextRef="i9db0b5443200492482544d7c90204e4a_I20221231" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjExNA_bb65ea6f-8b35-4bd5-ab84-4053f4cbf075">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of December&#160;31, 2022. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into <ix:nonFraction unitRef="agreement" contextRef="if64321b9c6e247da8443d05133b342ff_I20160928" decimals="INF" name="arwr:NumberOfAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ3NjczMw_81452d31-487e-44f9-91ac-ffed6aa6ead3">two</ix:nonFraction> collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi Olpasiran program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the first collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license to ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $<ix:nonFraction unitRef="usd" contextRef="iae284bdb5fea480a9e15773836d59063_D20160928-20160928" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk4Mg_24b24309-1b96-4f42-befa-af8491a59424">35.0</ix:nonFraction>&#160;million in upfront payments, $<ix:nonFraction unitRef="usd" contextRef="iae284bdb5fea480a9e15773836d59063_D20160928-20160928" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk5Nw_0d7f3d8d-3884-4925-9700-360c463fcabe">21.5</ix:nonFraction>&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock, and $<ix:nonFraction unitRef="usd" contextRef="ibc17c83235054c9298c89a26c8fb35e1_I20160928" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjAxMg_1ce3d4ae-edfb-486c-9e75-bfe92a78866c">30.0</ix:nonFraction>&#160;million in milestone payments. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $<ix:nonFraction unitRef="usd" contextRef="id0f7402c90cf488f944efc5f47b5caeb_I20200731" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjAyNw_1816d054-1d2a-4f69-9316-760f1de260f1">20.0</ix:nonFraction>&#160;million milestone payment to the Company. In December 2022, Amgen enrolled the first subject in its Phase 3 trial of Olpasiran, which triggered a $<ix:nonFraction unitRef="usd" contextRef="i5db3274cc4d14160ae2d5f647d651c24_D20230101-20230331" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA1NQ_16168c3a-b730-4b55-bf56-315c3bce99f4">25.0</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. Revenue for the three months ended December&#160;31, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="i7c6d551c455a4169899e5d3a186b7638_D20221001-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA1OA_1ea02a9a-f24d-41a9-8c33-0ba3cfcd9468">25.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic2933262b7b1411284a2bb299c20d306_D20211001-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA3Mw_4c091a3d-f383-4d61-9cc9-935e79da13e3">0</ix:nonFraction>, respectively. There were $<ix:nonFraction unitRef="usd" contextRef="i1f61a8d393224431a507b3f200215db7_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA3Nw_2516118e-c3b5-405a-b5e2-ebdb222b27b6">25.0</ix:nonFraction>&#160;million in contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="i1f61a8d393224431a507b3f200215db7_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA5Mg_139ed1a0-d90d-4a9c-a49b-0cef42c3643b">0</ix:nonFraction> in contract liabilities recorded as deferred revenue as of December 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in November 2022, Royalty Pharma and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i9cfe482a057d4dca8df5560f98cef3e3_I20221231" decimals="-5" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA5Ng_761200a7-5059-4f13-9e70-296e62abe7d0">375.0</ix:nonFraction>&#160;million in remaining development, regulatory and sales milestone payments payable by Amgen under the Olpasiran Agreement. See Note 11.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibc97933b1123427ba912e92fdfe38114" continuedAt="iec829b38001c42d791dda9b481ac22cd"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, Visirna and the Company entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $<ix:nonFraction unitRef="usd" contextRef="i0ee8ab30ad3445958f3b561928b95608_D20220425-20220425" decimals="-5" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ3OTYyNQ_e820f7b8-317b-4bb0-a6f4-1b963a027702">60.0</ix:nonFraction>&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iec829b38001c42d791dda9b481ac22cd">During the three months ended December&#160;31, 2022, the Company performed manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received $<ix:nonFraction unitRef="usd" contextRef="ia9c7506b5d91485d9801a47dca99e510_D20221001-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjEzNA_a544184d-8808-4a1c-bfd8-2b68c384f221">0.7</ix:nonFraction>&#160;million as consideration for this manufacturing and development work, and there were <ix:nonFraction unitRef="usd" contextRef="ic3e51d9c60c54ce1a159fc24a37a7ae1_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjEyNQ_35df77fc-ce66-480c-ba28-817eaa0015d3"><ix:nonFraction unitRef="usd" contextRef="ic3e51d9c60c54ce1a159fc24a37a7ae1_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjEyNQ_9aa5eda7-79bb-4b0f-a269-576310b0b7b9">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of December&#160;31, 2022.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RleHRyZWdpb246OTdiZDRkZTc1YzcwNDM4YTk4ODhkZDVhOTc4ZmRhYzNfNTQy_3467cb1b-079c-4bae-b36e-bb1040a9ced8" continuedAt="i379317752f72436ca962198e5c72a59b" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i379317752f72436ca962198e5c72a59b"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RleHRyZWdpb246OTdiZDRkZTc1YzcwNDM4YTk4ODhkZDVhOTc4ZmRhYzNfNTQz_e1217fff-ca52-4654-b96e-ef8b010edc37" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computers, software, office equipment and furniture</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMi0xLTEtMS0yODkwNA_1587386e-f533-4eef-a0b4-63de2526d057">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMi0zLTEtMS0yODkwNA_54e48fab-b6ec-4453-bd43-1eb264ca2a23">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMy0xLTEtMS0yOTU0OA_62dbc8ae-b4d9-4059-99e6-ed19fc6a3a61">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMy0zLTEtMS0yOTU0OA_de6ef278-fc95-48d3-866b-c61caf7f3e6e">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMy0xLTEtMS0yODkwNA_c514b4af-9121-4556-827b-84866c549cfa">43,739</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMy0zLTEtMS0yODkwNA_05d86dcd-fecc-4af1-9cce-7e86d3778914">38,283</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNC0xLTEtMS0yODkwNA_00a93f59-5cd9-4328-8c31-0e1c1fbee78c">42,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNC0zLTEtMS0yODkwNA_8dbc05f1-4dff-4bca-bd89-3e3bc392179e">42,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNS0xLTEtMS0yODkwNA_6fb1b3f9-b672-4135-ac0c-185fb9a755cd">90,215</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNS0zLTEtMS0yODkwNA_4393d005-5f46-42df-a8b9-7152c6928f07">56,373</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNy0xLTEtMS0yODkwNA_a7ebc5ff-8a12-4279-927a-541a69dd9b27">181,149</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNy0zLTEtMS0yODkwNA_0216927a-5827-4b6e-a2fa-2defaea02274">141,851</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfOC0xLTEtMS0yODkwNA_0b0808ec-e04c-4be0-a90e-440d60354965">33,835</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfOC0zLTEtMS0yODkwNA_4cea00e8-949a-4783-a8a1-159c6637ada0">31,554</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfOS0xLTEtMS0yODkwNA_0eb998bc-4603-40c3-bd3b-dbaefccaafb9">147,314</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfOS0zLTEtMS0yODkwNA_fdaf8cb6-34f3-4839-9d3e-310edfdf2816">110,297</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property and equipment for the three months ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RleHRyZWdpb246OTdiZDRkZTc1YzcwNDM4YTk4ODhkZDVhOTc4ZmRhYzNfMjMx_d38add70-2fdd-43ad-9bc9-e96ceddd35e6">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RleHRyZWdpb246OTdiZDRkZTc1YzcwNDM4YTk4ODhkZDVhOTc4ZmRhYzNfMjM4_3bbe5882-3b48-45ca-b92a-b9f5ffbfdd68">2.1</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the construction in progress during the three months ended December&#160;31, 2022 was mainly due to the continuing developments of manufacturing, laboratory and office facilities in Verona, Wisconsin as well as a new laboratory and office facility in San Diego, California. See Note 7.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RleHRyZWdpb246YjQ5MWNmZTE2OGZmNGIzMjlmY2IxYWJhOWI5M2MyOTFfMTYzMA_b89d5153-3299-40fa-9db9-12cb7c7e5cbf" continuedAt="i6f9c8de1c69646dc873f29f1077e83df" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i6f9c8de1c69646dc873f29f1077e83df"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RleHRyZWdpb246YjQ5MWNmZTE2OGZmNGIzMjlmY2IxYWJhOWI5M2MyOTFfMTYzMQ_1ae8db4c-1e4a-4e74-85c4-240be1626a11" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNS0xLTEtMS0zMzgyNA_b6e403f5-38bb-4937-8c7c-57c61361c5c7">299,582</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNS0zLTEtMS0zMzgyNA_cbc0d8f6-df5a-48db-8287-0cb4762a261b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNS01LTEtMS0zMzgyNA_5cd34c6b-b795-4276-890d-5ec2be219156">2,644</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNS03LTEtMS0zMzgyNA_7a85147d-eaae-474f-a688-6c6a5157ddba">296,938</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i917462b04ff841eaac0e3339bd0cb7bf_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNi0xLTEtMS0zMzgyNA_22c0917a-4f64-4f93-a111-acdc20fd338a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i917462b04ff841eaac0e3339bd0cb7bf_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNi0zLTEtMS0zMzgyNA_a3f2c466-d0bf-47cb-bcfe-426ae348d0b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i917462b04ff841eaac0e3339bd0cb7bf_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNi01LTEtMS0zMzgyNA_de97a377-1221-4cbf-b9cc-cf7a27f62dff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i917462b04ff841eaac0e3339bd0cb7bf_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNi03LTEtMS0zMzgyNA_21061b90-1904-46dd-859f-767fbcf59a58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNy0xLTEtMS0zNDYyNg_f0a3baab-5876-4f67-83b6-9c3d1140fe88">299,582</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNy0zLTEtMS0zNDYyNg_c2819cc2-77a2-485d-8419-ebd5dfb2bc32">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNy01LTEtMS0zNDYyNg_b88a948e-7392-4d47-8280-63417ee160d9">2,644</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNy03LTEtMS0zNDYyNg_1d34afe7-409b-4a35-b744-d01fc7b3f313">296,938</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTAtMS0xLTEtMzM4MjQ_7ef6aabe-fa72-413e-b6d7-720b721b2f73">115,774</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTAtMy0xLTEtMzM4MjQ_c8a302ed-6ef3-4cb8-86d0-4f3767252c15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTAtNS0xLTEtMzM4MjQ_af301659-f827-4202-88e5-7bb00232742d">4,440</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTAtNy0xLTEtMzM4MjQ_ba244613-34f8-44cc-bc06-6cfd0a3e7c11">111,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTEtMS0xLTEtMzM4MjQ_681924c1-54b9-4b52-a5c1-8254d2d1563b">115,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTEtMy0xLTEtMzM4MjQ_c76423b7-5f09-4b85-813c-82540a5e6163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTEtNS0xLTEtMzM4MjQ_78ae3a41-1234-44fd-bca0-b708235ac452">4,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTEtNy0xLTEtMzM4MjQ_d19be83f-82bb-4582-89f5-ea17a152a0bb">111,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"><tr><td style="width:1.0%"></td><td style="width:45.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f7584f587e4681907eb42f27510096_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNS0xLTEtMS0zODA2Nw_3c04f251-9f4a-41ca-94be-a2d96324807a">218,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f7584f587e4681907eb42f27510096_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNS0zLTEtMS0zODA2Nw_62c2b01b-b8ca-430f-ab4e-97bd95954dc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie3f7584f587e4681907eb42f27510096_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNS01LTEtMS0zODA2Nw_c6f15074-9b5a-4fb1-b7a6-d40a9c4e1540">3,661</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f7584f587e4681907eb42f27510096_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNS03LTEtMS0zODA2Nw_5905a4df-6fa8-4cd7-b4e2-5ab963fafe58">214,730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iea276053053c4bb59f85d31ebab93a3e_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNi0xLTEtMS0zODA2Nw_f24454e3-fa41-4014-81c6-fe278022e52c">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iea276053053c4bb59f85d31ebab93a3e_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNi0zLTEtMS0zODA2Nw_48a49ba5-57c5-4040-ace2-689eff8f64eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iea276053053c4bb59f85d31ebab93a3e_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNi01LTEtMS0zODA2Nw_6d49b477-bb5b-4885-a8fc-7416569a04ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iea276053053c4bb59f85d31ebab93a3e_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNi03LTEtMS0zODA2Nw_c37d7ade-29fc-451a-a661-245214f559a6">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNy0xLTEtMS0zODA2Nw_e0164fba-107f-45b8-a614-6868c0a0fea7">268,391</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNy0zLTEtMS0zODA2Nw_1b288f23-e4a8-4ddc-998a-42c3ba6b83f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNy01LTEtMS0zODA2Nw_2a5b6362-4557-417e-9bb2-8aec63872ce6">3,661</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNy03LTEtMS0zODA2Nw_524c3265-2619-4deb-8140-67c0b7e8593c">264,730</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f7584f587e4681907eb42f27510096_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTAtMS0xLTEtMzgwNzM_d1de46b0-db33-48a6-9b7f-0a5b76a886eb">105,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f7584f587e4681907eb42f27510096_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTAtMy0xLTEtMzgwNzM_d8d577d1-3c29-4575-bbbd-8f8e0f08a5cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie3f7584f587e4681907eb42f27510096_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTAtNS0xLTEtMzgwNzM_cb8c04df-b293-44d0-95fa-e323d1d36144">5,569</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3f7584f587e4681907eb42f27510096_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTAtNy0xLTEtMzgwNzM_679b69f6-8802-47ba-a60a-665abef53e08">100,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTEtMS0xLTEtMzgwNzM_513aa2e7-7b83-47ac-8eb2-1fa76ba636ab">105,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTEtMy0xLTEtMzgwNzM_04ec07f5-07c0-4431-b724-7d70bba0e49d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTEtNS0xLTEtMzgwNzM_a6a15903-f503-4899-a7be-b09a71587ae7">5,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTEtNy0xLTEtMzgwNzM_2353b861-acc1-4511-8bc6-e228ba5d25d1">100,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfOTgz_ed6f1dd6-64c5-4bd4-a449-e4de6866e480" continuedAt="ia4de6fe5f3b14616ac3deaa9a22f3d6e" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="ia4de6fe5f3b14616ac3deaa9a22f3d6e"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfMjE5OTAyMzI2MDQyMw_62555f15-591f-4d2d-a65a-c7df9e8a7973" continuedAt="ia07e0c4c2cfb44f899eceb8c1fcecd43" escape="true">The following table presents the components of intangible assets: </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="ia07e0c4c2cfb44f899eceb8c1fcecd43"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(amounts in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy0xLTEtMS0yOTYzNQ_a0c977aa-4b5f-4266-8cd2-b952b0e570aa">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy0zLTEtMS0yOTYzNQ_4f140f41-b517-4f2e-b85d-0351b40d6a6a">12,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy01LTEtMS0yOTYzNQ_9150f043-1f1f-4e23-8ffc-6a0d4bd6fe6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy03LTEtMS0yOTYzNQ_e3d76bfc-a622-41fb-ad47-51f8c81786d8">9,570</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0889a0226de945a0aaa5c52879fb13f4_D20221001-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy05LTEtMS0yOTYzNQ_6848471e-0971-432c-aa58-a46397d78c30">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC0xLTEtMS0yOTYzNQ_9d88446c-e29f-4c1b-b42e-0d5700e779dd">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC0zLTEtMS0yOTYzNQ_3b2b78a5-477b-41bc-97bf-1d84084f1f59">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC01LTEtMS0yOTYzNQ_d5cb16c8-405c-44c1-b2d8-925c5f3d8ef8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC03LTEtMS0yOTYzNQ_1b292803-aa5c-4946-ab1f-dc5f690dab28">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i714564a42c4645a4aa8fec5fbfae6cf1_D20221001-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC05LTEtMS0yOTYzNQ_e5a80e71-1b84-43d4-a131-54932515332c">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNS0xLTEtMS0yOTYzNQ_84ad085d-e271-40fa-912b-06d7832da504">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNS0zLTEtMS0yOTYzNQ_9d959d02-3f3c-4094-b180-296035ebf96e">13,320</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNS01LTEtMS0yOTYzNQ_5ec5c449-732c-4c58-9029-c05d5ae75573">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNS03LTEtMS0yOTYzNQ_b333b4a2-658d-4907-be9e-be1cc4cffdc0">11,537</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0223aca615484a88a1f963d53db983b5_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC0xLTEtMS0yOTYzNQ_943815df-bf86-4780-aaff-8ce7ece5da68">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0223aca615484a88a1f963d53db983b5_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC0zLTEtMS0yOTYzNQ_bd842208-8fc8-4b98-a6b0-798f27f7cc8e">11,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0223aca615484a88a1f963d53db983b5_I20220930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC01LTEtMS0yOTYzNQ_486ca27a-36f4-43f3-b4fc-5e4e57b77a3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0223aca615484a88a1f963d53db983b5_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC03LTEtMS0yOTYzNQ_6e7287eb-03cb-459a-85ce-523a2c9240c1">9,958</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4a3b5deb088e42a4b098ad5687964c9e_D20211001-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC05LTEtMS0yOTYzNQ_445e9d5f-d3bf-4d27-8773-26752d6fda0d">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d52a26129d84983ad9bb9f0ee488966_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS0xLTEtMS0yOTYzNQ_f863b509-e665-480e-8bf6-fcf8d7c7f350">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d52a26129d84983ad9bb9f0ee488966_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS0zLTEtMS0yOTYzNQ_a97291fd-4e4e-47b9-91c0-179ba1a4dd1e">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d52a26129d84983ad9bb9f0ee488966_I20220930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS01LTEtMS0yOTYzNQ_2d35795c-57d0-4585-a7a1-c912e0cbc04a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d52a26129d84983ad9bb9f0ee488966_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS03LTEtMS0yOTYzNQ_dbd6d4a0-cf09-4ace-82f9-5ebe688b3be1">2,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i449ded4307a74763bf247ab23aa3b5f9_D20211001-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS05LTEtMS0yOTYzNQ_6b29165b-99de-4cb4-9405-5bab5c8f091d">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i34f581ef502d44a597740c97e5d034bf_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMTAtMS0xLTEtMjk2MzU_3eda6dce-7886-48a6-beaf-c9a531d1459c">24,857</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i34f581ef502d44a597740c97e5d034bf_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMTAtMy0xLTEtMjk2MzU_0e84c5f5-ec77-4b5e-9268-385e2f2a8463">12,895</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i34f581ef502d44a597740c97e5d034bf_I20220930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMTAtNS0xLTEtMjk2MzU_c95d8e08-d9d2-4ec2-a4b6-94c93f7015ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i34f581ef502d44a597740c97e5d034bf_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMTAtNy0xLTEtMjk2MzU_8d0728b0-513c-4e04-a415-479a38282e5d">11,962</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the three months ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense for each of the three months ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfMTA5OTUxMTYzMjY1MQ_7378eb55-716a-47fb-be20-636df446ffc9"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfMTA5OTUxMTYzMjY1MQ_fe5f1b9c-bc60-4b8c-aa31-8352343d5b59">0.4</ix:nonFraction></ix:nonFraction> million. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfMjE5OTAyMzI2MDQyNA_68c8a3b7-8705-4b59-9b4a-c8b735937889" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of December&#160;31, 2022:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:71.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfMi0yLTEtMS0yOTYzNQ_1c2c92ee-a798-4ad5-bb08-3cbafdd6b135">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfMy0yLTEtMS0yOTYzNQ_d3a4076a-9e22-4f17-89fd-8827468220e7">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfNC0yLTEtMS0yOTYzNQ_bfb1b670-eeed-4f6a-a82c-94a88a8e8546">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfNS0yLTEtMS0yOTYzNQ_a0c7289c-9ad7-41e7-ac88-6af4113f31b4">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfNi0yLTEtMS0yOTYzNQ_94c68bbf-4380-4a46-9bba-d75cca019e9e">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfNy0yLTEtMS0yOTYzNQ_2604fc6f-1317-4956-b7ee-a94cebfc3892">3,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfOC0yLTEtMS0yOTYzNQ_aacf7f75-7517-48d6-a6fd-a7b59f45649c">11,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMTM3NA_8d6b131c-077c-4008-8f18-bbcd4a5eccf8" continuedAt="ibaa9335f331a45a78bcbe96c20816f26" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ibaa9335f331a45a78bcbe96c20816f26"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMjE5OTAyMzI1OTUwOQ_69e53527-61c4-453f-b52c-f115f736eb44" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:27.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNC0xLTEtMS0zMzg1Ng_54c10861-1c98-4b78-bb03-cd38e2e77c36">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNC0yLTEtMS0zMzg1Ng_725d05bc-8ef9-44f2-a324-fa78f12839e1">145,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNC0zLTEtMS0zMzg1Ng_72464929-0271-40b3-8d86-b2066b6c3c16">106,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNC00LTEtMS0zMzg1Ng_acbcc736-5853-4e71-82a6-8ed11141b9ad">106,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNS0xLTEtMS0zMzg1Ng_cd6488ae-b736-4484-b56b-1a5588b2fe0a">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNS0yLTEtMS0zMzg1Ng_f4fdc226-ce1d-46a1-878f-8ebd3db6e8d4">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNS0zLTEtMS0zMzg1Ng_a29ad637-7ee4-4907-ab3e-6d252b3d1581">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNS00LTEtMS0zMzg1Ng_b9296855-5242-426d-8b40-64e14c625c73">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOC0xLTEtMS0zMzg1Ng_28febc85-138c-412e-a713-e624cbec252e">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOC0yLTEtMS0zMzg1Ng_275fd7d2-3de4-4971-8999-74c6cad027a9">145,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOC0zLTEtMS0zMzg1Ng_63bd21d3-c0c6-40b1-ac01-154924cb61c6">105,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOC00LTEtMS0zMzg1Ng_d6766863-bde9-458f-85de-237aa74ac341">105,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOS0xLTEtMS0zMzg1Ng_70e9e881-14e7-4971-a7d5-915cda44dcd7">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOS0yLTEtMS0zMzg1Ng_8d16a3cd-daf7-4b35-913f-f85345d2ab98">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOS0zLTEtMS0zMzg1Ng_5aabe4c0-31ec-4a59-ae23-067095d5a97e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOS00LTEtMS0zMzg1Ng_fb2f2b7c-053d-43bc-9170-e2843a58cabc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i03c5e2040b97478685482edb1a081bb8_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMjE5OTAyMzI2MjY4MA_44fbde76-75ac-4038-a2c9-24099f93bab3">13,769,984</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic2aeef9c8ccd4d24a3762ad0cae17f16_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMjE5OTAyMzI2MjY5Mg_073daf89-ceb8-447b-8326-b7376988972c">14,000,392</ix:nonFraction> shares of common stock as of December&#160;31, 2022 and September 30, 2022, respectively, were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="i953cacdb283b4570974e198523332adc_I20200831" decimals="INF" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfNTQ5NzU1ODE3MjM0_724f5fae-edf4-4bdb-bfab-d6efd7caeee3">250,000,000</ix:nonFraction> in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="number" contextRef="if602610bd9274f15ab350c697c16fbcd_D20200801-20200831" decimals="3" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfNTQ5NzU1ODE3NTE3_14558e83-3d59-4be3-8355-b27c3104ccc9">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i75f84a2f705547a9a7be5905324c37e9_I20221231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMjE5OTAyMzI2MjcwMw_40cb32cd-5615-48e3-b75a-cc64bb45a41c">no</ix:nonFraction> shares have been issued under the Open Market Sale Agreement.</span></div></ix:continuation><div id="i9e436183b5b546b1bf8bde17c7a99c90_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfMjM0MQ_50e5ee09-9d37-4cf1-a89e-c03783b12745" continuedAt="i0bd92179f35c4e77a8bb8d4f7f114567" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i0bd92179f35c4e77a8bb8d4f7f114567" continuedAt="ibce4011193ca4ff0bbef85cc05c3515a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were <ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfMzky_17f0c5b2-f021-4d06-a9d3-0092d902793c">no</ix:nonFraction> contingent liabilities recorded as of December&#160;31, 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;20, 2021, the Company completed a purchase of <ix:nonFraction unitRef="acre" contextRef="i8614ef1e09dc4ad7b48305618623004c_D20211220-20211220" decimals="INF" name="arwr:NumberOfAcresOfLandPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNDkz_f64d1c89-513c-4a06-a2b8-45262c69d59b">13</ix:nonFraction> acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately <ix:nonFraction unitRef="sqft" contextRef="i7b3dac9a5a774156b890ac8ed0751a6a_I20211220" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNjE0_d98a608c-d491-42ca-8a57-679882c1a131">160,000</ix:nonFraction> square foot drug manufacturing facility and an approximately <ix:nonFraction unitRef="sqft" contextRef="i0f1aae662bc6418db9f0619cc2642795_I20211220" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNjc4_05ec4d8b-fcfa-4d8e-8f2c-3c1f37c96692">140,000</ix:nonFraction> square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company intends to invest between $<ix:nonFraction unitRef="usd" contextRef="i62abdefe617a488691c724830dcd72c9_I20211220" decimals="-6" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfODE4_40ed1e7b-8af4-4143-91d2-493614020d6f">200.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie59ded034230456484b32676c5f7bea0_I20211220" decimals="-6" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfODI1_ec99873f-fed5-4400-a822-3a34ee4099da">260.0</ix:nonFraction> million into the build-out of the facilities. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and will be reimbursed up to $<ix:nonFraction unitRef="usd" contextRef="i475551cf88cb4dccacdf1b2a61c7583d_I20211220" decimals="-5" name="arwr:TaxIncrementFinancingAward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNzE0NjgyNTU4NTI2NQ_2e198982-6ea4-43d6-b661-68bcf69aade4">16.0</ix:nonFraction>&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that the City of Verona will pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property. The Company will also receive up to $<ix:nonFraction unitRef="usd" contextRef="i0154bab3efba4f2b94e2b7c59316083b_D20211220-20211220" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNzE0NjgyNTU4NzI1Ng_392ce842-d39d-41f2-84af-39c3cd99b55a">2.5</ix:nonFraction> million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology License Commitments</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibce4011193ca4ff0bbef85cc05c3515a">The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. During the three months ended December&#160;31, 2022 and 2021, the Company did <ix:nonFraction unitRef="usd" contextRef="ic881a18f95ea4f17a15cc3756a39574f_D20221001-20221231" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNzE0NjgyNTU4ODQzMQ_365f7bbf-faaf-41d3-b075-648c8f524420"><ix:nonFraction unitRef="usd" contextRef="i349f57ec0207498e87e4c69e2bce507c_D20211001-20211231" decimals="INF" name="arwr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNzE0NjgyNTU4ODQzMQ_d76a95d5-5576-4248-8839-c1618afb2dd6">not</ix:nonFraction></ix:nonFraction> reach any milestones.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTMxNQ_897c350a-9ae2-4325-8240-34f520aafd1d" continuedAt="ifcbb24d033cc4a1189cadc6f79868910" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ifcbb24d033cc4a1189cadc6f79868910" continuedAt="i4bd7181fc65c4891bafb12b875fcd68d"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a new <ix:nonNumeric contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODIzOTIy_d5cff41f-171f-4b6a-98a9-45a73e805053">15</ix:nonNumeric>-year lease for approximately <ix:nonFraction unitRef="sqft" contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODIzOTU1_b9be657e-21df-4cf0-9513-0489d4eb40a5">144,000</ix:nonFraction> square feet of office and research and development laboratory space under construction in San Diego, California. This facility will replace the Company&#8217;s current office and research facility sublease located in San Diego, California. The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for its expanding pipeline of current and future drug candidates. The estimated rent commencement date for the new lease is in April 2023 after construction and leasehold improvements have been completed. The lease payments, which begin on the rent commencement date, will be approximately $<ix:nonFraction unitRef="usd" contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0NjIy_12a35a54-70d2-4e68-995e-e2b5519743a8">119.0</ix:nonFraction> million over the initial <ix:nonNumeric contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0NjQz_d5cff41f-171f-4b6a-98a9-45a73e805053">15</ix:nonNumeric>-year term. The Company also estimates payments for operating expenses to be approximately $<ix:nonFraction unitRef="usd" contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119" decimals="-5" name="arwr:EstimatedPaymentsForOperatingExpensesYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0NzM3_070fb251-8b77-4c6b-9c1a-ed55494a319d">3.0</ix:nonFraction> million for the first year of the lease, and these payments will continue throughout the initial <ix:nonNumeric contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0ODMw_d5cff41f-171f-4b6a-98a9-45a73e805053">15</ix:nonNumeric>-year term. The Company expects to pay approximately $<ix:nonFraction unitRef="usd" contextRef="ib156f4f74fcf40dab1e99dda624e5df7_D20211119-20211119" decimals="-5" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0ODg2_bdf7d363-f0b0-4a3e-b83a-889058423590">31.0</ix:nonFraction> million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial <ix:nonNumeric contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1MDMz_d5cff41f-171f-4b6a-98a9-45a73e805053">15</ix:nonNumeric>-year term, the Company has the option to extend the lease for up to <ix:nonFraction unitRef="option" contextRef="ide63f19f872342da8608f446fb18d4de_I20211119" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1MTA1_a1d222b8-481f-4344-acbd-df34eb1924fb">one</ix:nonFraction> additional <ix:nonNumeric contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI2OTE1Nw_71674e8b-be98-49d7-b550-7d36d668479f">ten-year</ix:nonNumeric> term, with certain annual increases in base rent. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Significant Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases office space located at 177 Colorado Blvd for its corporate headquarters from 177 Colorado Owner, LLC. The lease began on September&#160;30, 2019 and expires on April&#160;30, 2027. The lease contains an option to renew for <ix:nonFraction unitRef="option" contextRef="ic35d28a67b834f6484c8d5ee20d55588_I20190930" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1NDM0_75627060-9a47-46ca-a6f7-2ba4bc761377">one</ix:nonFraction> term of <ix:nonNumeric contextRef="ic35d28a67b834f6484c8d5ee20d55588_I20190930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1NDQ2_59c77e9a-0266-44e7-b249-ac19e62328fd">five years</ix:nonNumeric>. On October&#160;23, 2020, the Company entered into a lease expansion to add an additional approximately <ix:nonFraction unitRef="sqft" contextRef="i2811668ed19749b68707a9ed9f6d8253_I20201023" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1NTM3_cbacb659-7e04-4622-ada4-d9211352432e">24,000</ix:nonFraction> square feet of office with a lease expiration date of April&#160;30, 2027. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company subleased space from Halozyme, Inc. for additional research and development facility in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and ended on January&#160;14, 2023. On December 23, 2022, the Company entered into a new <ix:nonNumeric contextRef="iea10d5800b11488baca5f307e6d73957_I20221223" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI3MjI0NQ_c9ee2731-d99d-49ac-b195-a5a38f3bb8e7">six-month</ix:nonNumeric> lease agreement with 11404 &amp; 11408 Sorrento Valley Owner (DE) LLC, effective January 15, 2023. The lease will end on July 15, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which expires on September 30, 2031. The lease contains options to renew for <ix:nonFraction unitRef="option" contextRef="i12ce5e7d49bd492c9e566ef7247a28c3_I20221231" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI3MTkyOQ_13234722-9eaa-44d9-a0ae-30db96202bde">two</ix:nonFraction> terms of <ix:nonNumeric contextRef="i12ce5e7d49bd492c9e566ef7247a28c3_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI3MTkzNw_ee20c459-831f-4bf3-9b4e-9ebe0b2ac412">five years</ix:nonNumeric>. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of <ix:nonFraction unitRef="sqft" contextRef="i12ce5e7d49bd492c9e566ef7247a28c3_I20221231" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI3MTk1Mw_34f51549-47cd-4620-93dc-5f18433bcaed">111,000</ix:nonFraction> square feet.</span></div><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI2OTE1NA_a4a5c42d-864c-4dcf-b701-59af9cb15173" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:28.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfMy0zLTEtMS0zMzg2NA_00f1bb8f-9202-41e8-8690-e2db173e4229">41,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfMy01LTEtMS0zMzg2NA_07fdcfa1-5d09-4f70-b962-098e4604ad2a">58,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfNS0zLTEtMS0zMzg2NA_92b3e927-601a-4098-9e4d-4b02065e740c">2,664</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfNS01LTEtMS0zMzg2NA_b5315208-bdad-418d-b06c-2951ef11b653">2,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfNi0zLTEtMS0zMzg2NA_68857d5e-9d17-4e1a-9870-c489b7f4485f">79,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfNi01LTEtMS0zMzg2NA_e4a3fa43-345f-4ae0-8558-3a3a481fbb3a">78,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:28.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8040ef89c2154b74b3e460ed12cd081a_D20221001-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfMy0zLTEtMS0zMzg2Ng_d3e3a9e8-fe6b-4817-b42f-52ca460b04d8">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b5a7a96684442d296082eb9d52b8bcd_D20211001-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfMy01LTEtMS0zMzg2Ng_b1b6c2de-e964-462f-afbd-dc72e05b574a">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i35831effd60d42e480dad85b0cf9984c_D20221001-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNC0zLTEtMS0zMzg2Ng_39ea498b-9522-4d0f-bac3-cc0ae1fa5070">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia4bfba6d666f497ab7f1a694161b0c89_D20211001-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNC01LTEtMS0zMzg2Ng_def0159b-e272-4958-9770-fcd82a201f4e">420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8040ef89c2154b74b3e460ed12cd081a_D20221001-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNi0zLTEtMS0zMzg2Ng_61505725-1133-4508-985d-1de4b54d19bc">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b5a7a96684442d296082eb9d52b8bcd_D20211001-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNi01LTEtMS0zMzg2Ng_425b0a29-8433-4b01-94b4-4aaf7f1432e0">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i35831effd60d42e480dad85b0cf9984c_D20221001-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNy0zLTEtMS0zMzg2Ng_69be2035-67d0-45f1-a19d-ed6e6232659a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia4bfba6d666f497ab7f1a694161b0c89_D20211001-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNy01LTEtMS0zMzg2Ng_a6cd832b-a536-41d0-b47b-8d9523389d13">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfOS0zLTEtMS0zMzg2Ng_4df6f415-c6b6-4475-b73c-b579e90ddd70">2,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc2a8a0b4a714ac7bf244c847af32ed7_D20211001-20220930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfOS01LTEtMS0zMzg2Ng_3e3778c5-b07f-42b6-8dec-f9acbf72b449">1,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost primarily related to operating expenses associated with the Company&#8217;s operating leases. There was $<ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI3NTMw_cc31f92b-d70f-4cb7-9baa-5291dffe055a">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI3NTM4_1fcf8313-bfb8-4a59-a023-caad320df9f1">0</ix:nonFraction> short-term lease cost during the three months ended December&#160;31, 2022, and 2021, respectively.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTMxMA_7308e346-b1fe-4200-8e93-d77cfeefb2c7" continuedAt="i14a01d7931644677b3075897247e54e7" escape="true">The following table presents payments of operating lease liabilities on an undiscounted basis as of December&#160;31, </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4bd7181fc65c4891bafb12b875fcd68d"><ix:continuation id="i14a01d7931644677b3075897247e54e7"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"><tr><td style="width:1.0%"></td><td style="width:79.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2023 (remainder of fiscal year)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfMi0xLTEtMS0zMzg2OA_85d95cc4-8fba-4e00-93ea-ad76082794d8">4,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfMy0xLTEtMS0zMzg2OA_e07d3963-8af5-4ae5-ab72-ca4bc59ae824">8,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfNC0xLTEtMS0zMzg2OA_90d88c47-7057-4e58-a310-dcf0951492a5">11,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfNS0xLTEtMS0zMzg2OA_1a14b939-8a07-4099-9c69-80b8dc1125f0">12,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfNi0xLTEtMS0zMzg2OA_1bb844dc-9d81-43f3-92d6-7729663d1fc1">11,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfOC0xLTEtMS0zNDg4NA_f794d792-1cb6-4736-bdf4-e36d530d3476">102,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfOC0xLTEtMS0zMzg2OA_8db28541-1035-4bfa-8b0a-540beb2557e8">150,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfOS0xLTEtMS0zMzg2OA_12e1dbb5-9ce3-496a-a088-6db8b49e164e">68,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfMTAtMS0xLTEtMzM4Njg_8d84904c-a911-494e-97c9-7478b8f7eb0c">82,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"></td><td style="width:60.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfMi0yLTEtMS0zMzg3MA_21a29d53-1fee-4111-9345-ba9f234496c6">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc2a8a0b4a714ac7bf244c847af32ed7_D20211001-20220930" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfMi00LTEtMS0zMzg3MA_9dd07153-755b-4022-8a41-94df6293012c">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfNC0yLTEtMS0zMzg3MA_021cad58-3f78-448b-ad57-8b65eb0e8456">6.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfNC00LTEtMS0zMzg3MA_1ed7688e-27e6-4a31-8be8-a8844f0aa9dd">7.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfNS0yLTEtMS0zMzg3MA_b410d858-e838-474e-8af5-b1ccd53628f3">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfNS00LTEtMS0zMzg3MA_a36930f4-9864-49e6-a01e-3d5f06f6360f">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNTQ5Nw_4322f017-e89d-4d24-8493-eeeb9cfb4b26" continuedAt="i240cb165677d426f869c40b387554861" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i240cb165677d426f869c40b387554861" continuedAt="ifc9860eeb6e74f35a3f641e9d15f3b01"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="i7af89e8de2144f908cdf6eed480d28b4_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4NjUwMg_a514affa-2b8c-460c-ac82-14708c2dc2d1">175,083</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iba8a5ebb90254f6f8963f5d5f42509a0_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4NjUwNg_77bbdef4-b518-4860-b27b-6c5de65ea0ce">3,991,304</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others as of December&#160;31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorizes <ix:nonFraction unitRef="shares" contextRef="i90cda53c17144e44900529474c8dade0_I20210318" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMjE5OTAyMzI3ODA1OQ_62fe8999-c51b-4fbd-bf99-9bb592867054">8,000,000</ix:nonFraction> shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of December&#160;31, 2022, the total number of shares reserved for issuance under the 2021 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i2eda0cf364544def8987efed665491a6_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4ODQyMw_fcad36a0-d71b-41d0-9d85-a5d9a4475be6">7,155,527</ix:nonFraction> shares, which includes <ix:nonFraction unitRef="shares" contextRef="i47739b2328c247bab0fc929214a7ba52_D20221001-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4ODQzMw_71e0d293-35ef-4b47-9e97-2283b9f38a0e">136,972</ix:nonFraction> shares that were forfeited under the 2013 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were <ix:nonFraction unitRef="shares" contextRef="ie5eaa8a48bce4fa6b14d1cc81a3b2f78_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4ODYwNA_aa0bfb4d-c481-4991-9734-7fe6da6e431f">762,150</ix:nonFraction> shares reserved for options and <ix:nonFraction unitRef="shares" contextRef="if5d653e654b143c2b0c47570e75b7f38_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4ODYwOA_6506ac33-4814-42a9-bb55-422c99001c92">739,625</ix:nonFraction> shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMjE5OTAyMzI3ODA1Nw_b94491e4-dabf-4563-932b-3b2dab644484" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7af89e8de2144f908cdf6eed480d28b4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy0xLTEtMS00MDM3Mw_02a00669-92ca-4b3b-95d2-97b26574dbca">175,083</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iba8a5ebb90254f6f8963f5d5f42509a0_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy0zLTEtMS00MDY4MA_9ea7bbb3-8e39-4bf0-ae4c-df609eb115e2">1,685,543</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2eda0cf364544def8987efed665491a6_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy01LTEtMS00MDY4MA_907b84c1-1dcd-44a3-8b39-18c6ee54a01f">3,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie5eaa8a48bce4fa6b14d1cc81a3b2f78_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy03LTEtMS00MjQ5MQ_bd61efb1-be9d-445b-99a1-88d0f20fefb6">762,150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy03LTEtMS00MDY4OA_2a71d59e-c7f7-4bf8-886f-d538c4477112">2,625,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6801c6b77c1f498681559c7a2dce2274_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC0xLTEtMS00MDY4MA_4103b55c-a0a7-4c71-806c-1b9d08e6727e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5982379dbbec4d4c87792e3a1fcdf6b7_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC0zLTEtMS00MDY4MA_ec1d5628-525d-42e8-81a5-b3ece5493a29">2,305,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ieed10835a1c94a47a82efe00a8e128c3_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC01LTEtMS00MDY4MA_10825c2f-3ef4-4533-aece-f9f58dd28c0f">918,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if5d653e654b143c2b0c47570e75b7f38_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC03LTEtMS00MjQ5MQ_11fc747f-fa6e-4830-8afe-430314f9ccb8">739,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie3a67532b13e4f299f83c7328786c6b2_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC03LTEtMS00MDY4OA_267fcf31-2caa-4d71-8433-6a4a607786e2">3,964,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7af89e8de2144f908cdf6eed480d28b4_I20221231" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS0xLTEtMS00MDY4MA_023d115f-fd5d-4c10-b4d0-9c90d50d069f">175,083</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iba8a5ebb90254f6f8963f5d5f42509a0_I20221231" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS0zLTEtMS00MDY4MA_2e04df6a-7264-41cf-80fa-9e23dc2b3cef">3,991,304</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2eda0cf364544def8987efed665491a6_I20221231" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS01LTEtMS00MDY4MA_26ff4a51-a9a7-4662-93f4-2ea6fca77bff">921,795</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie5eaa8a48bce4fa6b14d1cc81a3b2f78_I20221231" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS03LTEtMS00MjQ5MQ_10361086-22d0-43e2-9da0-21c0f2a638f1">1,501,775</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS03LTEtMS00MDY4OA_b9dda023-daa7-4d38-9321-430eb44d8088">6,589,957</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNTQ5NA_d5f2bff3-e9bf-485a-a006-8fbc3036791f" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the three months ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMS0xLTEtMS0yODkwNA_dda9c353-9f45-4b11-98d5-7aa61d1dfefd">2,721,384</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMS0zLTEtMS0yODkwNA_ac469df0-a1bc-4825-a5b1-73e7ca559ae4">20.73</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMi0xLTEtMS0yODkwNA_e3a828ac-47fa-4f1b-b484-0001c6ef757e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMi0zLTEtMS0yODkwNA_37ac9415-1539-4bee-bd49-80c4e90f5303">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMy0xLTEtMS0yODkwNA_ac913c5f-1d04-400f-8a69-92ebde5333d7">13,875</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMy0zLTEtMS0yODkwNA_8e9530b5-c890-48f2-aa0d-9cd10e3640e3">45.57</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNC0xLTEtMS0yODkwNA_9d6f7456-f49d-4fd0-b42d-b9bfeca8c8af">81,733</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNC0zLTEtMS0yODkwNA_284fe6ee-a237-46ac-bf2c-7605e67ebb50">7.04</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNS0xLTEtMS0yODkwNA_4244b421-8a66-4dd0-8d71-596a593d6552">2,625,776</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNS0zLTEtMS0yODkwNA_4bd94663-3490-442f-9259-31ed2c05299e">21.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNS01LTEtMS0yODkwNA_17badbf6-e81f-4d69-ad0f-779d918f08a3">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNS03LTEtMS0yODkwNA_dba30ca0-0f69-4183-a544-add4d62fb823">61,867,396</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at December&#160;31, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNi0xLTEtMS0yODkwNA_d22ef150-21b9-48e9-b61e-df6272ff8e43">2,346,710</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNi0zLTEtMS0yODkwNA_efc748d9-120e-42a0-925e-dc3f8b7689a9">17.83</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNi01LTEtMS0yODkwNA_e48c62f0-c4d2-4726-828f-a3f582a32ebd">4.4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNi03LTEtMS0yODkwNA_a78d6f7a-19df-4887-a47f-eac769dcb64c">60,525,256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company&#8217;s closing stock price and the stock option exercise price) that would have been received by the stock option holders had all stock options been exercised on December&#160;31, 2022. The total intrinsic value of the options exercised during the three months ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i52d4a7405e154645aec245988ba1db1e_D20221001-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMTY0OTI2NzQ1NzQ4OA_90584f1e-122d-4ba4-b411-596ee2e31b6c">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieded460c29c84a3bae41035d3b604b0a_D20211001-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMTY0OTI2NzQ1NzUwNA_474f94ad-0236-4056-b61b-5925cf9d5eac">12.5</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options oustanding for the three months ended December&#160;31, 2022 and 2021, was $<ix:nonFraction unitRef="usd" contextRef="i52d4a7405e154645aec245988ba1db1e_D20221001-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMTY0OTI2NzQ1NzQzMg_a3d238d9-609b-45f8-94d9-6c37e2eefa0e">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieded460c29c84a3bae41035d3b604b0a_D20211001-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMTY0OTI2NzQ1NzQ0OA_e58974cd-c49a-4d6a-801b-7ab994f2d3a2">3.0</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $<ix:nonFraction unitRef="usd" contextRef="i7371c7b684f24f2ea135c09ba65d9460_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU5ODYxMQ_5c1b9a30-f67b-4faa-ae06-a249740189f6">9.5</ix:nonFraction> million will be recognized in the Company&#8217;s results of operations over a weighted average period of <ix:nonNumeric contextRef="i52d4a7405e154645aec245988ba1db1e_D20221001-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMjE5OTAyMzI3ODA2OQ_0bfc3ed8-20a2-4319-89ca-d2456be417b4">1.3</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifc9860eeb6e74f35a3f641e9d15f3b01"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. No options were granted during the three months ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNTQ5Ng_5164cdff-8ecf-4e12-ba3f-60d5e340a508" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia962a8cd9cbf48eab5243a5e151c89a3_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMS0xLTEtMS0yODkwNA_c93c3dad-049e-4fa3-87d2-b3111853017b">4,069,431</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia962a8cd9cbf48eab5243a5e151c89a3_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMS0zLTEtMS0yODkwNA_8adb4fcf-4b6f-4ad5-b0a2-d0b94c1f93dd">62.96</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMi0xLTEtMS0yODkwNA_2d265d1a-1b41-4305-bc91-1dae0f53d680">18,875</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMi0zLTEtMS0yODkwNA_bd6d5da0-8348-471d-ba02-1c2c13b7446f">31.77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMy0xLTEtMS0yODkwNA_2a99c5a5-e239-499a-b149-388204716f7c">98,250</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMy0zLTEtMS0yODkwNA_6d389bce-3472-443c-ba8c-9a089a955d61">51.70</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfNC0xLTEtMS0yODkwNA_333b2d2a-0f75-4bc8-849e-e728fe29363c">25,875</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfNC0zLTEtMS0yODkwNA_d30f9d84-970c-4513-a273-4906b4c4c64a">44.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ie3a67532b13e4f299f83c7328786c6b2_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfNS0xLTEtMS0yODkwNA_99a1bcba-cc4b-4398-a0ea-45fa0232b4f4">3,964,181</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3a67532b13e4f299f83c7328786c6b2_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfNS0zLTEtMS0yODkwNA_06adf065-1456-4608-9874-0c4ea08df3c0">63.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended December&#160;31, 2022 and 2021, the Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTYwMTk1NQ_4c4be914-b332-4136-852c-b87314dec7ac">17.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i54ad8857cb6d490a9939df3c07ff4518_D20211001-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTYwMTk2Mw_2efdd9f6-fee2-4e26-a981-e0355bd9e22f">21.5</ix:nonFraction> million, respectively, related to shares of RSUs. As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="ie3a67532b13e4f299f83c7328786c6b2_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTYwMjAwMQ_c4cff005-a1b4-4034-8ed7-575e6806004f">128.3</ix:nonFraction> million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTYwMjAxNQ_396ce3ce-f45f-4067-a324-a27fced82c0e">2.2</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RleHRyZWdpb246MWE4MDQwMDM1ZmY4NGZmYTlmMWVlYTkwM2VjMTY5ZGFfMTY0OQ_8e6183f3-ba9b-40b9-bfa8-bbd3b55e16f4" continuedAt="i19239b7df2e941c6adfe32fc44ce17ca" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i19239b7df2e941c6adfe32fc44ce17ca"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At December&#160;31, 2022 and September&#160;30, 2022, the Company did not have any financial assets or financial liabilities based on Level 3 measurements</span></div><ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RleHRyZWdpb246MWE4MDQwMDM1ZmY4NGZmYTlmMWVlYTkwM2VjMTY5ZGFfMTY1MA_3e30c408-6fa2-42f7-a778-bd280b561c3a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic12f642c28fd43bb8bf90642994bc4ea_I20221231" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNC0xLTEtMS0zMzk1Ng_a0e92fe3-c517-4cca-bd22-531c27d6646f">27,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d7c02af510c4a37adf92b11b0e43eaf_I20221231" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNC0zLTEtMS0zMzk1Ng_12e9851a-6e58-4f4c-9420-4bbd80f09965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia208947dbdb34f48ac070a4eaf8f6ab8_I20221231" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNC01LTEtMS0zMzk1Ng_9e402e21-af92-41d6-b997-7231a26c829d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i04b788dc055c47f289db232c658f93a3_I20221231" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNC03LTEtMS0zMzk1Ng_74257e78-3b37-482f-9bcc-7cbb27563e11">27,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4024a6c45e8b453eb06624488de7893b_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNS0xLTEtMS0zMzk1Ng_61fb2312-dccc-4f0a-a171-a8c8634d7978">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i39044bf341fe482cbbdce983d914bbec_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNS0zLTEtMS0zMzk1Ng_a76d0ce1-aacd-4c34-a412-720581e22079">104,311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if8310bcf25814821b30b9f25902a564d_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNS01LTEtMS0zMzk1Ng_c585d5c4-8930-48dd-b9f8-9df96f80e6d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b8edd077cc145338ae4844a504c6d15_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNS03LTEtMS0zMzk1Ng_0b97c854-1db9-4f6a-aef3-f3a5b3246f8a">104,311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e5f5182517047a2857c3e4a25738d82_I20221231" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNi0xLTEtMS0zMzk1Ng_6afb2acc-af89-424b-bfbf-e5a80a7a3865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia323910ecf904687b25c3160e49c81a9_I20221231" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNi0zLTEtMS0zMzk1Ng_cd88ba86-8c78-48dc-b893-bad87dcf0790">319,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ida69711b30dc4c71b1277eaf63e7bdd5_I20221231" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNi01LTEtMS0zMzk1Ng_123bd2f5-e942-4b79-ae19-d93414800bae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7481b819e6694390ada33ee48dd204bc_I20221231" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNi03LTEtMS0zMzk1Ng_d761efab-c845-4b0b-be9f-8da5c059c4a8">319,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0cba61c40f15431a97004a8eed248d67_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNy0xLTEtMS0zMzk1Ng_1417edfe-6f59-41f5-b9cb-f9c90f961628">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f8630cb003e4706a57151bdfa8dc88c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNy0zLTEtMS0zMzk1Ng_d50eb2fa-489b-4cc3-8907-8e7bd2e3340e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5851c535fb2c4a6ab422410bef2bbd02_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNy01LTEtMS0zMzk1Ng_48686be2-1d21-4b27-8c7a-65088a4505b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ied344ba18ef64e3d9de729f6de914532_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNy03LTEtMS0zMzk1Ng_cafd0f8e-0e95-42ce-8f97-dc9d0dcf38da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i452920e837684080b738d48ba1b27ff2_I20221231" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfOC0xLTEtMS0zMzk1Ng_4592ef43-1fc3-4f21-b243-9d6a3603212f">82,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7cd572b180c415db97822ca50b32ac9_I20221231" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfOC0zLTEtMS0zMzk1Ng_5b2f1d31-393d-442f-a8c3-c3880ee43a8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5fefec5d13e145909fc3b74408e1e444_I20221231" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfOC01LTEtMS0zMzk1Ng_5c7eabaa-02ed-4fcf-9e39-e9d400decb86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8c9ae1d799ee4d03923270e5ee1d6d21_I20221231" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfOC03LTEtMS0zMzk1Ng_504fd356-fb03-48db-98c5-34bf5d56a2c3">82,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4ce3b6dcc92d46758613038bc30d2d06_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNC0xLTEtMS0zMzk2MA_2bd5753b-f2f8-48ae-b654-52c162c2f150">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ieb6ea8e37eb3434eb30ea1ab2ceca664_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNC0zLTEtMS0zMzk2MA_683a9b17-c477-44ba-89a0-7d044b98e626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i39634f9fa175451b8ba8d5d58bf3740c_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNC01LTEtMS0zMzk2MA_45041b8c-29e1-4b06-b313-bbc37a4a8ed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7c4faae844d34e619c9019b81d17f07e_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNC03LTEtMS0zMzk2MA_15f44422-8b5b-4d84-b001-b1b2edcf2f3f">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ieb683bdc076a49628834f62824ed68f4_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNS0xLTEtMS0zMzk2MA_8839b792-6bae-42c1-b7c0-a5ccbe28bb49">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1a05dee7c43b439f82b54c288eea3838_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNS0zLTEtMS0zMzk2MA_0ae17dce-b7bd-463b-8698-6aa393654e23">41,727</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib0c9e1d3a53545b2ad24da42f70a1040_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNS01LTEtMS0zMzk2MA_3d8713af-9c12-4501-9c2e-53036cf5f7d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic813502c9a304662b9dfbd3942bd3230_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNS03LTEtMS0zMzk2MA_ee1762a2-5290-4809-bd68-3a4ef86cd8f9">41,727</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id85626261eb446dcaddc667f6dabc5cc_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNi0xLTEtMS0zMzk2MA_8212d001-4261-42fb-b9ee-6b3b1648cf79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i406ec781c5d644bdb1d8414e80314cc6_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNi0zLTEtMS0zMzk2MA_5cfee262-cb2e-48d4-8a38-e0186e19a69a">271,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i039e74dffa1f49d9a35ad0d64a55d837_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNi01LTEtMS0zMzk2MA_2a2e0fd0-8e88-4b76-9662-096163b1e0f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9f10fb8f48cc4003b37f0dce7bcf8710_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNi03LTEtMS0zMzk2MA_21e7b06d-7919-473f-9200-cff835bab756">271,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad0de95aea0445adaf44a4746fbc4967_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNy0xLTEtMS0zMzk2MA_31843ff4-4554-4c35-b852-17a42ac9fc2f">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1aa3981837334860a25583d48dd904d9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNy0zLTEtMS0zMzk2MA_68c4c156-c7b4-4e3a-8e7a-e8e145bacde4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i42efed8b98314bbfbbb3748a5f769fa7_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNy01LTEtMS0zMzk2MA_2c28a3a9-b7fa-4cc0-a286-c6d8df81e972">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i67a183941914437b8b3a7e507c345f29_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNy03LTEtMS0zMzk2MA_6edcef68-443f-47d2-9add-3407b00095f8">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i66a7f0c6944640a18b75bccffab1cb19_I20211231" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfOC0xLTEtMS0zODU3MA_3cb49a82-3d0c-4e81-b50b-c7d9871d6ac1">39,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i782e0824540f448daa350332d8e73bac_I20211231" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfOC0zLTEtMS0zODU3MA_94a590f3-5feb-4757-b1e6-f914cc8e6656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i582fc5eed03a4994b06179429d92df7d_I20211231" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfOC01LTEtMS0zODU3MA_0cd928dd-7331-4cb0-a8e2-ca86de29bc33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i462d644c71d546a9af599d5543f3d5c8_I20211231" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfOC03LTEtMS0zODU3MA_6fe29e61-55f6-4183-a6bc-a6fe0d6754b0">39,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231" name="arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODM3MA_c6bd7e4a-ce54-4ca6-9843-56a763df7b3b" continuedAt="i7c484220458f4d5899890226ba09c4a0" escape="true">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><ix:continuation id="i7c484220458f4d5899890226ba09c4a0" continuedAt="ia99a769e99b4436896129dabaeb53b88"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="ifd2e69018bdb4a98bb2a58ba8c80e25a_D20221109-20221109" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODM5OQ_bd9e6d4a-ee93-476b-b11a-3866db50284a">410.0</ix:nonFraction>&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $<ix:nonFraction unitRef="usd" contextRef="i645dd71143994cfd81a4843c13790bbb_D20221109-20221109" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQxNQ_45ec8fb4-99fe-46e6-8b20-94a8f6ba833c">250.0</ix:nonFraction>&#160;million upfront and agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQzMQ_44fb32e0-722e-469c-9ad8-9ff4c0291513">160.0</ix:nonFraction>&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $<ix:nonFraction unitRef="usd" contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQ0Nw_dba3ee51-f14b-4507-9a73-5f870283620b">50.0</ix:nonFraction>&#160;million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $<ix:nonFraction unitRef="usd" contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivableUponFDAApproval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQ2Mg_50a4ea58-db4c-4e9d-a2fb-e936cf5b3457">50.0</ix:nonFraction>&#160;million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $<ix:nonFraction unitRef="usd" contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQ3Nw_87da7fb5-0616-45d9-a245-35b3295fdc0f">60.0</ix:nonFraction>&#160;million upon Royalty Pharma&#8217;s receipt of at least $<ix:nonFraction unitRef="usd" contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109" decimals="-5" name="arwr:RoyaltyPaymentThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQ5Mg_df57c94c-1a5a-4655-8d3e-5358e02740d7">70.0</ix:nonFraction>&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia99a769e99b4436896129dabaeb53b88">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $<ix:nonFraction unitRef="usd" contextRef="ia4521874a9864ab3bed52ad5aa487856_I20221231" decimals="-5" name="arwr:LiabilitySaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODUwNw_4431c8e1-f44b-420e-9be3-1bf706d58c7c">250.0</ix:nonFraction>&#160;million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate quarterly based on its current revenue forecasts utilizing the prospective method. For the three months ended December&#160;31, 2022, the Company recognized non-cash interest expense of $<ix:nonFraction unitRef="usd" contextRef="icba7f05878cb48c783c8d12cf1ff5540_D20221001-20221231" decimals="-5" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODM4NQ_a345bf44-1a89-4348-867f-a80e0cc349cf">2.8</ix:nonFraction>&#160;million on the consolidated statements of operations and comprehensive loss.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Quarterly Report on Form 10-Q except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;forecast&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements included herein are based on current expectations of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond the Company&#8217;s control. As such, our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated or indicated in any forward-looking statements. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and cash flows may differ materially. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in &#8220;Item 1. Business&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8221; of Part I and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part II of the Company&#8217;s most recent Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents the Company files from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;), including this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2022. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Statements made herein are as of the date of the filing of this Quarterly Report on Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_70"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNAi  mechanism to induce rapid, deep and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has focused its resources on therapeutics that exclusively utilize its high levels of pharmacologic activity in multiple animal models spanning several therapeutic areas. The Company believes that TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enabled therapeutics offer several potential advantages over prior generation and competing technologies, including: simplified manufacturing and reduced costs; multiple routes of administration including subcutaneous injection and inhaled administration; the ability to target multiple tissue types including liver, lung, muscle and others; and the potential for improved safety and reduced risk of intracellular buildup, because there are fewer metabolites from smaller, simpler molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pipeline includes:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Hypertriglyceridemia - ARO-APOC3</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Dyslipidemia - ARO-ANG3</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Facioscapulohumeral muscular dystrophy - ARO-DUX4</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Complement mediated diseases - ARO-C3</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Muco-obstructive or inflammatory pulmonary conditions - ARO-RAGE and ARO-MUC5AC</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Idiopathic pulmonary fibrosis - ARO-MMP7</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Liver disease - ARO-HSD (out-licensed to GSK)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Uncontrolled gout - HZN-457 (formerly ARO-XDH, out-licensed to Horizon)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Non-alcoholic steatohepatitis (NASH) - NJ-75220795 (formerly ARO-JNJ1, out-licensed to Janssen) </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) - Fazirsiran (formerly ARO-AAT, a collaboration with Takeda)</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Chronic hepatitis B virus - JNJ-3989 (formerly ARO-HBV, out-licensed to Janssen) </span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cardiovascular disease - Olpasiran (formerly AMG 890 or ARO-LPA, out-licensed to Amgen) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to develop other clinical candidates for future clinical trials. Clinical candidates are tested internally and through GLP toxicology studies at outside laboratories. Drug materials for such studies and clinical trials are either manufactured internally or contracted to third-party manufacturers. The Company engages third-party contract research organizations (&#8220;CROs&#8221;) to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up. These outside costs, relating to the preparation for and administration of clinical trials, are referred to as &#8220;candidate costs.&#8221; As clinical candidates progress through clinical development, candidate costs will increase. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The First Quarter Business Highlights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key recent developments during the first quarter of fiscal 2023 included the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety tolerability, pharmacokinetics and pharmacodynamics of a development-stage medicine, HZN-457 (previously known as ARO-XDH), which is out-licensed to Horizon, triggering a $15.0 million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="background-color:#def3c0;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in Amgen&#8217;s Phase 3 trial of Olpasiran, which triggered a $25.0 million milestone payment to the Company, which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">entered into the Royalty Pharma Agreement on November 9, 2022, pursuant to which Royalty Pharma paid $250.0 million upfront (See Note 11 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced top line results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease in which:</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Fibrosis regression was observed in 50% of patients receiving Fazirsiran;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Median reductions of 94% of Z-AAT accumulation in the liver and mean reductions of 68% in histologic globule burden were observed;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Treatment emergent adverse events were generally well balanced between Fazirsiran and placebo groups;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Results were consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $41.3 million for the three months ended December&#160;31, 2022 as compared to net loss of $62.9 million for the three months ended December&#160;31, 2021. Net loss per share &#8211; diluted was $0.39 for the three months ended December&#160;31, 2022 as compared to net loss per share &#8211; diluted of $0.60 for the three months ended December&#160;31, 2021. The decrease in net loss for the three months ended December&#160;31, 2022 was due to an increase in revenue from the Company&#8217;s license and collaboration agreements, primarily from the license agreements with Horizon, Takeda and Amgen, partially offset by increased research and development and general and administrative expenses, which have continued to increase as the Company&#8217;s pipeline of candidates has expanded and progressed through clinical trial phases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $202.2 million of cash, cash equivalents and restricted cash, $299.6 million in short-term investments, $115.8 million of long-term investments and $891.5 million of total assets as of December&#160;31, 2022, as compared to $108.0 million of cash, cash equivalents and restricted cash, $268.4 million in short-term investments, $105.9 million of long-term investments and $691.9 million of total assets as of September&#160;30, 2022. Based upon the Company&#8217;s </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund operations for at least the next twelve months. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the Company&#8217;s critical accounting estimates disclosed in the most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_73"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following data summarizes the Company&#8217;s results of operations for the following periods indicated: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"><tr><td style="width:1.0%"></td><td style="width:68.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(62,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss per share-diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue for the three months ended December&#160;31, 2022 increased to $62.5 million, 127.9% from the same period of 2021. The increase was primarily driven by the revenue recognition associated with Horizon, Takeda and Amgen license agreements, as discussed below. The Company has evaluated each agreement in accordance with FASB Topic 808&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Topic 606-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Horizon and the Company entered into the Horizon License Agreement. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon is responsible for managing future clinical development and commercialization of HZN-457. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocates the total $40.0 million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;D Services. Revenue is recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2022, Horizon announced that it enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $15.0 million milestone payment to the Company which was paid in the second quarter of fiscal 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended December&#160;31, 2022 and 2021 were $21.7 million and $6.7 million, respectively. There were $15.0 million in contract assets recorded as accounts receivable and $0 in contract liabilities recorded as deferred revenue as of December 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, Takeda and the Company entered into the Takeda License Agreement. At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of Fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $300.0 million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the Fazirsiran license and the associated Takeda R&amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company recognized $16.3 million and $20.8 million in connection with these efforts for the three months ended December&#160;31, 2022 and 2021, respectively. There were $0 of contract assets recorded as accounts receivable and $107.1 million of contract liabilities recorded as deferred revenue, of which $66.3&#160;million was classified as current deferred revenue, as of December&#160;31, 2022. The Company also recorded $9.8 million as accrued expenses as of December 31, 2022 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Olpasiran Agreement, Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi Olpasiran program. Olpasiran is designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Amgen is wholly responsible for clinical development and commercialization. The Company has substantially completed its performance obligations under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in November 2022, Royalty Pharma and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2022, Amgen enrolled the first subject in its Phase 3 trial of Olpasiran, which triggered a $25.0 million milestone payment to the Company, which was paid in the second quarter of fiscal 2023. The Company is further eligible to receive up to an additional $535 million in aggregate development, regulatory, and sales milestone payments from Amgen and Royalty Pharma. Revenue for the three months ended December&#160;31, 2022 and 2021 were $25.0 million and $0, respectively. There were $25.0 million in contract assets recorded as accounts receivable and $0 in contract liabilities recorded as deferred revenue as of December 31, 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. For purposes of comparison, the amounts for the three months ended December&#160;31, 2022 and 2021 are shown in the tables below. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are related to the Company&#8217;s research and development discovery efforts and related candidate costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses. Internal costs primarily relate to discovery operations at the Company&#8217;s research facilities in San Diego, California and Madison, Wisconsin, including facility costs and laboratory-related expenses. The Company does not separately track R&amp;D expenses by individual research and development projects, or by individual drug candidates. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of research and development expenses for the three months ended December 31:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,402&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,218&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Candidate costs increased $9.9 million to $42.3 million for the three months ended December&#160;31, 2022 compared to $32.3 million for the same period of 2021. This increase was primarily due to the progression of the Company&#8217;s pipeline of candidates into and through clinical trials, which resulted in higher outsourced clinical trial, toxicity study and manufacturing costs. For example, the Company&#8217;s cardiometabolic candidates, ARO-ANG3 and ARO-APOC3, have advanced into Phase 2 and Phase 3 clinical trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D discovery costs increased $1.7 million to $12.7 million for the three months ended December&#160;31, 2022 compared to $11.0 million for the same period of 2021. This increase was due to the growth of the Company&#8217;s discovery efforts and continued advancement into novel therapeutic areas and tissue types. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and stock compensation expense consist of salary, bonuses, payroll taxes, related benefits and stock compensation for the Company&#8217;s R&amp;D personnel. The increases in salaries and stock comp expenses were primarily due to an increase in R&amp;D headcount that has occurred as the Company has expanded its pipeline of candidates, in addition to annual salary increases. Stock compensation expense was based upon the valuation of stock options and restricted stock units granted to employees, directors and certain consultants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities-related expense included lease costs for the Company&#8217;s research and development facilities in San Diego, California and Madison, Wisconsin. Facilities-related costs increased $1.3 million to $3.3 million for the three months ended December&#160;31, 2022, compared to $2.0 million for the same period of 2021. This increase was mainly due to the additional lease expense as the Company expands discovery efforts to identify new drug candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of depreciation and amortization expense, a non-cash expense, relates to depreciation on lab equipment and leasehold improvements at the facilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates these R&amp;D expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods and services and the labor market. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of the Company&#8217;s general and administrative expenses for the three months ended </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Professional, outside services, and others </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total general &amp; administrative expense, excluding non-cash expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,595&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,300)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total general &amp; administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,995&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,010)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries expense increased $0.8 million to $4.2 million for the three months ended December&#160;31, 2022 compared to $3.4 million for the same period of 2021. The increase was driven by the combination of annual salary increases and increased headcount required to support the Company&#8217;s growth. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional, outside services, and others expense includes legal, consulting, patent expenses, business insurance expenses, other outside services, travel, and communication and technology expenses. This expense increased $1.2 million to $4.4 million for the three months ended December&#160;31, 2022 compared to $3.2 million for the same period of 2021. The increase was mainly due to consulting expenses related to software implementation and administrative expenses in support of additional headcount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities related expense primarily includes rental costs and other facilities-related costs for the Company&#8217;s corporate headquarters in Pasadena, California. Depreciation and amortization expense, a noncash expense, was primarily related to amortization of leasehold improvements for the Company&#8217;s corporate headquarters. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, decreased by $6.3 million to $11.0 million for the three months ended December&#160;31, 2022 compared to $17.3 million for the same period of 2021. The decrease in the current period was mainly due to the reversal of recognized compensation costs related to a performance award where the minimum performance goal was not met. The fair value of market condition-based awards was expensed ratably over the service period and was not adjusted for actual achievement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates these general and administrative expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods and services and the labor market. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is primarily related to interest income and realized and unrealized gain/loss on investments. Other income decreased $0.1 million to $0.3 million for the three months ended December&#160;31, 2022 compared to $0.4 million for the same period of 2021. The decrease was due to the interest expense on the liability related to the sale of future royalties, offset by higher yields on investments due to increased interest rates as well as credits the Company received during the first quarter of fiscal 2023. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically financed its operations through the sale of its common stock, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure as the Company&#8217;s pipeline continues to expand and matures into later stage clinical trials. Additionally, the Company plans to expand its facilities with its purchase of land in Verona, Wisconsin, and its entry into a new lease in San Diego, California. Each of these expansions is designed to increase the Company&#8217;s internal manufacturing and discovery capabilities, and each will require significant capital investment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and restricted cash increased to $202.2 million at December&#160;31, 2022 compared to $108.0 million at September&#160;30, 2022. Cash invested in short-term fixed income securities was $299.6 million at December&#160;31, 2022 compared to $268.4 million at September&#160;30, 2022. Cash invested in long-term fixed income securities was $115.8 million at December&#160;31, 2022, compared to $105.9 million at September&#160;30, 2022. On December 2, 2022, the Company entered into the Open Market Sale Agreement, pursuant to which the Company may, from time to time, sell up to $250.0 million in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. As of  December&#160;31, 2022, no shares have been issued under the Open Market Sale Agreement. The Company believes its current financial resources are sufficient to fund its operations through at least the next twelve months. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of cash flows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash Flow from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(75,516)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(61,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(80,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(33,385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">250,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">94,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(92,808)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">202,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">91,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2022, cash flows used by operating activities was $75.5 million, which was primarily due to the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses, partially offset by the receipt of $6.0&#160;million from GSK (see Note 2 &#8212; Collaboration and License Agreements to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221;) and Horizon. Cash used in investing activities was $80.7 million, which was primarily related to capital expenditures, primarily construction in progress, of $38.9 million and investments of $111.2 million, offset by net sales and maturities of investments of $69.4 million. Cash provided by financing activities of $250.6 million was primarily related to the $250.0 million payment from Royalty Pharma as well as cash received from stock option exercises.</span><span style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2021, cash flows used by operating activities was $61.3 million, which was primarily related to ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses. Cash used in investing activities was $33.4 million, which was primarily related to the purchase of property and equipment of $5.8 million and net purchases of investments of $27.6 million. Cash provided by financing activities of $1.9 million was related to cash received from stock option exercises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company intends to invest between $200.0&#160;million and $260.0&#160;million into the build out of the facilities with cash on hand. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and expects to be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona is expected to pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property. The Company also expects receive up to $2.5&#160;million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> exposure to market risk from that described in Item 7A of its Annual Report on Form 10-K for the year ended September 30, 2022.</span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in its reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of its management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures as of the end of the quarter covered by this Quarterly Report on Form 10-Q. Based on the foregoing, the Company&#8217;s Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in the Company&#8217;s internal control over financial reporting during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company&#8217;s process for evaluating controls and procedures is continuous and encompasses constant improvement of the design and effectiveness of established controls and procedures and the remediation of any deficiencies which may be identified during this process.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of its business. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of legal proceedings, particularly complex legal proceedings, cannot be predicted with any certainty. There have been no material developments in the legal proceedings that the Company disclosed in Part I, Item 3 of its Annual Report on Form 10-K for the year ended September 30, 2022.</span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business, results of operations and financial conditions are subject to various risks. These risks are described elsewhere in this Quarterly Report on Form 10-Q and in the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s other filings with the SEC, including the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Annual report on Form 10-K for the year ended September 30, 2022. There have been no material changes from the risk factors identified in the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Annual Report on Form 10-K for the year ended September 30, 2022.</span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable. </span></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Document Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.1 of the Company&#8217;s Form 8-K filed on April 6, 2016)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit32.htm">Second Amended and Restated Bylaws (incorporated by reference from Exhibit 3.1 of the Company&#8217;s Form 8-K filed on January 30, 2023)</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit101.htm">Royalty Purchase Agreement, dated as of November 9, 2022, by and between Arrowhead Pharmaceuticals, Inc. and Royalty Pharma Investments 2019 ICAV. </a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20221231xexx311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20221231xexx312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20221231xexx321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-20221231xexx322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document </span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">Furnished herewith.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i9e436183b5b546b1bf8bde17c7a99c90_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: February&#160;6, 2023</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Kenneth A. Myszkowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kenneth A. Myszkowski<br/>Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exhibit31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5c02218a8dd14e3e8aa5c5f150ae9412_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMENDED AND RESTATED<br>CERTIFICATE OF INCORPORATION<br><br>OF<br><br>ARROWHEAD RESEARCH CORPORATION<br>(a Delaware corporation)</font></div><div><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Arrowhead Research Corporation, a corporation organized and existing under the laws of the State of Delaware (the &#8220;Corporation&#8221;), does hereby certify as follows&#58;</font></div><div style="text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">The name of the Corporation is Arrowhead Research Corporation. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on February 13, 2001 under the Corporation&#8217;s former name, InterActive Group, Inc.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">This Amended and Restated Certificate of Incorporation has been duly authorized and adopted by the Board of Directors of the Corporation in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Effective as of 4&#58;01 p.m. (Eastern Time) on April 6, 2016, the Corporation&#8217;s Certificate of Incorporation shall be amended and restated in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FIRST&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The name of the corporation is Arrowhead Pharmaceuticals, Inc. (the &#8220;Corporation&#8221;).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECOND&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The address of the Corporation&#8217;s registered office in the State of Delaware is 2140 South Dupont Hwy, Camden, Kent County, Delaware 19934. The name of its registered agent at such address is Paracorp Incorporated.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THIRD&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FOURTH&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The total number of shares which the Corporation shall have authority to issue is 150,000,000, of which 145,000,000 shares shall be common stock, $.001 par value (&#8220;Common Stock&#8221;), and 5,000,000 shares shall be preferred stock, $.001 par value (&#8220;Preferred Stock&#8221;). The Board of Directors (the &#8220;Board&#8221;) is authorized, subject to the limitations prescribed by law and the provisions of this Article FOURTH, to provide for the issuance of the Preferred Stock in series, and by filing a certificate pursuant to the applicable laws of the State of Delaware, to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof. The authority of the Board with respect to each such series shall include, but not be limited to, the determination of the following&#58; (a) The number of shares constituting that series and the distinctive designation of that series&#59; (b) The dividend rate, if any, on the shares of that series, whether dividends shall be cumulative, and, if so, from which date or dates, and the relative priority, if any, of payment of dividends on shares of that series&#59; (c) Whether that series shall have voting rights, in addition to the voting rights expressly required by law, and, if so, the terms of such voting rights&#59; (d) Whether that series shall have conversion privileges, and, if so, the terms and conditions of such conversion, including provisions for adjustment of the conversion rate in such events as the Board shall determine&#59; (e) Whether or not the shares of that series shall be redeemable, and, if so, the terms and conditions of such redemption, including the date or dates upon or after which they shall be redeemable, and the amount per share payable in the case of redemption, which amount may vary under different conditions and at different redemption dates&#59; (f) Whether that series shall have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such sinking fund&#59; (g) The rights of the shares of that series in the event of a voluntary or involuntary liquidation, dissolution or winding up of the Corporation, and the relative rights of priority, if any, of payment of shares of that series&#59; and (h) Any other relative rights, preferences and limitations of that series.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Series C Convertible Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the authority conferred by this Article FOURTH upon the Board, the Board created a series of 46,000 shares of Preferred Stock designated as Series C Convertible Preferred Stock by filing a certificate of designations with the Secretary of State of the State of Delaware on October 10, 2013. The voting powers, designations, preferences and relative, participating, optional or other special rights, and the qualifications, limitations and restrictions thereof, of the Series C Convertible Preferred Stock of the Corporation are as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto and are incorporated herein by reference.<br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FIFTH&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Board is expressly authorized to make, alter or repeal the Bylaws of the Corporation, but the stockholders may make additional Bylaws and may alter or repeal any bylaw whether adopted by them or otherwise.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIXTH&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Elections of directors need not be by written ballot except to the extent provided in the Bylaws of the Corporation.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SEVENTH&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;A director of the Corporation shall not be liable to the Corporation or any of its stockholders for monetary damages for breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL as the same exists or may hereafter be amended. Any repeal or modification of the foregoing paragraph by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation in respect of any act or omission occurring prior to the time of such repeal or modification.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIGHTH&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Corporation reserves the right at any time and from time to time to amend, alter, change or repeal any provision contained in this Certificate of Incorporation in the manner now or hereafter prescribed by law, and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons whomsoever by and pursuant to this Certificate of Incorporation in its present form or as hereafter amended are granted subject to the right reserved in this Article EIGHTH.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Remainder of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:center"><font><br></font></div></div></div><div id="i5c02218a8dd14e3e8aa5c5f150ae9412_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-right:-19.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Arrowhead Research Corporation has caused this Amended and Restated Certificate of Incorporation to be signed by the undersigned duly authorized officer on this 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> day of April, 2016.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARROWHEAD RESEARCH CORPORATION</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.277%"><tr><td style="width:1.0%"></td><td style="width:11.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Anzalone</font></div><div style="padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Amended &#38; Restated Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div></div></div><div id="i5c02218a8dd14e3e8aa5c5f150ae9412_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ANNEX A</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARROWHEAD RESEARCH CORPORATION</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATE OF DESIGNATION OF PREFERENCES,<br>RIGHTS AND LIMITATIONS<br>OF<br>SERIES C CONVERTIBLE PREFERRED STOCK</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>PURSUANT TO SECTION 151 OF THE<br>DELAWARE GENERAL CORPORATION LAW<br></font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  For the purposes of this Annex A, the following terms shall have the following meanings&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(d).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(c)(iv).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Securities and Exchange Commission.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Corporation&#8217;s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities may be reclassified or changed after October 10, 2013.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the sum of the Stated Value at issue.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(a).  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(b).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock in accordance with the terms hereof.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7(c).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date that the Resale Registration Statement filed by the Corporation pursuant to the Purchase Agreement first becomes effective under the Securities Act.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7(d).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given such term in Section 2.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-1</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Junior Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Common Stock and all other Common Stock Equivalents of the Corporation other than those securities which are explicitly senior or pari passu to the Series C Preferred Stock in dividend rights or liquidation preference.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 5.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">New York Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 8(d).  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(a).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Original Issue Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date of the first issuance of any shares of the Series C Preferred Stock regardless of the number of transfers of any particular shares of Series C Preferred Stock and regardless of the number of certificates which may be issued to evidence such Series C Preferred Stock.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Securities Purchase Agreement, dated October 8, 2013, among the Corporation and the original Holders, as amended, modified or supplemented from time to time in accordance with its terms.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reference Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7(d).  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reference Property Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7(d).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Resale Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a registration statement that registers the resale of the Conversion Shares of the Holders, who shall be named as &#8220;selling stockholders&#8221; therein and meets the requirements of the Purchase Agreement.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Series C Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Share Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 6(c)(i).  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stated Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any Subsidiary of the Corporation as defined in the Purchase Agreement and shall, where applicable, also include any direct or indirect subsidiary of the Corporation formed or acquired after the date of the Purchase Agreement.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Successor Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 7(d).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a day on which the principal Trading Market is open for business.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question&#58; the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Purchase Agreement, this Certificate of Designation and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Computershare Trust Company, N.A., the current transfer agent for the Common Stock, and any successor transfer agent of the Corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-2</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Designation, Amount and Par Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The series of preferred stock shall be designated as the Corporation&#8217;s Series C Convertible Preferred Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Series C Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and the number of shares so designated shall be 46,000 (which shall not be subject to increase without the written consent of a majority of the holders of the Series C Preferred Stock (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)).  Each share of Series C Preferred Stock shall have a par value of $0.001 per share and a stated value equal to $1,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stated Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Dividends&#59; Restrictions on Repurchases and Redemptions of Junior Securities&#58; No Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-Common-Stock basis, without regard to any limitation in Section 6(d) on the conversion of the Series C Preferred Stock) to and in the same form, and in the same manner, as dividends (other than dividends in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock) are paid on shares of the Common Stock.  Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series C Preferred Stock&#59; and the Corporation shall pay no dividends (other than dividends in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Repurchases and Redemptions of Junior Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  So long as any Series C Preferred Stock shall remain outstanding, the Corporation shall not redeem, purchase or otherwise acquire directly or indirectly more than a de minimis amount of any Junior Securities other than as to repurchases of Common Stock or Common Stock Equivalents from departing, officers, directors or employees of the Company or any Subsidiary, and provided that, while any of the Series C Preferred Stock remains outstanding, such repurchases shall not exceed an aggregate of $100,000 in any fiscal year.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Series C Preferred Stock shall not be redeemable at the election of the Corporation.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In addition to the voting rights provided by applicable law, the Series C Preferred Stock shall have the right to vote on any matter on which the Common Stock is eligible to vote on an as-if-converted-to-Common-Stock basis&#59; provided that each Holder shall only have the right to vote such shares of Series C Preferred Stock as are eligible for conversion without exceeding the Beneficial Ownership Limitation.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), after the satisfaction in full of the debts of the Corporation and the payment of any liquidation preference owed to the holders of shares of capital stock of the Corporation ranking prior to the Series C Preferred Stock upon liquidation, the Holders of the Series C Preferred Stock shall participate pari passu with the holders of the Common Stock (on an as-if-converted-to-Common-Stock basis without regard to any limitation in Section 6(d) on the conversion of the Series C Preferred Stock) in the net assets of the Corporation.  The Corporation shall mail written notice of any such Liquidation, not less than 45 days prior to the payment date stated therein, to each Holder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-3</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conversions at Option of Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each share of Series C Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section 6(d)) determined by dividing the Stated Value of such share of Series C Preferred Stock by the Conversion Price in effect on the Conversion Date for such conversion, subject to Section 6(c)(vi).  Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as Exhibit A (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Each Notice of Conversion shall specify the number of shares of Series C Preferred Stock to be converted, the number of shares of Series C Preferred Stock owned prior to the conversion at issue, the number of shares of Series C Preferred Stock owned subsequent to the conversion at issue and the date on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers (as provided in Section 8(a)) such Notice of Conversion to the Corporation (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder.  The calculations and entries set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.  No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required.  To effect conversions of shares of Series C Preferred Stock, a Holder shall not be required to surrender the certificate(s) representing the shares of Series C Preferred Stock to the Corporation unless all of the shares of Series C Preferred Stock represented thereby are so converted, in which case such Holder shall deliver the certificate representing such shares of Series C Preferred Stock promptly following the Conversion Date at issue.  Shares of Series C Preferred Stock converted into Common Stock in accordance with the terms hereof or repurchased by the Corporation shall be canceled and shall not be reissued.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The conversion price for the Series C Preferred Stock shall initially equal $5.86, subject to adjustment as provided herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Mechanics of Conversion</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Delivery of Certificate Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Not later than three (3) Trading Days after each Conversion Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Share Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Corporation shall deliver, or cause to be delivered, to the converting Holder a certificate or certificates representing the applicable Conversion Shares which, on or after the earlier of (i) the one-year anniversary of the Original Issue Date or (ii) the Effective Date, shall be free of restrictive legends and trading restrictions (other than those which may then be required by the Purchase Agreement) representing the number of Conversion Shares being acquired upon the conversion of the Series C Preferred Stock.  Subject to clauses (ii) and (iv)(B) below, on the Conversion Date with respect to any Conversion Shares, the Person to which such Conversion Shares are to be issued shall be deemed to be the holder of record of such Conversion Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that, subject to clauses (ii) and (iv)(B) below, if such Conversion Date occurs after a record date for the payment of dividends on the Series C Preferred Stock pursuant to Section 3(a) and prior to the related dividend payment date, then such Person shall be deemed to have been the holder of record of such Conversion Shares on such record date (and, for the avoidance of doubt, will be entitled to receive such dividends in respect of such Conversion Shares on such dividend payment date).  On or after the earlier of (i) the one-year anniversary of the Original Issue Date or (ii) the Effective Date, the Corporation shall use its best efforts to deliver any certificate or certificates required to be delivered by the Corporation under this Section 6 electronically through the Depository Trust Company or another established clearing corporation performing similar functions.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Failure to Deliver Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If, in the case of any Notice of Conversion, such certificate or certificates are not delivered to or as directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation at any time on or before its receipt of such certificate or certificates, to rescind such Conversion, in which event the Corporation shall promptly return to the Holder any original Series C Preferred Stock certificate delivered to the Corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-4</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Obligation Absolute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series C Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that such delivery shall not operate as a waiver by the Corporation of any such action that the Corporation may have against such Holder.  In the event a Holder shall elect to convert any or all of the Stated Value of its Series C Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law or agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and&#47;or enjoining conversion of all or part of the Series C Preferred Stock of such Holder shall have been sought and obtained, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the Stated Value of Series C Preferred Stock which is subject to the injunction, which bond shall remain in effect until the completion of arbitration&#47;litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment.  In the absence of such injunction, the Corporation shall issue Conversion Shares and, if applicable, cash, upon a properly noticed conversion.  Nothing herein shall limit a Holder&#8217;s right to pursue all remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and&#47;or injunctive relief.  The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iv.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In addition to any other rights available to the Holder, if the Corporation fails for any reason to deliver to a Holder the applicable certificate or certificates by the Share Delivery Date pursuant to Section 6(c)(i), and if on or after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount, if any, by which (x) such Holder&#8217;s total purchase price (or, in the case of a purchase by such brokerage firm, the cost charged by such brokerage firm to such Holder with respect thereto) (including any brokerage commissions) for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue and which was the subject of such sale multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such Holder, either reissue (if surrendered) the shares of Series C Preferred Stock equal to the number of shares of Series C Preferred Stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section 6(c)(i).  For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Series C Preferred Stock with respect to which the actual sale price of the Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000.  The Holder shall provide the Corporation written notice indicating the amounts payable to such Holder in respect of the Buy-In and, upon request of the Corporation, evidence of the amount of such loss.  Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series C Preferred Stock as required pursuant to the terms hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-5</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">v.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reservation of Shares Issuable Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series C Preferred Stock, as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other Holders of the Series C Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall (subject to the terms and conditions set forth herein) be issuable (taking into account the adjustments and restrictions of Section 7) upon the conversion of the then-outstanding shares of Series C Preferred Stock.  The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable and, if the Resale Registration Statement is then effective under the Securities Act, shall be registered for public resale in accordance with such Resale Registration Statement (subject to such Holder&#8217;s compliance with its related obligations under the Purchase Agreement).</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">vi.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the conversion of the Series C Preferred Stock.  As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price in effect on the relevant Conversion Date or round up to the next whole share.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">vii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Taxes and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The issuance of certificates for shares of the Common Stock upon conversion of the Series C Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the Holders of such Series C Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.  The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of the Series C Preferred Stock, and a Holder shall not have the right to convert any portion of the Series C Preferred Stock, in each case to the extent that, after giving effect to such conversion, such Holder would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of this Section 6(d), beneficial ownership of a Holder shall be calculated in accordance with Section 16(a) and (b) of the Exchange Act and the rules and regulations promulgated thereunder for purposes of determining whether such Holder is subject to the reporting and liability provisions of Section 16(a) and 16(b) of the Exchange Act.  For purposes of complying with this Section 6(d), the Corporation shall be entitled to conclusively rely on the information set forth in any Holder&#8217;s Notice of Conversion, and each Holder delivering a Notice of Conversion shall be deemed to represent to the Corporation that such Notice of Conversion does not violate the restrictions set forth in this paragraph, and the Corporation shall have no obligation to verify or confirm the accuracy of such representation.  Upon the written or oral request of a Holder, the Corporation shall, within two Trading Days, confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding.  The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Series C Preferred Stock held by the applicable Holder.  By written notice to the Company, a Purchaser may from time to time increase or decrease the Beneficial Ownership Limitation applicable solely to such Purchaser to any other percentage not in excess of 19.99% specified in such notice&#59; provided that any such increase will not be effective until the sixty-fifth (65th) day after such notice is delivered to the Company.  The express purpose of this Section 6(d) is to preclude any Holder&#8217;s ownership of any shares of Series C Preferred Stock from causing such Holder to become subject to the reporting and liability provisions of Section 16(a) and 16(b) of the Exchange Act, including pursuant to Rule 16a-2 promulgated by the Commission, and this Section 6(d) shall be interpreted according to such express purpose.  Solely for purposes of this Section 6(d) and for purposes of the provisos to Section 7(b) and (c) hereof, the term &#8220;Holder&#8221; shall include all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-6</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">persons whose beneficial ownership of the Common Stock is aggregated pursuant to Section 13(d)(3) of the Exchange Act or Rule 13d-5 thereunder.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Adjustments&#58; Rights of Holders Upon Certain Dividends, Distributions or Fundamental Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Dividends and Stock Splits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If the Corporation, at any time while any Series C Preferred Stock is outstanding&#58; (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock, (ii) subdivides outstanding shares of Common Stock into a larger number of shares or (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Price shall be adjusted to equal adjustment multiplied by a fraction of which the numerator shall be the number of shares of Common an amount equal to such Conversion Price immediately before such Stock outstanding immediately before giving effect to such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately after giving effect to such event.  Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination, as applicable.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Subsequent Rights Offerings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase  Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), then, without duplication of any dividends to be due on Series C Preferred Stock pursuant to Section 3(a), each Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if such Holder had held the number of shares of Common Stock acquirable upon conversion of such Holder&#8217;s Series C Preferred Stock (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) on the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that, to the extent that any Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Purchase Rights to which such Holder is entitled pursuant hereto shall be limited to the same extent provided in Section 6(d) hereof.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Pro Rata Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  During such time as the Series C Preferred Stock is outstanding, if the Corporation declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), at any time after the issuance of the Series C Preferred Stock, then, in each such case, without duplication of any dividends to be due on Series C Preferred Stock pursuant to Section 3(a), each Holder shall be entitled to participate in such Distribution to the same extent that such Holder would have participated therein if such Holder had held the number of shares of Common Stock acquirable upon complete Conversion of the Series C Preferred Stock (without regard to any limitations on Conversion hereof, including without limitation, the Beneficial Ownership Limitation) on the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that, to the extent that any Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the rights appurtenant to such securities, property or options to which such Holder is entitled pursuant hereto shall be limited to the same extent provided in Section 6(d) hereof. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If, at any time while the Series C Preferred Stock is outstanding, (i) the Corporation, directly or indirectly, in one or more related transactions is a party to any merger or consolidation of the Corporation, (ii) the Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed, (iv) the Corporation, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange, in each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-7</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">case pursuant to which the Common Stock is converted into, exchanged for or represents solely the right to receive, other securities, cash or property, or any combination thereof (such other securities, cash or property, or combination thereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reference  Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; and the amount and kind of Reference Property that a holder of one share of Common Stock would be entitled to receive on account of such transaction, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reference Property Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) (each such transaction, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), then, notwithstanding anything to the contrary herein, (I) at the effective time of such Fundamental Transaction, the Conversion Shares due upon conversion of any Series C Preferred Stock shall be determined in the same manner as if each reference to any number of shares of Common Stock in this Certificate of Designation were instead a reference to the same number of Reference Property Units and (II) if such Reference Property Unit consists of any security of a Person other than the Corporation, then such Person (and, as a condition to the Corporation effecting such Fundamental Transaction, the Corporation shall ensure that such Person) shall execute such instruments as shall be necessary to give effect to this Section 7(d).  If holders of Common Stock arc given any choice as to the securities, cash or property to be received in such Fundamental Transaction, then each Holder shall be given the same choice as to the Reference Property Unit it receives upon any conversion of the Series C Preferred Stock following such Fundamental Transaction.  To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Reference Property Units.  The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation is not the survivor (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Successor Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) to assume in writing all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents in accordance with the provisions of this Section 7(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holders and approved by the Holders (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holders, deliver to the Holder in exchange for the Series C Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Series C Preferred Stock which is convertible in accordance with this Section 7(d), and which is reasonably satisfactory in form and substance to the Holders.  Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and, except in the case of a lease, be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation and the other Transaction Documents referring to the &#8220;Corporation&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Corporation herein.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Calculations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All calculations under this Section 7 shall be made to the nearest cent or the nearest 1&#47;100th of a share, as the case may be.  For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notice to the Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Adjustment to Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notice to Allow Conversion by Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of the Series C </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-8</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, and shall cause to be delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer, share exchange, dissolution, liquidation or winding up is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer, share exchange, dissolution, liquidation or winding up, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.  To the extent that any notice provided hereunder constitutes, or contains, material non-public information regarding the Corporation or any of the Subsidiaries, the Corporation shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.  For the avoidance of doubt, notwithstanding such notice or corporate event, each Holder shall remain entitled to convert the Conversion Amount of its Series C Preferred Stock (or any part hereof) as provided herein.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any and all notices or other communications or deliveries to be provided by the Holders hereunder, including, without limitation, any Notice of Conversion, shall be in writing and delivered personally, by facsimile or other electronic delivery, or sent by a nationally recognized overnight courier service, addressed to the Corporation, at the address set forth above Attention&#58; Corporate Secretary, facsimile number (626) 304-3401, or such other facsimile number or address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 8(a).  Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by facsimile or other electronic delivery, or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number or address of such Holder appearing on the books of the Corporation, or if no such facsimile number or address appears on the books of the Corporation, at the principal place of business of such Holder, as set forth in the Purchase Agreement.  Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth in this Section prior to 5&#58;30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth in this Section on a day that is not a Trading Day or later than 5&#58;30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Absolute Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except as expressly provided herein, no provision of this Certificate of Designation shall alter or impair the obligation of the Corporation, which is absolute and unconditional, to pay liquidated damages, accrued dividends and accrued interest, as applicable, on the shares of Series C Preferred Stock at the time, place, and rate, and in the coin or currency, herein or in the Purchase Agreement prescribed.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Lost or Mutilated Series C Preferred Stock Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If a Holder&#8217;s Series C Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series C Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership thereof, reasonably satisfactory to the Corporation.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof.  Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by any of the Transaction Documents </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-9</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">New York Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such proceeding.  Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by applicable law.  Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or the transactions contemplated hereby.  If any party shall commence an action or proceeding to enforce any provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys&#8217; fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders.  The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation on any other occasion.  Any waiver by the Corporation or a Holder must be in writing.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances.  If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Next Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Status of Converted or Reacquired Series C Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Shares of Series C Preferred Stock may only be issued pursuant to the Purchase Agreement.  If any shares of Series C Preferred Stock shall be converted or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series C Convertible Preferred Stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-10</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOTICE OF CONVERSION</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES C PREFERRED STOCK)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned hereby elects to convert the number of shares of Series C Convertible Preferred Stock indicated below into shares of common stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), of Arrowhead Research Corporation, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as may be required by the Corporation in accordance with the Purchase Agreement. No fee will be charged to the Holders for any conversion, except for any such transfer taxes.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion calculations&#58;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date to Effect Conversion&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares of Series C Preferred Stock owned prior to Conversion&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares of Series C Preferred Stock to be Converted&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stated Value of shares of Series C Preferred Stock to be Converted&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares of Common Stock to be Issued&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Applicable Conversion Price&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares of Series C Preferred Stock subsequent to Conversion&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address for Delivery&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;<br>or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>DWAC Instructions&#58;<br>Broker no&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Account no&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;HOLDER&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;<br>&#160;&#160;&#160;&#160;Title&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-11</font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>exhibit32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1333c33ebefa4b11938ca7b1dffe9f63_1"></div><div style="min-height:72pt;width:100%"><div style="padding-right:7.2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Exhibit 3.1</font></div><div style="padding-right:7.2pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECOND AMENDED AND RESTATED <br>BYLAWS OF<br>ARROWHEAD PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24pt"><br>STOCKHOLDERS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt">Annual Meeting.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt;text-decoration:underline">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The annual meeting of stockholders shall be held at the hour, date and place, if any, within or without the State of Delaware which is fixed by the Board of Directors, which time, date and place may subsequently be changed at any time by vote of the Board of Directors.  If no annual meeting has been held for a period of thirteen (13) months after the corporation&#8217;s last annual meeting, a special meeting in lieu thereof may be held, and such special meeting shall have, for the purposes of these bylaws or otherwise, all the force and effect of an annual meeting.  Any and all references hereafter in these bylaws to an annual meeting or annual meetings also shall be deemed to refer to any special meeting(s) in lieu thereof. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Notice of Stockholder Business and Nominations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Nominations of persons for election to the Board of Directors and the proposal of other business to be considered by the stockholders may be brought before an annual meeting&#58;  (i) by or at the direction of the Board of Directors, (ii) by any stockholder of the corporation who was a stockholder of record at the time of giving of notice provided for in this bylaw, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in this bylaw as to such nomination or other business, or (iii) by an Eligible Stockholder (as defined in Section 1.11 below) pursuant to and in accordance with Section 1.11 of these bylaws.  For the avoidance of doubt, the foregoing clauses (ii) and (iii) shall be the exclusive means for a stockholder to bring nominations and the foregoing clause (ii) shall be the exclusive means for a stockholder to bring other business properly before an annual meeting (other than matters properly brought under Rule 14a-8 (or any successor rule) under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)), and such stockholder must comply with the notice and other procedures set forth in Article I, Section 1.1(b) or Article I, Section 1.11, as applicable, of this bylaw to bring such nominations or other business properly before an annual meeting.  In addition to the other requirements set forth in this bylaw, for any proposal of business to be considered at an annual meeting, it must be a proper subject for action by stockholders of the corporation under applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (iii) of Article I, Section 1.1(b)(1) of this bylaw, the stockholder must (i) have given Timely Notice (as defined below) thereof in writing to the Secretary of the corporation, (ii) have provided any updates or supplements to such notice at the times and in the forms required by this bylaw and (iii) together with the beneficial owner(s), if any, on whose behalf the nomination or other business proposal is made, have acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this bylaw.  To be timely, a stockholder&#8217;s written notice shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the one-year anniversary of the preceding year&#8217;s annual meeting&#59; provided, however, that in the event the annual meeting is first convened more than 30 days before or more than 60 days after such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be received by the Secretary of the corporation not later than the close of business on the later of the 90th day prior to the scheduled date of such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Timely Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  In no event shall an adjournment or recess of an annual meeting, or a postponement of an annual meeting for which notice of the meeting has already been given to stockholders or a public announcement of the meeting date has already been made, commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above.  Such stockholder&#8217;s Timely Notice shall set forth&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">as to each person whom the stockholder proposes to nominate for election or reelection as a director, (i) all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act, (ii)  the information required under Article I, Section 1.12 with respect to any nominee for election as a director, and (iii) a written statement, not to exceed 500 words, in support of such person&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend these bylaws, the language of the proposed amendment), the reasons for conducting such business at the meeting, and any substantial interest (within the meaning of Item 5 of Schedule 14A under the Exchange Act) in such business of each Proposing Person (as defined below)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">(i) the name and address of the stockholder giving the notice, as they appear on the corporation&#8217;s books, and the names and addresses of the other Proposing Persons (if any) and (ii) as to each Proposing Person, the following information&#58;  (a) the class or series and number of all shares of capital stock of the corporation which are, directly or indirectly, owned beneficially or of record by such Proposing Person, including any shares of any class or series of capital stock of the corporation as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future, (b) all Synthetic Equity Interests (as defined below) in which such Proposing Person, directly or indirectly, holds an interest including a description of the material terms of each such Synthetic Equity Interest, including without limitation, identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each such Synthetic Equity Interest, as to (x) whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in such shares to such Proposing Person, (y) whether or not such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of such shares and (z) whether or not such Proposing Person and&#47;or, to the extent known, the counterparty to such Synthetic Equity Interest has entered into other transactions that hedge or mitigate the economic effect of such Synthetic Equity Interest, (c) any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person has or shares a right to, directly or indirectly, vote any shares of any class or series of capital stock of the corporation, (d) any rights to dividends or other distributions on the shares of any class or series of capital stock of the corporation, directly or indirectly, owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the corporation, (e) any performance-related fees (other than an asset based fee) that such Proposing Person, directly or indirectly, is entitled to based on any increase or decrease in the value of shares of any class or series of capital stock of the corporation or any Synthetic Equity Interests, and (f) any equity interests or Synthetic Equity Interest in the securities of any principal competitor (for purposes of this Section 1.1(b), as defined for purposes of Section 8 of the Clayton Antitrust Act of 1914) of the corporation held by or on behalf of such Proposing Person (the disclosures to be made pursuant to the foregoing clauses (a) through (f) are referred to, collectively, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Material Ownership Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and (iii) a description of the material terms of all agreements, arrangements or understandings (whether or not in writing) entered into by any Proposing Person with any other person for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">(i) any plans or proposals which such Proposing Person may have with respect to securities of the corporation that would be required to be disclosed pursuant to Item 4 of Exchange Act Schedule 13D, (ii) a description of all agreements, arrangements or understandings by and among any of the Proposing Persons, or by and among any Proposing Persons and any other person (including with any proposed nominee(s)), pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders, including, without limitation any agreements that would be required to be disclosed pursuant to Item&#160;5 or Item&#160;6 of Exchange Act Schedule&#160;13D, (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding), and (iii) identification of the names and addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to support such nominations or other business proposal(s), and to the extent known the class and number of all shares of the corporation&#8217;s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s)&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">a representation that the stockholder (or a qualified representative of the stockholder) intends to appear at the meeting to make such nomination or propose such other business&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">a representation as to whether the stockholder giving the notice, any other Proposing Person, or any other participant (as defined in Item 4 of Schedule 14A under the Exchange Act) will engage in a solicitation with respect to such nomination or proposal of other business and, if so, a statement of whether such solicitation will be conducted as an exempt </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">solicitation under Rule 14a-2(b) of the Exchange Act, the name of each participant in such solicitation and the amount of the cost of solicitation that has been and will be borne, directly or indirectly, by each participant in such solicitation and (i) in the case of a proposal of business other than nominations, whether such person or group intends to deliver, through means satisfying each of the conditions that would be applicable to the corporation under either Exchange Act Rule 14a-16(a) or Exchange Act Rule 14a-16(n), a proxy statement and form of proxy to holders (including any beneficial owners pursuant to Rule 14b-1 and Rule 14b-2 of the Exchange Act) of at least the percentage of the corporation's voting shares required under applicable law to carry the proposal or (ii) in the case of any solicitation that is subject to Rule 14a-19 of the Exchange Act, confirming that such person or group will deliver, through means satisfying each of the conditions that would be applicable to the corporation under either Exchange Act Rule 14a-16(a) or Exchange Act Rule 14a-16(n), a proxy statement and form of proxy to holders (including any beneficial owners pursuant to Rule 14b-1 and Rule 14b-2 of the Exchange Act) of at least 67% of the voting power of the corporation&#8217;s stock entitled to vote generally in the election of directors&#59;</font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">a representation that promptly after soliciting proxies from the percentage of stockholders referred to in the representation required under the immediately preceding clause (F), such stockholder or any Proposing Person will provide the corporation with documents, which may take the form of a certified statement and documentation from a proxy solicitor, specifically demonstrating that the necessary steps have been taken to deliver a proxy statement and form of proxy to holders of such percentage of the corporation&#8217;s stock (such representation, together with the representations required under the immediately preceding clause (F) above, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">A stockholder providing Timely Notice of nominations or other business proposed to be brought before an annual meeting shall further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided in such notice pursuant to this bylaw shall be true and correct as of the record date for the meeting and as of the date that is ten business days prior to such annual meeting, and such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the fifth business day after the record date for the annual meeting (in the case of the update and supplement required to be made as of the record date), and not later than the close of business on the eighth business day prior to the date of the annual meeting (in the case of the update and supplement required to be made as of ten business days prior to the meeting). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Notwithstanding anything in the second sentence of Article I, Section 1.1(b)(2) of this bylaw to the contrary, in the event that the number of directors to be elected to the Board of Directors of the corporation is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the corporation at least ten (10) days before the last day a stockholder may deliver a notice of nomination in accordance with the second sentence of Article I, Section 1.1(b)(2), a stockholder&#8217;s notice required by this bylaw shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary of the corporation not later than the close of business on the tenth (10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) day following the day on which such public announcement is first made by the corporation.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt;text-decoration:underline">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Only such persons who are nominated in accordance with the provisions of this Section 1.1 or Article I, Section 1.11 shall be eligible for election and to serve as directors and only such business shall be conducted at an annual meeting of stockholders as shall have been brought before the meeting in accordance with the provisions of this Article I, Section 1.1.  The Chairman of the Board, the chairman of the meeting or any other person designated by the Board of Directors shall have the power to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the provisions of these bylaws (including whether a stockholder or any other Proposing Person provided all information and complied with all requirements and representations required under this Article I, Section 1.1).  If the Chairman of the Board, the chairman of the meeting or any other person designated by the Board of Directors determines that such nomination or other business was not made in accordance with the provisions of these bylaws, such nomination shall be disregarded and such other business shall not be transacted, notwithstanding that votes and proxies in respect of any such nomination or other business may have been received by the corporation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Except as otherwise required by law, nothing in this Article I, Section 1.1 shall obligate the corporation or the Board of Directors to include in any proxy statement or other stockholder </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">communication distributed on behalf of the corporation or the Board of Directors information with respect to any nominee for director or any other matter of business submitted by a stockholder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">In furtherance and not by way of limitation of the foregoing provisions of this Article I, Section 1.1, if the proposing stockholder (or a qualified representative of the stockholder) does not appear at the annual meeting to present a nomination or other business, such nomination shall be disregarded and such other business shall not be transacted, notwithstanding that votes and proxies in respect of any such nomination or other business may have been received by the corporation.  For purposes of this Article I, Section 1.1, to be considered a qualified representative of the proposing stockholder, a person must be authorized by a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such written instrument or electronic transmission, or a reliable reproduction of the written instrument or electronic transmission, to the corporation prior to the making of such nomination or proposal of other business at the meeting of the stockholders (and in any event not fewer than five business days before such meeting).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Notwithstanding the foregoing provisions of this bylaw, a stockholder (and any other Proposing Person) shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this bylaw.  Nothing in this bylaw shall be deemed to affect any rights of (i) stockholders to have proposals included in the corporation&#8217;s proxy statement pursuant to Rule 14a-8 (or any successor rule) under the Exchange Act and, to the extent required by such rule, have such proposals considered and voted on at an annual meeting or (ii) the holders of any series of Preferred Stock to elect directors under specified circumstances.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use for solicitation by the Board of Directors. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.   For purposes of this bylaw, the &#8220;close of business&#8221; shall mean 6&#58;00 p.m. local time at the principal executive offices of the corporation on any calendar day, whether or not the day is a business day and &#8220;public announcement&#8221; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.  For purposes of this Article I of these bylaws, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Proposing Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the following persons&#58;  (i) the stockholder of record providing the notice of nominations or other business proposed to be brought before a stockholders&#8217; meeting, and (ii) the beneficial owner(s), if different, on whose behalf the nominations or other business proposed to be brought before a stockholders&#8217; meeting is made, and if such stockholder or beneficial owner is an entity, each individual who is a director, executive officer, general partner or managing member of such entity or of any other entity that has or shares control of such entity.  For purposes of this Section 1.1 of Article I of these bylaws, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Synthetic Equity Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean (a) any transaction, agreement or arrangement (or series of transactions, agreements or arrangements), including, without limitation, any option, warrant, forward contract, contract of sale or other derivative, swap, hedge, pledge, repurchase, voting rights, or so-called &#8220;stock borrowing&#8221; agreement or arrangement, whether the instrument or agreement is to be settled with shares or with cash based on the notional amount or value of outstanding shares of stock of the corporation, the purpose or effect of which is to, directly or indirectly&#58;  (1) give a person or entity economic benefit and&#47;or risk similar to ownership of shares of any class or series of capital stock of the corporation, in whole or in part, including due to the fact that such transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit or avoid a loss from any increase or decrease in the value of any shares of any class or series of capital stock of the corporation, (2) mitigate loss to, reduce the economic risk of or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock of the corporation, (3) otherwise provide in any manner the opportunity to profit or avoid a loss from any decrease in the value of any shares of any class or series of capital stock of the corporation, or (4) increase or decrease the voting power of any person or entity with respect to any shares of any class or series of capital stock of the corporation, and (b) any interest in the foregoing clause (a) with respect to any class or series of capital stock of any principal competitor of the corporation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Special Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of Preferred Stock, special meetings of the stockholders of the corporation may be called only by the Board of Directors.  The Board of Directors may postpone, reschedule or cancel any previously scheduled special meeting of stockholders.  Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the corporation.  Nominations of persons for election to the Board of Directors of the corporation and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with Article I, Section 1.1(a) of these bylaws, in which case </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">such special meeting in lieu thereof shall be deemed an annual meeting for purposes of these bylaws and the provisions of Article I, Section 1.1(b) of these bylaws shall govern such special meeting.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Notice of Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, if any, date and hour of the meeting, the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for determining the stockholders entitled to notice of the meeting) and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.  Unless otherwise provided by law, the written notice of any meeting shall be given not less than ten nor more than sixty days before the date of the meeting to each stockholder entitled to vote at such meeting.  If mailed, such notice shall be deemed to be given when deposited in the mail, postage prepaid, directed to the stockholder at his&#47;her address as it appears on the records of the corporation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Adjournments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene at the same or some other place (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), and notice need not be given of any such adjourned meeting if the place, if any, date and hour thereof, and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxyholders to participate in the meeting by means of remote communication, or (iii) set forth in the notice of meeting given in accordance with Section 1.3 of these bylaws).  At the adjourned meeting the corporation may transact any business which might have been transacted at the original meeting.  If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Quorum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  At each meeting of stockholders, except where otherwise provided by law or the corporation&#8217;s Amended and Restated Certificate of Incorporation, as it may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or these bylaws, the holders of shares representing a majority of the votes entitled to be cast by the holders of the outstanding shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum.  In the absence of a quorum, the stockholders so present may, by majority vote, adjourn the meeting from time to time in the manner provided in Section 1.4 of these bylaws until a quorum shall attend.  Shares of its own stock belonging to the corporation or to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation is held, directly or indirectly, by the corporation, shall neither be entitled to vote nor be counted for quorum purposes&#59; provided, however, that the foregoing shall not limit the right of the corporation to vote stock, including but not limited to its own stock, held by it in a fiduciary capacity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Meetings of stockholders shall be presided over by the Chairman of the Board, if any, or in his&#47;her absence by the Vice Chairman of the Board, if any, or in his&#47;her absence by the President, or in his&#47;her absence by a Vice President, or in the absence of the foregoing persons by a chairman designated by the Board of Directors, or in the absence of such designation by a chairman chosen at the meeting.  The Secretary shall act as secretary of the meeting, but in his&#47;her absence the chairman of the meeting may appoint any person to act as secretary of the meeting.  The Board of Directors may adopt such rules and regulations for the conduct of any meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the chairman of the meeting shall have the authority to adopt and enforce such rules and regulations for the conduct of any meeting of stockholders and the safety of those in attendance as, in the judgment of the chairman, are necessary, appropriate or convenient for the conduct of the meeting. Rules and regulations for the conduct of meetings of stockholders, whether adopted by the Board of Directors or by the chairman of the meeting, may include, without limitation, establishing&#58; (i) an agenda or order of business for the meeting&#59; (ii) rules and procedures for maintaining order at the meeting and the safety of those present&#59; (iii) limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted proxies and such other persons as the chairman of the meeting shall permit&#59; (iv) restrictions on entry to the meeting after the time fixed for the commencement thereof&#59; (v) limitations on the time allotted for consideration of each agenda item and for questions and comments by participants&#59; (vi)&#160;regulations for the opening and closing of the polls for balloting and matters which are to be voted on by ballot (if any)&#59; and (vii) procedures (if any) requiring attendees to provide the corporation advance notice of their intent to attend the meeting. Subject to any rules and regulations adopted by the Board of Directors, the chairman of the meeting may convene and, for any or no reason, from time to time, adjourn and&#47;or recess any meeting of stockholders pursuant to Section 1.4.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Proxies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except as otherwise provided in the Certificate of Incorporation or any amendment thereto, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of stock held by him which has voting power upon the matter in question.  Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for him by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period.  A duly executed proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power.  A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by filing an instrument in writing revoking the proxy or another duly executed proxy bearing a later date with the Secretary of the corporation.  Voting at meetings of stockholders need not be by written ballot and need not be conducted by inspectors unless the holders of shares representing a majority of the votes entitled to be cast by the holders of the outstanding shares of all classes of stock entitled to vote thereon present in person or by proxy at such meeting shall so determine.  At all meetings of stockholders for the election of directors a plurality of the votes cast shall be sufficient to elect.  All other elections and questions shall, unless otherwise provided by law or by the Certificate of Incorporation or these bylaws, be decided by the vote of shares representing a majority of the votes entitled to be cast by the holders of the outstanding shares of stock entitled to vote thereon present in person or by proxy at the meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Fixing Date for Determination of Stockholders of Record</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not be more than sixty nor less than ten days prior to any other action.  If no record date is fixed&#58;  (1) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held&#59; and (2) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.  A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting&#59; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">List of Stockholders Entitled to Vote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Secretary shall prepare and make, no later than the tenth (10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) day before each meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder&#59; provided, however, that if the record date for determining the stockholders entitled to vote is less than ten (10) days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth (10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) day before the meeting date.  Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for ten (10) days ending on the day before the meeting date&#58; (a)&#160;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of meeting&#59; or (b)&#160;during ordinary business hours at the principal place of business of the corporation.  The stock ledger shall be the only evidence as to who are the stockholders entitled to examine the stock ledger, the list of stockholders or the books of the corporation, or to vote in person or by proxy at any meeting of stockholders.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.04pt;text-decoration:underline">Action by Consent of Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless otherwise restricted by the Certificate of Incorporation, any action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted.  Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.04pt;text-decoration:underline">Proxy Access for Director Nominations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of these bylaws, in connection with an annual meeting of stockholders at which directors are to be elected, the corporation&#58;  (1) shall include in its proxy statement and on its form of proxy the names of, and (2) shall include in its proxy statement the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; (as defined below) relating to, a number of nominees specified pursuant to Article I, Section 1.11(b)(1) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Authorized Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for election to the Board of Directors submitted pursuant to this Section 1.11 (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stockholder Nominee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), if&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the Stockholder Nominee satisfies the eligibility requirements in this  Section&#160;1.11&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Stockholder Nominee is identified in a timely notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stockholder Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) that satisfies this Section 1.11 and is delivered by a stockholder that qualifies as, or is acting on behalf of, an Eligible Stockholder (as defined below)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the Eligible Stockholder satisfies the requirements in this Section 1.11 and expressly elects at the time of the delivery of the Stockholder Notice to have the Stockholder Nominee included in the corporation&#8217;s proxy materials&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;the additional requirements of these bylaws are met.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Definitions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The maximum number of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholder Nominees appearing in the corporation&#8217;s proxy materials with respect to an annual meeting of stockholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Authorized Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall not exceed the greater of two or 20% of the number of directors in office as of the last day on which a Stockholder Notice may be delivered pursuant to this Section 1.11 with respect to the annual meeting, or if such amount is not a whole number, the closest whole number (rounding down) below 20%&#59; provided that the Authorized Number shall be reduced&#58;  (i) by any Stockholder Nominee whose name was submitted for inclusion in the corporation&#8217;s proxy materials pursuant to this Section 1.11 but either is subsequently withdrawn or that the Board of Directors decides to nominate as a Board nominee&#59; (ii) by any directors in office or director nominees that in either case shall be included in the corporation&#8217;s proxy materials with respect to the annual meeting as an unopposed (by the corporation) nominee pursuant to an agreement, arrangement or other understanding between the corporation and a stockholder or group of stockholders (other than any such agreement, arrangement or understanding entered into in connection with an acquisition of capital stock, by the stockholder or group of stockholders, from the corporation)&#59; (iii) by any directors serving on the Board of Directors who were previously elected to the Board of Directors as Stockholder Nominees at any of the preceding two annual meetings and who are nominated for election at the annual meeting by the Board of Directors as a Board nominee&#59; and (iv)&#160;by any Stockholder Nominee who is not included in the corporation&#8217;s proxy materials or is not submitted for director election for any reason, in accordance with the last sentence of Article I, Section&#160;1.11(d)(2).  In the event that one or more vacancies for any reason occurs after the date of the Stockholder Notice but before the annual meeting and the Board of Directors resolves to reduce the size of the Board of Directors in connection therewith, the Authorized Number shall be calculated based on the number of directors in office as so reduced.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">To qualify as an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; a stockholder or a group as described in this Section&#160;1.11 must&#58; (i) Own and have Owned (as defined below), continuously for at least three years as of the date of the Stockholder Notice, a number of shares (as adjusted to account for any stock dividend, stock split, subdivision, combination, reclassification or recapitalization of shares of stock of the corporation that are entitled to vote generally in the election of directors) that represents at least 3% of the outstanding shares of stock of the corporation that are entitled to vote generally in the election of directors as of the date of the Stockholder Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Required Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and (ii) thereafter continue to Own the Required Shares through such annual meeting of stockholders.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of satisfying the ownership requirements of this Section 1.11(b)(2), a group of not more than 20 stockholders and&#47;or beneficial owners may aggregate the number of shares of stock of the corporation that are entitled to vote generally in the election of directors that each group member has individually Owned continuously for at least three years as of the date of the Stockholder Notice if all other requirements and obligations for an Eligible Stockholder set forth in this Section 1.11 are satisfied by and as to each stockholder or beneficial owner comprising the group whose shares are aggregated.  No shares may be attributed to more than one Eligible Stockholder, and no stockholder or beneficial owner, alone or together with any of its affiliates, may individually or as a member of a group qualify as or constitute more than one Eligible Stockholder under this Section&#160;1.11.  A group of any two or more funds shall be treated as only one stockholder or beneficial owner for this purpose if they are (a) under common management and investment control, (b) under common management and funded primarily by a single employer or (c) part of a &#8220;group of investment companies,&#8221; as such term is defined in Section&#160;12(d)(1)(G)(ii) of the Investment Company Act of 1940. For purposes of this Section 1.11, the term &#8220;affiliate&#8221; or &#8220;affiliates&#8221; shall have the meanings ascribed thereto under the rules and regulations promulgated under the Exchange Act. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">For purposes of this Section 1.11&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) &#160;&#160;&#160;&#160;A stockholder or beneficial owner is deemed to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Own</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; only those outstanding shares of stock of the corporation that are entitled to vote generally in the election of directors as to which the person possesses both&#58; (A) the full voting and investment rights pertaining to the shares&#59; and (B) the full economic interest in (including the opportunity for profit and risk of loss </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">on) such shares, except that the number of shares calculated in accordance with clauses (A) and (B) shall not include any shares&#58; (i) sold by such person in any transaction that has not been settled or closed&#59; (ii) borrowed by the person for any purposes or purchased by the person pursuant to an agreement to resell&#59; or (iii) subject to any option, warrant, forward contract, swap, contract of sale, or other derivative or similar agreement entered into by the person, whether the instrument or agreement is to be settled with shares or with cash based on the notional amount or value of outstanding shares of stock of the corporation that are entitled to vote generally in the election of directors, if the instrument or agreement has, or is intended to have, or if exercised would have, the purpose or effect of&#58; (x) reducing in any manner, to any extent or at any time in the future, the person&#8217;s full right to vote or direct the voting of the shares&#59; and&#47;or (y) hedging, offsetting or altering to any degree any gain or loss arising from the full economic ownership of the shares by the person.  The terms &#8220;Owned,&#8221; &#8220;Owning&#8221; and other variations of the word &#8220;Own,&#8221; when used with respect to a stockholder or beneficial owner, have correlative meanings.  For purposes of clauses (i) through (iii), the term &#8220;person&#8221; includes its affiliates (as such term is defined in Rule 12b-2 promulgated under the Exchange Act).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;A stockholder or beneficial owner &#8220;Owns&#8221; shares held in the name of a nominee or other intermediary so long as the person retains both&#58; (A) the full voting and investment rights pertaining to the shares&#59; and (B) the full economic interest in the shares.  The person&#8217;s Ownership of shares is deemed to continue during any period in which the person has delegated any voting power by means of a proxy, power of attorney, or other instrument or arrangement that is revocable at any time by the stockholder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;A stockholder or beneficial owner&#8217;s Ownership of shares shall be deemed to continue during any period in which the person has loaned the shares if the person has the power to recall the loaned shares on not more than five business days&#8217; notice and (A) the person recalls the loaned shares within five business days of being notified that its Stockholder Nominee shall be included in the Corporation&#8217;s proxy materials for the relevant annual meeting&#59; and (B) the person holds the recalled shares through the annual meeting.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;For purposes of this Section 1.11, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; referred to in Article I, Section 1.11(a)(2) that the corporation will include in its proxy statement is&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the information set forth in the Schedule 14N provided with the Stockholder Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">concerning each Stockholder Nominee and the Eligible Stockholder that is required to be disclosed in the corporation&#8217;s proxy statement by the applicable requirements of the Exchange Act and the rules and regulations thereunder&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;if the Eligible Stockholder so elects, a written statement of the Eligible Stockholder (or, in the case of a group, a written statement of the group), not to exceed 500 words, in support of its Stockholder Nominee(s), which must be provided at the same time as the Stockholder Notice for inclusion in the corporation&#8217;s proxy statement for the annual meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary contained in this Section 1.11, the corporation may omit from its proxy materials any information or Statement that it, in good faith, believes is untrue in any material respect (or omits a material fact necessary in order to make the statements made, in light of the circumstances under which they are made, not misleading) or would violate any applicable law, rule, regulation or listing standard.  Nothing in this Section 1.11 shall limit the corporation&#8217;s ability to solicit against and include in its proxy materials its own statements relating to any Eligible Stockholder or Stockholder Nominee.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Stockholder Notice and Other Informational Requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Stockholder Notice shall set forth&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160; all information required under Article I, Section 1.1(b)(2)(C) and (D) of these bylaws (and for such purposes, references in Article I, Section 1.1(b)(2) of these bylaws to the &#8220;Proposing Person&#8221; shall be deemed to refer to the &#8220;Eligible Stockholder&#8221; on whose behalf the Stockholder Notice is delivered)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;a copy of the Schedule 14N that has been or concurrently is filed with the SEC under the Exchange Act&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;a written statement of the Eligible Stockholder (and in the case of a group, the written statement of each stockholder or beneficial owner whose shares are aggregated for purposes of constituting an Eligible Stockholder), which statement(s) shall also be included in the Schedule 14N filed with the SEC&#58; (A) setting forth and certifying to the number of shares of stock of the corporation that are entitled to vote generally in the election of directors the Eligible Stockholder Owns and has Owned (as defined in Article I, Section 1.11(b)(3) above) continuously for at least three years as of the date of the Stockholder Notice&#59; (B) agreeing to continue to Own such shares through the annual meeting&#59; and (C) regarding whether or not it intends to maintain Ownership of the Required Shares for at least one year following the annual meeting&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;the written agreement of the Eligible Stockholder (and in the case of a group, the written agreement of each stockholder or beneficial owner whose shares are aggregated for purposes of constituting an Eligible Stockholder) addressed to the corporation, setting forth the following additional agreements, representations, and warranties&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;it shall provide&#58; (i) within five business days after the date of the Stockholder Notice, one or more written statements from the record holder(s) of the Required Shares and from each intermediary through which the Required Shares are or have been held, in each case during the requisite three-year holding period, specifying the number of shares that the Eligible Stockholder Owns, and has Owned continuously in compliance with this Section 1.11&#59; (ii) within the time period specified in Article I, Section 1.1(b)(3) of these bylaws, an updated or supplemental notice so that the information provided or required to be provided pursuant to clause (c)(1) of this Section 1.11 shall be true and correct as of the dates specified in Article I, Section 1.1(b)(3)&#59; and (iii) immediate notice to the corporation if the Eligible Stockholder ceases to own any of the Required Shares prior to the annual meeting&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;it&#58; (i) acquired the Required Shares in the ordinary course of business and not with the intent to change or influence control at the corporation, and does not presently have this intent&#59; (ii) has not nominated and shall not nominate for election to the Board of Directors at the annual meeting any person other than the Stockholder Nominee(s) being nominated pursuant to this Section 1.11&#59; (iii) has not engaged and shall not engage in, and has not been and shall not be a participant (as defined in Item&#160;4 of Exchange Act Schedule&#160;14A) in a solicitation within the meaning of Exchange Act Rule 14a-1(l), in support of the election of any individual as a director at the annual meeting other than its Stockholder Nominee(s) or any nominee(s) of the Board of Directors&#59; and (iv) shall not distribute to any stockholder any form of proxy for the annual meeting other than the form distributed by the corporation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)&#160;&#160;&#160;&#160;it will&#58; (i) assume all liability stemming from any legal or regulatory violation arising out of the Eligible Stockholder&#8217;s communications with the stockholders of the corporation or out of the information that the Eligible Stockholder provided to the corporation&#59; (ii) indemnify and hold harmless the corporation and each of its directors, officers and employees individually against any liability, loss or damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the corporation or any of its directors, officers or employees arising out of the nomination or solicitation process pursuant to this Section&#160;1.11&#59; (iii) comply with all laws, rules, regulations and listing standards applicable to its nomination or any solicitation in connection with the annual meeting&#59; (iv) file with the SEC any solicitation or other communication by or on behalf of the Eligible Stockholder relating to the corporation&#8217;s annual meeting of stockholders, one or more of the corporation&#8217;s directors or director nominees or any Stockholder Nominee, regardless of whether the filing is required under Exchange Act Regulation 14A, or whether any exemption from filing is available for the materials under Exchange Act Regulation 14A&#59; and (v) at the request of the corporation, promptly, but in any event within five business days after such request (or by the day prior to the day of the annual meeting, if earlier), provide to the corporation such additional information as reasonably requested by the corporation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;in the case of a nomination by a group, the designation by all group members of one group member that is authorized to act on behalf of all members of the group with respect to the nomination and matters related thereto, including withdrawal of the nomination, and the written agreement, representation, and warranty of the Eligible Stockholder that it shall provide, within five business days after the date of the Stockholder Notice, documentation reasonably </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">satisfactory to the corporation demonstrating that the number of stockholders and&#47;or beneficial owners within such group does not exceed 20, including whether a group of funds qualifies as one stockholder or beneficial owner within the meaning of Section 1.11(b)(2) of these bylaws.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Within the time period for delivery of the Stockholder Notice, the Eligible Stockholder shall deliver to the Secretary at the principal executive offices of the Corporation the information as to each Stockholder Nominee required to be submitted by nominees under Article I, Section 1.12 of these bylaws with respect to any nominee for election as a director, which information shall be deemed part of the Stockholder Notice.  The corporation may request such additional information as necessary to permit the Board of Directors to determine if each Stockholder Nominee satisfies the requirements of this Section 1.11. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">To be timely under this Section 1.11, the Stockholder Notice must be delivered by a stockholder to the Secretary of the corporation at the principal executive offices of the corporation not later than the close of business on the 120th day nor earlier than the close of business on the 150th day prior to the first anniversary of the date (as stated in the corporation&#8217;s proxy materials) the definitive proxy statement was first released to stockholders in connection with the preceding year&#8217;s annual meeting of stockholders&#59; provided, however, that in the event that the date of the annual meeting is more than 30 days before or after the anniversary of the previous year&#8217;s annual meeting, or if no annual meeting was held in the preceding year, to be timely, the Stockholder Notice must be so delivered not earlier than the close of business on the 150th day prior to such annual meeting and not later than the close of business on the later of the 120th day prior to such annual meeting or the 10th day following the day on which public announcement (as defined in Article I, Section 1.1(c)(3)) of the date of such meeting is first made by the corporation.  In no event shall an adjournment or recess of an annual meeting, or a postponement of an annual meeting for which notice of the meeting has already been given to stockholders or a public announcement of the meeting date has already been made, commence a new time period (or extend any time period) for the giving of the Stockholder Notice as described above.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">In the event that any information or communications provided by the Eligible Stockholder or any Stockholder Nominees to the corporation or its stockholders is not, when provided, or thereafter ceases to be, true, correct and complete in all material respects (including omitting a material fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading), such Eligible Stockholder or Stockholder Nominee, as the case may be, shall promptly notify the Secretary and provide the information that is required to make such information or communication true, correct, complete and not misleading&#59; it being understood that providing any such notification shall not be deemed to cure any defect or limit the corporation&#8217;s right to omit a Stockholder Nominee from its proxy materials as provided in this Section 1.11.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All information provided pursuant to this Section 1.11(c) shall be deemed part of the Stockholder Notice for purposes of this Section 1.11(c). </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Proxy Access Procedures.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Notwithstanding anything to the contrary contained in this Article I, Section 1.11, the corporation may omit from its proxy materials any Stockholder Nominee, and such nomination and any proxies or votes in respect of any such nomination shall be disregarded and no vote on such Stockholder Nominee shall occur, notwithstanding that proxies or votes in respect of any such nomination may have been received by the corporation, if&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) &#160;&#160;&#160;&#160;the Eligible Stockholder or Stockholder Nominee breaches any of its agreements, representations or warranties set forth in the Stockholder Notice or otherwise submitted pursuant to this Section 1.11, any of the information in the Stockholder Notice or otherwise submitted pursuant to this Section 1.11 was not, when provided, true, correct and complete, or the Eligible Stockholder or applicable Stockholder Nominee otherwise fails to comply with its obligations pursuant to these bylaws, including, but not limited to, its obligations under this Section 1.11&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Stockholder Nominee&#58; (A) is not independent under any applicable listing standards, any applicable rules of the SEC and any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of the corporation&#8217;s directors&#59; (B) is or has been, within the past three years, an officer or director of a competitor, as defined for the purposes of Section 8 of the Clayton Antitrust Act of 1914&#59; (C) is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been convicted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in a criminal proceeding (excluding traffic violations and other minor offenses) within the past ten years&#59; or (D) is subject to any order of the type specified in Rule 506(d) of Regulation D promulgated under the Securities Act of 1933&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the corporation receives a notice (whether or not subsequently withdrawn) that a stockholder intends to nominate any candidate for election to the Board of Directors pursuant to the advance notice requirements for stockholder nominees for director in Article I, Section 1.1(b)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;the election of the Stockholder Nominee to the Board of Directors would cause the corporation to violate the Certificate of Incorporation, these bylaws, or any applicable law, rule, regulation or listing standard.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">An Eligible Stockholder submitting more than one Stockholder Nominee for inclusion in the corporation&#8217;s proxy materials pursuant to Section 1.11 shall rank such Stockholder Nominees based on the order that the Eligible Stockholder desires such Stockholder Nominees to be selected for inclusion in the corporation&#8217;s proxy materials and include such assigned rank in its Stockholder Notice submitted to the corporation.  In the event that the number of Stockholder Nominees submitted by Eligible Stockholders pursuant to this Section 1.11 exceeds the Authorized Number, the Stockholder Nominees to be included in the corporation&#8217;s proxy materials shall be determined in accordance with the following provisions&#58; one Stockholder Nominee who satisfies the eligibility requirements in this Section&#160;1.11 shall be selected from each Eligible Stockholder for inclusion in the corporation&#8217;s proxy materials until the Authorized Number is reached, going in order of the amount (largest to smallest) of shares of the corporation each Eligible Stockholder disclosed as Owned in its Stockholder Notice submitted to the corporation and going in the order of the rank (highest to lowest) assigned to each Stockholder Nominee by such Eligible Stockholder.  If the Authorized Number is not reached after one Stockholder Nominee who satisfies the eligibility requirements in this Section 1.11 has been selected from each Eligible Stockholder, this selection process shall continue as many times as necessary, following the same order each time, until the Authorized Number is reached.  Following such determination, if any Stockholder Nominee who satisfies the eligibility requirements in this Section 1.11 thereafter is nominated by the Board of Directors, thereafter is not included in the corporation&#8217;s proxy materials or thereafter is not submitted for director election for any reason (including the Eligible Stockholder&#8217;s or Stockholder Nominee&#8217;s failure to comply with this Section 1.11), no other nominee or nominees shall be included in the corporation&#8217;s proxy materials or otherwise submitted for election as a director at the applicable annual meeting in substitution for such Stockholder Nominee.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Any Stockholder Nominee who is included in the corporation&#8217;s proxy materials for a particular annual meeting of stockholders but either&#58; (i) withdraws from or becomes ineligible or unavailable for election at the annual meeting for any reason, including for the failure to comply with any provision of these bylaws (provided that in no event shall any such withdrawal, ineligibility or unavailability commence a new time period (or extend any time period) for the giving of a Stockholder Notice)&#59; or (ii) does not receive a number of votes cast in favor of his or her election that is at least equal to 25% of the shares present in person or represented by proxy and entitled to vote in the election of directors, shall be ineligible to be a Stockholder Nominee pursuant to this Section 1.11 for the next two annual meetings. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Notwithstanding the foregoing provisions of this Section 1.11, unless otherwise required by law or otherwise determined by the chairman of the meeting or the Board of Directors, if the stockholder delivering the Stockholder Notice (or a qualified representative of the stockholder, as defined in Article I, Section 1.1(c)(2) of these bylaws) does not appear at the annual meeting of stockholders of the corporation to present its Stockholder Nominee or Stockholder Nominees, such nomination or nominations shall be disregarded, notwithstanding that proxies in respect of the election of the Stockholder Nominee or Stockholder Nominees may have been received by the corporation.  Without limiting the Board of Directors&#8217; power and authority to interpret any other provisions of these bylaws, the Board of Directors (and any other person or body authorized by the Board of Directors) shall have the power and authority to interpret this Section 1.11 and to make any and all determinations necessary or advisable to apply this Section 1.11 to any persons, facts or circumstances, in each case acting in good faith.  Except for a nomination made in accordance with Article I, Section 1.1(b) of these bylaws, this Section 1.11 shall be the exclusive method for stockholders to include nominees for director election in the corporation&#8217;s proxy materials.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.04pt;text-decoration:underline">Information Regarding Director Nominees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">As to each person whom the stockholder proposes to nominate for election or reelection as a director of the corporation pursuant to Section 1.1(b) or Section 1.11 of these bylaws, the stockholder must deliver to the Secretary at the principal executive offices of the corporation the following information&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">a written representation and agreement, which shall be signed by the person proposed to be nominated and pursuant to which such person shall represent and agree that such person&#58;  (i)&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">consents to being named as a nominee in a proxy statement and form of proxy relating to the meeting at which directors are to be elected and to serving as a director if elected, and currently intends to serve as a director for the full term for which such person is standing for election&#59; (ii)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">is not and will not become a party to any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity&#58; (A)&#160;as to how the person, if elected as a director, will act or vote on any issue or question, except as disclosed in such representation and agreement or (B)&#160;that could limit or interfere with the person&#8217;s ability to comply, if elected as a director, with such person&#8217;s fiduciary duties under applicable law&#59; (iii)&#160;is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director or nominee except as disclosed in such representation and agreement&#59; and (iv)&#160;if elected as a director, will comply with all of the corporation&#8217;s corporate governance policies and guidelines related to conflict of interest, confidentiality, stock ownership and trading policies and guidelines, and any other policies and guidelines applicable to directors (which will be promptly provided following a request therefor)&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">a fully completed and signed questionnaire in the same form required of the corporation&#8217;s director nominees (which form will be promptly provided following a request therefor)&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">a representation that such person will provide to the corporation such other information as the corporation may reasonably request, including such information reasonably necessary for the corporation to determine whether a nominee will satisfy any qualifications or requirements imposed by the Certificate of Incorporation or these bylaws, any law, rule, regulation or listing standard that may be applicable to the corporation, or relevant to a determination whether such person can be considered an independent director, which information shall be promptly provided following a request therefor.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The written and signed representations and agreements and fully completed and signed questionnaires described in Article I, Section 1.12(a)(2) above shall be provided to the corporation at the time specified pursuant to Article I, Section 1.1(b) or Article I, Section 1.11 of these bylaws, and the additional information described in Article I, Section 1.12(a)(3) above shall be provided to the corporation promptly upon request by the corporation, but in any event within five business days after such request.  All information provided pursuant to this Section 1.12 shall be deemed part of the stockholder&#8217;s notice submitted pursuant to Article I, Section 1.1(b) of these bylaws or a Stockholder Notice submitted pursuant to Article I, Section 1.11 of these bylaws as applicable.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Notwithstanding the foregoing, if any information or communication submitted pursuant to this Section 1.12 is inaccurate or incomplete in any material respect (as determined by the Board of Directors (or any designated committee thereof)) such information shall be deemed not to have been provided in accordance with this Section 1.12.  Any stockholder providing information pursuant to this Section 1.12 shall promptly notify the Secretary of the corporation in writing at the principal executive office of the corporation of any inaccuracy or change in any previously provided information within two business days after becoming aware of such inaccuracy or change.  Upon written request of the Secretary, such stockholder shall provide, within seven business days after delivery of such request (or such longer period as may be specified in such request), (i) written verification, reasonably satisfactory to the corporation, to demonstrate the accuracy of any information submitted and (ii) a written affirmation of any information submitted as of an earlier date.  If the stockholder giving notice of an intent to nominate a candidate for election fails to provide such written verification or affirmation within such period, the information as to which written verification or affirmation was requested may be deemed not to have been provided in accordance with this Section 1.12.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.67pt"><br>BOARD OF DIRECTORS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Board of Directors shall consist of one or more members, the number thereof to be determined from time to time by resolution of the Board of Directors.  Directors need not be stockholders.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Removal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Vacancies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Board of Directors shall initially consist of the persons named as Directors by the Incorporator, and each Director so elected shall hold office until the first </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">annual meeting of stockholders or until his&#47;her successor is elected and qualified.  At the first annual meeting of stockholders and at each annual meeting thereafter, the stockholders shall elect Directors each of whom shall hold office for a term of one year or until his&#47;her successor is elected and qualified.  Any Director may resign at any time upon written notice to the corporation.  Any vacancy occurring in the Board of Directors for any cause may be filled by a majority of the remaining members of the Board of Directors, although such majority is less than a quorum, or by a plurality of the votes cast at a meeting of stockholders, and each Director so elected shall hold office until the expiration of the term of office of the Director whom he has replaced or until his&#47;her successor is elected and qualified.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Regular Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Regular meetings of the Board of Directors may be held at such places within or without the State of Delaware and at such times as the Board of Directors may from time to time determine, and if so determined notices thereof need not be given.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Special Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Special meetings of the Board of Directors may be held at any time or place within or without the State of Delaware whenever called by the President, any Vice President, the Secretary, or by any member of the Board of Directors.  Reasonable notice thereof shall be given by the person or persons calling the meeting, not later than the second day before the date of the special meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Telephonic Meetings Permitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Members of the Board of Directors, or any committee designated by the Board, may participate in a meeting of such Board or committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this bylaw shall constitute presence in person at such meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Quorum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Vote Required for Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  At all meetings of the Board of Directors a majority of the directors then in office shall constitute a quorum for the transaction of business.  Except in cases in which the Certificate of Incorporation or these bylaws otherwise provide, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Meetings of the Board of Directors shall be presided over by the Chairman of the Board, if any, or in his&#47;her absence by the Vice Chairman of the Board, if any, or in his&#47;her absence by the President, or in their absence by a chairman chosen at the meeting.  The Secretary shall act as secretary of the meeting, but in his&#47;her absence the chairman of the meeting may appoint any person to act as secretary of the meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Informal Action by Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless otherwise restricted by the Certificate of Incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board or committee.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.34pt"><br>COMMITTEES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the corporation.  The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.  In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of any such absent or disqualified member.  Any such committee, to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it, but no such committee shall have the power or authority in reference to amending the Certificate of Incorporation (except that any such committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of Preferred Stock adopted by the Board of Directors pursuant to Article Fourth of the Certificate of Incorporation, fix any of the preferences or rights of such shares relating to dividends, redemption, dissolution, any distribution of the assets of the corporation or the conversion into, or the exchange of such shares for, shares of any other class or classes or any other series of the same or any other class or classes of stock of the corporation), adopting an agreement of merger or consolidation under Sections 251 or 252 of the General Corporation Law of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), recommending to the stockholders the sale, lease or exchange of all or substantially all of the corporation&#8217;s property and assets, recommending to the stockholders a dissolution of the corporation or a revocation of a dissolution, or amending these bylaws&#59; and unless the resolution or the Certificate of Incorporation expressly so provides, no such committee shall have the power or authority to declare a dividend, to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">authorize the issuance of stock, or to adopt a certificate of ownership and merger pursuant to Section 253 of the DGCL.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Committee Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless the Board of Directors otherwise provides, each committee designated by the Board may make, alter and repeal rules for the conduct of its business.  In the absence of such rules each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to Article II of these bylaws.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.78pt"><br>OFFICERS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Term of Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Removal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Vacancies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Board of Directors shall choose a President and Secretary, and it may, if it so determines, choose a Chairman of the Board and a Vice Chairman of the Board from among its members.  The Board of Directors may also choose one or more Vice Presidents, one or more Assistant Secretaries, a Treasurer and one or more Assistant Treasurers.  Each such officer shall hold office until the first meeting of the Board of Directors after the annual meeting of stockholders next succeeding this election, and until his&#47;her successor is elected and qualified or until his&#47;her earlier resignation or removal.  Any officer may resign at any time upon written notice to the corporation.  The Board of Directors may remove any officer with or without cause at any time, but such removal shall be without prejudice to the contractual rights of such officer, if any, with the corporation.  Any number of offices may be held by the same person.  Any vacancy occurring in any office of the corporation by death, resignation, removal or otherwise may be filled for the unexpired portion of the term by the Board of Directors at any regular or special meeting.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Powers and Duties of Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The officers of the corporation shall have such powers and duties in the management of the corporation as may be prescribed by the Board of Directors and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board of Directors.  The Board of Directors may require any officer, agent or employee to give security for the faithful performance of his&#47;her duties.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.11pt"><br>STOCK</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Board may provide by resolution or resolutions that some or all of any or all classes or series of the stock of the Company shall be uncertificated shares.  Certificates, if any, representing shares of stock of the Company will be in such form as is determined by the Board, subject to applicable legal requirements.  Each such certificate shall be numbered and shall be signed by or in the name of the corporation by the Chairman or Vice Chairman of the Board of Directors, if any, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the corporation, certifying the number of shares owned by him in the corporation.  Any of or all the signatures on the certificate may be a facsimile.  In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued by the corporation with the same effect as if he were such officer, transfer agent, or registrar at the date of issue.  Records shall be kept of the amount of stock of the corporation issued and outstanding, the manner in which and the time when such stock was paid for, the respective names, alphabetically arranged, and the addresses, of the persons, firms or corporations owning of record the stock represented by certificates for stock of the corporation, the number, class and series of shares represented by such certificates, respectively, the time when each became an owner of record thereof, and the respective dates of such certificates, and in case of cancellation, the respective dates of cancellation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Lost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stolen or Destroyed Stock Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of New Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The corporation may issue a new certificate of stock in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the corporation may require the owner of the lost, stolen or destroyed certificate, or his&#47;her legal representative, to give the corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Transfers of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Transfers of shares shall be made upon the books of the Company (i) only by the holder of record thereof, or by a duly authorized agent, transferee or legal representative and (ii) in the case of certificated shares, upon the surrender to the Company of the certificate or certificates for such shares.  No transfer shall be made that is inconsistent with the provisions of applicable law.  The person in whose name shares of stock stand on the books of the corporation shall be deemed the owner thereof for all purposes as regards the corporation.  Whenever any transfer of shares shall be made for collateral security and not absolutely, such fact shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">be so expressed in the entry of transfer if, when the certificate of certificates shall be presented to the corporation for transfer, both the transferor and the transferee request the corporation to do so.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Regulations Concerning Transfer of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Board of Directors may make such rules and regulations as it may deem expedient, not inconsistent with these bylaws, concerning the issue, transfer and registration of certificates for stock of the corporation.  The Board of Directors may appoint, or authorize any officer or officers to appoint, one or more transfer agents and one or more registrars, and may require all certificates for stock to bear the signature or signatures of any of them.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.78pt"><br>INDEMNIFICATION OF DIRECTORS, <br>OFFICERS, EMPLOYEES AND AGENTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Right to Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person who was or is made or is threatened to be made a party or is otherwise involved in any action, suit, or proceeding, whether brought by or in the right of the corporation or otherwise, including civil, criminal, administrative, or investigative (a &#8220;proceeding&#8221;) by reason of the fact that he, or a person for whom he is the legal representative, is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person.  The corporation shall indemnify a person in connection with a proceeding initiated by such person only if the proceeding was authorized by the Board of Directors of the corporation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Prepayment of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The corporation shall pay the expenses incurred in defending any proceeding in advance of its final disposition, provided, however, that the payment of expenses incurred by a director or officer in his&#47;her capacity as a director or officer (except with regard to service to an employee benefit plan or non-profit organization) in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking by the director or officer to repay all amounts advanced if it should be determined that the director or officer is not entitled to be indemnified under this Article VI or otherwise.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If a claim for indemnification or payment of expenses under this Article VI is not paid in full within 90 days after a written claim therefor has been received by the corporation, the claimant may file suit to recover the unpaid amount of such claims and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim.  In any such action the corporation shall have the burden of proving that the claimant was not entitled to the requested indemnification or payment of expenses under applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Non-Exclusivity of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The rights conferred on any person by this Article VI shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, these Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Amendment or Repeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any repeal or modification of the foregoing provisions of this Article VI shall not adversely affect any right or protection of a director, officer or employee of the corporation in respect of any act or omission occurring prior to the time of such repeal or modification.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.45pt"><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The fiscal year of the corporation shall be determined by resolution of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Seal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Board of Directors may, but need not, adopt a corporate seal.  If adopted, the corporate seal shall have the name of the corporation inscribed thereon and shall be in such form as may be approved from time to time by the Board of Directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Waiver of Notice of Meetings of Stockholders, Directors and Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any written waiver of notice, signed by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice.  Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.  Neither the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">business to be transacted at, nor the purpose of any regular or special meeting of the stockholders, directors, or members of a committee of directors need be specified in any written waiver of notice.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Interested Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Quorum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  No contract or transaction between the corporation and one or more of its directors or officers, or between the corporation and any other corporation, partnership, association, or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board or committee thereof which authorizes the contract or transaction, or solely because his&#47;her or their votes are counted for such purpose, if&#58;  (a) the material facts as to his&#47;her relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum&#59; (b) the material facts as to his&#47;her relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders&#59; or (c) the contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee thereof, or the stockholders.  Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee, which authorizes the contract or transaction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Form of Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any records maintained by the corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be kept on, or be in the form of, punch cards, magnetic tape, photographs, microphotographs, or any other information storage device, provided that the records so kept can be converted into clearly legible form within a reasonable time.  The corporation shall so convert any records so kept upon the request of any person entitled to inspect the same.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.04pt;text-decoration:underline">Amendment of Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  These Bylaws may be altered or repealed, and new bylaws made, by the Board of Directors, but the stockholders may make additional bylaws and may alter and repeal any bylaws whether adopted by them or otherwise.</font></div><div style="margin-bottom:10.4pt;margin-top:1.15pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">***</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id7ad370358644ffdbee5adb7ca72c276_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royalty Purchase Agreement</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By and Between</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arrowhead Pharmaceuticals, Inc.</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royalty Pharma Investments 2019 ICAV</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated as of November 9, 2022</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id7ad370358644ffdbee5adb7ca72c276_4"></div><hr style="page-break-after:always"><div style="min-height:120.24pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Table of Contents</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 1 DEFINED TERMS AND RULES OF CONSTRUCTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.1</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.2</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Interpretations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.3</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Headings</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 2 PURCHASE, SALE AND ASSIGNMENT OF THE ROYALTY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.1</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Assumed Obligations, Excluded Assets</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">True Sale</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 3 CLOSING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.1</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closings&#59; Payment of Purchase Price.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.2</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bill of Sale</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.3</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensee Instruction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.4</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Form W-9</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.5</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Form W-8BEN-E</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.6</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Room</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.7</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bilateral Common Interest Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4 REPRESENTATIONS AND WARRANTIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.1</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller&#8217;s Representations and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.2</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">The Buyer&#8217;s Representations and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">18</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4.3</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Implied Representations and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 5</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> COVENANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.1</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosures</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.2</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payments Received In Error</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.3</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reduction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Late Fee</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.5</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reports&#59; Notices and Other Information from Licensee</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.6</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices and Other Information to Licensee</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Inspections and Audits of Licensee</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.8</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment or Assignment of License Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.9</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Maintenance of License Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcement of License Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.11</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of License Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">23</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.12</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New Arrangements.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">23</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.13</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Preservation of Rights</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">24</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.14</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcement&#59; Defense&#59; Prosecution and Maintenance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">25</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.15</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.16</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 6 CONFIDENTIALITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">27</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-i-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.24pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Table of Contents</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(continued)</font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.1</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.2</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Authorized Disclosure</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 7 INDEMNIFICATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.1</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">General Indemnity</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.2</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Claims</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.3</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on Liability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.4</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Claims</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.5</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusive Remedy</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.6</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Time Limitations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.7</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Treatment for Indemnification Payments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8 TERMINATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.1</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grounds for Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.2</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Automatic Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.3</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9 MISCELLANEOUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.1</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.2</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.3</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.4</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment and Waiver</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.5</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.6</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Third Party Beneficiaries</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.7</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.8</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JURISDICTION&#59; VENUE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.9</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">34</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.10</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Specific Performance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">35</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.11</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">35</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.12</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Relationship of the Parties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a href="#id7ad370358644ffdbee5adb7ca72c276_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none">35</a></font></div></td></tr></table></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Index of Exhibits</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit A-1&#58; &#160;&#160;&#160;&#160;Bilateral Common Interest Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit A-2&#58; &#160;&#160;&#160;&#160;Trilateral Common Interest Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit B&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seller&#8217;s Wire Transfer Instructions</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit C&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Bill of Sale</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit D&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Licensee Instruction Letter</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit E&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;License Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit F&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Knowledge Parties</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit G&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Licensed Patents</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-ii-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="id7ad370358644ffdbee5adb7ca72c276_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ROYALTY PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This ROYALTY PURCHASE AGREEMENT, dated as of November 9, 2022 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is made and entered into by and between Arrowhead Pharmaceuticals, Inc., a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), on the one hand, and Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), on the other hand.  Unless otherwise defined in this Agreement, capitalized terms have the meanings ascribed to them in Section 1 below.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">W I T N E S S E T H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, pursuant to the License Agreement, the Seller granted to Licensee a license under the Arrowhead Licensed Technology with respect to the Licensed Compounds and Licensed Products and the Seller&#8217;s rights under the Joint IPR (as such term is defined in the License Agreement), and Licensee, in partial consideration thereof, agreed to pay specified royalties to the Seller with respect to Net Sales of the Licensed Products&#59; and</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Buyer desires to purchase the Royalty from the Seller, and the Seller desires to sell the Royalty to the Buyer. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Seller and the Buyer hereby agree as follows&#58;</font></div><div style="text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:29.72pt"> &#160;&#160;&#160;&#160;<br>DEFINED TERMS AND RULES OF CONSTRUCTION</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As used in this Agreement, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Purchase Price Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 2.1(b).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any particular Person, any other Person directly or indirectly, and whether by contract or otherwise, controlling, controlled by or under common control with such Person.  For purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. Notwithstanding the foregoing, with respect to the Seller, the term &#8220;Affiliate&#8221; shall not include Visirna or its respective Subsidiaries.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in the preamble.  References to this Agreement include the Bill of Sale and the Licensee Instruction Letter. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amgen Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all patents, other than the Licensed Patents, owned or in-licensed by Amgen Inc. or its Affiliates that claim the Licensed Product.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arrowhead In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an In-License to which the Seller is a party pursuant to which the Seller has in-licensed any Arrowhead Licensed Technology from a Third Party. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arrowhead Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to the term Arrowhead Licensed Technology in Section 1.12 of the License Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arrowhead Platform Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Patents listed as &#8220;Arrowhead Platform Patents&#8221; on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arrowhead Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Patents listed as &#8220;Arrowhead Product Patents&#8221; on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ASCVD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 2.1(b). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws affecting the enforcement of creditors&#8217; rights generally.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bilateral Common Interest Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Common Interest Agreement between the Seller and the Buyer, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bill of Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 3.3.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day other than (a)&#160;a Saturday or Sunday or (b)&#160;a day on which banking institutions located in New York are permitted or required by applicable law or regulation to remain closed.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in the preamble.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 7.1(a).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 3.1.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date on which the Closing occurs.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Collaboration Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 1.28 of the License Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Credit Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any insolvency, bankruptcy, receivership, assignment for the benefit of creditors, similar proceeding, or financial distress of Licensee, as a result of which Licensee fails to pay, or is delayed in paying, all or a portion of the Royalty . </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Room</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 3.7.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Food and Drug Administration, or a successor federal agency thereto in the United States. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FDA Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the FDA&#8217;s approval of an NDA for Olpasiran, including all licenses, registrations, and pricing or reimbursement approvals, that are necessary for the sale and marketing of Olpasiran in the United States. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any&#58; (a)&#160;nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature&#59; (b)&#160;federal, state, local, municipal, foreign or other government&#59; (c)&#160;governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tribunal)&#59; (d)&#160;multi-national organization or body&#59; or (e)&#160;individual, body or other entity exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an agreement with a Third Party pursuant to which such Third Party grants a license to the counterparty under such Third Party&#8217;s intellectual property rights.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 7.2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 7.2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in Section 1.60 of the License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means $250,000,000.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to the term Joint Patent in Section 9.2(a) of the License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Judgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any judgment, order, writ, injunction, citation, award or decree of any nature.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Knowledge of the Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the actual knowledge of the Seller&#8217;s executive officers or personnel identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, exercising reasonably diligent inquiry.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) that certain Second Collaboration and License Agreement by and between the Seller and Licensee dated September 28, 2016, as may be amended and&#47;or restated from time to time, and (b) if applicable, solely from and after the date of execution of a New License Agreement entered into by the Seller in accordance with Section 5.12, any such New License Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">License Agreement Correspondence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) all reports provided to the Seller by Licensee since January 1, 2020 pursuant to Section 6.3 of the License Agreement&#59; (b) all minutes from, and meeting agendas and materials of, the Joint Research Committee (as such term is defined in Section 4.1 of the License Agreement) and all committees thereof since January 1, 2020 related to the Royalty or any Licensed Product&#59; (c) any written updates Seller has received from Licensee&#8217;s Alliance Manager (as such term is defined in the License Agreement and as designated in accordance with Section 4.1(f) of the License Agreement) since January 1, 2020 related to the Royalty or any Licensed Product, including manufacturing updates under Section 7.4 of the License Agreement&#59; (d) the Arrowhead In-Licenses listed in Exhibit E of the License Agreement&#59; (e) any agreements between Seller and Licensee (or their Affiliates) relating to the License Agreement, including any manufacturing or services agreements contemplated in Section 7.1 of the License Agreement (but excluding any work orders to such agreements which such work orders are unrelated to the Royalty and which do not amend or waive any provisions under the License Agreement) and any pharmacovigilance agreement contemplated in Section 5.3(b) of the License Agreement&#59; (f) any audit records provided by Licensee to the Seller under Section 8.9 of the License Agreement&#59; (g) any safety database information provided by Licensee to the Seller under Section 5.3(a) of the License Agreement&#59; (h) notifications received by Seller from Licensee of inventions developed by Licensee under Section 9.2(b) of the License Agreement&#59; (i) any patent infringement notices provided by Licensee to the Seller under Section 9.4(a) of the License Agreement&#59; (j) any patent enforcement and defense updates provided by Licensee to the Seller under Section 9.4(b)&#59; (k) any updates regarding Third Party infringement claims provided by Licensee to the Seller under Section 9.6 of the License Agreement&#59; and (l) all other material written communications between the Seller and Licensee under the License </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement since January 1, 2020 relating to the Royalty, the Licensed Patents, or the Licensed Products.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to the term Licensed Compound in Section 1.71 of the License Agreement</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 4.1(k)(i).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to (a) the term Licensed Product in Section 1.72 of the License Agreement, and (b) if applicable, solely from and after the date of execution of a New License Agreement entered into by the Seller in accordance with Section 5.12, the analogous term for &#8220;licensed product&#8221; or any comparable concept as defined in such New License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Licensed Patents, other than any Arrowhead Platform Patents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) Amgen Inc., a Delaware corporation and (b) if applicable, solely from and after the date of execution of a New License Agreement entered into by the Seller in accordance with Section 5.12, the licensee party to such New License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensee Instruction Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 3.3.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any mortgage, lien, pledge, license, charge, adverse claim, security interest, encumbrance or restriction of any kind, including any restriction on use, transfer or exercise of any other attribute of ownership of any kind.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Judgments, damages, losses, claims, costs, liabilities and expenses, including reasonable fees and out-of-pocket expenses of counsel.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lp(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 2.1(b). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i)&#160;a material adverse effect on the legality, validity or enforceability of any provision of this Agreement, (ii)&#160;a material adverse effect on the ability of the Seller to perform any of its obligations hereunder, (iii)&#160;a material adverse effect on the rights or remedies of the Buyer hereunder, (iv) a material adverse effect on the rights of the Seller under the License Agreement related to the Royalty, or (v) an adverse effect in any material respect on the timing, amount or duration of the payments to be made to the Buyer in respect of any portion of the Royalty or the right of the Buyer to receive such payments.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mutually Agreed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">for matters (i) related solely to the Royalty, (ii) that would reasonably be expected (with or without the giving of notice or passage of time, or both) to result in a Material Adverse Effect, (iii) that relate to patent filing, maintenance, prosecution, defense, enforcement, or seeking to extend the term of a patent or exclusivity period for a Licensed Product (including any patent term extension, pediatric exclusivity period, supplementary protection certificate or the like), in each case with respect to any of the Licensed Product Patents, or (iv) that relate to patent enforcement or seeking to extend the term of a patent or exclusivity period for a Licensed Product (including any patent term extension, pediatric exclusivity period, supplementary protection certificate or the like), in each case with respect to any of the Arrowhead Platform Patents that cover or claim Olpasiran, the Seller shall take, or refrain from taking, such reasonable actions (in each case, unless </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prohibited under the License Agreement) in respect of each such matter as are reasonably instructed by the Buyer&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">for matters related (i) solely to any amounts owed to the Seller under Section 8.2 of the License Agreement, or (ii) except as set forth in clause (a), to patent filing, maintenance, prosecution defense, enforcement , or seeking to extend the term of a patent or exclusivity period for a Licensed Product (including any patent term extension, pediatric exclusivity period, supplementary protection certificate or the like), in each case, with respect to any of the Arrowhead Platform Patents, the Seller shall have the right to take, or refrain from taking, such actions (in each case, unless prohibited under the License Agreement) in respect of each such matter as the Seller, acting reasonably, deems appropriate&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">for (i) matters related solely to any amounts owed to the Seller under Section 8.3 of the License Agreement, or (ii) all other matters under the License Agreement that do not meet the criteria set forth in clauses (a) or (b) above, the Seller shall take, or refrain from taking, actions (in each case, unless prohibited under the License Agreement) in respect of each such matter as the Seller and the Buyer, each acting reasonably, mutually agree. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to the term Net Sales in Section 1.74 of the License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 5.12(a)(ii).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 5.12(b).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Olpasiran</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an N-acetyl-galactosamine (GalNAc)-conjugated siRNA that lowers lipoprotein(a) by directly inhibiting the expression of apolipoprotein(a) that is referred to by Licensee as of the date hereof as olpasiran and formerly as AMG 890.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Olpasiran In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Arrowhead In-License in respect of which the Patents or Information licensed thereunder to the Seller or any of its Affiliates are necessary or reasonably useful to make, have made, use, sell, offer for sale, import or otherwise exploit Olpasiran.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to the term Patents in Section 1.77 of the License Agreement</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Triggering Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 2.1(b). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any (a)&#160;mechanic&#8217;s, materialmen&#8217;s, and similar liens for amounts not yet due and payable, (b)&#160;statutory liens for taxes, assessments or governmental charges or levies not yet due and payable or that the taxpayer is contesting in good faith, (c) any liens created, permitted or required by this Agreement in favor of the Buyer or its Affiliates, (d) pledges or deposits in the ordinary course of business in connection with workers&#8217; compensation, unemployment insurance and other social security legislation, (e) deposits to secure the performance of bids, trade contracts and leases (other than indebtedness), statutory obligations, surety and appeal bonds, indemnity and performance bonds and other obligations of a like nature incurred in the ordinary course of business, (f) normal and customary banker&#8217;s liens and rights of setoff upon deposits of cash in favor of banks or other depository institutions with respect to the deposit accounts for which such cash is maintained with such banks or other depository institutions, (g) any licenses granted to Licensee pursuant to the License Agreement, (h) non-exclusive sub-licenses granted by Licensee to Third Party contractors pursuant to the License </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement, for the sole purpose of performing any activity on such Licensee&#8217;s behalf in connection with Licensee&#8217;s exercise of any of its rights granted under Section 3.1 of the License Agreement, where such activity is to be performed at the direction and control and for the sole benefit of Licensee, its Affiliates and&#47;or Sublicensees, and (i) a license or other right granted  to any Person that is not an Affiliate of the Seller under the Arrowhead Platform Patents, other than with respect to the Licensed Compounds, Licensed Products, or the Collaboration Target (including any products directed thereto).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Royalty Reduction pursuant to Section 8.4(c) or 8.5 of, but subject to Section 8.4(d) of, the License Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any individual, firm, corporation, company, partnership, limited liability company, trust, joint venture, association, estate, trust, Governmental Entity or other entity, enterprise, association or organization.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prime Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the prime rate published by the Wall Street Journal, from time to time, as the prime rate.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any amounts actually recovered by the Seller as a result of any settlement or resolution of any actions, suits, proceedings, claims or disputes related to the License Agreement or any Licensed Product or related to or involving the Royalty.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Initial Purchase Price and any Additional Purchase Price Payments. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Related Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Licensee Instruction Letter and that certain (a) Master Services Agreement by and between the Seller and Licensee dated January 23, 2017 and (b) Confidentiality Disclosure Agreement by and between the Seller and Licensee dated April 21, 2014, each as may be amended and&#47;or restated from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, (i)&#160;any direct or indirect stockholder, member or partner of such Person and (ii)&#160;any manager, director, officer, employee, agent, advisor or other representative (including attorneys, accountants, consultants, bankers, financial advisors and actual and potential lenders and investors) of such Person.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) any and all amounts owed to the Seller under Section 8.4(a) of the License Agreement, (ii) any and all amounts owed to the Seller under the License Agreement in lieu of such payments of the foregoing clause (i), (iii) any and all payments or amounts owed to the Seller under Sections 8.9 (solely with respect to amounts owed to the Seller under Section 8.4(a) of the License Agreement) or 9.4(d) of the License Agreement, (iv) any and all amounts owed to the Seller under Section 11.2 of the License Agreement (solely with respect to amounts owed to the Seller under Section 8.4(a) of the License Agreement), and (v) any and all interest payments to the Seller under Section 8.8 of the License Agreement assessed on any payments described in the foregoing clauses (i), (ii) (iii) and (iv).  Except for purposes of Section 4.1(i)(xii), &#8220;Royalty&#8221; shall be net of any Permitted Reductions applicable to amounts owed to the Seller under Section 8.4(a) of the License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 4.1(i)(xii).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the quarterly reports deliverable by Licensee pursuant to Section&#160;8.4(e) of the License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in the preamble.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined in Section 7.1(b). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to the term Sublicensee in Section 3.3(a) of the License Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any corporation, partnership, joint venture or other entity, whether or not incorporated, of which at least 50% of the securities having, by their terms, ordinary voting power to elect members of the board of directors, or other bodies performing similar functions with respect to such entity, is directly or indirectly owned by such Person.  Notwithstanding the foregoing, with respect to the Seller,  the term &#8220;Subsidiary&#8221; shall not include Visirna or its Subsidiaries.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any federal, state, local or non-U.S. income, gross receipts, license, payroll, employment, excise, severance, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, abandoned property, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to the term Third Party in Section 1.94 of the License Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trilateral Common Interest Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Common Interest Agreement among the Seller, the Licensee and the Buyer, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Article&#160;9 of the New York Uniform Commercial Code, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Visirna</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Visirna Therapeutics, Inc.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Certain Interpretations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;either&#8221; and &#8220;or&#8221; are not exclusive and &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; are not limiting and shall be deemed to be followed by the words &#8220;without limitation&#59;&#8221;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#8220;if&#59;&#8221;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">references to a Person are also to its permitted successors and assigns&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">definitions are applicable to the singular as well as the plural forms of such terms&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">unless otherwise indicated, references to an &#8220;Article&#8221;, &#8220;Section&#8221; or&#160;&#8220;Exhibit&#8221; refer to an Article or Section of, or an Exhibit to, this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">references to &#8220;$&#8221; or otherwise to dollar amounts refer to the lawful currency of the United States&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">references to a law include any amendment or modification to such law and any rules and regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules and regulations occurs, before or after the date of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The table of contents and the descriptive headings of the several Articles and Sections of this Agreement and the Exhibits are for convenience only, do not constitute a part of this Agreement and shall not control or affect, in any way, the meaning or interpretation of this Agreement.&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:29.72pt"><br>PURCHASE, SALE AND ASSIGNMENT OF THE ROYALTY</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Closing&#59; Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">Upon the terms and subject to the conditions of this Agreement, at the Closing, the Seller shall sell, transfer, assign and convey to the Buyer, and the Buyer shall purchase, acquire and accept from the Seller, free and clear of all Liens, other than any Liens under clauses (a) through (f), inclusive, of the definition of Permitted Liens, all of the Seller&#8217;s right, title and interest in and to the Royalty. The purchase price to be paid at the Closing to the Seller for the sale, transfer, assignment and conveyance of the Seller&#8217;s right, title and interest in and to the Royalty to the Buyer is the Initial Purchase Price.  At the Closing, the Buyer shall pay the Seller the Initial Purchase Price by wire transfer of immediately available funds to one or more accounts specified by the Seller on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, without any deduction or withholding on account of any Taxes.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">Following the Closing, upon the occurrence of each of the following events (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Triggering Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), if the Seller is in compliance in all material respects with its obligations under this Agreement, the Buyer shall make a cash payment (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Purchase Price Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the Seller in the amount corresponding to such Payment Triggering Event&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">#</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PAYMENT TRIGGERING EVENT</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ADDITIONAL PURCHASE PRICE PAYMENT AMOUNT</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Completion of the enrollment of  the OCEAN(a) Phase 3 clinical trial (NCT05581303) for Olpasiran to reduce the risk of coronary heart disease death, myocardial infarction or urgent coronary revascularization in adults with atherosclerotic cardiovascular disease (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ASCVD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and elevated lipoprotein(a) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lp(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as reasonably evidenced by (i) public disclosure of such completion by Licensee, (ii) written notice of such completion by Licensee to Seller (a copy of which shall be provided to Buyer) or (iii) the date on which clinicaltrials.gov shows the status of the OCEAN(a) Phase 3 clinical trial (NCT05581303) as &#8220;Active, not Recruiting&#8221;.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$50,000,000</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Receipt of FDA Approval for Olpasiran to reduce the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a) (or any substantially similar indication for the reduction of cardiovascular event risk in adults with established cardiovascular disease and elevated Lp(a)).</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$50,000,000</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.36pt;text-align:center;text-indent:0.36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon the actual receipt by the Buyer of at least $70,000,000 in Royalty payments in the aggregate attributable to Net Sales that occur in any single calendar year.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$60,000,000</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$160,000,000</font></td></tr></table></div><div style="padding-left:90pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">The Seller hereby agrees and acknowledges that&#58; (i) the Additional Purchase Price Payments are contingent payment obligations of the Buyer and there can be no assurance regarding the occurrence of any of the Payment Triggering Events and (ii) the Buyer shall have no obligation or liability with respect to any Additional Purchase Price Payment unless and until the corresponding Payment Triggering Event has occurred. With respect to (A) the first two Payment Triggering Events set forth in the table of Section 2.1(b), the Seller shall notify the Buyer in writing promptly after the Seller is aware of the achievement of such Payment Triggering Events, and (B) the third Payment Triggering Event set forth in the table of Section 2.1(b), the Buyer shall notify the Seller in writing promptly after the Buyer is aware of the achievement of such Payment Triggering Event, and in each case, the Buyer shall pay the amount of the corresponding Additional Purchase Price Payment owed to the Seller by the Buyer in accordance with Section 2.1(b) by wire transfer of immediately available funds to the account(s) specified by the Seller on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (or such other account(s) as specified by the Seller in a writing delivered to the Buyer in accordance with Section 9.1 of this Agreement) within ten (10) Business Days following the Buyer&#8217;s receipt or delivery, as applicable, of such written notice, without any deduction or withholding on account of any Taxes.  For clarity, only one Additional Purchase Price Payment shall be due hereunder with respect to each Payment Triggering Event&#59; no Additional Purchase Price Payment shall be payable for repeated achievements of any Payment Triggering Events. Each party hereto further agrees and acknowledges that the other party shall have the right to offset any amounts owed by such party to the other party hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">The parties hereto further agree that&#58; (i) the aggregate Additional Purchase Price Payments payable by the Buyer hereunder shall not exceed $160,000,000 and (ii) the total Purchase Price payable to the Seller by the Buyer hereunder (inclusive of the Initial Purchase Price and, if required to be paid under this Agreement, all of the Additional Purchase Price Payments) shall in no event exceed $410,000,000 in the aggregate.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">No Assumed Obligations, Excluded Assets.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any provision in this Agreement to the contrary, the Buyer is purchasing, acquiring and accepting only the Royalty, and is not assuming any liability or obligation of the Seller of whatever nature, whether presently in existence or arising or asserted hereafter, under the License Agreement or otherwise. Except as specifically set forth herein in respect of the Royalty purchased, acquired and accepted hereunder, the Buyer does not, by such purchase, acquisition and acceptance, acquire any other contract rights of the Seller under the License Agreement or otherwise or any other assets of the Seller.</font></div><div style="text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">True Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. It is the intention of the parties hereto that the sale, transfer, assignment and conveyance contemplated by this Agreement be, and is, a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by the Seller to the Buyer of all of the Seller&#8217;s rights, title and interests in and to the Royalty and the Seller hereby relinquishes all title and control over the Royalty upon such sale, transfer, assignment and conveyance. Neither the Seller nor the Buyer intends the transactions contemplated by this Agreement to be, or for any purpose characterized as, a loan from the Buyer to the Seller or to any of the Seller&#8217;s Affiliates, or a pledge, a financing transaction or a borrowing. It is the intention of the parties hereto that the beneficial interest in and title to the Royalty and any &#8220;proceeds&#8221; (as such term is defined in the UCC) thereof shall not be part of Seller&#8217;s estates in the event of the filing of a petition by or against the Seller under any Bankruptcy Laws.  Each of the Seller and the Buyer hereby waives, to the maximum extent permitted by applicable law, any right to contest or otherwise assert that the sale contemplated by this Agreement does not constitute a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by the Seller to the Buyer of all of the Seller&#8217;s right, title and interest in and to the Royalty under applicable law, which waiver shall, to the maximum extent permitted by applicable law, be enforceable against the Seller in any bankruptcy or insolvency proceeding relating to (a) the Seller or its Subsidiaries or (b) Visirna or its Subsidiaries (if Visirna or such Subsidiary is an affiliate of the Seller as of the date of commencement of such proceeding). Accordingly, the Seller shall treat the sale, transfer, assignment and conveyance of the Royalty as a sale of an &#8220;account&#8221; or a &#8220;payment intangible&#8221; (as appropriate) in accordance with the UCC, and the Seller hereby authorizes the Buyer to file financing statements (and continuation statements with respect to such financing statements when applicable) naming the Seller as the seller and the Buyer as the buyer in respect of the Royalty.  Not in derogation of the foregoing statement of the intent of the parties hereto in this regard, and for the purposes of providing additional assurance to the Buyer in the event that, despite the intent of the parties hereto, the sale, transfer, assignment and conveyance contemplated hereby is hereafter held not to be a sale, the Seller does hereby grant to the Buyer a security interest in and to all right, title and interest of the Seller, in, to and under the Royalty and any &#8220;proceeds&#8221; (as such term is defined in the UCC) thereof as security for all of the Seller&#8217;s obligations hereunder, including the payment of the Royalty, and the Seller does hereby authorize the Buyer, from and after the Closing, to file such financing statements (and continuation statements with respect to such financing statements when applicable) in such manner and such jurisdictions as are necessary or appropriate to perfect such security interest.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:29.72pt"><br>CLOSING </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Closings&#59; Payment of Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The purchase and sale of the Royalty shall take place remotely via the exchange of documents and signatures on the date hereof or such other place, time and date as the parties hereto may mutually agree (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). At the Closing, the Buyer shall deliver (or cause to be delivered) payment of the Initial Purchase Price to the Seller by wire transfer of immediately available funds to one or more accounts specified by the Seller on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Bill of Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At the Closing, upon confirmation of the receipt of the Initial Purchase Price, each of the Seller and the Buyer shall deliver to the other party hereto a duly executed bill of sale evidencing the sale, transfer, assignment and conveyance of the Royalty, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bill of Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Licensee Instruction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At the Closing, the Seller shall deliver to the Buyer an instruction letter, in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensee Instruction Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), duly executed by the Seller, instructing Licensee to pay the Royalty to the account specified by the Buyer, which shall be delivered (with Buyer&#8217;s IRS Form W-8BEN-E) to Licensee following the Closing. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Form W-9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At the Closing, the Seller shall deliver to the Buyer a valid, properly executed IRS Form W-9 certifying that the Seller is exempt from U.S. federal withholding tax and &#8220;backup&#8221; withholding tax. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Form W-8BEN-E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At the Closing (and thereafter, at the Seller&#8217;s request), the Buyer shall deliver to the Seller a valid, properly executed IRS Form W-8BEN-E certifying that the Buyer is exempt from U.S. federal withholding tax with respect to any and all royalty payments in respect of the Royalty.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Data Room</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Within ten (10) days after the Closing, the Seller shall have delivered to the Buyer an electronic copy of all of the information and documents posted to the virtual data room established by the Seller as of the date hereof and made available to the Buyer via Intralinks (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Room</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Bilateral Common Interest Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At the Closing each of the Seller and the Buyer shall execute and deliver to the other party hereto the Bilateral Common Interest Agreement.</font></div><div style="text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:29.72pt"><br>REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Seller&#8217;s Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller represents and warrants to the Buyer that as of the Closing Date&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Existence&#59; Good Standing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller is a corporation duly incorporated, validly existing and in good standing under the laws of Delaware. The Seller is duly licensed or qualified to do business and is in corporate good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in corporate good standing has not and would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement. The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary corporate action on the part of the Seller.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Agreement has been duly executed and delivered and constitutes a valid and binding obligation of the Seller enforceable against the Seller in accordance with its terms, except as such enforceability may be limited by applicable Bankruptcy Laws or general principles of equity (whether considered in a proceeding in equity or at law).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The execution, delivery and performance by the Seller of this Agreement and the consummation of the transactions contemplated hereby do not and shall not (i)&#160;contravene or conflict with the organizational documents of the Seller, (ii)&#160;contravene or conflict with or constitute a material default under any law or Judgment binding upon or applicable to the Seller, (iii) contravene or conflict with or constitute a default under the License Agreement or (iv)&#160;contravene or conflict with or constitute a material default under any other material contract or material agreement binding upon or applicable to the Seller.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except for the consents that have been obtained on or prior to the Closing or filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Seller in connection with (i)&#160;the execution and delivery by the Seller of this Agreement, (ii)&#160;the performance by the Seller of its obligations under this Agreement or (iii)&#160;the consummation by the Seller of any of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">No Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. There is no action, suit, claim, investigation or proceeding pending or, to the Knowledge of the Seller, threatened, before any Governmental Entity, court or arbitrator, against or involving the Seller or any of its Subsidiaries that, individually or in the aggregate, would be reasonably be expected (with or without the giving of notice or passage of time, or both) to result in a Material Adverse Effect, nor has the Seller or any of its Subsidiaries received any letter or similar correspondence challenging or questioning the validity of this Agreement or the transactions contemplated hereby or any action taken or to be taken pursuant hereto.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither the Seller nor any of its Subsidiaries is in violation of, and to the Knowledge of the Seller, none of the Seller or any of its Subsidiaries is under investigation with respect to nor has the Seller or any of its Subsidiaries been threatened to be charged with or given notice of any violation of, any law or Judgment applicable to the Seller or any of its Subsidiaries, which violation would reasonably be expected (with or without the giving of notice or passage of time, or both) to have, either individually or in the aggregate, a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Undisclosed Events or Circumstances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the Knowledge of the Seller, no event or circumstance has occurred or exists with respect to the Seller, any of its Subsidiaries, or their respective businesses, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Seller but which has not been so publicly announced or disclosed and which, individually or in the aggregate, would constitute a Material Adverse Effect.</font></div><div style="text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is a true, correct and complete copy of the License Agreement. The Seller has delivered to the Buyer via the Data </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Room true, correct and complete copies of each Related Agreement and all License Agreement Correspondence. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">No Other Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The License Agreement and the Related Agreements are the only agreements, contracts, or other arrangements (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) between the Seller (or any predecessor or Affiliate thereof), on the one hand, and Licensee (or any predecessor or Affiliate thereof), on the other hand, relating to the subject matter thereof, and there are no other Contracts between the Seller (or any predecessor or any Affiliate thereof), on the one hand, and any other Person, including Licensee (or any predecessor or Affiliate thereof), on the other hand, that relate to the License Agreement, any Related Agreement, any Arrowhead Platform Patent (with respect to the Licensed Compounds, Licensed Products, or the Collaboration Target (including products directed thereto)), any Licensed Product Patent, a Licensed Compound or Licensed Product (including the development or commercialization thereof), or the Royalty.  There is no proposal to amend or waive any provision of the License Agreement or any Related Agreement in any manner that (x) would result in a breach of this Agreement or (y) would otherwise reasonably be expected to have a Material Adverse Effect. None of the executed Contracts and no draft or proposed Contracts, in each case, between the Seller (or any predecessor or any Affiliate thereof), on the one hand, and any other Person, including Licensee (or any predecessor or Affiliate thereof), on the other hand, contains any provision, term or condition that would reasonably be expected (with or without the giving of notice or passage of time, or both) to result in a Material Adverse Effect.    </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt;text-decoration:underline">Licenses&#47;Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except for any Liens under clause (h) of the definition of Permitted Liens, to the Knowledge of the Seller, there are no licenses or sublicenses entered into by Licensee or any other Person (or any predecessor or Affiliate thereof) in respect of Licensee&#8217;s rights and obligations under the License Agreement (including any Licensed Patents). The Seller has not received any written notice from Licensee pursuant to Section 3.3(a) of the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Validity and Enforceability of License Agreement&#59; No Repudiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The License Agreement is legal, valid, binding, enforceable (except as such enforceability may be limited by applicable Bankruptcy Laws or general principles of equity (whether considered in a proceeding in equity or at law)), and in full force and effect. The License Agreement will continue to be legal, valid, binding, enforceable (except as such enforceability may be limited by applicable Bankruptcy Laws or general principles of equity (whether considered in a proceeding in equity or at law)), and in full force and effect on identical terms  immediately following the consummation of the transactions contemplated by this Agreement. No party to the License Agreement or any Related Agreements has repudiated any provision of the License Agreement or any Related Agreements and the Seller has not received any written notice challenging the validity, enforceability or interpretation of any provision of the License Agreement or any Related Agreements, including the obligation to pay any portion of the Royalty without set-off of any kind.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">No Breaches or Defaults&#59; No Repudiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller is not nor has at any time been in, and, to the Knowledge of the Seller, Licensee is not nor has at any time been in, material breach or material default under the License Agreement. To the Knowledge of the Seller, no event has occurred that with notice or lapse of time would constitute such a material breach or material default.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Olpasiran is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Licensed Product under the License Agreement. To the Knowledge of the Seller, Olpasiran is the sole Licensed Product being researched, developed or commercialized by or on behalf of Licensee under the License Agreement. The Seller has the right to receive the royalties under Section 8.4(a) of the License Agreement during the Royalty Term (as defined in the License Agreement) applicable to each Licensed Product for so long as Licensee, one of its Affiliates or any of its or their Sublicensees is selling such Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">No Liens or Assignments by the Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not, except for Permitted Liens and as contemplated hereby, conveyed, assigned or in any other way transferred or granted any Liens upon or with respect to all or any portion of its right, title and interest in and to the Royalty, the Seller&#8217;s interest in any Licensed Patent or the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt;text-decoration:underline">No Waivers or Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not granted any material waiver under the License Agreement and has not released Licensee, in whole or in part, from any of its material obligations under the License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">No Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not (A) given Licensee any notice of termination of the License Agreement (whether in whole or in part) or any notice expressing any intention to terminate the License Agreement or (B) received any written notice, or to the Knowledge of the Seller, any other notice of termination of the License Agreement (whether in whole or in part) or any written notice, or to the Knowledge of the Seller, any other notice expressing any intention to terminate the License Agreement. To the Knowledge of the Seller, no event has occurred that would give rise to the termination of, or either Seller or Licensee having the right to terminate, the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Payments Made</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has timely received from Licensee the full amount of the payments due and payable under the License Agreement, to the extent such amounts have come due.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Assignments by Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not consented to any assignment, delegation or other transfer by Licensee or any of its predecessors of any of their rights or obligations under the License Agreement, and, to the Knowledge of the Seller, Licensee has not, except for Permitted Liens, assigned or otherwise transferred or granted any Lien upon or with respect to any of its rights or obligations under the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">No Indemnification Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not notified Licensee or any other Person of any claims for indemnification under the License Agreement nor has the Seller received any claims for indemnification under the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt;text-decoration:underline">No Royalty Reductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the Knowledge of the Seller, the amount of the Royalty payable under Section 8.4(a) of the License Agreement is not subject to any claim by Licensee alleging a right of set-off, counterclaim, credit, reduction or deduction by contract or otherwise against the Royalty (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), including any Permitted Reduction. To</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Knowledge of the Seller, no event or condition exists that, upon notice or passage of time or both, would reasonably be expected (with or without the giving of notice or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">passage of time, or both) to permit Licensee to claim, or have the right to claim, a Permitted Reduction or another Royalty Reduction.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">No Notice of Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not received any written notice from, or given any written notice to, Licensee pursuant to Section 9.4(a) of the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.69pt;text-decoration:underline">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not initiated, pursuant to Section&#160;8.9 of the License Agreement, any inspection or audit of books of accounts or other records pertaining to Net Sales of the Licensed Product, or the calculation of royalties payable to the Seller on Net Sales of the Licensed Product under the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">In-Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. There are no Olpasiran In-Licenses.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Title to Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has good and marketable title to the Royalty, free and clear of all Liens, other than any Liens under clauses (a) through (f), inclusive, of the definition of Permitted Liens. Upon payment of the Initial Purchase Price by the Buyer, the Buyer will acquire, subject to the terms and conditions set forth in this Agreement and the License Agreement, good and marketable title to the Royalty, free and clear of all Liens, other than any Liens under clauses (a) through (f), inclusive, of the definition of Permitted Liens.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> lists all Arrowhead Platform Patents, all Arrowhead Product Patents, and all Joint Patents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  There are no Joint Patents.  The Seller is the sole owner of all of the Arrowhead Platform Patents and all of the Arrowhead Product Patents. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> specifies as to each of the Licensed Patents, (x) whether each such Licensed Patent is an Arrowhead Platform Patent or an Arrowhead Product Patent, and (y) the jurisdictions by or in which each such patent has issued as a patent or such patent application has been filed, including the respective patent numbers and application numbers and issue and filing dates. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">There are no pending or, to the Knowledge of the Seller, threatened litigations, interferences, reexamination, oppositions or like procedures involving any Arrowhead Platform Patents to which the Seller or any of its Subsidiaries is a party or, to the Knowledge of the Seller, to which Licensee or any of its Affiliates is a party. To the Knowledge of the Seller, there are no pending or threatened litigations, interferences, reexamination, oppositions or like procedures involving any Licensed Product Patents or Amgen Product Patents to which the Seller or any of its Subsidiaries or Licensee or any of its Affiliates is a party. The Seller has not received any patent prosecution-related updates from Licensee pursuant to Section 9.3 of the License Agreement that contain any information that have resulted in, or would reasonably be expected (with or without the giving of notice or passage of time, or both) to result in, a Material Adverse Effect. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">No Arrowhead Platform Patent and, to the Knowledge of the Seller, no Licensed Product Patent has lapsed, expired or otherwise terminated, and, to the Knowledge of the Seller, all issued Licensed Patents are valid, enforceable and in full force and effect. The Seller has not received any written notice relating to the lapse, expiration or other termination of any of the Licensed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patents, or any written legal opinion that alleges that any of the issued Licensed Patents are invalid or unenforceable. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To the Knowledge of the Seller, there is no Person who is or claims to be an inventor under any of the Licensed Patents who is not a named inventor thereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Seller has not, and, to the Knowledge of the Seller, Licensee has not, received any written notice of any claim by any Person (A) challenging the inventorship or ownership of, the rights of the Seller or Licensee, as applicable, in and to, or the patentability, validity or enforceability of, any Licensed Patent, or (B) asserting that the development, manufacture, importation, sale, offer for sale or use of any Licensed Product infringes any issued patent of such Person. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To the Knowledge of the Seller, the discovery and development of the Licensed Products did not and does not infringe, misappropriate or otherwise violate any patent rights or other intellectual property rights owned by any third party, other than the Amgen Product Patents. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">To the Knowledge of the Seller, the manufacture, use, marketing, sale, offer for sale, importation or distribution of the Licensed Products has not and will not, infringe, misappropriate or otherwise violate any patent rights or other intellectual property rights owned by any Third Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">To the Knowledge of the Seller, Licensee has not obtained or been granted an In-License from a Third Party under any Patents of such Third Party that are necessary or useful to allow Licensee (and its Affiliates and Sublicensees) to make, have made, use, import, offer for sale, sell, export or otherwise exploit, Licensed Products in a particular country.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To the Knowledge of the Seller, no third party has infringed or is infringing any of the Licensed Patents.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">All required maintenance fees, annuities and like payments with respect to the Licensed Patents for which the Seller controls the prosecution and maintenance in accordance with Section 9.3 of the License Agreement, and to the Knowledge of the Seller, with respect to all other Licensed Patents, have been paid timely.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">The Licensed Patents constitute all of the Patents owned or controlled by the Seller or any of its Affiliates that are necessary or reasonably useful to make, have made, use, sell, offer for sale, import or otherwise exploit Olpasiran.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">UCC Representation and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller&#8217;s exact legal name is, and for the immediately preceding six (6) years has been, &#8220;Arrowhead Pharmaceuticals, Inc.&#8221;. The Seller is, and for the prior six (6) years has been, incorporated in Delaware.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Brokers&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Seller who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller has not received written notice from Licensee of any intention to withhold or deduct any material tax from future payments to the Seller. To the Knowledge of the Seller, there are no existing Liens for taxes on the Royalty (or any portion thereof), other than Permitted Liens.  To the Knowledge of the Seller, there are no ongoing audits or investigations by any tax authority with respect to any payment made to the Seller under the License Agreement. The Seller has never taken the position for U.S. federal income tax purposes that the License Agreement is treated as a partnership for U.S. federal income tax purposes. The Seller has never received a Schedule K-1 furnished to it as a partner in a partnership as a result of being a party to the License Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">The Buyer&#8217;s Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Buyer represents and warrants to the Seller that as of the Closing Date&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Existence&#59; Good Standing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Buyer is an Irish collective asset-management vehicle that is duly organized, validly existing and in good standing under the laws of the Republic of Ireland.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Buyer has the requisite right, power and authority to execute, deliver and perform its obligations under this Agreement. The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary action on the part of the Buyer.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement has been duly executed and delivered by an authorized person of the owner trustee of the Buyer and constitutes the valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The execution, delivery and performance by the Buyer of this Agreement do not and shall not (i)&#160;contravene or conflict with the organizational documents of the Buyer, (ii)&#160;contravene or conflict with or constitute a default under any material provision of any law binding upon or applicable to the Buyer or (iii)&#160;contravene or conflict with or constitute a default under any material contract or other material agreement or Judgment binding upon or applicable to the Buyer.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Other than the filing of financing statement(s) in accordance with Section 2.3 or filings required by federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Buyer in connection with (i)&#160;the execution and delivery by the Buyer of this Agreement, (ii)&#160;the performance by the Buyer of its obligations under this Agreement, or (iii)&#160;the consummation by the Buyer of any of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">No Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. There is no action, suit, investigation or proceeding pending or, to the knowledge of the Buyer, threatened before any Governmental Entity to which the Buyer is a party that would, if determined adversely, reasonably be expected to prevent or materially and adversely affect the ability of the Buyer to perform its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Buyer has sufficient cash on hand to pay the Purchase Price. The Buyer acknowledges that its obligations under this Agreement are not contingent on obtaining financing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Brokers&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Buyer who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">No Implied Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. EXCEPT AS EXPRESSLY SET FORTH IN SECTION 4.1, THE SELLER MAKES NO REPRESENTATION OR WARRANTY, EXPRESSED OR IMPLIED, AT LAW OR IN EQUITY, INCLUDING WITH RESPECT TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, AND ANY SUCH REPRESENTATIONS OR WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED. BUYER ACKNOWLEDGES THAT, EXCEPT AS SPECIFICALLY PROVIDED IN THIS ARTICLE 4, THE SELLER HAS ASSUMED NO RESPONSIBILITIES OF ANY KIND WITH RESPECT TO ANY ACT OR OMISSION OF LICENSEE WITH RESPECT TO THE DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE, DISTRIBUTION, MARKETING OR OTHER ACTIVITIES OF LICENSEE WITH RESPECT TO ANY OF THE LICENSED PRODUCTS.</font></div><div style="text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:29.72pt">&#160;&#160;&#160;&#160;<br>COVENANTS</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except for a press release previously approved in form and substance by the Seller and the Buyer or any other public announcement using substantially the same text as such press release or any other public disclosure permitted under this Agreement following the Closing, neither the Buyer nor the Seller shall, and each party hereto shall cause its respective Representatives, Affiliates and Affiliates&#8217; Representatives not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Agreement or the subject matter hereof without the prior written consent of the other party hereto (which consent shall not be unreasonably withheld, conditioned or delayed).  Notwithstanding the foregoing, the Buyer and the Seller and their respective Representatives, Affiliates, and Affiliates&#8217; Representatives may (a) make disclosures as may be required by applicable law or stock exchange rule, and (b) publicly announce the achievement of (i) a Payment Triggering Event and the payment of the corresponding Additional Purchase Price Payment, or (ii) the occurrence of a milestone event under Section 8.2 or 8.3 of the License Agreement and the payment of the corresponding milestone payment&#59; provided that, in each case (a) and (b), the party making such disclosure shall allow the other party hereto reasonable time to comment on such press release or other public announcement or disclosure in advance of such issuance. The Buyer acknowledges that, subject to the requirements of this Section 5.1, it will be necessary for the Seller to file this Agreement with the SEC and to make other public disclosures regarding the terms of this Agreement and payments made under this Agreement in its reports filed with the SEC.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Payments Received In Error</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Commencing on the Closing Date and at all times thereafter, if any payment of any portion of the Royalty is made to the Seller, the Seller shall pay such amount to the Buyer, promptly (and in any event within ten (10) Business Days) after the receipt thereof, by wire transfer of immediately available funds to an account designated in writing by the Buyer. The Seller shall notify the Buyer of such wire transfer and provide reasonable details regarding the Royalty payment so received by the Seller. The Buyer shall, if requested by the Seller, provide a valid, properly executed IRS Form W-8BEN-E certifying that the Buyer is exempt from U.S. federal withholding tax with respect to any such payment. The Seller agrees that, in the event any payment of the Royalty is paid to the Seller, the Seller shall (i)&#160;until paid to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer, hold such payment received in trust for the benefit of the Buyer and (ii)&#160;have no right, title or interest in such payment and that it shall not pledge or otherwise grant any security interest therein.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Commencing on the Closing Date and at all times thereafter, if any payment due under the License Agreement that does not constitute any payment of any portion the Royalty is made to the Buyer, the Buyer shall pay such amount to the Seller, promptly (and in any event within ten (10) Business Days) after the receipt thereof, by wire transfer of immediately available funds to an account designated in writing by the Seller. The Buyer shall notify the Seller of such wire transfer and provide reasonable details regarding the erroneous payment so received by the Buyer. The Buyer agrees that, in the event any payment due under the License Agreement that does not constitute the Royalty is paid to the Buyer, the Buyer shall (i)&#160;until paid to the Seller, hold such payment received in trust for the benefit of the Seller and (ii)&#160;have no right, title or interest in such payment and that it shall not pledge or otherwise grant any security interest therein. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If Licensee exercises any Royalty Reduction against any payment of the Royalty other than for a Permitted Reduction, then the Seller shall promptly (and in any event within ten (10) Business Days following the earlier of the Seller first becoming aware of such Royalty Reduction (including by Seller&#8217;s receipt of written notice by Licensee or the Buyer evidencing such Royalty Reduction) and the Seller&#8217;s receipt of the applicable Royalty Report) make a true-up payment to the Buyer such that the Buyer receives the full amount of such Royalty payments that would have been payable to the Buyer had such Royalty Reduction that is not a Permitted Reduction not occurred, unless the Seller, acting in good faith, believes such shortfall is a material breach by Licensee of the License Agreement and has provided notice to the Buyer under Section 5.10(a) regarding such shortfall, in which case Section 5.10(b) shall govern the enforcement of such breach, and Section 5.10(c) shall govern the disbursement of the Proceeds of such enforcement. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Late Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A late fee of 4% over the Prime Rate shall accrue on all unpaid amounts on an annualized basis with respect to any sum that is otherwise payable by the Buyer or by the Seller to the other party under this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Royalty Reports&#59; Notices and Other Information from Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Promptly (and in any event within five (5) Business Days) following the receipt by the Seller of any Royalty Report, License Agreement Correspondence or patent prosecution correspondence provided between Licensee and the Seller under Section 9.3 of the License Agreement, the Seller shall furnish a true, correct and complete copy of the same to the Buyer, provided that the Seller may redact any information that does not relate to the Royalty, the Licensed Patents, or the Licensed Products and would not reasonably be expected (with or without the giving of notice or passage of time, or both) to have a Material Adverse Effect. After the Closing, the Seller shall (a) execute the Trilateral Common Interest Agreement and (b) use commercially reasonably efforts to obtain from Licensee (i) an agreement to send Royalty Reports directly to both the Seller and the Buyer, and (ii) Licensee&#8217;s signature to the Trilateral Common Interest Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Notices and Other Information to Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller shall, only as Mutually Agreed, send written notices or correspondence to Licensee.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Inspections and Audits of Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller shall, only as Mutually Agreed, cause an inspection or audit to be made by an independent public accounting firm under and in accordance with Section&#160;8.9 of the License Agreement.  With respect to any inspection or audit requested by the Buyer, the Seller shall, for purposes of Section&#160;8.9 of the License Agreement, select such independent public accounting firm as reasonably designated by the Buyer for such purpose (as long as such independent certified public accountant is reasonably </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acceptable to Licensee as required by Section&#160;8.9 of the License Agreement).  The Buyer shall pay the Seller the expenses of any inspection or audit requested by the Buyer (including the fees and expenses of such independent public accounting firm designated for such purpose) that would otherwise be borne by the Seller pursuant to the License Agreement (if and as such expenses are actually incurred by the Seller). </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Amendment or Assignment of License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller shall, only as Mutually Agreed, amend, modify, supplement or restate (or consent to any amendment, modification, supplement or restatement of) any provision of the License Agreement. The Seller shall not assign or otherwise transfer, in whole or in part, the License Agreement or any provision thereof or right thereunder without the consent of the Buyer, except for any assignment that is made in connection with an assignment of this Agreement in accordance with Section 9.3. Subject to the foregoing, promptly, and in any event within five (5) Business Days, following receipt by the Seller of any final assignment, amendment, modification, supplement or restatement of the License Agreement, the Seller shall furnish a copy of the same to the Buyer.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Maintenance of License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller shall comply in all material respects with its obligations under the License Agreement, and shall not take any action or forego any action that would reasonably be expected (with or without the giving of notice or passage of time, or both) to constitute a material breach thereof or material default thereunder. Promptly, and in any event within five (5) Business Days, after receipt of any (written or oral) notice from Licensee of an alleged breach or default under the License Agreement, the Seller shall give notice thereof to the Buyer, including delivering the Buyer a copy of any such written notice or a detailed written summary of any such oral notice. The Seller shall consult with the Buyer regarding such alleged breach or default and shall, only as Mutually Agreed, cure any breaches or defaults and shall give written notice within five (5) Business Days to the Buyer upon curing any such breach or default. The Seller shall, only as Mutually Agreed (a) forgive, release or compromise any amount owed to or becoming owed to the Seller under the License Agreement in respect of the Royalty, or (b) waive any obligation of, or grant any consent to, Licensee under, in respect of or related to the Royalty, Olpasiran, the Collaboration Target or the Arrowhead Licensed Technology.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">Enforcement of License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Notice of Breaches by Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Promptly (and in any event within five (5) Business Days) after the Seller becomes aware of, or comes to believe in good faith that there has been a material breach of the License Agreement by Licensee, the Seller shall provide notice of such breach to the Buyer.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Enforcement of License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller shall consult with the Buyer regarding the timing, manner and conduct of any enforcement of Licensee&#8217;s obligations under the License Agreement, relating to (i) any actual, anticipated or alleged breach or default under the License Agreement related to the Royalty (including any purported Royalty Reduction), Olpasiran, the Collaboration Target or the Arrowhead Licensed Technology or any matter that would reasonably be expected (with or without the giving of notice or passage of time, or both) to have a Material Adverse Effect, or (ii) any other actual, anticipated or alleged breach or default under the License Agreement.  The Seller shall keep the Buyer reasonably informed of any such breach or default and provide copies as soon as practicable, but in any event within five (5) Business Days following the Seller&#8217;s receipt or delivery of (A) any written notice of such breach or default, and (B) any and all filings, notices and written communications relating thereto. Following such consultation, the Seller shall exercise such rights and remedies relating to any such breach or default, in the case of clause (i), as reasonably instructed by the Buyer, and in the case of clause (ii) only as Mutually Agreed, in each case whether under the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">License Agreement or by operation of law. In connection with any dispute related to any such breach or default, Seller shall employ such counsel as Mutually Agreed and reasonably acceptable to the other party and shall provide the Buyer with access to such counsel.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Allocation of Proceeds and Costs of Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the case of any breach or default by Licensee referred to in Section 5.10(b)(i), the Buyer shall reimburse the Seller for all reasonable out-of-pocket costs and expenses (including the reasonable fees and expenses of the Seller&#8217;s counsel) incurred by the Seller, as such costs and expenses are incurred.  The Proceeds resulting from any enforcement of Licensee&#8217;s obligations under the License Agreement shall be allocated to the Seller, except with respect to such Proceeds that are related to an unpaid portion of the Royalty, which shall be allocated to the Buyer. The Seller hereby assigns and, if not presently assignable, agrees to assign to the Buyer, the amount of Proceeds due to the Buyer in accordance with this Section 5.10(c).</font></div><div style="text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">Termination of License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller shall not, (a) without the prior written consent of the Buyer (such consent to be granted or withheld in the sole discretion of the Buyer), exercise any right to terminate, agree with Licensee to terminate, or take, or permit any Affiliate or Visirna or any sublicensee of any Affiliate or Visirna to take, any action that would reasonably be expected (with or without the giving of notice or passage of time, or both) to give Licensee the right to terminate, the License Agreement in its entirety, or (b) except as Mutually Agreed, exercise any right to terminate, agree with Licensee to terminate, or take, or permit any Affiliate or Visirna or any sublicensee of any Affiliate or Visirna to take, any action that would reasonably be expected to give Licensee the right to terminate, the License Agreement in part.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">New Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Without limiting the provisions of this Article 5 or any other rights or remedies the Buyer may have under this Agreement, if the License Agreement is terminated in its entirety prior to the expiration of the Term (as defined in the License Agreement)&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the Seller will use commercially reasonable efforts to act as reasonably instructed by the Buyer, to negotiate and enter into a license, assignment or transfer agreement with Licensee for the regulatory approvals, data and patent rights owned or controlled by Licensee, including a license to the Amgen Product Patents, in each case, that are necessary or useful to make, have made, use, market, sell, offer for sale, import or otherwise exploit the Licensed Products&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">the Buyer shall have the exclusive right to negotiate or cause the Seller to use commercially reasonable efforts to negotiate and enter into, a license under the Licensed Patents with a third party, pursuant to which such third party will be granted rights to make, have made, use, market, sell, offer for sale, import and otherwise exploit the Licensed Products for any purpose that Licensee would have been permitted to make, have made, use, market, sell, offer for sale, import and otherwise exploit the Licensed Products under the License Agreement, subject to rights retained by Licensee following such termination&#59; provided, however, that (a) the Seller shall not be required to grant licenses broader than those set forth in the License Agreement or otherwise agree to terms, conditions and limitations (including financial terms) that are, in the aggregate, materially less favorable to the Seller (taking into account the transactions under this Agreement) than those contained in the License Agreement and (b) the Buyer shall not agree to financial terms that are, in the aggregate, materially less favorable to the Seller (taking into account the transactions under this Agreement) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than those contained in the License Agreement (such a replacement licensing arrangement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Seller and the Buyer shall each provide reasonable assistance to and cooperate with the other party in connection with the negotiation of, and entry into, such a license agreement, which shall not become effective earlier than the effective date of such termination of the License Agreement. Except in the case of the termination of the License Agreement by Licensee pursuant to Section 13.3 of the License Agreement, the Buyer shall reimburse the Seller for all reasonable out-of-pocket costs and expenses (including the reasonable fees and expenses of the Seller&#8217;s counsel) incurred by the Seller with respect to actions taken by the Seller at the Buyer&#8217;s written request in connection with the negotiation of a New Arrangement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Without limiting Section 5.12(a), should the Buyer identify any New Arrangement(s), the Seller agrees to execute and deliver a new license agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) effectuating such New Arrangement that satisfies the foregoing requirements of Section 5.12(a). Thereafter, the New License Agreement shall be included for all purposes in the definition of &#8220;License Agreement&#8221; under this Agreement, any payments that are equivalent to the Royalty payment due under such New License Agreement and any rights similar shall be included for all purposes under this Agreement, and the Seller&#8217;s rights and obligations under this Agreement in respect of the License Agreement shall apply in respect of its rights and obligations under the New License Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in each case without any further action by the parties hereto to amend this Agreement or the Bill of Sale.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">Preservation of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller shall not impose a Lien upon, or otherwise sell, transfer, hypothecate, assign, convey title (in whole or in part), grant any right to, or otherwise dispose of any portion of the Royalty or any of its other properties or assets if such Lien or other such transaction would have, or would reasonably be expected (with or without the giving of notice or passage of time, or both) to have, either individually or in the aggregate, a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">Enforcement&#59; Defense&#59; Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Buyer and the Seller shall promptly inform each other of any suspected infringement by a third party they become aware of with respect to any of the Licensed Patents. The Seller shall (i) provide to the Buyer a copy of any written notice the Seller or any of its Affiliates receives of any suspected infringement of any of the Licensed Patents and all pleadings filed in such action and (ii) notify the Buyer of any material developments in any claim, suit or proceeding resulting from such infringement that are communicated by Licensee to the Seller under Section 9.4(a) of the License Agreement or otherwise as soon as practicable and in any event not less than ten (10) Business Days following such delivery. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Seller shall, only as Mutually Agreed, and to the extent permitted under the terms of Section 9.4(b) of the License Agreement (i) pursue an enforcement action in accordance with Section 9.4(b) of the License Agreement, and (ii) as to the timing, manner and conduct of any enforcement action. The Seller shall, if requested in writing by the Buyer, promptly, and in any event within ten (10) Business Days after receipt of such request, provide to the Buyer all reasonably requested documentation and information relating to any such enforcement action brought by the Seller. The Seller shall, only as Mutually Agreed, take any action in any infringement action under Section 9.4(b) of the License Agreement that the Seller has joined. In the event Licensee brings or controls an enforcement action in accordance with Section 9.4(b) of the License Agreement, the Seller shall&#58; (x) provide copies or summaries of any status and progress reports and drafts of all material papers to be filed with the court to the extent provided by Licensee to the Seller pursuant to Section 9.4(b) of the License Agreement, and (y) otherwise act or refrain from acting as Mutually Agreed regarding such enforcement action and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the extent of the Seller&#8217;s permitted participation under the terms of Section 9.4(b) of the License Agreement. To the extent Licensee enforces any of the Licensed Patents in accordance with Section 9.4(b) of the License Agreement together with any Amgen Product Patents owned or controlled by Licensee, the Seller agrees to, only as Mutually Agreed, negotiate in good faith with Licensee and agree on a reasonable allocation of Proceeds as between the Licensed Patents and any Amgen Product Patents that were subject to such enforcement action. Solely in connection with an enforcement action involving the Licensed Patents and any Amgen Product Patents, the Seller shall obtain and deliver to the Buyer an accounting detailing the Proceeds allocated to the Licensed Patents. The Seller shall be responsible for all reasonable and documented out-of-pocket costs and expenses (including the reasonable and documented fees and expenses of the Seller&#8217;s counsel) incurred by the Seller in connection with the Seller&#8217;s actions pursuant to this Section 5.14(b) using counsel of the Seller&#8217;s choice that is reasonably acceptable to the Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, if the Seller&#8217;s actions under this Section 5.14(b) were taken at the direction of the Buyer over the good faith objection of the Seller, then, to the extent the Seller is not entitled to reimbursement by Licensee for such actions, the Buyer shall promptly on demand reimburse the Seller for the reasonable, out-of-pocket costs and expenses incurred by the Seller in connection with such Seller actions pursuant to this Section 5.14(b).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Seller shall, only as Mutually Agreed, (i) take any and all actions, and prepare, execute, deliver and file any and all agreements, documents and instruments, that are reasonably necessary or desirable to diligently prosecute, preserve and maintain any Licensed Patents for which it controls the prosecution and maintenance and to seek to extend the term of a patent or exclusivity period for a Licensed Product (including any patent term extension(s) or supplementary protection certificate(s) with respect to any such patent, regulatory exclusivity periods with respect to a Licensed Product, or the like), in each case in accordance with Sections 9.3 and 9.8 of the License Agreement, including payment of maintenance fees or annuities on any such Licensed Patents, (ii) prosecute any corrections, substitutions, reissues, reviews and reexaminations, and any other forms of patent term restoration in any applicable jurisdiction of any Licensed Patents for which it controls the prosecution and maintenance in accordance with Sections 9.3 and 9.8 of the License Agreement, (iii) defend any Licensed Patents for which it controls the defense in accordance with Section 9.7 of the License Agreement, including by bringing any legal action for infringement or defending any counterclaim of invalidity or unenforceability or action of a third party for declaratory judgment of non-infringement or non-interference raised as a defense in any such legal action for infringement, in accordance with Section 5.14(b) of this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, if the Seller&#8217;s actions under this clause (iii) were taken at the direction of the Buyer over the good faith objection of the Seller, then, to the extent the Seller is not entitled to reimbursement by Licensee for such actions, the Buyer shall promptly on demand reimburse the Seller for the reasonable, out-of-pocket costs and expenses incurred by the Seller in connection with such Seller&#8217;s actions pursuant to this clause (iii), and (iv) not disclaim or abandon, or fail to take any action necessary or desirable to prevent the disclaimer or abandonment (including through lack of enforcement against third party infringers), of any Licensed Patents for which it controls the prosecution and maintenance in accordance with Sections 9.3 and 9.8 of the License Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if Seller desires to disclaim or abandon any Licensed Patent for which it controls the prosecution and maintenance in accordance with Sections 9.3 and 9.8 of the License Agreement, and Licensee fails to exercise its rights under Sections 9.3 and 9.8 of the License Agreement with respect to any such Licensed Patent, then the Seller shall notify the Buyer at least sixty (60) days prior to such disclaiming or abandonment, and, at Buyer&#8217;s request, shall promptly assign all such Licensed Patents to Buyer. Except to the extent that the proviso to clause (iii) or (iv) above applies, the Seller shall be responsible for all reasonable and documented out-of-pocket costs and expenses (including the reasonable and documented fees and expenses of the Seller&#8217;s counsel) incurred by the Seller in connection with the Seller&#8217;s actions pursuant to clauses (i) through (iv) of the immediately preceding sentence using counsel of the Seller&#8217;s choice that is reasonably </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acceptable to the Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Buyer hereby acknowledges that Honigman LLP for purposes of clauses (i), (ii) and (iv) of this Section 5.14(c) is acceptable.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Upon Buyer&#8217;s request (not to exceed more than one request per calendar year), the Seller agrees to use its commercially reasonable efforts to obtain from Licensee, and deliver to the Buyer, a complete and accurate docket report for all Licensed Patents&#59; provided, that if the Seller is unable to obtain such a docket report from Licensee in any given year, the Seller shall deliver a complete and accurate, to the Seller&#8217;s knowledge, docket report for all Licensed Patents. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. After the Closing, the Seller and the Buyer agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to give effect to the transactions contemplated by this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding anything to the contrary in this Agreement, the Seller and the Buyer shall treat the transactions contemplated by this Agreement as a sale of the Royalty for United States federal, state, local and non-U.S. Tax purposes. Accordingly, any and all Royalty payments made pursuant to the License Agreement after the Closing Date shall be treated as sold to the Buyer for United States federal, state, local and non-U.S. Tax purposes. The parties shall cooperate to effect the foregoing treatment for United States federal, state, local and non-U.S. Tax purposes in the event that, notwithstanding the Licensee Instruction Letter, Licensee, any Sublicensee (as defined in the License Agreement) or any other Person makes any future remittance of Royalty payments to the Seller which the Seller must remit to the Buyer pursuant to Section 5.2(a) of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To the extent any amount of the Royalty is withheld at source from a payment made pursuant to the License Agreement, as applicable, such withheld amount shall for all purposes of this Agreement be treated as paid to the Buyer. Any amounts withheld described in this Section 5.16(b) attributable to the Buyer shall be credited for the account of the Buyer. Notwithstanding anything to the contrary in this Agreement (including, for the avoidance of doubt, Section 5.3), the Seller shall have no obligation to gross-up or otherwise pay the Buyer any amounts with respect to source withholding. All amounts withheld as described herein shall for all purposes of this Agreement be deemed to have been received by the Buyer.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The parties hereto agree not to take any position that is inconsistent with the provisions of this Section 5.16 on any Tax return or in any audit or other administrative or judicial proceeding unless (i) the other party hereto has consented in writing to such actions or (ii) the party hereto that contemplates taking such an inconsistent position has been advised by nationally recognized tax counsel in writing that there is no &#8220;reasonable basis&#8221; (within the meaning of Treasury Regulation Section 1.6662-3(b)(3)) for the position specified in this Section 5.16. If there is an inquiry by any Governmental Entity of the Seller or the Buyer related to this Section 5.16, the parties hereto shall cooperate with each other in responding to such inquiry in a reasonable manner consistent with this Section 5.16. </font></div><div style="text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:29.72pt"><br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller and the Buyer each agree and acknowledge that the confidentiality provisions set forth in Section 12.1 of the License </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement shall apply to this Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and each of the Seller and the Buyer shall be bound by the terms set forth therein, as if the Seller and the Buyer were Parties (as such term is defined in the License Agreement) thereunder. The parties hereto agree that the terms of this Agreement are also the Confidential Information (as such term is defined in the License Agreement) of both parties hereto.</font></div><div style="text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller and the Buyer each agree and acknowledge that the authorized disclosures set forth in Section 12.2 of the License Agreement shall apply to this Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and each of the Seller and the Buyer shall be authorized to disclose Confidential Information (as such term is defined in the License Agreement) in accordance with the terms set forth therein, as if the Seller and the Buyer were Parties (as such term is defined in the License Agreement) thereunder.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:29.72pt"><br>INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">General Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to Section 7.3, from and after the Closing&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Seller hereby agrees to indemnify, defend and hold harmless the Buyer and its Affiliates and its and their directors, managers, trustees, officers, agents and employees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from, against and in respect of all Losses suffered or incurred by the Buyer Indemnified Parties to the extent arising out of or resulting from (i) any breach of any of the representations or warranties (in each case, when made) of the Seller in this Agreement or (ii) any breach of any of the covenants or agreements of the Seller in this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the foregoing shall exclude any indemnification to any Buyer Indemnified Party (A) that has the effect of imposing on the Seller any liability to make payments of or in lieu of the Royalty because of any Credit Event, (B) that results from the failure of Licensee to perform any of its obligations under the License Agreement, unless directly resulting from the breach or default by the Seller of or under the License Agreement, (C) that results from the gross negligence, willful misconduct, or fraud of any Buyer Indemnified Party, (D) for any matter in respect of which any Seller Indemnified Party would be entitled to indemnification under Section 7.1(b), or (E) to the extent resulting from acts or omissions of the Seller that are in accordance with specific written instructions from the Buyer&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Buyer hereby agrees to indemnify, defend and hold harmless the Seller and its Affiliates and its and their directors, officers, agents and employees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from, against and in respect of all Losses suffered or incurred by the Seller Indemnified Parties to the extent arising out of or resulting from (i)&#160;any breach of any of the representations or warranties (in each case, when made) of the Buyer in this Agreement or (ii)&#160;any breach of any of the covenants or agreements of the Buyer in this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the foregoing shall exclude any indemnification to any Seller Indemnified Party (A) that results from the gross negligence, willful misconduct, or fraud of any Seller Indemnified Party, (B) for any matter in respect of which any Buyer Indemnified Party would be entitled to indemnification under Section 7.1(a), or (C) to the extent resulting from acts or omissions of the Buyer that are in accordance with specific written instructions from the Seller.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Notice of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If either a Buyer Indemnified Party, on the one hand, or a Seller Indemnified Party, on the other hand (the Buyer on behalf of such Buyer Indemnified Party on the one hand and the Seller on behalf of such Seller Indemnified Party on the other hand being hereinafter referred to as an&#160;&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), has suffered or incurred any Losses for which indemnification may be sought under this Article 7, the Indemnified Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall so notify the other party hereto from whom indemnification is sought under this Article 7 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) promptly in writing describing such Loss, the amount or estimated amount thereof, if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement in respect of which such Loss shall have occurred.  If any claim, action, suit or proceeding is asserted or instituted by or against a third party with respect to which an Indemnified Party intends to claim any Loss under this Article 7, such Indemnified Party shall promptly notify the Indemnifying Party of such claim, action, suit or proceeding and tender to the Indemnifying Party the defense of such claim, action, suit or proceeding.  A failure by an Indemnified Party to give notice and to tender the defense of such claim, action, suit or proceeding in a timely manner pursuant to this Section 7.2 shall not limit the obligation of the Indemnifying Party under this Article 7, except to the extent such Indemnifying Party is actually prejudiced thereby.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Limitations on Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except for a party hereto&#8217;s breach of its confidentiality obligations under Article 6, no party hereto shall be liable for any indirect, consequential (including lost profits), punitive, special or incidental damages as a result of any breach or violation of any covenant or agreement of such party (including under this Article 7) in or pursuant to this Agreement. Notwithstanding the foregoing, the Buyer shall be entitled to make indemnification claims, in accordance with the procedures set forth in this Article 7, for Losses that include any portion of the Royalty that the Buyer was entitled to receive but did not receive timely or at all due to any indemnifiable events under this Agreement, and such portion of the Royalty shall not be deemed indirect, consequential, punitive, special or incidental damages for any purpose of this Agreement. Other than with respect to any fraud, willful misconduct, or intentional misrepresentation, (a) in no event shall the Seller&#8217;s aggregate liability for Losses under Section 7.1(a)(i) or the Buyer&#8217;s aggregate liability for Losses under Section 7.1(b)(i) exceed the Purchase Price less fifty percent (50%) of the Royalty payments actually received by the Buyer following the fourth anniversary of the date of the First Commercial Sale (as defined in the License Agreement) of Olpasiran in the United States, and (b) the Seller shall not have any liability for Losses under Section 7.1(a)(i) and the Buyer shall not have any liability for Losses under Section 7.1(b)(i) unless and until the aggregate amount of all Losses incurred by the indemnified party equals or exceeds $500,000, in which event the indemnifying party shall be liable for all Losses including such amount. For the avoidance of doubt, the Seller shall have no liability to the Buyer for any Permitted Reduction or Credit Event.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Following the receipt of notice provided by an Indemnified Party pursuant to Section 7.2 of the commencement of any action, suit or proceeding against such Indemnified Party by a third party with respect to which such Indemnified Party intends to claim any Loss under this Article&#160;7, an Indemnifying Party shall have the right to defend such claim, at such Indemnifying Party&#8217;s expense and with counsel of its choice reasonably satisfactory to the Indemnified Party.  If the Indemnifying Party assumes the defense of such claim, the Indemnified Party shall, at the request of the Indemnifying Party, use commercially reasonable efforts to cooperate in such defense&#59; provided, that the Indemnifying Party shall bear the Indemnified Party&#8217;s reasonable out-of-pocket costs and expenses incurred in connection with such cooperation.  So long as the Indemnifying Party is conducting the defense of such claim as provided in this Section&#160;7.4, the Indemnified Party may retain separate co-counsel at its expense and may participate in the defense of such claim, and neither the Indemnified Party nor the Indemnifying Party shall consent to the entry of any Judgment or enter into any settlement with respect to such claim without the prior written consent of the other party hereto unless such Judgment or settlement (A)&#160;provides for the payment by the Indemnifying Party of money as sole relief (if any) for the claimant (other than customary and reasonable confidentiality obligations relating to such claim, Judgment or settlement), (B)&#160;results in the full and general release of the Indemnified Party from all liabilities arising out of, relating to or in connection with such claim and (C)&#160;does not involve a finding or admission of any violation of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any law, rule, regulation or Judgment, or the rights of any Person, and has no effect on any other claims that may be made against the Indemnified Party.  In the event the Indemnifying Party does not or ceases to conduct the defense of such claim as so provided, (i)&#160;subject to the limitations set forth in Section 7.3 and this Section 7.4, the Indemnified Party may defend against, and consent to the entry of any reasonable Judgment or enter into any reasonable settlement with respect to, such claim in any manner it may reasonably deem to be appropriate, (ii)&#160;subject to the limitations set forth in Section 7.3, the Indemnifying Party shall reimburse the Indemnified Party promptly and periodically for the reasonable out-of-pocket costs of defending against such claim, including reasonable attorneys&#8217; fees and expenses against reasonably detailed invoices, and (iii)&#160;the Indemnifying Party shall remain responsible for any Losses the Indemnified Party may suffer as a result of such claim to the full extent provided in this Article 7.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Exclusive Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as set forth in Section&#160;9.10, from and after Closing, the rights of the parties hereto pursuant to (and subject to the conditions of) this Article 7 shall be the sole and exclusive remedy of the parties hereto and their respective Affiliates with respect to any claims (whether based in contract, tort or otherwise) resulting from or relating to any breach of the representations, warranties covenants and agreements made under this Agreement or any certificate, document or instrument delivered hereunder, and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert after Closing, any other claim or action in respect of any such breach.  Notwithstanding the foregoing, claims for common law fraud shall not be waived or limited in any way by this Article&#160;7. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Time Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Seller shall have liability under Section 7.1(a)(i) only if, on or prior to the date that is eighteen (18) months after the Closing Date, the Buyer notifies the Seller of a claim in respect of such breach, specifying the factual basis of such claim in reasonable detail (other than Sections 4.1(a), 4.1(b), 4.1(c), 4.1(d), 4.1(e), 4.1(i) (solely with respect to the first two sentences thereof), 4.1(i)(i), 4.1(i)(iii), 4.1(i)(v), 4.1(i)(vi), 4.1(i)(vii), 4.1(i)(viii), 4.1(i)(x), 4.1(i)(xii), 4.1(i)(xv), 4.1(j), 4.1(k)(i), 4.1(k)(iv), 4.1(k)(v), 4.1(k)(vi), 4.1(k)(vii), 4.1(k)(xi), 4.1(l) and 4.1(m), as to which any claims may be made at any time until the date that is six (6) months after the termination of this Agreement)&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Buyer shall have liability under Section 7.1(b)(i), only if, on or prior to the date that is eighteen (18) months after the Closing Date, the Seller notifies the Buyer of a claim in respect of such breach, specifying the factual basis of such claim in reasonable detail (other than Sections 4.2(a), 4.2(b), 4.2(c), 4.2(d), 4.2(e), and 4.2(h), as to which any claims may be made at any time until the date that is six (6) months after the termination of this Agreement).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Tax Treatment for Indemnification Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any indemnification payments made pursuant to this Article 7 will be treated as an adjustment to the Purchase Price for U.S. federal income tax to the fullest extent permitted by applicable law.</font></div><div style="text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:29.72pt"><br>TERMINATION</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Grounds for Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be terminated at any time by mutual written agreement of the Buyer and the Seller.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Automatic Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Unless earlier terminated as provided in Section 8.1, this Agreement shall continue in full force and effect until sixty (60) days after the full satisfaction of all amounts due under the License Agreement to the Seller and any payments in respect of the Royalty due under this Agreement to the Buyer, at which point this Agreement shall automatically terminate, except with respect to any rights that shall have accrued prior to such termination.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary in this Article 8, the following provisions shall survive termination of this Agreement&#58; Section 2.3 (True Sale), Section 5.1 (Disclosures), Section 5.2(b) (Payments Received in Error), Section 5.4 (Late Fee) (solely with respect to Section 5.2(b)), Section 5.7 (Inspections and Audits of Licensee) (for the period set forth in Section 8.9 of the License Agreement), Article 6 (Confidentiality) (for the period set forth in Section 12.1 of the License Agreement), Article 7 (Indemnification), this Section 8.3 (Survival) and Article 9 (Miscellaneous). Termination of the Agreement shall not relieve any party of liability in respect of breaches under this Agreement by any party on or prior to termination.  In addition, in the event the License Agreement is terminated prior to its expiration date, Section 5.12 (New Arrangements) shall survive the termination of this Agreement.</font></div><div style="text-align:center"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:29.72pt"><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices and other communications under this Agreement shall be in writing and shall be by email with PDF attachment, certified mail, courier service or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a party hereto in accordance with this Section 9.1&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to the Seller, to it at&#58;</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arrowhead Pharmaceuticals, Inc. </font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">177 East Colorado Boulevard, Suite 700</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pasadena, CA 91105</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; General Counsel</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; general.counsel&#64;arrowheadpharma.com</font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With a copy to&#58;</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gibson, Dunn &#38; Crutcher LLP</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">555 Mission Street</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">San Francisco, CA 94105</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Ryan Murr&#59; Karen Spindler&#59; Todd Trattner</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; rmurr&#64;gibsondunn.com&#59; kspindler&#64;gibsondunn.com&#59; ttrattner&#64;gibsondunn.com</font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to the Buyer, to it at&#58;</font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RP Management, LLC</font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">110 E. 59th Street, Suite 3300</font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New York, New York 10022</font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; General Counsel</font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; legaltransactions&#64;royaltypharma.com</font></div><div style="padding-left:72pt;padding-right:36pt"><font><br></font></div><div style="padding-left:72pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With a copy to&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Goodwin Procter LLP</font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100 Northern Avenue</font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston, Massachusetts 02210</font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Jacqueline Mercier and</font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                  Robert M. Crawford, Jr. </font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58;  jmercier&#64;goodwinlaw.com&#59; </font></div><div style="padding-left:90pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">            rcrawford&#64;goodwinlaw.com</font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All notices and communications under this Agreement shall be deemed to have been duly given (i)&#160;when delivered by hand, if personally delivered, (ii)&#160;when received by a recipient, if sent by email, with such receipt to be effective the date acknowledged by the recipient, (iii) upon receipt when sent via certified mail, return receipt requested, postage prepaid, with such receipt to be effective the date of delivery indicated on the return receipt, or (iv)&#160;one Business Day following sending within the United States by overnight delivery via commercial one-day overnight courier service. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as otherwise provided herein, all fees, costs and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby shall be paid by the party hereto incurring such fees, costs and expenses.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Seller shall not sell, assign or otherwise transfer all or any portion of its interest in (including its rights or obligations under) this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Seller may assign this Agreement in its entirety to an Affiliate of the Seller or to any third party that acquires all or substantially all of the Seller&#8217;s business to which this Agreement relates, whether by merger, sale of assets or otherwise, so long as, (a) such Person acquires all of the Seller&#8217;s interest in the Licensed Product Patents, the License Agreement and this Agreement and (b) prior to closing any such transaction, the Seller causes such Person to deliver a writing to the Buyer in which (i) if such Person is not Licensee, such Person assumes all of the obligations of the Seller to the Buyer under this Agreement, and (ii) if such Person is Licensee, Licensee assumes all of the obligations of the Seller to the Buyer hereunder and agrees to pay the Royalty to the Buyer notwithstanding any subsequent termination of the License Agreement by Licensee. Following the Closing, the Buyer may assign this Agreement, provided that (A) the Buyer promptly notifies the Seller of such assignment, (B) no such assignment shall relieve the Buyer of its obligations under this Agreement to pay any Additional Purchase Price Payments when due, (C) Buyer shall not assign to any competitor of the Seller without the Seller&#8217;s prior written consent, (D) each such assignee complies with Section 3.5 (replacing &#8220;Buyer&#8221; wherever it appears with such assignee and replacing the &#8220;Closing&#8221; with the date that such assignee acquires an interest in the Buyer&#8217;s rights hereunder, and (E) if the Buyer assigns its right under this Agreement to more than one party, the Licensee shall not be required to pay the Royalty to more than one bank account. This Agreement shall be binding upon, inure to the benefit of and be enforceable by, the parties hereto and their respective permitted successors and assigns. Any purported assignment in violation of this Section 9.3 shall be null and void.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">This Agreement may be amended, modified or supplemented only in a writing signed by each of the parties hereto. Any provision of this Agreement may be waived only in a writing signed by the parties hereto granting such waiver.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">No failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. No course of dealing between the parties hereto shall be effective to amend, modify, supplement or waive any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement and the Exhibits annexed hereto constitute the entire understanding between the parties hereto with respect to the subject matter hereof and supersede all other understandings and negotiations with respect thereto. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement is for the sole benefit of the Seller and the Buyer and their permitted successors and assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">JURISDICTION&#59; VENUE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS RESPECTIVE PROPERTY AND ASSETS, TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN NEW YORK COUNTY, NEW YORK, AND ANY APPELLATE COURT THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, AND THE BUYER AND THE SELLER HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREE THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN ANY SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. THE BUYER AND THE SELLER HEREBY AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY APPLICABLE LAW. EACH OF THE BUYER AND THE SELLER HEREBY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION AND VENUE OF SUCH NEW YORK STATE AND FEDERAL COURTS. THE BUYER AND THE SELLER AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THAT PROCESS MAY BE SERVED ON THE BUYER OR THE SELLER IN THE SAME MANNER THAT NOTICES MAY BE GIVEN PURSUANT TO SECTION&#160;9.1 HEREOF.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY NEW YORK STATE OR FEDERAL COURT. EACH OF THE BUYER AND THE SELLER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">EACH PARTY HEREBY JOINTLY AND SEVERALLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER DOCUMENT DELIVERED HEREUNDER OR IN </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONNECTION HEREWITH, OR ANY TRANSACTION ARISING FROM OR CONNECTED TO ANY OF THE FOREGOING.  EACH OF THE PARTIES REPRESENTS THAT THIS WAIVER IS KNOWINGLY, WILLINGLY, AND VOLUNTARILY GIVEN.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">EACH OF THE PARTIES HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 9.1.  NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.  EACH OF THE PARTIES HERETO WAIVES PERSONAL SERVICE OF ANY SUMMONS, COMPLAINT OR OTHER PROCESS, WHICH MAY BE MADE BY ANY OTHER MEANS PERMITTED BY NEW YORK LAW.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any term or provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any situation in any jurisdiction, then, to the extent that the economic and legal substance of the transactions contemplated hereby is not affected in a manner that is materially adverse to either party hereto, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect and the enforceability and validity of the offending term or provision shall not be affected in any other situation or jurisdiction. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the parties acknowledges and agrees that the other parties may be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated, or, in the case of Article 6, are threatened to be breached. Accordingly, notwithstanding Section 7.5, each party hereto agrees that, without posting bond or other undertaking, the other party hereto shall be entitled to seek an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement, or, in the case of Article 6, to prevent threatened breaches, and to seek to enforce specifically this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity. Each party further agrees that, in the event of any action for specific performance in respect of such a breach or violation of Article 6, it shall not assert the defense that a remedy at law would be adequate.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Copies of executed counterparts transmitted by email or other similar means of electronic transmission, including &#8220;PDF,&#8221; shall be considered original executed counterparts, provided receipt of such counterparts is confirmed.</font></div><div style="text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt;text-decoration:underline">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The relationship between the Buyer and the Seller is solely that of purchaser and seller, and neither the Buyer nor the Seller has any fiduciary or other special relationship with the other party or any of its Affiliates.  This Agreement is not a partnership or similar agreement, and nothing contained herein shall be deemed to constitute the Buyer and the Seller as a partnership, an association, a joint venture or any other kind of entity or legal form for any purposes, including any Tax purposes.  The Buyer and the Seller agree that they shall not take any inconsistent position with respect to such treatment in a filing with any Governmental Entity.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><div id="id7ad370358644ffdbee5adb7ca72c276_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Royalty Purchase Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above written.</font></div><div style="padding-left:230.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.961%"><tr><td style="width:1.0%"></td><td style="width:16.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.290%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.3pt;padding-right:2.75pt;text-indent:-6.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARROWHEAD PHARMACEUTICALS INC.</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ROYALTY PHARMA INVESTMENTS 2019 ICAV</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RP Management, LLC, its Manager and lawfully appointed attorney</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE TO THE ROYALTY PURCHASE AGREEMENT&#93;</font></div></div></div><div id="id7ad370358644ffdbee5adb7ca72c276_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A-1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bilateral Common Interest Agreement</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;See attached&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A-2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Trilateral Common Interest Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;See attached&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Seller&#8217;s Wire Transfer Instructions<br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;See attached&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit C</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Bill of Sale<br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;See attached&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit D</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Licensee Instruction Letter</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;See attached&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit E</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Agreement</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;See attached&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit F</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Knowledge Parties</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Chris Anzalone&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Ken Myszkowski&#160;&#160;&#160;&#160;Chief Financial Officer</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">James Hamilton&#160;&#160;&#160;&#160;Senior Vice President, Discovery and Translational Medicine</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Patrick O&#8217;Brien&#160;&#160;&#160;&#160;Chief Operating Officer and General Counsel</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Javier San Martin&#160;&#160;&#160;&#160;Chief Medical Officer</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Tracie Oliver&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Commercial Officer</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Robert Teigen&#160;&#160;&#160;&#160;Vice President, Intellectual Property</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit G</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Patents</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;See attached&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>arwr-20221231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia2a2252aa76b4942b2ffa193e86676cf_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;6, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; CHRISTOPHER ANZALONE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>arwr-20221231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia098f3e20d6d456194b88ee894c00ea8_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;6, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth A. Myszkowski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth A. Myszkowski,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>arwr-20221231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i710e5128487a42a0b113f143fd5a8f0d_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended December&#160;31, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;6, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">NZALONE</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>arwr-20221231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i33eecde64c8241f5adff954d3a6bc120_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended December&#160;31, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;6, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth A. Myszkowski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth A. Myszkowski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>arwr-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e8083e98-eeaa-4076-9e59-e239858f4776,g:e1942b16-5fc3-435c-8ded-c247fb91952b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arrowheadresearch.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>0000007 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000008 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment">
        <link:definition>0000009 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.arrowheadresearch.com/role/Investments">
        <link:definition>0000010 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets">
        <link:definition>0000011 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity">
        <link:definition>0000012 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.arrowheadresearch.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements">
        <link:definition>0000016 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyalties" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties">
        <link:definition>0000017 - Disclosure - Liability Related to the Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>0000018 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesTables" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables">
        <link:definition>0000019 - Disclosure - Organization and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables">
        <link:definition>0000020 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables">
        <link:definition>0000021 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables">
        <link:definition>0000022 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables">
        <link:definition>0000023 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.arrowheadresearch.com/role/LeasesTables">
        <link:definition>0000024 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables">
        <link:definition>0000025 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables">
        <link:definition>0000026 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>0000027 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails">
        <link:definition>0000028 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails">
        <link:definition>0000029 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
        <link:definition>0000030 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails">
        <link:definition>0000031 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAmgenIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails">
        <link:definition>0000032 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails">
        <link:definition>0000033 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryofPropertyandEquipmentDetail" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail">
        <link:definition>0000034 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail">
        <link:definition>0000035 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails">
        <link:definition>0000036 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000037 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsExpectedFutureAmortizationDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails">
        <link:definition>0000038 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails">
        <link:definition>0000039 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>0000040 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails">
        <link:definition>0000041 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseAssetsandLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails">
        <link:definition>0000042 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails">
        <link:definition>0000043 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1">
        <link:definition>0000043 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails">
        <link:definition>0000044 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000045 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails">
        <link:definition>0000046 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails">
        <link:definition>0000047 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUsActivityDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails">
        <link:definition>0000048 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000049 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails">
        <link:definition>0000050 - Disclosure - Liability Related to the Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" abstract="true" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfDistinctBundle" abstract="false" name="NumberOfDistinctBundle" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RoyaltiesLiabilityNoncurrent" abstract="false" name="RoyaltiesLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandTwentyOneIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_RoyaltyPharmaAgreementMember" abstract="true" name="RoyaltyPharmaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_HorizonTherapeuticsIrelandDACMember" abstract="true" name="HorizonTherapeuticsIrelandDACMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" abstract="false" name="ComputersSoftwareOfficeEquipmentAndFurnitureGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JNJ3989AROHBVAgreementMember" abstract="true" name="JNJ3989AROHBVAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ScheduleOfCurrentProductsTableTextBlock" abstract="false" name="ScheduleOfCurrentProductsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_InducementAwardsMember" abstract="true" name="InducementAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_RoyaltyPharmaMember" abstract="true" name="RoyaltyPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentEarned" abstract="false" name="MilestonePaymentEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" abstract="false" name="MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommonStockPurchaseAgreementMember" abstract="true" name="CommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DrugManufacturingFacilityMember" abstract="true" name="DrugManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TechnologyLicenseCommitmentsMember" abstract="true" name="TechnologyLicenseCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_VisirnaTherapeuticsIncMember" abstract="true" name="VisirnaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_SorrentoValleyOwnerDELLCMember" abstract="true" name="SorrentoValleyOwnerDELLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchEquipmentGross" abstract="false" name="ResearchEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ColoradoOwnerLLCMember" abstract="true" name="ColoradoOwnerLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" abstract="true" name="JohnsonAndJohnsonInnovationJJDCIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchFacilityInSanDiegoMember" abstract="true" name="ResearchFacilityInSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfDistinctPerformanceObligations" abstract="false" name="NumberOfDistinctPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_InitialTransactionPrice" abstract="false" name="InitialTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_ResearchFacilityInMadisonMember" abstract="true" name="ResearchFacilityInMadisonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_VisirnaLicenseAgreementMember" abstract="true" name="VisirnaLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arwr_TwoThousandsThirteenIncentivePlanMember" abstract="true" name="TwoThousandsThirteenIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfOptionsToRenew" abstract="false" name="NumberOfOptionsToRenew" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" abstract="false" name="MilestonePaymentReceivableAtStartOfPhaseTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" abstract="true" name="TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_CashReceivedAsDueUnderCollaborationAgreement" abstract="false" name="CashReceivedAsDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" abstract="false" name="MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_DeferredRevenueMember" abstract="true" name="DeferredRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_IncreaseDecreaseInCashAndInvestments" abstract="false" name="IncreaseDecreaseInCashAndInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OlpasiranAndAROAMG1AgreementMember" abstract="true" name="OlpasiranAndAROAMG1AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" abstract="true" name="GlaxosmithklineIntellectualPropertyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" abstract="false" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="DevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivable" abstract="false" name="MilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" abstract="false" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" abstract="false" name="PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AmgenIncorporatedMember" abstract="true" name="AmgenIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_UpfrontMilestonePaymentReceived" abstract="false" name="UpfrontMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_SalesRelatedMilestonePayments" abstract="false" name="SalesRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AROHSDAgreementMember" abstract="true" name="AROHSDAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TaxIncrementFinancingAward" abstract="false" name="TaxIncrementFinancingAward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_FacilitiesMember" abstract="true" name="FacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfAcresOfLandPurchased" abstract="false" name="NumberOfAcresOfLandPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_JanssenPharmaceuticalsIncorporationMember" abstract="true" name="JanssenPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LaboratoryAndOfficeFacilityMember" abstract="true" name="LaboratoryAndOfficeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" abstract="false" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AmountIntendsToInvestForBuildoutOfFacilities" abstract="false" name="AmountIntendsToInvestForBuildoutOfFacilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetsImpairment" abstract="false" name="FiniteLivedIntangibleAssetsImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_LicenseAndCoFundingAgreementMember" abstract="true" name="LicenseAndCoFundingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LiabilitySaleOfFutureRoyalties" abstract="false" name="LiabilitySaleOfFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OlpasiranAgreementMember" abstract="true" name="OlpasiranAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" abstract="false" name="CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RoyaltyPaymentThreshold" abstract="false" name="RoyaltyPaymentThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JNJ75220795AROJNJ1Member" abstract="true" name="JNJ75220795AROJNJ1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AROXDHAgreementMember" abstract="true" name="AROXDHAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_CorporateHeadquartersInPasadenaMember" abstract="true" name="CorporateHeadquartersInPasadenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceived" abstract="false" name="MilestonePaymentReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandsFourEquityIncentivePlanMember" abstract="true" name="TwoThousandsFourEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponFDAApproval" abstract="false" name="MilestonePaymentReceivableUponFDAApproval" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" abstract="false" name="MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialNotesMember" abstract="true" name="CommercialNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_VeronaTechnologyParkMember" abstract="true" name="VeronaTechnologyParkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfAgreements" abstract="false" name="NumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_EstimatedPaymentsForOperatingExpensesYearOne" abstract="false" name="EstimatedPaymentsForOperatingExpensesYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" abstract="false" name="CommercialMilestonePaymentsAtFirstCommercialSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesValueReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>arwr-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e8083e98-eeaa-4076-9e59-e239858f4776,g:e1942b16-5fc3-435c-8ded-c247fb91952b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c7a2496e-e5a4-4fcf-a8fa-cef295acc516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9feee874-2c90-4367-a21f-c1e224d59476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c7a2496e-e5a4-4fcf-a8fa-cef295acc516" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9feee874-2c90-4367-a21f-c1e224d59476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_f885504c-ec22-459c-95ea-dffeb61d89a7" xlink:href="arwr-20221231.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c7a2496e-e5a4-4fcf-a8fa-cef295acc516" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_f885504c-ec22-459c-95ea-dffeb61d89a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3dac4a24-6f2e-4052-9187-981b5a223411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c7a2496e-e5a4-4fcf-a8fa-cef295acc516" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3dac4a24-6f2e-4052-9187-981b5a223411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f3988e16-85da-4594-8561-e45e4efda417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07862cd4-bcf6-4539-ae9a-d0ff50fc8327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f3988e16-85da-4594-8561-e45e4efda417" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07862cd4-bcf6-4539-ae9a-d0ff50fc8327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_64a40697-b9c7-4a8b-883a-1a6ce0b059af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f3988e16-85da-4594-8561-e45e4efda417" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_64a40697-b9c7-4a8b-883a-1a6ce0b059af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_7c450a65-5cd6-469c-b7ea-5ec00f11f417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f3988e16-85da-4594-8561-e45e4efda417" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_7c450a65-5cd6-469c-b7ea-5ec00f11f417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b13e1c4d-5656-4799-9537-955e3cb8abfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f3988e16-85da-4594-8561-e45e4efda417" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b13e1c4d-5656-4799-9537-955e3cb8abfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_18b5b2c2-3e5a-4c41-9ecb-ebc34e7d23df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f3988e16-85da-4594-8561-e45e4efda417" xlink:to="loc_us-gaap_OtherAssetsCurrent_18b5b2c2-3e5a-4c41-9ecb-ebc34e7d23df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e95da46d-29a8-4505-8c22-ac038538b827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_646d4432-f508-422d-9421-fdc118506152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e95da46d-29a8-4505-8c22-ac038538b827" xlink:to="loc_us-gaap_LiabilitiesCurrent_646d4432-f508-422d-9421-fdc118506152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_928f9e90-b267-4f9b-9f59-c9d73d89587e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e95da46d-29a8-4505-8c22-ac038538b827" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_928f9e90-b267-4f9b-9f59-c9d73d89587e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fa8baf76-2ea0-4946-8956-ae673dc259c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e95da46d-29a8-4505-8c22-ac038538b827" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fa8baf76-2ea0-4946-8956-ae673dc259c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a37b096-82dd-42d9-bdef-10b8678a2668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e95da46d-29a8-4505-8c22-ac038538b827" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a37b096-82dd-42d9-bdef-10b8678a2668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5592893d-904d-41ac-a92b-035047ac0107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_558106f9-95a2-41e9-9205-2404e0732bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5592893d-904d-41ac-a92b-035047ac0107" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_558106f9-95a2-41e9-9205-2404e0732bae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f927afad-35d0-4b7c-8a94-0cc5c9760389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5592893d-904d-41ac-a92b-035047ac0107" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f927afad-35d0-4b7c-8a94-0cc5c9760389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f8e9e861-a92e-4a24-a8ab-6d2d62d50043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5592893d-904d-41ac-a92b-035047ac0107" xlink:to="loc_us-gaap_CommonStockValue_f8e9e861-a92e-4a24-a8ab-6d2d62d50043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89bdf570-edd5-4d6d-b243-891d56d34c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5592893d-904d-41ac-a92b-035047ac0107" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89bdf570-edd5-4d6d-b243-891d56d34c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_88d04836-17a9-43b4-9508-6f734fcdaa87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_73fc2477-2e79-4f9d-9276-3a432b12f323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_88d04836-17a9-43b4-9508-6f734fcdaa87" xlink:to="loc_us-gaap_AssetsCurrent_73fc2477-2e79-4f9d-9276-3a432b12f323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4e40cc32-d0a9-49e3-b2b9-11a0572e2688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_88d04836-17a9-43b4-9508-6f734fcdaa87" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4e40cc32-d0a9-49e3-b2b9-11a0572e2688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_19a044e4-5932-496a-b67c-f84b5d129855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_88d04836-17a9-43b4-9508-6f734fcdaa87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_19a044e4-5932-496a-b67c-f84b5d129855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1eda8e8b-2192-4947-b3f4-3e3b90f97247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_88d04836-17a9-43b4-9508-6f734fcdaa87" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1eda8e8b-2192-4947-b3f4-3e3b90f97247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_56caf0c2-c779-4937-b84d-c235443fe93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_88d04836-17a9-43b4-9508-6f734fcdaa87" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_56caf0c2-c779-4937-b84d-c235443fe93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_36278790-105b-4b5c-b588-335f310ab073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_88d04836-17a9-43b4-9508-6f734fcdaa87" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_36278790-105b-4b5c-b588-335f310ab073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d7c3361-1499-4812-8f77-a8143971b6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1144f7d6-9a4b-4707-87d5-934481def128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d7c3361-1499-4812-8f77-a8143971b6dd" xlink:to="loc_us-gaap_AccountsPayableCurrent_1144f7d6-9a4b-4707-87d5-934481def128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1e2ecab1-a44f-49a7-bf53-c622432dfa40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d7c3361-1499-4812-8f77-a8143971b6dd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1e2ecab1-a44f-49a7-bf53-c622432dfa40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_07bb59cd-ea40-4e8a-aede-ec8617bd800c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d7c3361-1499-4812-8f77-a8143971b6dd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_07bb59cd-ea40-4e8a-aede-ec8617bd800c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e694dae-f12f-425e-a1dd-a1b3cf348bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d7c3361-1499-4812-8f77-a8143971b6dd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e694dae-f12f-425e-a1dd-a1b3cf348bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_57f9f124-40e8-4ee0-bdbe-5751e51cf1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d7c3361-1499-4812-8f77-a8143971b6dd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_57f9f124-40e8-4ee0-bdbe-5751e51cf1a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9b583623-6ec0-43ef-95b7-f31e8cdaa524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56b775bb-beca-480a-bfac-b126aa1f010f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9b583623-6ec0-43ef-95b7-f31e8cdaa524" xlink:to="loc_us-gaap_StockholdersEquity_56b775bb-beca-480a-bfac-b126aa1f010f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2f56e1bc-7821-4176-9364-2c41140ba735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9b583623-6ec0-43ef-95b7-f31e8cdaa524" xlink:to="loc_us-gaap_MinorityInterest_2f56e1bc-7821-4176-9364-2c41140ba735" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arwr-20221231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d64d0512-dd28-46e4-895f-ba8bea8d9c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_45a9637a-3992-474f-a2f8-bdd3c9b6c3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d64d0512-dd28-46e4-895f-ba8bea8d9c66" xlink:to="loc_us-gaap_ProfitLoss_45a9637a-3992-474f-a2f8-bdd3c9b6c3f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_000fb656-1d54-4610-ad48-cd15a0c03eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d64d0512-dd28-46e4-895f-ba8bea8d9c66" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_000fb656-1d54-4610-ad48-cd15a0c03eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_30f4e8d3-934a-40a6-a678-e4911f502024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_aa772d7e-962a-4d0d-b7a8-0236cf4ac6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_30f4e8d3-934a-40a6-a678-e4911f502024" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_aa772d7e-962a-4d0d-b7a8-0236cf4ac6b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a14321d7-a302-454b-8648-d84b721bb775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_30f4e8d3-934a-40a6-a678-e4911f502024" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a14321d7-a302-454b-8648-d84b721bb775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a1fb9a41-4ef2-4ee8-98cd-58e8fc160ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6e6d1588-44e8-4dcd-8920-7f14510a2c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a1fb9a41-4ef2-4ee8-98cd-58e8fc160ac8" xlink:to="loc_us-gaap_ProfitLoss_6e6d1588-44e8-4dcd-8920-7f14510a2c77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1595ae4e-e458-4939-a508-546fc2d53550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a1fb9a41-4ef2-4ee8-98cd-58e8fc160ac8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1595ae4e-e458-4939-a508-546fc2d53550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_952827bf-dc3f-4310-867f-e6ca7595c687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1f22c896-c2ef-4ab2-88b1-382e04a1153a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_952827bf-dc3f-4310-867f-e6ca7595c687" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1f22c896-c2ef-4ab2-88b1-382e04a1153a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_587bc0d7-810b-40b6-b150-389d7afde97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_952827bf-dc3f-4310-867f-e6ca7595c687" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_587bc0d7-810b-40b6-b150-389d7afde97a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4b304fc4-efee-4671-bfe7-2ad9edb768c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e0e51a77-96ee-4d81-8d49-b0cb2b63777f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4b304fc4-efee-4671-bfe7-2ad9edb768c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e0e51a77-96ee-4d81-8d49-b0cb2b63777f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_732e4eab-610d-45bd-8f68-d40202a10503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4b304fc4-efee-4671-bfe7-2ad9edb768c6" xlink:to="loc_us-gaap_OperatingExpenses_732e4eab-610d-45bd-8f68-d40202a10503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_139ddfda-c7d5-4abf-b2d3-076c428dbe3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f12407ad-0e68-41ab-9e56-64d3c86c2b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_139ddfda-c7d5-4abf-b2d3-076c428dbe3f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f12407ad-0e68-41ab-9e56-64d3c86c2b57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_93b3ee3e-d5f9-4b48-ad40-346b14e2d087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_139ddfda-c7d5-4abf-b2d3-076c428dbe3f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_93b3ee3e-d5f9-4b48-ad40-346b14e2d087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7261bdd-d58b-40eb-9cf9-902c68950e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_11a1cc26-d0d2-4509-a359-604536685153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7261bdd-d58b-40eb-9cf9-902c68950e18" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_11a1cc26-d0d2-4509-a359-604536685153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_630d96cd-19c7-45c5-81a4-0e26fe9b7c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7261bdd-d58b-40eb-9cf9-902c68950e18" xlink:to="loc_us-gaap_OperatingIncomeLoss_630d96cd-19c7-45c5-81a4-0e26fe9b7c10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27762cba-eb8e-4705-9451-d3390004d727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9e66e957-d2e8-4d07-bf7a-96afb610a7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27762cba-eb8e-4705-9451-d3390004d727" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9e66e957-d2e8-4d07-bf7a-96afb610a7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_a490b7a1-95c5-4a8a-9221-34c00849fdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27762cba-eb8e-4705-9451-d3390004d727" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_a490b7a1-95c5-4a8a-9221-34c00849fdbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04e8f4b6-a718-431b-8bdc-7046ec59a578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9609e52e-b4ad-458f-89ef-82f4af0b4077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04e8f4b6-a718-431b-8bdc-7046ec59a578" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9609e52e-b4ad-458f-89ef-82f4af0b4077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f13b0c2-02b7-4d05-b004-db0a6fd4e913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04e8f4b6-a718-431b-8bdc-7046ec59a578" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f13b0c2-02b7-4d05-b004-db0a6fd4e913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b016cba-cd0e-4ca6-a90c-ec4839e3d865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04e8f4b6-a718-431b-8bdc-7046ec59a578" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b016cba-cd0e-4ca6-a90c-ec4839e3d865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3bd70467-11ea-46aa-89ed-ffabde9ffa30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_617a7f14-3e71-4f83-b41c-c5107e9fe149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3bd70467-11ea-46aa-89ed-ffabde9ffa30" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_617a7f14-3e71-4f83-b41c-c5107e9fe149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_aadd9f8e-68dc-4e27-a042-0f30dbcc27f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3bd70467-11ea-46aa-89ed-ffabde9ffa30" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_aadd9f8e-68dc-4e27-a042-0f30dbcc27f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d9fdae72-c6bb-4be6-8334-0edbd3639abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3bd70467-11ea-46aa-89ed-ffabde9ffa30" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d9fdae72-c6bb-4be6-8334-0edbd3639abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c96dc706-5ba9-4349-804c-a2a485d80a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_ShareBasedCompensation_c96dc706-5ba9-4349-804c-a2a485d80a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a1cd95f8-508b-40c7-8f83-262338267838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a1cd95f8-508b-40c7-8f83-262338267838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3ec961f5-e686-4e19-9595-800f5bdb02b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_DepreciationAndAmortization_3ec961f5-e686-4e19-9595-800f5bdb02b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_84833a1e-830c-4f9f-8c81-c55d18eb90cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_84833a1e-830c-4f9f-8c81-c55d18eb90cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_d20ed3cf-5fc5-4b18-856d-52a0156be894" xlink:href="arwr-20221231.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_d20ed3cf-5fc5-4b18-856d-52a0156be894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2db8f5a9-5f46-4733-aabe-725bc743f3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2db8f5a9-5f46-4733-aabe-725bc743f3cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3e4e4b62-0850-4a31-af73-79eef10b11ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3e4e4b62-0850-4a31-af73-79eef10b11ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e06c29a9-df95-4800-857e-a8feba81b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e06c29a9-df95-4800-857e-a8feba81b1e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2d1e8720-4045-44b8-bf19-a143d5f69cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2d1e8720-4045-44b8-bf19-a143d5f69cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc72dd9c-7785-423b-8b86-1661346f719c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc72dd9c-7785-423b-8b86-1661346f719c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_50269b18-ed7f-4bdf-ae39-129e93e4841b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e0134d4-3a70-4cc8-a007-01623eeaf4d0" xlink:to="loc_us-gaap_ProfitLoss_50269b18-ed7f-4bdf-ae39-129e93e4841b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="arwr-20221231.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetail"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c450dc3e-0bdb-4f5f-9f2c-0399755433ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_977e8237-761a-47fe-b196-2b8aad13516d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c450dc3e-0bdb-4f5f-9f2c-0399755433ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_977e8237-761a-47fe-b196-2b8aad13516d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_176ce817-f740-4227-87ee-ea92627375fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c450dc3e-0bdb-4f5f-9f2c-0399755433ba" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_176ce817-f740-4227-87ee-ea92627375fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e5d971eb-8b0c-4ba0-9c77-7cf3206d9656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_4370662f-ec98-4a0b-b361-4781dd988a55" xlink:href="arwr-20221231.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_e5d971eb-8b0c-4ba0-9c77-7cf3206d9656" xlink:to="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_4370662f-ec98-4a0b-b361-4781dd988a55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_5452c72e-b224-4497-9148-6fb4bc462e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_e5d971eb-8b0c-4ba0-9c77-7cf3206d9656" xlink:to="loc_us-gaap_Land_5452c72e-b224-4497-9148-6fb4bc462e3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_7b083c1e-11ea-4b5f-a3ed-b5f3749bc3e4" xlink:href="arwr-20221231.xsd#arwr_ResearchEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_e5d971eb-8b0c-4ba0-9c77-7cf3206d9656" xlink:to="loc_arwr_ResearchEquipmentGross_7b083c1e-11ea-4b5f-a3ed-b5f3749bc3e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_eb4e898c-9dd9-4dab-a33e-408f7a90621f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_e5d971eb-8b0c-4ba0-9c77-7cf3206d9656" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_eb4e898c-9dd9-4dab-a33e-408f7a90621f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_d25c4649-6a33-49cf-b445-5810bda456ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_e5d971eb-8b0c-4ba0-9c77-7cf3206d9656" xlink:to="loc_us-gaap_ConstructionInProgressGross_d25c4649-6a33-49cf-b445-5810bda456ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7a5fc8f7-8288-41d5-925c-b439573833be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_cd3b1beb-c2ec-4475-b609-6f7ce932bdcb" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7a5fc8f7-8288-41d5-925c-b439573833be" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_cd3b1beb-c2ec-4475-b609-6f7ce932bdcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_ba3e1ddd-5fb3-4c3b-be0b-80565f68870e" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7a5fc8f7-8288-41d5-925c-b439573833be" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_ba3e1ddd-5fb3-4c3b-be0b-80565f68870e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_75bb9ec9-0cf0-412a-aee3-070de828d34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7a5fc8f7-8288-41d5-925c-b439573833be" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_75bb9ec9-0cf0-412a-aee3-070de828d34f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_ee578b6c-9cb3-4c8f-a686-faf45d66e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_0f56d443-b96a-446e-abf3-a857390bc143" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_ee578b6c-9cb3-4c8f-a686-faf45d66e4c3" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_0f56d443-b96a-446e-abf3-a857390bc143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_2465ff9e-55f6-46bf-8ec2-dc383825f7c4" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_ee578b6c-9cb3-4c8f-a686-faf45d66e4c3" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_2465ff9e-55f6-46bf-8ec2-dc383825f7c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_71782ec7-871b-45f6-b12f-ffb03e12fd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_ee578b6c-9cb3-4c8f-a686-faf45d66e4c3" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_71782ec7-871b-45f6-b12f-ffb03e12fd56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dc7e2a4e-81db-4007-b722-d08100643e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_94b4cccc-5f26-4389-bf0c-950ef74d9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dc7e2a4e-81db-4007-b722-d08100643e3e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_94b4cccc-5f26-4389-bf0c-950ef74d9bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_78725131-9ebf-404d-aab0-2539852c02db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dc7e2a4e-81db-4007-b722-d08100643e3e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_78725131-9ebf-404d-aab0-2539852c02db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_4eed2bc9-eb3e-471a-90a1-47dc8b990300" xlink:href="arwr-20221231.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dc7e2a4e-81db-4007-b722-d08100643e3e" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_4eed2bc9-eb3e-471a-90a1-47dc8b990300" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2ea982e-fd01-4f5e-83b5-850a1087d7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_55b2a1d6-98df-4fcb-8e14-b6442b3bfada" xlink:href="arwr-20221231.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2ea982e-fd01-4f5e-83b5-850a1087d7a6" xlink:to="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_55b2a1d6-98df-4fcb-8e14-b6442b3bfada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_170e5dc8-2bd5-4b03-b9cc-811a7f99c51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2ea982e-fd01-4f5e-83b5-850a1087d7a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_170e5dc8-2bd5-4b03-b9cc-811a7f99c51d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6121f62e-7e14-438d-9c70-0bf5f7fcc7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2ea982e-fd01-4f5e-83b5-850a1087d7a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6121f62e-7e14-438d-9c70-0bf5f7fcc7b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c5fe2d56-07b7-461b-8534-2f5a007c6929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2ea982e-fd01-4f5e-83b5-850a1087d7a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c5fe2d56-07b7-461b-8534-2f5a007c6929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d6987a65-a44d-4a12-91db-b894339b1f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2ea982e-fd01-4f5e-83b5-850a1087d7a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d6987a65-a44d-4a12-91db-b894339b1f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_daa8b855-c9ab-407d-8bef-e92701e017ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2ea982e-fd01-4f5e-83b5-850a1087d7a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_daa8b855-c9ab-407d-8bef-e92701e017ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_31adbb25-aa7a-403d-8ec4-c17f4f757a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_344f47cf-a970-470f-8461-a3dd7153ad1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_31adbb25-aa7a-403d-8ec4-c17f4f757a5c" xlink:to="loc_us-gaap_VariableLeaseCost_344f47cf-a970-470f-8461-a3dd7153ad1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_58faaf77-7074-457f-bfec-4b27a9561050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_31adbb25-aa7a-403d-8ec4-c17f4f757a5c" xlink:to="loc_us-gaap_OperatingLeaseCost_58faaf77-7074-457f-bfec-4b27a9561050" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3137c4b5-5b44-49ab-96d3-a6f3300fed9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0263a543-cc58-4103-8285-3d043f8aec52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3137c4b5-5b44-49ab-96d3-a6f3300fed9b" xlink:to="loc_us-gaap_OperatingLeaseLiability_0263a543-cc58-4103-8285-3d043f8aec52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e9e371e4-85da-41de-9bd6-ead5a2b9f9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3137c4b5-5b44-49ab-96d3-a6f3300fed9b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e9e371e4-85da-41de-9bd6-ead5a2b9f9bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f949354-4679-4237-8af4-0c9c5d6dc3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_abcd8bb4-ddb0-4f5b-99aa-cc8ced2d0de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f949354-4679-4237-8af4-0c9c5d6dc3ab" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_abcd8bb4-ddb0-4f5b-99aa-cc8ced2d0de1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_529d8705-0c9c-461a-968a-28b72914c7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f949354-4679-4237-8af4-0c9c5d6dc3ab" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_529d8705-0c9c-461a-968a-28b72914c7e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8ecefb5c-48b7-4eff-9a9f-8774e7216c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f949354-4679-4237-8af4-0c9c5d6dc3ab" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8ecefb5c-48b7-4eff-9a9f-8774e7216c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16415408-b8af-4f0b-8d70-3237c6ef117c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f949354-4679-4237-8af4-0c9c5d6dc3ab" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16415408-b8af-4f0b-8d70-3237c6ef117c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_fa411134-f586-4321-b75d-85eea9bbdc51" xlink:href="arwr-20221231.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f949354-4679-4237-8af4-0c9c5d6dc3ab" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_fa411134-f586-4321-b75d-85eea9bbdc51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_823d57ad-a0ba-4452-828d-4d481fb2302e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f949354-4679-4237-8af4-0c9c5d6dc3ab" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_823d57ad-a0ba-4452-828d-4d481fb2302e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_ab04c90c-50d9-4d7c-bae9-e209577e2020" xlink:href="arwr-20221231.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c634ca99-68dc-4025-9f02-55749fcdde2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_ab04c90c-50d9-4d7c-bae9-e209577e2020" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c634ca99-68dc-4025-9f02-55749fcdde2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2229626-4d71-4940-b620-9f849cb3e609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_ab04c90c-50d9-4d7c-bae9-e209577e2020" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2229626-4d71-4940-b620-9f849cb3e609" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>arwr-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e8083e98-eeaa-4076-9e59-e239858f4776,g:e1942b16-5fc3-435c-8ded-c247fb91952b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i29b7ce37cf7d43cba960b0fd399b8153_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f1a3ac2d-6454-435e-be8e-28dafba432ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f1a3ac2d-6454-435e-be8e-28dafba432ed" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0285f28b-27af-4a87-9be1-200643a1f8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0285f28b-27af-4a87-9be1-200643a1f8f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f69b3912-27f5-42ea-92eb-ac9aa0d01d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_SharesOutstanding_f69b3912-27f5-42ea-92eb-ac9aa0d01d50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4943d0e2-0c74-480a-9525-70237af53120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4943d0e2-0c74-480a-9525-70237af53120" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1706d83a-bca7-4a13-abcb-a38939f0311b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1706d83a-bca7-4a13-abcb-a38939f0311b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c1ca4e8a-96a9-4539-bed9-2839f2c4c91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c1ca4e8a-96a9-4539-bed9-2839f2c4c91a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_9f057bd9-78dc-4d43-9652-221c64b41cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_9f057bd9-78dc-4d43-9652-221c64b41cab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_212eb022-8a02-4de8-a596-46b3d7e3c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_212eb022-8a02-4de8-a596-46b3d7e3c0a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_91c0b0ce-c9aa-4c2f-b207-7a40db7821f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_91c0b0ce-c9aa-4c2f-b207-7a40db7821f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_28c0ea1d-1aaa-43bb-b0e9-589b99f527ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_28c0ea1d-1aaa-43bb-b0e9-589b99f527ec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a19a281b-3ddb-46bb-8d34-8f6b5387e203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_NetIncomeLoss_a19a281b-3ddb-46bb-8d34-8f6b5387e203" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a937163-c033-4bb0-83cc-c15726362c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_971be393-d8cb-4b82-aec7-8f34a5cb3277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_995313c4-844e-465b-b121-741cb12f65de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f1a3ac2d-6454-435e-be8e-28dafba432ed" xlink:to="loc_us-gaap_StatementTable_995313c4-844e-465b-b121-741cb12f65de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c8a82cc8-914b-4277-824c-b71ce48f5b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_995313c4-844e-465b-b121-741cb12f65de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c8a82cc8-914b-4277-824c-b71ce48f5b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8a82cc8-914b-4277-824c-b71ce48f5b45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8a82cc8-914b-4277-824c-b71ce48f5b45" xlink:to="loc_us-gaap_EquityComponentDomain_c8a82cc8-914b-4277-824c-b71ce48f5b45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8a82cc8-914b-4277-824c-b71ce48f5b45" xlink:to="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5dfbd82b-39cc-4489-a5df-8ba24546e760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_CommonStockMember_5dfbd82b-39cc-4489-a5df-8ba24546e760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dcacbb8e-33cb-4a8b-8cc9-1753d990621f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dcacbb8e-33cb-4a8b-8cc9-1753d990621f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f51513d9-558e-481d-a91b-58eb1176e5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f51513d9-558e-481d-a91b-58eb1176e5e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7d5a7fbf-5516-408b-9bb9-9a217d0abecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_RetainedEarningsMember_7d5a7fbf-5516-408b-9bb9-9a217d0abecb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_471c65d3-3e4f-4cb6-91d7-27e34b02a2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_NoncontrollingInterestMember_471c65d3-3e4f-4cb6-91d7-27e34b02a2c8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20221231.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="iea4754a122b64f1d8ffef6387c531b81_OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:href="arwr-20221231.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_2254ca8f-f853-4c33-8d69-2944e10c223b" xlink:href="arwr-20221231.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_2254ca8f-f853-4c33-8d69-2944e10c223b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bea486da-4cbb-4ca3-9603-42149c28cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bea486da-4cbb-4ca3-9603-42149c28cf32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4448e31f-98a8-4e70-ac44-20ad696cec56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4448e31f-98a8-4e70-ac44-20ad696cec56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_bcf264cb-e3a1-4b56-9228-7b8439d820ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_bcf264cb-e3a1-4b56-9228-7b8439d820ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_12cf2a15-cac0-4ab9-8759-9a324117bf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_12cf2a15-cac0-4ab9-8759-9a324117bf4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_90eade8d-f20a-4bd3-99d1-c5671f89cad3" xlink:href="arwr-20221231.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_90eade8d-f20a-4bd3-99d1-c5671f89cad3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_88599702-ce95-42cd-83ea-cb3ae3dd3475" xlink:href="arwr-20221231.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_88599702-ce95-42cd-83ea-cb3ae3dd3475" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_1459cf45-b8f9-4738-af51-61102a795981" xlink:href="arwr-20221231.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_1459cf45-b8f9-4738-af51-61102a795981" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2f86d485-1228-4616-9967-e2b548275d9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_1459cf45-b8f9-4738-af51-61102a795981" xlink:to="loc_dei_LegalEntityAxis_2f86d485-1228-4616-9967-e2b548275d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f86d485-1228-4616-9967-e2b548275d9d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2f86d485-1228-4616-9967-e2b548275d9d" xlink:to="loc_dei_EntityDomain_2f86d485-1228-4616-9967-e2b548275d9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2f86d485-1228-4616-9967-e2b548275d9d" xlink:to="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_07dfd0c3-6e7e-49f0-80ab-2bc2d91adeaa" xlink:href="arwr-20221231.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_07dfd0c3-6e7e-49f0-80ab-2bc2d91adeaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_4608a10b-012a-4098-ab84-03b16952fc8b" xlink:href="arwr-20221231.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:to="loc_arwr_AmgenIncorporatedMember_4608a10b-012a-4098-ab84-03b16952fc8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaMember_14485d6d-065f-458e-94fb-64997f1b90ec" xlink:href="arwr-20221231.xsd#arwr_RoyaltyPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:to="loc_arwr_RoyaltyPharmaMember_14485d6d-065f-458e-94fb-64997f1b90ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ce110395-4541-49a2-be70-d3444937edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_1459cf45-b8f9-4738-af51-61102a795981" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ce110395-4541-49a2-be70-d3444937edd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ce110395-4541-49a2-be70-d3444937edd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ce110395-4541-49a2-be70-d3444937edd0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ce110395-4541-49a2-be70-d3444937edd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0369145a-3d95-4e05-8bc7-ab6f0829e910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ce110395-4541-49a2-be70-d3444937edd0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0369145a-3d95-4e05-8bc7-ab6f0829e910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_65994d3c-7c9c-4aa9-86f3-13c5241f1fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0369145a-3d95-4e05-8bc7-ab6f0829e910" xlink:to="loc_us-gaap_SubsequentEventMember_65994d3c-7c9c-4aa9-86f3-13c5241f1fde" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended" id="ia3675d521a3a4aa89fa63f29ec651203_CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_f11e8960-9c00-4c47-b70f-470c1a9514fe" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_MilestonePaymentEarned_f11e8960-9c00-4c47-b70f-470c1a9514fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_4d920f1e-6079-47e6-98cd-90fcff4b378c" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_4d920f1e-6079-47e6-98cd-90fcff4b378c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_ced8ff38-4fe3-4e08-b1f8-38f398654146" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_ced8ff38-4fe3-4e08-b1f8-38f398654146" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_71d06ad3-a2d3-42ed-8a24-97943bd10b9d" xlink:href="arwr-20221231.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_71d06ad3-a2d3-42ed-8a24-97943bd10b9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_14b2aedc-becd-4831-9227-03f5de84b8db" xlink:href="arwr-20221231.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_SalesRelatedMilestonePayments_14b2aedc-becd-4831-9227-03f5de84b8db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_15221bd9-dbff-43a3-9fbf-9d3562de7a69" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_InitialTransactionPrice_15221bd9-dbff-43a3-9fbf-9d3562de7a69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c990abce-8c15-4c64-a56c-e651438bbc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c990abce-8c15-4c64-a56c-e651438bbc76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_300b1dac-7275-4c25-9b81-95772dd2eeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_300b1dac-7275-4c25-9b81-95772dd2eeb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_64e836fd-76f0-41eb-a262-bf9153b944c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_64e836fd-76f0-41eb-a262-bf9153b944c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_40058f8d-eab8-459d-9d86-e0e16c044037" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:to="loc_dei_LegalEntityAxis_40058f8d-eab8-459d-9d86-e0e16c044037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_40058f8d-eab8-459d-9d86-e0e16c044037_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_40058f8d-eab8-459d-9d86-e0e16c044037" xlink:to="loc_dei_EntityDomain_40058f8d-eab8-459d-9d86-e0e16c044037_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bf7bd17f-6658-4b18-8674-82e960b37a1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_40058f8d-eab8-459d-9d86-e0e16c044037" xlink:to="loc_dei_EntityDomain_bf7bd17f-6658-4b18-8674-82e960b37a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_15333418-90bd-4217-a78d-5ccc48bc0488" xlink:href="arwr-20221231.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bf7bd17f-6658-4b18-8674-82e960b37a1b" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_15333418-90bd-4217-a78d-5ccc48bc0488" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_52e3f59f-204f-41bf-9e42-381d298f4129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:to="loc_us-gaap_TypeOfArrangementAxis_52e3f59f-204f-41bf-9e42-381d298f4129" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52e3f59f-204f-41bf-9e42-381d298f4129_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52e3f59f-204f-41bf-9e42-381d298f4129" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52e3f59f-204f-41bf-9e42-381d298f4129_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30d5fec1-43fb-45b2-964e-e8f0c966daad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52e3f59f-204f-41bf-9e42-381d298f4129" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30d5fec1-43fb-45b2-964e-e8f0c966daad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_c53a4e68-70a8-4108-be7e-75bdd9eac9a9" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30d5fec1-43fb-45b2-964e-e8f0c966daad" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_c53a4e68-70a8-4108-be7e-75bdd9eac9a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROHSDAgreementMember_ad9280c4-a0c8-4cdb-84a9-0afedbbe130d" xlink:href="arwr-20221231.xsd#arwr_AROHSDAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30d5fec1-43fb-45b2-964e-e8f0c966daad" xlink:to="loc_arwr_AROHSDAgreementMember_ad9280c4-a0c8-4cdb-84a9-0afedbbe130d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e32d45ce-91de-4e03-8341-556a9da02e31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:to="loc_srt_RangeAxis_e32d45ce-91de-4e03-8341-556a9da02e31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e32d45ce-91de-4e03-8341-556a9da02e31_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e32d45ce-91de-4e03-8341-556a9da02e31" xlink:to="loc_srt_RangeMember_e32d45ce-91de-4e03-8341-556a9da02e31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_88f9d645-b0cd-4670-8956-dd7a96d09003" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e32d45ce-91de-4e03-8341-556a9da02e31" xlink:to="loc_srt_RangeMember_88f9d645-b0cd-4670-8956-dd7a96d09003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd2d5757-5ee2-4085-a079-086ba2fb3601" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_88f9d645-b0cd-4670-8956-dd7a96d09003" xlink:to="loc_srt_MaximumMember_cd2d5757-5ee2-4085-a079-086ba2fb3601" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended" id="if0deb76fdcf6418085fce1a4763cf23f_CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e2497c6a-8bb5-43f4-a3e7-5aeec0c6814e" xlink:href="arwr-20221231.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e2497c6a-8bb5-43f4-a3e7-5aeec0c6814e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_49d8bd13-6a9d-4116-afcf-740f94234f93" xlink:href="arwr-20221231.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_49d8bd13-6a9d-4116-afcf-740f94234f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_063de665-055b-41bf-bfe8-335311e3b354" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_NumberOfDistinctBundle_063de665-055b-41bf-bfe8-335311e3b354" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_54080c39-d4e0-44ed-91ca-ded66c686233" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_54080c39-d4e0-44ed-91ca-ded66c686233" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_8592b8d4-c5f9-4f57-992f-8d3d56203abc" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_InitialTransactionPrice_8592b8d4-c5f9-4f57-992f-8d3d56203abc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_da88f8f6-14f1-45d0-b2ce-d768e8c32c3c" xlink:href="arwr-20221231.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_da88f8f6-14f1-45d0-b2ce-d768e8c32c3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_18bd0209-d120-48a2-b479-6af82c7b2a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_18bd0209-d120-48a2-b479-6af82c7b2a81" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_97856a07-67ed-4046-9dd1-47d5876c5e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_97856a07-67ed-4046-9dd1-47d5876c5e41" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17ba4f2e-9458-4575-9ad3-288184574eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17ba4f2e-9458-4575-9ad3-288184574eea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e7552954-14f7-4c9a-8937-1e2f09ef6d35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:to="loc_dei_LegalEntityAxis_e7552954-14f7-4c9a-8937-1e2f09ef6d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e7552954-14f7-4c9a-8937-1e2f09ef6d35_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e7552954-14f7-4c9a-8937-1e2f09ef6d35" xlink:to="loc_dei_EntityDomain_e7552954-14f7-4c9a-8937-1e2f09ef6d35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_740b1346-74e1-451f-bcd4-c25ff82c5302" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e7552954-14f7-4c9a-8937-1e2f09ef6d35" xlink:to="loc_dei_EntityDomain_740b1346-74e1-451f-bcd4-c25ff82c5302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_9b53ab7e-5bc6-4794-8366-4f3bde5ca907" xlink:href="arwr-20221231.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_740b1346-74e1-451f-bcd4-c25ff82c5302" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_9b53ab7e-5bc6-4794-8366-4f3bde5ca907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d4421b7-bcfd-4e05-858f-c817f991ffe2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:to="loc_srt_RangeAxis_9d4421b7-bcfd-4e05-858f-c817f991ffe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d4421b7-bcfd-4e05-858f-c817f991ffe2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9d4421b7-bcfd-4e05-858f-c817f991ffe2" xlink:to="loc_srt_RangeMember_9d4421b7-bcfd-4e05-858f-c817f991ffe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc08bfb4-e40a-4c99-b763-0fffb9dae691" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9d4421b7-bcfd-4e05-858f-c817f991ffe2" xlink:to="loc_srt_RangeMember_cc08bfb4-e40a-4c99-b763-0fffb9dae691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e6308c13-cecd-41a4-8314-ecc6a09d2dfe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cc08bfb4-e40a-4c99-b763-0fffb9dae691" xlink:to="loc_srt_MaximumMember_e6308c13-cecd-41a4-8314-ecc6a09d2dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1d8ec676-96a8-4588-87e8-f24c46aea1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1d8ec676-96a8-4588-87e8-f24c46aea1d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d8ec676-96a8-4588-87e8-f24c46aea1d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d8ec676-96a8-4588-87e8-f24c46aea1d2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d8ec676-96a8-4588-87e8-f24c46aea1d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d1f0643-c2b0-44ae-8efa-62b3a89bff2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d8ec676-96a8-4588-87e8-f24c46aea1d2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d1f0643-c2b0-44ae-8efa-62b3a89bff2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember_cd20db71-2dc9-4854-a19e-c96215bf1a27" xlink:href="arwr-20221231.xsd#arwr_AROXDHAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d1f0643-c2b0-44ae-8efa-62b3a89bff2f" xlink:to="loc_arwr_AROXDHAgreementMember_cd20db71-2dc9-4854-a19e-c96215bf1a27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_1d2e627a-e27b-46dd-9328-72b49ed9230a" xlink:href="arwr-20221231.xsd#arwr_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d1f0643-c2b0-44ae-8efa-62b3a89bff2f" xlink:to="loc_arwr_LicenseAgreementMember_1d2e627a-e27b-46dd-9328-72b49ed9230a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_24cb11a5-19d4-4a62-a065-4cf5d94d4031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_24cb11a5-19d4-4a62-a065-4cf5d94d4031" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_24cb11a5-19d4-4a62-a065-4cf5d94d4031_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_24cb11a5-19d4-4a62-a065-4cf5d94d4031" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_24cb11a5-19d4-4a62-a065-4cf5d94d4031_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ef12dae2-699d-4333-b46c-bf87a67921f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_24cb11a5-19d4-4a62-a065-4cf5d94d4031" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ef12dae2-699d-4333-b46c-bf87a67921f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_38e5d762-d6c1-4e77-ad21-6b3ffd6fbbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ef12dae2-699d-4333-b46c-bf87a67921f1" xlink:to="loc_us-gaap_SubsequentEventMember_38e5d762-d6c1-4e77-ad21-6b3ffd6fbbae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended" id="i44162346d0a5475dbdd8851d693df9f9_CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_a3bf754d-882f-4c64-afbd-c1614b7e238f" xlink:href="arwr-20221231.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_a3bf754d-882f-4c64-afbd-c1614b7e238f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_57ea419a-6a03-4245-a47c-cb11f3b07134" xlink:href="arwr-20221231.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_57ea419a-6a03-4245-a47c-cb11f3b07134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d7b5e415-0f4f-42a9-b21e-f7da4c1c26dd" xlink:href="arwr-20221231.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d7b5e415-0f4f-42a9-b21e-f7da4c1c26dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_6b91e63f-79f4-43b7-b756-39feb940a78c" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_NumberOfDistinctBundle_6b91e63f-79f4-43b7-b756-39feb940a78c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_d2db7573-7018-47f6-bd07-7f1840c9a572" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_d2db7573-7018-47f6-bd07-7f1840c9a572" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_8d7e9aa2-7c61-431b-8e9c-44d3b6e31289" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_InitialTransactionPrice_8d7e9aa2-7c61-431b-8e9c-44d3b6e31289" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_574f9b99-49a4-4ac5-bc35-5686aa97e861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_574f9b99-49a4-4ac5-bc35-5686aa97e861" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d6a4a958-40c8-48ef-b667-4e83369ed28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d6a4a958-40c8-48ef-b667-4e83369ed28b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a1d64936-11c2-42fb-b176-93ab3347cbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a1d64936-11c2-42fb-b176-93ab3347cbd7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f7cd174-13b4-4835-9b51-90702397983e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f7cd174-13b4-4835-9b51-90702397983e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b17972fb-3784-44f8-824b-7ca58dd77b3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:to="loc_dei_LegalEntityAxis_b17972fb-3784-44f8-824b-7ca58dd77b3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b17972fb-3784-44f8-824b-7ca58dd77b3d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b17972fb-3784-44f8-824b-7ca58dd77b3d" xlink:to="loc_dei_EntityDomain_b17972fb-3784-44f8-824b-7ca58dd77b3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_01f7c8de-8391-4ab9-82e4-8548ee88a62f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b17972fb-3784-44f8-824b-7ca58dd77b3d" xlink:to="loc_dei_EntityDomain_01f7c8de-8391-4ab9-82e4-8548ee88a62f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_6fdc34aa-1afa-4cda-a52d-5efd3c4157e4" xlink:href="arwr-20221231.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_01f7c8de-8391-4ab9-82e4-8548ee88a62f" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_6fdc34aa-1afa-4cda-a52d-5efd3c4157e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4266af1d-2c23-4f6b-b30c-aaef1d7636aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4266af1d-2c23-4f6b-b30c-aaef1d7636aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4266af1d-2c23-4f6b-b30c-aaef1d7636aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4266af1d-2c23-4f6b-b30c-aaef1d7636aa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4266af1d-2c23-4f6b-b30c-aaef1d7636aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e89db1c9-4c96-4775-af66-e96b0c69b48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4266af1d-2c23-4f6b-b30c-aaef1d7636aa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e89db1c9-4c96-4775-af66-e96b0c69b48e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_f700dc1a-10f9-443f-9d1c-0b0c17ba91a9" xlink:href="arwr-20221231.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e89db1c9-4c96-4775-af66-e96b0c69b48e" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_f700dc1a-10f9-443f-9d1c-0b0c17ba91a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c18bb1a3-da5a-4834-b18f-94fc58ed3112" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:to="loc_srt_RangeAxis_c18bb1a3-da5a-4834-b18f-94fc58ed3112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c18bb1a3-da5a-4834-b18f-94fc58ed3112_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c18bb1a3-da5a-4834-b18f-94fc58ed3112" xlink:to="loc_srt_RangeMember_c18bb1a3-da5a-4834-b18f-94fc58ed3112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d6729f2-e5be-497a-8032-82d079703669" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c18bb1a3-da5a-4834-b18f-94fc58ed3112" xlink:to="loc_srt_RangeMember_1d6729f2-e5be-497a-8032-82d079703669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4bc3e4bc-85c6-49d4-b544-e25d37e442ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1d6729f2-e5be-497a-8032-82d079703669" xlink:to="loc_srt_MinimumMember_4bc3e4bc-85c6-49d4-b544-e25d37e442ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b14ae32-03d4-469e-b9f4-23f45b1b5d17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1d6729f2-e5be-497a-8032-82d079703669" xlink:to="loc_srt_MaximumMember_2b14ae32-03d4-469e-b9f4-23f45b1b5d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b5e1fcca-aa0c-46eb-9497-13b0247e221f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b5e1fcca-aa0c-46eb-9497-13b0247e221f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b5e1fcca-aa0c-46eb-9497-13b0247e221f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b5e1fcca-aa0c-46eb-9497-13b0247e221f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b5e1fcca-aa0c-46eb-9497-13b0247e221f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc762a76-8e83-44a8-82c1-214dea14169b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b5e1fcca-aa0c-46eb-9497-13b0247e221f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc762a76-8e83-44a8-82c1-214dea14169b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember_c3e01dbb-ea9f-4a59-8af9-6068b933aadf" xlink:href="arwr-20221231.xsd#arwr_DeferredRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc762a76-8e83-44a8-82c1-214dea14169b" xlink:to="loc_arwr_DeferredRevenueMember_c3e01dbb-ea9f-4a59-8af9-6068b933aadf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_0dacc3c8-fad2-49c3-9100-c6ebd47f0403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc762a76-8e83-44a8-82c1-214dea14169b" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_0dacc3c8-fad2-49c3-9100-c6ebd47f0403" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="extended" id="i0e3caa4e76d74c7ea565a18ed7945245_CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_7f51caf5-af56-4aec-900b-a1a878edc993" xlink:href="arwr-20221231.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_7f51caf5-af56-4aec-900b-a1a878edc993" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bf2ed409-8a55-4d86-b2fc-96860a5bb459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bf2ed409-8a55-4d86-b2fc-96860a5bb459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_43444472-65a3-4fb5-9f55-fb2e89c4e523" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_MilestonePaymentEarned_43444472-65a3-4fb5-9f55-fb2e89c4e523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_82ee74a8-a82f-405b-9783-068ada0d47cf" xlink:href="arwr-20221231.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_82ee74a8-a82f-405b-9783-068ada0d47cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_6ab11d1a-5698-45fc-94e1-62256362c43e" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_6ab11d1a-5698-45fc-94e1-62256362c43e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_4b7af80d-dce6-428b-81cc-f7da7b37498f" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_InitialTransactionPrice_4b7af80d-dce6-428b-81cc-f7da7b37498f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f39d9943-a167-4392-b898-249c6b23afed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f39d9943-a167-4392-b898-249c6b23afed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_817b0bf9-0e43-4517-9a98-4f6eb600ce7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_817b0bf9-0e43-4517-9a98-4f6eb600ce7a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63627bfa-a3e0-4ec4-9c85-84c643f9f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63627bfa-a3e0-4ec4-9c85-84c643f9f6ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e3a4be97-3f80-4657-ae21-a0df2ee4fd05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:to="loc_dei_LegalEntityAxis_e3a4be97-3f80-4657-ae21-a0df2ee4fd05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e3a4be97-3f80-4657-ae21-a0df2ee4fd05_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e3a4be97-3f80-4657-ae21-a0df2ee4fd05" xlink:to="loc_dei_EntityDomain_e3a4be97-3f80-4657-ae21-a0df2ee4fd05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_008606d6-753c-4cea-b044-141932f6bda9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e3a4be97-3f80-4657-ae21-a0df2ee4fd05" xlink:to="loc_dei_EntityDomain_008606d6-753c-4cea-b044-141932f6bda9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_2a32b24f-502e-4a0f-8a03-454b7006df62" xlink:href="arwr-20221231.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_008606d6-753c-4cea-b044-141932f6bda9" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_2a32b24f-502e-4a0f-8a03-454b7006df62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_36184082-e4dd-4abc-95e5-02b32e64e7b1" xlink:href="arwr-20221231.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_008606d6-753c-4cea-b044-141932f6bda9" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_36184082-e4dd-4abc-95e5-02b32e64e7b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1062b803-f1c8-44e6-ab91-6db3b5c8868f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1062b803-f1c8-44e6-ab91-6db3b5c8868f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1062b803-f1c8-44e6-ab91-6db3b5c8868f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1062b803-f1c8-44e6-ab91-6db3b5c8868f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1062b803-f1c8-44e6-ab91-6db3b5c8868f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8b0691c-3433-49c8-89f2-48e634dad88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1062b803-f1c8-44e6-ab91-6db3b5c8868f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8b0691c-3433-49c8-89f2-48e634dad88e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_46a70e89-b599-4234-a837-92e866db0fbe" xlink:href="arwr-20221231.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8b0691c-3433-49c8-89f2-48e634dad88e" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_46a70e89-b599-4234-a837-92e866db0fbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_39433a62-2701-468d-b1c4-cf5a41228448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_39433a62-2701-468d-b1c4-cf5a41228448" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39433a62-2701-468d-b1c4-cf5a41228448_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_39433a62-2701-468d-b1c4-cf5a41228448" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_39433a62-2701-468d-b1c4-cf5a41228448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_39433a62-2701-468d-b1c4-cf5a41228448" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_460dd629-fab2-4723-bea8-7b54dc2f26f4" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_460dd629-fab2-4723-bea8-7b54dc2f26f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_7c655e8e-5de4-4201-bf33-cbfa5ae216ac" xlink:href="arwr-20221231.xsd#arwr_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_LicenseAgreementMember_7c655e8e-5de4-4201-bf33-cbfa5ae216ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAgreementMember_09088fcb-822f-402a-998a-b0f04fc315e2" xlink:href="arwr-20221231.xsd#arwr_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_CollaborationAgreementMember_09088fcb-822f-402a-998a-b0f04fc315e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_6db6dd6c-7aca-4fad-a18f-989bd71d9a30" xlink:href="arwr-20221231.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_6db6dd6c-7aca-4fad-a18f-989bd71d9a30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member_b7bbde18-d67e-4d9e-81dc-1798c809b9da" xlink:href="arwr-20221231.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_JNJ75220795AROJNJ1Member_b7bbde18-d67e-4d9e-81dc-1798c809b9da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_72974c70-77bc-4511-8005-db9b9741fb83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:to="loc_srt_RangeAxis_72974c70-77bc-4511-8005-db9b9741fb83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72974c70-77bc-4511-8005-db9b9741fb83_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_72974c70-77bc-4511-8005-db9b9741fb83" xlink:to="loc_srt_RangeMember_72974c70-77bc-4511-8005-db9b9741fb83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc9cc4f2-7bbd-47db-9587-c39905ded5b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_72974c70-77bc-4511-8005-db9b9741fb83" xlink:to="loc_srt_RangeMember_fc9cc4f2-7bbd-47db-9587-c39905ded5b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_01320536-515e-4991-b1ab-c94c33908afb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc9cc4f2-7bbd-47db-9587-c39905ded5b5" xlink:to="loc_srt_MaximumMember_01320536-515e-4991-b1ab-c94c33908afb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended" id="i3b91365618e0483dacb35243dbfdd1ff_CollaborationandLicenseAgreementsAmgenIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_a8f0c7fb-5148-4712-9094-0cf8382a3a90" xlink:href="arwr-20221231.xsd#arwr_NumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_NumberOfAgreements_a8f0c7fb-5148-4712-9094-0cf8382a3a90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_5ff36ec9-62e5-453c-9fe7-8ceef6845f92" xlink:href="arwr-20221231.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_5ff36ec9-62e5-453c-9fe7-8ceef6845f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_534a9ed7-1cf2-4d0d-a99a-1facfcdf7c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_534a9ed7-1cf2-4d0d-a99a-1facfcdf7c23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_d226d92f-a992-49b8-b108-d43e02a7e836" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_MilestonePaymentReceived_d226d92f-a992-49b8-b108-d43e02a7e836" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_f9c6de22-668d-4cb1-833d-20dcb85bf166" xlink:href="arwr-20221231.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_f9c6de22-668d-4cb1-833d-20dcb85bf166" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dd935d5-f14d-44df-8219-dd558f9df80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dd935d5-f14d-44df-8219-dd558f9df80a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_81d32683-ef9a-48e8-8726-6e2125d9c47d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_81d32683-ef9a-48e8-8726-6e2125d9c47d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_40b5bfbf-baf8-4adc-9345-bfd74adfab45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_40b5bfbf-baf8-4adc-9345-bfd74adfab45" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_90fc1ec4-e2bb-4c54-9db4-e5dbdf1a0041" xlink:href="arwr-20221231.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_90fc1ec4-e2bb-4c54-9db4-e5dbdf1a0041" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_392cbf0e-44b9-4eca-b8ec-d37dadd0191a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:to="loc_dei_LegalEntityAxis_392cbf0e-44b9-4eca-b8ec-d37dadd0191a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_392cbf0e-44b9-4eca-b8ec-d37dadd0191a_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_392cbf0e-44b9-4eca-b8ec-d37dadd0191a" xlink:to="loc_dei_EntityDomain_392cbf0e-44b9-4eca-b8ec-d37dadd0191a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bae49b5e-f9b6-4b46-b173-72959ca242d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_392cbf0e-44b9-4eca-b8ec-d37dadd0191a" xlink:to="loc_dei_EntityDomain_bae49b5e-f9b6-4b46-b173-72959ca242d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_f031ff77-90c5-4284-ae57-020e76a8b778" xlink:href="arwr-20221231.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bae49b5e-f9b6-4b46-b173-72959ca242d0" xlink:to="loc_arwr_AmgenIncorporatedMember_f031ff77-90c5-4284-ae57-020e76a8b778" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_02abdba5-a03a-4219-bc55-5f7a66ae627e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_02abdba5-a03a-4219-bc55-5f7a66ae627e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02abdba5-a03a-4219-bc55-5f7a66ae627e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_02abdba5-a03a-4219-bc55-5f7a66ae627e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02abdba5-a03a-4219-bc55-5f7a66ae627e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_02abdba5-a03a-4219-bc55-5f7a66ae627e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_d3d4d348-82f2-44bd-97f1-242a8497ffb0" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_d3d4d348-82f2-44bd-97f1-242a8497ffb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_0defde3c-30d1-45f3-8b1d-d4cba6fc65ff" xlink:href="arwr-20221231.xsd#arwr_OlpasiranAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:to="loc_arwr_OlpasiranAgreementMember_0defde3c-30d1-45f3-8b1d-d4cba6fc65ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember_09a47744-ef4c-4a57-9664-c533f157ced8" xlink:href="arwr-20221231.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:to="loc_arwr_OlpasiranAndAROAMG1AgreementMember_09a47744-ef4c-4a57-9664-c533f157ced8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_27e140ec-650f-4631-a0a8-4db95fa96b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_27e140ec-650f-4631-a0a8-4db95fa96b2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_27e140ec-650f-4631-a0a8-4db95fa96b2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27e140ec-650f-4631-a0a8-4db95fa96b2f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_27e140ec-650f-4631-a0a8-4db95fa96b2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d1a6bca3-6cc4-4c7d-abdd-5ae82d682d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27e140ec-650f-4631-a0a8-4db95fa96b2f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d1a6bca3-6cc4-4c7d-abdd-5ae82d682d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8fb27ced-c2d6-44a8-9fd3-cd934cc7da3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d1a6bca3-6cc4-4c7d-abdd-5ae82d682d8c" xlink:to="loc_us-gaap_SubsequentEventMember_8fb27ced-c2d6-44a8-9fd3-cd934cc7da3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18f523c4-82be-41c8-b3ec-a34cd83d3129" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:to="loc_srt_RangeAxis_18f523c4-82be-41c8-b3ec-a34cd83d3129" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18f523c4-82be-41c8-b3ec-a34cd83d3129_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_18f523c4-82be-41c8-b3ec-a34cd83d3129" xlink:to="loc_srt_RangeMember_18f523c4-82be-41c8-b3ec-a34cd83d3129_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45c1be0d-ff41-4485-b1b8-6eaf08b84a41" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_18f523c4-82be-41c8-b3ec-a34cd83d3129" xlink:to="loc_srt_RangeMember_45c1be0d-ff41-4485-b1b8-6eaf08b84a41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8c68e772-e42f-4b76-94e3-e8cd08c06bd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45c1be0d-ff41-4485-b1b8-6eaf08b84a41" xlink:to="loc_srt_MaximumMember_8c68e772-e42f-4b76-94e3-e8cd08c06bd7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="extended" id="ibd7aa4cd95144eaaadac07442c9719ce_CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_eee7af1f-bfbf-41f8-9a9d-9dbefb97f28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_eee7af1f-bfbf-41f8-9a9d-9dbefb97f28f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1bd75d24-fc76-4dbb-bd16-d77b04c27257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1bd75d24-fc76-4dbb-bd16-d77b04c27257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c238b50e-1613-499d-9156-56da4d4f9ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c238b50e-1613-499d-9156-56da4d4f9ddb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3d9ac619-1a87-4c30-b307-716cf2981ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3d9ac619-1a87-4c30-b307-716cf2981ab0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9baa6ce-508c-4d8c-86b1-5951e78394f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:to="loc_dei_LegalEntityAxis_d9baa6ce-508c-4d8c-86b1-5951e78394f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d9baa6ce-508c-4d8c-86b1-5951e78394f8_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d9baa6ce-508c-4d8c-86b1-5951e78394f8" xlink:to="loc_dei_EntityDomain_d9baa6ce-508c-4d8c-86b1-5951e78394f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_443a904f-72e0-438c-ab01-c939939af5cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d9baa6ce-508c-4d8c-86b1-5951e78394f8" xlink:to="loc_dei_EntityDomain_443a904f-72e0-438c-ab01-c939939af5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_f23cf6e6-03e6-4453-84bd-89abdd01a7c5" xlink:href="arwr-20221231.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_443a904f-72e0-438c-ab01-c939939af5cf" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_f23cf6e6-03e6-4453-84bd-89abdd01a7c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c2eb2f88-31bd-4e4b-aed1-23d3be448999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c2eb2f88-31bd-4e4b-aed1-23d3be448999" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2eb2f88-31bd-4e4b-aed1-23d3be448999_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c2eb2f88-31bd-4e4b-aed1-23d3be448999" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2eb2f88-31bd-4e4b-aed1-23d3be448999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a913edb-3fae-42f4-b809-4a721e27e229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c2eb2f88-31bd-4e4b-aed1-23d3be448999" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a913edb-3fae-42f4-b809-4a721e27e229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaLicenseAgreementMember_0c3e46eb-0125-4259-a90e-08ff18234012" xlink:href="arwr-20221231.xsd#arwr_VisirnaLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a913edb-3fae-42f4-b809-4a721e27e229" xlink:to="loc_arwr_VisirnaLicenseAgreementMember_0c3e46eb-0125-4259-a90e-08ff18234012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_48c0ce91-79ed-4954-a1c3-79d687955f1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_48c0ce91-79ed-4954-a1c3-79d687955f1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_48c0ce91-79ed-4954-a1c3-79d687955f1f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_48c0ce91-79ed-4954-a1c3-79d687955f1f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_48c0ce91-79ed-4954-a1c3-79d687955f1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_978caea4-63fa-4106-ad18-333a6c74e4e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_48c0ce91-79ed-4954-a1c3-79d687955f1f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_978caea4-63fa-4106-ad18-333a6c74e4e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_a19200d1-ee24-44d7-814a-ea32b27de6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_978caea4-63fa-4106-ad18-333a6c74e4e2" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_a19200d1-ee24-44d7-814a-ea32b27de6c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended" id="i4155fbed2fe34264a707d7b86e727c46_InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:href="arwr-20221231.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9560933b-94d6-4ed2-878c-20b88522ce81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9560933b-94d6-4ed2-878c-20b88522ce81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_7f1fc414-59ec-4fd2-8d82-fe28efae3ced" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_7f1fc414-59ec-4fd2-8d82-fe28efae3ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_ce0bddfe-22ba-4833-8349-c7e4ce2083e0" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_ce0bddfe-22ba-4833-8349-c7e4ce2083e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_ce383285-5dd5-4c55-9702-0180c6e33163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_ce383285-5dd5-4c55-9702-0180c6e33163" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e51fb3c2-f9a4-449e-9ac2-f0946ef0f206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e51fb3c2-f9a4-449e-9ac2-f0946ef0f206" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_c9cbabd2-2ae0-452c-aff1-471ad36648db" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_c9cbabd2-2ae0-452c-aff1-471ad36648db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_e659fd13-bc93-4993-a91d-373cfcebf3a2" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_e659fd13-bc93-4993-a91d-373cfcebf3a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_68803959-56b7-47c1-b6ad-754931aaa460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_68803959-56b7-47c1-b6ad-754931aaa460" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_773b9b51-0acb-44b4-a893-5b6650066f6c" xlink:href="arwr-20221231.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_773b9b51-0acb-44b4-a893-5b6650066f6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1830c72f-7201-491d-9509-f227082d327f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_773b9b51-0acb-44b4-a893-5b6650066f6c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1830c72f-7201-491d-9509-f227082d327f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1830c72f-7201-491d-9509-f227082d327f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1830c72f-7201-491d-9509-f227082d327f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1830c72f-7201-491d-9509-f227082d327f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4304499d-3f77-4025-86bc-1226259fc2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1830c72f-7201-491d-9509-f227082d327f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4304499d-3f77-4025-86bc-1226259fc2fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_1a21f6f1-573c-4b57-bab3-20dbdf5a4b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4304499d-3f77-4025-86bc-1226259fc2fd" xlink:to="loc_us-gaap_DebtSecuritiesMember_1a21f6f1-573c-4b57-bab3-20dbdf5a4b5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_96d7f510-4de1-4835-9b10-5adf6b23e4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4304499d-3f77-4025-86bc-1226259fc2fd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_96d7f510-4de1-4835-9b10-5adf6b23e4be" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i78339524bd5a432e90b7ad43568c3646_IntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ff9f5d77-e6b4-49d9-83ab-eef36297c437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ff9f5d77-e6b4-49d9-83ab-eef36297c437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bd5315ed-348f-473a-b3d9-7e73827a989a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bd5315ed-348f-473a-b3d9-7e73827a989a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_9c688fb4-3317-45ef-b26c-a0f4ba998686" xlink:href="arwr-20221231.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_9c688fb4-3317-45ef-b26c-a0f4ba998686" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d989e9d8-244a-453d-ba1c-7147b4b8988c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d989e9d8-244a-453d-ba1c-7147b4b8988c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_705f06ab-d135-49a4-98e0-68c18fd91c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_705f06ab-d135-49a4-98e0-68c18fd91c58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51391f0d-ba99-4d2b-9faf-5ffc2bcc38b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51391f0d-ba99-4d2b-9faf-5ffc2bcc38b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1dec924e-92a4-42dc-965a-a5e186fdcc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51391f0d-ba99-4d2b-9faf-5ffc2bcc38b7" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1dec924e-92a4-42dc-965a-a5e186fdcc70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1dec924e-92a4-42dc-965a-a5e186fdcc70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1dec924e-92a4-42dc-965a-a5e186fdcc70" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1dec924e-92a4-42dc-965a-a5e186fdcc70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b9e026ec-e950-49e6-a99f-853fd13d92af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1dec924e-92a4-42dc-965a-a5e186fdcc70" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b9e026ec-e950-49e6-a99f-853fd13d92af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_3cee8ee6-d203-40bf-9f2e-3e3a981adfe9" xlink:href="arwr-20221231.xsd#arwr_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b9e026ec-e950-49e6-a99f-853fd13d92af" xlink:to="loc_arwr_NovartisMember_3cee8ee6-d203-40bf-9f2e-3e3a981adfe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0ae3ed2a-39d3-41ea-93ba-58380e126271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51391f0d-ba99-4d2b-9faf-5ffc2bcc38b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0ae3ed2a-39d3-41ea-93ba-58380e126271" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ae3ed2a-39d3-41ea-93ba-58380e126271_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0ae3ed2a-39d3-41ea-93ba-58380e126271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ae3ed2a-39d3-41ea-93ba-58380e126271_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb5e3f7-e3a2-441d-bc3b-173c3a1d9118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0ae3ed2a-39d3-41ea-93ba-58380e126271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb5e3f7-e3a2-441d-bc3b-173c3a1d9118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_d5e154d9-a33a-475f-a70f-571137c926fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb5e3f7-e3a2-441d-bc3b-173c3a1d9118" xlink:to="loc_us-gaap_PatentsMember_d5e154d9-a33a-475f-a70f-571137c926fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_2e85c980-7b5a-4b4a-ba86-e8c98ef0f0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb5e3f7-e3a2-441d-bc3b-173c3a1d9118" xlink:to="loc_us-gaap_LicensingAgreementsMember_2e85c980-7b5a-4b4a-ba86-e8c98ef0f0f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended" id="i4da0db4eb2234892853aa9d1c6f1fad6_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c185a10-d3be-401c-9272-be2955a4c32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c185a10-d3be-401c-9272-be2955a4c32e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8ac85bee-1a08-4303-8436-484a209e70a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8ac85bee-1a08-4303-8436-484a209e70a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4c8908ed-015d-46e6-8f91-60a2acff9fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_CommonStockSharesIssued_4c8908ed-015d-46e6-8f91-60a2acff9fba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_29ebd519-0a97-443b-9623-e749fbdd3fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_29ebd519-0a97-443b-9623-e749fbdd3fad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e5ef2ec-43dc-4b6e-9274-0aa914e734d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e5ef2ec-43dc-4b6e-9274-0aa914e734d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3ec3ffc1-e4f0-46df-8de1-362867c0f74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3ec3ffc1-e4f0-46df-8de1-362867c0f74a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1fc47c4b-24db-44b3-9e8b-00374ff6f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1fc47c4b-24db-44b3-9e8b-00374ff6f25a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8c75ced0-41e8-45f4-a0da-64cb111c03ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8c75ced0-41e8-45f4-a0da-64cb111c03ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a0214e9f-4efc-4b72-8f0a-353e14d74f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a0214e9f-4efc-4b72-8f0a-353e14d74f0c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_d2b63280-850d-42fc-8481-af3fc878f048" xlink:href="arwr-20221231.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_d2b63280-850d-42fc-8481-af3fc878f048" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_4f882865-100c-4152-9eed-901d4fccf3ce" xlink:href="arwr-20221231.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_4f882865-100c-4152-9eed-901d4fccf3ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8735540b-d67e-42b4-87ac-41b7a7826e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_SharesIssued_8735540b-d67e-42b4-87ac-41b7a7826e26" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_da1ec343-e4fe-4db5-9451-f38e7208d393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:to="loc_us-gaap_PlanNameAxis_da1ec343-e4fe-4db5-9451-f38e7208d393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_da1ec343-e4fe-4db5-9451-f38e7208d393_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_da1ec343-e4fe-4db5-9451-f38e7208d393" xlink:to="loc_us-gaap_PlanNameDomain_da1ec343-e4fe-4db5-9451-f38e7208d393_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_010f7cb8-c88e-4b6b-a8ee-abebe8315b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_da1ec343-e4fe-4db5-9451-f38e7208d393" xlink:to="loc_us-gaap_PlanNameDomain_010f7cb8-c88e-4b6b-a8ee-abebe8315b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_df6cbf1b-533d-41ed-93ac-812db8af050c" xlink:href="arwr-20221231.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_010f7cb8-c88e-4b6b-a8ee-abebe8315b90" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_df6cbf1b-533d-41ed-93ac-812db8af050c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5d92b3d6-0da3-4f82-9e47-cd8c2a39cfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5d92b3d6-0da3-4f82-9e47-cd8c2a39cfcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d92b3d6-0da3-4f82-9e47-cd8c2a39cfcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5d92b3d6-0da3-4f82-9e47-cd8c2a39cfcc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d92b3d6-0da3-4f82-9e47-cd8c2a39cfcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2ce9097-9412-4a55-aa7a-5a34e176ef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5d92b3d6-0da3-4f82-9e47-cd8c2a39cfcc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2ce9097-9412-4a55-aa7a-5a34e176ef4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_1a15f1f5-bd62-4a72-809d-bb518ca7bca7" xlink:href="arwr-20221231.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2ce9097-9412-4a55-aa7a-5a34e176ef4a" xlink:to="loc_arwr_AtTheMarketAgreementMember_1a15f1f5-bd62-4a72-809d-bb518ca7bca7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_005919f1-4205-444b-bd19-c8fbeee990ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:to="loc_srt_RangeAxis_005919f1-4205-444b-bd19-c8fbeee990ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_005919f1-4205-444b-bd19-c8fbeee990ee_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_005919f1-4205-444b-bd19-c8fbeee990ee" xlink:to="loc_srt_RangeMember_005919f1-4205-444b-bd19-c8fbeee990ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0019acaf-ed90-4612-80f9-a47ccdf5af21" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_005919f1-4205-444b-bd19-c8fbeee990ee" xlink:to="loc_srt_RangeMember_0019acaf-ed90-4612-80f9-a47ccdf5af21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_630d6e83-580b-405b-9591-dd89cf8b47e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0019acaf-ed90-4612-80f9-a47ccdf5af21" xlink:to="loc_srt_MaximumMember_630d6e83-580b-405b-9591-dd89cf8b47e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i78bab32838d84366b9261323a250da61_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f531321d-0ddc-45ea-9bad-79672f0025a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f531321d-0ddc-45ea-9bad-79672f0025a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_ad55ac01-d362-4b21-a41c-875491a31400" xlink:href="arwr-20221231.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_ad55ac01-d362-4b21-a41c-875491a31400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_67baf91d-154c-4093-9b29-ab2f9c379ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_us-gaap_AreaOfLand_67baf91d-154c-4093-9b29-ab2f9c379ed6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_e6b41d42-22ca-4691-888c-ddf96a1fd918" xlink:href="arwr-20221231.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_e6b41d42-22ca-4691-888c-ddf96a1fd918" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_9dfedf3a-54e0-4836-bc37-7009c51f5f07" xlink:href="arwr-20221231.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_arwr_TaxIncrementFinancingAward_9dfedf3a-54e0-4836-bc37-7009c51f5f07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_4635e053-b52b-4f65-9fd3-299dbecf4a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_4635e053-b52b-4f65-9fd3-299dbecf4a3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_aea0bd8c-8ee8-46dd-8c2d-fb56da4899d3" xlink:href="arwr-20221231.xsd#arwr_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_arwr_MilestonePayments_aea0bd8c-8ee8-46dd-8c2d-fb56da4899d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17293c10-215d-4358-bdf5-c9b2916a85d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17293c10-215d-4358-bdf5-c9b2916a85d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17293c10-215d-4358-bdf5-c9b2916a85d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17293c10-215d-4358-bdf5-c9b2916a85d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17293c10-215d-4358-bdf5-c9b2916a85d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17293c10-215d-4358-bdf5-c9b2916a85d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_c21432c8-c2e6-4af7-8754-c26c8cc1ace5" xlink:href="arwr-20221231.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:to="loc_arwr_VeronaTechnologyParkMember_c21432c8-c2e6-4af7-8754-c26c8cc1ace5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_b4acb15f-8125-43d4-a837-50300ffb2fd6" xlink:href="arwr-20221231.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:to="loc_arwr_DrugManufacturingFacilityMember_b4acb15f-8125-43d4-a837-50300ffb2fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_cb2e917a-6b85-447b-9b57-fcfe14f982b8" xlink:href="arwr-20221231.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_cb2e917a-6b85-447b-9b57-fcfe14f982b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_b7d13f35-82c2-451d-859b-c4737b6b66d5" xlink:href="arwr-20221231.xsd#arwr_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:to="loc_arwr_FacilitiesMember_b7d13f35-82c2-451d-859b-c4737b6b66d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_777b57b8-952c-40d4-9308-2d5b1cc5932b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:to="loc_srt_StatementGeographicalAxis_777b57b8-952c-40d4-9308-2d5b1cc5932b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_777b57b8-952c-40d4-9308-2d5b1cc5932b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_777b57b8-952c-40d4-9308-2d5b1cc5932b" xlink:to="loc_srt_SegmentGeographicalDomain_777b57b8-952c-40d4-9308-2d5b1cc5932b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_09a3203d-824f-4804-9770-337ceedd06fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_777b57b8-952c-40d4-9308-2d5b1cc5932b" xlink:to="loc_srt_SegmentGeographicalDomain_09a3203d-824f-4804-9770-337ceedd06fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_4615a21d-d3ff-4629-a85c-0a5b4bb1853c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_09a3203d-824f-4804-9770-337ceedd06fb" xlink:to="loc_stpr_WI_4615a21d-d3ff-4629-a85c-0a5b4bb1853c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1667830c-89b7-41e1-b67a-9d4bafe8b833" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:to="loc_srt_RangeAxis_1667830c-89b7-41e1-b67a-9d4bafe8b833" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1667830c-89b7-41e1-b67a-9d4bafe8b833_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1667830c-89b7-41e1-b67a-9d4bafe8b833" xlink:to="loc_srt_RangeMember_1667830c-89b7-41e1-b67a-9d4bafe8b833_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39b6401a-b3f8-42e7-b02e-c1565f229669" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1667830c-89b7-41e1-b67a-9d4bafe8b833" xlink:to="loc_srt_RangeMember_39b6401a-b3f8-42e7-b02e-c1565f229669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3e91061-0538-4af8-9be4-997e06e243d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39b6401a-b3f8-42e7-b02e-c1565f229669" xlink:to="loc_srt_MinimumMember_b3e91061-0538-4af8-9be4-997e06e243d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd31ca81-af54-415e-a49a-33c17cab2065" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39b6401a-b3f8-42e7-b02e-c1565f229669" xlink:to="loc_srt_MaximumMember_cd31ca81-af54-415e-a49a-33c17cab2065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_a4ba7d5a-b163-4801-9f04-545737e17b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:to="loc_us-gaap_OtherCommitmentsAxis_a4ba7d5a-b163-4801-9f04-545737e17b35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_a4ba7d5a-b163-4801-9f04-545737e17b35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_a4ba7d5a-b163-4801-9f04-545737e17b35" xlink:to="loc_us-gaap_OtherCommitmentsDomain_a4ba7d5a-b163-4801-9f04-545737e17b35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_cd23b400-a451-49f0-bc36-36187f457eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_a4ba7d5a-b163-4801-9f04-545737e17b35" xlink:to="loc_us-gaap_OtherCommitmentsDomain_cd23b400-a451-49f0-bc36-36187f457eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_f1ff59a9-745e-45cc-b5cc-b390f2e6fb16" xlink:href="arwr-20221231.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_cd23b400-a451-49f0-bc36-36187f457eef" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_f1ff59a9-745e-45cc-b5cc-b390f2e6fb16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i94ba6bc6193d405c81f915ee7a3993c5_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d7c9b255-4008-45c4-9ac1-bb31fe907185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d7c9b255-4008-45c4-9ac1-bb31fe907185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_57821ad7-7690-4539-b677-0d4c02756246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_57821ad7-7690-4539-b677-0d4c02756246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_761c9278-4b9f-4bb7-a43b-53e076ad636d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_761c9278-4b9f-4bb7-a43b-53e076ad636d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_8209a422-e9f3-4f48-9260-abc5d18d3bf6" xlink:href="arwr-20221231.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_8209a422-e9f3-4f48-9260-abc5d18d3bf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_0191fdc9-ab23-42b8-990f-2545819dc452" xlink:href="arwr-20221231.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_0191fdc9-ab23-42b8-990f-2545819dc452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_2f08c103-b423-43fd-9351-a666b92c5870" xlink:href="arwr-20221231.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_arwr_NumberOfOptionsToRenew_2f08c103-b423-43fd-9351-a666b92c5870" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e7403dda-bb08-4380-91db-c6f221f2490d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e7403dda-bb08-4380-91db-c6f221f2490d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_4c0be09b-9a33-426a-932f-74f4b7ddc5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_ShortTermLeaseCost_4c0be09b-9a33-426a-932f-74f4b7ddc5e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_701bf35d-24f0-4059-8118-093adb09a6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_701bf35d-24f0-4059-8118-093adb09a6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_701bf35d-24f0-4059-8118-093adb09a6a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_701bf35d-24f0-4059-8118-093adb09a6a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_701bf35d-24f0-4059-8118-093adb09a6a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_701bf35d-24f0-4059-8118-093adb09a6a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_874d9e66-9795-4c6f-86b2-b809395054aa" xlink:href="arwr-20221231.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_874d9e66-9795-4c6f-86b2-b809395054aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_e04b5258-b6c2-4e6a-aa30-a0083836f9e4" xlink:href="arwr-20221231.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_e04b5258-b6c2-4e6a-aa30-a0083836f9e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_38b05c97-9bd3-43be-bfd8-1c2dd69421c3" xlink:href="arwr-20221231.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_38b05c97-9bd3-43be-bfd8-1c2dd69421c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_710fd3fe-b6de-4d3a-9cbe-616a0aff0b05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:to="loc_srt_StatementGeographicalAxis_710fd3fe-b6de-4d3a-9cbe-616a0aff0b05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_710fd3fe-b6de-4d3a-9cbe-616a0aff0b05_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_710fd3fe-b6de-4d3a-9cbe-616a0aff0b05" xlink:to="loc_srt_SegmentGeographicalDomain_710fd3fe-b6de-4d3a-9cbe-616a0aff0b05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_566eeb0d-6a9d-4d8c-a014-3fbc218b3bf7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_710fd3fe-b6de-4d3a-9cbe-616a0aff0b05" xlink:to="loc_srt_SegmentGeographicalDomain_566eeb0d-6a9d-4d8c-a014-3fbc218b3bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_bda69dbd-8650-4b54-a669-4fb8062743c5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_566eeb0d-6a9d-4d8c-a014-3fbc218b3bf7" xlink:to="loc_stpr_CA_bda69dbd-8650-4b54-a669-4fb8062743c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_b4138f90-db4c-42a3-8332-69105aed508c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_566eeb0d-6a9d-4d8c-a014-3fbc218b3bf7" xlink:to="loc_stpr_WI_b4138f90-db4c-42a3-8332-69105aed508c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3bf3ec0c-ba0c-48fe-b467-5c35415b76a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:to="loc_srt_RangeAxis_3bf3ec0c-ba0c-48fe-b467-5c35415b76a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bf3ec0c-ba0c-48fe-b467-5c35415b76a5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3bf3ec0c-ba0c-48fe-b467-5c35415b76a5" xlink:to="loc_srt_RangeMember_3bf3ec0c-ba0c-48fe-b467-5c35415b76a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57bb6eff-6e1e-4152-a5b5-dd8a73d68ed1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3bf3ec0c-ba0c-48fe-b467-5c35415b76a5" xlink:to="loc_srt_RangeMember_57bb6eff-6e1e-4152-a5b5-dd8a73d68ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa81379c-fb9e-4459-8ff9-f9523babee87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57bb6eff-6e1e-4152-a5b5-dd8a73d68ed1" xlink:to="loc_srt_MaximumMember_fa81379c-fb9e-4459-8ff9-f9523babee87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_420d908f-0fcf-4415-9d24-88f83e0ee569" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:to="loc_srt_CounterpartyNameAxis_420d908f-0fcf-4415-9d24-88f83e0ee569" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_420d908f-0fcf-4415-9d24-88f83e0ee569_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_420d908f-0fcf-4415-9d24-88f83e0ee569" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_420d908f-0fcf-4415-9d24-88f83e0ee569_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bfbc53ed-0efb-4547-b818-b7af29f6db97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_420d908f-0fcf-4415-9d24-88f83e0ee569" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bfbc53ed-0efb-4547-b818-b7af29f6db97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_db6369aa-2893-41b2-9ae0-82ebb8d8351a" xlink:href="arwr-20221231.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bfbc53ed-0efb-4547-b818-b7af29f6db97" xlink:to="loc_arwr_ColoradoOwnerLLCMember_db6369aa-2893-41b2-9ae0-82ebb8d8351a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SorrentoValleyOwnerDELLCMember_fead2f44-22e7-4398-97e5-979b7d604cc6" xlink:href="arwr-20221231.xsd#arwr_SorrentoValleyOwnerDELLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bfbc53ed-0efb-4547-b818-b7af29f6db97" xlink:to="loc_arwr_SorrentoValleyOwnerDELLCMember_fead2f44-22e7-4398-97e5-979b7d604cc6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended" id="i6f2a69ddbc8141e9af7bab44e5588655_LeasesComponentsofLeaseAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_028d2636-7ca1-43ec-b03b-d21352cbf11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_028d2636-7ca1-43ec-b03b-d21352cbf11c" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c78bff5f-cd1c-4057-a187-9a89b24d0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c78bff5f-cd1c-4057-a187-9a89b24d0ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_270e7845-649f-44ff-b6db-90c6eab386b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_270e7845-649f-44ff-b6db-90c6eab386b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f308d256-19e0-4abd-a34a-b138e0839f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f308d256-19e0-4abd-a34a-b138e0839f91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_028d2636-7ca1-43ec-b03b-d21352cbf11c" xlink:to="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_944d790d-4cc0-4f9d-80c9-78a5a2462337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:to="loc_us-gaap_OperatingLeaseCost_944d790d-4cc0-4f9d-80c9-78a5a2462337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_079ead99-66ba-4834-afac-c9af36ec49ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:to="loc_us-gaap_VariableLeaseCost_079ead99-66ba-4834-afac-c9af36ec49ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_2b24eb26-0d1f-41ef-b60d-929ee529321e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:to="loc_us-gaap_LeaseCost_2b24eb26-0d1f-41ef-b60d-929ee529321e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cd5a4f78-3016-450a-8a47-c165f8fceec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_028d2636-7ca1-43ec-b03b-d21352cbf11c" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cd5a4f78-3016-450a-8a47-c165f8fceec5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_661350b8-320e-4098-a85b-2619eae9feb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cd5a4f78-3016-450a-8a47-c165f8fceec5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_661350b8-320e-4098-a85b-2619eae9feb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_661350b8-320e-4098-a85b-2619eae9feb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_661350b8-320e-4098-a85b-2619eae9feb4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_661350b8-320e-4098-a85b-2619eae9feb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2e26c998-a6dd-49a7-934c-0079082de7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_661350b8-320e-4098-a85b-2619eae9feb4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2e26c998-a6dd-49a7-934c-0079082de7f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c718b8d1-8737-4d2a-867e-11621ec5d515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2e26c998-a6dd-49a7-934c-0079082de7f7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c718b8d1-8737-4d2a-867e-11621ec5d515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d2555366-33f8-47ad-ad37-be7765ef9058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2e26c998-a6dd-49a7-934c-0079082de7f7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d2555366-33f8-47ad-ad37-be7765ef9058" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i61f7e09ec45c4ec0b3a0c6335ee4442d_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a1f9d496-813e-4310-bc48-9abac09dae1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a1f9d496-813e-4310-bc48-9abac09dae1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4be322b8-bd5a-48a7-968a-6fde2e862ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4be322b8-bd5a-48a7-968a-6fde2e862ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_32a04abc-e57a-43cc-918d-7f1287d908dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_32a04abc-e57a-43cc-918d-7f1287d908dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c769784b-f117-4961-bb86-5d9c421ea4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c769784b-f117-4961-bb86-5d9c421ea4bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_39bdd114-ebf4-468f-a5f5-d97648b9d59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_39bdd114-ebf4-468f-a5f5-d97648b9d59a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1c2e828e-653d-49fd-9165-7052298b9164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1c2e828e-653d-49fd-9165-7052298b9164" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f54af613-9019-4cb1-a422-f11133577840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f54af613-9019-4cb1-a422-f11133577840" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5863d584-33ba-4015-ab75-443671d1c74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5863d584-33ba-4015-ab75-443671d1c74a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5644ebde-7999-414f-b4ed-8b22fea11f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5644ebde-7999-414f-b4ed-8b22fea11f7f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7037b87-7557-44fb-8b34-ef3ca2abf3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7037b87-7557-44fb-8b34-ef3ca2abf3e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e83d0372-bda7-45e3-8524-97fcf23c0b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7037b87-7557-44fb-8b34-ef3ca2abf3e8" xlink:to="loc_us-gaap_PlanNameAxis_e83d0372-bda7-45e3-8524-97fcf23c0b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e83d0372-bda7-45e3-8524-97fcf23c0b96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e83d0372-bda7-45e3-8524-97fcf23c0b96" xlink:to="loc_us-gaap_PlanNameDomain_e83d0372-bda7-45e3-8524-97fcf23c0b96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e83d0372-bda7-45e3-8524-97fcf23c0b96" xlink:to="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_ef076717-ccd9-46f3-bdf3-b1bc23b97a67" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_ef076717-ccd9-46f3-bdf3-b1bc23b97a67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_27741930-d8b0-4485-a6f5-45bb84f63a23" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_27741930-d8b0-4485-a6f5-45bb84f63a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_ec076df2-15e6-4202-b738-c7e53b311c89" xlink:href="arwr-20221231.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_ec076df2-15e6-4202-b738-c7e53b311c89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_517a5ce1-1843-4dd1-a98f-e83b6d04486b" xlink:href="arwr-20221231.xsd#arwr_InducementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:to="loc_arwr_InducementAwardsMember_517a5ce1-1843-4dd1-a98f-e83b6d04486b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_de9d60af-a310-4537-9d0a-a98cb1dfd7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7037b87-7557-44fb-8b34-ef3ca2abf3e8" xlink:to="loc_us-gaap_AwardTypeAxis_de9d60af-a310-4537-9d0a-a98cb1dfd7d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_de9d60af-a310-4537-9d0a-a98cb1dfd7d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_de9d60af-a310-4537-9d0a-a98cb1dfd7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_de9d60af-a310-4537-9d0a-a98cb1dfd7d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a0787b3-18f3-46ae-b7e5-74b16cd85979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_de9d60af-a310-4537-9d0a-a98cb1dfd7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a0787b3-18f3-46ae-b7e5-74b16cd85979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_23da6c10-99cb-4fc6-bf32-417a8011def3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a0787b3-18f3-46ae-b7e5-74b16cd85979" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_23da6c10-99cb-4fc6-bf32-417a8011def3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_befad587-ce9f-4b8b-bafe-8acbfe3647d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a0787b3-18f3-46ae-b7e5-74b16cd85979" xlink:to="loc_us-gaap_EmployeeStockOptionMember_befad587-ce9f-4b8b-bafe-8acbfe3647d0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended" id="if8a9b95d3d754388a5aa0f3a01d35fd6_StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5491e490-f798-44ae-b800-4eecbae2a6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5491e490-f798-44ae-b800-4eecbae2a6fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_159c442a-febe-4f5e-be70-499f76a7e1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_159c442a-febe-4f5e-be70-499f76a7e1b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_badc54ce-54e6-4036-aa77-2b4b7f99eeb5" xlink:href="arwr-20221231.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_badc54ce-54e6-4036-aa77-2b4b7f99eeb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6daee082-304b-408b-86b2-3b0778ebfbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6daee082-304b-408b-86b2-3b0778ebfbc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8c710ba-9536-4032-aa90-9b4120752bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6daee082-304b-408b-86b2-3b0778ebfbc2" xlink:to="loc_us-gaap_AwardTypeAxis_b8c710ba-9536-4032-aa90-9b4120752bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8c710ba-9536-4032-aa90-9b4120752bd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b8c710ba-9536-4032-aa90-9b4120752bd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8c710ba-9536-4032-aa90-9b4120752bd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6393d984-0703-4c70-b6f8-158983aceeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b8c710ba-9536-4032-aa90-9b4120752bd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6393d984-0703-4c70-b6f8-158983aceeaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_191ab5d0-b492-49b8-bc27-d65610605c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6393d984-0703-4c70-b6f8-158983aceeaf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_191ab5d0-b492-49b8-bc27-d65610605c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6c4e818f-5a16-4b00-beb2-c0af708a53b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6daee082-304b-408b-86b2-3b0778ebfbc2" xlink:to="loc_us-gaap_PlanNameAxis_6c4e818f-5a16-4b00-beb2-c0af708a53b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6c4e818f-5a16-4b00-beb2-c0af708a53b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6c4e818f-5a16-4b00-beb2-c0af708a53b7" xlink:to="loc_us-gaap_PlanNameDomain_6c4e818f-5a16-4b00-beb2-c0af708a53b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6c4e818f-5a16-4b00-beb2-c0af708a53b7" xlink:to="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_3a3a86bc-d6ac-4e9f-b850-5ecfc06ec40e" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_3a3a86bc-d6ac-4e9f-b850-5ecfc06ec40e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_8d8fd1cd-7dd5-4929-9337-4c07d5b25d55" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_8d8fd1cd-7dd5-4929-9337-4c07d5b25d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_bbc3e2f3-35ae-4df7-880c-35e8aedea958" xlink:href="arwr-20221231.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_bbc3e2f3-35ae-4df7-880c-35e8aedea958" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_08188417-073e-4469-8d91-eaed3b4d5535" xlink:href="arwr-20221231.xsd#arwr_InducementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:to="loc_arwr_InducementAwardsMember_08188417-073e-4469-8d91-eaed3b4d5535" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended" id="idde8b1cf90fe4e32b5f77f0c8d539133_StockBasedCompensationSummaryofRSUsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abdfe87b-241f-4b93-ae22-e4de60838f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abdfe87b-241f-4b93-ae22-e4de60838f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_01486936-0349-480e-a864-9723aea7e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_01486936-0349-480e-a864-9723aea7e4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6c6ac121-1eea-40d2-a2d4-406a5892d5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6c6ac121-1eea-40d2-a2d4-406a5892d5b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_66a7a362-e5e1-4f9a-9c9d-6b7992e6903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_66a7a362-e5e1-4f9a-9c9d-6b7992e6903e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b803a10f-8623-4608-9375-43e18a328b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b803a10f-8623-4608-9375-43e18a328b4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0ea0af85-bb4e-448d-b42f-907f83240136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abdfe87b-241f-4b93-ae22-e4de60838f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad681786-f722-4428-a68e-fbffc9449d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad681786-f722-4428-a68e-fbffc9449d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ec29b20-9b70-41ed-8ba5-79ebf3faa7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ec29b20-9b70-41ed-8ba5-79ebf3faa7c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_384b64a3-1f0a-430b-b0bd-8e8bf9a40103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_384b64a3-1f0a-430b-b0bd-8e8bf9a40103" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_092d4e6d-ea23-4577-a7ff-6bfec79dbe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_092d4e6d-ea23-4577-a7ff-6bfec79dbe7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e1c1c4ab-23c3-449b-a5a7-3c3d93ad442f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b447795f-7479-4ee3-b323-5f7afc402a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abdfe87b-241f-4b93-ae22-e4de60838f3b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b447795f-7479-4ee3-b323-5f7afc402a07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_306db0fb-8465-4f9a-8103-5205e9facfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b447795f-7479-4ee3-b323-5f7afc402a07" xlink:to="loc_us-gaap_AwardTypeAxis_306db0fb-8465-4f9a-8103-5205e9facfc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_306db0fb-8465-4f9a-8103-5205e9facfc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_306db0fb-8465-4f9a-8103-5205e9facfc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_306db0fb-8465-4f9a-8103-5205e9facfc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd20b6f-2ec4-4bf7-a043-d2041efc44c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_306db0fb-8465-4f9a-8103-5205e9facfc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd20b6f-2ec4-4bf7-a043-d2041efc44c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_873baf07-2ffe-47a6-bd81-2cce56e0ab55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd20b6f-2ec4-4bf7-a043-d2041efc44c1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_873baf07-2ffe-47a6-bd81-2cce56e0ab55" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i9c097ac094fb4ffc8c8de791762b57a7_FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_80a8edbc-e146-4a10-b215-44f6141a76a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_80a8edbc-e146-4a10-b215-44f6141a76a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b78f3e4-e06c-4dd5-883d-e44d4d65c251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b78f3e4-e06c-4dd5-883d-e44d4d65c251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d7b229c-9b41-4981-ac93-ca3221cecd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d7b229c-9b41-4981-ac93-ca3221cecd8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66213113-aced-4ab9-8938-2bcc51d191b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66213113-aced-4ab9-8938-2bcc51d191b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66213113-aced-4ab9-8938-2bcc51d191b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66213113-aced-4ab9-8938-2bcc51d191b9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_66213113-aced-4ab9-8938-2bcc51d191b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c221634-b1d9-4753-9830-9b2e9000e302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66213113-aced-4ab9-8938-2bcc51d191b9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c221634-b1d9-4753-9830-9b2e9000e302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3f70ab68-156a-4256-a93f-a0191410b549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c221634-b1d9-4753-9830-9b2e9000e302" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3f70ab68-156a-4256-a93f-a0191410b549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6167625-63f0-46cd-bf2f-77227a7e5b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6167625-63f0-46cd-bf2f-77227a7e5b66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6167625-63f0-46cd-bf2f-77227a7e5b66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6167625-63f0-46cd-bf2f-77227a7e5b66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6167625-63f0-46cd-bf2f-77227a7e5b66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6167625-63f0-46cd-bf2f-77227a7e5b66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_94cb24a7-85d8-4551-946a-cba58bb1795e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_94cb24a7-85d8-4551-946a-cba58bb1795e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_82bf9f50-6747-486d-a128-153d591f065d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_82bf9f50-6747-486d-a128-153d591f065d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d8bb5ff5-01db-4de4-a3c5-b78914165bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d8bb5ff5-01db-4de4-a3c5-b78914165bac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3faab942-2283-4ded-9ca7-92016f61ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3faab942-2283-4ded-9ca7-92016f61ab59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3faab942-2283-4ded-9ca7-92016f61ab59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3faab942-2283-4ded-9ca7-92016f61ab59" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3faab942-2283-4ded-9ca7-92016f61ab59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3faab942-2283-4ded-9ca7-92016f61ab59" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_06c0e7d0-4467-465b-961b-8da45c95f161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_06c0e7d0-4467-465b-961b-8da45c95f161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_4a821ba1-e07c-4d79-b7c4-ece7de4fb304" xlink:href="arwr-20221231.xsd#arwr_CommercialNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:to="loc_arwr_CommercialNotesMember_4a821ba1-e07c-4d79-b7c4-ece7de4fb304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0a925492-fe3c-401a-8b3b-396f8ff89649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0a925492-fe3c-401a-8b3b-396f8ff89649" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_906b062d-eb7a-46fe-a699-f2d31bfef29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:to="loc_us-gaap_CertificatesOfDepositMember_906b062d-eb7a-46fe-a699-f2d31bfef29a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_d103d6b9-480c-4964-913d-ba2f7804a44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_d103d6b9-480c-4964-913d-ba2f7804a44a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d103d6b9-480c-4964-913d-ba2f7804a44a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_d103d6b9-480c-4964-913d-ba2f7804a44a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d103d6b9-480c-4964-913d-ba2f7804a44a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cba5be3b-b6c1-43e9-a301-be3209af74f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_d103d6b9-480c-4964-913d-ba2f7804a44a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cba5be3b-b6c1-43e9-a301-be3209af74f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_164aa7bd-38ba-4527-83fa-568196deec1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cba5be3b-b6c1-43e9-a301-be3209af74f5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_164aa7bd-38ba-4527-83fa-568196deec1b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="extended" id="i4c1507a45cb241bda2626be0465cf821_LiabilityRelatedtotheSaleofFutureRoyaltiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_2dd7a1e7-14d9-49eb-b596-5b1ee5075d3f" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_InitialTransactionPrice_2dd7a1e7-14d9-49eb-b596-5b1ee5075d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_5f2c2855-86cc-41ed-895b-de2f66aed6d2" xlink:href="arwr-20221231.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_5f2c2855-86cc-41ed-895b-de2f66aed6d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_e0203af5-c7ae-40f1-a215-669adb232851" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_MilestonePaymentReceivable_e0203af5-c7ae-40f1-a215-669adb232851" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_7a73edfa-e15e-433e-ab85-4839bb4a3cf7" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_7a73edfa-e15e-433e-ab85-4839bb4a3cf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_af0da58c-e720-40f5-b2af-260380e06477" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_af0da58c-e720-40f5-b2af-260380e06477" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_10e1d940-da29-4722-af3c-8e08aef3152a" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_10e1d940-da29-4722-af3c-8e08aef3152a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_0dcda15c-0e0a-44a6-a827-3fb1aa2ad5ea" xlink:href="arwr-20221231.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_RoyaltyPaymentThreshold_0dcda15c-0e0a-44a6-a827-3fb1aa2ad5ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyalties_88779d43-2301-4f6e-a16a-3dfa660b4fb8" xlink:href="arwr-20221231.xsd#arwr_LiabilitySaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyalties_88779d43-2301-4f6e-a16a-3dfa660b4fb8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_39622f9d-a448-4a99-a200-573b25f9f374" xlink:href="arwr-20221231.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_39622f9d-a448-4a99-a200-573b25f9f374" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e0a1238-f5f4-4f62-ba20-e6db055959a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e0a1238-f5f4-4f62-ba20-e6db055959a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_73db81c6-d7c6-4a6c-9446-352ae6d3ed57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e0a1238-f5f4-4f62-ba20-e6db055959a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_73db81c6-d7c6-4a6c-9446-352ae6d3ed57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73db81c6-d7c6-4a6c-9446-352ae6d3ed57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_73db81c6-d7c6-4a6c-9446-352ae6d3ed57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73db81c6-d7c6-4a6c-9446-352ae6d3ed57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14d55469-d03b-42ed-8a69-44c6e6a0e3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_73db81c6-d7c6-4a6c-9446-352ae6d3ed57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14d55469-d03b-42ed-8a69-44c6e6a0e3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_39e66341-6bd4-4a4b-9729-742cee6aca8b" xlink:href="arwr-20221231.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14d55469-d03b-42ed-8a69-44c6e6a0e3b7" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_39e66341-6bd4-4a4b-9729-742cee6aca8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ab74c3b-cd33-4577-a647-8d82c9385c4d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e0a1238-f5f4-4f62-ba20-e6db055959a5" xlink:to="loc_srt_RangeAxis_3ab74c3b-cd33-4577-a647-8d82c9385c4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ab74c3b-cd33-4577-a647-8d82c9385c4d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3ab74c3b-cd33-4577-a647-8d82c9385c4d" xlink:to="loc_srt_RangeMember_3ab74c3b-cd33-4577-a647-8d82c9385c4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_787498e1-892b-426e-ab7d-20912c23cb71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3ab74c3b-cd33-4577-a647-8d82c9385c4d" xlink:to="loc_srt_RangeMember_787498e1-892b-426e-ab7d-20912c23cb71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e2a02adc-771e-489f-bd7f-19d864f28929" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_787498e1-892b-426e-ab7d-20912c23cb71" xlink:to="loc_srt_MaximumMember_e2a02adc-771e-489f-bd7f-19d864f28929" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>arwr-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e8083e98-eeaa-4076-9e59-e239858f4776,g:e1942b16-5fc3-435c-8ded-c247fb91952b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_1668d203-a5ff-4422-9f8e-fdb6af906445_terseLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_label_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_documentation_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:href="arwr-20221231.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:to="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4033a28c-d0d0-4806-9264-cade1cc56383_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_11c7e416-669a-4a4d-a20d-6943e9219375_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_603fed83-3eac-4288-9f85-b89300b77a06_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_852d0a66-b1aa-4e94-a224-36b3cf7f8d29_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_08f6d6d8-d6da-4f08-a3c4-9c9b4127605c_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f55fbe8d-2f82-4f03-bdd7-8a3fb9d26c22_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9be8679e-fc42-4b8a-9a93-cebd3481493c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_78b1948f-1663-4a70-a660-dfd2eb873a9a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_bd8c2f8c-ccda-41db-b430-e77af8a9d732_terseLabel_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_label_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments [Member]</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_documentation_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology license commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:href="arwr-20221231.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:to="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d58adcf1-a89e-4964-84d7-a17af66f71f1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_04578b2b-a7d5-4ac2-8593-1e82389a77c1_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable at start of phase two</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable At Start Of Phase Two</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable at start of phase two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:to="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a136fbbd-bc6d-493c-bc99-62375d22b506_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_1b7a726d-3838-474d-a41a-f375b97345c6_terseLabel_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax increment financing award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_label_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_documentation_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward" xlink:href="arwr-20221231.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TaxIncrementFinancingAward" xlink:to="lab_arwr_TaxIncrementFinancingAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1bb8212-17d6-408f-9eb6-0d4e0ed7e1d5_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a59df13d-0501-4df3-9082-3fab5ad56ee5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_156a8d8d-ff54-4425-8b97-0a09cb90f1ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_95e40248-ea2d-4573-a0a7-703031427992_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3bea49ee-8dbd-4b4f-a212-5d8baacf4c27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6ab307f-180b-4226-98ff-199d488521d4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6f682ef7-c25f-4d73-ba02-6b2c0c0f37c3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_91d2942a-6fea-43e4-90a8-2ab90d30695f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b9964143-91eb-4990-aefa-cc9803fb02df_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e25cfc11-8ad8-427d-b19a-6965b0db1030_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_ade184a9-a0cc-406e-bfff-1477648226ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2ef5c701-1101-483d-8c65-82bc164963d7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_b938b158-ca1f-4590-b76a-4be7ea321a64_terseLabel_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received As Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:href="arwr-20221231.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0fe74f6d-4513-4015-9c7e-66f5930392d6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1eb101fa-48cb-4114-995c-97d9fbc83158_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_b6b20a01-a77c-437d-b471-70ae0eb08e4b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_59e3576b-adde-4eba-8c4e-d03a7b27fdbc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_887d0576-1152-4766-bc00-2de2a8856edc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9f68e029-4a3d-4c27-99a7-1ead0e64eff7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_00dcb255-07b5-4530-90d4-74f8eb61fd4f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposits</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROHSDAgreementMember_0f6e60ed-0d16-492e-bbf4-5633129dd3a4_terseLabel_en-US" xlink:label="lab_arwr_AROHSDAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-HSD Agreement</link:label>
    <link:label id="lab_arwr_AROHSDAgreementMember_label_en-US" xlink:label="lab_arwr_AROHSDAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O H S D Agreement [Member]</link:label>
    <link:label id="lab_arwr_AROHSDAgreementMember_documentation_en-US" xlink:label="lab_arwr_AROHSDAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AROHSD agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROHSDAgreementMember" xlink:href="arwr-20221231.xsd#arwr_AROHSDAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROHSDAgreementMember" xlink:to="lab_arwr_AROHSDAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_86f3ca00-3b58-4d92-b791-778c6c97ac51_terseLabel_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares value reserved for future issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_label_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_documentation_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:href="arwr-20221231.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fef24dba-88a2-4a43-83d0-c0e791b65b7d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4b078551-174c-4461-99ce-57d8c8298b39_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7abf2c61-9a9f-43c8-8ccd-6d9d21d0f36c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_adff6f79-2ef2-449c-9a9e-77bcfaa16bc0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">45199</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_f61abf09-b2fe-4c9c-98c2-0a4b2064cfe2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_506c8823-a158-454e-b3d6-40614020bb1d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f387e8b5-6985-4e13-ae79-c42e00df1570_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_046aa35f-6a20-425a-b02b-ef08d8e694ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SorrentoValleyOwnerDELLCMember_bc17a129-4b7f-44a9-8192-65e181675652_terseLabel_en-US" xlink:label="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Valley Owner (DE) LLC</link:label>
    <link:label id="lab_arwr_SorrentoValleyOwnerDELLCMember_label_en-US" xlink:label="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Valley Owner (DE) LLC [Member]</link:label>
    <link:label id="lab_arwr_SorrentoValleyOwnerDELLCMember_documentation_en-US" xlink:label="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Valley Owner (DE) LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SorrentoValleyOwnerDELLCMember" xlink:href="arwr-20221231.xsd#arwr_SorrentoValleyOwnerDELLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SorrentoValleyOwnerDELLCMember" xlink:to="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ba2eb2a1-ae62-4b7b-9ce4-25a3c00e5a64_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_999973d3-e185-4069-91fc-8836aa5444a8_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_597bf844-647f-4796-9f2a-c89277fb5101_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands thirteen incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_8d3d5479-279c-44ce-8357-41322152ec8e_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planned area of the site (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e08cd007-95b7-4ce2-95ab-010e14454697_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_018a5d24-8403-4e60-8bf5-603b84041ef9_terseLabel_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Related Milestone Payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments" xlink:href="arwr-20221231.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SalesRelatedMilestonePayments" xlink:to="lab_arwr_SalesRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c1c2b46e-c7cd-479a-b2f5-6b8559733af5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_77d62fd1-1a8f-4bb9-a633-d23ac7810240_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_422d0bea-aa54-4a6a-ab22-2d5199b1fd88_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_28d20e48-0b9f-4149-ab1c-be6bbc92c3dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_2f9b3661-7ae5-489f-a79e-fc8a627f25dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f6fa8444-80cd-45d7-848d-0c3cad56a5dc_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_e21f1775-018f-4af0-9fe5-bd7bbca26f8e_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposits</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_749c30a3-615c-44f8-b2ab-c5e8edaf34a1_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_label_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Performance Obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:to="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_572173e1-2ea4-40be-9a6c-7ae7edd99edd_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission to sales agent</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:href="arwr-20221231.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c929b1e2-84fd-46d9-a529-e05b804d1047_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3ef0812-917b-4222-8cd5-977058d14200_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_44ce7a4f-1e93-4df5-a653-95013740b36d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bce8877a-331b-41bd-9f8d-eb68c120bc8d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_4f785277-d4c5-4235-a725-dea8d2c63b3c_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization (accretion) of note premiums/discounts</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNotesMember_c3f73363-598d-4331-8232-6208669c65bb_terseLabel_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial notes</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_label_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes [Member]</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_documentation_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember" xlink:href="arwr-20221231.xsd#arwr_CommercialNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNotesMember" xlink:to="lab_arwr_CommercialNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_adc76ec8-1078-4994-a0f4-b3199fcc2aec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_75fa4c26-4ad7-4425-b751-50fafcfd7046_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9993a93d-b534-404a-bd23-0503147cbe7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2d77d058-f10d-4c70-83ac-b612dbcabec7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3c0c48fa-c5a0-4189-9283-b1f74e5a692b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_93654644-2f0f-4ca8-8ab6-528d0084b791_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bb57afa2-7a5b-4cdb-a57e-20cc7a75837f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_177c56cb-63d1-4572-8b9f-c3d4a35e036b_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space leases (in sq ft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38da027f-136c-4dcf-9dd5-8e0fb2dbb7d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc512e2-c68c-4e41-8b02-4c5fa5c77a98_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_9172a740-0619-45c2-9018-ec38f44a44bf_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In San Diego [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:href="arwr-20221231.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:to="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_3d938c82-ad6b-4246-9c31-2f7766b8493c_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_2ca78bb8-d1b8-4e95-9d8e-11383ff478ac_verboseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20221231.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_49e6041b-c8de-4a26-8470-5aed68bf43e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b14ec99a-1fa2-4246-866b-6721645e581a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_e95b16e9-6cfd-4279-a410-d660f03c58e6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_be22f19a-de21-421c-ab76-35f6f30b1704_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_38800dab-476e-4ecc-ae71-7fe3dedcb2ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b0b0fb00-d7b6-475f-b357-57ec4952e6d1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_51e53879-a3e5-4e93-b77a-bbe2896e9bf5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_40f62b40-07ad-4137-88aa-ce92f6fca2ad_terseLabel_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Short-term and Long-term Investments and Marketable Securities</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_label_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held To Maturity Securities And Marketable Securities Table [Table Text Block]</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_documentation_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:href="arwr-20221231.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:to="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d807ae5b-e9e6-4a34-b647-ac292ec2402b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_38796dbe-e5df-4bdb-9206-d1582824810d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_60884092-3d1b-4dfe-baac-c5fd383c5fd4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2cdd7c09-c3f7-4c2d-a905-5ad32ccea213_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_6395b6ba-b90a-4317-8840-65736cb72ff7_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_532da4d6-32b0-4633-afa9-195413fc4ab8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9deba163-0a19-4d94-9f93-a518e38743cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_eab86d98-c003-410e-b460-74b50919c6e3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_865c5eaf-8bf6-4d15-bfc7-ff93ca149861_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_bb986835-caec-46a9-9286-53e711e86813_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_55962154-025f-47c2-badb-4bcb15a81240_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_18348dcb-cce7-4e6f-b346-acfda9f46174_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_699d648d-bc74-4498-acf0-359540cd3ec0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax expense and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_dae2f290-d059-4a2f-b9e7-cdbd74dea3f4_terseLabel_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement</link:label>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Receivable As Upfront Payment Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receivable as upfront payment due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:href="arwr-20221231.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_494a827c-5510-4de3-9a9f-cffc116becea_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Current Pipeline</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Products [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:href="arwr-20221231.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:to="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_1abb1e23-12af-4e08-88f7-afa047af8dac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in joint venture</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_dd7e24b1-bd1a-4d03-bc58-4fbb1e200520_terseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:href="arwr-20221231.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:to="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9126c8a4-9218-4e96-8cf3-674f9e68e7c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5c4bad1a-0c08-4c5a-817c-6ac2448e3367_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_330c0903-3c37-4de3-9b8a-e167cd73dba9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_47ac828b-d16b-4d9a-8c0a-2910d86a21f8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InducementAwardsMember_a8ba8f9f-ad34-42b7-8f3a-543c128862b3_terseLabel_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_label_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards [Member]</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_documentation_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember" xlink:href="arwr-20221231.xsd#arwr_InducementAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InducementAwardsMember" xlink:to="lab_arwr_InducementAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5755d14c-03cd-447c-82dd-dbdb44574cbb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_621d01d8-6ce6-46b0-b2a3-faeddeac93ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_d18820e1-b5ad-4e4e-8fb6-316451e13dd1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InitialTransactionPrice_96d157fc-1531-4e83-9e6f-bb9a24be4ea6_terseLabel_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_label_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Transaction Price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_documentation_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InitialTransactionPrice" xlink:to="lab_arwr_InitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fe128b7c-cbf1-41c7-89e7-4cbae0e9e167_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_9e615650-5429-438f-86c2-c05e1144cfb8_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2354e016-aa26-45f2-b66f-686792a89c2e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_4ac08a44-8ef1-48f3-bcbf-5348e3d229da_terseLabel_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_label_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone Payments At First Commercial Sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_documentation_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:href="arwr-20221231.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:to="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_1e99c1bb-7b02-4de3-8259-dfcb510a176e_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d0e59226-b0cd-46b3-8e02-8d3c3e3ff575_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7b30332-4ddd-4d47-940e-43b7339f9dbf_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncontrolling interest and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9720bffe-ba9b-4bf7-994c-a942aa02087f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8eb8dd87-251d-4f8a-bb3d-5f4128398e52_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e542694f-687e-47a9-8d14-3560f5edb116_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_90201c73-32a1-40f0-99ec-feca257b78a2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_2fe3a6e4-2905-4f86-b5a6-5dd2dceb0ad5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e8306a9e-2bc7-4126-86e6-662595f6c091_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_58f98851-121d-4197-b5a6-5a00dbb259a2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_bf1777f9-6b2c-4f71-9c0e-b7e673212b8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_c6e658e5-18b1-4b66-8e49-88b08c1ce412_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran and ARO-AMG1 Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran And A R O A M G1 Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran and ARO-AMG1 agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:href="arwr-20221231.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:to="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c226411d-6a9e-4d1d-b722-106fb7357386_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_caa9c873-6a83-4eb7-bd05-94a0de32ae97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_fc76bb52-da93-414b-b0a2-90802696bfda_terseLabel_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20221231.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_b3d4837f-f074-439d-92e6-fe3ee7aea451_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand twenty one incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:href="arwr-20221231.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:to="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f34ab46c-20a2-404a-ae99-52962de64bb9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3473374e-27e9-4cee-9e97-6ad6aca87af6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_dbd295c4-5a3a-43e4-888c-5493ae49a087_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a1473c6b-66b0-47da-b129-01f23eb20016_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7a57bdf6-d758-47e0-a12f-6c02ac332e19_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_64a47b39-8c9a-40d5-bc6d-a099a1a8575a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_be18351a-c94c-4ee2-8ca2-c9657d5f3616_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_396ed9a1-b9bc-4ccc-8dab-205504caf85b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4cf5b0c2-bdec-4617-8bc3-d9fce3828703_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAgreementMember_ebe7b248-e184-4c14-a26c-7da2fe8f9227_terseLabel_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_arwr_LicenseAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember" xlink:href="arwr-20221231.xsd#arwr_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAgreementMember" xlink:to="lab_arwr_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_81cee260-18cc-4bdc-b34d-089fc00a2148_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future royalties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributedCapital" xlink:to="lab_us-gaap_ProceedsFromContributedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e4ab6b8e-b7a9-4cfc-8c94-cd9221902f16_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_98807e65-3fef-4dd3-b4bd-0bfa10c05b13_terseLabel_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_label_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember" xlink:href="arwr-20221231.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaTherapeuticsIncMember" xlink:to="lab_arwr_VisirnaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_3378cac5-3975-4f23-990a-379d5ffbdf58_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentEarned_930defad-a524-4c4d-a3f8-56c988a08aa4_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_label_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Earned</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentEarned" xlink:to="lab_arwr_MilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_3c8a4c05-a1f2-42f4-a788-4d0e2e50b46b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_857738f2-938c-4a06-8b05-7b0d80f87991_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_86a56684-5b39-4831-b92f-117c60189d37_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_1a044591-8b5d-4cea-9c33-9cf61e0c2c13_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d2af39c3-5b38-42d5-8c28-ac432efc9988_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f2d81b6d-124c-4aed-accc-5539085a31cb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_9a5b9716-5aca-47cb-a439-4206c8a87ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_437a0de1-50d2-4c6d-9b62-c4339df70354_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:href="arwr-20221231.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_a19595a8-223c-4e2f-8429-0712e867e03b_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_0335cf5d-dc3c-4dcc-a3a3-8a76306f1140_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Adjusted Bases</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d1323b50-769c-4b50-b7bc-1f0701db9917_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAgreementMember_441f7ebb-4ba1-4b97-aa9e-c479676c48f5_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember" xlink:href="arwr-20221231.xsd#arwr_OlpasiranAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAgreementMember" xlink:to="lab_arwr_OlpasiranAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_49079267-56f4-432c-8661-7f8d3d6f9b65_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_45531295-c6c8-43aa-b25e-944acec15557_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BEGINNING OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_690704f7-a3eb-4bb3-ab80-2096100713e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_8ca16a12-fbdc-4235-91bf-81b16a5ee61d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a1de27e-3e88-4896-9b05-a13dc68b9706_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_cd6fcd16-528b-4e7c-a132-209516cba4b4_verboseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8ad012fa-f65c-4823-b909-d466fec7fd7f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_44c7d9e3-d9a9-43af-9ef3-47cfdbfac44b_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6c7aad94-454c-43c9-80b3-d904147589e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_380f38f6-e41b-40d2-97f4-3ec7619dfff1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e3a187c4-ec46-475f-9499-ecb8896f6f0d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_1a1a0229-6df5-49a3-a030-3b98a22374cf_terseLabel_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_label_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility [Member]</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_documentation_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug manufacturing facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember" xlink:href="arwr-20221231.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DrugManufacturingFacilityMember" xlink:to="lab_arwr_DrugManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4d752ccd-e1c9-4229-9b21-9eb5ce1db25f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6c35f319-e56f-47b2-ba25-f8ab1407980b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_b56b1b2e-1d52-4c13-b2d1-56f8ae93d78d_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_label_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:href="arwr-20221231.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:to="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_1cc694dd-5706-4b92-b0bc-0eb889ea1e88_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_eb4459a1-28c9-452b-b7a9-178e607dbdb0_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c2996842-84e8-4d2b-8eb2-84bdb6d24b90_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ad1ad214-f529-486a-ab81-f8af922f17f4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets and Liabilities and Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_12abfa7c-2b78-4227-b5c5-f76f5abee073_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, share reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0d766905-2a14-449a-a709-2b88c008ba57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b69e12a2-7fd5-4b56-8b25-972ab3b62c66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_d613a96d-5dc8-4574-89db-360e1ea337fa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_f36ded72-8be3-4bfc-a0bf-7e2b75b6c8ff_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:href="arwr-20221231.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0263957f-b5f3-4990-bd3a-4dc52b85588e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8b6eff9d-1a59-4514-b18f-58d626490761_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyalties_43ee70f7-8734-49a8-a4ff-860ccb5bf125_terseLabel_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyalties" xlink:href="arwr-20221231.xsd#arwr_LiabilitySaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyalties" xlink:to="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_3d4053d3-2f94-42c1-ab34-69df90fb08a3_terseLabel_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for leasehold improvements, net of tenant improvement allowances</link:label>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_label_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances</link:label>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_documentation_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of leasehold improvements net of tenant improvement allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:href="arwr-20221231.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:to="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b2ddf4ec-9ecd-4722-a2bb-a36511733bc1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_e9e107cc-746d-4523-96fb-1a8bde3c4a7e_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:href="arwr-20221231.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6f0d45c2-3c1d-43aa-8c0b-fd2ec39b0f07_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_149b4428-64d3-4591-b4fb-4a3c4b8e104a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPharmaMember_826ca4fb-6f09-4b33-b906-7a8b2327d112_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaMember_label_en-US" xlink:label="lab_arwr_RoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma [Member]</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaMember_documentation_en-US" xlink:label="lab_arwr_RoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaMember" xlink:href="arwr-20221231.xsd#arwr_RoyaltyPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPharmaMember" xlink:to="lab_arwr_RoyaltyPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_eab56e0f-c79d-4f28-bfc4-27c1db2b0e9c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e2b3bbec-df15-42d5-b56e-254a97e18d20_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_acf1ad96-da45-4a3b-86d3-01651953f98c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7378409c-b0cd-472e-bffb-457f54c84037_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7263c2b2-a600-4cbe-9b62-a78a1c17241b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9c1fd325-370c-4336-b844-6f2d56c9d93a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_291315df-c1e0-4803-ba2d-48e8aaaa65e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_4d52c5ab-1f11-49ba-bfa9-4925c14ba1a0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c5175ad8-d64e-4177-8401-083dd658bd55_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_9eb00855-1469-42e9-8c00-e3aa08d28146_terseLabel_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_label_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew" xlink:href="arwr-20221231.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfOptionsToRenew" xlink:to="lab_arwr_NumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_59291ad3-b77e-4311-8636-a0801c472581_terseLabel_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda License Agreement</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_label_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:href="arwr-20221231.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e2260cab-85a8-4125-aabe-6ae26df798a8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_731685ea-9627-42fc-916f-b7599711c886_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6647baba-d4b7-44c0-90aa-c525e220cd56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_027379bf-171e-4883-b907-0174f512db34_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17ecaf64-2f94-4dc5-87f2-5d9a140b1c56_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_3c37ed50-1851-4d74-929b-3da1062a3951_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7bf8e21e-0830-4325-8e8d-1e7e36ec608a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_787586b2-4111-4199-9c19-48466b6772e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d6f2af25-b481-4a24-bfa2-0f975cc34eaf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_0d6f6b8c-21a0-4c12-a848-95762d500f00_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_86104b14-5bc1-4283-96b0-7e0c89604bcc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dfcf4e65-4da2-4df8-b773-f31e44ad7c15_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_d75a4a9f-680d-4911-89f5-6fd63587ce41_terseLabel_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_label_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland D A C [Member]</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_documentation_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:href="arwr-20221231.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:to="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_54b78a80-2b28-42b8-a268-98950c64f03e_terseLabel_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:href="arwr-20221231.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cc301d53-f803-4608-a985-5ff9899a3990_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a542cd0b-962b-4da6-be68-c46edd4126b4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_11660b54-05a1-4e53-b35f-767218282752_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information about Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ce71894f-a9a7-4d17-b55d-06e1d7517621_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_b8f1f62b-de20-4ba7-95dd-4e4fc76526bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Awards Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_97f1b708-e6f0-4a10-aa9d-075190bae75a_terseLabel_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Milestone Payment Received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived" xlink:href="arwr-20221231.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_UpfrontMilestonePaymentReceived" xlink:to="lab_arwr_UpfrontMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8d116063-060b-49f4-8399-b740b4da1094_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePayments_6c023f6d-a67a-437e-ba55-5e992a268e62_verboseLabel_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_label_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_documentation_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments" xlink:href="arwr-20221231.xsd#arwr_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePayments" xlink:to="lab_arwr_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08ffc03b-896d-4a74-b205-68ad41050b43_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c32ae723-f6f2-4b86-b649-96a2eb3ebe34_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_34c1893d-683b-451d-937c-59c21eef7216_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_942e1eb6-ad22-4ad8-aa3c-c0f47db651b2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6385728-5411-406e-9d4b-e5803a438ea1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash flow from operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4a3e87b7-08f1-45a6-a9b6-281ea2254ff5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_520eb3d7-315c-4d46-bb82-2b9669bfc979_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983f1ece-e11c-48e8-b741-8005aa151a51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2aa913e9-95e4-4456-8c53-333ce3935796_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d6b7256-bf38-4e84-80b2-d416e20fb535_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6ab847c0-a2f6-4867-8862-c4cf919716f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43c197e5-90c7-4a66-bb35-68473c033e38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_843c0cbf-6d0e-4724-ac53-4ee541fbd4d5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_3afff95b-b1dd-423a-bb2a-f3aba56cc7d6_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7799efee-e5ad-47db-a763-863484519925_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b51e1229-55a8-40d1-9a4e-5e84dd8ac7f4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ae3b6a2c-f25d-48b0-8388-4dd8be115d25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_86934d44-a1a4-4b8c-8ae8-a67509f8966b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eb13767b-4164-4b25-bfe0-73043df09726_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_a7f5b91b-200a-4e02-8359-fd91ca02adc0_terseLabel_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers, software, office equipment and furniture</link:label>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_label_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers Software Office Equipment And Furniture Gross</link:label>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_documentation_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers, software, office equipment and furniture gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:href="arwr-20221231.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:to="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Abstract]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:href="arwr-20221231.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92fc7970-4dc2-424d-8a20-e332dd6d94b5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NovartisMember_5e984f57-ce66-4087-b69c-2689f918d66b_terseLabel_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_arwr_NovartisMember_label_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_arwr_NovartisMember_documentation_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember" xlink:href="arwr-20221231.xsd#arwr_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NovartisMember" xlink:to="lab_arwr_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_c76a1c20-e5d2-46b0-b6fc-2ec6cc8a5070_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7f2436e5-0c1a-4016-a6c8-d35a518e41a8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 106,140 and 105,960 shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_5eb48fc4-4d3e-4836-b342-060b2ba318d6_terseLabel_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash and investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_label_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash And Investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_documentation_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in cash and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:href="arwr-20221231.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_1c9bc9d6-f4d5-4658-ba79-200ea0fb1b76_terseLabel_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Co-Funding Agreement</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Co Funding Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and co-funding agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:href="arwr-20221231.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:to="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68c2ded7-fdf3-447b-b1cb-0d750ea08f5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0b5a6554-2ce1-42d4-b1f1-c481f9532870_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_335b1d3d-98d0-4743-921d-3846928bfb19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6e876881-d5f1-4e2e-82a4-02e72d5fefb9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_0309620b-67a8-4271-a55a-4c23206de80e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_53fe8758-5976-4e99-a681-d57a22b332c9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49c33804-31ba-47a9-8d15-ca3a24780e7c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c284c183-aaa5-4c17-96c6-32bc7208e9e8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ae978b9a-9f65-4332-b4ac-b5e54a657bb3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fd350a62-d1da-4d6d-b4b9-b965dc08f068_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:href="arwr-20221231.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_96cea98a-54a5-440d-a528-ff96f8c94a53_terseLabel_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember" xlink:href="arwr-20221231.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AtTheMarketAgreementMember" xlink:to="lab_arwr_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_9303685d-072d-45f5-ba1c-23e2b956ad63_terseLabel_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_label_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_documentation_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters in Pasadena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:href="arwr-20221231.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:to="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bce2accb-011e-4549-8400-bc3196543c75_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_396cbbad-5871-4cc8-b261-322cc98fc68d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4f9e4bda-7dc9-451f-a9b3-420e489d5cbb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_fda885ec-05e0-4d5b-8140-bb093849d231_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5b2d9e84-a032-4696-a7b3-c1df04b6697d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_30a6a2f4-3727-4950-8425-eace647791c7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8295e629-24b1-42e4-bef3-49ec4dfc5cd7_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAgreementMember_fdd79639-c0ae-4f02-8c82-e6bdd3cc2ece_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CollaborationAgreementMember_label_en-US" xlink:label="lab_arwr_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arwr_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_arwr_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAgreementMember" xlink:href="arwr-20221231.xsd#arwr_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAgreementMember" xlink:to="lab_arwr_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctBundle_40121b3b-32ce-414e-824d-89742b5a2dc1_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_label_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctBundle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctBundle" xlink:to="lab_arwr_NumberOfDistinctBundle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_04ef5aa0-be28-4b38-afba-fbb531700bdb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_247cd97f-691e-44de-8e28-ff71f7df9a08_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_label_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_documentation_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold" xlink:href="arwr-20221231.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPaymentThreshold" xlink:to="lab_arwr_RoyaltyPaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c402a512-1d74-4a72-8942-fa95c274586d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_14f76811-2065-4fc3-ad81-3b42b7917095_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FacilitiesMember_fa254e3a-8c0c-455c-b55d-40a01d24c64c_terseLabel_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_arwr_FacilitiesMember_label_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities [Member]</link:label>
    <link:label id="lab_arwr_FacilitiesMember_documentation_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember" xlink:href="arwr-20221231.xsd#arwr_FacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FacilitiesMember" xlink:to="lab_arwr_FacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_91f93864-768c-4c1e-b6c9-b0fe216d8f6c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f96f7fbe-9be5-45d5-a8e3-88f9c7ae4ed7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_3137cc0d-f02e-4fff-8398-4de79a650264_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROXDHAgreementMember_871d2a27-56b7-4032-bd04-de8b8da1b64d_terseLabel_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH</link:label>
    <link:label id="lab_arwr_AROXDHAgreementMember_label_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O X D H Agreement [Member]</link:label>
    <link:label id="lab_arwr_AROXDHAgreementMember_documentation_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember" xlink:href="arwr-20221231.xsd#arwr_AROXDHAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROXDHAgreementMember" xlink:to="lab_arwr_AROXDHAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_b277734e-674e-4c12-a4b1-ea9add755338_terseLabel_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20221231.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a51aa99b-d474-47ef-a845-571e70b5c229_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_63cce689-beab-4430-9b72-512171ad57fc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2edcd473-1176-43ed-bc06-aafdc49878a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_08ec0e51-6d45-4eef-916a-22eb876c2eb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Outstanding, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d1dc9125-9d13-4a53-a1d5-18042730f8ac_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense for property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_30d58203-14ec-4589-88d1-ce47b61a51be_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_label_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement [Member]</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_documentation_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember" xlink:href="arwr-20221231.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPharmaAgreementMember" xlink:to="lab_arwr_RoyaltyPharmaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_31743baa-b331-420e-83f0-e44127220133_terseLabel_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember" xlink:href="arwr-20221231.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockPurchaseAgreementMember" xlink:to="lab_arwr_CommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_48ef6936-e914-4e63-a9f5-55ebd63d71c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_53f07965-cd46-4751-b9e6-3374532e51d4_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_babbc95f-3a51-4384-b51f-960705f71bc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59afb65e-9103-48f7-a2e0-4026f4309381_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a0bea468-61cb-4a07-80b7-09ceac8ba950_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_634962d1-bbb9-4ffc-b4f7-83dfa4851d5b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_f394fe8a-6a2c-494b-8264-c69a11394634_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2cbf5aa3-2ab4-4b66-98dd-4bd2113de396_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ad6cbbb2-52ab-4bc0-8b19-1e952c4fafb6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45fd89ee-6d96-4142-aa81-e3e85ba9f187_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2fac0c2f-689c-4636-afac-5fa302a24b37_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a1482613-0b92-46ac-b57a-a9e0a5e7a01b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_ff0373c9-7cde-4f62-b305-9285bb207c24_terseLabel_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_label_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park [Member]</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_documentation_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona technology park.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember" xlink:href="arwr-20221231.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VeronaTechnologyParkMember" xlink:to="lab_arwr_VeronaTechnologyParkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_6ea43882-35c3-486e-9c07-79daad5e1308_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2324f5f7-7126-4dfc-bbef-905a84a38a83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_c796bfe7-d49a-487a-8c3c-26b78f1e6880_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a0eac7f6-946c-41d9-a1ee-88b974cefde8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmgenIncorporatedMember_da640c63-2f9f-435c-9288-821b9abb2d57_terseLabel_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_label_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated [Member]</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember" xlink:href="arwr-20221231.xsd#arwr_AmgenIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmgenIncorporatedMember" xlink:to="lab_arwr_AmgenIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ae459439-8e92-4d8d-92c6-9f13c0368f9c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8622b0bb-1df0-41cc-9e0d-23afca3a0d66_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_049424ce-4706-420c-a59e-e4bdf5b22b00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e36c6adf-5949-466b-82d4-0d34df3772b3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ad890541-9389-40e8-973d-d0f0c9354042_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_433947c4-7ebe-4a8a-937f-ca7279015fd5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_745d5ecd-366c-4c3d-826f-6d2196fd5ea6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_30296f13-0ff2-4439-8b9c-886dcea51fea_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_857322a2-e5ad-4489-957b-b72d4ec4f520_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_14011f9f-9c02-4041-a914-9e2aff55198c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f6d81eaa-065a-4725-9b41-7a0365133472_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_0f0d7a34-6490-4c86-9581-9bf5d8068f40_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (paid) refunded</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_db5ba058-efdd-44d0-8ab8-12a28ff856ed_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_778089bf-3633-4c6e-80cd-16096035f4e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f5ae297e-d140-4914-9107-6f8c11c6dcb7_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_9b512ee9-0924-427d-a53a-3808101b60f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_cf9d5ad4-a6b5-4ee0-ad13-e9ab808cb14a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a1dae74f-94a7-4e8c-8ff9-2dc560ff43b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredRevenueMember_095189bb-db15-48e2-a75b-a063434d2844_terseLabel_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_arwr_DeferredRevenueMember_label_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Member]</link:label>
    <link:label id="lab_arwr_DeferredRevenueMember_documentation_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember" xlink:href="arwr-20221231.xsd#arwr_DeferredRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredRevenueMember" xlink:to="lab_arwr_DeferredRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e7e527c3-1f0c-4714-9c1a-623fe3082268_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f8fdd80f-160e-4ced-98a2-6157bcb37d16_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9623d9e1-f7da-47f3-b98a-9fd5ef033f52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_09d23c95-7a42-4d36-a39e-f7b1e2551b50_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_4dc66c30-68b7-4a6b-887f-aed3e7954c5a_terseLabel_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_label_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And After Year Five</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_documentation_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due year five and after year five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:href="arwr-20221231.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:to="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_7ec760f7-71d5-49e6-a57c-6e17c5c03abb_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon FDA approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:to="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_874e2dc9-8e47-472f-b036-b548925a3639_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_85c9dae6-6aaf-4416-87af-ff81117c93b9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaLicenseAgreementMember_2e65535b-19bf-413d-b5da-7566f1b3b7bf_terseLabel_en-US" xlink:label="lab_arwr_VisirnaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna License Agreement</link:label>
    <link:label id="lab_arwr_VisirnaLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_VisirnaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna License Agreement [Member]</link:label>
    <link:label id="lab_arwr_VisirnaLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_VisirnaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaLicenseAgreementMember" xlink:href="arwr-20221231.xsd#arwr_VisirnaLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaLicenseAgreementMember" xlink:to="lab_arwr_VisirnaLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_668b9bda-1d81-426e-8705-97911697170d_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8607438c-afa1-42d8-8a81-edf81e477fd8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a605a044-e46d-4119-bf89-fc988560b42b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_fbc3a709-98e0-464c-87c9-1adf60d3ead6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_0530c85a-0383-4e9a-8133-16cd3f99584d_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_95a9ad6d-f4bf-47d9-bfe8-00a5401ef5f6_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:href="arwr-20221231.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:to="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_14e93e75-2166-4acf-83c7-175ed74ea3f7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_338d2049-9668-46db-bc59-4c16e518db50_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities (includes current portion)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_5503d679-255f-4707-bdf9-19ea14c5a69d_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceived_63659712-57af-49a6-b9e7-3c084de3c8eb_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceived" xlink:to="lab_arwr_MilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_edcb1739-7cc4-482b-9dec-fc6381e287d9_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Equity Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Four Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands four equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b27cd832-1e0f-456b-ab76-9dd8c51542a1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3244cede-17b6-4a0a-aa6a-671916bda9ae_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchEquipmentGross_14e17eb5-7f98-46d3-ab67-c2f11b3b0d6e_terseLabel_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_label_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment Gross</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_documentation_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross" xlink:href="arwr-20221231.xsd#arwr_ResearchEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchEquipmentGross" xlink:to="lab_arwr_ResearchEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c5b1b12-ffe1-4681-84cd-ded73a73d27b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7bcff1c9-dd20-478d-b9ab-ae4ef82e2bb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_e6e5d0ac-7070-401f-93b2-d0d97f34d6fc_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_label_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:href="arwr-20221231.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77ff2224-ed27-4e4e-b1c9-2eed082a0666_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_3afd510d-8788-4290-b371-5597347e74a1_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land purchased, number of acres</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_label_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Acres Of Land Purchased</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_documentation_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of acres of land purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased" xlink:href="arwr-20221231.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAcresOfLandPurchased" xlink:to="lab_arwr_NumberOfAcresOfLandPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9a3726b3-ccf6-4c80-b1b3-112051879e43_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a4031be6-ea2c-4d4a-9701-db75fe68a8b2_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3d0d91e2-bf57-4069-b782-c0f4c538a4a7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_37ce59a2-1c09-45c8-a137-b8267966478e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f57de174-0997-44dc-af29-ea50d1c04cd6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b841aabb-e8e1-41f7-a07a-8a1e8ea16ebf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest and stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_ac80e604-50f6-4983-9a44-380d76e6ee09_totalLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_label_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_documentation_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:href="arwr-20221231.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_df2474db-13f1-48d2-96e5-be30d9997c19_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4f38d1ea-786f-4770-81d2-60e3d4070bdf_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_0bbd1dc4-0960-4540-94a5-99e3e0348db5_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7bac1917-8663-41c5-b0ca-1db7e1b67c58_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cf2ebbff-f7cd-43d8-aa06-36b7592df446_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46852b0c-d292-4d5a-a408-f78ef20418b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_044e6934-9580-41d8-95a3-f268b2c500e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_72b9fdcc-8fdb-46ca-acce-b013f9974d7c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_988333eb-a000-4367-8bd7-17fe0b1f2217_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54ec502-2d99-4e8d-b4c3-60b4167ccc3e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_3c089966-0cda-4a57-9211-0e56f37a2f80_terseLabel_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_label_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited [Member]</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_documentation_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:href="arwr-20221231.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9955155a-8467-4458-8d8d-15d84d2923e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_19533799-1a9b-4a4e-8912-de0ff848e4f3_terseLabel_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_label_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner L L C [Member]</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_documentation_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember" xlink:href="arwr-20221231.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ColoradoOwnerLLCMember" xlink:to="lab_arwr_ColoradoOwnerLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a4845a46-382b-47c6-87fc-85ff643a208f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_2c0d4f6c-1b48-4454-9ccf-9ef6b0133849_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ba826cde-aca9-479f-8b5d-11310ba76db0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_cb435782-5fd2-43bb-bb77-9dbd2604252e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAgreements_0e9bf6fa-bc24-4300-89a0-9419878efb70_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_label_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_documentation_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements" xlink:href="arwr-20221231.xsd#arwr_NumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAgreements" xlink:to="lab_arwr_NumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_270975b1-beb9-4a34-a5d2-9decedc9f3f7_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0dcd75fa-3baa-466a-a682-492ff91d4667_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_c8575cb3-3cae-4f33-8140-21475fd88824_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_b1bd5a06-adc1-43a3-bd81-3fe1e9d5b0ae_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_6abe104d-0ab7-49d5-ad75-82b941333f2c_terseLabel_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-3989 (ARO-HBV) Agreement</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_label_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J3989 A R O H B V Agreement [Member]</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_documentation_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-3989 (ARO-HBV) Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:href="arwr-20221231.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:to="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_cf162fdf-8ea9-4c94-afeb-c21fbdfd8381_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_92d835b0-e3cc-4209-83ca-a91c729982cc_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_cf1507b7-e163-44b5-927a-201ab55d25c4_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_2ab620d1-8b85-463e-baa4-cde664941549_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controllling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9fb1a139-a290-41a3-b1e6-d12b6cf1fb87_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_53c83469-2c08-4a46-a3df-3b131b71fda8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_e118522a-3036-4c2d-bca6-63e029720870_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_40712991-34ae-4d67-a6af-f5c5b8e4ebf1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_34d8e476-690b-49d5-af80-ae8cececb534_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a7743fc3-1f6b-4bf7-af07-40e455c17e75_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_7eae546a-ba21-455b-9b81-3bb73e94ac12_terseLabel_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intends to invest for buildout of the facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_label_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Intends To Invest For Buildout Of Facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_documentation_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intends to invest for buildout of facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:href="arwr-20221231.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:to="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_39542804-2a95-4cfb-9b14-c6d7d981365e_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_b2d36f96-aae8-462c-93db-98d2aa5deaee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6937a256-7cc1-414e-87a6-63bbbec9e980_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_963b0f51-9561-4608-bb88-3fb9087b1848_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_2825f492-e247-48f7-92c8-da3094425df1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares of Common Stock and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c36d6746-1a83-4afa-b0d5-ddcf0bb931ec_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_aafbea02-172d-40da-9d0d-ee629e4a57e3_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon receipt of royalty payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:to="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_342a878d-d1d5-4fc6-8b15-08deecee0929_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_454129c4-8f38-40e8-99da-d30403726481_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_e6416ff2-dc30-4e48-84b7-8282de0a1506_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3a42c0b2-e359-4162-8a3e-fca7b2e61a70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share Activity Related to RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_f65ffed2-d88b-4f83-984e-b7a68bac5929_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License agreements</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementMember" xlink:to="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_4599ca9c-8b1a-491f-a8a1-06d555076910_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1499532d-0bd1-4de8-8b82-dda46dc79074_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2de0eb6b-3434-4414-beeb-3f30d708b273_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_3e3e12ac-eb07-4097-8296-5d8518be9556_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_93eb7af4-4752-4c12-b6c5-2f15ce7073b7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_a98bf3b6-f3d9-480e-8254-474dfa93ddee_terseLabel_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-75220795 (ARO-JNJ1)</link:label>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_label_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J75220795 A R O J N J1 [Member]</link:label>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_documentation_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ 75220795 ARO JNJ1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member" xlink:href="arwr-20221231.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JNJ75220795AROJNJ1Member" xlink:to="lab_arwr_JNJ75220795AROJNJ1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9eadcac1-5435-4487-abf4-66d1d198d17a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5759559e-add2-4a32-afa4-887c15432bc9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_eda2e8c0-2d70-45c3-b20a-d0813b2b77e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_779dca12-161e-4571-a997-5bb1112fe534_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bf7040d2-5c37-4183-8747-9d28ea222dd3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_049d14b1-2f01-4e8c-b1f3-0e1d6cb251b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivable_c9fc4b21-4730-4ea3-9875-2dcf6df56445_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivable" xlink:to="lab_arwr_MilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WI_29973a2d-8bd1-4a85-b444-b1e487abc602_terseLabel_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wisconsin</link:label>
    <link:label id="lab_stpr_WI_label_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WISCONSIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WI" xlink:to="lab_stpr_WI" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_2f131070-6056-41e1-99e8-c47c56c35a70_terseLabel_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JJDC</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_label_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson and Johnson Innovation-JJDC, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:href="arwr-20221231.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_912c6d40-fc5e-4d09-9fb1-c20289607f0c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remainder)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_65406dd7-ef61-4a41-b95c-0eb77723ec73_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_d8a02e46-b252-43cc-968b-515cb371b3a9_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1f401f72-f96b-48cf-b074-9c871bc6d056_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c6e87056-065d-43bc-992e-6b2a08dd0242_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="arwr-20221231.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e62ff68c-b33e-4e0c-827f-0da4a28ddcf9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_e67f40a4-4517-4c1f-ac19-1e0acf49efea_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4525b0e9-bc37-47c0-8ed0-7fc562bfe6da_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_0cedc55a-2588-44a9-bc57-e94411ac3915_terseLabel_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated payments for operating expenses</link:label>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_label_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Payments For Operating Expenses Year One</link:label>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_documentation_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated payments for operating expenses year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:href="arwr-20221231.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:to="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a5b28b35-d412-4ff6-900b-17467ebe61b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d31698e-45a4-4678-97c3-dad63e21b693_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_993dc853-0a06-461c-bb56-ec5ee1ff3647_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_42d9aeef-14f9-4061-8e10-e463765b3894_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d37b8445-6c37-489c-8896-7ce7e4d6a521_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_dd2cf974-a659-4c85-a34b-426d8ee4c56e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_87130f88-3535-476d-b7fc-dda31a437f9d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_faccb71b-3b24-410d-81a5-c7851a8968f3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b35be8e9-36b0-4279-856c-208cf72d75cf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_8c801c2a-daeb-4e58-a77c-9682390b5ec4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_084172cb-11b3-4d1a-ad7f-76c44179e593_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_4f7dc7b7-9c55-40b1-9f9d-22b798f89835_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_133c9eef-37ee-46b9-b18e-4dc7c7bb3107_terseLabel_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Office Facility</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_label_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Office Facility [Member]</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_documentation_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and office facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:href="arwr-20221231.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:to="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ab2805e-0609-4a28-86ec-3e0c1f943a2a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_8f9df20f-629a-416a-b6ff-79d979394eb4_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7171f1c0-2663-4f33-a42f-25124decb536_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_159cb84a-31f8-4b78-b1a7-e274322e54ec_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in Madison</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In Madison [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research facility in Madison.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember" xlink:href="arwr-20221231.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInMadisonMember" xlink:to="lab_arwr_ResearchFacilityInMadisonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_c1960776-cd16-4a9f-9738-ac5d32f42829_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_96fc70cc-812a-41d8-840d-9d6fa353eb97_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8baa888a-0112-4df3-8279-f3b5dd53b6ba_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2b0e608d-5f3a-466c-bcf6-06c4c2ec250b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>arwr-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e8083e98-eeaa-4076-9e59-e239858f4776,g:e1942b16-5fc3-435c-8ded-c247fb91952b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Cover" xlink:type="simple" xlink:href="arwr-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e48e8c57-de4c-4189-bab7-a87527f43eb4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_DocumentType_e48e8c57-de4c-4189-bab7-a87527f43eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c39021be-7440-4475-9f28-221da4cc8762" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_DocumentQuarterlyReport_c39021be-7440-4475-9f28-221da4cc8762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8990a975-a753-40e1-ae9e-6e17e4617a9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_DocumentPeriodEndDate_8990a975-a753-40e1-ae9e-6e17e4617a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_47a9264d-dbdd-4fe8-95c2-7bce880e706a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_DocumentTransitionReport_47a9264d-dbdd-4fe8-95c2-7bce880e706a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6864fc56-6843-492b-aa14-feb549fed243" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityFileNumber_6864fc56-6843-492b-aa14-feb549fed243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_852da2cf-670f-4472-8c13-b1d4f6733173" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityRegistrantName_852da2cf-670f-4472-8c13-b1d4f6733173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6d5a5341-1f6c-412d-9370-814920711481" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6d5a5341-1f6c-412d-9370-814920711481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_269b16e8-1689-431d-98a9-3a4bf859d747" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityTaxIdentificationNumber_269b16e8-1689-431d-98a9-3a4bf859d747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_62fd0f3d-6cb6-4b6d-afb4-a543dd9bdfda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityAddressAddressLine1_62fd0f3d-6cb6-4b6d-afb4-a543dd9bdfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_70b6b8f3-1caa-4741-a43b-48823dfbccac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityAddressAddressLine2_70b6b8f3-1caa-4741-a43b-48823dfbccac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cd339392-7eeb-4606-a323-cc4c9a1b0482" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityAddressCityOrTown_cd339392-7eeb-4606-a323-cc4c9a1b0482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b78257fd-1132-455d-a89f-f109fdb19f8f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityAddressStateOrProvince_b78257fd-1132-455d-a89f-f109fdb19f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4007841f-5d7a-4557-90cf-9e377d995dcc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityAddressPostalZipCode_4007841f-5d7a-4557-90cf-9e377d995dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ed29a77c-5453-4b23-b045-8c55038e7818" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_CityAreaCode_ed29a77c-5453-4b23-b045-8c55038e7818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1db5a1b4-2681-4999-bfae-3e6ada5fe522" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_LocalPhoneNumber_1db5a1b4-2681-4999-bfae-3e6ada5fe522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2787a061-4280-4118-a561-a8ca10751dfb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_Security12bTitle_2787a061-4280-4118-a561-a8ca10751dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4f106feb-6482-4312-9d0f-055436edeaef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_TradingSymbol_4f106feb-6482-4312-9d0f-055436edeaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_86b6f9c1-3bbe-464e-a42c-a35e2cc8908f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_SecurityExchangeName_86b6f9c1-3bbe-464e-a42c-a35e2cc8908f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_91e3a9fe-c85e-4575-b02f-c8746aa54086" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityCurrentReportingStatus_91e3a9fe-c85e-4575-b02f-c8746aa54086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_97a0ef2c-68dd-426b-8341-63600fc6bd9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityInteractiveDataCurrent_97a0ef2c-68dd-426b-8341-63600fc6bd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_433da3a2-fabf-4675-a563-7c3006af5cd7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityFilerCategory_433da3a2-fabf-4675-a563-7c3006af5cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d72cb7e0-1f40-42c8-b6de-525e60b1848a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityEmergingGrowthCompany_d72cb7e0-1f40-42c8-b6de-525e60b1848a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_54a78adb-8a73-40c3-931c-bc15b51cffed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntitySmallBusiness_54a78adb-8a73-40c3-931c-bc15b51cffed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e347baf6-2324-4860-b9b7-8455ee21bf75" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityShellCompany_e347baf6-2324-4860-b9b7-8455ee21bf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b5dc5ccc-47b7-4b74-99d2-2e12a88d7fd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b5dc5ccc-47b7-4b74-99d2-2e12a88d7fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a3d83583-e55d-4ff4-a612-fde36f1cb0a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_EntityCentralIndexKey_a3d83583-e55d-4ff4-a612-fde36f1cb0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_850bb233-97b7-4230-a375-62bcf8fffff3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_CurrentFiscalYearEndDate_850bb233-97b7-4230-a375-62bcf8fffff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_825a5084-78ec-479c-be52-422b7b40ae6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_DocumentFiscalYearFocus_825a5084-78ec-479c-be52-422b7b40ae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fefae40a-4bb8-41d4-9bc8-4ec938a7a6fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fefae40a-4bb8-41d4-9bc8-4ec938a7a6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_57e09bdc-d1cf-4940-89b2-0f7803279391" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_979d3572-74a3-4c2a-bb7d-c79db1342f51" xlink:to="loc_dei_AmendmentFlag_57e09bdc-d1cf-4940-89b2-0f7803279391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b52197f9-07c6-48ab-b227-5ad9734fd7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bb8cdb87-13db-41cf-9174-e6cc2cb0142e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b52197f9-07c6-48ab-b227-5ad9734fd7bd" xlink:to="loc_us-gaap_AssetsAbstract_bb8cdb87-13db-41cf-9174-e6cc2cb0142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6ca8623f-efdb-449d-b3cc-def07bf59248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bb8cdb87-13db-41cf-9174-e6cc2cb0142e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6ca8623f-efdb-449d-b3cc-def07bf59248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37e77c3d-d2f2-476a-8099-dcaaef1f5d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ca8623f-efdb-449d-b3cc-def07bf59248" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37e77c3d-d2f2-476a-8099-dcaaef1f5d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a5e7b085-5a6d-4ddd-a417-8ddb70551410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ca8623f-efdb-449d-b3cc-def07bf59248" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a5e7b085-5a6d-4ddd-a417-8ddb70551410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_3585a0e5-cd1a-4a9a-8c1c-ac50aceac84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ca8623f-efdb-449d-b3cc-def07bf59248" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_3585a0e5-cd1a-4a9a-8c1c-ac50aceac84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_c0f807a1-613c-4e01-9131-fc3d99ae65d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ca8623f-efdb-449d-b3cc-def07bf59248" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_c0f807a1-613c-4e01-9131-fc3d99ae65d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_eecabfe1-7faa-4e39-bda0-e0d8f9bfa452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ca8623f-efdb-449d-b3cc-def07bf59248" xlink:to="loc_us-gaap_OtherAssetsCurrent_eecabfe1-7faa-4e39-bda0-e0d8f9bfa452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_15b3fee8-52c0-41f9-8582-40427dbabb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ca8623f-efdb-449d-b3cc-def07bf59248" xlink:to="loc_us-gaap_AssetsCurrent_15b3fee8-52c0-41f9-8582-40427dbabb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f0e917a8-6740-4bc8-b4b9-deea52757c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bb8cdb87-13db-41cf-9174-e6cc2cb0142e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f0e917a8-6740-4bc8-b4b9-deea52757c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_43bd01f2-4edc-41fc-ac94-f239cc41ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bb8cdb87-13db-41cf-9174-e6cc2cb0142e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_43bd01f2-4edc-41fc-ac94-f239cc41ca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0780d19b-3640-446a-a56e-6cc805bedf16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bb8cdb87-13db-41cf-9174-e6cc2cb0142e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0780d19b-3640-446a-a56e-6cc805bedf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c8f60ac0-b9bb-4a67-aae0-fe7a1a7a009d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bb8cdb87-13db-41cf-9174-e6cc2cb0142e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c8f60ac0-b9bb-4a67-aae0-fe7a1a7a009d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9d6449be-1ecc-40db-b9e3-e58f6b577ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bb8cdb87-13db-41cf-9174-e6cc2cb0142e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9d6449be-1ecc-40db-b9e3-e58f6b577ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f6f9e11a-89db-43f3-9daa-c63999f90533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bb8cdb87-13db-41cf-9174-e6cc2cb0142e" xlink:to="loc_us-gaap_Assets_f6f9e11a-89db-43f3-9daa-c63999f90533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc13c05a-4d64-4a9b-a5a9-778e855fe782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b52197f9-07c6-48ab-b227-5ad9734fd7bd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc13c05a-4d64-4a9b-a5a9-778e855fe782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_75ef9d7e-14ac-4bba-bf33-4525ccfcbb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc13c05a-4d64-4a9b-a5a9-778e855fe782" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_75ef9d7e-14ac-4bba-bf33-4525ccfcbb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6d4a0346-430f-49bd-9ffe-a64d364766ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75ef9d7e-14ac-4bba-bf33-4525ccfcbb32" xlink:to="loc_us-gaap_AccountsPayableCurrent_6d4a0346-430f-49bd-9ffe-a64d364766ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e234f3b8-f5b9-4fad-997d-cf93c54270c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75ef9d7e-14ac-4bba-bf33-4525ccfcbb32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e234f3b8-f5b9-4fad-997d-cf93c54270c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7b7894c4-cca4-437d-a81f-e5f797717d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75ef9d7e-14ac-4bba-bf33-4525ccfcbb32" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7b7894c4-cca4-437d-a81f-e5f797717d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1339c733-20e9-4e48-aeb4-36f3e04d39c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75ef9d7e-14ac-4bba-bf33-4525ccfcbb32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1339c733-20e9-4e48-aeb4-36f3e04d39c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e639c61d-2147-496e-af57-046b2bcc10f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75ef9d7e-14ac-4bba-bf33-4525ccfcbb32" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e639c61d-2147-496e-af57-046b2bcc10f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2c00ed82-5586-45e3-9afb-f1802f885ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_75ef9d7e-14ac-4bba-bf33-4525ccfcbb32" xlink:to="loc_us-gaap_LiabilitiesCurrent_2c00ed82-5586-45e3-9afb-f1802f885ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0bcb76db-a314-41e0-b14e-2907ddaf5e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc13c05a-4d64-4a9b-a5a9-778e855fe782" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0bcb76db-a314-41e0-b14e-2907ddaf5e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c9f42d98-c998-41bb-81be-38f968dd0c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0bcb76db-a314-41e0-b14e-2907ddaf5e7e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c9f42d98-c998-41bb-81be-38f968dd0c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2b488fe2-446f-43ae-97c6-1fbceee04546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0bcb76db-a314-41e0-b14e-2907ddaf5e7e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2b488fe2-446f-43ae-97c6-1fbceee04546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_319604da-dcc8-4088-9279-dfb848ac9685" xlink:href="arwr-20221231.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0bcb76db-a314-41e0-b14e-2907ddaf5e7e" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_319604da-dcc8-4088-9279-dfb848ac9685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_7af20627-cc30-425e-9842-5880e65506ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0bcb76db-a314-41e0-b14e-2907ddaf5e7e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_7af20627-cc30-425e-9842-5880e65506ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_63fd8274-6694-45e5-934c-58338fc8f651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc13c05a-4d64-4a9b-a5a9-778e855fe782" xlink:to="loc_us-gaap_CommitmentsAndContingencies_63fd8274-6694-45e5-934c-58338fc8f651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa1efde9-3eca-4caa-ab8b-9aebf105df40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc13c05a-4d64-4a9b-a5a9-778e855fe782" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa1efde9-3eca-4caa-ab8b-9aebf105df40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_41bf584c-1732-4a05-9103-fe4512b96425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa1efde9-3eca-4caa-ab8b-9aebf105df40" xlink:to="loc_us-gaap_CommonStockValue_41bf584c-1732-4a05-9103-fe4512b96425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86a5d057-58ac-457e-a18a-7ff8b1ef88ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa1efde9-3eca-4caa-ab8b-9aebf105df40" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_86a5d057-58ac-457e-a18a-7ff8b1ef88ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8abe0ff4-7c79-4ac5-9488-cef483b3af3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa1efde9-3eca-4caa-ab8b-9aebf105df40" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8abe0ff4-7c79-4ac5-9488-cef483b3af3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1fbc14a7-6049-4742-93a2-e6af0bdedd75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa1efde9-3eca-4caa-ab8b-9aebf105df40" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1fbc14a7-6049-4742-93a2-e6af0bdedd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e4751b6d-391b-4501-b94b-66656b8e5e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa1efde9-3eca-4caa-ab8b-9aebf105df40" xlink:to="loc_us-gaap_StockholdersEquity_e4751b6d-391b-4501-b94b-66656b8e5e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4677be18-e16e-4350-9a6b-cf41fdfdd59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa1efde9-3eca-4caa-ab8b-9aebf105df40" xlink:to="loc_us-gaap_MinorityInterest_4677be18-e16e-4350-9a6b-cf41fdfdd59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48f726b0-8cb0-4e6d-becc-5b8965a92ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa1efde9-3eca-4caa-ab8b-9aebf105df40" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48f726b0-8cb0-4e6d-becc-5b8965a92ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_094ead31-45d9-4ecf-bb89-b49890ce659b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cc13c05a-4d64-4a9b-a5a9-778e855fe782" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_094ead31-45d9-4ecf-bb89-b49890ce659b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arwr-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a599d6b8-17c6-4fb9-8627-3717befa80ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b7f9e12-a04d-4b1c-9d13-db7cacefed4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a599d6b8-17c6-4fb9-8627-3717befa80ce" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b7f9e12-a04d-4b1c-9d13-db7cacefed4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_24ca16bb-b34d-47ae-a2a3-18f8bcb8b157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a599d6b8-17c6-4fb9-8627-3717befa80ce" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_24ca16bb-b34d-47ae-a2a3-18f8bcb8b157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_204debba-fdb5-4e56-8223-18571cfac458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a599d6b8-17c6-4fb9-8627-3717befa80ce" xlink:to="loc_us-gaap_CommonStockSharesIssued_204debba-fdb5-4e56-8223-18571cfac458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_69f5b183-e0d8-4742-814f-b5d1a96de58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a599d6b8-17c6-4fb9-8627-3717befa80ce" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_69f5b183-e0d8-4742-814f-b5d1a96de58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arwr-20221231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c056594f-ddb9-429b-829a-282d930c74f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c056594f-ddb9-429b-829a-282d930c74f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9ebd8f0e-3eb8-4691-afa2-de11691114d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9ebd8f0e-3eb8-4691-afa2-de11691114d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_16b762af-aa2f-4596-ace7-d9784e574d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9ebd8f0e-3eb8-4691-afa2-de11691114d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_16b762af-aa2f-4596-ace7-d9784e574d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9e1a1621-c5ea-4acb-9752-78fcfd0548eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9ebd8f0e-3eb8-4691-afa2-de11691114d4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9e1a1621-c5ea-4acb-9752-78fcfd0548eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a00cdc6d-55b9-4cde-94e9-13ec53e7478c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9ebd8f0e-3eb8-4691-afa2-de11691114d4" xlink:to="loc_us-gaap_OperatingExpenses_a00cdc6d-55b9-4cde-94e9-13ec53e7478c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_69d58859-3eb5-46ca-b2eb-a21a7b8a2dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_OperatingIncomeLoss_69d58859-3eb5-46ca-b2eb-a21a7b8a2dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e67140fc-430b-46d4-80a2-88fd43680ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e67140fc-430b-46d4-80a2-88fd43680ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_6b0d95ec-8ecc-4a95-b55f-be6f6fe8c9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e67140fc-430b-46d4-80a2-88fd43680ec8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_6b0d95ec-8ecc-4a95-b55f-be6f6fe8c9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_73937be1-f77a-46e6-95d1-171e54b131d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e67140fc-430b-46d4-80a2-88fd43680ec8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_73937be1-f77a-46e6-95d1-171e54b131d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9c919574-8787-4738-8a39-048e6bab6c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e67140fc-430b-46d4-80a2-88fd43680ec8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9c919574-8787-4738-8a39-048e6bab6c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9c34db0-97bd-4ab9-9d56-bd467fb2a465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9c34db0-97bd-4ab9-9d56-bd467fb2a465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9f3d3b95-bdfa-44dd-9207-db8f5be2838a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9f3d3b95-bdfa-44dd-9207-db8f5be2838a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2cb5fc47-fc9d-4fa1-8662-5490f04905ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_ProfitLoss_2cb5fc47-fc9d-4fa1-8662-5490f04905ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_97465d59-7d10-4e3a-b9f3-d65565c4d062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_97465d59-7d10-4e3a-b9f3-d65565c4d062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5893a788-3f41-4796-8bb1-3557925c88ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_NetIncomeLoss_5893a788-3f41-4796-8bb1-3557925c88ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_49cefac5-326d-4259-b040-ad809fba92aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_49cefac5-326d-4259-b040-ad809fba92aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3576f116-32c8-46e7-bd55-5c54912e35ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_49cefac5-326d-4259-b040-ad809fba92aa" xlink:to="loc_us-gaap_EarningsPerShareBasic_3576f116-32c8-46e7-bd55-5c54912e35ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dc1234c5-e8de-475b-8b76-8570891c2aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_49cefac5-326d-4259-b040-ad809fba92aa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dc1234c5-e8de-475b-8b76-8570891c2aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c39206d-8521-45db-88ae-90093ae9189a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c39206d-8521-45db-88ae-90093ae9189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_84f10e80-216b-4f53-965f-d4befc6174c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c39206d-8521-45db-88ae-90093ae9189a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_84f10e80-216b-4f53-965f-d4befc6174c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a2be611f-aedc-4e7d-8972-349199c4ba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6c39206d-8521-45db-88ae-90093ae9189a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a2be611f-aedc-4e7d-8972-349199c4ba1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_76379330-63ad-4ce2-b88e-6f09254464d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_76379330-63ad-4ce2-b88e-6f09254464d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d542b5f1-6e42-4d7e-ab64-7b8557ef8f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_76379330-63ad-4ce2-b88e-6f09254464d3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d542b5f1-6e42-4d7e-ab64-7b8557ef8f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f77068bf-c2ce-4b2e-9af7-56d73879b34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e9918f32-1623-4544-b133-1fac0b02c1f4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f77068bf-c2ce-4b2e-9af7-56d73879b34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_54168972-1cec-40f0-a0e7-266c40e5efb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_995313c4-844e-465b-b121-741cb12f65de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_54168972-1cec-40f0-a0e7-266c40e5efb7" xlink:to="loc_us-gaap_StatementTable_995313c4-844e-465b-b121-741cb12f65de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c8a82cc8-914b-4277-824c-b71ce48f5b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_995313c4-844e-465b-b121-741cb12f65de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c8a82cc8-914b-4277-824c-b71ce48f5b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8a82cc8-914b-4277-824c-b71ce48f5b45" xlink:to="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5dfbd82b-39cc-4489-a5df-8ba24546e760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_CommonStockMember_5dfbd82b-39cc-4489-a5df-8ba24546e760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dcacbb8e-33cb-4a8b-8cc9-1753d990621f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dcacbb8e-33cb-4a8b-8cc9-1753d990621f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f51513d9-558e-481d-a91b-58eb1176e5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f51513d9-558e-481d-a91b-58eb1176e5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7d5a7fbf-5516-408b-9bb9-9a217d0abecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_RetainedEarningsMember_7d5a7fbf-5516-408b-9bb9-9a217d0abecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_471c65d3-3e4f-4cb6-91d7-27e34b02a2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7578c943-d30d-42f3-9829-9abceb0257af" xlink:to="loc_us-gaap_NoncontrollingInterestMember_471c65d3-3e4f-4cb6-91d7-27e34b02a2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f1a3ac2d-6454-435e-be8e-28dafba432ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_995313c4-844e-465b-b121-741cb12f65de" xlink:to="loc_us-gaap_StatementLineItems_f1a3ac2d-6454-435e-be8e-28dafba432ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f1a3ac2d-6454-435e-be8e-28dafba432ed" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0285f28b-27af-4a87-9be1-200643a1f8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0285f28b-27af-4a87-9be1-200643a1f8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f69b3912-27f5-42ea-92eb-ac9aa0d01d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_SharesOutstanding_f69b3912-27f5-42ea-92eb-ac9aa0d01d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4943d0e2-0c74-480a-9525-70237af53120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4943d0e2-0c74-480a-9525-70237af53120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1706d83a-bca7-4a13-abcb-a38939f0311b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1706d83a-bca7-4a13-abcb-a38939f0311b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c1ca4e8a-96a9-4539-bed9-2839f2c4c91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c1ca4e8a-96a9-4539-bed9-2839f2c4c91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_9f057bd9-78dc-4d43-9652-221c64b41cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_9f057bd9-78dc-4d43-9652-221c64b41cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_212eb022-8a02-4de8-a596-46b3d7e3c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_212eb022-8a02-4de8-a596-46b3d7e3c0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_91c0b0ce-c9aa-4c2f-b207-7a40db7821f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_91c0b0ce-c9aa-4c2f-b207-7a40db7821f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_28c0ea1d-1aaa-43bb-b0e9-589b99f527ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_28c0ea1d-1aaa-43bb-b0e9-589b99f527ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a19a281b-3ddb-46bb-8d34-8f6b5387e203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_NetIncomeLoss_a19a281b-3ddb-46bb-8d34-8f6b5387e203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a937163-c033-4bb0-83cc-c15726362c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a937163-c033-4bb0-83cc-c15726362c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_971be393-d8cb-4b82-aec7-8f34a5cb3277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9078c3e-3604-4cd6-818e-5982c9e6626b" xlink:to="loc_us-gaap_SharesOutstanding_971be393-d8cb-4b82-aec7-8f34a5cb3277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b6da68bb-00ca-4112-a2cc-194147e1ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6da68bb-00ca-4112-a2cc-194147e1ca7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bdc2814f-898f-4d75-83cf-b5ebe05e3264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:to="loc_us-gaap_ProfitLoss_bdc2814f-898f-4d75-83cf-b5ebe05e3264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33c47604-19f4-4a17-9de6-211c9f884aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33c47604-19f4-4a17-9de6-211c9f884aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_eaf87bf0-6cc5-4215-bb29-7497b1b40ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:to="loc_us-gaap_ShareBasedCompensation_eaf87bf0-6cc5-4215-bb29-7497b1b40ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_0a5cb8d5-a52c-43cd-9395-de05d0dd81a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:to="loc_us-gaap_DepreciationAndAmortization_0a5cb8d5-a52c-43cd-9395-de05d0dd81a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_c005967b-2d7f-4d60-b320-90f346692916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_c005967b-2d7f-4d60-b320-90f346692916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_a7dfa906-ed8a-4ef0-800e-f5cdeb021d0a" xlink:href="arwr-20221231.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_a7dfa906-ed8a-4ef0-800e-f5cdeb021d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_786e378f-81f3-4f8f-b4a3-966500bcb0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_786e378f-81f3-4f8f-b4a3-966500bcb0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a5f02224-61ac-404a-b381-6ed9d553a102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_786e378f-81f3-4f8f-b4a3-966500bcb0ee" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a5f02224-61ac-404a-b381-6ed9d553a102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3c649a52-cdc1-4663-9e15-afcf16a27987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_786e378f-81f3-4f8f-b4a3-966500bcb0ee" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3c649a52-cdc1-4663-9e15-afcf16a27987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6de5ed31-0808-477e-90b7-8d8b05596084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_786e378f-81f3-4f8f-b4a3-966500bcb0ee" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6de5ed31-0808-477e-90b7-8d8b05596084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3d1aaabb-eb62-426f-ab29-3213aebe1283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_786e378f-81f3-4f8f-b4a3-966500bcb0ee" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3d1aaabb-eb62-426f-ab29-3213aebe1283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9f116f6d-4fe2-4426-b88a-3294fab6c0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_786e378f-81f3-4f8f-b4a3-966500bcb0ee" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9f116f6d-4fe2-4426-b88a-3294fab6c0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_db35b510-234c-4dd0-9ae8-b2b1cdd191cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_786e378f-81f3-4f8f-b4a3-966500bcb0ee" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_db35b510-234c-4dd0-9ae8-b2b1cdd191cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b9558715-7f2b-4954-ab94-64ae031054c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4fe3a9d-8b8d-4e8e-889e-b2e694f20bdb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b9558715-7f2b-4954-ab94-64ae031054c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61b97ecd-908d-4535-bf86-399b4e9a9238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6da68bb-00ca-4112-a2cc-194147e1ca7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61b97ecd-908d-4535-bf86-399b4e9a9238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2356ec63-5cb0-41ac-974e-2b71123ea120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61b97ecd-908d-4535-bf86-399b4e9a9238" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2356ec63-5cb0-41ac-974e-2b71123ea120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_ce602bb1-4ae1-4113-a70e-d57b8b006df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61b97ecd-908d-4535-bf86-399b4e9a9238" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_ce602bb1-4ae1-4113-a70e-d57b8b006df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_298c4a0f-3b35-4972-881b-1504b1eca9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61b97ecd-908d-4535-bf86-399b4e9a9238" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_298c4a0f-3b35-4972-881b-1504b1eca9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a6e5bc1f-0122-47c0-bef4-37cbf08eaaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61b97ecd-908d-4535-bf86-399b4e9a9238" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a6e5bc1f-0122-47c0-bef4-37cbf08eaaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a71f41a2-ac68-44d4-8a74-32c0ed07b7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6da68bb-00ca-4112-a2cc-194147e1ca7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a71f41a2-ac68-44d4-8a74-32c0ed07b7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b1ae1748-cd8a-4889-9691-f9db0286b07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a71f41a2-ac68-44d4-8a74-32c0ed07b7c5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b1ae1748-cd8a-4889-9691-f9db0286b07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_20e3276e-3c2d-46e9-8b73-dd33e522e3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a71f41a2-ac68-44d4-8a74-32c0ed07b7c5" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_20e3276e-3c2d-46e9-8b73-dd33e522e3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34cd7c42-d875-42eb-86f5-c6acc0dd0ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a71f41a2-ac68-44d4-8a74-32c0ed07b7c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34cd7c42-d875-42eb-86f5-c6acc0dd0ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ce8b5f7f-fe6d-4519-bcfd-4e00e6c3efe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6da68bb-00ca-4112-a2cc-194147e1ca7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ce8b5f7f-fe6d-4519-bcfd-4e00e6c3efe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a354ce2-55b4-4c4d-aa1b-4fca0a67a01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6da68bb-00ca-4112-a2cc-194147e1ca7b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a354ce2-55b4-4c4d-aa1b-4fca0a67a01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_f396c6b7-7bff-4130-9605-fc00bee90659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6da68bb-00ca-4112-a2cc-194147e1ca7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_f396c6b7-7bff-4130-9605-fc00bee90659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0c887312-0da3-4523-841a-0da38fbf5122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_f396c6b7-7bff-4130-9605-fc00bee90659" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0c887312-0da3-4523-841a-0da38fbf5122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_721034c0-3b24-4a45-b553-17ecf8ea1b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_f396c6b7-7bff-4130-9605-fc00bee90659" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_721034c0-3b24-4a45-b553-17ecf8ea1b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5a71e9bd-4ea7-4975-a0a2-811821bec7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6da68bb-00ca-4112-a2cc-194147e1ca7b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5a71e9bd-4ea7-4975-a0a2-811821bec7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4bef8c08-e3d6-426c-9cf4-820788a25f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5a71e9bd-4ea7-4975-a0a2-811821bec7aa" xlink:to="loc_us-gaap_InterestPaidNet_4bef8c08-e3d6-426c-9cf4-820788a25f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_f8ce02c8-c185-419b-890a-ff0977f8e0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5a71e9bd-4ea7-4975-a0a2-811821bec7aa" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_f8ce02c8-c185-419b-890a-ff0977f8e0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arwr-20221231.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9e3997ec-ddf4-416e-85c3-c6afebe1d683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_fe2668a4-244f-4370-a475-5ca261a3a753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e3997ec-ddf4-416e-85c3-c6afebe1d683" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_fe2668a4-244f-4370-a475-5ca261a3a753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05930a8d-7d4a-42ee-a061-8e50458984be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e09b4233-6a40-49ef-af82-634ccec9cd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05930a8d-7d4a-42ee-a061-8e50458984be" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e09b4233-6a40-49ef-af82-634ccec9cd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="arwr-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9581a2ba-1b7d-4cdb-b852-654ef7858a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7211422f-9738-4f84-b747-f579d418f846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9581a2ba-1b7d-4cdb-b852-654ef7858a4f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7211422f-9738-4f84-b747-f579d418f846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Investments" xlink:type="simple" xlink:href="arwr-20221231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b0ae4167-0107-4b0b-aa05-892a60172552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b29efc86-7568-4e50-b1f7-99ab562d9108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b0ae4167-0107-4b0b-aa05-892a60172552" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b29efc86-7568-4e50-b1f7-99ab562d9108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="simple" xlink:href="arwr-20221231.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a825f0f1-931e-412d-97a5-707a90025e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a7b0874c-f791-4e40-ad7b-0ffa5e5ed601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a825f0f1-931e-412d-97a5-707a90025e7d" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a7b0874c-f791-4e40-ad7b-0ffa5e5ed601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_88bc47f0-7567-4cf4-851b-1426d9832725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2baa46e2-f083-4870-a690-81c32db8eea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_88bc47f0-7567-4cf4-851b-1426d9832725" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2baa46e2-f083-4870-a690-81c32db8eea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arwr-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56fd2a16-0391-4d6c-b05a-f9f8fcc57589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b1cfb49a-a1d7-457e-a556-31f4058c493f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56fd2a16-0391-4d6c-b05a-f9f8fcc57589" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b1cfb49a-a1d7-457e-a556-31f4058c493f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Leases" xlink:type="simple" xlink:href="arwr-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1a112e37-817b-4d04-aebd-b969be4b8ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_3b9825c9-b2f3-459b-8984-f3515f4d2200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a112e37-817b-4d04-aebd-b969be4b8ba1" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_3b9825c9-b2f3-459b-8984-f3515f4d2200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9611349-c320-4979-94c6-0b210ea63759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e08344f3-7d0a-43c7-bf54-ff36f2b2404c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9611349-c320-4979-94c6-0b210ea63759" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e08344f3-7d0a-43c7-bf54-ff36f2b2404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arwr-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d8c2eae8-5fb4-4760-8bf3-e5742aef43fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0f49655c-f83e-4d6a-a615-10fbac76b354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8c2eae8-5fb4-4760-8bf3-e5742aef43fc" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0f49655c-f83e-4d6a-a615-10fbac76b354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="simple" xlink:href="arwr-20221231.xsd#LiabilityRelatedtotheSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_6196b0ef-8194-4cc5-9489-1dc10a5f7bd5" xlink:href="arwr-20221231.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_d1f1fcec-c245-445d-9b55-35c21956d06f" xlink:href="arwr-20221231.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_6196b0ef-8194-4cc5-9489-1dc10a5f7bd5" xlink:to="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_d1f1fcec-c245-445d-9b55-35c21956d06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arwr-20221231.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05164d17-4a1b-4449-a365-a18bc4611769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_06ccc7b5-b642-4756-8562-2f503830f72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05164d17-4a1b-4449-a365-a18bc4611769" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_06ccc7b5-b642-4756-8562-2f503830f72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arwr-20221231.xsd#OrganizationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ec3c9318-13a2-4eb3-878a-5524527855df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_c36c32c9-256e-4a69-a027-2ecf09f989f4" xlink:href="arwr-20221231.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec3c9318-13a2-4eb3-878a-5524527855df" xlink:to="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_c36c32c9-256e-4a69-a027-2ecf09f989f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="arwr-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_41313d08-92d5-45d0-ad7d-a4936b716fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c55cd91d-10be-4785-84ac-0f07b55da3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_41313d08-92d5-45d0-ad7d-a4936b716fa2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c55cd91d-10be-4785-84ac-0f07b55da3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="simple" xlink:href="arwr-20221231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1cd072e3-8e8c-4505-b3a4-3f8c0633679a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_b1797df5-a40f-432e-93bc-97c61b207b46" xlink:href="arwr-20221231.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1cd072e3-8e8c-4505-b3a4-3f8c0633679a" xlink:to="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_b1797df5-a40f-432e-93bc-97c61b207b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="arwr-20221231.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26a716a5-da7b-459f-a7ba-3b030d96a291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_64810427-756a-4603-a991-ddd881506c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26a716a5-da7b-459f-a7ba-3b030d96a291" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_64810427-756a-4603-a991-ddd881506c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_95e95509-62da-45ca-ad17-f16fc51438cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_26a716a5-da7b-459f-a7ba-3b030d96a291" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_95e95509-62da-45ca-ad17-f16fc51438cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f738f376-3bf3-48c8-a457-dcc41b2f779f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_6cdfcb23-5346-4439-b656-9e7738a475ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f738f376-3bf3-48c8-a457-dcc41b2f779f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_6cdfcb23-5346-4439-b656-9e7738a475ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_45ffd2d3-faad-4897-8ddc-4491c898a965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_80af9eda-006e-4224-8fbb-a46e33426407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45ffd2d3-faad-4897-8ddc-4491c898a965" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_80af9eda-006e-4224-8fbb-a46e33426407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_25addc1e-541a-4b5d-851b-02afbdd4efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45ffd2d3-faad-4897-8ddc-4491c898a965" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_25addc1e-541a-4b5d-851b-02afbdd4efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_889a6c65-495b-427f-a4b4-40861499aa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_0c3c3a59-745d-4303-9bdf-a53a1e8116b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_889a6c65-495b-427f-a4b4-40861499aa3d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_0c3c3a59-745d-4303-9bdf-a53a1e8116b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4126cbab-31c1-40ee-9094-0abf5dbdc1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_889a6c65-495b-427f-a4b4-40861499aa3d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4126cbab-31c1-40ee-9094-0abf5dbdc1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_298a6b29-b9c3-4cc0-99d4-841b7be73de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_889a6c65-495b-427f-a4b4-40861499aa3d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_298a6b29-b9c3-4cc0-99d4-841b7be73de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arwr-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fecb385d-b4c0-4590-82b6-1f38127f3b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_aed50d48-8a8e-41dc-81d3-d5acefab9389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fecb385d-b4c0-4590-82b6-1f38127f3b93" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_aed50d48-8a8e-41dc-81d3-d5acefab9389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20221231.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_684138b3-8007-4a17-9c1b-104a94332e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_1459cf45-b8f9-4738-af51-61102a795981" xlink:href="arwr-20221231.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_684138b3-8007-4a17-9c1b-104a94332e53" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_1459cf45-b8f9-4738-af51-61102a795981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2f86d485-1228-4616-9967-e2b548275d9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_1459cf45-b8f9-4738-af51-61102a795981" xlink:to="loc_dei_LegalEntityAxis_2f86d485-1228-4616-9967-e2b548275d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2f86d485-1228-4616-9967-e2b548275d9d" xlink:to="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_07dfd0c3-6e7e-49f0-80ab-2bc2d91adeaa" xlink:href="arwr-20221231.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_07dfd0c3-6e7e-49f0-80ab-2bc2d91adeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_4608a10b-012a-4098-ab84-03b16952fc8b" xlink:href="arwr-20221231.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:to="loc_arwr_AmgenIncorporatedMember_4608a10b-012a-4098-ab84-03b16952fc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaMember_14485d6d-065f-458e-94fb-64997f1b90ec" xlink:href="arwr-20221231.xsd#arwr_RoyaltyPharmaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a1c614a5-08f8-4b9f-885b-14a153724ff8" xlink:to="loc_arwr_RoyaltyPharmaMember_14485d6d-065f-458e-94fb-64997f1b90ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ce110395-4541-49a2-be70-d3444937edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_1459cf45-b8f9-4738-af51-61102a795981" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ce110395-4541-49a2-be70-d3444937edd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0369145a-3d95-4e05-8bc7-ab6f0829e910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ce110395-4541-49a2-be70-d3444937edd0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0369145a-3d95-4e05-8bc7-ab6f0829e910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_65994d3c-7c9c-4aa9-86f3-13c5241f1fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0369145a-3d95-4e05-8bc7-ab6f0829e910" xlink:to="loc_us-gaap_SubsequentEventMember_65994d3c-7c9c-4aa9-86f3-13c5241f1fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:href="arwr-20221231.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_1459cf45-b8f9-4738-af51-61102a795981" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_2254ca8f-f853-4c33-8d69-2944e10c223b" xlink:href="arwr-20221231.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_2254ca8f-f853-4c33-8d69-2944e10c223b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bea486da-4cbb-4ca3-9603-42149c28cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bea486da-4cbb-4ca3-9603-42149c28cf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4448e31f-98a8-4e70-ac44-20ad696cec56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4448e31f-98a8-4e70-ac44-20ad696cec56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_bcf264cb-e3a1-4b56-9228-7b8439d820ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_bcf264cb-e3a1-4b56-9228-7b8439d820ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_12cf2a15-cac0-4ab9-8759-9a324117bf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_12cf2a15-cac0-4ab9-8759-9a324117bf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_90eade8d-f20a-4bd3-99d1-c5671f89cad3" xlink:href="arwr-20221231.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_90eade8d-f20a-4bd3-99d1-c5671f89cad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_88599702-ce95-42cd-83ea-cb3ae3dd3475" xlink:href="arwr-20221231.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_9276ae5c-70e8-4b46-ab7e-441cadeff5bb" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_88599702-ce95-42cd-83ea-cb3ae3dd3475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_61e08ff3-954c-4db7-8fdd-b31df6038718" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_61e08ff3-954c-4db7-8fdd-b31df6038718" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_40058f8d-eab8-459d-9d86-e0e16c044037" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:to="loc_dei_LegalEntityAxis_40058f8d-eab8-459d-9d86-e0e16c044037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bf7bd17f-6658-4b18-8674-82e960b37a1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_40058f8d-eab8-459d-9d86-e0e16c044037" xlink:to="loc_dei_EntityDomain_bf7bd17f-6658-4b18-8674-82e960b37a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_15333418-90bd-4217-a78d-5ccc48bc0488" xlink:href="arwr-20221231.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bf7bd17f-6658-4b18-8674-82e960b37a1b" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_15333418-90bd-4217-a78d-5ccc48bc0488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_52e3f59f-204f-41bf-9e42-381d298f4129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:to="loc_us-gaap_TypeOfArrangementAxis_52e3f59f-204f-41bf-9e42-381d298f4129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30d5fec1-43fb-45b2-964e-e8f0c966daad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52e3f59f-204f-41bf-9e42-381d298f4129" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30d5fec1-43fb-45b2-964e-e8f0c966daad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_c53a4e68-70a8-4108-be7e-75bdd9eac9a9" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30d5fec1-43fb-45b2-964e-e8f0c966daad" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_c53a4e68-70a8-4108-be7e-75bdd9eac9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROHSDAgreementMember_ad9280c4-a0c8-4cdb-84a9-0afedbbe130d" xlink:href="arwr-20221231.xsd#arwr_AROHSDAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30d5fec1-43fb-45b2-964e-e8f0c966daad" xlink:to="loc_arwr_AROHSDAgreementMember_ad9280c4-a0c8-4cdb-84a9-0afedbbe130d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e32d45ce-91de-4e03-8341-556a9da02e31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:to="loc_srt_RangeAxis_e32d45ce-91de-4e03-8341-556a9da02e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_88f9d645-b0cd-4670-8956-dd7a96d09003" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e32d45ce-91de-4e03-8341-556a9da02e31" xlink:to="loc_srt_RangeMember_88f9d645-b0cd-4670-8956-dd7a96d09003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd2d5757-5ee2-4085-a079-086ba2fb3601" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_88f9d645-b0cd-4670-8956-dd7a96d09003" xlink:to="loc_srt_MaximumMember_cd2d5757-5ee2-4085-a079-086ba2fb3601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b212474-945c-48fd-b29f-f21f56bc3d65" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_f11e8960-9c00-4c47-b70f-470c1a9514fe" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_MilestonePaymentEarned_f11e8960-9c00-4c47-b70f-470c1a9514fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_4d920f1e-6079-47e6-98cd-90fcff4b378c" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_4d920f1e-6079-47e6-98cd-90fcff4b378c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_ced8ff38-4fe3-4e08-b1f8-38f398654146" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_ced8ff38-4fe3-4e08-b1f8-38f398654146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_71d06ad3-a2d3-42ed-8a24-97943bd10b9d" xlink:href="arwr-20221231.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_71d06ad3-a2d3-42ed-8a24-97943bd10b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_14b2aedc-becd-4831-9227-03f5de84b8db" xlink:href="arwr-20221231.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_SalesRelatedMilestonePayments_14b2aedc-becd-4831-9227-03f5de84b8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_15221bd9-dbff-43a3-9fbf-9d3562de7a69" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_arwr_InitialTransactionPrice_15221bd9-dbff-43a3-9fbf-9d3562de7a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c990abce-8c15-4c64-a56c-e651438bbc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c990abce-8c15-4c64-a56c-e651438bbc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_300b1dac-7275-4c25-9b81-95772dd2eeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_300b1dac-7275-4c25-9b81-95772dd2eeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_64e836fd-76f0-41eb-a262-bf9153b944c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa4ead7c-14ec-45d2-8dbb-a345ae83c1ed" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_64e836fd-76f0-41eb-a262-bf9153b944c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_a7c79720-3bcd-4a4f-9344-ea443a325efe" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_a7c79720-3bcd-4a4f-9344-ea443a325efe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e7552954-14f7-4c9a-8937-1e2f09ef6d35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:to="loc_dei_LegalEntityAxis_e7552954-14f7-4c9a-8937-1e2f09ef6d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_740b1346-74e1-451f-bcd4-c25ff82c5302" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e7552954-14f7-4c9a-8937-1e2f09ef6d35" xlink:to="loc_dei_EntityDomain_740b1346-74e1-451f-bcd4-c25ff82c5302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_9b53ab7e-5bc6-4794-8366-4f3bde5ca907" xlink:href="arwr-20221231.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_740b1346-74e1-451f-bcd4-c25ff82c5302" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_9b53ab7e-5bc6-4794-8366-4f3bde5ca907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d4421b7-bcfd-4e05-858f-c817f991ffe2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:to="loc_srt_RangeAxis_9d4421b7-bcfd-4e05-858f-c817f991ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc08bfb4-e40a-4c99-b763-0fffb9dae691" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9d4421b7-bcfd-4e05-858f-c817f991ffe2" xlink:to="loc_srt_RangeMember_cc08bfb4-e40a-4c99-b763-0fffb9dae691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e6308c13-cecd-41a4-8314-ecc6a09d2dfe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cc08bfb4-e40a-4c99-b763-0fffb9dae691" xlink:to="loc_srt_MaximumMember_e6308c13-cecd-41a4-8314-ecc6a09d2dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1d8ec676-96a8-4588-87e8-f24c46aea1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1d8ec676-96a8-4588-87e8-f24c46aea1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d1f0643-c2b0-44ae-8efa-62b3a89bff2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d8ec676-96a8-4588-87e8-f24c46aea1d2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d1f0643-c2b0-44ae-8efa-62b3a89bff2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember_cd20db71-2dc9-4854-a19e-c96215bf1a27" xlink:href="arwr-20221231.xsd#arwr_AROXDHAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d1f0643-c2b0-44ae-8efa-62b3a89bff2f" xlink:to="loc_arwr_AROXDHAgreementMember_cd20db71-2dc9-4854-a19e-c96215bf1a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_1d2e627a-e27b-46dd-9328-72b49ed9230a" xlink:href="arwr-20221231.xsd#arwr_LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d1f0643-c2b0-44ae-8efa-62b3a89bff2f" xlink:to="loc_arwr_LicenseAgreementMember_1d2e627a-e27b-46dd-9328-72b49ed9230a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_24cb11a5-19d4-4a62-a065-4cf5d94d4031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_24cb11a5-19d4-4a62-a065-4cf5d94d4031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ef12dae2-699d-4333-b46c-bf87a67921f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_24cb11a5-19d4-4a62-a065-4cf5d94d4031" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ef12dae2-699d-4333-b46c-bf87a67921f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_38e5d762-d6c1-4e77-ad21-6b3ffd6fbbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ef12dae2-699d-4333-b46c-bf87a67921f1" xlink:to="loc_us-gaap_SubsequentEventMember_38e5d762-d6c1-4e77-ad21-6b3ffd6fbbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d141c8cc-7f68-436a-8c57-b621404bcab6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e2497c6a-8bb5-43f4-a3e7-5aeec0c6814e" xlink:href="arwr-20221231.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_e2497c6a-8bb5-43f4-a3e7-5aeec0c6814e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_49d8bd13-6a9d-4116-afcf-740f94234f93" xlink:href="arwr-20221231.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_49d8bd13-6a9d-4116-afcf-740f94234f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_063de665-055b-41bf-bfe8-335311e3b354" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_NumberOfDistinctBundle_063de665-055b-41bf-bfe8-335311e3b354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_54080c39-d4e0-44ed-91ca-ded66c686233" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_54080c39-d4e0-44ed-91ca-ded66c686233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_8592b8d4-c5f9-4f57-992f-8d3d56203abc" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_InitialTransactionPrice_8592b8d4-c5f9-4f57-992f-8d3d56203abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_da88f8f6-14f1-45d0-b2ce-d768e8c32c3c" xlink:href="arwr-20221231.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_da88f8f6-14f1-45d0-b2ce-d768e8c32c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_18bd0209-d120-48a2-b479-6af82c7b2a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_18bd0209-d120-48a2-b479-6af82c7b2a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_97856a07-67ed-4046-9dd1-47d5876c5e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_97856a07-67ed-4046-9dd1-47d5876c5e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17ba4f2e-9458-4575-9ad3-288184574eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87920018-061b-49fd-a1fc-f5b6289049be" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17ba4f2e-9458-4575-9ad3-288184574eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65748192-1f40-4052-9356-420f9ff31875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65748192-1f40-4052-9356-420f9ff31875" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b17972fb-3784-44f8-824b-7ca58dd77b3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:to="loc_dei_LegalEntityAxis_b17972fb-3784-44f8-824b-7ca58dd77b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_01f7c8de-8391-4ab9-82e4-8548ee88a62f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b17972fb-3784-44f8-824b-7ca58dd77b3d" xlink:to="loc_dei_EntityDomain_01f7c8de-8391-4ab9-82e4-8548ee88a62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_6fdc34aa-1afa-4cda-a52d-5efd3c4157e4" xlink:href="arwr-20221231.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_01f7c8de-8391-4ab9-82e4-8548ee88a62f" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_6fdc34aa-1afa-4cda-a52d-5efd3c4157e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4266af1d-2c23-4f6b-b30c-aaef1d7636aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4266af1d-2c23-4f6b-b30c-aaef1d7636aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e89db1c9-4c96-4775-af66-e96b0c69b48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4266af1d-2c23-4f6b-b30c-aaef1d7636aa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e89db1c9-4c96-4775-af66-e96b0c69b48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_f700dc1a-10f9-443f-9d1c-0b0c17ba91a9" xlink:href="arwr-20221231.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e89db1c9-4c96-4775-af66-e96b0c69b48e" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_f700dc1a-10f9-443f-9d1c-0b0c17ba91a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c18bb1a3-da5a-4834-b18f-94fc58ed3112" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:to="loc_srt_RangeAxis_c18bb1a3-da5a-4834-b18f-94fc58ed3112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d6729f2-e5be-497a-8032-82d079703669" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c18bb1a3-da5a-4834-b18f-94fc58ed3112" xlink:to="loc_srt_RangeMember_1d6729f2-e5be-497a-8032-82d079703669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4bc3e4bc-85c6-49d4-b544-e25d37e442ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1d6729f2-e5be-497a-8032-82d079703669" xlink:to="loc_srt_MinimumMember_4bc3e4bc-85c6-49d4-b544-e25d37e442ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2b14ae32-03d4-469e-b9f4-23f45b1b5d17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1d6729f2-e5be-497a-8032-82d079703669" xlink:to="loc_srt_MaximumMember_2b14ae32-03d4-469e-b9f4-23f45b1b5d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b5e1fcca-aa0c-46eb-9497-13b0247e221f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b5e1fcca-aa0c-46eb-9497-13b0247e221f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc762a76-8e83-44a8-82c1-214dea14169b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b5e1fcca-aa0c-46eb-9497-13b0247e221f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc762a76-8e83-44a8-82c1-214dea14169b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember_c3e01dbb-ea9f-4a59-8af9-6068b933aadf" xlink:href="arwr-20221231.xsd#arwr_DeferredRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc762a76-8e83-44a8-82c1-214dea14169b" xlink:to="loc_arwr_DeferredRevenueMember_c3e01dbb-ea9f-4a59-8af9-6068b933aadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_0dacc3c8-fad2-49c3-9100-c6ebd47f0403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc762a76-8e83-44a8-82c1-214dea14169b" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_0dacc3c8-fad2-49c3-9100-c6ebd47f0403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_361dc23b-5077-448e-9706-d3377caa8ef0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_a3bf754d-882f-4c64-afbd-c1614b7e238f" xlink:href="arwr-20221231.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_a3bf754d-882f-4c64-afbd-c1614b7e238f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_57ea419a-6a03-4245-a47c-cb11f3b07134" xlink:href="arwr-20221231.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_57ea419a-6a03-4245-a47c-cb11f3b07134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d7b5e415-0f4f-42a9-b21e-f7da4c1c26dd" xlink:href="arwr-20221231.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d7b5e415-0f4f-42a9-b21e-f7da4c1c26dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_6b91e63f-79f4-43b7-b756-39feb940a78c" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_NumberOfDistinctBundle_6b91e63f-79f4-43b7-b756-39feb940a78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_d2db7573-7018-47f6-bd07-7f1840c9a572" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_d2db7573-7018-47f6-bd07-7f1840c9a572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_8d7e9aa2-7c61-431b-8e9c-44d3b6e31289" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_arwr_InitialTransactionPrice_8d7e9aa2-7c61-431b-8e9c-44d3b6e31289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_574f9b99-49a4-4ac5-bc35-5686aa97e861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_574f9b99-49a4-4ac5-bc35-5686aa97e861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d6a4a958-40c8-48ef-b667-4e83369ed28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_d6a4a958-40c8-48ef-b667-4e83369ed28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a1d64936-11c2-42fb-b176-93ab3347cbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a1d64936-11c2-42fb-b176-93ab3347cbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f7cd174-13b4-4835-9b51-90702397983e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3557a791-c752-4df0-99bf-1131c6c69e9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f7cd174-13b4-4835-9b51-90702397983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f7b2e315-df78-4e05-bfbb-6680b4ccea4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f7b2e315-df78-4e05-bfbb-6680b4ccea4b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e3a4be97-3f80-4657-ae21-a0df2ee4fd05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:to="loc_dei_LegalEntityAxis_e3a4be97-3f80-4657-ae21-a0df2ee4fd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_008606d6-753c-4cea-b044-141932f6bda9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e3a4be97-3f80-4657-ae21-a0df2ee4fd05" xlink:to="loc_dei_EntityDomain_008606d6-753c-4cea-b044-141932f6bda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_2a32b24f-502e-4a0f-8a03-454b7006df62" xlink:href="arwr-20221231.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_008606d6-753c-4cea-b044-141932f6bda9" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_2a32b24f-502e-4a0f-8a03-454b7006df62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_36184082-e4dd-4abc-95e5-02b32e64e7b1" xlink:href="arwr-20221231.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_008606d6-753c-4cea-b044-141932f6bda9" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_36184082-e4dd-4abc-95e5-02b32e64e7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1062b803-f1c8-44e6-ab91-6db3b5c8868f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1062b803-f1c8-44e6-ab91-6db3b5c8868f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8b0691c-3433-49c8-89f2-48e634dad88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1062b803-f1c8-44e6-ab91-6db3b5c8868f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8b0691c-3433-49c8-89f2-48e634dad88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_46a70e89-b599-4234-a837-92e866db0fbe" xlink:href="arwr-20221231.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c8b0691c-3433-49c8-89f2-48e634dad88e" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_46a70e89-b599-4234-a837-92e866db0fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_39433a62-2701-468d-b1c4-cf5a41228448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_39433a62-2701-468d-b1c4-cf5a41228448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_39433a62-2701-468d-b1c4-cf5a41228448" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_460dd629-fab2-4723-bea8-7b54dc2f26f4" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_460dd629-fab2-4723-bea8-7b54dc2f26f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_7c655e8e-5de4-4201-bf33-cbfa5ae216ac" xlink:href="arwr-20221231.xsd#arwr_LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_LicenseAgreementMember_7c655e8e-5de4-4201-bf33-cbfa5ae216ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAgreementMember_09088fcb-822f-402a-998a-b0f04fc315e2" xlink:href="arwr-20221231.xsd#arwr_CollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_CollaborationAgreementMember_09088fcb-822f-402a-998a-b0f04fc315e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_6db6dd6c-7aca-4fad-a18f-989bd71d9a30" xlink:href="arwr-20221231.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_6db6dd6c-7aca-4fad-a18f-989bd71d9a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member_b7bbde18-d67e-4d9e-81dc-1798c809b9da" xlink:href="arwr-20221231.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3120c25e-618b-4d8a-9b0c-13f71ef6b296" xlink:to="loc_arwr_JNJ75220795AROJNJ1Member_b7bbde18-d67e-4d9e-81dc-1798c809b9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_72974c70-77bc-4511-8005-db9b9741fb83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:to="loc_srt_RangeAxis_72974c70-77bc-4511-8005-db9b9741fb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc9cc4f2-7bbd-47db-9587-c39905ded5b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_72974c70-77bc-4511-8005-db9b9741fb83" xlink:to="loc_srt_RangeMember_fc9cc4f2-7bbd-47db-9587-c39905ded5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_01320536-515e-4991-b1ab-c94c33908afb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc9cc4f2-7bbd-47db-9587-c39905ded5b5" xlink:to="loc_srt_MaximumMember_01320536-515e-4991-b1ab-c94c33908afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_310d5d06-7b8f-4b32-8a10-db54accbf22a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_7f51caf5-af56-4aec-900b-a1a878edc993" xlink:href="arwr-20221231.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_7f51caf5-af56-4aec-900b-a1a878edc993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bf2ed409-8a55-4d86-b2fc-96860a5bb459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bf2ed409-8a55-4d86-b2fc-96860a5bb459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_43444472-65a3-4fb5-9f55-fb2e89c4e523" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_MilestonePaymentEarned_43444472-65a3-4fb5-9f55-fb2e89c4e523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_82ee74a8-a82f-405b-9783-068ada0d47cf" xlink:href="arwr-20221231.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_82ee74a8-a82f-405b-9783-068ada0d47cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_6ab11d1a-5698-45fc-94e1-62256362c43e" xlink:href="arwr-20221231.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_6ab11d1a-5698-45fc-94e1-62256362c43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_4b7af80d-dce6-428b-81cc-f7da7b37498f" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_arwr_InitialTransactionPrice_4b7af80d-dce6-428b-81cc-f7da7b37498f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f39d9943-a167-4392-b898-249c6b23afed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f39d9943-a167-4392-b898-249c6b23afed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_817b0bf9-0e43-4517-9a98-4f6eb600ce7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_817b0bf9-0e43-4517-9a98-4f6eb600ce7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63627bfa-a3e0-4ec4-9c85-84c643f9f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7139247c-13cc-42f2-88ee-032d429c67e2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_63627bfa-a3e0-4ec4-9c85-84c643f9f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d19e119-456e-46bb-8c17-0610228ef172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d19e119-456e-46bb-8c17-0610228ef172" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_392cbf0e-44b9-4eca-b8ec-d37dadd0191a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:to="loc_dei_LegalEntityAxis_392cbf0e-44b9-4eca-b8ec-d37dadd0191a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bae49b5e-f9b6-4b46-b173-72959ca242d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_392cbf0e-44b9-4eca-b8ec-d37dadd0191a" xlink:to="loc_dei_EntityDomain_bae49b5e-f9b6-4b46-b173-72959ca242d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_f031ff77-90c5-4284-ae57-020e76a8b778" xlink:href="arwr-20221231.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bae49b5e-f9b6-4b46-b173-72959ca242d0" xlink:to="loc_arwr_AmgenIncorporatedMember_f031ff77-90c5-4284-ae57-020e76a8b778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_02abdba5-a03a-4219-bc55-5f7a66ae627e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_02abdba5-a03a-4219-bc55-5f7a66ae627e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_02abdba5-a03a-4219-bc55-5f7a66ae627e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_d3d4d348-82f2-44bd-97f1-242a8497ffb0" xlink:href="arwr-20221231.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_d3d4d348-82f2-44bd-97f1-242a8497ffb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_0defde3c-30d1-45f3-8b1d-d4cba6fc65ff" xlink:href="arwr-20221231.xsd#arwr_OlpasiranAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:to="loc_arwr_OlpasiranAgreementMember_0defde3c-30d1-45f3-8b1d-d4cba6fc65ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember_09a47744-ef4c-4a57-9664-c533f157ced8" xlink:href="arwr-20221231.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d0a08f9-35c6-418b-b5d6-92ff2c276e66" xlink:to="loc_arwr_OlpasiranAndAROAMG1AgreementMember_09a47744-ef4c-4a57-9664-c533f157ced8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_27e140ec-650f-4631-a0a8-4db95fa96b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_27e140ec-650f-4631-a0a8-4db95fa96b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d1a6bca3-6cc4-4c7d-abdd-5ae82d682d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27e140ec-650f-4631-a0a8-4db95fa96b2f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d1a6bca3-6cc4-4c7d-abdd-5ae82d682d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8fb27ced-c2d6-44a8-9fd3-cd934cc7da3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d1a6bca3-6cc4-4c7d-abdd-5ae82d682d8c" xlink:to="loc_us-gaap_SubsequentEventMember_8fb27ced-c2d6-44a8-9fd3-cd934cc7da3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18f523c4-82be-41c8-b3ec-a34cd83d3129" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:to="loc_srt_RangeAxis_18f523c4-82be-41c8-b3ec-a34cd83d3129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45c1be0d-ff41-4485-b1b8-6eaf08b84a41" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_18f523c4-82be-41c8-b3ec-a34cd83d3129" xlink:to="loc_srt_RangeMember_45c1be0d-ff41-4485-b1b8-6eaf08b84a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8c68e772-e42f-4b76-94e3-e8cd08c06bd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45c1be0d-ff41-4485-b1b8-6eaf08b84a41" xlink:to="loc_srt_MaximumMember_8c68e772-e42f-4b76-94e3-e8cd08c06bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d6986bf-3f51-48fc-bf68-01469d4a322e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_a8f0c7fb-5148-4712-9094-0cf8382a3a90" xlink:href="arwr-20221231.xsd#arwr_NumberOfAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_NumberOfAgreements_a8f0c7fb-5148-4712-9094-0cf8382a3a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_5ff36ec9-62e5-453c-9fe7-8ceef6845f92" xlink:href="arwr-20221231.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_5ff36ec9-62e5-453c-9fe7-8ceef6845f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_534a9ed7-1cf2-4d0d-a99a-1facfcdf7c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_534a9ed7-1cf2-4d0d-a99a-1facfcdf7c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_d226d92f-a992-49b8-b108-d43e02a7e836" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_MilestonePaymentReceived_d226d92f-a992-49b8-b108-d43e02a7e836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_f9c6de22-668d-4cb1-833d-20dcb85bf166" xlink:href="arwr-20221231.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_f9c6de22-668d-4cb1-833d-20dcb85bf166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dd935d5-f14d-44df-8219-dd558f9df80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dd935d5-f14d-44df-8219-dd558f9df80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_81d32683-ef9a-48e8-8726-6e2125d9c47d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_81d32683-ef9a-48e8-8726-6e2125d9c47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_40b5bfbf-baf8-4adc-9345-bfd74adfab45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_40b5bfbf-baf8-4adc-9345-bfd74adfab45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_90fc1ec4-e2bb-4c54-9db4-e5dbdf1a0041" xlink:href="arwr-20221231.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_080a228f-5dca-4cb3-88bf-a9600c33a9a4" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_90fc1ec4-e2bb-4c54-9db4-e5dbdf1a0041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0114e3cc-a0d8-425f-a63c-15c3a00d4950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0114e3cc-a0d8-425f-a63c-15c3a00d4950" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9baa6ce-508c-4d8c-86b1-5951e78394f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:to="loc_dei_LegalEntityAxis_d9baa6ce-508c-4d8c-86b1-5951e78394f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_443a904f-72e0-438c-ab01-c939939af5cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d9baa6ce-508c-4d8c-86b1-5951e78394f8" xlink:to="loc_dei_EntityDomain_443a904f-72e0-438c-ab01-c939939af5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_f23cf6e6-03e6-4453-84bd-89abdd01a7c5" xlink:href="arwr-20221231.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_443a904f-72e0-438c-ab01-c939939af5cf" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_f23cf6e6-03e6-4453-84bd-89abdd01a7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c2eb2f88-31bd-4e4b-aed1-23d3be448999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c2eb2f88-31bd-4e4b-aed1-23d3be448999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a913edb-3fae-42f4-b809-4a721e27e229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c2eb2f88-31bd-4e4b-aed1-23d3be448999" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a913edb-3fae-42f4-b809-4a721e27e229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaLicenseAgreementMember_0c3e46eb-0125-4259-a90e-08ff18234012" xlink:href="arwr-20221231.xsd#arwr_VisirnaLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a913edb-3fae-42f4-b809-4a721e27e229" xlink:to="loc_arwr_VisirnaLicenseAgreementMember_0c3e46eb-0125-4259-a90e-08ff18234012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_48c0ce91-79ed-4954-a1c3-79d687955f1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_48c0ce91-79ed-4954-a1c3-79d687955f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_978caea4-63fa-4106-ad18-333a6c74e4e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_48c0ce91-79ed-4954-a1c3-79d687955f1f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_978caea4-63fa-4106-ad18-333a6c74e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_a19200d1-ee24-44d7-814a-ea32b27de6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_978caea4-63fa-4106-ad18-333a6c74e4e2" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_a19200d1-ee24-44d7-814a-ea32b27de6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00ac648b-ef85-4b67-a9cb-dc098763e63c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_eee7af1f-bfbf-41f8-9a9d-9dbefb97f28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_eee7af1f-bfbf-41f8-9a9d-9dbefb97f28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1bd75d24-fc76-4dbb-bd16-d77b04c27257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1bd75d24-fc76-4dbb-bd16-d77b04c27257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c238b50e-1613-499d-9156-56da4d4f9ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c238b50e-1613-499d-9156-56da4d4f9ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3d9ac619-1a87-4c30-b307-716cf2981ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00d1104f-ec8c-44c3-9ae6-d3141915f3f5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3d9ac619-1a87-4c30-b307-716cf2981ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="arwr-20221231.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75b3d815-20c7-4d4f-a0fc-6751dc30dac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_25d45494-a147-4f90-bddf-6be5c72fb713" xlink:href="arwr-20221231.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75b3d815-20c7-4d4f-a0fc-6751dc30dac3" xlink:to="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_25d45494-a147-4f90-bddf-6be5c72fb713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_d968ae26-27cc-4823-a8cb-7e37ff78fe16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75b3d815-20c7-4d4f-a0fc-6751dc30dac3" xlink:to="loc_us-gaap_Land_d968ae26-27cc-4823-a8cb-7e37ff78fe16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_2953bad9-a662-4d45-8ff9-8bb488dc2299" xlink:href="arwr-20221231.xsd#arwr_ResearchEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75b3d815-20c7-4d4f-a0fc-6751dc30dac3" xlink:to="loc_arwr_ResearchEquipmentGross_2953bad9-a662-4d45-8ff9-8bb488dc2299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_075fec9f-48f5-4af7-9ee2-cd9e4d55014f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75b3d815-20c7-4d4f-a0fc-6751dc30dac3" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_075fec9f-48f5-4af7-9ee2-cd9e4d55014f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_33de8fd2-dd89-49fa-8a59-a2df64b423be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75b3d815-20c7-4d4f-a0fc-6751dc30dac3" xlink:to="loc_us-gaap_ConstructionInProgressGross_33de8fd2-dd89-49fa-8a59-a2df64b423be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_08888bed-f9a9-45c1-9699-305abd6d9767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75b3d815-20c7-4d4f-a0fc-6751dc30dac3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_08888bed-f9a9-45c1-9699-305abd6d9767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cc3d102a-8698-4361-aa2e-fa61b9c3d0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75b3d815-20c7-4d4f-a0fc-6751dc30dac3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cc3d102a-8698-4361-aa2e-fa61b9c3d0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fa00a4e8-67bd-4b0e-8309-ca94298ca848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75b3d815-20c7-4d4f-a0fc-6751dc30dac3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fa00a4e8-67bd-4b0e-8309-ca94298ca848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20221231.xsd#PropertyandEquipmentAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2713a858-ff1c-48c4-93bf-d33a8e76462d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a37255e6-8a16-4f81-83e3-043302718f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2713a858-ff1c-48c4-93bf-d33a8e76462d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a37255e6-8a16-4f81-83e3-043302718f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9a76c3b-a84a-456f-9ad6-19bf5b88e57a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_773b9b51-0acb-44b4-a893-5b6650066f6c" xlink:href="arwr-20221231.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9a76c3b-a84a-456f-9ad6-19bf5b88e57a" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_773b9b51-0acb-44b4-a893-5b6650066f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1830c72f-7201-491d-9509-f227082d327f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_773b9b51-0acb-44b4-a893-5b6650066f6c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1830c72f-7201-491d-9509-f227082d327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4304499d-3f77-4025-86bc-1226259fc2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1830c72f-7201-491d-9509-f227082d327f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4304499d-3f77-4025-86bc-1226259fc2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_1a21f6f1-573c-4b57-bab3-20dbdf5a4b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4304499d-3f77-4025-86bc-1226259fc2fd" xlink:to="loc_us-gaap_DebtSecuritiesMember_1a21f6f1-573c-4b57-bab3-20dbdf5a4b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_96d7f510-4de1-4835-9b10-5adf6b23e4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4304499d-3f77-4025-86bc-1226259fc2fd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_96d7f510-4de1-4835-9b10-5adf6b23e4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:href="arwr-20221231.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_773b9b51-0acb-44b4-a893-5b6650066f6c" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9560933b-94d6-4ed2-878c-20b88522ce81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_9560933b-94d6-4ed2-878c-20b88522ce81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_7f1fc414-59ec-4fd2-8d82-fe28efae3ced" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_7f1fc414-59ec-4fd2-8d82-fe28efae3ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_ce0bddfe-22ba-4833-8349-c7e4ce2083e0" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_ce0bddfe-22ba-4833-8349-c7e4ce2083e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_ce383285-5dd5-4c55-9702-0180c6e33163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_ce383285-5dd5-4c55-9702-0180c6e33163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e51fb3c2-f9a4-449e-9ac2-f0946ef0f206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e51fb3c2-f9a4-449e-9ac2-f0946ef0f206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_c9cbabd2-2ae0-452c-aff1-471ad36648db" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_c9cbabd2-2ae0-452c-aff1-471ad36648db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_e659fd13-bc93-4993-a91d-373cfcebf3a2" xlink:href="arwr-20221231.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_e659fd13-bc93-4993-a91d-373cfcebf3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_68803959-56b7-47c1-b6ad-754931aaa460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a76d9319-788c-4627-b5ae-b6ce494ecd8b" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_68803959-56b7-47c1-b6ad-754931aaa460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c34441f3-e28d-4ed3-b8c1-a9d0e29d42a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51391f0d-ba99-4d2b-9faf-5ffc2bcc38b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c34441f3-e28d-4ed3-b8c1-a9d0e29d42a2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51391f0d-ba99-4d2b-9faf-5ffc2bcc38b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1dec924e-92a4-42dc-965a-a5e186fdcc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51391f0d-ba99-4d2b-9faf-5ffc2bcc38b7" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1dec924e-92a4-42dc-965a-a5e186fdcc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b9e026ec-e950-49e6-a99f-853fd13d92af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1dec924e-92a4-42dc-965a-a5e186fdcc70" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b9e026ec-e950-49e6-a99f-853fd13d92af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_3cee8ee6-d203-40bf-9f2e-3e3a981adfe9" xlink:href="arwr-20221231.xsd#arwr_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b9e026ec-e950-49e6-a99f-853fd13d92af" xlink:to="loc_arwr_NovartisMember_3cee8ee6-d203-40bf-9f2e-3e3a981adfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0ae3ed2a-39d3-41ea-93ba-58380e126271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51391f0d-ba99-4d2b-9faf-5ffc2bcc38b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0ae3ed2a-39d3-41ea-93ba-58380e126271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb5e3f7-e3a2-441d-bc3b-173c3a1d9118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0ae3ed2a-39d3-41ea-93ba-58380e126271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb5e3f7-e3a2-441d-bc3b-173c3a1d9118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_d5e154d9-a33a-475f-a70f-571137c926fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb5e3f7-e3a2-441d-bc3b-173c3a1d9118" xlink:to="loc_us-gaap_PatentsMember_d5e154d9-a33a-475f-a70f-571137c926fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_2e85c980-7b5a-4b4a-ba86-e8c98ef0f0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb5e3f7-e3a2-441d-bc3b-173c3a1d9118" xlink:to="loc_us-gaap_LicensingAgreementsMember_2e85c980-7b5a-4b4a-ba86-e8c98ef0f0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51391f0d-ba99-4d2b-9faf-5ffc2bcc38b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ff9f5d77-e6b4-49d9-83ab-eef36297c437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ff9f5d77-e6b4-49d9-83ab-eef36297c437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bd5315ed-348f-473a-b3d9-7e73827a989a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bd5315ed-348f-473a-b3d9-7e73827a989a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_9c688fb4-3317-45ef-b26c-a0f4ba998686" xlink:href="arwr-20221231.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_9c688fb4-3317-45ef-b26c-a0f4ba998686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d989e9d8-244a-453d-ba1c-7147b4b8988c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d989e9d8-244a-453d-ba1c-7147b4b8988c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_705f06ab-d135-49a4-98e0-68c18fd91c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e268ae25-c3f8-48d0-8bed-f52f7804aadf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_705f06ab-d135-49a4-98e0-68c18fd91c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_22e2ad89-7040-4861-916b-541e60a4cd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c34441f3-e28d-4ed3-b8c1-a9d0e29d42a2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_22e2ad89-7040-4861-916b-541e60a4cd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c06b3c89-4235-441c-a566-927b319eb41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c2992762-9c53-4000-a12b-4d80fceb6443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c06b3c89-4235-441c-a566-927b319eb41e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c2992762-9c53-4000-a12b-4d80fceb6443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9922920e-a3ac-44f3-b674-de4a9d46b4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c06b3c89-4235-441c-a566-927b319eb41e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9922920e-a3ac-44f3-b674-de4a9d46b4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bd2dbae6-acb7-4e39-9c96-5f88e166d43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c06b3c89-4235-441c-a566-927b319eb41e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bd2dbae6-acb7-4e39-9c96-5f88e166d43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c225c92d-b6ca-4240-aba8-7fd1ae936a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c06b3c89-4235-441c-a566-927b319eb41e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c225c92d-b6ca-4240-aba8-7fd1ae936a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_97a42718-7ff1-450e-bc41-482791d1b7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c06b3c89-4235-441c-a566-927b319eb41e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_97a42718-7ff1-450e-bc41-482791d1b7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_6ac96bcd-9add-4c88-b2b5-2d12297c52db" xlink:href="arwr-20221231.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c06b3c89-4235-441c-a566-927b319eb41e" xlink:to="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_6ac96bcd-9add-4c88-b2b5-2d12297c52db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_65da98ea-305e-430e-8cc0-bbed64294cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c06b3c89-4235-441c-a566-927b319eb41e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_65da98ea-305e-430e-8cc0-bbed64294cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e8ad75df-329a-46f7-80cc-309ef90f8a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e8ad75df-329a-46f7-80cc-309ef90f8a1d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_da1ec343-e4fe-4db5-9451-f38e7208d393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:to="loc_us-gaap_PlanNameAxis_da1ec343-e4fe-4db5-9451-f38e7208d393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_010f7cb8-c88e-4b6b-a8ee-abebe8315b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_da1ec343-e4fe-4db5-9451-f38e7208d393" xlink:to="loc_us-gaap_PlanNameDomain_010f7cb8-c88e-4b6b-a8ee-abebe8315b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_df6cbf1b-533d-41ed-93ac-812db8af050c" xlink:href="arwr-20221231.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_010f7cb8-c88e-4b6b-a8ee-abebe8315b90" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_df6cbf1b-533d-41ed-93ac-812db8af050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5d92b3d6-0da3-4f82-9e47-cd8c2a39cfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5d92b3d6-0da3-4f82-9e47-cd8c2a39cfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2ce9097-9412-4a55-aa7a-5a34e176ef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5d92b3d6-0da3-4f82-9e47-cd8c2a39cfcc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2ce9097-9412-4a55-aa7a-5a34e176ef4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_1a15f1f5-bd62-4a72-809d-bb518ca7bca7" xlink:href="arwr-20221231.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2ce9097-9412-4a55-aa7a-5a34e176ef4a" xlink:to="loc_arwr_AtTheMarketAgreementMember_1a15f1f5-bd62-4a72-809d-bb518ca7bca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_005919f1-4205-444b-bd19-c8fbeee990ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:to="loc_srt_RangeAxis_005919f1-4205-444b-bd19-c8fbeee990ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0019acaf-ed90-4612-80f9-a47ccdf5af21" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_005919f1-4205-444b-bd19-c8fbeee990ee" xlink:to="loc_srt_RangeMember_0019acaf-ed90-4612-80f9-a47ccdf5af21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_630d6e83-580b-405b-9591-dd89cf8b47e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0019acaf-ed90-4612-80f9-a47ccdf5af21" xlink:to="loc_srt_MaximumMember_630d6e83-580b-405b-9591-dd89cf8b47e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a459e6-85b5-4958-b518-8485a5b8cddf" xlink:to="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c185a10-d3be-401c-9272-be2955a4c32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c185a10-d3be-401c-9272-be2955a4c32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8ac85bee-1a08-4303-8436-484a209e70a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8ac85bee-1a08-4303-8436-484a209e70a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4c8908ed-015d-46e6-8f91-60a2acff9fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_CommonStockSharesIssued_4c8908ed-015d-46e6-8f91-60a2acff9fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_29ebd519-0a97-443b-9623-e749fbdd3fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_29ebd519-0a97-443b-9623-e749fbdd3fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e5ef2ec-43dc-4b6e-9274-0aa914e734d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e5ef2ec-43dc-4b6e-9274-0aa914e734d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3ec3ffc1-e4f0-46df-8de1-362867c0f74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3ec3ffc1-e4f0-46df-8de1-362867c0f74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1fc47c4b-24db-44b3-9e8b-00374ff6f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1fc47c4b-24db-44b3-9e8b-00374ff6f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8c75ced0-41e8-45f4-a0da-64cb111c03ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8c75ced0-41e8-45f4-a0da-64cb111c03ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a0214e9f-4efc-4b72-8f0a-353e14d74f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a0214e9f-4efc-4b72-8f0a-353e14d74f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_d2b63280-850d-42fc-8481-af3fc878f048" xlink:href="arwr-20221231.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_d2b63280-850d-42fc-8481-af3fc878f048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_4f882865-100c-4152-9eed-901d4fccf3ce" xlink:href="arwr-20221231.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_4f882865-100c-4152-9eed-901d4fccf3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8735540b-d67e-42b4-87ac-41b7a7826e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_48834fa2-4a23-4cf8-bca3-eee2f8382add" xlink:to="loc_us-gaap_SharesIssued_8735540b-d67e-42b4-87ac-41b7a7826e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="arwr-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_13b5bb30-e4e2-4e5a-95b8-ee6fd41b94a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_13b5bb30-e4e2-4e5a-95b8-ee6fd41b94a7" xlink:to="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17293c10-215d-4358-bdf5-c9b2916a85d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17293c10-215d-4358-bdf5-c9b2916a85d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17293c10-215d-4358-bdf5-c9b2916a85d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_c21432c8-c2e6-4af7-8754-c26c8cc1ace5" xlink:href="arwr-20221231.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:to="loc_arwr_VeronaTechnologyParkMember_c21432c8-c2e6-4af7-8754-c26c8cc1ace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_b4acb15f-8125-43d4-a837-50300ffb2fd6" xlink:href="arwr-20221231.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:to="loc_arwr_DrugManufacturingFacilityMember_b4acb15f-8125-43d4-a837-50300ffb2fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_cb2e917a-6b85-447b-9b57-fcfe14f982b8" xlink:href="arwr-20221231.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_cb2e917a-6b85-447b-9b57-fcfe14f982b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_b7d13f35-82c2-451d-859b-c4737b6b66d5" xlink:href="arwr-20221231.xsd#arwr_FacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ce7c62a-9d1c-480e-b52d-601fa29b7b50" xlink:to="loc_arwr_FacilitiesMember_b7d13f35-82c2-451d-859b-c4737b6b66d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_777b57b8-952c-40d4-9308-2d5b1cc5932b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:to="loc_srt_StatementGeographicalAxis_777b57b8-952c-40d4-9308-2d5b1cc5932b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_09a3203d-824f-4804-9770-337ceedd06fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_777b57b8-952c-40d4-9308-2d5b1cc5932b" xlink:to="loc_srt_SegmentGeographicalDomain_09a3203d-824f-4804-9770-337ceedd06fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_4615a21d-d3ff-4629-a85c-0a5b4bb1853c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_09a3203d-824f-4804-9770-337ceedd06fb" xlink:to="loc_stpr_WI_4615a21d-d3ff-4629-a85c-0a5b4bb1853c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1667830c-89b7-41e1-b67a-9d4bafe8b833" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:to="loc_srt_RangeAxis_1667830c-89b7-41e1-b67a-9d4bafe8b833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39b6401a-b3f8-42e7-b02e-c1565f229669" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1667830c-89b7-41e1-b67a-9d4bafe8b833" xlink:to="loc_srt_RangeMember_39b6401a-b3f8-42e7-b02e-c1565f229669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3e91061-0538-4af8-9be4-997e06e243d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39b6401a-b3f8-42e7-b02e-c1565f229669" xlink:to="loc_srt_MinimumMember_b3e91061-0538-4af8-9be4-997e06e243d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cd31ca81-af54-415e-a49a-33c17cab2065" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39b6401a-b3f8-42e7-b02e-c1565f229669" xlink:to="loc_srt_MaximumMember_cd31ca81-af54-415e-a49a-33c17cab2065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_a4ba7d5a-b163-4801-9f04-545737e17b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:to="loc_us-gaap_OtherCommitmentsAxis_a4ba7d5a-b163-4801-9f04-545737e17b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_cd23b400-a451-49f0-bc36-36187f457eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_a4ba7d5a-b163-4801-9f04-545737e17b35" xlink:to="loc_us-gaap_OtherCommitmentsDomain_cd23b400-a451-49f0-bc36-36187f457eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_f1ff59a9-745e-45cc-b5cc-b390f2e6fb16" xlink:href="arwr-20221231.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_cd23b400-a451-49f0-bc36-36187f457eef" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_f1ff59a9-745e-45cc-b5cc-b390f2e6fb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_c1e46294-0eb2-467c-a6b0-eb0f4021d152" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f531321d-0ddc-45ea-9bad-79672f0025a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f531321d-0ddc-45ea-9bad-79672f0025a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_ad55ac01-d362-4b21-a41c-875491a31400" xlink:href="arwr-20221231.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_ad55ac01-d362-4b21-a41c-875491a31400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_67baf91d-154c-4093-9b29-ab2f9c379ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_us-gaap_AreaOfLand_67baf91d-154c-4093-9b29-ab2f9c379ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_e6b41d42-22ca-4691-888c-ddf96a1fd918" xlink:href="arwr-20221231.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_e6b41d42-22ca-4691-888c-ddf96a1fd918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_9dfedf3a-54e0-4836-bc37-7009c51f5f07" xlink:href="arwr-20221231.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_arwr_TaxIncrementFinancingAward_9dfedf3a-54e0-4836-bc37-7009c51f5f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_4635e053-b52b-4f65-9fd3-299dbecf4a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_4635e053-b52b-4f65-9fd3-299dbecf4a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_aea0bd8c-8ee8-46dd-8c2d-fb56da4899d3" xlink:href="arwr-20221231.xsd#arwr_MilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92b2bc7-8946-44c8-a356-2d1e12ad01ad" xlink:to="loc_arwr_MilestonePayments_aea0bd8c-8ee8-46dd-8c2d-fb56da4899d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_eaa38146-54ae-4e86-94e5-ff044b5ef1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eaa38146-54ae-4e86-94e5-ff044b5ef1c4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_701bf35d-24f0-4059-8118-093adb09a6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_701bf35d-24f0-4059-8118-093adb09a6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_701bf35d-24f0-4059-8118-093adb09a6a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_874d9e66-9795-4c6f-86b2-b809395054aa" xlink:href="arwr-20221231.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_874d9e66-9795-4c6f-86b2-b809395054aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_e04b5258-b6c2-4e6a-aa30-a0083836f9e4" xlink:href="arwr-20221231.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_e04b5258-b6c2-4e6a-aa30-a0083836f9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_38b05c97-9bd3-43be-bfd8-1c2dd69421c3" xlink:href="arwr-20221231.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5954ec2-4297-4317-bfd1-54d697fa68e8" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_38b05c97-9bd3-43be-bfd8-1c2dd69421c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_710fd3fe-b6de-4d3a-9cbe-616a0aff0b05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:to="loc_srt_StatementGeographicalAxis_710fd3fe-b6de-4d3a-9cbe-616a0aff0b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_566eeb0d-6a9d-4d8c-a014-3fbc218b3bf7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_710fd3fe-b6de-4d3a-9cbe-616a0aff0b05" xlink:to="loc_srt_SegmentGeographicalDomain_566eeb0d-6a9d-4d8c-a014-3fbc218b3bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_bda69dbd-8650-4b54-a669-4fb8062743c5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_566eeb0d-6a9d-4d8c-a014-3fbc218b3bf7" xlink:to="loc_stpr_CA_bda69dbd-8650-4b54-a669-4fb8062743c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_b4138f90-db4c-42a3-8332-69105aed508c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_566eeb0d-6a9d-4d8c-a014-3fbc218b3bf7" xlink:to="loc_stpr_WI_b4138f90-db4c-42a3-8332-69105aed508c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3bf3ec0c-ba0c-48fe-b467-5c35415b76a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:to="loc_srt_RangeAxis_3bf3ec0c-ba0c-48fe-b467-5c35415b76a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57bb6eff-6e1e-4152-a5b5-dd8a73d68ed1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3bf3ec0c-ba0c-48fe-b467-5c35415b76a5" xlink:to="loc_srt_RangeMember_57bb6eff-6e1e-4152-a5b5-dd8a73d68ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa81379c-fb9e-4459-8ff9-f9523babee87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57bb6eff-6e1e-4152-a5b5-dd8a73d68ed1" xlink:to="loc_srt_MaximumMember_fa81379c-fb9e-4459-8ff9-f9523babee87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_420d908f-0fcf-4415-9d24-88f83e0ee569" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:to="loc_srt_CounterpartyNameAxis_420d908f-0fcf-4415-9d24-88f83e0ee569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bfbc53ed-0efb-4547-b818-b7af29f6db97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_420d908f-0fcf-4415-9d24-88f83e0ee569" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bfbc53ed-0efb-4547-b818-b7af29f6db97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_db6369aa-2893-41b2-9ae0-82ebb8d8351a" xlink:href="arwr-20221231.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bfbc53ed-0efb-4547-b818-b7af29f6db97" xlink:to="loc_arwr_ColoradoOwnerLLCMember_db6369aa-2893-41b2-9ae0-82ebb8d8351a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SorrentoValleyOwnerDELLCMember_fead2f44-22e7-4398-97e5-979b7d604cc6" xlink:href="arwr-20221231.xsd#arwr_SorrentoValleyOwnerDELLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bfbc53ed-0efb-4547-b818-b7af29f6db97" xlink:to="loc_arwr_SorrentoValleyOwnerDELLCMember_fead2f44-22e7-4398-97e5-979b7d604cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6fc9e738-eb22-40ec-b1ea-5f5596ddc374" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d7c9b255-4008-45c4-9ac1-bb31fe907185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d7c9b255-4008-45c4-9ac1-bb31fe907185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_57821ad7-7690-4539-b677-0d4c02756246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_57821ad7-7690-4539-b677-0d4c02756246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_761c9278-4b9f-4bb7-a43b-53e076ad636d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_761c9278-4b9f-4bb7-a43b-53e076ad636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_8209a422-e9f3-4f48-9260-abc5d18d3bf6" xlink:href="arwr-20221231.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_8209a422-e9f3-4f48-9260-abc5d18d3bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_0191fdc9-ab23-42b8-990f-2545819dc452" xlink:href="arwr-20221231.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_0191fdc9-ab23-42b8-990f-2545819dc452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_2f08c103-b423-43fd-9351-a666b92c5870" xlink:href="arwr-20221231.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_arwr_NumberOfOptionsToRenew_2f08c103-b423-43fd-9351-a666b92c5870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e7403dda-bb08-4380-91db-c6f221f2490d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e7403dda-bb08-4380-91db-c6f221f2490d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_4c0be09b-9a33-426a-932f-74f4b7ddc5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ed3bc4f-e261-451f-a6e5-d78ae106249e" xlink:to="loc_us-gaap_ShortTermLeaseCost_4c0be09b-9a33-426a-932f-74f4b7ddc5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e853ddf1-5faf-40ae-ac72-52a43f8eb387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cd5a4f78-3016-450a-8a47-c165f8fceec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e853ddf1-5faf-40ae-ac72-52a43f8eb387" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cd5a4f78-3016-450a-8a47-c165f8fceec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_661350b8-320e-4098-a85b-2619eae9feb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cd5a4f78-3016-450a-8a47-c165f8fceec5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_661350b8-320e-4098-a85b-2619eae9feb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2e26c998-a6dd-49a7-934c-0079082de7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_661350b8-320e-4098-a85b-2619eae9feb4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2e26c998-a6dd-49a7-934c-0079082de7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c718b8d1-8737-4d2a-867e-11621ec5d515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2e26c998-a6dd-49a7-934c-0079082de7f7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c718b8d1-8737-4d2a-867e-11621ec5d515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d2555366-33f8-47ad-ad37-be7765ef9058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2e26c998-a6dd-49a7-934c-0079082de7f7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d2555366-33f8-47ad-ad37-be7765ef9058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_028d2636-7ca1-43ec-b03b-d21352cbf11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cd5a4f78-3016-450a-8a47-c165f8fceec5" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_028d2636-7ca1-43ec-b03b-d21352cbf11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_028d2636-7ca1-43ec-b03b-d21352cbf11c" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c78bff5f-cd1c-4057-a187-9a89b24d0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c78bff5f-cd1c-4057-a187-9a89b24d0ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_270e7845-649f-44ff-b6db-90c6eab386b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_270e7845-649f-44ff-b6db-90c6eab386b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f308d256-19e0-4abd-a34a-b138e0839f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9bb8e9fc-b780-4c5c-8321-100f69be96de" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f308d256-19e0-4abd-a34a-b138e0839f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_028d2636-7ca1-43ec-b03b-d21352cbf11c" xlink:to="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_944d790d-4cc0-4f9d-80c9-78a5a2462337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:to="loc_us-gaap_OperatingLeaseCost_944d790d-4cc0-4f9d-80c9-78a5a2462337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_079ead99-66ba-4834-afac-c9af36ec49ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:to="loc_us-gaap_VariableLeaseCost_079ead99-66ba-4834-afac-c9af36ec49ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_2b24eb26-0d1f-41ef-b60d-929ee529321e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5c99eed5-0762-4afe-a646-0baf30f53d06" xlink:to="loc_us-gaap_LeaseCost_2b24eb26-0d1f-41ef-b60d-929ee529321e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_004ec0d9-a4c3-4947-93a7-f7a4efca0e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_004ec0d9-a4c3-4947-93a7-f7a4efca0e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8327d1eb-1f57-42a9-baa9-6b6f09742131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8327d1eb-1f57-42a9-baa9-6b6f09742131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8d7bfada-c581-4686-900e-9472d964972d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8d7bfada-c581-4686-900e-9472d964972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_af0c56c7-5ca0-47d8-a294-fdadfb1a55e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_af0c56c7-5ca0-47d8-a294-fdadfb1a55e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fb657acc-bc45-4537-a63a-6a1e147ecc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fb657acc-bc45-4537-a63a-6a1e147ecc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_cd7e01e7-031b-4871-923a-37df6402ce5f" xlink:href="arwr-20221231.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_cd7e01e7-031b-4871-923a-37df6402ce5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d202a42e-9ecf-4c30-be76-2d35cb541d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d202a42e-9ecf-4c30-be76-2d35cb541d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_39b6acca-a30d-4da1-bc23-1d3579b05eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_39b6acca-a30d-4da1-bc23-1d3579b05eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1a979f0d-d621-48bf-87c0-afda33d8b953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ffccd76-8fe3-4628-9bb7-4d1ce4ca494c" xlink:to="loc_us-gaap_OperatingLeaseLiability_1a979f0d-d621-48bf-87c0-afda33d8b953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b09b1252-666a-4743-942f-913d146ef6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_cd555ae2-8b62-4eb1-8eb6-1e524f889240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b09b1252-666a-4743-942f-913d146ef6c8" xlink:to="loc_us-gaap_OperatingLeasePayments_cd555ae2-8b62-4eb1-8eb6-1e524f889240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f81f9d3b-39b4-4a07-b243-ae63a9c117f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b09b1252-666a-4743-942f-913d146ef6c8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f81f9d3b-39b4-4a07-b243-ae63a9c117f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6504a556-a8a4-4395-9ad1-7dc1702d58e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b09b1252-666a-4743-942f-913d146ef6c8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6504a556-a8a4-4395-9ad1-7dc1702d58e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ddb25f94-28d5-48b8-bfdf-10acbafdd47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7037b87-7557-44fb-8b34-ef3ca2abf3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ddb25f94-28d5-48b8-bfdf-10acbafdd47b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7037b87-7557-44fb-8b34-ef3ca2abf3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e83d0372-bda7-45e3-8524-97fcf23c0b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7037b87-7557-44fb-8b34-ef3ca2abf3e8" xlink:to="loc_us-gaap_PlanNameAxis_e83d0372-bda7-45e3-8524-97fcf23c0b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e83d0372-bda7-45e3-8524-97fcf23c0b96" xlink:to="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_ef076717-ccd9-46f3-bdf3-b1bc23b97a67" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_ef076717-ccd9-46f3-bdf3-b1bc23b97a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_27741930-d8b0-4485-a6f5-45bb84f63a23" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_27741930-d8b0-4485-a6f5-45bb84f63a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_ec076df2-15e6-4202-b738-c7e53b311c89" xlink:href="arwr-20221231.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_ec076df2-15e6-4202-b738-c7e53b311c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_517a5ce1-1843-4dd1-a98f-e83b6d04486b" xlink:href="arwr-20221231.xsd#arwr_InducementAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_74e36f7d-a6b5-455a-bdb9-73f605ec5df5" xlink:to="loc_arwr_InducementAwardsMember_517a5ce1-1843-4dd1-a98f-e83b6d04486b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_de9d60af-a310-4537-9d0a-a98cb1dfd7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7037b87-7557-44fb-8b34-ef3ca2abf3e8" xlink:to="loc_us-gaap_AwardTypeAxis_de9d60af-a310-4537-9d0a-a98cb1dfd7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a0787b3-18f3-46ae-b7e5-74b16cd85979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_de9d60af-a310-4537-9d0a-a98cb1dfd7d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a0787b3-18f3-46ae-b7e5-74b16cd85979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_23da6c10-99cb-4fc6-bf32-417a8011def3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a0787b3-18f3-46ae-b7e5-74b16cd85979" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_23da6c10-99cb-4fc6-bf32-417a8011def3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_befad587-ce9f-4b8b-bafe-8acbfe3647d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a0787b3-18f3-46ae-b7e5-74b16cd85979" xlink:to="loc_us-gaap_EmployeeStockOptionMember_befad587-ce9f-4b8b-bafe-8acbfe3647d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7037b87-7557-44fb-8b34-ef3ca2abf3e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a1f9d496-813e-4310-bc48-9abac09dae1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a1f9d496-813e-4310-bc48-9abac09dae1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4be322b8-bd5a-48a7-968a-6fde2e862ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4be322b8-bd5a-48a7-968a-6fde2e862ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_32a04abc-e57a-43cc-918d-7f1287d908dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_32a04abc-e57a-43cc-918d-7f1287d908dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c769784b-f117-4961-bb86-5d9c421ea4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c769784b-f117-4961-bb86-5d9c421ea4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_39bdd114-ebf4-468f-a5f5-d97648b9d59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_39bdd114-ebf4-468f-a5f5-d97648b9d59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1c2e828e-653d-49fd-9165-7052298b9164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1c2e828e-653d-49fd-9165-7052298b9164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f54af613-9019-4cb1-a422-f11133577840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f54af613-9019-4cb1-a422-f11133577840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5863d584-33ba-4015-ab75-443671d1c74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5863d584-33ba-4015-ab75-443671d1c74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5644ebde-7999-414f-b4ed-8b22fea11f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c91d266e-38f0-43cc-97f8-a732307792be" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5644ebde-7999-414f-b4ed-8b22fea11f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10815a1a-e42e-46de-8292-b2393204d642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6daee082-304b-408b-86b2-3b0778ebfbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10815a1a-e42e-46de-8292-b2393204d642" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6daee082-304b-408b-86b2-3b0778ebfbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8c710ba-9536-4032-aa90-9b4120752bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6daee082-304b-408b-86b2-3b0778ebfbc2" xlink:to="loc_us-gaap_AwardTypeAxis_b8c710ba-9536-4032-aa90-9b4120752bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6393d984-0703-4c70-b6f8-158983aceeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b8c710ba-9536-4032-aa90-9b4120752bd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6393d984-0703-4c70-b6f8-158983aceeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_191ab5d0-b492-49b8-bc27-d65610605c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6393d984-0703-4c70-b6f8-158983aceeaf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_191ab5d0-b492-49b8-bc27-d65610605c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6c4e818f-5a16-4b00-beb2-c0af708a53b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6daee082-304b-408b-86b2-3b0778ebfbc2" xlink:to="loc_us-gaap_PlanNameAxis_6c4e818f-5a16-4b00-beb2-c0af708a53b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6c4e818f-5a16-4b00-beb2-c0af708a53b7" xlink:to="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_3a3a86bc-d6ac-4e9f-b850-5ecfc06ec40e" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_3a3a86bc-d6ac-4e9f-b850-5ecfc06ec40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_8d8fd1cd-7dd5-4929-9337-4c07d5b25d55" xlink:href="arwr-20221231.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_8d8fd1cd-7dd5-4929-9337-4c07d5b25d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_bbc3e2f3-35ae-4df7-880c-35e8aedea958" xlink:href="arwr-20221231.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_bbc3e2f3-35ae-4df7-880c-35e8aedea958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_08188417-073e-4469-8d91-eaed3b4d5535" xlink:href="arwr-20221231.xsd#arwr_InducementAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_735bd8e6-d12d-4fe6-a91b-ef7b8c146fc8" xlink:to="loc_arwr_InducementAwardsMember_08188417-073e-4469-8d91-eaed3b4d5535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6daee082-304b-408b-86b2-3b0778ebfbc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5491e490-f798-44ae-b800-4eecbae2a6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5491e490-f798-44ae-b800-4eecbae2a6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_159c442a-febe-4f5e-be70-499f76a7e1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_159c442a-febe-4f5e-be70-499f76a7e1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_badc54ce-54e6-4036-aa77-2b4b7f99eeb5" xlink:href="arwr-20221231.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1a1da7bd-5f1a-4ed2-96a8-942182b525b3" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_badc54ce-54e6-4036-aa77-2b4b7f99eeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fbac64d-18ec-4a5b-a1d0-0b22fb78e37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24ea8fe2-a033-4493-80da-59cc2c8a9a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fbac64d-18ec-4a5b-a1d0-0b22fb78e37a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24ea8fe2-a033-4493-80da-59cc2c8a9a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75069f3e-9ccd-4fcd-b3d3-b6dd5e2f6622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24ea8fe2-a033-4493-80da-59cc2c8a9a83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75069f3e-9ccd-4fcd-b3d3-b6dd5e2f6622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5838c589-14c6-4954-8f1e-290a56909192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24ea8fe2-a033-4493-80da-59cc2c8a9a83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5838c589-14c6-4954-8f1e-290a56909192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7393ec7f-7554-4768-9d83-c5e7051fd10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24ea8fe2-a033-4493-80da-59cc2c8a9a83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7393ec7f-7554-4768-9d83-c5e7051fd10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a829b4c-e5e8-46d8-8a69-a8271f1c62df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24ea8fe2-a033-4493-80da-59cc2c8a9a83" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a829b4c-e5e8-46d8-8a69-a8271f1c62df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6f07e2df-8ed3-458c-869e-6cf8debfed37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_24ea8fe2-a033-4493-80da-59cc2c8a9a83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6f07e2df-8ed3-458c-869e-6cf8debfed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d5974c56-309e-41a7-848c-fd6e37f8e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fbac64d-18ec-4a5b-a1d0-0b22fb78e37a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d5974c56-309e-41a7-848c-fd6e37f8e11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5582eba1-96b5-4838-ad8a-b787de289c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fbac64d-18ec-4a5b-a1d0-0b22fb78e37a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5582eba1-96b5-4838-ad8a-b787de289c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ddd0b25b-3148-4e6f-a9d8-01863ec26e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5582eba1-96b5-4838-ad8a-b787de289c5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ddd0b25b-3148-4e6f-a9d8-01863ec26e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5fd42ffc-f35a-4a31-95a1-f49dc0da3b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5582eba1-96b5-4838-ad8a-b787de289c5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5fd42ffc-f35a-4a31-95a1-f49dc0da3b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_58b2fad7-9582-4dc1-b66f-4c1daf76d3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5582eba1-96b5-4838-ad8a-b787de289c5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_58b2fad7-9582-4dc1-b66f-4c1daf76d3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b1cc3e70-4414-429f-9f8e-ca0946cde915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5582eba1-96b5-4838-ad8a-b787de289c5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b1cc3e70-4414-429f-9f8e-ca0946cde915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_74bb4bc6-2144-4556-bf2f-e0082bc48694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5582eba1-96b5-4838-ad8a-b787de289c5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_74bb4bc6-2144-4556-bf2f-e0082bc48694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_49e91f5a-a53a-4a2e-a0e1-ccec3cb0a60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fbac64d-18ec-4a5b-a1d0-0b22fb78e37a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_49e91f5a-a53a-4a2e-a0e1-ccec3cb0a60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e5cbdea9-7660-44f6-b4be-551f72dfed2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fbac64d-18ec-4a5b-a1d0-0b22fb78e37a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e5cbdea9-7660-44f6-b4be-551f72dfed2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7cd83ece-0d6f-4beb-a499-7346f9593e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fbac64d-18ec-4a5b-a1d0-0b22fb78e37a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7cd83ece-0d6f-4beb-a499-7346f9593e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a82b3273-6654-46c9-b682-4c5513cfb40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fbac64d-18ec-4a5b-a1d0-0b22fb78e37a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a82b3273-6654-46c9-b682-4c5513cfb40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8da6ddf2-290f-4246-8a89-97876c6d927e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5fbac64d-18ec-4a5b-a1d0-0b22fb78e37a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8da6ddf2-290f-4246-8a89-97876c6d927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b001b22-d4da-4462-b792-96823da0d5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b447795f-7479-4ee3-b323-5f7afc402a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b001b22-d4da-4462-b792-96823da0d5cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b447795f-7479-4ee3-b323-5f7afc402a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_306db0fb-8465-4f9a-8103-5205e9facfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b447795f-7479-4ee3-b323-5f7afc402a07" xlink:to="loc_us-gaap_AwardTypeAxis_306db0fb-8465-4f9a-8103-5205e9facfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd20b6f-2ec4-4bf7-a043-d2041efc44c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_306db0fb-8465-4f9a-8103-5205e9facfc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd20b6f-2ec4-4bf7-a043-d2041efc44c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_873baf07-2ffe-47a6-bd81-2cce56e0ab55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd20b6f-2ec4-4bf7-a043-d2041efc44c1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_873baf07-2ffe-47a6-bd81-2cce56e0ab55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abdfe87b-241f-4b93-ae22-e4de60838f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b447795f-7479-4ee3-b323-5f7afc402a07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abdfe87b-241f-4b93-ae22-e4de60838f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abdfe87b-241f-4b93-ae22-e4de60838f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_01486936-0349-480e-a864-9723aea7e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_01486936-0349-480e-a864-9723aea7e4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6c6ac121-1eea-40d2-a2d4-406a5892d5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6c6ac121-1eea-40d2-a2d4-406a5892d5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_66a7a362-e5e1-4f9a-9c9d-6b7992e6903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_66a7a362-e5e1-4f9a-9c9d-6b7992e6903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b803a10f-8623-4608-9375-43e18a328b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b803a10f-8623-4608-9375-43e18a328b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0ea0af85-bb4e-448d-b42f-907f83240136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f345eeba-aa12-4e99-81ad-4aa35cb658f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0ea0af85-bb4e-448d-b42f-907f83240136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_abdfe87b-241f-4b93-ae22-e4de60838f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad681786-f722-4428-a68e-fbffc9449d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad681786-f722-4428-a68e-fbffc9449d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ec29b20-9b70-41ed-8ba5-79ebf3faa7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ec29b20-9b70-41ed-8ba5-79ebf3faa7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_384b64a3-1f0a-430b-b0bd-8e8bf9a40103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_384b64a3-1f0a-430b-b0bd-8e8bf9a40103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_092d4e6d-ea23-4577-a7ff-6bfec79dbe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_092d4e6d-ea23-4577-a7ff-6bfec79dbe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e1c1c4ab-23c3-449b-a5a7-3c3d93ad442f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4d505c43-a79c-4b97-a05d-5e68aac9367c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e1c1c4ab-23c3-449b-a5a7-3c3d93ad442f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cf448c04-20a6-4dc3-b6cc-b9403af17809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cf448c04-20a6-4dc3-b6cc-b9403af17809" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66213113-aced-4ab9-8938-2bcc51d191b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66213113-aced-4ab9-8938-2bcc51d191b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c221634-b1d9-4753-9830-9b2e9000e302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66213113-aced-4ab9-8938-2bcc51d191b9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c221634-b1d9-4753-9830-9b2e9000e302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3f70ab68-156a-4256-a93f-a0191410b549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0c221634-b1d9-4753-9830-9b2e9000e302" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3f70ab68-156a-4256-a93f-a0191410b549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6167625-63f0-46cd-bf2f-77227a7e5b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6167625-63f0-46cd-bf2f-77227a7e5b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6167625-63f0-46cd-bf2f-77227a7e5b66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_94cb24a7-85d8-4551-946a-cba58bb1795e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_94cb24a7-85d8-4551-946a-cba58bb1795e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_82bf9f50-6747-486d-a128-153d591f065d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_82bf9f50-6747-486d-a128-153d591f065d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d8bb5ff5-01db-4de4-a3c5-b78914165bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9d0309-4e6e-446c-85e7-a648ce16b292" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d8bb5ff5-01db-4de4-a3c5-b78914165bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3faab942-2283-4ded-9ca7-92016f61ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3faab942-2283-4ded-9ca7-92016f61ab59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3faab942-2283-4ded-9ca7-92016f61ab59" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_06c0e7d0-4467-465b-961b-8da45c95f161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_06c0e7d0-4467-465b-961b-8da45c95f161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_4a821ba1-e07c-4d79-b7c4-ece7de4fb304" xlink:href="arwr-20221231.xsd#arwr_CommercialNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:to="loc_arwr_CommercialNotesMember_4a821ba1-e07c-4d79-b7c4-ece7de4fb304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0a925492-fe3c-401a-8b3b-396f8ff89649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0a925492-fe3c-401a-8b3b-396f8ff89649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_906b062d-eb7a-46fe-a699-f2d31bfef29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9286be07-ab0b-4e81-b6b8-399891f60aed" xlink:to="loc_us-gaap_CertificatesOfDepositMember_906b062d-eb7a-46fe-a699-f2d31bfef29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_d103d6b9-480c-4964-913d-ba2f7804a44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_d103d6b9-480c-4964-913d-ba2f7804a44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cba5be3b-b6c1-43e9-a301-be3209af74f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_d103d6b9-480c-4964-913d-ba2f7804a44a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cba5be3b-b6c1-43e9-a301-be3209af74f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_164aa7bd-38ba-4527-83fa-568196deec1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cba5be3b-b6c1-43e9-a301-be3209af74f5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_164aa7bd-38ba-4527-83fa-568196deec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_372d47dc-995c-4f42-afbb-8e413459dd83" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_80a8edbc-e146-4a10-b215-44f6141a76a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_80a8edbc-e146-4a10-b215-44f6141a76a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b78f3e4-e06c-4dd5-883d-e44d4d65c251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b78f3e4-e06c-4dd5-883d-e44d4d65c251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d7b229c-9b41-4981-ac93-ca3221cecd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b459c2e8-5c9f-44c6-a129-306b6d250c5b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d7b229c-9b41-4981-ac93-ca3221cecd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="arwr-20221231.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_c418e238-453b-4305-9ebc-af52b007e34d" xlink:href="arwr-20221231.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e0a1238-f5f4-4f62-ba20-e6db055959a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_c418e238-453b-4305-9ebc-af52b007e34d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e0a1238-f5f4-4f62-ba20-e6db055959a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_73db81c6-d7c6-4a6c-9446-352ae6d3ed57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e0a1238-f5f4-4f62-ba20-e6db055959a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_73db81c6-d7c6-4a6c-9446-352ae6d3ed57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14d55469-d03b-42ed-8a69-44c6e6a0e3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_73db81c6-d7c6-4a6c-9446-352ae6d3ed57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14d55469-d03b-42ed-8a69-44c6e6a0e3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_39e66341-6bd4-4a4b-9729-742cee6aca8b" xlink:href="arwr-20221231.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14d55469-d03b-42ed-8a69-44c6e6a0e3b7" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_39e66341-6bd4-4a4b-9729-742cee6aca8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ab74c3b-cd33-4577-a647-8d82c9385c4d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e0a1238-f5f4-4f62-ba20-e6db055959a5" xlink:to="loc_srt_RangeAxis_3ab74c3b-cd33-4577-a647-8d82c9385c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_787498e1-892b-426e-ab7d-20912c23cb71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3ab74c3b-cd33-4577-a647-8d82c9385c4d" xlink:to="loc_srt_RangeMember_787498e1-892b-426e-ab7d-20912c23cb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e2a02adc-771e-489f-bd7f-19d864f28929" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_787498e1-892b-426e-ab7d-20912c23cb71" xlink:to="loc_srt_MaximumMember_e2a02adc-771e-489f-bd7f-19d864f28929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e0a1238-f5f4-4f62-ba20-e6db055959a5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_2dd7a1e7-14d9-49eb-b596-5b1ee5075d3f" xlink:href="arwr-20221231.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_InitialTransactionPrice_2dd7a1e7-14d9-49eb-b596-5b1ee5075d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_5f2c2855-86cc-41ed-895b-de2f66aed6d2" xlink:href="arwr-20221231.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_5f2c2855-86cc-41ed-895b-de2f66aed6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_e0203af5-c7ae-40f1-a215-669adb232851" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_MilestonePaymentReceivable_e0203af5-c7ae-40f1-a215-669adb232851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_7a73edfa-e15e-433e-ab85-4839bb4a3cf7" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_7a73edfa-e15e-433e-ab85-4839bb4a3cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_af0da58c-e720-40f5-b2af-260380e06477" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_af0da58c-e720-40f5-b2af-260380e06477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_10e1d940-da29-4722-af3c-8e08aef3152a" xlink:href="arwr-20221231.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_10e1d940-da29-4722-af3c-8e08aef3152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_0dcda15c-0e0a-44a6-a827-3fb1aa2ad5ea" xlink:href="arwr-20221231.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_RoyaltyPaymentThreshold_0dcda15c-0e0a-44a6-a827-3fb1aa2ad5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyalties_88779d43-2301-4f6e-a16a-3dfa660b4fb8" xlink:href="arwr-20221231.xsd#arwr_LiabilitySaleOfFutureRoyalties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyalties_88779d43-2301-4f6e-a16a-3dfa660b4fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_39622f9d-a448-4a99-a200-573b25f9f374" xlink:href="arwr-20221231.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b71e1e2c-db5c-403a-921d-3d39d242c6bd" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_39622f9d-a448-4a99-a200-573b25f9f374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620829744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,310,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621189504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 202,249<span></span>
</td>
<td class="nump">$ 108,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">39,568<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="nump">299,582<span></span>
</td>
<td class="nump">268,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">8,412<span></span>
</td>
<td class="nump">7,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">25,188<span></span>
</td>
<td class="nump">20,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">574,999<span></span>
</td>
<td class="nump">405,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">147,314<span></span>
</td>
<td class="nump">110,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">11,537<span></span>
</td>
<td class="nump">11,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">115,774<span></span>
</td>
<td class="nump">105,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">41,655<span></span>
</td>
<td class="nump">58,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">891,489<span></span>
</td>
<td class="nump">691,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">2,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">48,174<span></span>
</td>
<td class="nump">46,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">4,094<span></span>
</td>
<td class="nump">12,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,664<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">66,281<span></span>
</td>
<td class="nump">74,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">122,009<span></span>
</td>
<td class="nump">138,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">79,470<span></span>
</td>
<td class="nump">78,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">40,789<span></span>
</td>
<td class="nump">55,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">252,849<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">373,108<span></span>
</td>
<td class="nump">134,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Noncontrolling interest and stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 106,140 and 105,960 shares</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,239,178<span></span>
</td>
<td class="nump">1,219,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(258)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(862,080)<span></span>
</td>
<td class="num">(820,755)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">377,039<span></span>
</td>
<td class="nump">398,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">19,333<span></span>
</td>
<td class="nump">19,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total noncontrolling interest and stockholders&#8217; equity</a></td>
<td class="nump">396,372<span></span>
</td>
<td class="nump">418,339<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 891,489<span></span>
</td>
<td class="nump">$ 691,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltiesLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltiesLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621178400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">106,140,000<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">106,140,000<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620645952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 62,546<span></span>
</td>
<td class="nump">$ 27,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">83,695<span></span>
</td>
<td class="nump">65,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,985<span></span>
</td>
<td class="nump">24,995<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">104,680<span></span>
</td>
<td class="nump">90,760<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(42,134)<span></span>
</td>
<td class="num">(63,321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income, net</a></td>
<td class="num">(167)<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">507<span></span>
</td>
<td class="num">(707)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense and noncontrolling interest</a></td>
<td class="num">(41,794)<span></span>
</td>
<td class="num">(62,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including noncontrolling interest</a></td>
<td class="num">(41,811)<span></span>
</td>
<td class="num">(62,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest, net of tax</a></td>
<td class="num">(486)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (41,325)<span></span>
</td>
<td class="num">$ (62,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares used in calculating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">106,039<span></span>
</td>
<td class="nump">104,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">106,039<span></span>
</td>
<td class="nump">104,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (122)<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (41,933)<span></span>
</td>
<td class="num">$ (62,911)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621614624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non- controllling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2021</a></td>
<td class="nump">$ 408,822<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 1,053,386<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
<td class="num">$ (644,692)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(62,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">372,560<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">1,080,035<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(707,564)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2022</a></td>
<td class="nump">418,339<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">1,219,213<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(820,755)<span></span>
</td>
<td class="nump">19,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">81,733<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Interest in joint venture</a></td>
<td class="num">(486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 396,372<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 1,239,178<span></span>
</td>
<td class="num">$ (258)<span></span>
</td>
<td class="num">$ (862,080)<span></span>
</td>
<td class="nump">$ 19,333<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621531872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (41,811)<span></span>
</td>
<td class="num">$ (62,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flow from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,390<span></span>
</td>
<td class="nump">24,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,689<span></span>
</td>
<td class="nump">2,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization (accretion) of note premiums/discounts</a></td>
<td class="nump">690<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="nump">2,849<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(38,157)<span></span>
</td>
<td class="nump">10,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,529<span></span>
</td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,072)<span></span>
</td>
<td class="num">(5,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(7,203)<span></span>
</td>
<td class="num">(2,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(22,979)<span></span>
</td>
<td class="num">(27,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(75,516)<span></span>
</td>
<td class="num">(61,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(38,911)<span></span>
</td>
<td class="num">(5,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(111,199)<span></span>
</td>
<td class="num">(65,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">69,416<span></span>
</td>
<td class="nump">38,268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(80,694)<span></span>
</td>
<td class="num">(33,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from the sale of future royalties</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">250,576<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">94,366<span></span>
</td>
<td class="num">(92,808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents and restricted cash</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">BEGINNING OF PERIOD</a></td>
<td class="nump">108,005<span></span>
</td>
<td class="nump">184,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">END OF PERIOD</a></td>
<td class="nump">202,249<span></span>
</td>
<td class="nump">91,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes (paid) refunded</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355623883296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:20.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-APOC3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Two Phase 2b and one Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ANG3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Two Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ENAC2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-HSD</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fazirsiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HZN-457 (formerly ARO-XDH)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-75220795</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Muscle</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DUX4</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2023, the Company continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety tolerability, pharmacokinetics and pharmacodynamics of a development-stage medicine, HZN-457 (formerly ARO-XDH), which is out-licensed to Horizon, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in Amgen&#8217;s Phase 3 trial of Olpasiran, triggering a $25.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;) with Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) on November 9, 2022, pursuant to which Royalty Pharma paid $250.0&#160;million upfront (See Note 11 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced Topline Results from SEQUOIA Phase 2 Study of Fazirsiran (formerly ARO-AAT) in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease in which;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Fibrosis regression was observed in 50% of patients receiving Fazirsiran;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Median reductions of 94% of Z-AAT accumulation in the liver and mean reductions of 68% in histologic globule burden were observed;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Treatment emergent adverse events were generally well balanced between Fazirsiran and placebo groups;</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Results were consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#8217;s financial position at December&#160;31, 2022 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#8217;s Annual Report on Form 10-K for the year ended September&#160;30, 2022 for more complete descriptions and discussions. Operating results and cash flows for the three months ended December&#160;31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had $202.2 million in cash and cash equivalents (including $7.3 million in restricted cash), $299.6 million in short-term investments and $115.8&#160;million in long-term investments to fund operations. During the three months ended December&#160;31, 2022, the Company&#8217;s cash and cash equivalents and investments balance increased by $135.3 million which was primarily due to the $250.0&#160;million upfront payment received from Royalty Pharma. See Note 11.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $4.1 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355623967024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTSGlaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for ARO-HSD. The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize ARO-HSD. The Company has completed its Phase 1/2 study of ARO-HSD, and GSK is now wholly responsible for all clinical development and commercialization of ARO-HSD in its territory. Under the terms of the agreement, the Company has received an upfront payment of $120.0&#160;million and is eligible for additional payments of $30.0&#160;million at the start of a Phase 2 trial and $100.0&#160;million upon achieving (i) a successful Phase 2 trial readout and (ii) the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0&#160;million at first commercial sale, and up to $590.0&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $120.0&#160;million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0&#160;million was fully recognized as of September&#160;30, 2022. There were no revenue recorded associated with the GSK License Agreement for the three months ended December&#160;31, 2022 and 2021. There were no contract assets and liabilities recorded as of December&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. The Company conducted all activities through the preclinical stages of development of, and Horizon is now wholly responsible for clinical development and commercialization of HZN-457. In July 2021, the Company received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an upfront payment and is eligible to receive up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$660.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon is responsible for managing future clinical development and commercialization of HZN-457. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $40.0&#160;million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocates the total $40.0&#160;million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;D Services. Revenue is recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended December&#160;31, 2022 and 2021 were $21.7&#160;million and $6.7&#160;million, respectively. There were $15.0&#160;million in contract assets recorded as accounts receivable and $0 in contract liabilities recorded as deferred revenue as of December&#160;31, 2022. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop its Fazirsiran program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, Fazirsiran, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize Fazirsiran, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$300.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $595.0&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of Fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $300.0&#160;million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the Fazirsiran license and the associated Takeda R&amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company recognized $16.3&#160;million and $20.8&#160;million in connection with these efforts for the three months ended December&#160;31, 2022 and 2021, respectively. There were $0 of contract assets recorded as accounts receivable and $107.1 million of contract liabilities recorded as deferred revenue, of which $66.3&#160;million was classified as current deferred revenue, as of December&#160;31, 2022. The Company also recorded $9.8&#160;million as accrued expenses as of December&#160;31, 2022 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson's venture capital arm (the &#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which the Company would develop clinical candidates. These candidates were subject to certain restrictions and did not include candidates that already were in the Company&#8217;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $175.0&#160;million as an upfront payment, $75.0&#160;million in the form of an equity investment by JJDC in the Company&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0&#160;million, and the Company may receive up to $0.8&#160;billion in development and sales milestone payments for the Janssen License Agreement, and up to $0.6&#160;billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement and up to low teens under the Janssen Collaboration Agreement. During 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Janssen License Agreement and Janssen Collaboration Agreement, the Company identified one distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price totaled approximately $252.7&#160;million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0&#160;million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $252.7&#160;million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were no contract assets and liabilities recorded as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement during 2022. In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0&#160;million milestone payment to the Company. This $10.0&#160;million milestone payment was recognized entirely as of September 30, 2021. There were no revenue recorded associated with the Company&#8217;s agreement with Janssen for the three months ended December&#160;31, 2022 and 2021. There were no contract assets and liabilities recorded as of December&#160;31, 2022. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi Olpasiran program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the first collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license to ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $35.0&#160;million in upfront payments, $21.5&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock, and $30.0&#160;million in milestone payments. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $20.0&#160;million milestone payment to the Company. In December 2022, Amgen enrolled the first subject in its Phase 3 trial of Olpasiran, which triggered a $25.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. Revenue for the three months ended December&#160;31, 2022 and 2021 were $25.0&#160;million and $0, respectively. There were $25.0&#160;million in contract assets recorded as accounts receivable and $0 in contract liabilities recorded as deferred revenue as of December 31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in November 2022, Royalty Pharma and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $375.0&#160;million in remaining development, regulatory and sales milestone payments payable by Amgen under the Olpasiran Agreement. See Note 11.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, Visirna and the Company entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60.0&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div>During the three months ended December&#160;31, 2022, the Company performed manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received $0.7&#160;million as consideration for this manufacturing and development work, and there were no contract assets and liabilities recorded as of December&#160;31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620679648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computers, software, office equipment and furniture</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,182&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,182&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,739&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,283&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,215&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,373&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">181,149&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">141,851&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(33,835)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(31,554)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">147,314&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,297&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property and equipment for the three months ended December&#160;31, 2022 and 2021 was $2.3 million and $2.1 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the construction in progress during the three months ended December&#160;31, 2022 was mainly due to the continuing developments of manufacturing, laboratory and office facilities in Verona, Wisconsin as well as a new laboratory and office facility in San Diego, California. See Note 7.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355623579904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,644)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299,582&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,644)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296,938&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,774&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,440)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"><tr><td style="width:1.0%"/><td style="width:45.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,661)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268,391&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,661)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264,730&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,569)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620852480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">INTANGIBLE ASSETS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(amounts in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,320&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,537&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,895&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,962&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the three months ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense for each of the three months ended December&#160;31, 2022 and 2021 was $0.4 million. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of December&#160;31, 2022:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"/><td style="width:71.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621596496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"/><td style="width:27.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,769,984 and 14,000,392 shares of common stock as of December&#160;31, 2022 and September 30, 2022, respectively, were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of December&#160;31, 2022, no shares have been issued under the Open Market Sale Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355626702608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of December&#160;31, 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company intends to invest between $200.0 million and $260.0 million into the build-out of the facilities. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and will be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that the City of Verona will pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property. The Company will also receive up to $2.5 million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Technology License Commitments</span></div>The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. During the three months ended December&#160;31, 2022 and 2021, the Company did not reach any milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621596496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a new 15-year lease for approximately 144,000 square feet of office and research and development laboratory space under construction in San Diego, California. This facility will replace the Company&#8217;s current office and research facility sublease located in San Diego, California. The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for its expanding pipeline of current and future drug candidates. The estimated rent commencement date for the new lease is in April 2023 after construction and leasehold improvements have been completed. The lease payments, which begin on the rent commencement date, will be approximately $119.0 million over the initial 15-year term. The Company also estimates payments for operating expenses to be approximately $3.0 million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $31.0 million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Significant Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases office space located at 177 Colorado Blvd for its corporate headquarters from 177 Colorado Owner, LLC. The lease began on September&#160;30, 2019 and expires on April&#160;30, 2027. The lease contains an option to renew for one term of five years. On October&#160;23, 2020, the Company entered into a lease expansion to add an additional approximately 24,000 square feet of office with a lease expiration date of April&#160;30, 2027. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company subleased space from Halozyme, Inc. for additional research and development facility in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and ended on January&#160;14, 2023. On December 23, 2022, the Company entered into a new six-month lease agreement with 11404 &amp; 11408 Sorrento Valley Owner (DE) LLC, effective January 15, 2023. The lease will end on July 15, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which expires on September 30, 2031. The lease contains options to renew for two terms of five years. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of 111,000 square feet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost primarily related to operating expenses associated with the Company&#8217;s operating leases. There was $0.1&#160;million and $0 short-term lease cost during the three months ended December&#160;31, 2022, and 2021, respectively.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents payments of operating lease liabilities on an undiscounted basis as of December&#160;31, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"><tr><td style="width:1.0%"/><td style="width:79.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2023 (remainder of fiscal year)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,470&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11,800&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">102,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">150,612&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(68,478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">82,134&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"/><td style="width:60.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355624052160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), 175,083 and 3,991,304 shares, respectively, of the Company&#8217;s common stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others as of December&#160;31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorizes 8,000,000 shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of December&#160;31, 2022, the total number of shares reserved for issuance under the 2021 Incentive Plan was 7,155,527 shares, which includes 136,972 shares that were forfeited under the 2013 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were 762,150 shares reserved for options and 739,625 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,685,543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">762,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,625,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,305,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">918,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">739,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,964,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175,083&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,991,304&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">921,795&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,501,775&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,589,957&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the three months ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,721,384</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">20.73&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(13,875)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">45.57&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(81,733)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,625,776</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21.02&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.7</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">61,867,396&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at December&#160;31, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,346,710</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">17.83&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">60,525,256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company&#8217;s closing stock price and the stock option exercise price) that would have been received by the stock option holders had all stock options been exercised on December&#160;31, 2022. The total intrinsic value of the options exercised during the three months ended December&#160;31, 2022 and 2021 was $2.3 million and $12.5 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options oustanding for the three months ended December&#160;31, 2022 and 2021, was $2.4 million and $3.0 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $9.5 million will be recognized in the Company&#8217;s results of operations over a weighted average period of 1.3 years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. No options were granted during the three months ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,069,431</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">62.96&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">18,875</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">31.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(98,250)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">51.70&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(25,875)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">44.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,964,181</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">63.31&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended December&#160;31, 2022 and 2021, the Company recorded stock-based compensation expense of $17.0 million and $21.5 million, respectively, related to shares of RSUs. As of December&#160;31, 2022, there was $128.3 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 2.2 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355626702608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At December&#160;31, 2022 and September&#160;30, 2022, the Company did not have any financial assets or financial liabilities based on Level 3 measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">319,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">319,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355623916336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract', window );"><strong>Liability Related To The Sale Of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock', window );">Liability Related to the Sale of Future Royalties</a></td>
<td class="text">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0&#160;million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#8217;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div>The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0&#160;million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate quarterly based on its current revenue forecasts utilizing the prospective method. For the three months ended December&#160;31, 2022, the Company recognized non-cash interest expense of $2.8&#160;million on the consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355624065984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355627366416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfCurrentProductsTableTextBlock', window );">Schedule of Company's Current Pipeline</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:20.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-APOC3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Two Phase 2b and one Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ANG3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Two Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-ENAC2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-HSD</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fazirsiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HZN-457 (formerly ARO-XDH)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-75220795</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Muscle</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DUX4</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfCurrentProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Current Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfCurrentProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355623564928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computers, software, office equipment and furniture</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,182&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,182&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,739&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,283&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,215&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,373&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">181,149&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">141,851&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(33,835)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(31,554)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">147,314&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">110,297&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620893792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock', window );">Summary of Short-term and Long-term Investments and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,644)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299,582&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,644)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296,938&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,774&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,440)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"><tr><td style="width:1.0%"/><td style="width:45.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,661)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268,391&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,661)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264,730&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,569)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355623923184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table presents the components of intangible assets: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(amounts in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,320&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,537&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,895&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,962&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Assets Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of December&#160;31, 2022:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"/><td style="width:71.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620893792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares of Common Stock and Preferred Stock</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"/><td style="width:27.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355624188528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Assets and Liabilities and Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text">The following table presents payments of operating lease liabilities on an undiscounted basis as of December&#160;31, <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"><tr><td style="width:1.0%"/><td style="width:79.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2023 (remainder of fiscal year)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,470&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11,800&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">102,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">150,612&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(68,478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">82,134&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"/><td style="width:60.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from operating leases (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620699584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Awards Outstanding</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,685,543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">762,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,625,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,305,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">918,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">739,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,964,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175,083&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,991,304&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">921,795&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,501,775&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,589,957&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information about Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the three months ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,721,384</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">20.73&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(13,875)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">45.57&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(81,733)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,625,776</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21.02&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.7</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">61,867,396&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at December&#160;31, 2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,346,710</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">17.83&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">60,525,256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Share Activity Related to RSUs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,069,431</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">62.96&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">18,875</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">31.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(98,250)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">51.70&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(25,875)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">44.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,964,181</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">63.31&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355623552192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">319,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">319,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621301936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,582<span></span>
</td>
<td class="nump">$ 268,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,774<span></span>
</td>
<td class="nump">$ 105,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Increase in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_RoyaltyPharmaMember', window );">Royalty Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_RoyaltyPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_RoyaltyPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355617619168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 22, 2021</div></th>
<th class="th"><div>Oct. 03, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,546,000<span></span>
</td>
<td class="nump">$ 27,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo', window );">Milestone payment receivable at start of phase two</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree', window );">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale', window );">Commercial milestone payments at first commercial sale</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="nump">$ 590,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | ARO-HSD Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments at first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialMilestonePaymentsAtFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable at start of phase two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableAtStartOfPhaseTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROHSDAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROHSDAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355617630992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2021 </div>
<div>USD ($) </div>
<div>obligation </div>
<div>bundle</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,546,000<span></span>
</td>
<td class="nump">$ 27,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,700,000<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | Maximum | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="nump">$ 660,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355617627600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2020 </div>
<div>USD ($) </div>
<div>bundle </div>
<div>obligation</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,546,000<span></span>
</td>
<td class="nump">$ 27,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,300,000<span></span>
</td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355622052912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 03, 2018 </div>
<div>USD ($) </div>
<div>obligation</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,546,000<span></span>
</td>
<td class="nump">$ 27,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 252,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-3989 (ARO-HBV) Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-75220795 (ARO-JNJ1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621733824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2016 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,546<span></span>
</td>
<td class="nump">$ 27,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran and ARO-AMG1 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355617600272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,546<span></span>
</td>
<td class="nump">$ 27,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_VisirnaTherapeuticsIncMember', window );">Visirna Therapeutics, Inc. | Visirna License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_VisirnaTherapeuticsIncMember', window );">Visirna Therapeutics, Inc. | Visirna License Agreement | Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from the sale of future royalties</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_VisirnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_VisirnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_VisirnaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621274128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross', window );">Computers, software, office equipment and furniture</a></td>
<td class="nump">$ 2,182<span></span>
</td>
<td class="nump">$ 2,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ResearchEquipmentGross', window );">Research equipment</a></td>
<td class="nump">43,739<span></span>
</td>
<td class="nump">38,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">42,017<span></span>
</td>
<td class="nump">42,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">90,215<span></span>
</td>
<td class="nump">56,373<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">181,149<span></span>
</td>
<td class="nump">141,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(33,835)<span></span>
</td>
<td class="num">(31,554)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 147,314<span></span>
</td>
<td class="nump">$ 110,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Computers, software, office equipment and furniture gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research equipment gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355623950480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355618476656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">$ 299,582<span></span>
</td>
<td class="nump">$ 268,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(2,644)<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">296,938<span></span>
</td>
<td class="nump">264,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments, Held to maturity, Adjusted Basis</a></td>
<td class="nump">115,774<span></span>
</td>
<td class="nump">105,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(4,440)<span></span>
</td>
<td class="num">(5,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Long-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">111,334<span></span>
</td>
<td class="nump">100,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">299,582<span></span>
</td>
<td class="nump">218,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(2,644)<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">296,938<span></span>
</td>
<td class="nump">214,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments, Held to maturity, Adjusted Basis</a></td>
<td class="nump">115,774<span></span>
</td>
<td class="nump">105,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(4,440)<span></span>
</td>
<td class="num">(5,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Long-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">111,334<span></span>
</td>
<td class="nump">100,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355617146336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 11,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,962,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">24,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,857,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">13,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,895,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">11,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,962,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">21,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,728,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">12,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,770,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 9,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,958,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,129,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,004,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620535024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Expected Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023 (remainder)</a></td>
<td class="nump">$ 1,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">3,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 11,537<span></span>
</td>
<td class="nump">$ 11,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620550944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,140,000<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,140,000<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">At The Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">At The Market Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember', window );">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,769,984<span></span>
</td>
<td class="nump">14,000,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620940256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> ft&#178; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>a</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_TaxIncrementFinancingAward', window );">Tax increment financing award</a></td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">State income tax credits</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember', window );">Technology License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember', window );">Verona Technology Park | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAcresOfLandPurchased', window );">Land purchased, number of acres | a</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember', window );">Drug Manufacturing Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember', window );">Laboratory and Office Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of the facilities</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of the facilities</a></td>
<td class="nump">$ 260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount intends to invest for buildout of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AmountIntendsToInvestForBuildoutOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAcresOfLandPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of acres of land purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAcresOfLandPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TaxIncrementFinancingAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Increment Financing Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TaxIncrementFinancingAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355617646432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>option</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne', window );">Estimated payments for operating expenses</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Sorrento Valley Owner (DE) LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California | Colorado Owner, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated payments for operating expenses year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EstimatedPaymentsForOperatingExpensesYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of leasehold improvements net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SorrentoValleyOwnerDELLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SorrentoValleyOwnerDELLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355618472048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 41,655<span></span>
</td>
<td class="nump">$ 58,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,664<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">79,470<span></span>
</td>
<td class="nump">78,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">2,812<span></span>
</td>
<td class="nump">1,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355627586928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">45199</a></td>
<td class="nump">$ 4,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">8,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">11,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">12,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">11,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive', window );">2028 and thereafter</a></td>
<td class="nump">102,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">150,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(68,478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities (includes current portion)</a></td>
<td class="nump">$ 82,134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and after year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355617166224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,331<span></span>
</td>
<td class="nump">$ 1,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355618528704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 17.0<span></span>
</td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">3,964,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,069,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 128.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">175,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">3,991,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="nump">136,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">2,305,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">7,155,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">918,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">762,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="nump">739,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">739,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621624496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">2,625,776<span></span>
</td>
<td class="nump">2,721,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">6,589,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">175,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">175,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">1,685,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">3,991,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">921,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">762,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">1,501,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">3,964,181<span></span>
</td>
<td class="nump">4,069,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">2,305,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">918,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">739,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355622257008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summarize Information about Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">2,721,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(13,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(81,733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2,625,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable (in shares) | shares</a></td>
<td class="nump">2,346,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">45.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">7.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">21.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term (Years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 61,867,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 60,525,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355620539856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSUs Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of period (in shares) | shares</a></td>
<td class="nump">4,069,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">18,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(98,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(25,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of period (in shares) | shares</a></td>
<td class="nump">3,964,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 62.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">31.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">51.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">44.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 63.31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355622067632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">$ 82,924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,262,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">27,423,000<span></span>
</td>
<td class="nump">$ 1,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">104,311,000<span></span>
</td>
<td class="nump">41,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">319,690,000<span></span>
</td>
<td class="nump">271,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Certificate of deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">82,924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,262,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">27,423,000<span></span>
</td>
<td class="nump">1,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Certificate of deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">104,311,000<span></span>
</td>
<td class="nump">41,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">319,690,000<span></span>
</td>
<td class="nump">271,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Certificate of deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Certificate of deposits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140355621194304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,849<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial', window );">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponFDAApproval', window );">Milestone payment receivable upon FDA approval</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments', window );">Milestone payment receivable upon receipt of royalty payments</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltyPaymentThreshold', window );">Royalty payment threshold</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilitySaleOfFutureRoyalties', window );">Liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilitySaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability, Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilitySaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon FDA Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Receipt Of Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltyPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltyPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>arwr-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20221231.xsd" xlink:type="simple"/>
    <context id="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6ac05044f5a45a9b425ea6471db9c99_I20230201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-02-01</instant>
        </period>
    </context>
    <context id="i06abac4e1f98416b8ae5ab270600de1a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f511f4c684146e7bb7fbc97f28a954f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0973239be0154868a5c0a6b435b415ac_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if88ea1264d34418cb7275044ad1fb1df_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0a0de3cc32924634a9ccf0a2bd93a727_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i51f153e0382f4ac28b7528ad3646cac2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie444a272a1eb4b079631b5b5db9909fd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iee0675bb73de4fd3ab4bc406773f8cb4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib3787aa308494e6fabfa34270e2a98a3_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a8f3fe7a23d4d658eabff5f9122ad89_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7ec8a43fe2b4ac39a998e248193d6bc_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2884a29569d49d4b0c8e85c4112ecd9_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0ca39c8d80949cf9a8b1394e754badd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i631979769d5c467191f41a0d5fc63ad8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e350ee9f64142d9bf9f4aed07b098ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96cd0d22a1684bd7aae80feb5bceb816_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9edc90c95f0b450b9cf755c9e4f7bf63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i496886d6abed4f999c1ace5f866fcb6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74a39646f95b4f89b1694a9939f5327a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie35381f0ea5a44e383a735802d46673f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0af42ecb0f284f94b06b37a27ff07368_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6449ff00713d4e21976744c273cccae8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id5b117b978284cd6a85fd88b72346e47_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i90a5c8c8db52479c96374a3a0f3d318b_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i66e8e9723fb342fc9b33826fac8e4171_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8d21df7082f14f328f24834628e5a4f9_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibf6ee791b62f4538b6bfc8ec3f396205_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1c40ddf690448b0bb93935296f8f5d6_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3aba4e2426de4a28acd5d29a6320c9bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18f94331985a400f846c766bf11f5925_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iced398649a794c4e8e8d86a2846c3ae1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c4dcde64e0e45438fe394fa33f8e503_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i381adb6a0c044161942d6a4204364b39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5cea4208cdeb42c9a22cc59d648953a0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5db3274cc4d14160ae2d5f647d651c24_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia65665136f1d40fd862086f2dd922e9f_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:RoyaltyPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied9e360396f44e37a5fa2c12b7d58208_I20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="if6d16e113b834a97a9fcbf8e0681786c_I20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="ief93fea769094d7eb5fb5948a8f0d52b_D20211122-20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="i342c597acfec441dab0f3b37209a55ba_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i00c306c538924e74a11b388564ca6b80_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i038818ff5b9843f1b9d17f64430e188b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i378c508c95df484ba3e6ef6a5454bc94_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="ide8cc0f14c60475299147a3dd0c03daa_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i7372fb791af34e0d8dd8edb75dff1a73_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i2a500b1709164996b845bbac989d7b84_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ida93008e93a8494783ed240b674e7a64_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i988f7cda978749b1b3f5337961e8742e_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09940e4ffb194a128c45cb16ba228ade_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia939243a8ac74e65952dd91c16f544b4_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="icda38447f5614cebb8ef1552acb61332_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="i9284be9df69d4141bedb600f69d1042c_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i3c44558d7e484eb2a6b9cae263a65437_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="i09ec1fea81bb4a3f85a50d428952c2a4_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idca13f49c2ac4338bd38897981c0e87b_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if05fdd27fe28461a9e78cc9c9d4e69d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0cf0f351abeb4ff9920e8f448a4b04d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3b9fa1ae2884a8d985db088de873bf2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idad13da460ff45d888e1281a60477acd_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="i1dbada01124d4560be0e826511f8dce1_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="i2a989d7ce0a44ccf9bf1022c8f7f9b2a_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="i92f82a268c774e9bb9992a060a63740b_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="iba27b7bdc69548378fef58b5f42961ff_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="i328d3ff81ad3491a99bdf175a0d11762_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="if317166287bb4b13944a83a251e50077_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="iadbb1a93d51d4301be4fa1d4b852337c_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="i2766009a08bc437580f4294c351f7cd6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c684d870f3a4136a5f54739f8a8b3a0_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i2b7883a42e42404293d06a18e9cd891e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2364b30800c9442ab7f8d6ccf86939e9_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23c624b66e784ad1baf3e3fb6bea568e_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9db0b5443200492482544d7c90204e4a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if64321b9c6e247da8443d05133b342ff_I20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="iae284bdb5fea480a9e15773836d59063_D20160928-20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="ibc17c83235054c9298c89a26c8fb35e1_I20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="id0f7402c90cf488f944efc5f47b5caeb_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i7c6d551c455a4169899e5d3a186b7638_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic2933262b7b1411284a2bb299c20d306_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1f61a8d393224431a507b3f200215db7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9cfe482a057d4dca8df5560f98cef3e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ee8ab30ad3445958f3b561928b95608_D20220425-20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="ia9c7506b5d91485d9801a47dca99e510_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic3e51d9c60c54ce1a159fc24a37a7ae1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2a387c1c2504379a168792bc1c3e50b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i917462b04ff841eaac0e3339bd0cb7bf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3f7584f587e4681907eb42f27510096_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iea276053053c4bb59f85d31ebab93a3e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0889a0226de945a0aaa5c52879fb13f4_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i714564a42c4645a4aa8fec5fbfae6cf1_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0223aca615484a88a1f963d53db983b5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4a3b5deb088e42a4b098ad5687964c9e_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4d52a26129d84983ad9bb9f0ee488966_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i449ded4307a74763bf247ab23aa3b5f9_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i34f581ef502d44a597740c97e5d034bf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i03c5e2040b97478685482edb1a081bb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2aeef9c8ccd4d24a3762ad0cae17f16_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i953cacdb283b4570974e198523332adc_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="if602610bd9274f15ab350c697c16fbcd_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i75f84a2f705547a9a7be5905324c37e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8614ef1e09dc4ad7b48305618623004c_D20211220-20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="i7b3dac9a5a774156b890ac8ed0751a6a_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i0f1aae662bc6418db9f0619cc2642795_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i62abdefe617a488691c724830dcd72c9_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="ie59ded034230456484b32676c5f7bea0_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i475551cf88cb4dccacdf1b2a61c7583d_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i0154bab3efba4f2b94e2b7c59316083b_D20211220-20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="ic881a18f95ea4f17a15cc3756a39574f_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i349f57ec0207498e87e4c69e2bce507c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5126eab2e8c467bbb24c03e16becfd7_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ib156f4f74fcf40dab1e99dda624e5df7_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="ide63f19f872342da8608f446fb18d4de_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ic35d28a67b834f6484c8d5ee20d55588_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2811668ed19749b68707a9ed9f6d8253_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="iea10d5800b11488baca5f307e6d73957_I20221223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SorrentoValleyOwnerDELLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="i12ce5e7d49bd492c9e566ef7247a28c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8040ef89c2154b74b3e460ed12cd081a_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2b5a7a96684442d296082eb9d52b8bcd_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i35831effd60d42e480dad85b0cf9984c_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia4bfba6d666f497ab7f1a694161b0c89_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idc2a8a0b4a714ac7bf244c847af32ed7_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7af89e8de2144f908cdf6eed480d28b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba8a5ebb90254f6f8963f5d5f42509a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i90cda53c17144e44900529474c8dade0_I20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="i2eda0cf364544def8987efed665491a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47739b2328c247bab0fc929214a7ba52_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie5eaa8a48bce4fa6b14d1cc81a3b2f78_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5d653e654b143c2b0c47570e75b7f38_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6801c6b77c1f498681559c7a2dce2274_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5982379dbbec4d4c87792e3a1fcdf6b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieed10835a1c94a47a82efe00a8e128c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3a67532b13e4f299f83c7328786c6b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52d4a7405e154645aec245988ba1db1e_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieded460c29c84a3bae41035d3b604b0a_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7371c7b684f24f2ea135c09ba65d9460_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia962a8cd9cbf48eab5243a5e151c89a3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i54ad8857cb6d490a9939df3c07ff4518_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic12f642c28fd43bb8bf90642994bc4ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d7c02af510c4a37adf92b11b0e43eaf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia208947dbdb34f48ac070a4eaf8f6ab8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04b788dc055c47f289db232c658f93a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4024a6c45e8b453eb06624488de7893b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i39044bf341fe482cbbdce983d914bbec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8310bcf25814821b30b9f25902a564d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b8edd077cc145338ae4844a504c6d15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e5f5182517047a2857c3e4a25738d82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia323910ecf904687b25c3160e49c81a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ida69711b30dc4c71b1277eaf63e7bdd5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7481b819e6694390ada33ee48dd204bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0cba61c40f15431a97004a8eed248d67_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f8630cb003e4706a57151bdfa8dc88c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5851c535fb2c4a6ab422410bef2bbd02_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied344ba18ef64e3d9de729f6de914532_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i452920e837684080b738d48ba1b27ff2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7cd572b180c415db97822ca50b32ac9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5fefec5d13e145909fc3b74408e1e444_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c9ae1d799ee4d03923270e5ee1d6d21_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ce3b6dcc92d46758613038bc30d2d06_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieb6ea8e37eb3434eb30ea1ab2ceca664_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i39634f9fa175451b8ba8d5d58bf3740c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7c4faae844d34e619c9019b81d17f07e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieb683bdc076a49628834f62824ed68f4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1a05dee7c43b439f82b54c288eea3838_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib0c9e1d3a53545b2ad24da42f70a1040_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic813502c9a304662b9dfbd3942bd3230_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id85626261eb446dcaddc667f6dabc5cc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i406ec781c5d644bdb1d8414e80314cc6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i039e74dffa1f49d9a35ad0d64a55d837_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9f10fb8f48cc4003b37f0dce7bcf8710_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iad0de95aea0445adaf44a4746fbc4967_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1aa3981837334860a25583d48dd904d9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i42efed8b98314bbfbbb3748a5f769fa7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i67a183941914437b8b3a7e507c345f29_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i66a7f0c6944640a18b75bccffab1cb19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i782e0824540f448daa350332d8e73bac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i582fc5eed03a4994b06179429d92df7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i462d644c71d546a9af599d5543f3d5c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd2e69018bdb4a98bb2a58ba8c80e25a_D20221109-20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="i645dd71143994cfd81a4843c13790bbb_D20221109-20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="i6d4193086f2a4fc198c05eae2aa999c6_I20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="ia4521874a9864ab3bed52ad5aa487856_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icba7f05878cb48c783c8d12cf1ff5540_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="bundle">
        <measure>arwr:bundle</measure>
    </unit>
    <unit id="obligation">
        <measure>arwr:obligation</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="agreement">
        <measure>arwr:agreement</measure>
    </unit>
    <unit id="acre">
        <measure>utr:acre</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>arwr:option</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF8yLTEtMS0xLTI4OTA0_95fa2075-5148-4f50-b516-4e5070bd9e7d">0000879407</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF8zLTEtMS0xLTI4OTA0_40e3692a-f9c1-4c61-867d-24bb597dd325">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF80LTEtMS0xLTI4OTA0_93f548a7-ba8f-4200-bacf-9acde9a1ac14">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF81LTEtMS0xLTI4OTA0_9c9f3e8e-d27a-44b8-b55b-09782d0d46bf">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80L2ZyYWc6OGVmMWExZmYwOTVjNGQzNmFiYTJkY2RhM2YyOWY0MzMvdGFibGU6ZGEzM2M3ODIyNzNkNGFiYWIwYjk1ZDI3ZWNjMDdhMWQvdGFibGVyYW5nZTpkYTMzYzc4MjI3M2Q0YWJhYjBiOTVkMjdlY2MwN2ExZF82LTEtMS0xLTI4OTA0_d8c5248b-1aac-4229-8248-a362522a1a3a">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjM4_9dbd034f-dec1-49b7-b4f6-020b633ba1c9">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6OTBkZGYyZTQyNzgxNGQzNGJiYjQzOTliMzlkNDQ5NzUvdGFibGVyYW5nZTo5MGRkZjJlNDI3ODE0ZDM0YmJiNDM5OWIzOWQ0NDk3NV8wLTAtMS0xLTI4OTA0_9a6aa884-d76f-456b-9729-38b46fe9ab6c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMDc_1640f9a4-b71a-4a51-b862-9fe9ade8e717">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6ZWVlNmQ0ZjllZTU3NGFjMDhkOWJmZGY3ZTY5MDQyY2UvdGFibGVyYW5nZTplZWU2ZDRmOWVlNTc0YWMwOGQ5YmZkZjdlNjkwNDJjZV8wLTAtMS0xLTI4OTA0_c86a1d24-7dbc-4c7e-8ae5-bc18de68c238">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQz_f2f134f2-7e72-4c1e-bb25-2de17ecfa798">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQ0_a81e043b-2c69-4e4c-a19c-9ec9cdbcba09">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MDJiZDUyM2M2ZDI0NDVlNjgzNDYwZWNiNGVmOGFhNmQvdGFibGVyYW5nZTowMmJkNTIzYzZkMjQ0NWU2ODM0NjBlY2I0ZWY4YWE2ZF8wLTAtMS0xLTI4OTA0_ab394b59-dfb4-43bc-b087-ed033228bf33">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MDJiZDUyM2M2ZDI0NDVlNjgzNDYwZWNiNGVmOGFhNmQvdGFibGVyYW5nZTowMmJkNTIzYzZkMjQ0NWU2ODM0NjBlY2I0ZWY4YWE2ZF8wLTItMS0xLTI4OTA0_7e32e2be-a23b-43f2-b433-5e7a2cddb06c">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80NjU_e0317a43-ac47-4ab9-b825-084b459ed023">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80Njk_f5f11cdb-9924-4119-b8da-ce486beff2f9">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80NzI_7fc296a2-e27e-4c22-8d05-b98c40b7af34">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80NzY_a7154408-15a2-422f-8715-70bef3d27776">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80Nzk_21f519b9-f441-48c2-b52a-5edc1fe44397">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80ODM_422a24f4-102d-4f13-bffa-8ecdab8403d5">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF80ODc_40e35636-a152-4c2a-be71-9df291e00fb2">304-3400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MmI1ZTExMDcwMDU1NDFiMWI3OTFmNTM5ZDE1MWNiNGMvdGFibGVyYW5nZToyYjVlMTEwNzAwNTU0MWIxYjc5MWY1MzlkMTUxY2I0Y18xLTAtMS0xLTI4OTA0_0953d03d-1708-40cd-a171-14e6e1c6a15f">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MmI1ZTExMDcwMDU1NDFiMWI3OTFmNTM5ZDE1MWNiNGMvdGFibGVyYW5nZToyYjVlMTEwNzAwNTU0MWIxYjc5MWY1MzlkMTUxY2I0Y18xLTItMS0xLTI4OTA0L3RleHRyZWdpb246ZDBiYTI2MWZhZDhhNGFiMDk3Mzk2ODYyYmI0MzVmYTZfNA_48c54a1f-2af3-4c2a-a4f6-fa972bf2f1d7">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MmI1ZTExMDcwMDU1NDFiMWI3OTFmNTM5ZDE1MWNiNGMvdGFibGVyYW5nZToyYjVlMTEwNzAwNTU0MWIxYjc5MWY1MzlkMTUxY2I0Y18xLTQtMS0xLTI4OTA0_2372c431-e404-4746-bcc2-ab074d4a34de">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQw_0bda6ae2-74db-4aa2-826f-4d675db2b2c7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQx_6376a4b5-eb1d-4876-a5d4-d056639071e9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MTAyOTYxNWJjODk5NGQ4MmIxMmZhNmJjOTdjMWMzMWUvdGFibGVyYW5nZToxMDI5NjE1YmM4OTk0ZDgyYjEyZmE2YmM5N2MxYzMxZV8wLTAtMS0xLTI4OTA0L3RleHRyZWdpb246MDcyZTQ0YzBjZmFkNGQ2ZmJiMTFmMmU5MmU2MDk1MzlfNA_18c4dec7-4afa-4780-aa56-07c22a41e809">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MTAyOTYxNWJjODk5NGQ4MmIxMmZhNmJjOTdjMWMzMWUvdGFibGVyYW5nZToxMDI5NjE1YmM4OTk0ZDgyYjEyZmE2YmM5N2MxYzMxZV8yLTMtMS0xLTI4OTA0_675b9530-fde9-4b3f-80fd-45bab442330d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGFibGU6MTAyOTYxNWJjODk5NGQ4MmIxMmZhNmJjOTdjMWMzMWUvdGFibGVyYW5nZToxMDI5NjE1YmM4OTk0ZDgyYjEyZmE2YmM5N2MxYzMxZV80LTEtMS0xLTI4OTA0_07bdac8d-8381-4455-9e9b-fc8fafe0e186">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjQy_5fc9a46d-7c62-49a4-87c1-4c4c23fdc4e8">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib6ac05044f5a45a9b425ea6471db9c99_I20230201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xL2ZyYWc6ZjU2MTA4ZTYxYzM1NGRiMWEwOTYzN2M0OGRiN2YwMjQvdGV4dHJlZ2lvbjpmNTYxMDhlNjFjMzU0ZGIxYTA5NjM3YzQ4ZGI3ZjAyNF8yMjMz_f8768db3-1e7b-4c89-be4f-0c2666d11e32"
      unitRef="shares">108310163</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMy0xLTEtMS0yODkwNA_63878d57-ef86-4c5d-93f2-fd8b748f540b"
      unitRef="usd">202249000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMy0zLTEtMS0yODkwNA_e1698ece-9d7a-43b5-b8c3-4686f71313cd"
      unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNC0xLTEtMS0yODkwNA_78205377-0e4c-4748-9af2-683581ad5bc2"
      unitRef="usd">39568000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNC0zLTEtMS0yODkwNA_b93b4b7d-fb01-4504-adcc-df60e4571a91"
      unitRef="usd">1410000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNi0xLTEtMS0zNzYwNw_d4b566f7-b2a2-4004-ac96-ca74fbb6a000"
      unitRef="usd">299582000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNi0zLTEtMS0zNzYwNw_ec47a4dc-d5b2-4c06-812a-01ba6d5d418d"
      unitRef="usd">268391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNy0xLTEtMS0zNzY2MQ_e3f434b0-bb40-4f57-a102-521c10e89ba2"
      unitRef="usd">8412000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNy0zLTEtMS0zNzY2MQ_0deaae0e-f74b-4092-b08f-00cc50001463"
      unitRef="usd">7289000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOC0xLTEtMS0zNzY3MQ_f001ced0-fba3-4994-9d13-f6c4d6e7e9c9"
      unitRef="usd">25188000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOC0zLTEtMS0zNzY3MQ_42eb09b6-3c9d-460b-b61f-f8f1a2c425e5"
      unitRef="usd">20204000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOS0xLTEtMS0zNzcxMg_0496aef7-2d4e-493f-a65a-2e131419bc7b"
      unitRef="usd">574999000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOS0zLTEtMS0zNzcxMg_ca6dc7bf-2f8c-4097-a411-8c9adb0fbf6d"
      unitRef="usd">405299000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNi0xLTEtMS0yODkwNA_d26aa808-db31-461b-aad7-bd7cbca9e7d4"
      unitRef="usd">147314000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfNi0zLTEtMS0yODkwNA_b2a13470-c323-41ce-9e67-6227f6b4dbb8"
      unitRef="usd">110297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOS0xLTEtMS0yODkwNA_4d416f4e-5b4b-4f3f-be28-d3f079f53596"
      unitRef="usd">11537000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfOS0zLTEtMS0yODkwNA_8d7310bd-26ba-4a0e-94d0-a5032fc1fb3e"
      unitRef="usd">11962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTAtMS0xLTEtMjg5MDQ_69b74367-464f-4ffe-b4fb-ab8103b9d2f4"
      unitRef="usd">115774000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTAtMy0xLTEtMjg5MDQ_fc1eb6bc-e850-474d-94bf-f4e90d3d7c66"
      unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTEtMS0xLTEtMjg5MDQ_8679106e-faaa-4cdb-ac27-01db55b64e62"
      unitRef="usd">41655000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTEtMy0xLTEtMjg5MDQ_0d428836-a817-45d3-a989-78ed5a2b4765"
      unitRef="usd">58291000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTItMS0xLTEtMjg5MDQ_e8cb0a8e-2b39-4273-b901-208946c51a97"
      unitRef="usd">210000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTItMy0xLTEtMjg5MDQ_ab381dda-dc52-4a80-ae67-5131c8dfedf6"
      unitRef="usd">218000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTMtMS0xLTEtMjg5MDQ_8e57ed22-b48a-4084-98ab-4b51d9cc15fa"
      unitRef="usd">891489000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTMtMy0xLTEtMjg5MDQ_8e9b4d6b-aeb6-4bc4-8604-f7c18362271c"
      unitRef="usd">691939000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTktMS0xLTEtMzc4MTk_c6da9df9-e514-46a5-b87a-99b6f8c5edce"
      unitRef="usd">796000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTktMy0xLTEtMzc4MTk_cf098efb-20fd-4ff4-8818-95b971793867"
      unitRef="usd">2868000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjAtMS0xLTEtMzc4MTk_83367a35-69fe-46a2-be4e-79f76b81121c"
      unitRef="usd">48174000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjAtMy0xLTEtMzc4MTk_1ae417a3-028d-49dc-ba65-d6b341a4a00d"
      unitRef="usd">46856000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTgtMS0xLTEtMjg5MDQ_810ec3d2-dead-48b2-a4f2-9cc114c8fe7a"
      unitRef="usd">4094000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTgtMy0xLTEtMjg5MDQ_73dfef19-b0ce-4885-83cf-647ba4c810e1"
      unitRef="usd">12251000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTktMS0xLTEtMjg5MDQ_22dcb1bb-4f00-4572-8e19-ef85c681ead3"
      unitRef="usd">2664000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMTktMy0xLTEtMjg5MDQ_7d919b0f-b09a-4792-9468-f4c73199314e"
      unitRef="usd">2776000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjAtMS0xLTEtMjg5MDQ_d24b11df-eac4-4035-8e65-72b72be2b266"
      unitRef="usd">66281000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjAtMy0xLTEtMjg5MDQ_6388824f-c7f5-4e47-ba09-85bd80508981"
      unitRef="usd">74099000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjItMS0xLTEtMjg5MDQ_b28196e4-1580-4d50-8911-56d731273513"
      unitRef="usd">122009000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjItMy0xLTEtMjg5MDQ_77878290-dbae-44fb-9462-5cc80cc9d983"
      unitRef="usd">138850000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjMtMS0xLTEtMjg5MDQ_1438baa3-d5b2-44fb-8176-53cadc92b303"
      unitRef="usd">79470000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjMtMy0xLTEtMjg5MDQ_b0c1ca87-6e7b-4cf3-8360-b9eada556ce3"
      unitRef="usd">78800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjctMS0xLTEtMzc4NTk_6aa7ee46-0980-4bc9-95a0-653cee8ef4c1"
      unitRef="usd">40789000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjctMy0xLTEtMzc4NTk_ccb64e36-98b8-4e0b-9b71-bf4e26d37a23"
      unitRef="usd">55950000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjUtMS0xLTEtMjg5MDQ_97ba8cd1-f25d-4c6d-8473-78ce7d18bc23"
      unitRef="usd">252849000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjUtMy0xLTEtMjg5MDQ_7ebeb1f1-9c7a-4ee4-91ca-c831bb9a863d"
      unitRef="usd">0</arwr:RoyaltiesLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjYtMS0xLTEtMjg5MDQ_c08698c7-999a-48b2-bcdc-62df822aa02f"
      unitRef="usd">373108000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjYtMy0xLTEtMjg5MDQ_090a802a-545b-4dd2-b1c3-c6ba0b6b7c47"
      unitRef="usd">134750000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjgtMS0xLTEtMzQzMDI_cb8a5089-8df6-4f83-b961-06260491f16f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjgtMy0xLTEtMzQzMDI_e5a7565b-4373-42e2-820a-443c8948bff6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTI3_5961f3ba-f1b9-463f-a55f-83e94170cd83"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTI3_edd585fe-af5c-4274-80f1-8ba6d487dc68"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTE3_3ea92019-92e1-49ab-9cee-b0feec3583fa"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTE3_bccc6362-b5d2-4c43-9a7f-d16bc9cdde16"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3ODk1_c4e740b8-d2d0-43cf-8d1e-25a14a49cc02"
      unitRef="shares">106140000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3ODk1_d9a87b6f-3b21-42f4-acc9-54cc5bdba0bc"
      unitRef="shares">106140000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTA2_dc91fb59-d0d5-4425-a522-1ff932a6a6f4"
      unitRef="shares">105960000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMjktMC0xLTEtMjg5MDQvdGV4dHJlZ2lvbjoxYTRmODM5OTcwYjE0NDk2YjlhMGU3NzFjZWMyNzg2MV8xMDk5NTExNjI3OTA2_e8191071-1565-4622-acfe-860d4393d642"
      unitRef="shares">105960000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzItMS0xLTEtMzc5NjM_d71f1b23-7cec-476e-8343-5149c3fb7b7a"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzItMy0xLTEtMzc5NjM_d8d79656-af11-489d-843e-70438a3ad811"
      unitRef="usd">198000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzMtMS0xLTEtMzc5NjM_73c40bcf-9c43-4bcf-88ae-d8aa1d65325b"
      unitRef="usd">1239178000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzMtMy0xLTEtMzc5NjM_ed7d6959-99ff-4534-b78a-55b0b2ec8a40"
      unitRef="usd">1219213000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzQtMS0xLTEtMzc5NjM_3c80236a-c6e2-4b10-a12b-74c2d75d4d87"
      unitRef="usd">-258000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzQtMy0xLTEtMzc5NjM_44d8d567-3472-423e-8f59-4f88a691ad69"
      unitRef="usd">-136000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzItMS0xLTEtMjg5MDQ_1531301a-7011-4fce-911f-8abb90b426e0"
      unitRef="usd">-862080000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzItMy0xLTEtMjg5MDQ_48c8f8f0-ea2a-4f65-b597-04dfa6602c82"
      unitRef="usd">-820755000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzMtMS0xLTEtMjg5MDQ_7fb6c163-97d5-4415-a094-824c38ece7cf"
      unitRef="usd">377039000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzMtMy0xLTEtMjg5MDQ_16c6e579-5d2e-467f-a265-874c3792a63a"
      unitRef="usd">398520000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzQtMS0xLTEtMjg5MDQ_1c4f3cae-3aef-4dda-b0fb-e9d85752c42a"
      unitRef="usd">19333000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzQtMy0xLTEtMjg5MDQ_c4f798e1-ddaa-44bd-a359-e033203f8c76"
      unitRef="usd">19819000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzctMS0xLTEtMjg5MDQ_cb339966-c17f-4cea-aa4a-4846b8011198"
      unitRef="usd">396372000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzctMy0xLTEtMjg5MDQ_78bd3ca1-54d0-4f8d-b6b8-9ecb5439fec6"
      unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzgtMS0xLTEtMjg5MDQ_72d84e09-945e-48bf-ac42-24e8ac8be888"
      unitRef="usd">891489000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xNi9mcmFnOjQxZGVkNDA3YzI2YjQ2N2ZhMWI4YTY2ZGVhYzVlMDJkL3RhYmxlOjU4OGM0YjFkZjcyODRlMzVhM2VmOTExZDExMmYxYjc3L3RhYmxlcmFuZ2U6NTg4YzRiMWRmNzI4NGUzNWEzZWY5MTFkMTEyZjFiNzdfMzgtMy0xLTEtMjg5MDQ_3b8ea548-a598-45d6-9654-70d64349c0a9"
      unitRef="usd">691939000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMi0xLTEtMS0yODkwNA_bdf0417d-38f3-49dc-89ab-f3b8c1a763cf"
      unitRef="usd">62546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMi0zLTEtMS0yODkwNA_3011601b-adc2-4bf1-8431-52f12740266c"
      unitRef="usd">27439000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNC0xLTEtMS0yODkwNA_06650c54-a2e7-4150-adc5-76368925fcd0"
      unitRef="usd">83695000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNC0zLTEtMS0yODkwNA_bd295fa4-e396-4f86-a156-2e91b3e5bb9f"
      unitRef="usd">65765000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNS0xLTEtMS0yODkwNA_f658c388-0dc3-4809-868e-0f05fa694736"
      unitRef="usd">20985000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNS0zLTEtMS0yODkwNA_19113029-08c3-4a28-b21c-212327e76b17"
      unitRef="usd">24995000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNi0xLTEtMS0yODkwNA_8de060bc-2dda-4ed9-9a05-147954b17eb5"
      unitRef="usd">104680000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNi0zLTEtMS0yODkwNA_1b9c8597-fe72-42f5-b301-01f663341692"
      unitRef="usd">90760000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNy0xLTEtMS0yODkwNA_9839a639-5aa5-4582-a91d-df356460f48f"
      unitRef="usd">-42134000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfNy0zLTEtMS0yODkwNA_df29e70c-bb5f-4745-adbf-81d712724b1f"
      unitRef="usd">-63321000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfOS0xLTEtMS0yODkwNA_a77e2711-b4b9-47b2-8364-22aa9eb3f5ec"
      unitRef="usd">-167000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfOS0zLTEtMS0yODkwNA_7bac3d93-a6b6-4b5e-87a9-12fd13a19df7"
      unitRef="usd">1156000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTAtMS0xLTEtMjg5MDQ_68747162-864d-4134-a70a-cbeb3b575edb"
      unitRef="usd">507000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTAtMy0xLTEtMjg5MDQ_1c12926b-3bd6-4e9a-83ab-02a23e647814"
      unitRef="usd">-707000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTEtMS0xLTEtMjg5MDQ_242e9b62-7408-42bd-877c-4e31747b8628"
      unitRef="usd">340000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTEtMy0xLTEtMjg5MDQ_550381a8-a211-4908-83aa-ec4efaafa24a"
      unitRef="usd">449000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTItMS0xLTEtMjg5MDQ_44055727-48bc-41e8-a6cd-916d609fb15d"
      unitRef="usd">-41794000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTItMy0xLTEtMjg5MDQ_50f04b8b-088e-4c0a-a6e7-7894966d9a38"
      unitRef="usd">-62872000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTMtMS0xLTEtMjg5MDQ_de64d088-f7ab-488f-9279-7073fc984cc5"
      unitRef="usd">17000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTMtMy0xLTEtMjg5MDQ_1ef7627b-67ba-4463-8e27-bdb54058b358"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTQtMS0xLTEtMjg5MDQ_c257f571-2207-4c93-bde5-59766b7b66a8"
      unitRef="usd">-41811000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTQtMy0xLTEtMjg5MDQ_f4c422cb-c2f6-47b8-b6c5-89d0435afdf2"
      unitRef="usd">-62872000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTctMS0xLTEtMzQ0NjI_abf01612-d8b6-4e40-a8e2-4aa35446c273"
      unitRef="usd">-486000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTctMy0xLTEtMzQ0NjI_e9eeba75-5e32-4849-8ad7-ef192ab633f7"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTgtMS0xLTEtMzQ0NjI_c592c263-704d-49fd-ab39-a0f6b693ed46"
      unitRef="usd">-41325000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTgtMy0xLTEtMzQ0NjI_8f2f8b6f-e423-4c63-afcf-4339bb3f65cb"
      unitRef="usd">-62872000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTUtMS0xLTEtMjg5MDQ_b750dd56-3d6a-4d84-a558-6c68ac7ff687"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTUtMy0xLTEtMjg5MDQ_04ce401a-97f7-41e0-bf35-31ed4df23fe9"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTYtMS0xLTEtMjg5MDQ_674a9cf5-c5f9-4030-b0f3-a7bdd3aef8c5"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTYtMy0xLTEtMjg5MDQ_823d0472-2929-4706-a67c-f9fa9f3fb577"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTctMS0xLTEtMjg5MDQ_46dbd57b-9f20-405f-a292-ce162f190f31"
      unitRef="shares">106039000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTctMy0xLTEtMjg5MDQ_7a378556-d265-468f-8025-8797fe57e1e2"
      unitRef="shares">104534000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTgtMS0xLTEtMjg5MDQ_b8b14665-968f-42b8-a1e6-a6a1eaff13ac"
      unitRef="shares">106039000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMTgtMy0xLTEtMjg5MDQ_def4d230-e264-405f-9318-ab6c7b5148bc"
      unitRef="shares">104534000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMjAtMS0xLTEtMjg5MDQ_f3a17311-2714-4fd1-9d64-901a71cadc1a"
      unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMjAtMy0xLTEtMjg5MDQ_a88ca69a-fb29-4f7f-b432-b5111e274fe5"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMjEtMS0xLTEtMjg5MDQ_4c76efe3-b5b5-4c74-8fad-a51402b45169"
      unitRef="usd">-41933000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8xOS9mcmFnOmUxOTA0MzcyYWFkNDRiZGJhYjExNjM4MzViOGQwOWE5L3RhYmxlOjk0NjFjODI3ODA2YTRkMDNhZjI1YjcyZDhlNTg0YTlmL3RhYmxlcmFuZ2U6OTQ2MWM4Mjc4MDZhNGQwM2FmMjViNzJkOGU1ODRhOWZfMjEtMy0xLTEtMjg5MDQ_f83690bd-470c-482c-ac36-6424a4f930d1"
      unitRef="usd">-62911000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i0973239be0154868a5c0a6b435b415ac_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS0xLTEtMS0yODkwNA_33b361ef-c6da-4d84-9f94-f3bdf0f5d771"
      unitRef="shares">104327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0973239be0154868a5c0a6b435b415ac_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS0zLTEtMS0yODkwNA_95f4d279-97cd-404c-acca-d8c29d842d51"
      unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if88ea1264d34418cb7275044ad1fb1df_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS01LTEtMS0yODkwNA_eb90de6a-6658-45e9-bd57-a111d31ce69b"
      unitRef="usd">1053386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a0de3cc32924634a9ccf0a2bd93a727_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS03LTEtMS0yODkwNA_7d8146da-6141-4c27-888c-a308bfadbdf6"
      unitRef="usd">-69000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51f153e0382f4ac28b7528ad3646cac2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS05LTEtMS0yODkwNA_17389b5f-cc75-4418-9809-a29fd690f5b3"
      unitRef="usd">-644692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie444a272a1eb4b079631b5b5db9909fd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS0xMS0xLTEtMjg5MDQ_caa42fbf-7b99-45e4-882f-a594d229cbb3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee0675bb73de4fd3ab4bc406773f8cb4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMS0xMy0xLTEtMjg5MDQ_68a92d0b-c647-4e7c-8ca6-9b34500e3993"
      unitRef="usd">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3787aa308494e6fabfa34270e2a98a3_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMi01LTEtMS0yODkwNA_03377828-8145-4dbc-ae6d-cfa547ce9181"
      unitRef="usd">24504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMi0xMy0xLTEtMjg5MDQ_f1208b2a-4166-4560-95e0-8db0bccff248"
      unitRef="usd">24504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3a8f3fe7a23d4d658eabff5f9122ad89_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMy0xLTEtMS0yODkwNA_3b8743d9-9944-45d8-963b-bc3d50e36b26"
      unitRef="shares">208000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib3787aa308494e6fabfa34270e2a98a3_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMy01LTEtMS0yODkwNA_532d253f-b11a-41a5-be8e-8d3ec82d8bdd"
      unitRef="usd">2145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfMy0xMy0xLTEtMjg5MDQ_f5c5b416-32bd-49cf-84fd-aacd78692d63"
      unitRef="usd">2145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i3a8f3fe7a23d4d658eabff5f9122ad89_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNC0xLTEtMS0yODkwNA_cec95e06-0069-4515-9755-eb335755a6b4"
      unitRef="shares">263000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if7ec8a43fe2b4ac39a998e248193d6bc_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNS03LTEtMS0yODkwNA_671c06c0-ebdb-4123-a86f-8f65cd8fe5d5"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNS0xMy0xLTEtMjg5MDQ_20e2dbbb-d812-4aed-bb75-500008d38d6f"
      unitRef="usd">-39000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie2884a29569d49d4b0c8e85c4112ecd9_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNi05LTEtMS0yODkwNA_ae91f4fd-78ec-42cf-995b-4813c54e2800"
      unitRef="usd">-62872000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNi0xMy0xLTEtMjg5MDQ_e42d496c-9f42-4d4e-90bd-ca6c4f9fd882"
      unitRef="usd">-62872000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia0ca39c8d80949cf9a8b1394e754badd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy0xLTEtMS0yODkwNA_b59a1be2-4f3e-401e-ad15-deee98f82049"
      unitRef="shares">104798000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia0ca39c8d80949cf9a8b1394e754badd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy0zLTEtMS0yODkwNA_910a9aba-fc50-41d9-8c3c-1ae9e26311be"
      unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i631979769d5c467191f41a0d5fc63ad8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy01LTEtMS0yODkwNA_be0489ba-6a50-4f6b-81b4-07c5a450f6fb"
      unitRef="usd">1080035000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e350ee9f64142d9bf9f4aed07b098ed_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy03LTEtMS0yODkwNA_a1d0f869-2896-4f0c-92c7-dd9ff9fdb551"
      unitRef="usd">-108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96cd0d22a1684bd7aae80feb5bceb816_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy05LTEtMS0yODkwNA_9fe4485d-13d3-42eb-b610-bb5ee6ea3777"
      unitRef="usd">-707564000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9edc90c95f0b450b9cf755c9e4f7bf63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy0xMS0xLTEtMjg5MDQ_12be9c0b-8985-4dce-8c39-6b058d2c9a6b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i496886d6abed4f999c1ace5f866fcb6c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOjMyZmYxZmFiYmM5YjQxZTA5NGQ4OWRmODhmODRhZjUxL3RhYmxlcmFuZ2U6MzJmZjFmYWJiYzliNDFlMDk0ZDg5ZGY4OGY4NGFmNTFfNy0xMy0xLTEtMjg5MDQ_6c8c53e8-2cbb-4c34-aa52-0c640d5d084d"
      unitRef="usd">372560000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i74a39646f95b4f89b1694a9939f5327a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS0xLTEtMS0yODkwNA_296e4528-2954-4310-bf3e-17f080af5ba5"
      unitRef="shares">105960000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74a39646f95b4f89b1694a9939f5327a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS0zLTEtMS0yODkwNA_3ae4ebbe-2917-4973-a21f-ce091b55d133"
      unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie35381f0ea5a44e383a735802d46673f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS01LTEtMS0yODkwNA_9e979dff-e220-4e07-a806-efccb86692a3"
      unitRef="usd">1219213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0af42ecb0f284f94b06b37a27ff07368_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS03LTEtMS0yODkwNA_18b1f8f9-cd8b-44e5-8fbc-49164849ed45"
      unitRef="usd">-136000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6449ff00713d4e21976744c273cccae8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS05LTEtMS0yODkwNA_9973b93a-9e88-4d8a-898d-1e2b1996a15f"
      unitRef="usd">-820755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5b117b978284cd6a85fd88b72346e47_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS0xMS0xLTEtMjg5MDQ_9857cacf-cd4a-4fbc-a054-0eaebac6aafd"
      unitRef="usd">19819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMS0xMy0xLTEtMjg5MDQ_e07b43c6-d330-4888-8bb9-0f447bf7033c"
      unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i90a5c8c8db52479c96374a3a0f3d318b_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMi01LTEtMS0yODkwNA_b36bf85a-2440-4443-8278-ed5792045489"
      unitRef="usd">19390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMi0xMy0xLTEtMjg5MDQ_01de59a2-f980-4a30-8a62-2f5bfee2df5e"
      unitRef="usd">19390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i66e8e9723fb342fc9b33826fac8e4171_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMy0xLTEtMS0yODkwNA_e5f99698-1187-448a-8dc7-e4f806a258ff"
      unitRef="shares">82000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i90a5c8c8db52479c96374a3a0f3d318b_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMy01LTEtMS0yODkwNA_8b646d67-6b37-4eec-bad2-60fdb0bcb453"
      unitRef="usd">576000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfMy0xMy0xLTEtMjg5MDQ_606b3c95-7751-4a3a-b028-c9e71d23bba9"
      unitRef="usd">576000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i66e8e9723fb342fc9b33826fac8e4171_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNC0xLTEtMS0yODkwNA_f353938b-e323-4b94-9f56-451e7969cbfe"
      unitRef="shares">98000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i66e8e9723fb342fc9b33826fac8e4171_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNC0zLTEtMS0yODkwNA_bc1b0f3e-d876-41e7-96a8-f03ee9f2fc27"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i90a5c8c8db52479c96374a3a0f3d318b_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNC01LTEtMS0yODkwNA_2586982a-2864-4e4b-ad48-18bb2c43a7c8"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNC0xMy0xLTEtMjg5MDQ_cd905b29-b3d6-4ea5-a839-53d6a5a54ec4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8d21df7082f14f328f24834628e5a4f9_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNS03LTEtMS0yODkwNA_d49ba82e-e370-4eec-b7ed-d9431c1ff768"
      unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNS0xMy0xLTEtMjg5MDQ_a92e3e3b-2409-4981-a4e8-dceb323e7664"
      unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ibf6ee791b62f4538b6bfc8ec3f396205_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNi0xMS0xLTEtMjg5MDQ_6c3e20a7-96a6-4482-b394-ad60041ec04e"
      unitRef="usd">486000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNi0xMy0xLTEtMjg5MDQ_cc3e69dc-2e0b-4035-a695-2ad2ef47ce00"
      unitRef="usd">486000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NetIncomeLoss
      contextRef="ie1c40ddf690448b0bb93935296f8f5d6_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNy05LTEtMS0yODkwNA_11e2727e-c4a6-4d8e-aa7c-0d71020f56fd"
      unitRef="usd">-41325000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfNy0xMy0xLTEtMjg5MDQ_6fc00d4b-8aee-49dc-a3eb-bd08bb72525c"
      unitRef="usd">-41325000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3aba4e2426de4a28acd5d29a6320c9bd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC0xLTEtMS0yODkwNA_840898af-1c50-46f5-8a7d-7c174c01a982"
      unitRef="shares">106140000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3aba4e2426de4a28acd5d29a6320c9bd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC0zLTEtMS0yODkwNA_9f2868e8-6584-45c2-a9ab-3862b67e90ab"
      unitRef="usd">199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18f94331985a400f846c766bf11f5925_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC01LTEtMS0yODkwNA_4eb1480d-840e-48f5-966e-fb0e1d92807e"
      unitRef="usd">1239178000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iced398649a794c4e8e8d86a2846c3ae1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC03LTEtMS0yODkwNA_01b2e890-5869-446c-bc5d-db70bdcff4af"
      unitRef="usd">-258000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3c4dcde64e0e45438fe394fa33f8e503_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC05LTEtMS0yODkwNA_8ab3795c-abff-45aa-a53a-eaa9fac9aaf2"
      unitRef="usd">-862080000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i381adb6a0c044161942d6a4204364b39_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC0xMS0xLTEtMjg5MDQ_b662d3b8-6321-4121-ba79-68d5252fc161"
      unitRef="usd">19333000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yMi9mcmFnOmJkMTQ3ZWE5ZDJjZjRmZWFhMTZjY2Q4OWU5ZjY5ZDI0L3RhYmxlOmM1MGFkOGZmMzY1NDQ1NTA5MjNmNDM5ZmI3N2E4ZDQ0L3RhYmxlcmFuZ2U6YzUwYWQ4ZmYzNjU0NDU1MDkyM2Y0MzlmYjc3YThkNDRfOC0xMy0xLTEtMjg5MDQ_dbd6e159-8af7-40c2-b336-9ed63251cf65"
      unitRef="usd">396372000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMy0xLTEtMS0yODkwNA_d227de26-a8cc-4811-b2dc-d6b4031f1657"
      unitRef="usd">-41811000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMy0zLTEtMS0yODkwNA_ee283d04-f3eb-460f-a3c4-5e3d0ac02a71"
      unitRef="usd">-62872000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNC0xLTEtMS0yODkwNA_cc1e060f-8694-4016-8669-5eef42c4d74f"
      unitRef="usd">19390000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNC0zLTEtMS0yODkwNA_09cf4c84-e79f-45e5-897a-a1622a2423f8"
      unitRef="usd">24504000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNS0xLTEtMS0yODkwNA_79fd2a01-4e79-47f8-b5da-4a7b133a175a"
      unitRef="usd">2689000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNS0zLTEtMS0yODkwNA_5b942b68-5797-45ff-be55-7ae11666d842"
      unitRef="usd">2573000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNy0xLTEtMS0yODkwNA_331dc219-6222-46df-a83d-303bf68a9732"
      unitRef="usd">-690000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfNy0zLTEtMS0yODkwNA_fb356eef-da66-4aeb-82b9-f728bacce13b"
      unitRef="usd">280000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfOC0xLTEtMS00MTcwNg_6507eb71-f2f6-4998-9190-5c8a2cb01ed8"
      unitRef="usd">2849000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfOC0zLTEtMS00MTUwMg_b042e20c-0c28-4c27-a21c-f95a03f75f66"
      unitRef="usd">0</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfOS0xLTEtMS0yODkwNA_376ae63f-0f27-4f87-8f3e-da22532f89f3"
      unitRef="usd">38157000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfOS0zLTEtMS0yODkwNA_7b535ebd-2c21-4623-894c-446a4430a76a"
      unitRef="usd">-10105000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTAtMS0xLTEtMjg5MDQ_9360862f-45a9-4d56-8d02-eb3602a1c597"
      unitRef="usd">-10529000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTAtMy0xLTEtMjg5MDQ_9910199c-b5b0-4694-a0fc-385d3931f746"
      unitRef="usd">450000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTItMS0xLTEtMjg5MDQ_77829db7-ae69-4d47-b697-a69156bb60ca"
      unitRef="usd">-2072000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTItMy0xLTEtMjg5MDQ_6bef847a-480a-4f93-ab29-5a896588b2e5"
      unitRef="usd">-5389000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTMtMS0xLTEtMjg5MDQ_ab0252cf-0ab9-4954-948f-eb71cc397435"
      unitRef="usd">-7203000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTMtMy0xLTEtMjg5MDQ_e69c3824-32e5-4fd7-bc26-3c0cc07a0e45"
      unitRef="usd">-2290000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMS0xLTEtNDEyOTg_c98939c3-0213-41bc-95f1-239b6c3cd0ff"
      unitRef="usd">-22979000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMy0xLTEtNDEyOTg_7ddc0841-befb-4279-8bec-b6d107ae9bb8"
      unitRef="usd">-27439000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMS0xLTEtNDE3MTU_a3c492e2-a371-454d-a985-88707b201206"
      unitRef="usd">559000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMy0xLTEtNDE1MjE_a0bfb1dd-c2f1-4546-a4a9-d702e9aec1a2"
      unitRef="usd">230000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMS0xLTEtMjg5MDQ_28e37e5d-8339-4932-a875-199748246b61"
      unitRef="usd">-75516000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTUtMy0xLTEtMjg5MDQ_61c10096-c7f0-4f73-8028-3a2ecb5094bd"
      unitRef="usd">-61308000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTctMS0xLTEtMjg5MDQ_990264d3-e0e6-4360-9c19-12ce19c5bf14"
      unitRef="usd">38911000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTctMy0xLTEtMjg5MDQ_9282896e-5cfb-4a06-9487-2be936d410d7"
      unitRef="usd">5778000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTgtMS0xLTEtMjg5MDQ_932148e2-a23d-4f83-bb9a-9d821498e6de"
      unitRef="usd">111199000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTgtMy0xLTEtMjg5MDQ_a5c493b4-4f25-4094-b08f-8e37c46fffb9"
      unitRef="usd">65875000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTktMS0xLTEtMjg5MDQ_72fd5267-a346-4223-9e56-4679db4a90f7"
      unitRef="usd">69416000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMTktMy0xLTEtMjg5MDQ_dd4e0803-ab6c-4230-b3b4-4b70c551fb99"
      unitRef="usd">38268000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjAtMS0xLTEtMjg5MDQ_8be82c63-41cb-4084-9091-6d15ff542c6b"
      unitRef="usd">-80694000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjAtMy0xLTEtMjg5MDQ_01d227eb-0b24-462f-a932-bb38e50f3cd7"
      unitRef="usd">-33385000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjItMS0xLTEtMjg5MDQ_0d8eddac-2792-479e-a37d-b9f4bcdbc66f"
      unitRef="usd">576000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjItMy0xLTEtMjg5MDQ_76405186-ebbc-4322-ad7b-2a17608f8cbf"
      unitRef="usd">1885000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjMtMS0xLTEtMjg5MDQ_25533600-0fcd-4d1b-8844-0a45d47adf9d"
      unitRef="usd">250000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjMtMy0xLTEtMjg5MDQ_5d3a619a-769a-43e8-94e4-50409d7a999b"
      unitRef="usd">0</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjQtMS0xLTEtMjg5MDQ_681ab7bd-4f57-42b6-ad43-d15dd4094583"
      unitRef="usd">250576000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjQtMy0xLTEtMjg5MDQ_b4b1e467-7003-490c-9c99-31463e47676f"
      unitRef="usd">1885000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjUtMS0xLTEtMjg5MDQ_d97f0fab-76d3-4b8e-bc5c-39ea0757c1ae"
      unitRef="usd">94366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjUtMy0xLTEtMjg5MDQ_bfd38335-b637-4d91-a32d-c4615b6e1d2d"
      unitRef="usd">-92808000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzEtMS0xLTEtNDE3Njg_7eae304d-eeab-4dec-a99b-4619abc7171f"
      unitRef="usd">-122000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzItMy0xLTEtNDE1NjQ_948e3c6d-d856-47c2-9754-6973b9d6c6cd"
      unitRef="usd">-39000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjYtMS0xLTEtMjg5MDQ_91116525-39fa-4d78-a772-0e88b895461d"
      unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="iee0675bb73de4fd3ab4bc406773f8cb4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjYtMy0xLTEtMjg5MDQ_7dd92bed-b3ad-4eb9-aedd-6b32b4c1923c"
      unitRef="usd">184434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjctMS0xLTEtMjg5MDQ_f28e4c9d-bc30-401a-acc5-3305747ae7b1"
      unitRef="usd">202249000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i496886d6abed4f999c1ace5f866fcb6c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMjctMy0xLTEtMjg5MDQ_4ffefd31-ad42-45df-8e7e-07b7946df91a"
      unitRef="usd">91587000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzctMS0xLTEtNDE4MTI_f21cdd8c-ac0a-4a6f-acbb-607b56997425"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzctMy0xLTEtNDE4MTI_54c494e0-4e61-4215-b025-ac8e65227c48"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzgtMS0xLTEtNDE4MTI_95dc6579-4263-4472-bef7-66d8581bd8ba"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8yNS9mcmFnOjg4YzZkMGI4OTE1YjRkNWE5ZTllZDQwYjZlZDhjOGM3L3RhYmxlOmMyNmM1NTUxZTM4ZDRmYmJiZmZkMmUxN2RlMWEyNDUxL3RhYmxlcmFuZ2U6YzI2YzU1NTFlMzhkNGZiYmJmZmQyZTE3ZGUxYTI0NTFfMzgtMy0xLTEtNDE4MTI_f79678d1-343a-4168-939d-d43c1780db0b"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMTE0MjY_5c260033-9646-445d-b372-36d696598e21">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#x201c;Company&#x201d;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#x2019;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#x201c;RNAi&#x201d;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#x2019;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-APOC3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Two Phase 2b and one Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ANG3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Two Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ENAC2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-HSD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fazirsiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HZN-457 (formerly ARO-XDH)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;JNJ-75220795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Muscle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#x2019;s principal executive offices are located in Pasadena, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of fiscal 2023, the Company continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety tolerability, pharmacokinetics and pharmacodynamics of a development-stage medicine, HZN-457 (formerly ARO-XDH), which is out-licensed to Horizon, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;enrolled the first subject in Amgen&#x2019;s Phase 3 trial of Olpasiran, triggering a $25.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;entered into a Royalty Purchase Agreement (the &#x201c;Royalty Pharma Agreement&#x201d;) with Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) on November 9, 2022, pursuant to which Royalty Pharma paid $250.0&#160;million upfront (See Note 11 &#x2014; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#x201c;Item 1. Financial Statements.&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;announced Topline Results from SEQUOIA Phase 2 Study of Fazirsiran (formerly ARO-AAT) in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease in which;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Fibrosis regression was observed in 50% of patients receiving Fazirsiran;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Median reductions of 94% of Z-AAT accumulation in the liver and mean reductions of 68% in histologic globule burden were observed;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Treatment emergent adverse events were generally well balanced between Fazirsiran and placebo groups;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Results were consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#x2019;s financial position at December&#160;31, 2022 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#x2019;s Annual Report on Form 10-K for the year ended September&#160;30, 2022 for more complete descriptions and discussions. Operating results and cash flows for the three months ended December&#160;31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s primary sources of financing have been through the sale of its securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#x2019;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#x2019;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#x2019;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company had $202.2 million in cash and cash equivalents (including $7.3 million in restricted cash), $299.6 million in short-term investments and $115.8&#160;million in long-term investments to fund operations. During the three months ended December&#160;31, 2022, the Company&#x2019;s cash and cash equivalents and investments balance increased by $135.3 million which was primarily due to the $250.0&#160;million upfront payment received from Royalty Pharma. See Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company is eligible to receive up to $4.1 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the significant accounting policies disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:ScheduleOfCurrentProductsTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMwMjkxNA_6899360e-8cf7-40b2-9290-170103979896">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-APOC3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Two Phase 2b and one Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ANG3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Two Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-ENAC2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-HSD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fazirsiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HZN-457 (formerly ARO-XDH)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;JNJ-75220795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Muscle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:ScheduleOfCurrentProductsTableTextBlock>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="i5cea4208cdeb42c9a22cc59d648953a0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMxMzg3MA_c77da3d2-db44-4040-b45b-6916a9bb9dc0"
      unitRef="usd">15000000</arwr:UpfrontMilestonePaymentReceived>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="i5db3274cc4d14160ae2d5f647d651c24_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMxMzg4NQ_16168c3a-b730-4b55-bf56-315c3bce99f4"
      unitRef="usd">25000000</arwr:UpfrontMilestonePaymentReceived>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="ia65665136f1d40fd862086f2dd922e9f_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMxMzg1MA_2ef64cd0-d7e7-444b-a20c-19502bd102ac"
      unitRef="usd">250000000</arwr:UpfrontMilestonePaymentReceived>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMzc2MA_6990d077-d865-470a-ab92-c312781ce98a"
      unitRef="usd">202200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMTY3Ng_b0532963-9da9-4083-af7e-cccc0d96f803"
      unitRef="usd">7300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMzc2NA_6c0c1cac-62ab-46c3-8e58-6dd1a2207ad7"
      unitRef="usd">299600000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMTA5OTUxMTY4NjkwNw_9116a637-674f-4cb6-acce-15ecbbfcc720"
      unitRef="usd">115800000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:IncreaseDecreaseInCashAndInvestments
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMzc4MA_ea2043b4-77de-47ba-8c4b-245610545655"
      unitRef="usd">135300000</arwr:IncreaseDecreaseInCashAndInvestments>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="ia65665136f1d40fd862086f2dd922e9f_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMjE5OTAyMzMxMzg2Nw_2ef64cd0-d7e7-444b-a20c-19502bd102ac"
      unitRef="usd">250000000</arwr:UpfrontMilestonePaymentReceived>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfNzE0NjgyNTYzMzQ3Mg_aa42b282-d14e-4c66-8ea8-bc182144a035"
      unitRef="usd">4100000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zMS9mcmFnOjJjOGRjZWQ3YTIzMDRmZDhhYTVmNGJiYzQyNDBhZjVjL3RleHRyZWdpb246MmM4ZGNlZDdhMjMwNGZkOGFhNWY0YmJjNDI0MGFmNWNfMTE0Mjk_1130cc84-0263-4d6d-af7e-38cc2e07c82f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recent accounting pronouncements that have significantly impacted this Quarterly Report on Form 10-Q, beyond those disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTk3NzQ_1017b446-61e7-4514-bf86-c53a78fd7b71">COLLABORATION AND LICENSE AGREEMENTSGlaxosmithkline Intellectual Property (No. 3) Limited (&#x201c;GSK&#x201d;)&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#x201c;GSK License Agreement&#x201d;). Under the GSK License Agreement, GSK has received an exclusive license for ARO-HSD. The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize ARO-HSD. The Company has completed its Phase 1/2 study of ARO-HSD, and GSK is now wholly responsible for all clinical development and commercialization of ARO-HSD in its territory. Under the terms of the agreement, the Company has received an upfront payment of $120.0&#160;million and is eligible for additional payments of $30.0&#160;million at the start of a Phase 2 trial and $100.0&#160;million upon achieving (i) a successful Phase 2 trial readout and (ii) the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0&#160;million at first commercial sale, and up to $590.0&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibility to complete the Phase 1/2 study (the &#x201c;GSK R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of the GSK R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price totaled $120.0&#160;million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0&#160;million was fully recognized as of September&#160;30, 2022. There were no revenue recorded associated with the GSK License Agreement for the three months ended December&#160;31, 2022 and 2021. There were no contract assets and liabilities recorded as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Horizon Therapeutics Ireland DAC (&#x201c;Horizon&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#x201c;Horizon License Agreement&#x201d;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. The Company conducted all activities through the preclinical stages of development of, and Horizon is now wholly responsible for clinical development and commercialization of HZN-457. In July 2021, the Company received &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$40.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as an upfront payment and is eligible to receive up to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$660.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#x201c;Horizon R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Horizon R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;amp;D Services, which are the responsibility of the Company, Horizon is responsible for managing future clinical development and commercialization of HZN-457. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price totaled $40.0&#160;million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocates the total $40.0&#160;million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;amp;D Services. Revenue is recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue for the three months ended December&#160;31, 2022 and 2021 were $21.7&#160;million and $6.7&#160;million, respectively. There were $15.0&#160;million in contract assets recorded as accounts receivable and $0 in contract liabilities recorded as deferred revenue as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;). Under the Takeda License Agreement, Takeda and the Company will co-develop its Fazirsiran program, the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, Fazirsiran, if approved, will be co-commercialized under a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50/50 profit sharing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize Fazirsiran, while the Company will be eligible to receive tiered royalties of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on net sales. In &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company received &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$300.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $595.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of Fazirsiran drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Takeda R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price totaled $300.0&#160;million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the Fazirsiran license and the associated Takeda R&amp;amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company recognized $16.3&#160;million and $20.8&#160;million in connection with these efforts for the three months ended December&#160;31, 2022 and 2021, respectively. There were $0 of contract assets recorded as accounts receivable and $107.1 million of contract liabilities recorded as deferred revenue, of which $66.3&#160;million was classified as current deferred revenue, as of December&#160;31, 2022. The Company also recorded $9.8&#160;million as accrued expenses as of December&#160;31, 2022 that was primarily driven by co-development and co-commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, and the Company entered into a License Agreement (the &#x201c;Janssen License Agreement&#x201d;) and a Research Collaboration and Option Agreement (the &#x201c;Janssen Collaboration Agreement&#x201d;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#x201c;JJDC&#x201d;), Johnson &amp;amp; Johnson's venture capital arm (the &#x201c;JJDC Stock Purchase Agreement&#x201d;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#x2019;s JNJ-3989 (ARO-HBV) program, the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#x2019;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which the Company would develop clinical candidates. These candidates were subject to certain restrictions and did not include candidates that already were in the Company&#x2019;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $175.0&#160;million as an upfront payment, $75.0&#160;million in the form of an equity investment by JJDC in the Company&#x2019;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0&#160;million, and the Company may receive up to $0.8&#160;billion in development and sales milestone payments for the Janssen License Agreement, and up to $0.6&#160;billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement and up to low teens under the Janssen Collaboration Agreement. During 2022, Janssen&#x2019;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Janssen License Agreement and Janssen Collaboration Agreement, the Company identified one distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#x2019;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#x201c;Janssen R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Janssen R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#x2019;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the transaction price totaled approximately $252.7&#160;million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0&#160;million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;amp;D Services to be performed. The Company has allocated the total $252.7&#160;million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;amp;D Services. The Company recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were no contract assets and liabilities recorded as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. Janssen&#x2019;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement during 2022. In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0&#160;million milestone payment to the Company. This $10.0&#160;million milestone payment was recognized entirely as of September 30, 2021. There were no revenue recorded associated with the Company&#x2019;s agreement with Janssen for the three months ended December&#160;31, 2022 and 2021. There were no contract assets and liabilities recorded as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amgen Inc. (&#x201c;Amgen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#x201c;Olpasiran Agreement&#x201d;), Amgen received a worldwide, exclusive license to the Company&#x2019;s novel RNAi Olpasiran program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the first collaboration and license agreement (the &#x201c;First Collaboration and License Agreement&#x201d; or the &#x201c;ARO-AMG1 Agreement&#x201d;), Amgen received an option to a worldwide, exclusive license to ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $35.0&#160;million in upfront payments, $21.5&#160;million in the form of an equity investment by Amgen in the Company&#x2019;s common stock, and $30.0&#160;million in milestone payments. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $20.0&#160;million milestone payment to the Company. In December 2022, Amgen enrolled the first subject in its Phase 3 trial of Olpasiran, which triggered a $25.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. Revenue for the three months ended December&#160;31, 2022 and 2021 were $25.0&#160;million and $0, respectively. There were $25.0&#160;million in contract assets recorded as accounts receivable and $0 in contract liabilities recorded as deferred revenue as of December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, in November 2022, Royalty Pharma and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $375.0&#160;million in remaining development, regulatory and sales milestone payments payable by Amgen under the Olpasiran Agreement. See Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2022, Visirna and the Company entered into a License Agreement (the &#x201c;Visirna License Agreement&#x201d;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#x2019;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#x2019;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#x201c;Visirna SPA&#x201d;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#x2019;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60.0&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.&lt;/span&gt;&lt;/div&gt;During the three months ended December&#160;31, 2022, the Company performed manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received $0.7&#160;million as consideration for this manufacturing and development work, and there were no contract assets and liabilities recorded as of December&#160;31, 2022.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <arwr:MilestonePaymentEarned
      contextRef="ied9e360396f44e37a5fa2c12b7d58208_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTM2OA_ac2f3c21-cfbe-43ea-8161-1b4358cf6a44"
      unitRef="usd">120000000</arwr:MilestonePaymentEarned>
    <arwr:MilestonePaymentReceivableAtStartOfPhaseTwo
      contextRef="ied9e360396f44e37a5fa2c12b7d58208_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTM4NA_2e163aff-c3b9-42bd-9908-e24bf8ec72ec"
      unitRef="usd">30000000</arwr:MilestonePaymentReceivableAtStartOfPhaseTwo>
    <arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree
      contextRef="ied9e360396f44e37a5fa2c12b7d58208_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTM5OQ_d33644fc-3be2-4603-9893-00aa726b8d4a"
      unitRef="usd">100000000</arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree>
    <arwr:CommercialMilestonePaymentsAtFirstCommercialSale
      contextRef="if6d16e113b834a97a9fcbf8e0681786c_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQxNQ_3730472e-b457-45bb-a4f8-677a435781f2"
      unitRef="usd">190000000</arwr:CommercialMilestonePaymentsAtFirstCommercialSale>
    <arwr:SalesRelatedMilestonePayments
      contextRef="if6d16e113b834a97a9fcbf8e0681786c_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQzMQ_7f7f6b85-86ac-40a1-9834-d42ad3e740bf"
      unitRef="usd">590000000</arwr:SalesRelatedMilestonePayments>
    <arwr:InitialTransactionPrice
      contextRef="ief93fea769094d7eb5fb5948a8f0d52b_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQ0Nw_e40a68eb-028b-46de-be13-a482cd36f863"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="ief93fea769094d7eb5fb5948a8f0d52b_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQ3Nw_e40a68eb-028b-46de-be13-a482cd36f863"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="ief93fea769094d7eb5fb5948a8f0d52b_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQ5NA_e40a68eb-028b-46de-be13-a482cd36f863"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i342c597acfec441dab0f3b37209a55ba_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4MzA0MA_568dc879-65df-4399-aeca-f96ff40ee744"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00c306c538924e74a11b388564ca6b80_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4MzA0MA_e1c94088-488b-444e-8e96-bb5697587192"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i038818ff5b9843f1b9d17f64430e188b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4MzE3Mg_510557a9-1a0e-4f8a-b3fc-ad0a1d73b5f1"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i038818ff5b9843f1b9d17f64430e188b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4MzE3Mg_8cafda81-dd15-4f42-b254-bbd453d924d2"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="i378c508c95df484ba3e6ef6a5454bc94_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTQ5Nw_5b7606a6-bf6b-4f8a-a32a-1407e39f1297"
      unitRef="usd">40000000</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="ide8cc0f14c60475299147a3dd0c03daa_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTUxMg_117b5c87-90cd-43c9-b762-54cc95387225"
      unitRef="usd">660000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctBundle
      contextRef="i7372fb791af34e0d8dd8edb75dff1a73_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTYzMA_fbd5d5dc-9dc2-4c31-9464-dc488a37b861"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i7372fb791af34e0d8dd8edb75dff1a73_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTYzMQ_b673ac1b-9851-41cd-80f8-5ada3385487b"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="i2a500b1709164996b845bbac989d7b84_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTUyOA_30515ad1-2a59-406d-973b-ff89333a3652"
      unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="i2a500b1709164996b845bbac989d7b84_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU1Ng_30515ad1-2a59-406d-973b-ff89333a3652"
      unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i2a500b1709164996b845bbac989d7b84_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU1OA_50c62331-a738-4016-b858-127410e137e6"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="i5cea4208cdeb42c9a22cc59d648953a0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU4MA_c77da3d2-db44-4040-b45b-6916a9bb9dc0"
      unitRef="usd">15000000</arwr:UpfrontMilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida93008e93a8494783ed240b674e7a64_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU4Mw_eec3097f-fcfc-4597-871d-26086231e710"
      unitRef="usd">21700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i988f7cda978749b1b3f5337961e8742e_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTU5OA_56cde5d1-363d-4443-a8b9-30a7d2e22466"
      unitRef="usd">6700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i09940e4ffb194a128c45cb16ba228ade_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTYxMg_117c1d16-8c8d-4679-9b99-ad248134c988"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i09940e4ffb194a128c45cb16ba228ade_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTYyNw_07cca7ae-2382-4d8f-8fb7-6d23770aeec3"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="ia939243a8ac74e65952dd91c16f544b4_D20201007-20201007"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY0Nw_d5b75edc-8b4b-4f50-b35f-a7f582ef3bdc"
      unitRef="number">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="icda38447f5614cebb8ef1552acb61332_D20201007-20201007"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY1Mg_2aa9351f-1a55-4647-b020-f14877e4f1f5"
      unitRef="number">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="i9284be9df69d4141bedb600f69d1042c_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY1Nw_800897c5-c522-46d2-946b-22071b88d0c5"
      unitRef="usd">300000000</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i3c44558d7e484eb2a6b9cae263a65437_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY3Mw_20e02e6a-44fd-40fc-a55a-3373a3413107"
      unitRef="usd">595000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctBundle
      contextRef="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY4OA_f81f8fdd-f612-4785-8bae-2bf768a1d254"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTY5NQ_bf16c4b1-dcd0-4fab-ba32-6d76b7433d67"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTcwNQ_9d62eded-943a-40a4-be08-2cee75652f41"
      unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="ic629cc217f3a44d9b02f96176e7908f8_D20201007-20201007"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTczNQ_9d62eded-943a-40a4-be08-2cee75652f41"
      unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09ec1fea81bb4a3f85a50d428952c2a4_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTczOA_8920ea92-1e2e-488e-bae0-53894e0d0012"
      unitRef="usd">16300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idca13f49c2ac4338bd38897981c0e87b_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTc1Mw_bc94f364-4209-4cab-88c6-ee1f7e72d571"
      unitRef="usd">20800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="if05fdd27fe28461a9e78cc9c9d4e69d0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTc2OA_6e9820ea-5b3c-494d-8eee-703a0d3300db"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0cf0f351abeb4ff9920e8f448a4b04d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ4Mzg4OA_d350d019-8830-4759-8758-a7db80d12f5d"
      unitRef="usd">107100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0cf0f351abeb4ff9920e8f448a4b04d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTgwMA_810097f6-e8db-4b56-a79b-8acecf03d1fb"
      unitRef="usd">66300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib3b9fa1ae2884a8d985db088de873bf2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTc3Mg_554ded45-4e03-4718-9ee7-f57c6bd1244f"
      unitRef="usd">9800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="idad13da460ff45d888e1281a60477acd_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTgxNQ_7ee849f2-19a5-477a-9d51-d1187b46b14e"
      unitRef="usd">175000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1dbada01124d4560be0e826511f8dce1_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTgzMQ_dc64e39c-e940-47d4-945d-bd8e69b139a7"
      unitRef="usd">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentEarned
      contextRef="i2a989d7ce0a44ccf9bf1022c8f7f9b2a_I20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg0Ng_0163bc28-3410-4ac1-a8fc-5f3f94722730"
      unitRef="usd">73000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i92f82a268c774e9bb9992a060a63740b_I20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg2MQ_4c21a42e-f412-46a7-b1c2-2a77b775a62f"
      unitRef="usd">800000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="iba27b7bdc69548378fef58b5f42961ff_I20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg3NQ_5138cd1f-b560-40d6-897b-e2eced81ad6e"
      unitRef="usd">600000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i328d3ff81ad3491a99bdf175a0d11762_D20181003-20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg4OA_e87f1d8b-fa62-4eee-ab98-19d5b431ef9a"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="if317166287bb4b13944a83a251e50077_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTg5Nw_79e75add-ad2c-4a7c-a57f-16bc510c0aaf"
      unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned
      contextRef="iadbb1a93d51d4301be4fa1d4b852337c_I20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTkxMw_35765347-e6f8-4364-8543-2923c8a24a57"
      unitRef="usd">25000000</arwr:MilestonePaymentEarned>
    <arwr:InitialTransactionPrice
      contextRef="if317166287bb4b13944a83a251e50077_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTkyOA_6593be39-f8f3-4e35-b06b-272d0860a037"
      unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2766009a08bc437580f4294c351f7cd6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk0Mw_844bec78-dfc3-486d-9e06-19418d4bf3dd"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i2766009a08bc437580f4294c351f7cd6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk0Mw_e7412e04-d4ac-4edd-a77d-264b2ed56843"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <arwr:MilestonePaymentEarned
      contextRef="i5c684d870f3a4136a5f54739f8a8b3a0_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk1Mg_c2f423f4-aca2-41f7-9d72-17606db8a757"
      unitRef="usd">10000000</arwr:MilestonePaymentEarned>
    <arwr:MilestonePaymentEarned
      contextRef="i2b7883a42e42404293d06a18e9cd891e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk2Nw_a5313577-420d-46e9-be92-56138f6a7cc8"
      unitRef="usd">10000000</arwr:MilestonePaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2364b30800c9442ab7f8d6ccf86939e9_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjE1MA_3fe0a415-bad3-4fc2-8a1c-a8eb2f907f9c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23c624b66e784ad1baf3e3fb6bea568e_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjE1MA_4ac6d9f5-1033-47d4-8227-89962c59e951"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i9db0b5443200492482544d7c90204e4a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjExNA_734c7869-7588-401b-b757-17060828325a"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9db0b5443200492482544d7c90204e4a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjExNA_bb65ea6f-8b35-4bd5-ab84-4053f4cbf075"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:NumberOfAgreements
      contextRef="if64321b9c6e247da8443d05133b342ff_I20160928"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ3NjczMw_81452d31-487e-44f9-91ac-ffed6aa6ead3"
      unitRef="agreement">2</arwr:NumberOfAgreements>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="iae284bdb5fea480a9e15773836d59063_D20160928-20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk4Mg_24b24309-1b96-4f42-befa-af8491a59424"
      unitRef="usd">35000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iae284bdb5fea480a9e15773836d59063_D20160928-20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNTk5Nw_0d7f3d8d-3884-4925-9700-360c463fcabe"
      unitRef="usd">21500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentReceived
      contextRef="ibc17c83235054c9298c89a26c8fb35e1_I20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjAxMg_1ce3d4ae-edfb-486c-9e75-bfe92a78866c"
      unitRef="usd">30000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived
      contextRef="id0f7402c90cf488f944efc5f47b5caeb_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjAyNw_1816d054-1d2a-4f69-9316-760f1de260f1"
      unitRef="usd">20000000</arwr:MilestonePaymentReceived>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="i5db3274cc4d14160ae2d5f647d651c24_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA1NQ_16168c3a-b730-4b55-bf56-315c3bce99f4"
      unitRef="usd">25000000</arwr:UpfrontMilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c6d551c455a4169899e5d3a186b7638_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA1OA_1ea02a9a-f24d-41a9-8c33-0ba3cfcd9468"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2933262b7b1411284a2bb299c20d306_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA3Mw_4c091a3d-f383-4d61-9cc9-935e79da13e3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i1f61a8d393224431a507b3f200215db7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA3Nw_2516118e-c3b5-405a-b5e2-ebdb222b27b6"
      unitRef="usd">25000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i1f61a8d393224431a507b3f200215db7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA5Mg_139ed1a0-d90d-4a9c-a49b-0cef42c3643b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i9cfe482a057d4dca8df5560f98cef3e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjA5Ng_761200a7-5059-4f13-9e70-296e62abe7d0"
      unitRef="usd">375000000</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i0ee8ab30ad3445958f3b561928b95608_D20220425-20220425"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMTY0OTI2NzQ3OTYyNQ_e820f7b8-317b-4bb0-a6f4-1b963a027702"
      unitRef="usd">60000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9c7506b5d91485d9801a47dca99e510_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjEzNA_a544184d-8808-4a1c-bfd8-2b68c384f221"
      unitRef="usd">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ic3e51d9c60c54ce1a159fc24a37a7ae1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjEyNQ_35df77fc-ce66-480c-ba28-817eaa0015d3"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic3e51d9c60c54ce1a159fc24a37a7ae1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNC9mcmFnOjIyODc5NTAzNGQ5MTRjNGRhMjUwOTRiNDFkNWRkNDYzL3RleHRyZWdpb246MjI4Nzk1MDM0ZDkxNGM0ZGEyNTA5NGI0MWQ1ZGQ0NjNfMjE5OTAyMzMyNjEyNQ_9aa5eda7-79bb-4b0f-a269-576310b0b7b9"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RleHRyZWdpb246OTdiZDRkZTc1YzcwNDM4YTk4ODhkZDVhOTc4ZmRhYzNfNTQy_3467cb1b-079c-4bae-b36e-bb1040a9ced8">PROPERTY AND EQUIPMENT&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computers, software, office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;181,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;141,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(33,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(31,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;147,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for property and equipment for the three months ended December&#160;31, 2022 and 2021 was $2.3 million and $2.1 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increase in the construction in progress during the three months ended December&#160;31, 2022 was mainly due to the continuing developments of manufacturing, laboratory and office facilities in Verona, Wisconsin as well as a new laboratory and office facility in San Diego, California. See Note 7.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RleHRyZWdpb246OTdiZDRkZTc1YzcwNDM4YTk4ODhkZDVhOTc4ZmRhYzNfNTQz_e1217fff-ca52-4654-b96e-ef8b010edc37">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computers, software, office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;181,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;141,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(33,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(31,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;147,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;110,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMi0xLTEtMS0yODkwNA_1587386e-f533-4eef-a0b4-63de2526d057"
      unitRef="usd">2182000</arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross>
    <arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMi0zLTEtMS0yODkwNA_54e48fab-b6ec-4453-bd43-1eb264ca2a23"
      unitRef="usd">2182000</arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross>
    <us-gaap:Land
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMy0xLTEtMS0yOTU0OA_62dbc8ae-b4d9-4059-99e6-ed19fc6a3a61"
      unitRef="usd">2996000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMy0zLTEtMS0yOTU0OA_de6ef278-fc95-48d3-866b-c61caf7f3e6e"
      unitRef="usd">2996000</us-gaap:Land>
    <arwr:ResearchEquipmentGross
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMy0xLTEtMS0yODkwNA_c514b4af-9121-4556-827b-84866c549cfa"
      unitRef="usd">43739000</arwr:ResearchEquipmentGross>
    <arwr:ResearchEquipmentGross
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfMy0zLTEtMS0yODkwNA_05d86dcd-fecc-4af1-9cce-7e86d3778914"
      unitRef="usd">38283000</arwr:ResearchEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNC0xLTEtMS0yODkwNA_00a93f59-5cd9-4328-8c31-0e1c1fbee78c"
      unitRef="usd">42017000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNC0zLTEtMS0yODkwNA_8dbc05f1-4dff-4bca-bd89-3e3bc392179e"
      unitRef="usd">42017000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNS0xLTEtMS0yODkwNA_6fb1b3f9-b672-4135-ac0c-185fb9a755cd"
      unitRef="usd">90215000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNS0zLTEtMS0yODkwNA_4393d005-5f46-42df-a8b9-7152c6928f07"
      unitRef="usd">56373000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNy0xLTEtMS0yODkwNA_a7ebc5ff-8a12-4279-927a-541a69dd9b27"
      unitRef="usd">181149000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfNy0zLTEtMS0yODkwNA_0216927a-5827-4b6e-a2fa-2defaea02274"
      unitRef="usd">141851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfOC0xLTEtMS0yODkwNA_0b0808ec-e04c-4be0-a90e-440d60354965"
      unitRef="usd">33835000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfOC0zLTEtMS0yODkwNA_4cea00e8-949a-4783-a8a1-159c6637ada0"
      unitRef="usd">31554000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfOS0xLTEtMS0yODkwNA_0eb998bc-4603-40c3-bd3b-dbaefccaafb9"
      unitRef="usd">147314000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RhYmxlOjlkNjFjZTkyM2M1ZjRjYjhhMTlmZjRkMWI5YzI1ZGVkL3RhYmxlcmFuZ2U6OWQ2MWNlOTIzYzVmNGNiOGExOWZmNGQxYjljMjVkZWRfOS0zLTEtMS0yODkwNA_fdaf8cb6-34f3-4839-9d3e-310edfdf2816"
      unitRef="usd">110297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RleHRyZWdpb246OTdiZDRkZTc1YzcwNDM4YTk4ODhkZDVhOTc4ZmRhYzNfMjMx_d38add70-2fdd-43ad-9bc9-e96ceddd35e6"
      unitRef="usd">2300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF8zNy9mcmFnOjk3YmQ0ZGU3NWM3MDQzOGE5ODg4ZGQ1YTk3OGZkYWMzL3RleHRyZWdpb246OTdiZDRkZTc1YzcwNDM4YTk4ODhkZDVhOTc4ZmRhYzNfMjM4_3bbe5882-3b48-45ca-b92a-b9f5ffbfdd68"
      unitRef="usd">2100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RleHRyZWdpb246YjQ5MWNmZTE2OGZmNGIzMjlmY2IxYWJhOWI5M2MyOTFfMTYzMA_b89d5153-3299-40fa-9db9-12cb7c7e5cbf">INVESTMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;264,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RleHRyZWdpb246YjQ5MWNmZTE2OGZmNGIzMjlmY2IxYWJhOWI5M2MyOTFfMTYzMQ_1ae8db4c-1e4a-4e74-85c4-240be1626a11">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;264,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNS0xLTEtMS0zMzgyNA_b6e403f5-38bb-4937-8c7c-57c61361c5c7"
      unitRef="usd">299582000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNS0zLTEtMS0zMzgyNA_cbc0d8f6-df5a-48db-8287-0cb4762a261b"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNS01LTEtMS0zMzgyNA_5cd34c6b-b795-4276-890d-5ec2be219156"
      unitRef="usd">2644000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNS03LTEtMS0zMzgyNA_7a85147d-eaae-474f-a688-6c6a5157ddba"
      unitRef="usd">296938000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i917462b04ff841eaac0e3339bd0cb7bf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNi0xLTEtMS0zMzgyNA_22c0917a-4f64-4f93-a111-acdc20fd338a"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i917462b04ff841eaac0e3339bd0cb7bf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNi0zLTEtMS0zMzgyNA_a3f2c466-d0bf-47cb-bcfe-426ae348d0b9"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i917462b04ff841eaac0e3339bd0cb7bf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNi01LTEtMS0zMzgyNA_de97a377-1221-4cbf-b9cc-cf7a27f62dff"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i917462b04ff841eaac0e3339bd0cb7bf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNi03LTEtMS0zMzgyNA_21061b90-1904-46dd-859f-767fbcf59a58"
      unitRef="usd">0</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNy0xLTEtMS0zNDYyNg_f0a3baab-5876-4f67-83b6-9c3d1140fe88"
      unitRef="usd">299582000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNy0zLTEtMS0zNDYyNg_c2819cc2-77a2-485d-8419-ebd5dfb2bc32"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNy01LTEtMS0zNDYyNg_b88a948e-7392-4d47-8280-63417ee160d9"
      unitRef="usd">2644000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfNy03LTEtMS0zNDYyNg_1d34afe7-409b-4a35-b744-d01fc7b3f313"
      unitRef="usd">296938000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTAtMS0xLTEtMzM4MjQ_7ef6aabe-fa72-413e-b6d7-720b721b2f73"
      unitRef="usd">115774000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTAtMy0xLTEtMzM4MjQ_c8a302ed-6ef3-4cb8-86d0-4f3767252c15"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTAtNS0xLTEtMzM4MjQ_af301659-f827-4202-88e5-7bb00232742d"
      unitRef="usd">4440000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="if2a387c1c2504379a168792bc1c3e50b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTAtNy0xLTEtMzM4MjQ_ba244613-34f8-44cc-bc06-6cfd0a3e7c11"
      unitRef="usd">111334000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTEtMS0xLTEtMzM4MjQ_681924c1-54b9-4b52-a5c1-8254d2d1563b"
      unitRef="usd">115774000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTEtMy0xLTEtMzM4MjQ_c76423b7-5f09-4b85-813c-82540a5e6163"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTEtNS0xLTEtMzM4MjQ_78ae3a41-1234-44fd-bca0-b708235ac452"
      unitRef="usd">4440000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjc1NDNlYjZjNDJhYzQzYTE5OGRlYjA2N2I5YWU5ZjQyL3RhYmxlcmFuZ2U6NzU0M2ViNmM0MmFjNDNhMTk4ZGViMDY3YjlhZTlmNDJfMTEtNy0xLTEtMzM4MjQ_d19be83f-82bb-4582-89f5-ea17a152a0bb"
      unitRef="usd">111334000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="ie3f7584f587e4681907eb42f27510096_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNS0xLTEtMS0zODA2Nw_3c04f251-9f4a-41ca-94be-a2d96324807a"
      unitRef="usd">218391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="ie3f7584f587e4681907eb42f27510096_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNS0zLTEtMS0zODA2Nw_62c2b01b-b8ca-430f-ab4e-97bd95954dc4"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="ie3f7584f587e4681907eb42f27510096_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNS01LTEtMS0zODA2Nw_c6f15074-9b5a-4fb1-b7a6-d40a9c4e1540"
      unitRef="usd">3661000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="ie3f7584f587e4681907eb42f27510096_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNS03LTEtMS0zODA2Nw_5905a4df-6fa8-4cd7-b4e2-5ab963fafe58"
      unitRef="usd">214730000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="iea276053053c4bb59f85d31ebab93a3e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNi0xLTEtMS0zODA2Nw_f24454e3-fa41-4014-81c6-fe278022e52c"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="iea276053053c4bb59f85d31ebab93a3e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNi0zLTEtMS0zODA2Nw_48a49ba5-57c5-4040-ace2-689eff8f64eb"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="iea276053053c4bb59f85d31ebab93a3e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNi01LTEtMS0zODA2Nw_6d49b477-bb5b-4885-a8fc-7416569a04ce"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="iea276053053c4bb59f85d31ebab93a3e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNi03LTEtMS0zODA2Nw_c37d7ade-29fc-451a-a661-245214f559a6"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNy0xLTEtMS0zODA2Nw_e0164fba-107f-45b8-a614-6868c0a0fea7"
      unitRef="usd">268391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNy0zLTEtMS0zODA2Nw_1b288f23-e4a8-4ddc-998a-42c3ba6b83f5"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNy01LTEtMS0zODA2Nw_2a5b6362-4557-417e-9bb2-8aec63872ce6"
      unitRef="usd">3661000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfNy03LTEtMS0zODA2Nw_524c3265-2619-4deb-8140-67c0b7e8593c"
      unitRef="usd">264730000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="ie3f7584f587e4681907eb42f27510096_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTAtMS0xLTEtMzgwNzM_d1de46b0-db33-48a6-9b7f-0a5b76a886eb"
      unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="ie3f7584f587e4681907eb42f27510096_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTAtMy0xLTEtMzgwNzM_d8d577d1-3c29-4575-bbbd-8f8e0f08a5cf"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="ie3f7584f587e4681907eb42f27510096_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTAtNS0xLTEtMzgwNzM_cb8c04df-b293-44d0-95fa-e323d1d36144"
      unitRef="usd">5569000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="ie3f7584f587e4681907eb42f27510096_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTAtNy0xLTEtMzgwNzM_679b69f6-8802-47ba-a60a-665abef53e08"
      unitRef="usd">100303000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTEtMS0xLTEtMzgwNzM_513aa2e7-7b83-47ac-8eb2-1fa76ba636ab"
      unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTEtMy0xLTEtMzgwNzM_04ec07f5-07c0-4431-b724-7d70bba0e49d"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTEtNS0xLTEtMzgwNzM_a6a15903-f503-4899-a7be-b09a71587ae7"
      unitRef="usd">5569000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80MC9mcmFnOmI0OTFjZmUxNjhmZjRiMzI5ZmNiMWFiYTliOTNjMjkxL3RhYmxlOjE5ZDNmZWE0YTQ1MDQ2NzA5YzRmZTg2NTQzZDVkZmZjL3RhYmxlcmFuZ2U6MTlkM2ZlYTRhNDUwNDY3MDljNGZlODY1NDNkNWRmZmNfMTEtNy0xLTEtMzgwNzM_2353b861-acc1-4511-8bc6-e228ba5d25d1"
      unitRef="usd">100303000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfOTgz_ed6f1dd6-64c5-4bd4-a449-e4de6866e480">INTANGIBLE ASSETS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the three months ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense for each of the three months ended December&#160;31, 2022 and 2021 was $0.4 million. None of the intangible assets with definite useful lives are anticipated to have a residual value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfMjE5OTAyMzI2MDQyMw_62555f15-591f-4d2d-a65a-c7df9e8a7973">The following table presents the components of intangible assets: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy0xLTEtMS0yOTYzNQ_a0c977aa-4b5f-4266-8cd2-b952b0e570aa"
      unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy0zLTEtMS0yOTYzNQ_4f140f41-b517-4f2e-b85d-0351b40d6a6a"
      unitRef="usd">12158000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy01LTEtMS0yOTYzNQ_9150f043-1f1f-4e23-8ffc-6a0d4bd6fe6c"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i98ea471447d2416e9a4bf7409f4bfaf5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy03LTEtMS0yOTYzNQ_e3d76bfc-a622-41fb-ad47-51f8c81786d8"
      unitRef="usd">9570000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0889a0226de945a0aaa5c52879fb13f4_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMy05LTEtMS0yOTYzNQ_6848471e-0971-432c-aa58-a46397d78c30">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC0xLTEtMS0yOTYzNQ_9d88446c-e29f-4c1b-b42e-0d5700e779dd"
      unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC0zLTEtMS0yOTYzNQ_3b2b78a5-477b-41bc-97bf-1d84084f1f59"
      unitRef="usd">1162000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC01LTEtMS0yOTYzNQ_d5cb16c8-405c-44c1-b2d8-925c5f3d8ef8"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i65b5440b9b964738b3f866dbfc7dc1ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC03LTEtMS0yOTYzNQ_1b292803-aa5c-4946-ab1f-dc5f690dab28"
      unitRef="usd">1967000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i714564a42c4645a4aa8fec5fbfae6cf1_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNC05LTEtMS0yOTYzNQ_e5a80e71-1b84-43d4-a131-54932515332c">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNS0xLTEtMS0yOTYzNQ_84ad085d-e271-40fa-912b-06d7832da504"
      unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNS0zLTEtMS0yOTYzNQ_9d959d02-3f3c-4094-b180-296035ebf96e"
      unitRef="usd">13320000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNS01LTEtMS0yOTYzNQ_5ec5c449-732c-4c58-9029-c05d5ae75573"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i147ce09cfd0f4870b34cc4128ee8fde3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfNS03LTEtMS0yOTYzNQ_b333b4a2-658d-4907-be9e-be1cc4cffdc0"
      unitRef="usd">11537000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0223aca615484a88a1f963d53db983b5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC0xLTEtMS0yOTYzNQ_943815df-bf86-4780-aaff-8ce7ece5da68"
      unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0223aca615484a88a1f963d53db983b5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC0zLTEtMS0yOTYzNQ_bd842208-8fc8-4b98-a6b0-798f27f7cc8e"
      unitRef="usd">11770000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i0223aca615484a88a1f963d53db983b5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC01LTEtMS0yOTYzNQ_486ca27a-36f4-43f3-b4fc-5e4e57b77a3a"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0223aca615484a88a1f963d53db983b5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC03LTEtMS0yOTYzNQ_6e7287eb-03cb-459a-85ce-523a2c9240c1"
      unitRef="usd">9958000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4a3b5deb088e42a4b098ad5687964c9e_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOC05LTEtMS0yOTYzNQ_445e9d5f-d3bf-4d27-8773-26752d6fda0d">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4d52a26129d84983ad9bb9f0ee488966_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS0xLTEtMS0yOTYzNQ_f863b509-e665-480e-8bf6-fcf8d7c7f350"
      unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4d52a26129d84983ad9bb9f0ee488966_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS0zLTEtMS0yOTYzNQ_a97291fd-4e4e-47b9-91c0-179ba1a4dd1e"
      unitRef="usd">1125000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i4d52a26129d84983ad9bb9f0ee488966_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS01LTEtMS0yOTYzNQ_2d35795c-57d0-4585-a7a1-c912e0cbc04a"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4d52a26129d84983ad9bb9f0ee488966_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS03LTEtMS0yOTYzNQ_dbd6d4a0-cf09-4ace-82f9-5ebe688b3be1"
      unitRef="usd">2004000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i449ded4307a74763bf247ab23aa3b5f9_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfOS05LTEtMS0yOTYzNQ_6b29165b-99de-4cb4-9405-5bab5c8f091d">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i34f581ef502d44a597740c97e5d034bf_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMTAtMS0xLTEtMjk2MzU_3eda6dce-7886-48a6-beaf-c9a531d1459c"
      unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i34f581ef502d44a597740c97e5d034bf_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMTAtMy0xLTEtMjk2MzU_0e84c5f5-ec77-4b5e-9268-385e2f2a8463"
      unitRef="usd">12895000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i34f581ef502d44a597740c97e5d034bf_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMTAtNS0xLTEtMjk2MzU_c95d8e08-d9d2-4ec2-a4b6-94c93f7015ff"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i34f581ef502d44a597740c97e5d034bf_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjdiZTNkNjlkNmM1OTRkNGZhZmI4ZmI3YjYxNWJlMDg4L3RhYmxlcmFuZ2U6N2JlM2Q2OWQ2YzU5NGQ0ZmFmYjhmYjdiNjE1YmUwODhfMTAtNy0xLTEtMjk2MzU_8d0728b0-513c-4e04-a415-479a38282e5d"
      unitRef="usd">11962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfMTA5OTUxMTYzMjY1MQ_7378eb55-716a-47fb-be20-636df446ffc9"
      unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfMTA5OTUxMTYzMjY1MQ_fe5f1b9c-bc60-4b8c-aa31-8352343d5b59"
      unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RleHRyZWdpb246NTlkZDZhMjNiNzhlNGZiNWFiZjcwYzEwZmE1NGJjZDFfMjE5OTAyMzI2MDQyNA_68c8a3b7-8705-4b59-9b4a-c8b735937889">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfMi0yLTEtMS0yOTYzNQ_1c2c92ee-a798-4ad5-bb08-3cbafdd6b135"
      unitRef="usd">1275000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfMy0yLTEtMS0yOTYzNQ_d3a4076a-9e22-4f17-89fd-8827468220e7"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfNC0yLTEtMS0yOTYzNQ_bfb1b670-eeed-4f6a-a82c-94a88a8e8546"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfNS0yLTEtMS0yOTYzNQ_a0c7289c-9ad7-41e7-ac88-6af4113f31b4"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfNi0yLTEtMS0yOTYzNQ_94c68bbf-4380-4a46-9bba-d75cca019e9e"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfNy0yLTEtMS0yOTYzNQ_2604fc6f-1317-4956-b7ee-a94cebfc3892"
      unitRef="usd">3462000</arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80My9mcmFnOjU5ZGQ2YTIzYjc4ZTRmYjVhYmY3MGMxMGZhNTRiY2QxL3RhYmxlOjgyYWM3ODE3NWUwNTQ3MTY4ZTg4ZTI0NDZhMzQ2ZDMxL3RhYmxlcmFuZ2U6ODJhYzc4MTc1ZTA1NDcxNjhlODhlMjQ0NmEzNDZkMzFfOC0yLTEtMS0yOTYzNQ_aacf7f75-7517-48d6-a6fd-a7b59f45649c"
      unitRef="usd">11537000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMTM3NA_8d6b131c-077c-4008-8f18-bbcd4a5eccf8">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,769,984 and 14,000,392 shares of common stock as of December&#160;31, 2022 and September 30, 2022, respectively, were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#x2019;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 2, 2022, the Company entered into an open market sale agreement (the &#x201c;Open Market Sale Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#x201c;ATM Offering&#x201d;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of December&#160;31, 2022, no shares have been issued under the Open Market Sale Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMjE5OTAyMzI1OTUwOQ_69e53527-61c4-453f-b52c-f115f736eb44">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNC0xLTEtMS0zMzg1Ng_54c10861-1c98-4b78-bb03-cd38e2e77c36"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNC0yLTEtMS0zMzg1Ng_725d05bc-8ef9-44f2-a324-fa78f12839e1"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNC0zLTEtMS0zMzg1Ng_72464929-0271-40b3-8d86-b2066b6c3c16"
      unitRef="shares">106140000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNC00LTEtMS0zMzg1Ng_acbcc736-5853-4e71-82a6-8ed11141b9ad"
      unitRef="shares">106140000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNS0xLTEtMS0zMzg1Ng_cd6488ae-b736-4484-b56b-1a5588b2fe0a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNS0yLTEtMS0zMzg1Ng_f4fdc226-ce1d-46a1-878f-8ebd3db6e8d4"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNS0zLTEtMS0zMzg1Ng_a29ad637-7ee4-4907-ab3e-6d252b3d1581"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfNS00LTEtMS0zMzg1Ng_b9296855-5242-426d-8b40-64e14c625c73"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOC0xLTEtMS0zMzg1Ng_28febc85-138c-412e-a713-e624cbec252e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOC0yLTEtMS0zMzg1Ng_275fd7d2-3de4-4971-8999-74c6cad027a9"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOC0zLTEtMS0zMzg1Ng_63bd21d3-c0c6-40b1-ac01-154924cb61c6"
      unitRef="shares">105960000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOC00LTEtMS0zMzg1Ng_d6766863-bde9-458f-85de-237aa74ac341"
      unitRef="shares">105960000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOS0xLTEtMS0zMzg1Ng_70e9e881-14e7-4971-a7d5-915cda44dcd7"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOS0yLTEtMS0zMzg1Ng_8d16a3cd-daf7-4b35-913f-f85345d2ab98"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOS0zLTEtMS0zMzg1Ng_5aabe4c0-31ec-4a59-ae23-067095d5a97e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RhYmxlOjE0ZmEwMGUzODhkNjQ5Mzc5YzU2Y2I1OWNiYzQ3MzYxL3RhYmxlcmFuZ2U6MTRmYTAwZTM4OGQ2NDkzNzljNTZjYjU5Y2JjNDczNjFfOS00LTEtMS0zMzg1Ng_fb2f2b7c-053d-43bc-9170-e2843a58cabc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i03c5e2040b97478685482edb1a081bb8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMjE5OTAyMzI2MjY4MA_44fbde76-75ac-4038-a2c9-24099f93bab3"
      unitRef="shares">13769984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic2aeef9c8ccd4d24a3762ad0cae17f16_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMjE5OTAyMzI2MjY5Mg_073daf89-ceb8-447b-8326-b7376988972c"
      unitRef="shares">14000392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance
      contextRef="i953cacdb283b4570974e198523332adc_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfNTQ5NzU1ODE3MjM0_724f5fae-edf4-4bdb-bfab-d6efd7caeee3"
      unitRef="usd">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock
      contextRef="if602610bd9274f15ab350c697c16fbcd_D20200801-20200831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfNTQ5NzU1ODE3NTE3_14558e83-3d59-4be3-8355-b27c3104ccc9"
      unitRef="number">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="i75f84a2f705547a9a7be5905324c37e9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80Ni9mcmFnOjgxMDZlOGVlZmYyYzQ1YjlhNDE3ODA4NmM3OWIwOTFkL3RleHRyZWdpb246ODEwNmU4ZWVmZjJjNDViOWE0MTc4MDg2Yzc5YjA5MWRfMjE5OTAyMzI2MjcwMw_40cb32cd-5615-48e3-b75a-cc64bb45a41c"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfMjM0MQ_50e5ee09-9d37-4cf1-a89e-c03783b12745">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#x2019;s process development and analytical activities. The Company intends to invest between $200.0 million and $260.0 million into the build-out of the facilities. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and will be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that the City of Verona will pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property. The Company will also receive up to $2.5 million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Technology License Commitments&lt;/span&gt;&lt;/div&gt;The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. During the three months ended December&#160;31, 2022 and 2021, the Company did not reach any milestones.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfMzky_17f0c5b2-f021-4d06-a9d3-0092d902793c"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <arwr:NumberOfAcresOfLandPurchased
      contextRef="i8614ef1e09dc4ad7b48305618623004c_D20211220-20211220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNDkz_f64d1c89-513c-4a06-a2b8-45262c69d59b"
      unitRef="acre">13</arwr:NumberOfAcresOfLandPurchased>
    <us-gaap:AreaOfLand
      contextRef="i7b3dac9a5a774156b890ac8ed0751a6a_I20211220"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNjE0_d98a608c-d491-42ca-8a57-679882c1a131"
      unitRef="sqft">160000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="i0f1aae662bc6418db9f0619cc2642795_I20211220"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNjc4_05ec4d8b-fcfa-4d8e-8f2c-3c1f37c96692"
      unitRef="sqft">140000</us-gaap:AreaOfLand>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities
      contextRef="i62abdefe617a488691c724830dcd72c9_I20211220"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfODE4_40ed1e7b-8af4-4143-91d2-493614020d6f"
      unitRef="usd">200000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities
      contextRef="ie59ded034230456484b32676c5f7bea0_I20211220"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfODI1_ec99873f-fed5-4400-a822-3a34ee4099da"
      unitRef="usd">260000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <arwr:TaxIncrementFinancingAward
      contextRef="i475551cf88cb4dccacdf1b2a61c7583d_I20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNzE0NjgyNTU4NTI2NQ_2e198982-6ea4-43d6-b661-68bcf69aade4"
      unitRef="usd">16000000</arwr:TaxIncrementFinancingAward>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i0154bab3efba4f2b94e2b7c59316083b_D20211220-20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNzE0NjgyNTU4NzI1Ng_392ce842-d39d-41f2-84af-39c3cd99b55a"
      unitRef="usd">2500000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <arwr:MilestonePayments
      contextRef="ic881a18f95ea4f17a15cc3756a39574f_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNzE0NjgyNTU4ODQzMQ_365f7bbf-faaf-41d3-b075-648c8f524420"
      unitRef="usd">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="i349f57ec0207498e87e4c69e2bce507c_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF80OS9mcmFnOjA3ZWIyNzllOTRjYjQ4MzQ4MmE4OGE1ZWE4YzNjODQ5L3RleHRyZWdpb246MDdlYjI3OWU5NGNiNDgzNDgyYTg4YTVlYThjM2M4NDlfNzE0NjgyNTU4ODQzMQ_d76a95d5-5576-4248-8839-c1618afb2dd6"
      unitRef="usd">0</arwr:MilestonePayments>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTMxNQ_897c350a-9ae2-4325-8240-34f520aafd1d">LEASES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, the Company entered into a new 15-year lease for approximately 144,000 square feet of office and research and development laboratory space under construction in San Diego, California. This facility will replace the Company&#x2019;s current office and research facility sublease located in San Diego, California. The increased capacity of this new facility compared to the Company&#x2019;s current research facility in San Diego will accommodate increased personnel for its expanding pipeline of current and future drug candidates. The estimated rent commencement date for the new lease is in April 2023 after construction and leasehold improvements have been completed. The lease payments, which begin on the rent commencement date, will be approximately $119.0 million over the initial 15-year term. The Company also estimates payments for operating expenses to be approximately $3.0 million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $31.0 million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Significant Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pasadena, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases office space located at 177 Colorado Blvd for its corporate headquarters from 177 Colorado Owner, LLC. The lease began on September&#160;30, 2019 and expires on April&#160;30, 2027. The lease contains an option to renew for one term of five years. On October&#160;23, 2020, the Company entered into a lease expansion to add an additional approximately 24,000 square feet of office with a lease expiration date of April&#160;30, 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;San Diego, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company subleased space from Halozyme, Inc. for additional research and development facility in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and ended on January&#160;14, 2023. On December 23, 2022, the Company entered into a new six-month lease agreement with 11404 &amp;amp; 11408 Sorrento Valley Owner (DE) LLC, effective January 15, 2023. The lease will end on July 15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Madison, Wisconsin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases space for office and laboratory facilities, which expires on September 30, 2031. The lease contains options to renew for two terms of five years. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of 111,000 square feet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;79,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost primarily related to operating expenses associated with the Company&#x2019;s operating leases. There was $0.1&#160;million and $0 short-term lease cost during the three months ended December&#160;31, 2022, and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents payments of operating lease liabilities on an undiscounted basis as of December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2023 (remainder of fiscal year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;12,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;102,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;150,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(68,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;82,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODIzOTIy_d5cff41f-171f-4b6a-98a9-45a73e805053">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODIzOTU1_b9be657e-21df-4cf0-9513-0489d4eb40a5"
      unitRef="sqft">144000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0NjIy_12a35a54-70d2-4e68-995e-e2b5519743a8"
      unitRef="usd">119000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0NjQz_d5cff41f-171f-4b6a-98a9-45a73e805053">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:EstimatedPaymentsForOperatingExpensesYearOne
      contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0NzM3_070fb251-8b77-4c6b-9c1a-ed55494a319d"
      unitRef="usd">3000000</arwr:EstimatedPaymentsForOperatingExpensesYearOne>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0ODMw_d5cff41f-171f-4b6a-98a9-45a73e805053">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="ib156f4f74fcf40dab1e99dda624e5df7_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI0ODg2_bdf7d363-f0b0-4a3e-b83a-889058423590"
      unitRef="usd">31000000</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1MDMz_d5cff41f-171f-4b6a-98a9-45a73e805053">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="ide63f19f872342da8608f446fb18d4de_I20211119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1MTA1_a1d222b8-481f-4344-acbd-df34eb1924fb"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="if5126eab2e8c467bbb24c03e16becfd7_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI2OTE1Nw_71674e8b-be98-49d7-b550-7d36d668479f">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <arwr:NumberOfOptionsToRenew
      contextRef="ic35d28a67b834f6484c8d5ee20d55588_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1NDM0_75627060-9a47-46ca-a6f7-2ba4bc761377"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic35d28a67b834f6484c8d5ee20d55588_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1NDQ2_59c77e9a-0266-44e7-b249-ac19e62328fd">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i2811668ed19749b68707a9ed9f6d8253_I20201023"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI1NTM3_cbacb659-7e04-4622-ada4-d9211352432e"
      unitRef="sqft">24000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iea10d5800b11488baca5f307e6d73957_I20221223"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI3MjI0NQ_c9ee2731-d99d-49ac-b195-a5a38f3bb8e7">P6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="i12ce5e7d49bd492c9e566ef7247a28c3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI3MTkyOQ_13234722-9eaa-44d9-a0ae-30db96202bde"
      unitRef="option">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i12ce5e7d49bd492c9e566ef7247a28c3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI3MTkzNw_ee20c459-831f-4bf3-9b4e-9ebe0b2ac412">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i12ce5e7d49bd492c9e566ef7247a28c3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI3MTk1Mw_34f51549-47cd-4620-93dc-5f18433bcaed"
      unitRef="sqft">111000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfMjE5OTAyMzI2OTE1NA_a4a5c42d-864c-4dcf-b701-59af9cb15173">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;79,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;78,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfMy0zLTEtMS0zMzg2NA_00f1bb8f-9202-41e8-8690-e2db173e4229"
      unitRef="usd">41655000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfMy01LTEtMS0zMzg2NA_07fdcfa1-5d09-4f70-b962-098e4604ad2a"
      unitRef="usd">58291000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfNS0zLTEtMS0zMzg2NA_92b3e927-601a-4098-9e4d-4b02065e740c"
      unitRef="usd">2664000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfNS01LTEtMS0zMzg2NA_b5315208-bdad-418d-b06c-2951ef11b653"
      unitRef="usd">2776000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfNi0zLTEtMS0zMzg2NA_68857d5e-9d17-4e1a-9870-c489b7f4485f"
      unitRef="usd">79470000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOjE4MTUzYTA0MTE1MzQ2ZDg5Y2I4YzdlYTAyNjE2YjEwL3RhYmxlcmFuZ2U6MTgxNTNhMDQxMTUzNDZkODljYjhjN2VhMDI2MTZiMTBfNi01LTEtMS0zMzg2NA_e4a3fa43-345f-4ae0-8558-3a3a481fbb3a"
      unitRef="usd">78800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="i8040ef89c2154b74b3e460ed12cd081a_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfMy0zLTEtMS0zMzg2Ng_d3e3a9e8-fe6b-4817-b42f-52ca460b04d8"
      unitRef="usd">2069000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2b5a7a96684442d296082eb9d52b8bcd_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfMy01LTEtMS0zMzg2Ng_b1b6c2de-e964-462f-afbd-dc72e05b574a"
      unitRef="usd">878000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i35831effd60d42e480dad85b0cf9984c_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNC0zLTEtMS0zMzg2Ng_39ea498b-9522-4d0f-bac3-cc0ae1fa5070"
      unitRef="usd">533000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ia4bfba6d666f497ab7f1a694161b0c89_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNC01LTEtMS0zMzg2Ng_def0159b-e272-4958-9770-fcd82a201f4e"
      unitRef="usd">420000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8040ef89c2154b74b3e460ed12cd081a_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNi0zLTEtMS0zMzg2Ng_61505725-1133-4508-985d-1de4b54d19bc"
      unitRef="usd">210000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2b5a7a96684442d296082eb9d52b8bcd_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNi01LTEtMS0zMzg2Ng_425b0a29-8433-4b01-94b4-4aaf7f1432e0"
      unitRef="usd">158000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i35831effd60d42e480dad85b0cf9984c_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNy0zLTEtMS0zMzg2Ng_69be2035-67d0-45f1-a19d-ed6e6232659a"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia4bfba6d666f497ab7f1a694161b0c89_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfNy01LTEtMS0zMzg2Ng_a6cd832b-a536-41d0-b47b-8d9523389d13"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfOS0zLTEtMS0zMzg2Ng_4df6f415-c6b6-4475-b73c-b579e90ddd70"
      unitRef="usd">2812000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="idc2a8a0b4a714ac7bf244c847af32ed7_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmE4MGY4MjFmMWIzMDRiOTk4YWI1YzU1N2IwZWY4Mjk3L3RhYmxlcmFuZ2U6YTgwZjgyMWYxYjMwNGI5OThhYjVjNTU3YjBlZjgyOTdfOS01LTEtMS0zMzg2Ng_3e3778c5-b07f-42b6-8dec-f9acbf72b449"
      unitRef="usd">1456000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI3NTMw_cc31f92b-d70f-4cb7-9baa-5291dffe055a"
      unitRef="usd">100000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i340acbb944cd442f8d5d3b49ba81c136_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTQ5NzU1ODI3NTM4_1fcf8313-bfb8-4a59-a023-caad320df9f1"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RleHRyZWdpb246MzVkOTQzYzNiOTY3NDk2ODgyY2Q5MWQ4NDA4MmE4MmJfNTMxMA_7308e346-b1fe-4200-8e93-d77cfeefb2c7">The following table presents payments of operating lease liabilities on an undiscounted basis as of December&#160;31, &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2023 (remainder of fiscal year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;12,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;102,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;150,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(68,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;82,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfMi0xLTEtMS0zMzg2OA_85d95cc4-8fba-4e00-93ea-ad76082794d8"
      unitRef="usd">4470000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfMy0xLTEtMS0zMzg2OA_e07d3963-8af5-4ae5-ab72-ca4bc59ae824"
      unitRef="usd">8094000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfNC0xLTEtMS0zMzg2OA_90d88c47-7057-4e58-a310-dcf0951492a5"
      unitRef="usd">11800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfNS0xLTEtMS0zMzg2OA_1a14b939-8a07-4099-9c69-80b8dc1125f0"
      unitRef="usd">12138000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfNi0xLTEtMS0zMzg2OA_1bb844dc-9d81-43f3-92d6-7729663d1fc1"
      unitRef="usd">11297000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfOC0xLTEtMS0zNDg4NA_f794d792-1cb6-4736-bdf4-e36d530d3476"
      unitRef="usd">102813000</arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfOC0xLTEtMS0zMzg2OA_8db28541-1035-4bfa-8b0a-540beb2557e8"
      unitRef="usd">150612000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfOS0xLTEtMS0zMzg2OA_12e1dbb5-9ce3-496a-a088-6db8b49e164e"
      unitRef="usd">68478000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmNmZTFmODU4MDIyZjQ1ODY4ZGYxOWZmMTAyMDIyOTZmL3RhYmxlcmFuZ2U6Y2ZlMWY4NTgwMjJmNDU4NjhkZjE5ZmYxMDIwMjI5NmZfMTAtMS0xLTEtMzM4Njg_8d84904c-a911-494e-97c9-7478b8f7eb0c"
      unitRef="usd">82134000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfMi0yLTEtMS0zMzg3MA_21a29d53-1fee-4111-9345-ba9f234496c6"
      unitRef="usd">1331000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="idc2a8a0b4a714ac7bf244c847af32ed7_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfMi00LTEtMS0zMzg3MA_9dd07153-755b-4022-8a41-94df6293012c"
      unitRef="usd">1023000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfNC0yLTEtMS0zMzg3MA_021cad58-3f78-448b-ad57-8b65eb0e8456">P6Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfNC00LTEtMS0zMzg3MA_1ed7688e-27e6-4a31-8be8-a8844f0aa9dd">P7Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfNS0yLTEtMS0zMzg3MA_b410d858-e838-474e-8af5-b1ccd53628f3"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81Mi9mcmFnOjM1ZDk0M2MzYjk2NzQ5Njg4MmNkOTFkODQwODJhODJiL3RhYmxlOmJiMGJlZWY1NTMyMjQ2ZDVhNzFmM2E0MGZiZTk2NDIxL3RhYmxlcmFuZ2U6YmIwYmVlZjU1MzIyNDZkNWE3MWYzYTQwZmJlOTY0MjFfNS00LTEtMS0zMzg3MA_a36930f4-9864-49e6-a01e-3d5f06f6360f"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNTQ5Nw_4322f017-e89d-4d24-8493-eeeb9cfb4b26">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#x201c;2004 Plan&#x201d;) and 2013 Incentive Plan (the &#x201c;2013 Plan&#x201d;), 175,083 and 3,991,304 shares, respectively, of the Company&#x2019;s common stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 18, 2021, the Company&#x2019;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#x201c;2021 Plan&#x201d;), which authorizes 8,000,000 shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of December&#160;31, 2022, the total number of shares reserved for issuance under the 2021 Incentive Plan was 7,155,527 shares, which includes 136,972 shares that were forfeited under the 2013 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there were 762,150 shares reserved for options and 739,625 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#x2019;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;175,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,685,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;762,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,625,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,305,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;918,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;739,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,964,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;175,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,991,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;921,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,501,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,589,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the three months ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,721,384&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(13,875)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;45.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(81,733)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,625,776&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;61,867,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,346,710&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;17.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;60,525,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company&#x2019;s closing stock price and the stock option exercise price) that would have been received by the stock option holders had all stock options been exercised on December&#160;31, 2022. The total intrinsic value of the options exercised during the three months ended December&#160;31, 2022 and 2021 was $2.3 million and $12.5 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to stock options oustanding for the three months ended December&#160;31, 2022 and 2021, was $2.4 million and $3.0 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $9.5 million will be recognized in the Company&#x2019;s results of operations over a weighted average period of 1.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. No options were granted during the three months ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units (&#x201c;RSUs&#x201d;), including market-based, time-based and performance-based awards, have been granted under the Company&#x2019;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#x2019;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,069,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;62.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;18,875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;31.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(98,250)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;51.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(25,875)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;44.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,964,181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;63.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs was determined based on the closing price of the Company&#x2019;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended December&#160;31, 2022 and 2021, the Company recorded stock-based compensation expense of $17.0 million and $21.5 million, respectively, related to shares of RSUs. As of December&#160;31, 2022, there was $128.3 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7af89e8de2144f908cdf6eed480d28b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4NjUwMg_a514affa-2b8c-460c-ac82-14708c2dc2d1"
      unitRef="shares">175083</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iba8a5ebb90254f6f8963f5d5f42509a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4NjUwNg_77bbdef4-b518-4860-b27b-6c5de65ea0ce"
      unitRef="shares">3991304</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i90cda53c17144e44900529474c8dade0_I20210318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMjE5OTAyMzI3ODA1OQ_62fe8999-c51b-4fbd-bf99-9bb592867054"
      unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2eda0cf364544def8987efed665491a6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4ODQyMw_fcad36a0-d71b-41d0-9d85-a5d9a4475be6"
      unitRef="shares">7155527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i47739b2328c247bab0fc929214a7ba52_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4ODQzMw_71e0d293-35ef-4b47-9e97-2283b9f38a0e"
      unitRef="shares">136972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie5eaa8a48bce4fa6b14d1cc81a3b2f78_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4ODYwNA_aa0bfb4d-c481-4991-9734-7fe6da6e431f"
      unitRef="shares">762150</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if5d653e654b143c2b0c47570e75b7f38_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU4ODYwOA_6506ac33-4814-42a9-bb55-422c99001c92"
      unitRef="shares">739625</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMjE5OTAyMzI3ODA1Nw_b94491e4-dabf-4563-932b-3b2dab644484">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;175,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,685,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;762,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,625,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,305,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;918,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;739,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,964,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;175,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,991,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;921,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,501,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,589,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7af89e8de2144f908cdf6eed480d28b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy0xLTEtMS00MDM3Mw_02a00669-92ca-4b3b-95d2-97b26574dbca"
      unitRef="shares">175083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iba8a5ebb90254f6f8963f5d5f42509a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy0zLTEtMS00MDY4MA_9ea7bbb3-8e39-4bf0-ae4c-df609eb115e2"
      unitRef="shares">1685543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2eda0cf364544def8987efed665491a6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy01LTEtMS00MDY4MA_907b84c1-1dcd-44a3-8b39-18c6ee54a01f"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie5eaa8a48bce4fa6b14d1cc81a3b2f78_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy03LTEtMS00MjQ5MQ_bd61efb1-be9d-445b-99a1-88d0f20fefb6"
      unitRef="shares">762150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfMy03LTEtMS00MDY4OA_2a71d59e-c7f7-4bf8-886f-d538c4477112"
      unitRef="shares">2625776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6801c6b77c1f498681559c7a2dce2274_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC0xLTEtMS00MDY4MA_4103b55c-a0a7-4c71-806c-1b9d08e6727e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5982379dbbec4d4c87792e3a1fcdf6b7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC0zLTEtMS00MDY4MA_ec1d5628-525d-42e8-81a5-b3ece5493a29"
      unitRef="shares">2305761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ieed10835a1c94a47a82efe00a8e128c3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC01LTEtMS00MDY4MA_10825c2f-3ef4-4533-aece-f9f58dd28c0f"
      unitRef="shares">918795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if5d653e654b143c2b0c47570e75b7f38_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC03LTEtMS00MjQ5MQ_11fc747f-fa6e-4830-8afe-430314f9ccb8"
      unitRef="shares">739625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie3a67532b13e4f299f83c7328786c6b2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNC03LTEtMS00MDY4OA_267fcf31-2caa-4d71-8433-6a4a607786e2"
      unitRef="shares">3964181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i7af89e8de2144f908cdf6eed480d28b4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS0xLTEtMS00MDY4MA_023d115f-fd5d-4c10-b4d0-9c90d50d069f"
      unitRef="shares">175083</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="iba8a5ebb90254f6f8963f5d5f42509a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS0zLTEtMS00MDY4MA_2e04df6a-7264-41cf-80fa-9e23dc2b3cef"
      unitRef="shares">3991304</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i2eda0cf364544def8987efed665491a6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS01LTEtMS00MDY4MA_26ff4a51-a9a7-4662-93f4-2ea6fca77bff"
      unitRef="shares">921795</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="ie5eaa8a48bce4fa6b14d1cc81a3b2f78_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS03LTEtMS00MjQ5MQ_10361086-22d0-43e2-9da0-21c0f2a638f1"
      unitRef="shares">1501775</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjVmMjI1Y2I1MmYyMTQwNTZiZTU0ZjNhYjNhNmRjNzJmL3RhYmxlcmFuZ2U6NWYyMjVjYjUyZjIxNDA1NmJlNTRmM2FiM2E2ZGM3MmZfNS03LTEtMS00MDY4OA_b9dda023-daa7-4d38-9321-430eb44d8088"
      unitRef="shares">6589957</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNTQ5NA_d5f2bff3-e9bf-485a-a006-8fbc3036791f">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the three months ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,721,384&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(13,875)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;45.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(81,733)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,625,776&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;61,867,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,346,710&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;17.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;60,525,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMS0xLTEtMS0yODkwNA_dda9c353-9f45-4b11-98d5-7aa61d1dfefd"
      unitRef="shares">2721384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8f511f4c684146e7bb7fbc97f28a954f_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMS0zLTEtMS0yODkwNA_ac469df0-a1bc-4825-a5b1-73e7ca559ae4"
      unitRef="usdPerShare">20.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMi0xLTEtMS0yODkwNA_e3a828ac-47fa-4f1b-b484-0001c6ef757e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMi0zLTEtMS0yODkwNA_37ac9415-1539-4bee-bd49-80c4e90f5303"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMy0xLTEtMS0yODkwNA_ac913c5f-1d04-400f-8a69-92ebde5333d7"
      unitRef="shares">13875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfMy0zLTEtMS0yODkwNA_8e9530b5-c890-48f2-aa0d-9cd10e3640e3"
      unitRef="usdPerShare">45.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNC0xLTEtMS0yODkwNA_9d6f7456-f49d-4fd0-b42d-b9bfeca8c8af"
      unitRef="shares">81733</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNC0zLTEtMS0yODkwNA_284fe6ee-a237-46ac-bf2c-7605e67ebb50"
      unitRef="usdPerShare">7.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNS0xLTEtMS0yODkwNA_4244b421-8a66-4dd0-8d71-596a593d6552"
      unitRef="shares">2625776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNS0zLTEtMS0yODkwNA_4bd94663-3490-442f-9259-31ed2c05299e"
      unitRef="usdPerShare">21.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNS01LTEtMS0yODkwNA_17badbf6-e81f-4d69-ad0f-779d918f08a3">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNS03LTEtMS0yODkwNA_dba30ca0-0f69-4183-a544-add4d62fb823"
      unitRef="usd">61867396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNi0xLTEtMS0yODkwNA_d22ef150-21b9-48e9-b61e-df6272ff8e43"
      unitRef="shares">2346710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNi0zLTEtMS0yODkwNA_efc748d9-120e-42a0-925e-dc3f8b7689a9"
      unitRef="usdPerShare">17.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNi01LTEtMS0yODkwNA_e48c62f0-c4d2-4726-828f-a3f582a32ebd">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i06abac4e1f98416b8ae5ab270600de1a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOmYyZDQwYmEzODUzMjRhNTc4MjIyNTcyN2QwZjA4MmFlL3RhYmxlcmFuZ2U6ZjJkNDBiYTM4NTMyNGE1NzgyMjI1NzI3ZDBmMDgyYWVfNi03LTEtMS0yODkwNA_a78d6f7a-19df-4887-a47f-eac769dcb64c"
      unitRef="usd">60525256</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i52d4a7405e154645aec245988ba1db1e_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMTY0OTI2NzQ1NzQ4OA_90584f1e-122d-4ba4-b411-596ee2e31b6c"
      unitRef="usd">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ieded460c29c84a3bae41035d3b604b0a_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMTY0OTI2NzQ1NzUwNA_474f94ad-0236-4056-b61b-5925cf9d5eac"
      unitRef="usd">12500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i52d4a7405e154645aec245988ba1db1e_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMTY0OTI2NzQ1NzQzMg_a3d238d9-609b-45f8-94d9-6c37e2eefa0e"
      unitRef="usd">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieded460c29c84a3bae41035d3b604b0a_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMTY0OTI2NzQ1NzQ0OA_e58974cd-c49a-4d6a-801b-7ab994f2d3a2"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i7371c7b684f24f2ea135c09ba65d9460_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTU5ODYxMQ_5c1b9a30-f67b-4faa-ae06-a249740189f6"
      unitRef="usd">9500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i52d4a7405e154645aec245988ba1db1e_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfMjE5OTAyMzI3ODA2OQ_0bfc3ed8-20a2-4319-89ca-d2456be417b4">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNTQ5Ng_5164cdff-8ecf-4e12-ba3f-60d5e340a508">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,069,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;62.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;18,875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;31.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(98,250)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;51.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(25,875)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;44.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,964,181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;63.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia962a8cd9cbf48eab5243a5e151c89a3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMS0xLTEtMS0yODkwNA_c93c3dad-049e-4fa3-87d2-b3111853017b"
      unitRef="shares">4069431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia962a8cd9cbf48eab5243a5e151c89a3_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMS0zLTEtMS0yODkwNA_8adb4fcf-4b6f-4ad5-b0a2-d0b94c1f93dd"
      unitRef="usdPerShare">62.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMi0xLTEtMS0yODkwNA_2d265d1a-1b41-4305-bc91-1dae0f53d680"
      unitRef="shares">18875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMi0zLTEtMS0yODkwNA_bd6d5da0-8348-471d-ba02-1c2c13b7446f"
      unitRef="usdPerShare">31.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMy0xLTEtMS0yODkwNA_2a99c5a5-e239-499a-b149-388204716f7c"
      unitRef="shares">98250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfMy0zLTEtMS0yODkwNA_6d389bce-3472-443c-ba8c-9a089a955d61"
      unitRef="usdPerShare">51.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfNC0xLTEtMS0yODkwNA_333b2d2a-0f75-4bc8-849e-e728fe29363c"
      unitRef="shares">25875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfNC0zLTEtMS0yODkwNA_d30f9d84-970c-4513-a273-4906b4c4c64a"
      unitRef="usdPerShare">44.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie3a67532b13e4f299f83c7328786c6b2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfNS0xLTEtMS0yODkwNA_99a1bcba-cc4b-4398-a0ea-45fa0232b4f4"
      unitRef="shares">3964181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie3a67532b13e4f299f83c7328786c6b2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RhYmxlOjA3NGYyNTc4M2Y2YzQ1ZWNhNTFmNTA3NzU4ZTM3MjFmL3RhYmxlcmFuZ2U6MDc0ZjI1NzgzZjZjNDVlY2E1MWY1MDc3NThlMzcyMWZfNS0zLTEtMS0yODkwNA_06adf065-1456-4608-9874-0c4ea08df3c0"
      unitRef="usdPerShare">63.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTYwMTk1NQ_4c4be914-b332-4136-852c-b87314dec7ac"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i54ad8857cb6d490a9939df3c07ff4518_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTYwMTk2Mw_2efdd9f6-fee2-4e26-a981-e0355bd9e22f"
      unitRef="usd">21500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ie3a67532b13e4f299f83c7328786c6b2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTYwMjAwMQ_c4cff005-a1b4-4034-8ed7-575e6806004f"
      unitRef="usd">128300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i27a0d09827a344949e7d3139c79147fc_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81NS9mcmFnOmFmZTcyMDJiNjIxNDQ4NzZhYjA4NWJlNTVlMjNlOTcwL3RleHRyZWdpb246YWZlNzIwMmI2MjE0NDg3NmFiMDg1YmU1NWUyM2U5NzBfNzE0NjgyNTYwMjAxNQ_396ce3ce-f45f-4067-a324-a27fced82c0e">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RleHRyZWdpb246MWE4MDQwMDM1ZmY4NGZmYTlmMWVlYTkwM2VjMTY5ZGFfMTY0OQ_8e6183f3-ba9b-40b9-bfa8-bbd3b55e16f4">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#x2019;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Quoted prices for similar assets or liabilities in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Quoted prices for identical or similar assets or liabilities in non-active markets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Either directly or indirectly observable inputs as of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At December&#160;31, 2022 and September&#160;30, 2022, the Company did not have any financial assets or financial liabilities based on Level 3 measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;319,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;319,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RleHRyZWdpb246MWE4MDQwMDM1ZmY4NGZmYTlmMWVlYTkwM2VjMTY5ZGFfMTY1MA_3e30c408-6fa2-42f7-a778-bd280b561c3a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;319,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;319,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic12f642c28fd43bb8bf90642994bc4ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNC0xLTEtMS0zMzk1Ng_a0e92fe3-c517-4cca-bd22-531c27d6646f"
      unitRef="usd">27423000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i4d7c02af510c4a37adf92b11b0e43eaf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNC0zLTEtMS0zMzk1Ng_12e9851a-6e58-4f4c-9420-4bbd80f09965"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ia208947dbdb34f48ac070a4eaf8f6ab8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNC01LTEtMS0zMzk1Ng_9e402e21-af92-41d6-b997-7231a26c829d"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i04b788dc055c47f289db232c658f93a3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNC03LTEtMS0zMzk1Ng_74257e78-3b37-482f-9bcc-7cbb27563e11"
      unitRef="usd">27423000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i4024a6c45e8b453eb06624488de7893b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNS0xLTEtMS0zMzk1Ng_61fb2312-dccc-4f0a-a171-a8c8634d7978"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i39044bf341fe482cbbdce983d914bbec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNS0zLTEtMS0zMzk1Ng_a76d0ce1-aacd-4c34-a412-720581e22079"
      unitRef="usd">104311000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if8310bcf25814821b30b9f25902a564d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNS01LTEtMS0zMzk1Ng_c585d5c4-8930-48dd-b9f8-9df96f80e6d4"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i4b8edd077cc145338ae4844a504c6d15_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNS03LTEtMS0zMzk1Ng_0b97c854-1db9-4f6a-aef3-f3a5b3246f8a"
      unitRef="usd">104311000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i4e5f5182517047a2857c3e4a25738d82_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNi0xLTEtMS0zMzk1Ng_6afb2acc-af89-424b-bfbf-e5a80a7a3865"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ia323910ecf904687b25c3160e49c81a9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNi0zLTEtMS0zMzk1Ng_cd88ba86-8c78-48dc-b893-bad87dcf0790"
      unitRef="usd">319690000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ida69711b30dc4c71b1277eaf63e7bdd5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNi01LTEtMS0zMzk1Ng_123bd2f5-e942-4b79-ae19-d93414800bae"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i7481b819e6694390ada33ee48dd204bc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNi03LTEtMS0zMzk1Ng_d761efab-c845-4b0b-be9f-8da5c059c4a8"
      unitRef="usd">319690000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0cba61c40f15431a97004a8eed248d67_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNy0xLTEtMS0zMzk1Ng_1417edfe-6f59-41f5-b9cb-f9c90f961628"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f8630cb003e4706a57151bdfa8dc88c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNy0zLTEtMS0zMzk1Ng_d50eb2fa-489b-4cc3-8907-8e7bd2e3340e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5851c535fb2c4a6ab422410bef2bbd02_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNy01LTEtMS0zMzk1Ng_48686be2-1d21-4b27-8c7a-65088a4505b3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied344ba18ef64e3d9de729f6de914532_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfNy03LTEtMS0zMzk1Ng_cafd0f8e-0e95-42ce-8f97-dc9d0dcf38da"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i452920e837684080b738d48ba1b27ff2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfOC0xLTEtMS0zMzk1Ng_4592ef43-1fc3-4f21-b243-9d6a3603212f"
      unitRef="usd">82924000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7cd572b180c415db97822ca50b32ac9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfOC0zLTEtMS0zMzk1Ng_5b2f1d31-393d-442f-a8c3-c3880ee43a8f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5fefec5d13e145909fc3b74408e1e444_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfOC01LTEtMS0zMzk1Ng_5c7eabaa-02ed-4fcf-9e39-e9d400decb86"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c9ae1d799ee4d03923270e5ee1d6d21_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjhjM2I3YTg3NzgyMzRmZjVhZGVkNjQ4YmY2MDMxYTIzL3RhYmxlcmFuZ2U6OGMzYjdhODc3ODIzNGZmNWFkZWQ2NDhiZjYwMzFhMjNfOC03LTEtMS0zMzk1Ng_504fd356-fb03-48db-98c5-34bf5d56a2c3"
      unitRef="usd">82924000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i4ce3b6dcc92d46758613038bc30d2d06_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNC0xLTEtMS0zMzk2MA_2bd5753b-f2f8-48ae-b654-52c162c2f150"
      unitRef="usd">1973000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ieb6ea8e37eb3434eb30ea1ab2ceca664_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNC0zLTEtMS0zMzk2MA_683a9b17-c477-44ba-89a0-7d044b98e626"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i39634f9fa175451b8ba8d5d58bf3740c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNC01LTEtMS0zMzk2MA_45041b8c-29e1-4b06-b313-bbc37a4a8ed5"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i7c4faae844d34e619c9019b81d17f07e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNC03LTEtMS0zMzk2MA_15f44422-8b5b-4d84-b001-b1b2edcf2f3f"
      unitRef="usd">1973000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ieb683bdc076a49628834f62824ed68f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNS0xLTEtMS0zMzk2MA_8839b792-6bae-42c1-b7c0-a5ccbe28bb49"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i1a05dee7c43b439f82b54c288eea3838_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNS0zLTEtMS0zMzk2MA_0ae17dce-b7bd-463b-8698-6aa393654e23"
      unitRef="usd">41727000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib0c9e1d3a53545b2ad24da42f70a1040_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNS01LTEtMS0zMzk2MA_3d8713af-9c12-4501-9c2e-53036cf5f7d0"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic813502c9a304662b9dfbd3942bd3230_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNS03LTEtMS0zMzk2MA_ee1762a2-5290-4809-bd68-3a4ef86cd8f9"
      unitRef="usd">41727000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id85626261eb446dcaddc667f6dabc5cc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNi0xLTEtMS0zMzk2MA_8212d001-4261-42fb-b9ee-6b3b1648cf79"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i406ec781c5d644bdb1d8414e80314cc6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNi0zLTEtMS0zMzk2MA_5cfee262-cb2e-48d4-8a38-e0186e19a69a"
      unitRef="usd">271333000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i039e74dffa1f49d9a35ad0d64a55d837_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNi01LTEtMS0zMzk2MA_2a2e0fd0-8e88-4b76-9662-096163b1e0f2"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i9f10fb8f48cc4003b37f0dce7bcf8710_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNi03LTEtMS0zMzk2MA_21e7b06d-7919-473f-9200-cff835bab756"
      unitRef="usd">271333000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad0de95aea0445adaf44a4746fbc4967_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNy0xLTEtMS0zMzk2MA_31843ff4-4554-4c35-b852-17a42ac9fc2f"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1aa3981837334860a25583d48dd904d9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNy0zLTEtMS0zMzk2MA_68c4c156-c7b4-4e3a-8e7a-e8e145bacde4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i42efed8b98314bbfbbb3748a5f769fa7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNy01LTEtMS0zMzk2MA_2c28a3a9-b7fa-4cc0-a286-c6d8df81e972"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67a183941914437b8b3a7e507c345f29_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfNy03LTEtMS0zMzk2MA_6edcef68-443f-47d2-9add-3407b00095f8"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i66a7f0c6944640a18b75bccffab1cb19_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfOC0xLTEtMS0zODU3MA_3cb49a82-3d0c-4e81-b50b-c7d9871d6ac1"
      unitRef="usd">39262000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i782e0824540f448daa350332d8e73bac_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfOC0zLTEtMS0zODU3MA_94a590f3-5feb-4757-b1e6-f914cc8e6656"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i582fc5eed03a4994b06179429d92df7d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfOC01LTEtMS0zODU3MA_0cd928dd-7331-4cb0-a8e2-ca86de29bc33"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i462d644c71d546a9af599d5543f3d5c8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF81OC9mcmFnOjFhODA0MDAzNWZmODRmZmE5ZjFlZWE5MDNlYzE2OWRhL3RhYmxlOjUzZDQyZGY4ZWI5ZjRmZjg5MzBhM2Y2MmI2ZThmYmY4L3RhYmxlcmFuZ2U6NTNkNDJkZjhlYjlmNGZmODkzMGEzZjYyYjZlOGZiZjhfOC03LTEtMS0zODU3MA_6fe29e61-55f6-4183-a6bc-a6fe0d6754b0"
      unitRef="usd">39262000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock
      contextRef="ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODM3MA_c6bd7e4a-ce54-4ca6-9843-56a763df7b3b">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#x2019;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0&#160;million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#x2019;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0&#160;million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate quarterly based on its current revenue forecasts utilizing the prospective method. For the three months ended December&#160;31, 2022, the Company recognized non-cash interest expense of $2.8&#160;million on the consolidated statements of operations and comprehensive loss.</arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock>
    <arwr:InitialTransactionPrice
      contextRef="ifd2e69018bdb4a98bb2a58ba8c80e25a_D20221109-20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODM5OQ_bd9e6d4a-ee93-476b-b11a-3866db50284a"
      unitRef="usd">410000000</arwr:InitialTransactionPrice>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="i645dd71143994cfd81a4843c13790bbb_D20221109-20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQxNQ_45ec8fb4-99fe-46e6-8b20-94a8f6ba833c"
      unitRef="usd">250000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <arwr:MilestonePaymentReceivable
      contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQzMQ_44fb32e0-722e-469c-9ad8-9ff4c0291513"
      unitRef="usd">160000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial
      contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQ0Nw_dba3ee51-f14b-4507-9a73-5f870283620b"
      unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial>
    <arwr:MilestonePaymentReceivableUponFDAApproval
      contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQ2Mg_50a4ea58-db4c-4e9d-a2fb-e936cf5b3457"
      unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponFDAApproval>
    <arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments
      contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQ3Nw_87da7fb5-0616-45d9-a245-35b3295fdc0f"
      unitRef="usd">60000000</arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments>
    <arwr:RoyaltyPaymentThreshold
      contextRef="i6d4193086f2a4fc198c05eae2aa999c6_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODQ5Mg_df57c94c-1a5a-4655-8d3e-5358e02740d7"
      unitRef="usd">70000000</arwr:RoyaltyPaymentThreshold>
    <arwr:LiabilitySaleOfFutureRoyalties
      contextRef="ia4521874a9864ab3bed52ad5aa487856_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODUwNw_4431c8e1-f44b-420e-9be3-1bf706d58c7c"
      unitRef="usd">250000000</arwr:LiabilitySaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="icba7f05878cb48c783c8d12cf1ff5540_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjllNDM2MTgzYjViNTQ2YjFiZjhiZGUxN2M3YTk5YzkwL3NlYzo5ZTQzNjE4M2I1YjU0NmIxYmY4YmRlMTdjN2E5OWM5MF82MS9mcmFnOjBhZTFmMzdhOTVlODRmYWJiODMyZWIxYjQ0YTRiNDRkL3RleHRyZWdpb246MGFlMWYzN2E5NWU4NGZhYmI4MzJlYjFiNDRhNGI0NGRfMjE5OTAyMzI2ODM4NQ_a345bf44-1a89-4348-867f-a80e0cc349cf"
      unitRef="usd">2800000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MB_B#[$$9B<NL3,,L4^4!M[],2IGZ8O?S%S_0.C1J(#6[H%XQM;,2(9^5#I5
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MV>4K-G]S\>K5AU=GGR[?)/R;,JDLUE]Q.GN7%>!QX((ER.ZCAF"BBRV[=Z9
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M/Q+T"YR[WY?7=P]_POGM%5S_\>G#\N;Z]@$>*H12"7J;7*[!LI7 _H'R[VC
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M7F@0N"35H#.(/5#UQ%0OC"S=E+*0AF8>)V8T9**R%^A\*:DBFX4UT(ZMT_\
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MN?T,5\WBBGG/GU<KGM*"THZ:D1J'A29>GF)#9MUNVR7=!%Q*\B[%XR8W$%X
MVB3\7B"):@D'O?"'E6!B08 +X9"Z3%M+7'6"F%K*+4'IMQF70W!R7IG&;T/8
MU^7[19$_ 9"=6?(NI2:C!P#%3NOV>ZH;2T$Q6Y-Z@[,5"I-+"D>)=.5.6S.>
MB[6$_SYX;#7[BPX2WU+D,?5<VN3\KNS*!FX5M!'M67M2BJT<'QI,"*7:K @C
MKHM!C4V)<[>WA%Z6BWH,&,;O \^=NI!ZD=I&)MC;=L$$9+"2(!-TMLR0(LCZ
MOGI5F9Z[^OM/GF,%FH5_=/+FJI2K7V;M:ONNG=3/N;5Y_2BFH M)QW*.<W(-
M>Q]&'3#U0[.>.%WZQ]U,.WHJ^K\9O<W1L %]GVOM5A,.T+[VQ_\ 4$L#!!0
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MK9@<"^"<1])ZP08V]^S)/U!+ P04    " !+@$96)_--)W8(  "B%0  &0
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M%$7(C4I:$%!5,$O\+76BA"Q203A(FZSY)56/R.H2.>I%)A?&2F_LLV#,1(7
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M!-Y*^N4*V$CIOMSR5.3A%HM0YC[TX6T?1)Y;LR!U6K]DAFTQ2^$P%'M,G@+
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M-BVP$K:C:U2\L]"F$L1+DX>V-B@R#ZK*,(ZBB[ 24@7)P/LF)AGH)952X<2
M75:5,)LQEGH]#+K!SC&5>4'.$2:#6N0X0_I63PROPI8EDQ4J*[4"@XMA,.I>
MC_LNW@=\E[BV>S:X2N9:/[K%IVP81$X0EIB28Q#\6^$MEJ4C8AF_MYQ!F](!
M]^T=^P=?.]<R%Q9O=?E#9E0,@ZL ,ER(94E3O?Z(VWK.'5^J2^N_L&YB+Z(
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MW%M-NX+B[&JMZ7ZU?00N<WC[JQ4-G;B%LT]\4Z$Y7_B6DCA7/QL KWO Z!^
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M-L=I#\HZX/U*2K,U+$'[_Y'\!5!+ P04    " !+@$968K@MVJ4$  !O"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R=5OMOVD@0_E=&M%<E$@$_
M>!@"2 F]EY3<14G:ZG2Z'Q9[P*O:7M_N.B3__<VLP4!":742LG>7F6^^>:UG
MLE;ZJTD1+3SG66&FK=3:<MSMFCC%7)B.*K&@?Y9*Y\+25J^ZIM0H$J>49]W
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MB@8DKF;.@DTN$[/>+OA:XEX=V& R60KQ8#ZNBYGCFX"PPEP;!$ZO[WB%566
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M;,V:VV[C-A"&7X5PBR(+-+%$GY+4-I!$TF[033:(N^U%T0M&IFTADNB2M)T
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M5U":"TKS0&D^*"V HND/F+4>K6WV:'ON9:N'RM28]>3395<UU'3;:JYWJ!Y
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MQJ TCJ+IR:]<3OO_+[9@1AR<_?K"![7L0UU'*(U!:1Q%6V>_O;7*6"32>;&
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M.< I7)8'O^6%%JOB9',FM!9945P"34#F%?#Y7 C]<I$W4!^_C_\%4$L#!!0
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M0A5"#V1<*/('5W4_GH/"A,H3/?%^,4?'1R?H"!&&[E)>2,P2.;&5!C/V=MQ
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MK/%6W)K0WMHZS;'E*Q9KPB2BL-(ZYS34Y1+U4:#N*)Y7N^F2*[TW5\U4GYY
MF EZ?,6Y>NZ8#;H]CT5_ 5!+ P04    " !+@$96QMXJ*ZL$  "8&@  &0
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MDI+:)Q04<9(HA[HZ]6-<*(^;1KEW3,NF@P]LJ35IU28>FUV\[WG]_=[=0Z;
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MT2E69&-%>RS?3[T#B<4#+#X%BVVP>!\6^*/4#DL&6'(*EMA@B26S8)S88>D
M2T_!4CA]!5(E@7J\4D38V.D^&X3^R X?#_#Q4?@35[BRX<;[N,B+_<".\[V_
M9<H["KPC4B):-ZVN,10J#1PX9:TFWIZ#RS@-DP.OUM\IE/[IE!$?JF%EJF&U
M4PW/*<NKMH!6W@I!F$(-%_KNN; :]??.<0J?X/^'R]VI[?J>O,=B39D$_ IT
MWE4"F8KNZNDZBC>FW"^Y@LO#-$NXKHG0"V!^Q;EZZ^@;9/@#D/T!4$L#!!0
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MTAW4YXLXEN]OT@[*7U68_@]02P,$%     @ 2X!&5HERHK 2!0  Z20  !D
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M B2H)R3)I/  2^NC'+U+#46K:U9@!=U3F]H0;Y7EZH+>H,(WJ.>WCYG::_K
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M)1.:Y0/D^U/&Q-M)_K1+]733\']02P,$%     @ 2X!&5ER/&L8/!   W X
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M2?T@BO' .L)>JY6>=<=_,1H/Z06ZW@%71>N !^B.9RJ7=RH2(PN]0NC]#[*
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MZB(BZO:IGBB^MBW+G"O= -GA2K><*,P&_7W!N=I/C(&VB<U^ %!+ P04
M" !+@$96G^G#]7T'  !:4   &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6S-G%UOVS84AO\*X0U#"[2Q1$IRW#D&VA!%"[1;T:#=Q; +Q:83H;+D4732
M OOQHV35%"OY2#1. ?6BL6/R$<^7HY<\]N(QEU^*>R$4^;I-L^)J<J_4[L5T
M6JSNQ38N+O*=R/0KFUQN8Z6?RKMIL9,B7E>3MNF4>EXTW<9)-EDNJM]]D,M%
MOE=IDHD/DA3[[3:6WUZ)-'^\FOB3[[_XF-S=J_(7T^5B%]^)&Z$^[3Y(_6QZ
MI*R3K<B*),^(%)NKR4O_!8^J"=6(SXEX+!J/26G*;9Y_*9^\75]-O')%(A4K
M52)B_>-!7(LT+4EZ'?_6T,GQFN7$YN/O]->5\=J8V[@0UWGZ5[)6]U>3RPE9
MBTV\3]7'_/&-J T*2]XJ3XOJ?_)8C_4F9+4O5+ZM)^L5;)/L\#/^6CNB,<$/
M3DR@]00Z= *K)["A$X)Z0E!YYF!*Y0<>JWBYD/DCD>5H32L?5,ZL9FOSDZR,
M^XV2^M5$SU/+UW$BR><XW0OR7L3%7@H=5%60Y^34*SK7R,NB$/IAG*W)NR2^
M3=)$):+X/FY-8M6<KL/[4:SV4B;9'7D5%TE!GG"AXB0MGEH7>F9=Z5ECUG/R
MZ8:3)[\^74R5MKI<^W156_CJ8"$]82$7JPO"_&>$>I1V3+^&I]^(G9[NG9S.
MAU_=MZ=/=:B.\:+'>-&*%YS@O<\S\4TG@/RBWQ.2K%!R7SFKRR\@J7Q#>5'L
MXI6XFNAWC$+(!S%9_O:+'WF_=WD)$\:18)8'V=&#K**S_HROT_CEJ33^LYFX
MY:@_\DS^D,E_O]-\\E:);?%/5Q 89A P81P)9@4A. 8A0$OC RFJ2.6?L8?E
M)9W3P/.\Q?2AZ1WPDJ[>:5^5S6E$FU>U+ ^/EH>@Y9\N;B[(7?X@9%9:3&[S
M;-UI-HAQ31Q,&$>"6>Z+CNZ+QE2]$680,&$<"68%878,P@S,X3<B71.5Z_I5
M>YFH;Z0HW5JYO\N)!UC8*"4Z"RAK%_"L57/^?-8>Q\'5G6G[Y='V2]#VZWR[
M%7*5Q"G)<M5M,$APS1I,&$>"69Z;'STW'U/ISC&#@ GC2# K"+YG;O@]S.*M
M:<WJ];V ^7Z[?#N&!OZ,SMH%#"_Q7!<T-(_?4\-RE\M8":T0;U6? T"6:R*A
MTC@6S?:CT2(^'5-%^ZB"!I7&L6AV)(RF\<&[=>>B9JU*9?X\FGL=1=T>2F<^
M8QU_EN$UGNL#(RE\6%-<"ZF23;(JZSK?Z-+>Y472+2E@DG,FH0H/+)KM12-/
M_'!4-8TJ<U!I'(MF1\(H'1^\AW?*YZA5I*TZ;@\)O<._'\OX9T@+WV@+'Q87
M[\2#2(E/_B,NFP0PU#F/,&D<BV8[U @6_W)4%8VJ?E!I'(MF1\(((!^\M7?:
M]:I1S7H]L>T%7]391>WKPAM?U"@/"BL/4]F#-\%@HO,>-B:-8]%L;QH10_TQ
ME35%E4&H-(Y%LR/1.)*!SV0<;[YKVH#]L(Z1W1MB\ +/=8!1'Q16'Z:PA^R.
MP3#G3$(]$\&BV8XT$H8&HZII5!F$2N-8-#L21@91^)C&M:;#WAOP_B$<7M.Y
M-AO!06'!T2QCAPTRF.J<1:BG)%@TVZ-&R]#9J.H9502ATC@6S8Z$$4$4/K9Q
MK>?+_GKN'<+A-9UKLY$;%)8;C7H>OI4 ,YUS"%6;8-'LOA&C7Y@WIFIFJ-H'
ME<:Q:'8DC/9A/0<XP_.Y)D&5W#'DQ-88O*QSS39"@\%"XU#0U'%K#(8ZYQ'J
ML0D6S79HHQ5L7+U@N,U@N-U@/T/Y,*-\&%Y#6(T"2QI5BX 7M TV H/! L/4
M\N#-,)CHG#ZH9R58--N;1KJP4;6%,53)@TKC6#0[$D;R,-3>,-9N#FO5<N\0
M#J_I7)N-N&"PN#"U/&3_"X8Y)P_J 0D6S7:D42QL5"UB#%7KH-(X%LUNSS9:
M)T#M$@N&=XEU##W1)08O\5P7&)$1P"*C6=4.VV$PU36I4&D<BV9[U.B78%3]
M8@&J\$&E<2R:'0DC? +4?K%@>+]8Q]!3_6+P&L_U0>,C*+#D:-3W\.T$F.F<
M4Z@R!8MF^],HFF!4G6,!JAI"I7$LFAT)HX8"M,ZQH+]SK'\(A]=SKKU&<P1#
M6L:8X[X8#'5.(-33$BR:[5 C:()1M8P%J(H(E<:Q:'8DC"(*\%K&@G;K5JN6
M435*38LZ+VA_.M((CW!(DQASV1>#B<X?E40]*,&BV=XT&B8<59-8B*I]4&D<
MBV9'PFB?$+5)+&RW?OU8R_U#.+RF<VTV*B,<TA?&!NZ+P3#GY$$]'<&BV8XT
M4B4<55]8B"IR4&D<BV9'HO'I?=2^L+"_+ZQ_"(?7=*[-1DZ$0_K"F.M&&$QU
MSB+40Q(LFNU1(UC"4?6%A:A*!Y7&L6AV)(S2"5'[PL+^OK#^(1Q>T[DV&TT1
M#ND+8VX;7S#3.8=0=0@6S?Y&$B-9HE'UA46H<@>5QK%H=B2,W(G0^L)J4K=V
MK5W3.X3#ZW&U=]KX'K?R6_?>Q_).:WZ2BHW&>Q<S_:8B#U]D=WBB\EWUU6ZW
MN5+YMGIX+^*UD.4 _?HFUS?;]9/RV^*.7R>X_!]02P,$%     @ 2X!&5LC+
M5HAN!   J!<  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULS9AM;]LV
M$,>_RD$KAA98HP<_)9EMP(T6+$!3!$FSO1CV@I;.%E%*U$C:3H!]^%&4+%NU
MK,8-@34O8E'B_>_X$X_B<;SAXHM,$!4\I2R3$R=1*K]T71DEF!)YQG/,]),%
M%RE1NBF6KLP%DM@8I<P-/&_HIH1FSG1L[MV)Z9BO%*,9W@F0JS0EXOD#,KZ9
M.+ZSO7%/EXDJ;KC3<4Z6^(#J,;\3NN76*C%-,9.49R!P,7%F_F7HCPH#T^,/
MBANY=PW%4.:<?RD:-_'$\8J(D&&D"@FB?]9XA8P52CJ.?RI1I_99&.Y?;]6O
MS>#U8.9$XA5G?])8)1/GW($8%V3%U#W?_([5@ :%7L29-/]A4_7U'(A64O&T
M,M81I#0K?\E3!6+/P.\?,0@J@^!K@\$1@UYET'NIAWYET#=DRJ$8#B%19#H6
M? .BZ*W5B@L#TUCKX=.L>.\/2NBG5-NIZ4=*YI11]0SWR(C"&!0'E2 \$(;
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MU+N^I]XIG]J8KCT_:WS^/:G.YWOC]?&7Y<])?%_4%YP#_/U=? -02P,$%
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ME:.8RE%0Y2BJ<A16.8JK' 56CB*K0)%5H,@J4&05*+(*%%D%BJP"15:!(JM
MD56@R"I19)4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR*A19%8JL"D56A2*K
M0I%5H<BJ4&15*+(J%%D5BJS#_Y3UW9C57_^3;.YII8OZF,_:'[_33U!+ 0(4
M Q0    ( $N 1E8'04UB@0   +$    0              "  0    !D;V-0
M<F]P<R]A<' N>&UL4$L! A0#%     @ 2X!&5C<VA%#M    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 2X!&
M5IE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !+@$96I\^3W/8%  #$'P  &
M@($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 2X!&
M5GR8N++(!@  %!T  !@              ("!. X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( $N 1E:V<@0$FP(  &P'   8
M      " @385  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !+@$96MTO$38(%  !(%P  &               @($'&   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 2X!&5FLO^X#H!@  L#(  !@
M             ("!OQT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( $N 1E:EKKG_^P8  -@<   8              " @=TD  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !+@$96?XE:.K,-  !]
M(@  &               @($.+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ 2X!&5O%':<TW%   0T\  !@              ("!]SD
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $N 1E:&9)$=
MU@,  %T(   8              " @61.  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !+@$96$@*O]TH#   B"0  &0
M@(%P4@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $N
M1E::)HZAC 0  ,(*   9              " @?%5  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ 2X!&5D-S^2,)!0  ^0L  !D
M         ("!M%H  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !+@$96)['K;B4%  !S"P  &0              @('T7P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $N 1E8G\TTG=@@  *(5
M   9              " @5!E  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ 2X!&5B0NX5YN"@  )QP  !D              ("!_6T
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !+@$96=B-
M#B,'  !2$P  &0              @(&B>   >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( $N 1E9IY"0\M 0  "(+   9
M  " @?Q_  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M2X!&5DZ#'2^> @  XP4  !D              ("!YX0  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !+@$96S6$PSD(#   >!P  &0
M            @(&\AP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( $N 1E9^/[<G& ,  )\&   9              " @36+  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 2X!&5I8-F+=A P
M70D  !D              ("!A(X  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !+@$96#33:!)$#  #:"   &0              @($<
MD@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $N 1E;J
M.,P.N0(  $L&   9              " @>25  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ 2X!&5F*X+=JE!   ;PL  !D
M     ("!U)@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $N 1E8FUV%F,08  -,U   9              "
M@6BP  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 2X!&
M5NH,=3*P!@  B3@  !D              ("!T+8  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " !+@$964]#@>:('  #>3P  &0
M        @(&WO0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( $N 1E9Z\+['/ 8  *(W   9              " @9#%  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 2X!&5C)]0A0Z!   BA<
M !D              ("! \P  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " !+@$96O<@0+T #  #K"0  &0              @(%TT
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $N 1E9>_9#W
M=@(  /,%   9              " @>O3  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ 2X!&5O]L_,E7!   YQ@  !D
M ("!F-8  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !+
M@$96HI^-?,@$  !A'0  &0              @($FVP  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $N 1E9VC<"6T (  )L)   9
M          " @27@  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#
M%     @ 2X!&5L;>*BNK!   F!H  !D              ("!+.,  'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !+@$96^/^G9!(%  #J
M'P  &0              @($.Z   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;%!+ 0(4 Q0    ( $N 1E:6KSUC(0<  *Q$   9              " @5?M
M  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 2X!&5G>W
M?&RQ P  $ \  !D              ("!K_0  'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6Q02P$"% ,4    " !+@$96W^-SJN0"   ,"   &0
M    @(&7^   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M $N 1E9Q\@77Y0(  -P'   9              " @;+[  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ 2X!&5H@6E)E0!P  84$  !D
M             ("!SOX  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " !+@$96B7*BL!(%  #I)   &0              @(%5!@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $N 1E9<CQK&#P0
M -P.   9              " @9X+ 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ 2X!&5AO&NQ-0 P  T H  !D              ("!
MY \! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !+@$96
MG^G#]7T'  !:4   &0              @(%K$P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( $N 1E;(RU:(;@0  *@7   9
M      " @1\; 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ 2X!&5E065:]' P  RA0   T              ( !Q!\! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !+@$96EXJ[',     3 @  "P
M@ $V(P$ 7W)E;',O+G)E;'-02P$"% ,4    " !+@$96L?%L;2L$  !_(0
M#P              @ $?) $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M2X!&5CB#;R;$ 0  #1X  !H              ( !=R@! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 2X!&5H"$^)W  0   !X  !,
M             ( !<RH! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #H
,.@#-#P  9"P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>189</ContextCount>
  <ElementCount>260</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Liability Related to the Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to the Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Organization and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/PropertyandEquipment</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Investments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IntangibleAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails</Role>
      <ShortName>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails</Role>
      <ShortName>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets - Expected Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Components of Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summarize Information about Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arwr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Liability Related to the Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="arwr-20221231.htm">arwr-20221231.htm</File>
    <File>arwr-20221231.xsd</File>
    <File>arwr-20221231_cal.xml</File>
    <File>arwr-20221231_def.xml</File>
    <File>arwr-20221231_lab.xml</File>
    <File>arwr-20221231_pre.xml</File>
    <File>arwr-20221231xexx311.htm</File>
    <File>arwr-20221231xexx312.htm</File>
    <File>arwr-20221231xexx321.htm</File>
    <File>arwr-20221231xexx322.htm</File>
    <File>exhibit101.htm</File>
    <File>exhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="486">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arwr-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 486,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 189,
   "dts": {
    "calculationLink": {
     "local": [
      "arwr-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "arwr-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arwr-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 433,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 47,
   "keyStandard": 213,
   "memberCustom": 40,
   "memberStandard": 27,
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.arrowheadresearch.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.arrowheadresearch.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.arrowheadresearch.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Liability Related to the Sale of Future Royalties",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties",
     "shortName": "Liability Related to the Sale of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Organization and Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables",
     "shortName": "Organization and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Investments (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.arrowheadresearch.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.arrowheadresearch.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
     "shortName": "Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ied9e360396f44e37a5fa2c12b7d58208_I20211122",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:MilestonePaymentEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
     "shortName": "Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i378c508c95df484ba3e6ef6a5454bc94_I20210731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i9284be9df69d4141bedb600f69d1042c_I20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
     "shortName": "Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "idad13da460ff45d888e1281a60477acd_D20181003-20181003",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
     "shortName": "Collaboration and License Agreements - Amgen, Inc (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "if64321b9c6e247da8443d05133b342ff_I20160928",
      "decimals": "INF",
      "lang": "en-US",
      "name": "arwr:NumberOfAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromContributedCapital",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
     "shortName": "Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ia9c7506b5d91485d9801a47dca99e510_D20221001-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
     "shortName": "Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Intangible Assets - Expected Future Amortization (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
     "shortName": "Intangible Assets - Expected Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShortTermLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Components of Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i27a0d09827a344949e7d3139c79147fc_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i27a0d09827a344949e7d3139c79147fc_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
     "shortName": "Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i06abac4e1f98416b8ae5ab270600de1a_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i8f511f4c684146e7bb7fbc97f28a954f_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ia962a8cd9cbf48eab5243a5e151c89a3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i27a0d09827a344949e7d3139c79147fc_D20221001-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i8c9ae1d799ee4d03923270e5ee1d6d21_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i8c9ae1d799ee4d03923270e5ee1d6d21_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "iee0675bb73de4fd3ab4bc406773f8cb4_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "iee0675bb73de4fd3ab4bc406773f8cb4_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Liability Related to the Sale of Future Royalties (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
     "shortName": "Liability Related to the Sale of Future Royalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "i645dd71143994cfd81a4843c13790bbb_D20221109-20221109",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20221231.htm",
      "contextRef": "ic200e288e0ac4f109abecbeadc1434ba_D20221001-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "arwr_AROHSDAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AROHSD agreement.",
        "label": "A R O H S D Agreement [Member]",
        "terseLabel": "ARO-HSD Agreement"
       }
      }
     },
     "localname": "AROHSDAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AROXDHAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARO-XDH Agreement.",
        "label": "A R O X D H Agreement [Member]",
        "terseLabel": "ARO-XDH"
       }
      }
     },
     "localname": "AROXDHAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional remaining development regulatory and sales milestones payments.",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Additional remaining development regulatory and sales milestones payments"
       }
      }
     },
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AmgenIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Incorporated.",
        "label": "Amgen Incorporated [Member]",
        "terseLabel": "Amgen"
       }
      }
     },
     "localname": "AmgenIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AmountIntendsToInvestForBuildoutOfFacilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount intends to invest for buildout of facilities.",
        "label": "Amount Intends To Invest For Buildout Of Facilities",
        "terseLabel": "Amount intends to invest for buildout of the facilities"
       }
      }
     },
     "localname": "AmountIntendsToInvestForBuildoutOfFacilities",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AtTheMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market agreement.",
        "label": "At The Market Agreement [Member]",
        "terseLabel": "At The Market Agreement"
       }
      }
     },
     "localname": "AtTheMarketAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receivable as upfront payment due under collaboration agreement.",
        "label": "Cash Receivable As Upfront Payment Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashReceivedAsDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received as due under collaboration agreement.",
        "label": "Cash Received As Due Under Collaboration Agreement",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CashReceivedAsDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreements [Abstract]",
        "terseLabel": "Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "xbrltype": "stringItemType"
    },
    "arwr_ColoradoOwnerLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Colorado Owner, LLC.",
        "label": "Colorado Owner L L C [Member]",
        "terseLabel": "Colorado Owner, LLC"
       }
      }
     },
     "localname": "ColoradoOwnerLLCMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments at first commercial sale.",
        "label": "Commercial Milestone Payments At First Commercial Sale",
        "terseLabel": "Commercial milestone payments at first commercial sale"
       }
      }
     },
     "localname": "CommercialMilestonePaymentsAtFirstCommercialSale",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommercialNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Notes",
        "label": "Commercial Notes [Member]",
        "terseLabel": "Commercial notes"
       }
      }
     },
     "localname": "CommercialNotesMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, capital shares value reserved for future issuance.",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "terseLabel": "Common stock shares value reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase agreement.",
        "label": "Common Stock Purchase Agreement [Member]",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers, software, office equipment and furniture gross.",
        "label": "Computers Software Office Equipment And Furniture Gross",
        "terseLabel": "Computers, software, office equipment and furniture"
       }
      }
     },
     "localname": "ComputersSoftwareOfficeEquipmentAndFurnitureGross",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Headquarters in Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "terseLabel": "Corporate Headquarters In Pasadena"
       }
      }
     },
     "localname": "CorporateHeadquartersInPasadenaMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current",
        "terseLabel": "Short-term investments, Held to maturity, Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent",
        "terseLabel": "Long-term investments, Held to maturity, Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current",
        "negatedTerseLabel": "Short-term investments, Held to maturity, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent",
        "negatedTerseLabel": "Long-term investments, Held to maturity, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development regulatory and sales milestones payments.",
        "label": "Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Development regulatory and sales milestones payments",
        "verboseLabel": "Development, regulatory and sales milestones payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DrugManufacturingFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug manufacturing facility.",
        "label": "Drug Manufacturing Facility [Member]",
        "terseLabel": "Drug Manufacturing Facility"
       }
      }
     },
     "localname": "DrugManufacturingFacilityMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EstimatedPaymentsForOperatingExpensesYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated payments for operating expenses year one.",
        "label": "Estimated Payments For Operating Expenses Year One",
        "terseLabel": "Estimated payments for operating expenses"
       }
      }
     },
     "localname": "EstimatedPaymentsForOperatingExpensesYearOne",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_FacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities.",
        "label": "Facilities [Member]",
        "terseLabel": "Facilities"
       }
      }
     },
     "localname": "FacilitiesMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_FiniteLivedIntangibleAssetsImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Impairment",
        "label": "Finite-Lived Intangible Assets, Impairment",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsImpairment",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxosmithkline Intellectual Property Limited.",
        "label": "Glaxosmithkline Intellectual Property Limited [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held to maturity securities and marketable securities.",
        "label": "Held To Maturity Securities And Marketable Securities Table [Table Text Block]",
        "terseLabel": "Summary of Short-term and Long-term Investments and Marketable Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_HorizonTherapeuticsIrelandDACMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horizon Therapeutics Ireland DAC.",
        "label": "Horizon Therapeutics Ireland D A C [Member]",
        "terseLabel": "Horizon Therapeutics Ireland DAC"
       }
      }
     },
     "localname": "HorizonTherapeuticsIrelandDACMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in cash and investments.",
        "label": "Increase (Decrease) In Cash And Investments",
        "terseLabel": "Increase in cash and investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_InducementAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Awards",
        "label": "Inducement Awards [Member]",
        "terseLabel": "Inducement Awards"
       }
      }
     },
     "localname": "InducementAwardsMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_InitialTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial transaction price.",
        "label": "Initial Transaction Price",
        "terseLabel": "Initial transaction price"
       }
      }
     },
     "localname": "InitialTransactionPrice",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_JNJ3989AROHBVAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ-3989 (ARO-HBV) Agreement.",
        "label": "J N J3989 A R O H B V Agreement [Member]",
        "terseLabel": "JNJ-3989 (ARO-HBV) Agreement"
       }
      }
     },
     "localname": "JNJ3989AROHBVAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JNJ75220795AROJNJ1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ 75220795 ARO JNJ1.",
        "label": "J N J75220795 A R O J N J1 [Member]",
        "terseLabel": "JNJ-75220795 (ARO-JNJ1)"
       }
      }
     },
     "localname": "JNJ75220795AROJNJ1Member",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals, Incorporation.",
        "label": "Janssen Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Johnson and Johnson Innovation-JJDC, Incorporation.",
        "label": "Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "JJDC"
       }
      }
     },
     "localname": "JohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LaboratoryAndOfficeFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and office facility.",
        "label": "Laboratory And Office Facility [Member]",
        "terseLabel": "Laboratory and Office Facility"
       }
      }
     },
     "localname": "LaboratoryAndOfficeFacilityMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due year five and after year five.",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Abstract]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "xbrltype": "stringItemType"
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Text Block]",
        "terseLabel": "Liability Related to the Sale of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_LiabilitySaleOfFutureRoyalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability, Sale of Future Royalties",
        "label": "Liability, Sale of Future Royalties",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "LiabilitySaleOfFutureRoyalties",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and co-funding agreement.",
        "label": "License And Co Funding Agreement [Member]",
        "terseLabel": "License and Co-Funding Agreement"
       }
      }
     },
     "localname": "LicenseAndCoFundingAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_MilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment earned.",
        "label": "Milestone Payment Earned",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentEarned",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable",
        "label": "Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "MilestonePaymentReceivable",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableAtStartOfPhaseTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable at start of phase two.",
        "label": "Milestone Payment Receivable At Start Of Phase Two",
        "terseLabel": "Milestone payment receivable at start of phase two"
       }
      }
     },
     "localname": "MilestonePaymentReceivableAtStartOfPhaseTwo",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "label": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "terseLabel": "Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.",
        "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three",
        "terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponFDAApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable Upon FDA Approval",
        "label": "Milestone Payment Receivable Upon FDA Approval",
        "terseLabel": "Milestone payment receivable upon FDA approval"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponFDAApproval",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "label": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "terseLabel": "Milestone payment receivable upon receipt of royalty payments"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponReceiptOfRoyaltyPayments",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "verboseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Expense, Liability Related to Sale of Future Royalties",
        "label": "Non-Cash Interest Expense, Liability Related to Sale of Future Royalties",
        "terseLabel": "Non-cash interest expense on liability related to the sale of future royalties"
       }
      }
     },
     "localname": "NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis.",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_NumberOfAcresOfLandPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of acres of land purchased.",
        "label": "Number Of Acres Of Land Purchased",
        "terseLabel": "Land purchased, number of acres"
       }
      }
     },
     "localname": "NumberOfAcresOfLandPurchased",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreements.",
        "label": "Number Of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfAgreements",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctBundle": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct bundle.",
        "label": "Number Of Distinct Bundle",
        "terseLabel": "Number of distinct bundle"
       }
      }
     },
     "localname": "NumberOfDistinctBundle",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct performance obligations.",
        "label": "Number Of Distinct Performance Obligations",
        "terseLabel": "Number of distinct performance obligations"
       }
      }
     },
     "localname": "NumberOfDistinctPerformanceObligations",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfOptionsToRenew": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options to renew.",
        "label": "Number Of Options To Renew",
        "terseLabel": "Number of options to renew"
       }
      }
     },
     "localname": "NumberOfOptionsToRenew",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_OlpasiranAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran agreement.",
        "label": "Olpasiran Agreement [Member]",
        "terseLabel": "Olpasiran Agreement"
       }
      }
     },
     "localname": "OlpasiranAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OlpasiranAndAROAMG1AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran and ARO-AMG1 agreement.",
        "label": "Olpasiran And A R O A M G1 Agreement [Member]",
        "terseLabel": "Olpasiran and ARO-AMG1 Agreement"
       }
      }
     },
     "localname": "OlpasiranAndAROAMG1AgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of leasehold improvements net of tenant improvement allowances.",
        "label": "Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances",
        "terseLabel": "Payments for leasehold improvements, net of tenant improvement allowances"
       }
      }
     },
     "localname": "PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock.",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "terseLabel": "Percentage of commission to sales agent"
       }
      }
     },
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of eligible to receive tiered royalties on net sales.",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "terseLabel": "Percentage of eligible to receive tiered royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_ResearchEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment gross.",
        "label": "Research Equipment Gross",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentGross",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research facility in Madison.",
        "label": "Research Facility In Madison [Member]",
        "terseLabel": "Research Facility in Madison"
       }
      }
     },
     "localname": "ResearchFacilityInMadisonMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ResearchFacilityInSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Facility in San Diego.",
        "label": "Research Facility In San Diego [Member]",
        "terseLabel": "Research Facility in San Diego"
       }
      }
     },
     "localname": "ResearchFacilityInSanDiegoMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_RoyaltiesLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties, Liability, Noncurrent",
        "label": "Royalties, Liability, Noncurrent",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "RoyaltiesLiabilityNoncurrent",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_RoyaltyPaymentThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payment Threshold",
        "label": "Royalty Payment Threshold",
        "terseLabel": "Royalty payment threshold"
       }
      }
     },
     "localname": "RoyaltyPaymentThreshold",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_RoyaltyPharmaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma Agreement",
        "label": "Royalty Pharma Agreement [Member]",
        "terseLabel": "Royalty Pharma Agreement"
       }
      }
     },
     "localname": "RoyaltyPharmaAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_RoyaltyPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma",
        "label": "Royalty Pharma [Member]",
        "terseLabel": "Royalty Pharma"
       }
      }
     },
     "localname": "RoyaltyPharmaMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_SalesRelatedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-related milestone payments.",
        "label": "Sales Related Milestone Payments",
        "terseLabel": "Sales-related milestone payments"
       }
      }
     },
     "localname": "SalesRelatedMilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ScheduleOfCurrentProductsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Current Products",
        "label": "Schedule of Current Products [Table Text Block]",
        "terseLabel": "Schedule of Company's Current Pipeline"
       }
      }
     },
     "localname": "ScheduleOfCurrentProductsTableTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "totalLabel": "Total (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arwr_SorrentoValleyOwnerDELLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sorrento Valley Owner (DE) LLC",
        "label": "Sorrento Valley Owner (DE) LLC [Member]",
        "terseLabel": "Sorrento Valley Owner (DE) LLC"
       }
      }
     },
     "localname": "SorrentoValleyOwnerDELLCMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated.",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "terseLabel": "Takeda License Agreement"
       }
      }
     },
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TaxIncrementFinancingAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Increment Financing Award",
        "label": "Tax Increment Financing Award",
        "terseLabel": "Tax increment financing award"
       }
      }
     },
     "localname": "TaxIncrementFinancingAward",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_TechnologyLicenseCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology license commitments.",
        "label": "Technology License Commitments [Member]",
        "terseLabel": "Technology License Commitments"
       }
      }
     },
     "localname": "TechnologyLicenseCommitmentsMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.",
        "label": "Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]",
        "terseLabel": "2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants"
       }
      }
     },
     "localname": "TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandTwentyOneIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one incentive plan.",
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "terseLabel": "2021 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsFourEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands four equity incentive plan.",
        "label": "Two Thousands Four Equity Incentive Plan [Member]",
        "terseLabel": "2004 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsFourEquityIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands thirteen incentive plan.",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "terseLabel": "2013 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_UpfrontMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront milestone payment received.",
        "label": "Upfront Milestone Payment Received",
        "terseLabel": "Upfront milestone payment received"
       }
      }
     },
     "localname": "UpfrontMilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_VeronaTechnologyParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verona technology park.",
        "label": "Verona Technology Park [Member]",
        "terseLabel": "Verona Technology Park"
       }
      }
     },
     "localname": "VeronaTechnologyParkMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_VisirnaLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visirna License Agreement",
        "label": "Visirna License Agreement [Member]",
        "terseLabel": "Visirna License Agreement"
       }
      }
     },
     "localname": "VisirnaLicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_VisirnaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visirna Therapeutics, Inc.",
        "label": "Visirna Therapeutics, Inc. [Member]",
        "terseLabel": "Visirna Therapeutics, Inc."
       }
      }
     },
     "localname": "VisirnaTherapeuticsIncMember",
     "nsuri": "http://www.arrowheadresearch.com/20221231",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "verboseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r160",
      "r325",
      "r326",
      "r329",
      "r330",
      "r366",
      "r433",
      "r487",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r160",
      "r325",
      "r326",
      "r329",
      "r330",
      "r366",
      "r433",
      "r487",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r243",
      "r248",
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r276",
      "r398",
      "r412",
      "r434",
      "r435",
      "r447",
      "r452",
      "r460",
      "r492",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r276",
      "r398",
      "r412",
      "r434",
      "r435",
      "r447",
      "r452",
      "r460",
      "r492",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r269",
      "r276",
      "r303",
      "r304",
      "r305",
      "r374",
      "r398",
      "r412",
      "r434",
      "r435",
      "r447",
      "r452",
      "r460",
      "r485",
      "r492",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r269",
      "r276",
      "r303",
      "r304",
      "r305",
      "r374",
      "r398",
      "r412",
      "r434",
      "r435",
      "r447",
      "r452",
      "r460",
      "r485",
      "r492",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r243",
      "r248",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r198",
      "r199",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r448",
      "r459",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r198",
      "r199",
      "r419",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r448",
      "r459",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WISCONSIN",
        "terseLabel": "Wisconsin"
       }
      }
     },
     "localname": "WI",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r458"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r60",
      "r130"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r137",
      "r408",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r22",
      "r25",
      "r95",
      "r365",
      "r413",
      "r414",
      "r470",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r476",
      "r477",
      "r478",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r84",
      "r85",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash flow from operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r40",
      "r52",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Planned area of the site (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r106",
      "r114",
      "r133",
      "r156",
      "r188",
      "r191",
      "r195",
      "r207",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r325",
      "r329",
      "r343",
      "r458",
      "r488",
      "r489",
      "r531"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r126",
      "r140",
      "r156",
      "r207",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r325",
      "r329",
      "r343",
      "r458",
      "r488",
      "r489",
      "r531"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r49",
      "r203",
      "r214",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Certificate of deposits"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r128",
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market instruments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r37",
      "r42",
      "r44"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r37",
      "r42",
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "END OF PERIOD",
        "periodStartLabel": "BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]",
        "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r37",
      "r103"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposits"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r109",
      "r119"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r227",
      "r228",
      "r420",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserve for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r476",
      "r477",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r458"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 106,140 and 105,960 shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss, net of tax:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r99",
      "r142",
      "r144",
      "r148",
      "r404",
      "r409"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r263",
      "r265",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r263",
      "r264",
      "r268"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r263",
      "r264",
      "r268"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r449",
      "r451",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Current",
        "terseLabel": "Short-term investments, Held to maturity, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityFairValueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Noncurrent",
        "terseLabel": "Long-term investments, Held to maturity, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityFairValueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r40",
      "r58"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r40",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense for property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r280",
      "r308",
      "r309",
      "r311",
      "r315",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r149",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r174",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r334",
      "r335",
      "r405",
      "r410",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r149",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r334",
      "r335",
      "r405",
      "r410",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r68",
      "r123",
      "r145",
      "r146",
      "r147",
      "r161",
      "r162",
      "r163",
      "r165",
      "r171",
      "r173",
      "r182",
      "r208",
      "r262",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r333",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r365",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r336",
      "r337",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r244",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r337",
      "r371",
      "r372",
      "r373",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r244",
      "r270",
      "r275",
      "r337",
      "r371",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r244",
      "r270",
      "r275",
      "r337",
      "r372",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r244",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r337",
      "r373",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r244",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r371",
      "r372",
      "r373",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r204",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r245",
      "r259",
      "r331",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r444",
      "r480",
      "r481",
      "r482",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r131",
      "r222"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2023 (remainder)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r55",
      "r402"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r53",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r55",
      "r401"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r48",
      "r479",
      "r484"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "terseLabel": "Short term investments",
        "totalLabel": "Short-term investments, Held to maturity, Adjusted Bases"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r50",
      "r205",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Held to maturity securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r48",
      "r479",
      "r484"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term investments",
        "totalLabel": "Long-term investments, Held to maturity, Adjusted Basis"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r26",
      "r104",
      "r110",
      "r121",
      "r188",
      "r190",
      "r194",
      "r196",
      "r406",
      "r443"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense and noncontrolling interest"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r172",
      "r173",
      "r187",
      "r316",
      "r319",
      "r320",
      "r411"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "terseLabel": "State income tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes (paid) refunded"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r399",
      "r473"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r473",
      "r528"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest (expense) income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r150",
      "r153",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization (accretion) of note premiums/discounts"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r51",
      "r105",
      "r112",
      "r122",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Office space leases (in sq ft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r362",
      "r457"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Assets and Liabilities and Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Estimated lease payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "45199"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r108",
      "r117",
      "r458",
      "r475",
      "r483",
      "r526"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities, Noncontrolling Interest and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r127",
      "r156",
      "r207",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r326",
      "r329",
      "r330",
      "r343",
      "r458",
      "r488",
      "r531",
      "r532"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r156",
      "r207",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r326",
      "r329",
      "r330",
      "r343",
      "r488",
      "r531",
      "r532"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r229",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r20",
      "r107",
      "r116",
      "r156",
      "r207",
      "r234",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r343"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r75",
      "r92",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Interest in joint venture"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market instruments"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r37",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r41",
      "r111",
      "r120",
      "r125",
      "r141",
      "r143",
      "r147",
      "r156",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r172",
      "r173",
      "r177",
      "r188",
      "r190",
      "r194",
      "r196",
      "r207",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r335",
      "r343",
      "r443",
      "r488"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to Arrowhead Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r94",
      "r98",
      "r141",
      "r143",
      "r172",
      "r173",
      "r472"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interest, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r89",
      "r262",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controllling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r188",
      "r190",
      "r194",
      "r196",
      "r443"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r356",
      "r457"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total operating lease liabilities (includes current portion)"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r354",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r361",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r360",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r139",
      "r458"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r138",
      "r218",
      "r219",
      "r438"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from the sale of future royalties"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r83"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r125",
      "r141",
      "r143",
      "r151",
      "r156",
      "r164",
      "r172",
      "r173",
      "r188",
      "r190",
      "r194",
      "r196",
      "r207",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r324",
      "r327",
      "r328",
      "r335",
      "r343",
      "r406",
      "r443",
      "r455",
      "r456",
      "r472",
      "r488"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss including noncontrolling interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r59",
      "r129"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r61",
      "r118",
      "r407",
      "r458"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r44",
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r75",
      "r115",
      "r416",
      "r418",
      "r458"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r123",
      "r161",
      "r162",
      "r163",
      "r165",
      "r171",
      "r173",
      "r208",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r333",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r184",
      "r185",
      "r189",
      "r192",
      "r193",
      "r197",
      "r198",
      "r200",
      "r266",
      "r267",
      "r400"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r53",
      "r54",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r53",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Awards Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r277",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Share Activity Related to RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r77",
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summarized Information about Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r134",
      "r135",
      "r136",
      "r183",
      "r246",
      "r247",
      "r248",
      "r250",
      "r254",
      "r259",
      "r261",
      "r447",
      "r467",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r65",
      "r66",
      "r67",
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Shares of Common Stock and Preferred Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "order": 2.0,
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "End of period (in shares)",
        "periodStartLabel": "Beginning of period (in shares)",
        "terseLabel": "Share-based payment award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock, share reserve for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options Outstanding, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of shares forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r284",
      "r285"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "order": 1.0,
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Number of options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r357",
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r68",
      "r123",
      "r145",
      "r146",
      "r147",
      "r161",
      "r162",
      "r163",
      "r165",
      "r171",
      "r173",
      "r182",
      "r208",
      "r262",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r333",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r365",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r182",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r68",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Common stock - restricted stock units vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r68",
      "r75",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r7",
      "r8",
      "r68",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Common stock - restricted stock units vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r68",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r47",
      "r458",
      "r475",
      "r483",
      "r526"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Arrowhead Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r89",
      "r90",
      "r97",
      "r123",
      "r124",
      "r146",
      "r161",
      "r162",
      "r163",
      "r165",
      "r171",
      "r208",
      "r262",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r333",
      "r345",
      "r346",
      "r350",
      "r365",
      "r414",
      "r415",
      "r475",
      "r483",
      "r526"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total noncontrolling interest and stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling interest and stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r155",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r262",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r351",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r351",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r351",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r204",
      "r206",
      "r245",
      "r259",
      "r331",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r480",
      "r481",
      "r482",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government bonds"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r96",
      "r325",
      "r326",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r358",
      "r457"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r175",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r174",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average shares used in calculating"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r462": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r463": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r464": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r465": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r466": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001628280-23-002413-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-002413-xbrl.zip
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M6OE'.%X%H].IN^'S+WJ[(?Y[J>[@=0)1*B#C6,1(&QN<A5LXS"BSYNM&WA0
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M53,PG3*I%V!+@S=*\ H CY9A&J$E3KS2.^8DMIA(&4P4-$CK_2(,U6^3ZQ4
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M*:IPQACGF0[:9M&I:&)  2OQ./,S16,PYS/7\0>QPN52_>$09ST^-).3S]\
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M!5%P$!K]8:+NSRHFLH6IEYC*F#V_8")6DR^8.%VHWLO6R:L3#M-L5AZNY/9
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M(U^]TSA:KC.//,\8(QS<<4(R'*.FQ @C(IL;\E>8NP5#5U!88R1QAKD = D
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M;/()<<:,<RQ)X=T"3&@/@G'S>_K?K@PY@_:%[B"SQ'D=]^_QA<_)@'@60<K
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MCY))UB26G%#JSERN<9V8QR#[3_5'#,A"H^QQK(VRO=:@%T.KZ+2@E7[0KI)
MW<KP^HO-]E(\XZ$I^Z.%E5UK=7VFOGOU/+_OP/"1>FW5VG4P.'6Q/$S5JM([
M'/1[?=O)(SJT%33GI/?@F3M*3R.#"T(Y9!+%0()%0A;6(>0CD301 X28Y.*P
M<AU?PX,?SW^O<=%=N)HOW$NW4?/'=],=JKFR3&DA) I4"L2E3DAC*I!61J4H
M5"21UC6@Q36%"%?>37?Y2<@-1L.9\&G6(Y@5QZ>'HB%#44S!5(-0]^*4.CI7
MU8YP">!D,CAQZC2R).:M,/QC4R+,^H41D>4[7VT4_>&)2*/H#^J9>9&]*O%
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M+KD'9H._#?X^+M=N\'>9\7<R6ZAFTF 7LNNH1UQ3CZQG$DE.N>7),!Q(E>K
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M@1HK&<7>N%"75)LA7JYZ^.&@W^O;3AZQ!LL6A66'TXE>-,?::)L0\0(C+I,
M4%,!*4\4]YA8H^G:)L%RG?#IC.BK4QQM@<K[R,="CX9/JUOC<I$CLYJ(/4U$
M%P;7"ZJ V<#X/# ^F3'()*JECAI)H3GBPE-D86N!F);4214-MB[7M5CE^I8-
MA#<0WD#X&(03G0QGC!@M+&A8TEQZ):5+A"1AJ'AH"&]H^L+P?3(5%8^.<(T#
M KX>$== TXV4$26'(PF&:JQRW:)URLPZ4=-I&1N4;U"^0?GE&9*Y3,8Q,*,E
M-U89[GD$FA>T!,H.<,]L)#?#_,^2"3:4_8$A?3*P'1-'HS88Y2R#B(,PD?,B
MH. 4=L&GQ&U:VZ1B&LSG]HUKP+0!TP9,:[.'Y\&'*'G$D0O.=(K,\&092SH*
MS!X-3!ORO#"DG72.T-8Q981'UJ6$N+ 66<$LBM::9+VQ-M&U32WI.M;3-NX&
M;1NT;=#V=C9F36QPTF*/.2>2&$Z#M)QBSB1WS#0&BI7%V*D8+2<E#<QI)!DE
MB!/XX6##@J0.@@J:/,B_KJS,6&.>:#!^>0"MP?B[8#R6%@:*1Y*,!HQWVD9A
M'5588APBL0W&KS#&3_B]!1=D),(@;9-"'/L<A\LD,C$ Z@OBDQ1KF\S(=::F
M4PHU(#^OP]X?U5P?.:N-10N>VO*XZ-3OGLARY&-6A47#AAD-<_7 %T4?7N9_
M/O 4P\ ?G<26];Y["HTYAS%I=;I]>)TMX>-.JX"F'I>VW3JS9;_533G>L!<!
M;2SH?:ZQ!AI>C:O-?Z2B8SN^@*_W^O!!E1EZXZH_W]@0#9O!!;3\K-LK\A1\
M4<:<:NQK_/-;$?HG+PC.;1R_:RAK?'F+==""0?_F6^Y][ G^U1ROAII-N#:.
M_<RMK0#/1&#>1#,GG.#2$9>T Y!67EECO,&?J%@;W7127L:F'D?DRFB_()N@
M@R]L^YL][ZW]<75.PH0<'_3)\:I'9?-?KOQC\[JF/NJ03BV#U9!NE67WVTFT
MH?7ZQ,*RXN.@TMC>>@L6IYOGWK*T?WM<?=Y=*$W6M&W;.VF];'>_]5I+WXW?
MB@X@0W< SPB]WQ^ON6:VUE[ U\U-G06_*^R_Q*5JL8$NM.U9+[X8_?)G*'IG
M;7O^HNA4+:EN^G/X^"&8966<6&NJ]]67+_5T ]>Z.G03'[YY>'FCNC2Q<M;7
M%-E02M]X&6^0&Z_][+&$;F!]\ZT_>^S/KPFA[J>Q?*;'SE@F]<80&G-31=7I
M6?0PV0[U3%N*HRJ-P'Z=1F#W2AJ!%B/K5[C978=H;%<\*TE;[L&[$KEPE]X^
MJR$C\TRJ61.;/HXE8W+IN:%8\=:[_[1>_GWXS[O6R[>'^ZW#U[MOMX[V#EZU
MMK:/]OZ[=[2W^^[%+//HIK%8S 2[=0+GQ;?P%C6K]898[EDPRN!REPPZCVRX
MFZVC<QONEL$ -UO7EB.D]'79345_=>))#]X-[6J?C_F''Q^_[+_:XX='NW#?
MVR\'V<9VU&Y_W'GS[</GC_#OR>?#5_MLS*YV?G"Z3PZ.WG__>+3//^Z\/?UP
M^E?Q\12><YK;!N_[9_?\8.?]]VF[VA[]\.,]W/NRO?_CY,O!JX\%W'OZ\?3-
M^<>C79;[]N%H#\/U=&%3&RMQ0:D*D4IDM?>(:T*0H\&C(!W'C"0BA:K"2>'*
M<B3*FH^770.F*XTO3Q-&& ?\<,YP[@/G-.D@ G-5]17B":O3@) 1C) &1AX;
M1B9C@"(L BQ@CE*.1><2)V29YTA$^-1Z3*TB:YN2KNMKC//W6;-XD44-"5]V
M^G59QJ+7ZG=;900M\T4[MCJCS'KP:?[=9Q-<:G>_M5+9/6UUSV)I^]E&GD7R
MM>@7\>;"AXO(Q?% C/PVO'NNQ6OYIT1UMHF<[55'&J=GL=.K*IX\E4(/LXW"
MHQ;AS4D%_IT%L#TV_LURM*CEZ& ZLX#W).*\"&EI..*82/A-&EB.8N+4\Z!X
MJAV"S+3399-U_:FH\@)H9:/*#ZS*D\P2&Y^XUQQ%9;(#=11(&V61)9)22SEE
M2:]M4KXN,%\B57Y>O',GG@'7+(;%LSNA94^SW]2/VS.-)4S(MOQ,8UP,6YVP
M-2:$!J,6AE'OIN@&(%.@%L3$ :005TDC)X)%W"I'&+-$"0L8M2[U= Z,Y<^O
M^$0+D2X_VVC4^6'4>9)R") A=5(CH8P"RI$2<E$(I&PD1$H9-*=9G86:CB9X
M/'5^7F:-<65H_6:]+V/^]??L7Y;]/%N@.J?%X+3W1RAZ'KK=O]F@]=RW2?=W
MB+?7^1IK>V2='O8@]L<%=YAVAL(!>'M="ZP!KWG :_I CS$2/"4&P?:((BY#
M0E:S@!AF+DEMC6( 7K*Q>ZR:0C_P>5JCR ^LR),L)#DF)+ #%*R4L)6(#FGJ
M#$J*:IC6/A+F@(4L(FJ\,7C,[>?4[:#J#*T8%=*.W[,],+9 ,=N%=46[Z)^W
MJIB/&/*I6RYGU0-]R 0E#7*I[5;9/;?MGQZU/?<MU<(L)+;\5KX H>70@U&\
MWFXML;]'TGI;"^NH^P[$=)A>5D)Z.Y)1L^-:%-:-98+&^T?^V\'Q)RFPBDX1
ME&@"K#-&(T-R>B*O+?4.DQBRD7==\\: \G2U?6&L9=':GHKO,: ?L>PVBCZ?
MHO^X5/3WW_://SG,::38(^RI1MQ3A2PE'B4C+&9)B23E1>F9)5+UYV5<V3ZQ
MG6-X6M$9]PSJ]6*_5YWNC @.*,KM7/IGW<@]YC,626@I7G:1;_G:2)9]QF+Q
M-8?R/2]6^J@UH6%37=6 'M6"WNN,Y/'V0AP- 5W8NC1]@L>4M%&RA'"")8DG
MK9!.+,+>FU+!@(J8Q-8VF5XG0BU'5:6&?"X=^;S1"-XH]X,J]Z0E33G!1'0!
M49_3@TG*D#;<Y[RWEG.&+2A_KC.T3O!TR;2GP3F7GX"\+N.9+<+(CE83S6[_
M))8M/RC+V.D/&6ASC/<(QWB3"#:4UDY,$603AIOKK4XXS!+;J@358-K" FZ.
MMOJ3.0\-DUA+6N64-8@'(9$.F*+HX *UQ NC*E 3],XVL^:H;WGW(O=PU'<[
M96_T>3Y]GLAO9PS!Q!B/G'"Y&*+AR.+D$=,@3\-(4ERN;7+Q!(_[EI^<7%A'
MSNQY8QI9%A(RDLKK6B@-WU@</NU-\0VE-#7!*61C+AD2N$).&OA3&B*D<Q+[
MRL<9SQ'@VQA(5DFU'\-"TJCV?:CV9$EY%Y/FRB*N,?Q(AB'KJ$'":B.%UHY&
ML;8IUMDUX0NK7%%^=<A'.8B7EI'G90!98O*1I?+WY5%H U*+ ZG]*?YA'::"
M^H2P=< _C.#(<)U0=AORGAG%&8"46J=X.BACB?(4-9:.5>$?C7;?IW9/4!#8
M4WBF*4<,N 90D "["T\E8AY[CY7-!=/R[H)>$[?0V#\>(+Z[-OVURO@U=@:-
M_6,I*,@VO#@WZ9^B?[(]Z,'XQ/+"O['!J\7AU?L+-G*PLWM^>'3\R1MM&$ 6
M@H6&(4Z<1T8DD"DS3GKF TZY@"I=-VI)]DR-.62%Z4BCZ0^GZ>=7-5V%X+'F
M!+F8'.)4&:0!TI&3@0 QB<:Y')J@UCE;$DU_7M:1PPL'Y7;6E7'?Y.=E*%DN
M_]4+L?R=_Q[#J@:.;DL\&/S]*6=5-3129)DBB L>D#5:(*T55HYB0K%<VQ2B
M\?EXNNK[ "X?C?HNG$V0_<^[GRQVR9$ TY6F2GTELMP:%!2FT=CHB<VI9=@R
M96=8I*F#T67G$P>C[,B#G#'W:@34KW,CS[ KND/UVJ4#K>6PC(#(<J3GZ[+[
MM0@Q_/O\/8AN#,.V+N36;)7N@YN,C+A41Z:B"$@SEH]H&+ 4K00BQBBN*9<N
ME^%68ET0>?>MTG(4NEZ@N>2Y L/]&5(:8'A<UG/A8 )RQ-A(Y%7"B"?%D,94
M(V8I+ $"&^["VJ8DZPSK90>&(1L:M6(XZT6E]<L2NKPLSWB&9>_V#OZ[^VZ1
M9>^:4AI+(^O7@]*?V!R;UDVMLS)O#/KG59Q:_-]!<9:SHSTOD^.CQLR_MN=5
MH9NC[I:'X2_CZZ%$7K=ME8=N=R249G%?W.+NIP/1#*:2!X8BCA)Q)C$RGAA$
MJ(_$>.$2X57HO%GN"G*-/7)Y8M :W7XDW9X,2J.::B,C$CX??EHLL].E0M1%
MPV3@! >5/<.5N@MO7U);Y8H1DN(B1>LSRR>Y7"SD,E-N8U18(#8=7Q, 3PG7
M^224LI!3]C $2Y!%)FBX8'24(:YM$D+6B5D2SXS&!VOEB$>CSO>ESA-4PPK/
M#<@.-)D*Q+'AR&&=4#Y3\%P"07!F;5.*=:VFD_2LO)_5"G"-L@M#%WIUP=B<
MR;I.T0,*,2@K&_HB2,C*;I<>E8,,1?,2)).SV>[7(CF'?=)VM]V.58MZAZG!
MLGO!LB_3L?(T!4&E0I9QB3BE#)DHX#>I3'#<&IQ4KL&QSJ\Y"&W\M)Z*HB^>
MG32*_LB*/D%:0N 1:YSCY:4'16<8N8K#.(6]$ 0XBZELGU1.&T@:CZY'\NBJ
M24KCT;4$QI3Y'#?V1H)K'#?N =\^3R<9U"YJZF6.</,.-F6:(X,-03(0D9+@
M<,VM;6J\+LUT\>4E<]QH/+I6R2S3 ,-R <,$\<$D4*JB0]A1GE,J)V2SOZ=S
M3$>!$_/Y8(BQ=:878*UI/+J6Y1G/T*/KY=[!UL%VX]'U](V:N41?_!Y+7PR/
M5'O]KO_2ZIY5V^K&GODH]LPL@L-: KM#V81F^9YK^9Y.YHF#CB%8CZ@R%'%E
M8HXG#<B9Q)T/SDN9UC:%:JR33U=M[]<Z>;W:-I1\@3H]0<F5Y%@0+5%TSB/.
M*$4V*(>H)4IBG;1WH--D75_#R)^&*7(5^493$GB9V$:59Z=P@WX,V_:LZ&=8
M:C!K49@UG=23"L&8Q!CAY /B@3BD-><(6RX"5S8D$]8VJ<#K,/V6J#33779:
MH))Z0SPCAZYEX22_4NZFRN_M]7J"BX#4K"3&(B7A!V=1(\,C1P)S;(*RQACW
MU,O\KM#!Z-G0G-YRYZU4=&S'+^!P=#@T3^D,Y#%IR@TG'R]'XFI./NX#VMY,
M41:IB77*98]SH1"G3L(VBS,4B @ANZT*S6K*LCCSR7(<C"[0L/),06'A]*8!
MA4<"A0F^X[@CD4N%%,8,<8,],MX8Q B7+'(EE5RP[67YCT07<5(U0>T>[<3L
M9^U8:+K55:",Q3!;8.NW,,P7^'OVJLM,<KWFDSD=PE< E%PQ+\<(E+$'.R\/
M&Z_J>G.2]E"D,2\.^;_=2X&\O9!%OK#5"5<_&/OF:^AN-TSGAO3M01;![G=_
M8CO'\:WMQ]V4HF]BL1>XQDQG5PM&)9RL@SUU@#7&Z8B<%QXQ$RU60GEBX]JF
MX>M,-L=V*X81R^%<UZ#%"J/%)"--@6G&!'*2P38U&((LHZ I7!+A9"2!!D +
MNJ[OE')M\2>!#>=L..=5<*SA(A^2QB&(M$I D5:WX9S+'<51"^XPC6/_8>=.
MJTRS+LRS+OS8O5(_X.#S\2<5;628!Q0C4$D.<D36&/@M']<XKX@BV5)![U+$
MN6&/RZOM]\<>&VU_;&W?NU)NX.#SFT^&Z\B\#"CH''ZN/$5&"8ZD4<R9(+WT
MP +O5+AH^7S!EIG+Y.""]5858K#[YOW>?[?^WCTX>M?:.MAIO=U]=_1V;_MH
M=Z>ZWH08/(T0@W_OOMH[.,CA(X<O6Z]WW^X=[CPO+CK'XJ23("1Q+S4G7$;E
MG$K.&Y6HMD;P]&DO,U!L&+Y'L^>%R6*GZ)UU>[;]"N1P!G? W[FU16<0PS"%
M?+?3'*PMT(SQ83K)&R%$"BH0,\D"754:6:4HPE%KIV%.2 (+&,%Z'>-E<FMN
M>.MBD2%&+)4 /& A\A28==QY#I\IEAW;>84,I$&&)XP,D^$.(1CJ8D".V8!X
M= ;9& *2CE''/3&4>4 &S=<YF\Y-T 0\/)#M#HCMC;SG'M,G+-LX_,\]]?VI
MX#N6%H:"1Y(,<#_IM(W".JJPQ#A$8FOF=\\'W@V^/QJ^3Y<5 ,X?N3> [YYA
MQ#&QR'H/1)!AH;BRL#L@:YLP*]8IOW.QTU5*0-.@9H.:0]3D1FHM V!G##P9
M8SRQ/HJDI4S>25^SX@8UGS!J3K!BGE*$[1')/ND4<1%R F45$59.&2Y#,L2N
M;1JR+K1:"="\WBN \,?*SC/66P9="MV!:\>KW7WLQ#WS-G'N'<GU 5=+NI!0
M#)CZ;G!VUHXY(:HMSUL!@*G=[0W*V+N=E?V^7$1^%AJZ#*XBA"VWF/=@;<Q^
M'ZTS6X2[;.Z7G1U5O9V='5W7PV7E0%77'M-G>C2)7L,<.HC])D9X(6?3?MP3
MA>\?[<$&C_@0M(=M';:(6YE0]DQ $KB*D+ED-!4+BQ%>/M-^ T=/$HX6'N+7
MP-$]P='Y53@2W'/#(T8\2H(X)0(Y3 5@DHY24*H\U\L(1PMB[RO"[WSW-+;Z
M]CL\\K=,\GYOE3%!Y^+L=&_6/"K+UOFYC6%/$E_O@>[E.764IU0#L8N$V.,I
MQF=$\%(H ^B:4\IS19&+22$I@Q::N*"=7<:L, LR"S2(]"01Z1X87X-(]X5(
M$Z0O*2.5#@0QSF /2J1&AIF  F>>*(V#P\N;I^J/OG7M"/^&XNOFO^#'Z-6G
MMCPN.K5%GEZ%$!_S=F+1.D7P2*FJ)[[(N=4*/X.:'9W$EO4PW:$UYSGG5*?;
MSW4%2_@XU^GIQ^/2MEMGMJSBO_HGL1=!%^T@%%5@5[=3'3?8_,<P<15\O=>'
M#ZKJ5QL7PID<HV$S>/:?.>OVBBS0%V5LVW[Q-?[YK0C]$^A6!05C=]52>($O
M;[$.6C#HWWS+ P[^3X>:7QV*\9^YM15\F,B9))HYX027CKBD78A$^9RQS1O\
MB>JUT4TG%V<R9_8X(E=&^P79!!U\8=O?['EO[8^KDQ)FY/B@3XY7/2J;_W(E
MW'=-4Q]U2-6U0[I5EMUO)\ ]6Z]/+."SCX-*97OK+<#PF^?>LK3_H%*V?K>U
M/:Y'+R_TZ-V%'K66OB^_7:#"[]-MG6URP[K\:S!]+%'!:MHB&ZTA+SD8G,)S
M_ *V1E>IQV%Y;#O%C^JD_G)2P!];G?"Z!/#M]*L_#]/%++F<)#L7QVKP[7<P
M(XH$VM#I;P' #[(?P/%K>)XO8N\(VOSO=M=_>5S:\F/_@K;\!93D[>>/_[R!
MY^W]V <* C3EY,/1?T\/7OU5?/CQ!NC'OT\^?O[O9Z @[?B?M^<?_PEGCG*Y
M?PJ4Y=4!T)IPLO]Y_QM0D"^'KUZ>'/SS 0,5^7RPLX?W7[T\/?CG(.T?[>+]
MSQ\^"4\EQHPA(W-]4"ZR%ROLAI@,TDAA=*2D9IF5\\16)G[,2,R<<YP3S3F.
MSMD(5"4FXZBFV*^U(I#!LZR2Y2"N;1Z^?;5UL/=QZVCO\*"*+WJW]^I@[^7>
M]M;!46MK>_OP_<%1CDIY??CWWO;>[KL1NQE.K0D,AFO#YE3RK\7VZR9=[8*&
M3L= *6S\*(_&F.R_S07%R3E)E%M[',6[D;-<KXJO8B=F4I*#S-_&#'JMG?@U
MMKMG5\L>_P1(Y%52]GG0ZQ?IO/ZHZ 1XS NJ'@!KKF<*OUC6JHX7L";T!JY7
MA,*6N?;S;V5,L2QA_8#UY"26,6>$&M8DA<$Y;]E>E>\\<VF*_]RN*5_U%_GS
M]XKQG96P)2JA/ZW8.09.4=5J#/709FYX&@.@1R<O62>VW^H#X\C)J/J9CF<F
MG,_U<\Z17DYCVBO:L4YCFM]Z'"]N\W8 '!(^/-UHO>]5>4Y;KNQ";\^Z93\!
M0G4SU7Q[L-7R\*4B>ST-2UT#>\_P!0(_[8:Z0DR(;>A>>;Y>O6:L5T3]676X
MM&?Y=GC(\7$LJV_E1V=J6\* 01LC="Q'S!:]TSQV(/^!SQD.SHJP#L^/9]6[
MPZ"L^OBE [ 9NM\Z%1^&*17[=>\VII_[VW"PX4)Q,=(%]&7LC6<UJN>AAI[D
MX?"QW1Z.5=$Y*5P6=5T9)W^WE[4?7FU;O3/8P\* 5*^O^E]&&'A;A0&/!OZL
M[$)W^M,WP84^S)&-UM$UXY8;C)S-Y3KK(:QF8*]U:L];;9@0)<P.N )=Z>0*
MN-4.H7\"I#._)#=G7/S=T3#E8>R=#+)'# S?14N&LP;EB9%O&([F%/[=P[)K
MRV_EBW<PS<*@'0_3]@ 4J--_78]9[R@+_-DNE9_AW4=;Y_L_]K_M?_[R_6#K
MD]3&,(DCTCXIQ+&CR%"#$5&88&:4T49.KH*_ N#'1]L\_P%UVMUOU6RME'RH
ME+UK0<77LZ1U5IS%_+@+%Z9K6A\C593?(R^]>6/PZ]&N^WJQLZZ<UO*28<]Z
M\<7HES]!/<_:]OQ%T:G>7MWTY_#AP^UXWDY.F$NJU]67ASM-PS<$%WFS.3PL
M&[YXN _=J/:A$S:<^AK%&UJ(&R_C#7+CM9\^5FX8SA?_6+9A\,V7[_38FV\=
M?^RO3B1K26=C]J3#Z,RNI-,FK<<Q'E^O%$>7:U9K"UC*+#Z&3Z/G!["L/9_>
MPM;W>([NEO6M3W+*#SE+ZVW^[&J]@ >&@\<[)+M^9+9M&8KN:82%*UL_[DL[
MENUL<.OM(=IZ?;C-GDN'C[YU\WX9]I;455N-+FQ#Z@_F&(/%8<2RC<^%56%!
MX#"'\_TJC5)6FX-7L\R8%>K5N&[<41=6J-?-C)]EE [;9[97E+;SM*;\8I!_
MA3J\=7H<.PWQ&YL!@_9IMV/+\^?"@/+:M7NPM4V?2X=?EQ%MP\>Y.0W%:Q:\
MV=7D[=:KW:>XWI$_YE#^E5_QFND^XW3??[\MMK:?Z(2?P[S;S/AG,^/W7ZMF
MOC?S?:59WO7[FK^SP\MSH?A9E__S[N:,S4^LNXMB<4]B,%Z]^[_-.O>3\7EI
M?Q3EDS7=/:.-S)']$H.M#JT:AC?+@/UU\!=B1IMFWJ_TO/\+;NTMS&C]-*?Z
M?SX>("Y4Z[<<@1K+]GDK4Z+_M_.?J0HQJ]W/(?-Y/I/_/]VR^-%M)O^OV/],
M'BPKU*?&4-M,]AM)C1*48F7$DYSRSV?"WY[8##WJK]_./UF3UOZ@Y]MS>/+^
M=)1692AN7O)VWO\_W@S&K0_X?SH@3]=<]I-5]FJFDLE XU6,D1V+6FQUJ]SV
M\.RV=:UD?=$N^CGFL^BTWD'+=HIXW%UO;4,_8 _5*6I#R[X-1:_;66_]4V7)
M[Q7PZ[<<0EF%UN;X+UOZDSKT\S*ZN)4SSWRM'K\.SQ\FWJ_"Q,:_5<>O%E>"
M)]=;??LEML[:UL?KHR[/2GAB<6;;K?@]^D&.VX4GI<(/,[*TN[Y*$ ']>FU[
M%D1@Q[MU<[Z+E9'JSJ <#6<JREZ_];\#6_9CF0<T%3G74HMBRJX$^U[&N.=0
MTZ$4*KG9\-7F,-PLT%&P7G4AI[/IQ+*J3-X)5=J-WD;K7178VFY]B><@_RJN
M?$RFO:&XXXN90^Z&V%$OVX+_>N018</LXX\Q^%6$LKQ(I_3P3;@Z8/F6M<W8
M*7,0>QB;$[V!^YSKT8,:V*%7,VF5(,CN*;PJK-<JYKHH3XS1W67.IP+SPP(O
MZ]5QG3V;8O\</FR#V%T&C7.XMXZX[WZ!ME4AS]5\&7X8SCO0:]^K0ZG')@?J
MY4BDBP#Y]=;-5IN,,@4 2P%/&?11&[2[TZOG[M BL#X*5J]CX_]GCE1HPD?+
M*=8^1,>I-Y92[X4)DFLCF,55*#3#I Z%9IA-I$(35P*CWY^E$IZ^7[1CK]_M
MQ-?V/'<VYUP : JS%1*1SS=N^OO^CV.VO_7)*Q4L"Q0%QSGBF&/DN'!(&B*M
M<<X$C]<VB=C -V0X TUK9\F?CB0!"%:)H@JN'X/">FI]L[TJ 7_6D&JB1Y@D
MX08L_;-!LV5!L\J#^X(-#!W8A] %0KMPU+\+0 3'J.+>\T X3"T;:1!)<A6D
M()[R!B >&B#XP9M/1!*I/;/(J5QJS0F!7!(2,2(\<SX:D_C:)FT XAD 1+_B
MI44G<Q5XQ[EM T=Y/8"]2(:#K>,R5LF^6K^-)?.Y^%K%4RZ_=)%SYEO1/VE-
M?&NO\Q7F2DUM*2:FM;>]]=_+E#57OGSQ()AC!]VO\=3!-#'K>7Y0X$R#LC>P
M]62K)]C$JZJY-@],62DD !*3B02.4] 22(U,-)><I=&D7R69;F!JT3!%@,?0
M""N%#Q@%%17BG#MD*?:(&(&I"P13ZS-,X5_BU*"62.NW=S&V<A;$%B&M89;7
MUM_%D(VWWN9TH#4WSK/]'0@B@]/+07\ V^%ZDA5U'J@Y4BG"MU_G?*9[ZR/]
MV8-+.;G?=5_?&,W]%<;!ZHFS)UA;2F2TG4YW +OYT#KJGE4[^;>Q-VB#/&$J
MG;;>[;YY?[BW-8IR!0$.0I6-ZM)):F(SMK5U]'MM2ND7U;RH0'*K#9L]1%I;
MG7[1+\_/>O"-G5BG'?/G:*O7Z\($R7.K<L-L[=3)J_*#*NB[W2PQ> EFR2]6
M2Z,P79HY83:,S&/QLG!EMU=D@]WQ*#E:9C==!R_Y6MO*!/X_>2*<C>1<5KB?
MN?/EW&C$]J!BVX^A@)8 TZESTU6@;'@EIX]9,W-2ZL'IH#U,=EG3U"K37V60
M.8U3=TO]?_+W3@I8XMO=XYP6K]UU U@QW* $2;2^9=ON:%Y,R/N/B?2:SSM3
MM9@8G+&?#YUT^MJTI[=.8]HH\*(4^"CG_JSV(<"2RN/J9"2 =L)*&+_6JVE6
MM^,Z52NLN-]BN]URMFVK)=S%_K<(.CFV.%=VUMIPV\II^\]Z#28_J$A'=*H2
M7'4BUNMGN=:TZ.TAH#)LMC#-QVT=U+8NYD3_F66=E?%KT1WT0,QG ]<N>B?U
MPIO/N'*#=SO'[2S>O[J#LE/;LO:'EO*9SJR6*OOPE:S<U:S]M\T$).\JQA)T
MK_Y97)9>E<VV.)UA4S4\'*O6:5OG&Z_&Y':YC+^== $T4/=;!]YWY5)UKM?Z
M"G]4R2N+4<'9F/GZ>=[)#TT0XU:OHC?,A9OS&Y\#^G0J1@^__[[1>C?^^"J)
M<MY&7K;[XJ XMW>]]=\"\*IC6T=7CG:KOHQL)\.OC#:.ZU<=^UM;(&< Q<*V
M7D.+_^X'V'A"LZ]T<[2=N-(-& X8TS)W)WX'6E'OC-OU>19,D+RL#JMTM+)%
MKWM:'SN//0*X;[<,O58G]EOM+MQH^_VR<(,Z%2@\#?;LHV.SS)!'XUNU*,OI
M2L6/WI5-=?>BQ'PK_N^@/FZKACV6F<[D [*)QN7.9!F7O9/B;.Q=9>S;HE.#
M2&\ HS"4KCNO;H<OG=5IK2>;FP]VSY_ .?A\NG=B821<7D\!B6$(ZH&#<<G[
MW3QN%82_WWBW,;8@@Y+&L_Q(>U$=8.2 T,XJ.)S+K[:V7H\F<NVU<%GF!9ID
M1R*]4+4:!\(H!7GV6[BH#+$!>E)].^<3'Z:DAK&"F9$[ GH"'.'4YF[G].XA
M"^5B=EF0->!'.T_A05D=?52YI^-8]T]MJ";Q**=VLD7>[5^7Q/>R%R-^#JH
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M(-^I?%-A@]0MAYN$T7E<[V(E&3W7CY"J/M(H1T<:65M_Z8%8M_D"8WJ7%7]
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MP"17'O+8$V\]DM0ZQ*5G2$>AD0R!V!PQ:8,",#%F0_YT5O1.8"N#8*T]'2,
M]3J]3-/CH-OQS0SY61G'+7%X]/X[( 8_^/SEV\&W3X80:2532"J>$/=.HFSA
M0D1$[USR7M'L8TW$AOZ%;U(NQ-;M'$_/$B!M:9#K"ER8?C9:8P$K,^]'KR]5
M=_,Z5Q'@L78,;407##)DN^@\T_=6!=-N]*[;&S8#.EO]N]<9KH=C#H;--)X!
MZ#BPIF@IYLQQI%2(P)J<1=ISAR@7DF !/X6 :<S$SY:_,2??BXJ.H=[ Y9G7
M.&*NU"R9<,2D ':+=\0<N8N70U'4AHVK;KPY0N["6_,);$?S642W;]M7=Y_Y
M< U:6PS/PX8# @.5_WH DJ"O:,Q88=NW\3C[0W7+\US=&52A=Z%'O:$BS8BS
MYIEIT%6<?</VCS]9RVFND8P"X8"S7DH@E%8CYPFLQYQ;S !G^0:91EEWR1/&
MS')Y&I47$JI+G689789D].ISX&Q9'DVJ?(S='?0NS7[9RIZ/9NM;YS0NKE_$
M$@V!/C.8H?F\VZD-8KW:VMWMQ;$;ZW.]D4DS'Q$?=^HCL:'9NQ=OMFB"O@SM
M]QDU!F4.><YC4^$$73TK^+O!:64DAG$:*Z'>NJRAWAH547\"!V5'5<#[I>F[
MTVWENL3'M2M]9:@>&X/QD^+1&(2ZYGR\B"6:Y+6GW5Y_%$X]PXG2Q '+^,%2
M:W2F-#&I[J<T\&B/!B-]*?O7L%A67NC5W*\FPGG]\]F6"3[:Q?N?OWPBA&'O
M-4>82H9XD*&VVC#M/8U8>4W3C+6!EPH.A@7FQ]7_RARX'R\^.E/6G*<)0$.L
MN.*6,C[B]0%M=<N54Y]6 <!3'UKEPN1OZF#&]ODU</-F'=YVWJW.XO)2N 0@
M-IF3Y7J/] I:3.1,$LV<<()+1US2#@BE\LH:XPW^Q/C:+Q9<?>VDN/<Y<$/-
MVL.C76 *K7L&\NU+!O,U;I5E7N;RA-JIA3\HEZ;4^\'V",/WS@]WO#@XVOIQ
M\.J-V#]Z^_G@U5O Y/??#H_>%@<[+[\<_//VR\'.AQ]3&/YYCQ_\^$+V=_;Q
MQYTOWP]>P;^O=H$#;XF#5X#?_[PA'U^] 5Z<,?P+._CQYA/!1#G.)9(D;RL%
MX0CFED1>,*MT"LHILG:9;F4K;S-@<R,M39$RRWE,UND@G524)>QPM&(2\[</
M__Y[Z]^';[>.]@X/6EL'.ZV_][9W#][MMK9>O=W=W=\].'HWK0R_ACFS1&O&
M]5$+OQZIJR/KB7"8PQ49'*>)&^JX2]%1(>'CO,%_U;;?N[W3HG_RI3J7W@.%
M:;=A Y#Q"9:ILUC"YOVW@^Y&B_W>^KLXS3YXEYY][_[OR+'O&K2Y:<B?73",
M7/)@F%].DXEI!<Q,81FP95YQ0XC./Y-FT6CNC"<_#9Y97B)Q.!:8GDWLL J0
M]1;,\0N7FY&!YVJ(?:>U^]VW![V\'?^[SL5S0Y!]?M;4-RY=8]_#$-2K_[5?
MK-N2W?PN3&SP[GCQ[F$>H(I"#&M>U-ORZ:\ N?G6+=L!ID^\=.F$[PV=>&#G
M>IS#<Z YVR=%SA%VO5?\A9=UE1*O-YD]RW=/ 7ZS7R&(X6J;+CTU>A=N?;63
MSD5RVV%H2(X J.^LK1]Y$"K?R&^MVL>_<N;.P2;9WI;;F7V +_QHKO@]3;3)
MCCH[?,'(0QWZ71;9"#,ND]H4,O3TLY="Z4_T9EPXD[91N'L>^U\,)C*)F9$)
M\)XI*Y*EGE"G@M 4Z\K^1PBA]"<6\TE3^:XM.ZMB*']P&G-I*(?K^_1PZY/U
M-#%/"?+)1<19M$@321!QG GMDX2E>&T3$.27AO+J$&[,-%Q-U0LOL]$<Z2W%
M)*G/4W)$QU;_71^V08>ITLNC;]UFYLPP<_A!SG5!)+,I(<^<09RZ@(S!&D4*
MJZN.7M$(#(S-,''ZM1TMRZ&.8QBE**@3.\WK>W#/,^8]@/&6/RD >/.%RYFS
MU0DO<\*J8;J$G;Q=WNO45_/)=S.S9IA9XO#-I\"8Y#QYQ%RDB(,HD=&&(8RM
M553"MH!;P"0\R^%=GE^5L+*9Y+?B=YA=O8'/7NYIT)Z8:$ )0G=0KZ._%?#=
MRQQDP]0(K3"R@=BKV<<V6B]KPWYVY%_/7C2#=DVJKB8IRZ_(60V',36P=I^O
M7_"OLVX.)\U?ZP#E&Z5*'*VXO2NG)V=G9?=KY:7;.K6?<P2!+;_$_C"8+<2,
MN/ -($!U/, E+YA.@=6;S($%2CC_:5Z2@<A("'.:<6N4-<EG(,!2$Z6EGTGM
MMB^:.:F O:U^I5V7W\@G?(U._5JGWGP_>/.)*88Y0'+.JY@M%\XARY-&4BD+
M*[W2)%'0*3,37-<Z,3:E\FE</8\?:=Y4I[W#9$A3,Z>9)#-,DA_[;SZII!+
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MZHHCH,*2HGDF]4/]W539:O%P!Z-G^SL_6F5-E["FN'YY',& 2AT=PE3GDOP
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M[0?4"+FZ8:S!C^0L36B?Y\7=&L[?1&/'-F5C7S[M*BI?!L-+4NR!$]EK-W.
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MJ$PGY(AC23"FC"01?D#C'069E90\EI2([/E)L)L"0@8F6<A%F0Q9[0QBV*I
M(X4[@.<G[Q*2K;$YK'GFUEBEY$HTV<9P''E*CAAN"=6>"^^(=&#4M0UQZ>E-
MJ];151(R-X4Y. 7U)$!$H+T&"9'*(.-RU39 OR:,0P2GE[+DY1C:B6JZ\>JY
MFT'1G9N*D=5GL=Q+?NY=:EL%D%E(KNJ7QUAY;Y6-B#)-$0\Z(9V<0C)0IA2V
MV1B]>CTK(1-"L:BN,N0YW$5/_,#GN;76LC;+I3K+G3JW_'(Q"^H\&KY?F0=1
M;3@/XIV\AE,\B$0#1#@IC922*RH-U2"XD3-%((@T9B$/XJU2\_1UO ?V6PQV
M,++#%W6\$ (-(Z=I$M#RTR,>T.<>(NVW:ON^U\ZI#E6  ]ZJ#59D=1[(_(TW
M;?2N7P[ZG4\+.;CZ4B6]BSZ[\!F+Q)%OHR$O8TX)O;/7C4ZWT;$Y/]L^Z=CS
M^0.ERG 8E1/?"SWI]IWO]VPKMOO=/(LU@"(VNN4J?*KO-/)EAK7?HPFL,Z7
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M6^8Y%T('0&[-HZ-6.N-MI))9*3A32VE$U9VT?B5@>Y?'%$=,H[2(\Q00QYG
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M20(U11KEO%&&,9<+93A@F36$1C"@(46F">$+2:/FYZJ?JG/N)H,Z@O$B3;%
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M[=FBIJEY-7+$\\2MZ:;;_$ZC#*+UIXWX/88QAH6;)R_- [C,-P]Y>0IO'@N
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M^A2P91'VF^0XAVPQ]@1QSEJ;1I]%06AS7BYTU9+;7^&\\2??_:6@\D-7D%9
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M$0<[C1P-&AD*H5=B0<>DJU'NE2I7::[-T^7I-!=QU%"-68Z_09<-E\@ZDE
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M*CP\D$P?*KB@.>R;1CKE.DK83&2EPT@9G:A*RGL=BW!:;7Y[804DOP*05,<
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M5>1>&J Z/@JLQL'_4:>2JE.?H%.#DC9OK41"*(DXY1IIS0SR1!)MDZ,AR+S
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MRJ\_BG87B1C7T8/RS:[S-XO#\RUC9[0AMKCU.-$SOV?99*TBA+-UUFNU\U3
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M0TR4E%&=PMIFRLG[>8+L3\^0&[6]3FW/#[K76^19@03XSB7P$B"*M9G^"!>
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M+@JV76_ ZP&]S170V_:L']^,?_D#F.Y9VUZ\:76*!BE.^F-T^=&NO;Q3;:I
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M^)=Q;F!J58$19KPRA*OD?V*ECGN1ZV;9I(IL+0VZ9K?LTT"E",0BXCA!G&&
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MEL2CF<7Q:#L,+2MYXK$\<4JIZ'2+@_8S.442.UER0GD*/"/\O\267_$'V'9
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MN-_%3/<ZPA,^S%=(R25(J+Z9U__%)]./9PP3]["$UGR]KB7Q9%-,1QKH\F$
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M5;:80)' '*E\0$P83W$46,8==V/Y$B*"/O6G^&\)"9"Y()LLA+Y\&'NXQE'
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M82];QZ-@DX*G,B @T_ A?:Q08#.@0U"99@RH5@%%G@)ZK\@Q>C9N([W!1PA
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MJ-/5ML(-D/69(T9^W@0]!R49QY9*)"TF)/*"LQU,8P"?/M+58;<<+P #="$
M)\1#U+X#36 VKA'T]QEB6IY_CO8="9S['H[; G3-4\81^"5NE]G<0)>&HDX
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M%N2P#:K:&%P@!A<QN.R3:7W:R"4 #5;FRGC9#47IX(VT :2OE7]+B6\0Q5$
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MS9 NS^QSKK=11\M+-!?+^6G7*MO=%/&!\NT5H"PT&1[EP1 .4#X5B$IIT/6
MT1R4-J&UU;\%SI":"'HD2"N%'*;TM-9:?5&!>7=$ 3\%-L>O9],/]?O:F\C3
M_1+F?V!W0/D[3+5?>XR+LP+-3@>G-$;0M%#5IW0:U:_^AI/\?G;>.?_UF?5T
MG]5=K3;HDL@$@1/UD@)>KXLG(A+UI-=6.LH/6Z^\WXUJK\CG.<;EUP^]_+"U
MC/;W*26TLP_3\;\P_QS&TS69I"PCCS3#DT":X<IJB(;1Q"PVH9<BYA0W"I+V
MAC*H?6F-V70IJ#JLTMJ$V#M@KFL,:Y@C18B4W&70)9+)3[+>X4J)GV/:Z&*<
ML^Q.$]D&RI"2L8'Q; ^=-6QIOQGVRS">_SU,3G%=/CI&C\D#2X61?$2 @%A/
M[6092699JM;!_Y80AY0I]D2X0RBO&<-NDL'YG>Z(VKIH*'])'>T=I;>U2[^$
MHG0V!FDF'"A.>'9_0<*Y-%C1)BLE(7I#R;XR""$6"<$1&3R+B2O99X1PK0@&
M&A[LPJ 6L<$NNKK7P. <L%#D2(I'T.1/0)E8P&$2]5(1)YW0%-!L5J/;#\=#
M" GN@UN[JNJPP< Y0LNMHX"X+KCQ"*K"C%P4*"4R"F1$R<V7N;;!]Q#"@'U(
MUKO.#E4)6H;IAW&<X-E6J7?I"//I!&?EV[_L5>S9]B&-ZSE[C;%1R>;E>$HL
M?3W^6!O=+C^V+N?G9%$$A>!X7<ZO'6[1"C(XS''&C)(H6Y=K;D>TKS&[Y=-7
M/2XJJD3_4;XER,1*YR$61I-0,RQ691^;=V#?A6E("]@-^?*MS6JJFF;>[Q94
M:P[[TKYBZZS07'+P2 Y:,97KYB<&0DOOM$A,Y-9+'=NC'%1+T?VPJH7^VD3P
MMX!\=7Q"_KIK:U*(641*U#'6E3S+ W@6:LM&3BYZSR1C&P7J&SUNRU#IP1&D
M)\'?3X!4=P774Q3/MO^NL[EA@'3W0WH-D+8<XV$"I"(P>(J>H616CZK3=3=_
MU. T$80YFVUHG>_T$R#=,1W.A;\N]J=EB?/_(:V]G)W.1UI'$7@VX%TFJUE2
MI-R4*XA&*1%E+"&'/:W3G2 >4*2T#7$V-%EM=720"&H-Z>I@@XKU/?$#1]PR
MU&1@0<1Z%1CEHA ]17^.\V"+]TGSUEL =H0ZI-)5#[0[I"+OB75O\3B,R5O,
MWY27XP5IL*(?&2YX,20L6R<))1RYMMXP8+'H8DM*-K8^];,!["'5N ;#QOT5
M?)_V\--LE'1!D;4!9NNQZ*8>;ZVE E%TW7B8C!>MSS/>">B06B\'P[Y=E'A/
M?/N5XN;WGW#R$7^939='BU$VWI$@- 1%B; *7("O659T7DGI(TV@UD?8[8=X
M2+V=@V'@7FJ]1]/7A:TY!!>=UI!\J.F]S> B%D O+*L[L6UH?:3!;DBW/![J
MWX-Z.ZGQ,&64KH%^43=/S:9G=Q9VKYP-)4S73XS9HXZRPU.:%E+V'66C2DKW
MT&>SQ7(D><@Q"K(]P08B@LQU&5M!XK:H8K4-NO5\OGCXOB;L[V$^KAW5:Z-1
MJBB;"@1?CX*PK( CUPY!YFRYEB'SUFMD5T ,J?"QFYZ_M3'[R;G]'<!?<6A7
M0BAU!P:SE#1H6R"6V@,<A0U>&\YT;U< ;Z7P0Y4<VBA\3TD?TF%<[+]8M520
MX9R5ZX^LJW^:ANGOT[PZ)!'S3V$QWM^=-,30@[/I2T+-7!'Y/KSAD,'SBT:>
MGR(16MJD*"S241$#:]SB39803)&2L8+9-]^KO"&VMI;MZQ&+3!@9M)*0DJZM
MQTS6)F0-,C,EBPN8=.NBUQXG81[.J?7 F-M-X&XJ:;C7]Y81K\_6%Y\3O94"
M_]/:M.916HZ*\H@<:N,Z@H_9 -D*'43TA7X[Y(2Y">BP_.<!N-6_.A^F!Q[Q
M(?A@0C%H+_RME [MAT7QRDM-I#?6US,2+;A0%+#DD\XF)]E\]_BA_/"FSSFO
M(8>8LHM10<Z1U<(-&0$? OD&ES"+S#*VKL=N"?%!^NUM&+:5;=U3A8?QYVL@
MKU2*M?#9U?OJJRCJHD4@K^,""!>M\%PEBZVW8NV*]4%Z]4,P;R^E'I:"UZ_4
M.DQ8HB:HKJZ<82G@0[TPQ5J%5G"37.OKN79'.Z05^.'0<'_%'MP67BQ=<*.X
M5LQ!))F0Q:X;L+-E($E,R6#AW+:O6&^'<4@+[\,AW:Y*;-/7O17$\<=Z0=37
MACWZ?52"XIQ+!477*\JDX!"MSI2.(08?8TZ:WY6K-$$RI$7U7MEU>+W=BU4[
MZ\QS0F9M0X; 8MVKK$4M+&5063E>HI!,M%ZZVAKDD-;4!V?7ME?C8:HT[Y:S
M],>5FV OZA$_ST.M,(1I?G.Z7"SI.PVTNSUVGX61_1_:M ;36 9[EEPZNW;]
M!;U/YP3E0W=ZX$]?OKYE1;6GG\(\OSFI;URL3J=;?GG5G2O7,;&[T?#]49BN
MWK,V&DITF4J>)="L.X70)H@!/:!@7EM+W\1F.Y8.#+R?NZDWA[L&Y=?3XXCS
M43)2I>#]ZH)[)C3XP@1H;94O*6<4K>OJS0<QA+K0X*?!9G=J'XI*S6*3G8=Q
MIZ!_G75G'F)>#0^%$-[4#<+9<E!>,8A&,!JC4_4D!32L=:/TP08WA/K6O\\,
MZI5Z&\9AJ]?KETCX?OS+_P-02P,$%     @ 2X!&5HZ,# AV50  P]$# !4
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M!%=PY9-PJ4C1.M[N NQ@36<X]0P0I5TEY'2#JY1R*'DA5R.00- R"$DILH%
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M7F7%NA%P-VNC]N2C-E54P_R_^QN.=0'VN#LT]E)=YXY\Z\A]JQT:L7!!T;L
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MY9&[2DU5-0 K_S9<E\\5'9 -=*>S&M5NKF_::*^#26P@^BWM+Q<(2[)&!&O
MH9.UN$E]34D<!%<9 U?<-*=(;MLH[KF"V;9-])%X>P)5P6GE$IZGNU[&#1(9
MSS$"!E] !>W!A>+!,..BES*$W(WS>>O';_]:I97P)TTE-\"[T%%*TS/,ERE8
M([R\*&(YI"23@Q*R(*\H2?"<,4ADQ%G9PA23C5?U*BP/7OU-A;UR0>^HYL(_
MR3>:X7CI6?3E. U9:N'>0;=:8:&?")8**S"4Y# JM"9;E2P&;73@%.];K[10
M^O[""O<.OT?U%"R77E2R+Y<IU:QABK,<(D5-(BOAD['=BL(_Q'H*5Z1IS$>S
M>TC2MFB>0JG7\]K0N8 )/&,1 @_.DG4DW['Q=I]1'WAB<A_C6D%G;ZR9 4[L
M-]-)0LRS2C1Z.9N=+?B-%-F>GD[&[^:3]/MQ+ *S8M61T!I4=@:B*(32.,."
MCE'I3K>F/=;8O: >H64-H[#6_OQR']B?PG2,^5A)1?]G!=!A5-^/HP9?"%R)
M IU/"K7HMOW<_OF/T!Q:2;MU%8.^%1><0+35[0V+@C%,4TQKR16F>"7DP,A=
M35U#O<=4$6-MDQE2/SLJB&!"Y#SS -KX6N^Z;G6U"Y(10AMI1%++M*S'7!!A
M;<L90!O;*HB@H@W%L0PY(?E8PD5PG&9?R[K8**WR'6N('69!A+5-HH6\]Z0@
M0I$^>Z\D^=V5V4P"@>C(@(6B^4<A0\&[F$A/!1&&]GN'5NJ."B(X;B.+Q0-#
MPJDTM^!#W3B+P6@82VBWT9O[L HB;&)GK96V[8((EQCK66MC"1 D,E"8%/CD
M-+A:E%$67TQI_5+_",CJK2UK([4-4 =AB.0&SK+.S("-CB*(6'-A F>0HU8A
MI5B$:+W#/9'5-S;6'1O"/I+54085T5N0Y-N",MI"0,&!HN!"4;(JF3TU?6^@
M^KN:OO=0P9 $YRXX#I"LWDO\*YN^KR&[0<GJS!EF,MFFEK1+)@P0F:I=T;F7
MHIB8EPD]>Z?#/DW?6ZBPC\A:OS#\<_)Q/".!C?/%5R_'X\GGQ>73/__Y_-D5
M5YI^<)E,&Z2(0A703""HP KM/K56M%;1,II(,=TJIO8?>Y?$]#Y*FFQ/PJW+
MOJ_,5[B!4II:D]4)0)5SI>HG\!HU,$$'$AJ%-O)N=M!UR >I_D'D.5!;GU$>
MA>F7^GCQNBQ>/\\[8#(CHB/[*[P6+%1H($3/P>0HHT[.F>7[WB:M?6X%\\B]
MN+;*&J @P34XOX13^O+:O"^64A>$0[61NQ?=[OK)-5#GLI$,HXLA]I[[D287
MF?$\@512UBQ,!Z[R@I1#(U4.V34O,+ K:^G0;&XGQM)'!:W]U&L9.6_.INEC
MN-EW59E@&3H/4=>BS4(J"$Y:\ *=(1&P$KL]7-\_U@Z:S#56SV0XV6ZM0)+T
M--':4U%8QBGX<ADB3PI2T4%Q(9Q2KO&6</ %DC;P23974L.,EW5+<'2!^U0@
M:2,E;UC09AT-[4&!),D%2T(C4)07:QII !]9?4PHEB,%D,*;0S2HM0HD;=6>
M>BBFO5=S/8G])GODZ^G+<C;"0PF1SG,K)$0,CC9IK7(219C2L9M>I_'VOU!2
M+YU-AA5XZPNX%9!L,EJC0] 9%7E@M"YB(3^/SN2@ZYVS"=T:ESTZG3<0Z+#K
M?@D8\\RYDB(XL<@1%C11[^I]8V&J),GU,@NKTVI_-/IN)MS6R?S__.6?TCM_
M]/;U/W[\;1D8!5&&]IP$-J0 JH0,85%@R/F8+<\^2-9)ZW>-<L!:;R;<UFGW
M!,QJ(9CUFL#1=_P"5+0Q9N0.LK%(4_4(CF>:JO4N.>:CSZ&KQF\=X;"UO;E0
M&^;+?ULLS I?V<(,K(VI)C1R<(QIBJ)I?*MXB:X3/?\QECE<XP)B?>$/80&7
M[D4'&(=7YK"7\%>4R5M'<@.6.2S)IZ2*@+JS4"R0(WCM+"3I/2/?,>MX5Y[:
MWBBP4YG#%OKK([#690Z_J?K&N!1,2P.:O#I0WI.'ST.$Y%62DAS!4#K5/GH8
ME?)ZB7UEI;P^,EL9^>ZHV,G1Z0<<#US;9'F,K98RN7."2Y5+9/1<&DV.%3+E
M9 XI2BV4S+'DS$NYOW+)\FA[5*B$.1:$( =!Y^K/T]3 N5@@^$H7D3+XH+JL
M[(=8J.22.'JEJ./@"DNV1%JTJG;-Y@(\\PI8*DXZ$4@>W6+'FY_]P DF?0SE
M5GKNFE)N?2G8JP:*+D4:3!Z,0$V'N$S@"UIP"2FF<DH7W_$"Z?%4IUG;4 ;3
MS !O5O<7.]%2!8_9 D\U<R"S3!+P 7@)J:1<;%JN+/)4G68 RQI&8:WO,Y?K
MI5PN@^,LA,E>U#GZ6C$O.G(BF8.L)#(1+#II.FU JT9XA";13N*M+SA__43B
M&L]78BL^F8Q"@*GON#1;BBFES*3NG*+3L7#3S1KN&>BQ&D5+^0]0N7J=2@,N
M9R]UUE"X(L@J%W"">\A9:U=\+B2KQL?0XRL?L<G!-+12!RACTJT209;". E8
M?.WR@0Z<%08,TE:DLT_*MBY;<OCE(S:QL]9*VU)9DAMU"!2+M-'2I&,H%#N&
M3(Z_5!IBR9:^*R&J3I?(3^4CAK2LC=36L#+)XE@_RGFABW#R%JMH:3?M6VW.
MLY)XK7F!(D:2CU;@<Z1O=8ZY\,"8ZL;0VQS+([2T76CQ@=0PR<8[0^*317/:
ML4NB%64<,*Z,SRI((9IS>9YJF&RZ8^[8$/:QAHGT(L7"D+S9Z&MYH0#188(L
M;0XY,^[Y77'*HZYATD?U=]0PZ:."(>M>=,%Q@#5,>HE_50&,=60WI"YC0.6C
M1B@^&E!1&8C<2K#":Y^"4"*S/==ACQHF35381V2MLZDO'ZHO*BI@OLR(8)*7
M8BUXEG2MFZH@H+; !$-K@HO6NF[N[^T#[+ <12]Q3QK+:FL$3R9"S#%H"$R2
MMU(OBV+2&G2QP9B 1MC6?N+!$SS7.';;*6F @A-]4XZ[P'TB>&ZDY T)>>MH
M: \(GCJSP%SQ(!<-@FM">]39@!>EB"2LP>5GKL,PJ+4(GMNTISZ*V1'!,\NL
MLE2U6UU]Q5<Q@[>% YWCP2GZLL1N"5R'0O#LI;,U")Y]!-XZE^OUR:<P&]&<
M;W#32!,990+),J^]'B2XR#-DE6(P)1F]7&-ZA16L&N& ]=Y$J*U7_Q6H<3YZ
M^_KHY[_SFWS$H*RM?>2+2K7#*'G@QBA(6LK"M4V8N\4H]X_U*+3?1-!#U$4[
MBS/\UQGA^>ESG3S]L\5!2.<<5XRB;:-9 65DK1T:'*@<O2[!FRB&J*UW"Y2G
M(*>9H@:H8W,+K(NK@"[ ABJGMPK4[JKH;:RZ^\UA [D/5+;S=H"9!Q-3D&!2
M4J"2S4!.=P8=T(ELZ/]=>M@&T:%0WO;LH8^XA[>#BU//E2CJT0:)()PWQ/8E
M2TC92Y4(8Y"=*'#KV\#."N:U4=3=ZE]#R@VCB6^IF]P5+23-R DZ>%6M !DE
M&7D@"-G)++GHU%CV,9+.U_ 7UA?^@*3S+C .CW3>2_@K2,OK2&Y TKG2B4=D
M&4I19)'*:8@\.C 8"G/1J;"<N;6?"NQ$.F^AOSX"&Y1T[I)Q:&VMXEX+#$5K
M:L-.">A29BXQ$[-MH+D](9WW$OM*TGD?F>T;Z?R?$Q+A;_35V11O^?L_1O./
MOXUFH^DXO/^(T_!IT0%@-C!+?6-06Z6UMQ7A$@^>3"<$VD>\YDIA""&'Q*Q2
M(GG+?<+[>? ;P]LGXCS+G#-5 )-+M%Z3!!_0 .VQBGNN"WE S?/0=T^<OXU/
MN4@ '\6S.>9GX=-H'DZ.$=&&P@LL<KX5+ZXVHLPUW19+]+:(YHTN[D;TT+.F
M>UC;7=37#54U0+[*.OPG3EN1SD)!273 J1PCQ,Q)&M9&II*P0G?R#)Y(;0.9
MW-!*'>#6IPL_*@GIHF8(W/#:%Z"N$JX-:).#RJKXG%O? 3T"4ML&=M9::0,\
M5W5B1\GL0S+< P_. HF 4=S&+%AN4A'>\;"<M?!$:MN^96VDMB%>LMK?WS%&
M$U(N A8*0%4T%H)/$7)BWEDCT<CF+QU/?*)-C77'AK"/?*+L8P@F(6A6Q9GI
M#V<B!TW1*UHGO2IW=;1YS'RB7JJ_@T_41P5#<E"ZX#A /E$O\:\BHZPCNR%U
MJ52M#4>[I!7(0$G"0V<LA^2EI_^%HM-=]PK[H,,>?*(F*NPCLM9I>[??YET2
M981,Q= 1QVA+H1-/2W U?=3Y^HC,>+!IZ09M1<+>7:/LD%G42_"3(:2V-7I1
M$AA%<0XDKQ5S444(F#D(F65$I9SWG5[,G^A%&YW"[92T!_2B+G"?Z$4;*7E#
M.L@Z&MH#>A$+GDO,$60)"$H4!=$Q#RI8P5%8%-W2>QZ:0:U%+]JF/?51S$">
MR@J2"TL2E<$(C(O*Z=6>-F.&P%PIW FIZ.=]7)6'2B;JI:%;7)H&XFV<]?>,
M)C<Y&>5*X%YX;R.<+0Q?N<02>@[6(QF^UPH"3Y*^S<99KW7AG5XP[\D^637^
M(_=DFJFFX;7K*DR7[GX'5 TS!E<CV7X"81M-W:/Z#<3<.$WM#G3>NA0P*#"T
M0X+BS$#(G$[/VH0U63H_ESL./@CEWY%\N$W=]Y'N ([F;V$ZJCO:R_$<ISB;
MGT?[;Z:CTS#]\B..2=AI1%]>G&J!>U%O]0%1J%JEU8+C*@ &*:*P&4WJ9 L]
M_,Q^"+>;[-A*KY.M*67+"9(OQY\)_^*(?7=V6N%/RKN/D^F<)G;Z:C+^4/][
M[9?"./\<IK_CO$[_'::SZ;E,U\^&;(R@9>KCD,)9RG-4G/:FB%D4E$H8\FV9
MS38Z@U;8I,QQ8RP;1"U7WMH_\"2_G_P<YO7#OUP-<G3[V%?OCL&:["7W8%V]
M8S;"0M3DW$>34'F%*;O8*;39',NF^_.J<2^?Z[TVS$L9P:M*+B(-@Z.=A^82
MG=-")'2=J  ]-N1[(&UO!]Z%N2QOU2WUT[J4Q'.,\RM$WR(]2NGLM%:7Q?SK
M>(II\F$\^A_,?R=Y7T*WY,PDQ15HCR264J%G)Z"@<.2+HDR8.ZVBS7 \#GO:
MML):WS6M ?W59/9UF21D,>>"($2L5=JE!">5AV11)13,2>Q6XF8S'$^V-H3"
M!GAXN0O]BS":_A9.SO *JW12. TZ9UU+9&OPE@E@W+%D4$IN6K>MZH/O<1C=
MX)H;(!EQE8#J5>$%0M2\1)EHD_6AQEX>P8?Z+?/*8&%%L-9UW>Y'];@LJK&6
M&A*P-SG4KZ%//L40Z307H29=:)$@E,)KD\F0I3'*+:?HMW7$'IMA[4!M#3L:
M;7*Z7U\R1ON2N828_()B("%XGD%:F4K"6&3H]CRX,90GHQM(;0.T.^ITNE^#
M:YQCTFL/VD1+*R-Q$E+(8+4B 880E&E-$ND)\7%8WS;TU[H%TMJB.G_"M59&
M'S4'%E*L13X5!$?+14=C-&/&%),Z;7";X1B:V+'S/6V+:MHU:>-R%;T8C<,X
MC<+)R_&,QON:>,2=9,F*FCW+R ^H^[+7S$,1PC(GLA2V-8-\!91MIV)LW1(F
M[34RP.OK(K&DX+1._!U./X_2:/SA=;D%[:RFLLUN_ZN+%\<N<QDHN;3E/':3
M>=K$0)93EG>MW7VW6"696I"79>TMHIC0E0N2@ MA!/FQ2936#57WWU+O26G=
M>T/MH]0!#/1;#_:R?EL0O!B*O36%0:"B)N<E1%F;7,=<=*"?M#:TVW!L/QEV
M=YJ],[!80RT#\'Z>X70^*B/ZM3KQY_AI,AM=IN]ZDVW1G('*6(L^2@T^TK<Z
MY&*BD*ABZ^9"=\!YQ(;32DDKMYJA$I_F8?QA1'[KHG;'[-+WG93EO]DHMZGO
M(&W3ES::XE*&DG52>BU4S+3NI4#/H@U926U<DF:1H=1WN(V#N-$<7XT^8UX>
MX"HJ1F%<0++G)&L+:)<9N(@9BA;%.J8"66+[B.Y>7 T"V%5C_'TZF<V.2_%%
M9UK,:"@,4SY[<#)$0"S2"&^3DJVK5=V':?M[9',+N25J;:>& 0[0._!=NZT^
M.IW0%OX_BPJ*Q[2\)=<T?ZE< 65E@"@)MD4KG;#!.W]73]S&AK,"Y>,RI1:J
M:IU.= ?<EZ>?PFAZNDBN2\:Y0I8O)2>_0F.!*$R"P(J*P7MGG+GO#.T^W %9
MQ4 R'B#1YPZ0O^#\.),1HL\.A%*!T,E,$01/8+FR447G7?,N%G<C.B C&4 %
M ^3HK$;WZPS+V<FK4<%CRW1AA@[&S"E&4#4)Q#MD0+XE=R5[GO1=E9/:FLD5
MKD=E+&NJHV$ZSDT^Z!WB.']ST%QZ7E@U:>\IS!01? D%=*&@-:8D76SMYW9'
MMZV:<(,;S4 *V9?GP 7^H_2OL]'L7#^+^]J,R0N%X$5-21,Y@3<Z0-#(G2DY
M)=LZ\^$V'+OG9+=5^7*YADU%/T1MCR5,EP\\'5 -51OF5D2[>8C;7&/WF, &
MXMZ>,42/3!A,@%XS.B'1 !E_ :=ES>[*!+KUO=(VC>">-ZYMV4 ?*;>.<'^9
M? X4:U\^A<B$Z+#61A5,@F*QT"8G$"3*4(ONYH)+!7Q6A++??NX.RJ\T$/6D
MC9RV>^/UXY>?PW]/IL].PNR\6  +*#&+ -)G@LHQ@)<Q@';2,>3""-N:FMD#
MWH$?_$,I:KM7'%= ?PFGEQT*N\ =R%'H"75GJ3S#J+Z[B373VP >1U_8&J-&
M62S0#BM *4[K,<D(W,HD Z=HG6_O[F2+9G9_'LY>6ED?=0U@76_"O#[\7YS6
MF7PSK;*'(&4 976!8!GMX)9S:<F=,Z5U<Y%O .S5!=OFZEIN@K2VK ?PC,[+
MX-7^-U];HUT $^AT\HZ!C>2NJZ@"'>C.U/Y]WE7R'2NM_:"58 [;(-KH8,N9
M,N_FD_3[Q\D)C33[B<*&^9<-,F)6?UC+S)>.D)=K\.3 <E08A9#*>4&A3P@^
M\V0*+R&;X]4?NV&>6S6QUV7Q\5<7MLHYJ4JUL2#H4$K%P:+O-2**0@>3"+EU
M3N2M0#9O1G1Z.ADO/O--F+Z>OIO7E^P%4>D-3M]]#%,\%HD['3B#6N"5HD:>
MP LK(*+P6@>5I&B>S7<_K!VT(MK8$F[V%&HK_2'2/*\@+O#,CL[F'R?32IX\
M=B$Y'1&!!^9 258KSTL#RI$LF$?+0NNSZ0XX!V80&TE[D'9X2]!>SF9G!$LE
MYYG##(SK#*HV(G#%<S LB)!JCE5LG9.T LI!&L :4AZD9]T2K-=G\QGY8[5E
MX['P&+/F'ECPEIRN6J_+T,S1*H*5LZ3S>6@+N(;G(,U@77D/D#/RAE2(TRGF
MN\\MB1J+J*6T9*[T!%/?'JPBT,%SA5:JW+IN4#=DAV ? ^A@@%21;U'>.- D
M)EE*XH"J,-K3<@%7J0C2"&=L8L6JUB?'W8@.SS(VDGG#LBIWH;LXX6KU/9M4
M!*'R@J LP:.+P)BTJA13A-Z&-1R.*]%(U@/4.;D-V?4#SB6K$V96+WO)T]5%
M 07_ 8Q*D7.>F RM \Y[(!VJ/:PK]8;52+X^;59 /X899G)^/N%X%LX%_+6/
MQ(]?KG[E3?BRX.[^$:;YE[,J21+5^5[W.8Q.Z@/HB\GT[_1OY\>!"3KK? &%
MI1Z"%#N[P@)(+9&K3 ;/FG>P'6@NAV"&>Z'GF_;K-LI'N>:O/PN?1O-P<HYR
MX8Z]Q1E./V,FI"_.YF=3K+MP&"<\SB(:*1P#IUFNW7,2A?2.0RBR)&<)OEIZ
M'5R1M[+>^ _9G+8E]IN6XC>R%/+-$UET^+!HJ'-Z.IK5!]/7XZ,/'Z;X@5SX
M!3?MS722$//L!4GP73BY^-V+J1ZKXARY:QHX8V3I7 LZOC&#9SRKDE*1Z=Z[
M_E9@'KP-;5LAMUS-;7Q)^XUSYZS46K$(V=C:DBLJ<#946-$&ZX1!T;JHZJ&Y
MSFO+\Q;E;GSQ>I7SM9CACU\6\SU/\@H\*%W3 9V.E0NB:9*:N[J=Z:"C2[DY
M@_H..-NB5 R@\$8RWA?2Q)N3,*[/XN=-HP.GJ%_)&O.3 6>:A5>:0Y$.K6 N
M2]_\)N[:^+O/E=Q0I\MQU+JR'2)AZ ++97/V#F@&2F[\%LEN<A?7U\P*%6\@
MUN&5S3@K-D4'R3FLE[L1@D,$^H<1G>0Z^M8<J&TH^9[,P:%TW$>:K=D,[_^8
MO/\X.:MMH5Y,SJ;GV2LOQ]4M'7W&"O3:;[S_.)K.$<?W_-8?].,OK\=XRZ\=
MC?/+<3Y+BR-G$3M_S8(K)L7"(V@I<[T'(A=6DJOCN,C1A<+T\E7)BL!B7V:T
M?6=T$[.:/'2;&"#_Y-U9G(UR[==W'G8MSO+%XM?9BRBS 9;)RZ,0K 9=RD+*
M+HD@?:+ J[7ONPK,H?DX;:0^0"+"-3AUE;TNU[H+7^: =D XD!-T/[K=.$:-
MU+EL),/H8@#/J0/2+!)ZYBTY$+R&D%I#"#: #E(AMP9+\\?H75G+/1[6SHRE
MCPI:NV!'\_<?\;QZ]G(O>AYX[4RL(68C%HWMP3&?(=;=- 4;Z?\[.46KQ]B^
MF]):'9/VLFSH3-1NPV_K^](YH8AISWWM)2,8'8Q*18+#/;EH)2*B]PP[/2_?
MTY+[ZX"'XARL+\6&66A?05Q85!<8?4[[+DIMOVCO/\HW$/ZR^C:07,-M]R8<
M[D,*!3#[FIG$Z]90/ 1E4ZKUC(OHE$R^:P6N.%V'T%]W@376V\_AS]'IV>D%
M$"-9-A3,@G8L@F(Z@J?I0<Z.7 (7E4750'/?#+K=3O5KBWW20F9;[CJ_> 3]
MVJ?\V60\']'LQZEV&,EY,4XM4UTFT]-%ZL8YS>I;L-WX9FN.U)*,UF*R-VHQ
MUS+LPDF7*S_#1"\,ET(&H<EO-OQXS3$W"X%>SS_B]-K(5^]FB9QZ$9,%YY6A
MO2@Y"%(;$)DC%R$SWCQ]?R68C7FTM<GN5X'6KF_3LW!R-']&)O"%?KA(##DN
M6I)">*8XIJ9%Z\HHC[7OEC=6%,:$#JU?R#L!VWX8T,8J;C!IFVNA=7/WRURR
MHU23(,LK6H=OSFACJ#EGQR%K'1*CS5C6("4*3IL[3^!J7S8>)%>L6SOMNT9Y
MZ+IN*\8A:H--,9Q#.C8VAE)[NG"MR-*8EV1I@H[L*(I/TGK,K=?[U>@/7=$;
MRK/A'?#YY<+IY&P\?SFN1^[L_>3E^#/.YB\FTQ_/1B=Y<C9_75Z$-#I9-$HY
MKH7=>58"A$B!?#5RL%QMP$?!K3>!UV*IW?(K^XSZT!4^K)@;7@6<OY.%/U^.
M:?NI$[]HHC+^L,@7/O:Y8"XR@%:UA;"3IA:#L& 9\TGSH@OK=G&W>HR#T'4C
M$0Y ("-8DU,D?&\Q3<;5WA8.,?W@V13)4YX=*R,U,BTA:D%Q5#$:?,D2A/<Y
M8BHJR-:/@/>">NA&,8ST6S?I_GET0EO29(P7'('9<<# 8J9]QV$EL)B<P261
MH41M<E".0,E.Z_W&1S]TC380V  TL.4YGM],)X[*"*^ 822WT=@$P40&&%E1
MC.(%KD7C%7TKD&TELPZS=C>7[=ZDLDXGGW Z_U*S5.9'XUR35SZ=\X1J[[3S
MZK96>)DX [&HCB#K:T8N&E)U2[D)3N=.-Y"]"(/WPMK5NT\#W=^@#K;5P1#)
MD:L@5H"75:L[0!PJ/?9^>#O*F6VMVJZFLZ%>=F5""6TR(D M/48.,</J^V0P
MC)<@?+11-T^ZW97IW)>)NP^6TT,=K5-&?L/I9!S>8_HXGIQ,/GQY$Z:_7[SN
M),&5%'1>)X%T<H=B%[=>]*U)+B4>$NI.GNCJ,7:0V=I:'Y/VPFQ]3_Q\>O;A
MYS ^*R'-SZ84%E_<>GRYP!952)'K4K-A=:VRHB XBH\UDXR5$D59OEE<H>A[
M!CHP;;<4:^ME_2K$R;3^PA>:]>M21@F7T*4HT',;P$17'^]M!%^[+Y=4D*OB
MG8C=;A7O'>K U-Y6M*UOEJ\N-"^MT&8NB]3@1"*/67,*C[6/D)25-IIH3.ZV
MBR]_\H&I=2/!-4X-6U3!6G 8</)A&CY]'*5PLG!%K*4)V.C :U$?+6A/\9(Y
MBJ9UY"EI+T6G:MKW9*FL!/#PH\%V\FVX=!>@SF\:KD.ZL.DNH!IF!ZX$LOU<
MP4:*F@PEY<89::O!,1^D8)*V(*%*W=8(G+4,I+2UHD-F':OH[Y?J[\@RW*;F
M^PBWI<;GGZ;'__GR6!FN0TTAR;+0\*:^03N=@ 4=58S<Z3M??V:8_O)A\OF'
M^G'GNJU?7=/K^3#;S35L).S)^I(:+/&>&V.=9 D<>1.52L@A&EL=#A5#01>=
M[%2(8-\3[]L>N>O);\"4^RXP#B_EOI?P5Z1LKR.Y 5/NI8]&,5X[T]>NLP(M
M1"80$M=&%R&\,?XA*+!3RGT+_?416.N4>Y+45?IXE!0F,\.!:>GJG1B=Z1'I
M// 6F4&A9&ZAN6\&W5W*?2^Q3UK(K/$1^&WN?\J2I["H-Z=5K1:&$)0/=(XG
M;E.(@AG=0GG[P9=86WEKRVR IZ'E$WVQHP3:.&S6-#-N9/7'./A"3IE6VDJ+
MW$;928\;9"H<AI?33,H#I* M8[KPQ;N@&N@I^79$NWD]WEQC]YC !N+>PC9P
M@2YE(:-BC+8DS4$1LIHE:4 :[FPAB(BMJ_!MTPCN>0?>E@WTD7+S"DU?'R;/
MN\3A-7@7)U3AI6@?/%A%AY/2*4%<_"$]*P(I-N?=G@+O'VOWZ8CKJ&0RG#RW
MS)!\A6&&LU_H-T*MG[1!Q[T5G]22X=@%[!*#T=/B-3$9[F563"?'BR>/"VV0
MWLNDCU=\YH;</9S-$!<?_1QG:3KZ=#'KBW1(@UG&I J@(">>#*Z09X$:LG4!
MR;$7RK?N"G /I(W9BHN/?TT^5ZA<N<4X[W%Z6HL+C^?3D.;'V=94&:V!5EDM
MRI\H7@F)0M<H>4'/+'>M?<S[46U__VEI&S?8BFVU,$ -M$JZ>G<6_QO3_/WD
M[]/)V3B?K\!C;9W@(5NPII+1M?3U4L,"RRHQ835-O#F3=168 [.*)C(?P >]
MS5Q?C4)<I%%<IO8_/\-C:WCRPI*]QMH4(49+Q[2L=?R061.RD:8UK[LKM@,S
ME2$TTCJ[Y:?9?'1:.X1= GHQF7Z%_-.?M1$'SOX?^0ZOQWCL!/-!"0'H2RWT
MI1QX8<C-BTEG[DA4I9LOVV?4PS"*887=FCUYB>]U64BAMD]^>?II.OE\WO_Z
M%YR_+N]Q',;S:S\^.CF9_%$;:<R.&?>\Y+2@_LI:&Y^PDWL.@N(\QWU.:IFL
MLZH3Q69 #LAVMJF2AO=EW]0#>+T0QNS]Y"V.\8]C49A+G$F(JD*2I9:0I8 Q
MF$5UE*2=[5=0X=O//R#E-Q#@ %W[;CO@%L#"2764C]$J)G,.Y \O.A,[!I[G
M",D4TF"AV;)M>!K7(!V&20PA_P%XG.\^3J;S"F0![-ED-C\F3S@B\Y'")%DW
M(1/(8$4!2\=;M#DGC:ZQ1=Q$<5A&L*&4!^C8=_MLSY^!3$D>K72 D3P;Q3!!
MY!A %ZV](6C2MF9DW@%G6US>X3>!S:7]D'B]EO%8I,X@%MUJF?;@.'? O PY
MDMML0J<TA\/@]3:S@#78O7TTL2-J9A>(3^S>#56[!D=S';WLR(2B]EIAY:P(
M;\F1XA9BR1RTRL;;$HQK[K8\9';OT);31QVM7WS?7CRD71+47H[?A?'S$7Z8
M7+Q/.JNR1V/ 6Z]!D:\-SD0!T='TO69:A:6& 2N"VOM&VD^V6"_=3(82;&N^
M[[/)]%.E*.(_,.1_G87I'*>SE^,W818RCL,%0F0J:E&Y[*8* ,GO#D$R"(PY
MZ:0I?KG@\<JVO1V&.S#]MQ?Q\$O_YY!'L\GX,J/11:93;8P0<[V-(>^-INZ
M)Y%I\DKPU*W.U#T#'9CB6XJU-8%P-66*LY)E(2@FUPYSDD+L1,@,-X&%4AAA
M;I"KNW>LT=:Q1CLI;X\[V@'4H^..]E%4-^[H&E+>&G=4&X,8609R9#.!<XD.
M(*Y EI@$=U'&8A^>ZM?CCC;7?!_AMN:./CLZCCD8GV,FYU)3\!*UJL\I'E0A
M1],(JV2Z:V?OQ!U]=K0OW-%>PIZL+ZF6Q)D+ZFI47+KB&>18JTV+(,%)*<!X
MSG3 K)D[()+OVHKJ*:DA:(6+C8( 2DR,?(+ :AF1NF4H8T$GJ177T9K0PF/:
M.<EW" ]I/2D.2/7M N/PJ+Z]A+^**KJ&Y :D^FH;H\%2P"#'RI\3$&KGMYQ=
ML#)3T)8/I[M6"_WU$5AKJN\WS,<2')?6)RC1$Q!5+UE+\5"\%C+2OT37P@?=
M$[9H+[&O9(OVD5ECJN^SVC<!IY_"=/[E:Y]Z)5CVS!5@)17"PS7X+!0X5YQ$
MAJB;$.UO&_N0CL>-9=LPWVUAN/CIHMO-USZGRQ OO+HN(%N>HUV!;?^4W5R'
MDVTIH/5QW!EL)%]?2\S L$106EF(CCN(-A3AB\G1M]CR=VPE=QSE.S*2/G)O
M_>CP;'(RF88\>?W'&*>O7CV[.,ER--+X$$ X+^D\C )\0 9.8(PN.ZEYMU?&
MVS]_RP?],)J8M!5CZS?%=Y/IE&8Z^2V<G."7!;#G/UU!*QBR*$J!J*4QE/0.
MO$5=7S^CS8:IE+IQ+>X>Y^ TW5"L*]?RD/3A9Y/33Y-Q3>F?G&?Z'Y'#M.@(
M>LD=&N%L8VIQKU':TX[7G^02)=D442\A<TR.*XX^%$M^O%*HM7-&7U*2>XVW
M82V(;]*Q\_E K[ZF>C+ALJ!-!VP*G.RO^KA,1LB"2RU2+)RW;DQU-Z*-^RDN
M/N[H&TF>._E'<79.D_6TEZ(O-%/K&*BD$S@I.'#&BO$1R;=OS="^']4.BB6T
MLXP;31C;*F$ KO(22V'TX>/\=?GU8B$>)^MB*;I 6M289MI"X,[28>Q\%"JS
M@)VNH=9>%4N MF\<K36X7#NEF?B'*)]S.T7VV=GB)#\6EJ%U2H-1E1ZK2JF/
MC1$\2P9#E,XLU]5O;!S+B [<.C920,,TC'O0_3(9IPN 13+:.[4![FL[RA S
M!*EJD2'ID#GIBQ]V^[@%U&,QDC75T/!QZNIJ\8( ]76Z.GF/F#4P6UM-AX(0
MC#+ 8B"L1<O,FI?!6 9Q4'[&9B(>_.A8L-^\4MEZELF\$UEA\1D<2QZL"SH(
M9824G6[)UMX,=L4QW$@U=R[VWG(=0-._A>FHOA)< 6+64XCI/1@30VU"K""4
MD"!1%"@-)D6S;ZSH&R >NIXWD^H A_T5$$&>)T9!\\B\U,+,U>L@\_."$&CA
MZ=QJ7]?K0-2ZGA0'.)/?I8^8STZPEBZXY52ZJ V;=5#%.I",&U":!7!!64C<
MZ.)*0KPSY6XM5G@'7%OK]#O<>=U<_/O"$C[O0?XU+?55_0=5-?5!R!@2#(LT
M'\&0HEGO:D^+",*07QK(_<78FF-^!YQ=/;2W5_VM;> W5\$ OL(*:!=/"UW
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MN#W53@&W3_8BJ*U--'/F7 '&HD 95R#HHB%[:Y2+/FL?&IMT-V2/SB@'4-@
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MZ"T+FD032K=+'8B34A.!_B)*@^&NJGV9RD$@X]]2,0XY]LO>.QNIASWKE\J
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M&G6SF3\&EB.SPEY$W158ZP!E7D"MA<.[3);XN+K19-KMM/>:+,$XN-UD^_Z
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M\6/*!N3&&B+*W!@ 1>J1RZ.&#<?!C"FF07=D5CD1;7P%UII<Z1LD5-3Y3J_
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M\[^?3YS_O?G^F#75<LMWJT^BR'*^2!(>!Y+[T"=80D1I"DD<AI '(6$)]KT
M>8N5N-.4:,8\(TAI-/G29O)MRSK>''RED^DMEVHEKGU/=>:](1$FCD?3C.E>
M:H1^?Q$B6YIJCT2CJ^/PCW$&PF5XAV,)IP_?& ?BH^$9(W4U-.>'ZDIG!5I?
MI41!P#TJ"-3Q%A"16/V-!@$,N,YD07W)L54(QD$/\[0LM82V:3KVH3/CUHL
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M>*N-9=34D+$RH\FQ\)^&)S?2@T;\*Z 4N ([ Y+7(1*U$H"LU'ZS4<,=2UZ
MH2.:'"+!I#QY 43[1'E)4P." _2YB2A81I8?U4PNVU!%%LHD#.,01JFR")&R
M$"$.P@#&@8?C.&5Q1*GQ<?_1+F9G^ZV%K"G-)JKH.(0&9^\7 S,R_6QA4@LX
M)#7R<7 LCKHO!FFBP^M]L!R=/O>JWWN>?/S-Z4Z(>R7?.?/M?]+%*2Z_+DM1
ME1O?->$LB07#T/<2#%&:(D@\B2 -U4!+Q@(B[&Z=]78W-[+;.S'DH)'W@N.$
M,W /.8.]!,1I3USM\+OP?/44+*.<IAYT]H)GIZ<4[S\I/?G6T"K:6X$FM=]^
MNYK-(HDD02R((2(\@0BIO2--(A]&GB2229YX*+:KI=W7W=QHI;WAM1U"=]4<
MA97;-:YLZVKW(M[/+.YQ')E9+H5P0*5M$V0NJ+?=V_S$5;=-5#VLO6WTUH45
MN#\HKGHJZI.!<OW#/V>*R0IV_]Q>[T[3-"1IR"&-0AV$C0BD/ BA%WFACQ)&
M16)U.<^J][F1S:80-5A+6OL_/E[_96#I;J-!,#-E1H-V9/[I0W6$6_B#8')=
M\=NH[Y>I 6X#R\FJX%:-#..Q3X4NDE ]Z\HHVC'UYA]/V:/N\%9\KWY>ZNCV
M@"<)]R(,I>]QB%CB01P2!FGL!YPRU2RSBI(]W^7<&.O+T\,#*9ZUP[83OIY:
M:\GM:,L <S.N<HODR 35"7M5%^NJ=@$$O]T2NM3QK=\K4$OND*O,87)$4 8=
M3LI*Y@#L4Y'%FT/Y1TA1%()O66GORO))\$7(/(:P))!%Q(/(QRE, QQ"ZLL$
MZ9K7:6#DRC[?U=SX9BUI<Q_FJDL7E]72#L\5UP.V*>&X@'!THNG0V]V%-8*Z
MI)5S8#BCDY,=34PCYQ0^I(^S;]A[<UZWQP*Z?NDB#>,(Q0C!0'I2&2<$0TQH
M#*, <\_#B":IO_@J"IJ;>&ZVF[;YHK<[&._#[J2SJ E\@-=YK\M0#$:>U6;*
M6WE1CFDZR%^RT]!DGI%CXF_[0([^_F7RQYZN&_[FNSX_*L6G(F/B<[Y<RKS0
M+RXHC1(B20 3$E$UL3F%)$J$ IZQA"01#A,Y97I9>Q7F9E6L;_>M;Y=UDH-:
M=)VFHUDKI\U .^#C,+-6YCWD(_.ER_RU6T <N:.X]Q6-$>[Y<B/YTK=JABOP
M^[B%<_$ N4Z?>X$D TLLJ,Z^/-'_$JRZS7\I\J<5K\\_RX6?)"R*&85QR'V(
MHB2 6.=:9R%')(R$%\96&^"3/<UMI;J14C-)_>OFYGDYN$+S:7C-%A$GH(W,
M]5I&T JI\]8T8C8A#@XKL9Z%PE65AI/]3%NMX9RZ!U4;SKXPL?6MO775\[N5
M6H_KG4!9)PF^O2>KENP^YG7,JN":SMZVQE6(.?&"1$(_C!E$G$F8<AY!+#Q)
M TYIPH-)+.]!XL^-RS;IVCY_^=4RNG[B@1_9JAY]..=O43<0@"T,0),RO5(H
M;.SM-1#JK^O/I_5B_J;! 2TZ<S"Q+QK6ES:OAPG_^S"M+QH89V;U95(,#,[)
M5EDEWF=?]44U9<S?970IFG#"#^2_\N+5DI3E1S75NTH6C$5^( +(8JQ6/(%\
M96A[ 40LDB1B24)2JYIFEOW/;<EJQ(>U_&"C0!LK>P5J'4"M!-!:6 ;M6 Z.
M8=C.>)"/';ACB?88P3S#P',5SF/9^[0!/<.@.0CI&=C,@'MAGT4I='S06\+J
MRL'O5E_(ZG4F[O+V"D_J)P%)D >]V$\ABE@ 4\_'4+ 02X0(0M3(LV[4V]RX
MK9,7= +K@EQ*9%#+;'$]ZBS,_;SE'+R16>H0MW=;N VY7W860(NK9BZ!G.C6
M6?^'Z"H%JBDPO??1SC8RW=4T4WUV;JD9OS2 ;5^+KV*9UR%1G\7=TU(/QO/U
MBNO<IN6'3/U1Y2M1MA9QN0AY&F*& TAXK'/KH1BF+/1A(),DCBE&:6AT?6U(
MYW/CXBWQ0;&6OPX,;#)O/ZQ5 (^M#A8$8SLT 2,)IA1#[JL_D$@CF'(LH.^'
M.)02)9@PLU"2L0=GHG"3C0)7<Q@?@P5U1,S'#F_9F@L;T<&U=NS76&^D[YQ*
M8V)ML?:.B/E$2_$0'G*U0 ]$KW>]MFUSNN5[H+8[J_G0-F9[]K)WS/R+:KIZ
M32JQOO&Q0*F(/>13R# 7$)$@AA@E'HR(X#&F$H4B73S6I5Z_5*2H9G,N<U8U
M&S;85W \0OA9W&6K.NLV)<NZJHX^?>;Y<DF*4E?;:<*OIZK4[?)3HCX2+$T)
M]'5L76U_8F5WPC@)_!A%(L(^:3^E-RO#5%ES4,S^0^K4&^\S>E-'D?SS?4.S
M.2=T^E7\,YX>'L3JU1 !C1'87!C]71TB&H_Y[^=H\;Q*_VP'CL:#^ +'D.:R
M#;,H:Z__-5/RE%DMO$Y$+=*(^K%(8<QT)9H@22%!O@=Y''O2"UF$A5'ZD;Y.
MYN;^J64$6T+:+85'<31;FBY%9^2EX@ 89TF]30!PQ)M'NYB4Q_J4W.>5WF>'
M)ASZ<B^62\U39/6\H"((I*\,;RX"7\UPGT%"DQB&D8QEZ%$_\9!=@J'MYN<V
MMQL)02TB:&6TS1ZT U__Q+X<E)&GM!4> U(!'5/[@M0_.\U-G.KGF"J'J7V.
M/C4TWS0K=)CN:]'\]]WJFK'B2?#W&:'ZP"@3Y2+$V/,XH1 EL8!J#ZVFKTA\
MF$@1<L$9#815SGV33N<VJ5L)@?BN+2_33*M6,)NMWZ[!&WGR=^*"'SJ!?]2'
MO1V<6T*[3/UL#I&S7,\&74Z<W-D<A,-LSA;O#KSY(Y35(7:S'G:M/W?^Z]=/
MXJ/X7MU^$\NOXD.^JN[+!?6H)ZFGM@<)C14C11+2,$I@E B&TB@0,?>M+@8-
M%&1N!*4^261Y.VCH$)@1U13 CDQ>C0KZ,NA>K<JU'E?ZRA$5X!/)^!7XFR %
MN%DY="I="J*K6TE#Q9CVTM*%8!W<:;JTO<$1W&2E\TIO/#;U_C[R111B[1T)
M1:1C-$)(=24DJK97.(U%2F5D&:E]K)^Y$=M:S"WGKU49M'.XFM&9 [1&9JLA
M0 T)E^Z#P5U8]-%>I@Y_[E/U2)AS[^,# NS^+);\-O] JJ=";_L$T__5Q896
M_ ,I_BXJG3=N\^,ZC5SSQSJ9'O)D'% =\)P0#I$?)A!C0B 3:2!CR4A C/9N
MCN29&[EL93?\<I\7%:RK?.OHE_?YZJ[YUZ:V25G_9J,JV.AJ$8_D8%3[*>L%
MQFID:M/*@-L<=.IL 5^'B1T=$M"D5;3(KCC*6%F$DTT[9A-%F-5CIZSDAV[L
MRLT(Z>GTL!F[S6]<A9BY0[0WZLQ!-],%HKG#9"<VS6&S \/5GF@I_O&DON@W
M7]4?W4T*K%8^$5$H4J$K'(0(TA@ED+ @#00+D&>72?-H+_-;UCHA02VE9:#-
M42#-S.2+X1EY)=E'YOSM'?M D#X(7$5F'.UCVE")/C4/8A=Z'QZ>!_-3%\ZF
MHQ06>G<<<RJ@B+B$B'(*T\"+(?<C'.  8=\S,G9/]C"W>;Y.#-E("928=8"3
M?8+,72#/GSA>#,_(\]P:F4'9,X]J?U$:S=T6)\^G>52A8XDUCS]X0510N8@]
MC)&7!C#DNK0WEP)20AADD>0A#O5_T*+**[(T6ZF;9JVF[+KQ\3[,6]U'>\%]
M0-"/59C/G+Q39S0>%L8S2N#.2X3J] ?G7.I1;FJR?E$[O3I.\+T&MXL:"QCG
M"?-2J*NG0L0"#DGJ13 B/ P8$R3P0\O#_5-]S6WU;$0%:UE!)^P@]W(?R&9S
MUA%T(T_DP:@-.<<_AX>[X_N3/4U]:G].Y2.']6=?N>#^5U<D(0[3B,:40)IZ
M!*+0UXYDY,$X2L*8T220,C&[(7RL>9OO>YH;P%^VRTX,N*AB5UQBIN4D&K&N
MG)>/&+%@Q,N5B# I"N&@#,3:,C@(R7GU5!2* 191&'""> S#@'H0Q6$(B20I
M]-,(^:%DB%"KE%XG>YK;@GY9D-YI0 U-;A<PC6V%'\;=78%63(>V^3DD7)GK
M)_N9UH(_I^Z!47_VA9$N;)=G$H!W:;[+=ZMF@]^7!GR1<D&)'X?0(SJ9%D\1
M3&6JR";RL0AQ@D)F58Y\6O'G1EZ=<'R:R[)N/P4+*V>6 SR%'77F FQI6I%B
M#8(.I&Y@.%N98L)KKJ.,X5076MT*/Z^KJZ,,C/4EU7&D&+9>?A35*U+>?RKR
MKQD7_.?G7TN=H[*-Y%K=7;,J^]I<SA#*9HYYBB%30P.1[PE(4>S!!-'(2_V4
MQ2*T<4Z;=STW![:2'# E.GAL9=>\)3NY 5D+;K=@68R%V6(S#L(C+Q0:7"TU
M^+0%[@]:<D7V/X*U\.#Z/,S6U&Z/F"-:MNAX4DJU!V2?#@>T,-@;D#^M=)CZ
MIWR9,1UWTY:B6N X8I$@$F(J8V6F^Q&DDB50*EN=$1^E.+:Z,7.ZJ[F9U!M)
M02>J28DN6X"-W0,.8!O?/S $L2$>@C-@N',1G.IH:A_!&86/. G.O3&,*MX\
M/"[S9R$^BR6ICOJ[*%6<@,,(,B(81#&IJT_', I%XOM"_<[N3/!LCS,DCMI-
M]DB>"UUR1,>I4K$2,K,]M#\/MAE[.(5P9!+I9(5%(^S(WD9C:!Q1ROG^)F46
M8_7W"<;\Q6$\\Q=29#J^M[XW]RHOJT44I7'@1PAZ020A2E@ *>$4(LJH'Q'L
M!\BSX96#'N;&(YV 32$_P)2(=O1QB*$975R$S,CTL :EO4S[J@\5:S8XJ;FC
MV7_8_J2S_:1Z^[/[](/#9G.=,^Q5_O"0-5>AZK@6'X<(<T8A8R*!2,3Z,CZ*
M(6&2DU2BV$^,$OOT=3*W.=VD'=P2TFY&'\71;%)?BL[(\_H &.<!07T .)K>
M1[N8=(;W*;D_R7N?O216\'U>EF^5:*]RO0-Y4IN0]AI\OBI_%C(O1//<+?DN
MRC??U;9$]9&M2/'\KA(/.J&@TK;2MK-Z]=U*S4NAUJXX37FL" -2EB"(4(HU
M4W@PC-((>8R'@GDV3M0199V;UU4KJ;8@6AN0-1%X%?G>13K4&Y35CB+JJ4:3
M(5&,XPR_&<O-9%!')LLVBO('K>>/0+, V*@*-KIV8]X^7ZM;I[G='NIWYX9Z
M8.CEJ(/@-'1S'$E?(/1S5,B/AXZ.V^6 M ?:8_Y9,)%])76EN%\?%5JKJCTL
M?/TD?EUQO>PMU1MY(^CU72'JX\4%)R*00>I![D6IKA>@3-)4&:>,4YX@+D@H
MC4S2BR69F]U:'RL5M3*" U("_B3 DY9?[4NW% "DT\#BGOQ%0]:_+DPZ$".S
M?CT&&SW =0E:3=;1'DH74"L#=K0!UU./BD7>@JE&9Z*,!5LSI1XE-5>>VE%J
M2^"<GSNN$ABX@+8W=<%%'4R7M, %#COI"IPT.&!Q^\+N!7]:BAO9>ED_%3E_
M8E6YG[@G100'"8-1Y'M0+5PA3$DJ(9.2^7Y,E>C$>!TS['1N2U8GMD[/T^:[
M_;>R.T  G[)'H3HVO.QL!;[!BC0"I",O/CMH=ABV0E^6)<<45HLE901X)UH]
M^F!VM"A8@M/+_Z9M34?UEMKML+KMN\-\9!^R55[4)36:S4Z7)U?OHCX++AZ:
M4,:%3RCU11!"/R 2(N%AB+%,]&T<#R5$8D[88B7N]/';K;F7W+![H[F1-G/C
M0(@Q/1^-U#IZ^;_R3,T.G1'DJ3#D<=LQ,',ZN81THDC!XRZ@*]")WCB5MH17
MGSCXI+J_U[]4Y-2]XC""T!)&1RX@TUXG=>=80K'OFK%]?8 E^O^255F*U:=[
M4CRH;^RIRAA9EMK74SRV%F^70XLG(D#4AY3[1-FB7@@IBS!$LN8WSXL"HW-[
MNV[G9HVV@EO81>8(&QB<H^ V,DFU,H,]H<&.U.=3<%WT[9K;G*,@/)'5>0+I
MJUVH77DEK)'J-4'-6YO."+76<,<,M7_;5?F6$]G*%ZD?Q P3!-/ KPN\QQ S
M&<(X03(5,18)LRJR9MSSW%A\D\N_B<E:&E0@N1![XW-/]XB.?XIYK+K+7KV$
M3;F$,6N\G$%KM$(OI_I]X6HO9^ X7_+E7 /#&$N[\0IQ+U9E]K4]5_PHJAMY
M2[ZK?RV?>!WO7M3NUJHJ,OI4YXV]S4_$%$0,4:*M4H^IW35B$8'83QB,"0L0
MPB(,X\0FI,2Q?',+(]E1#RSSTI+T7 ^?&36^X*",?2"X,QX[02%70%\&5/MT
MI65MQC5Z@E91L*VISJ\]>DS(2*/@B)A=2S<I?8\$[3[)C]7-U-E*ZC]N5:_7
M*_Y)S:>/:H:]SA](MEJ$H5H(4B^$(0N3]MB,8@*%'R>,)R&G))TF)\EI(>=F
M$M>2 BWJ5#E&>@;0;$5XZ6$9>5G8C CXK1'.97[R$;%[\3P=/2+^3K)QG ?9
M7<X-@[XNNV/Z111?,R:.2[@N.U^+4=:9D;=_KV^M?,RKOXGJLV#YW2K[;R5]
MG1/D;5ZT/]+/^0N4$(8#3"'W8YTZ.E6[ .81&*2^QW%, E]:9;R;5ORYK0?K
M7$*DS27TV.105T9FT6D"E"$!=00ZVTYGU(:C#[LB.]&W8K; S/<+&#M*Y%@&
MJ@V5U+'GC=)=8BJMI?II!9[5?F6CZ%67>E_F!=A2UOW%WVG'R/$MXHF$?Y$K
MR=,.S*G[S1-+,> D]MV*/S&Q7I7+]NB*8$JP3"4D/$00!32!6(8$1BAD?H!Q
M'%"C- P]?<QMZ=E(V;"+35V]$R@:'*U>CLWH?O8]6(:<F9[ Q^* ]'*<)CH-
M-?^,[,X]^P'H/>0\\>IT)YK]LN\<7YYY] )W#^W9I;2;%-J?&% [I/92 GX6
M>L>2K>[T#2:=(.>)+&]%\> OHB2*N(\8]$+&(4()@SC@''+**4)1@ABU*_XV
MO0YS8^A.;M@E&EU+#K9$!UKV=:I2K>\ U]+$'XN%YVF^G\"$NX-3B6PM\]AJ
M)([DKSW]63GVA+W,6+ITE$VLP?1^M)<9HJ-NMA<29>"2NXZ&?ZN:K\1[??7S
MG;*^5G=9?>E)UY;:NZ,1!S[W?(YAS'2]U)AZD 8DA)((S@5A:6A6,/P"&>:V
MY&W?Z&B4@+468*/&H()N0X;'<)$:%_2Q%QECO&VN+=FO#L-!=,7N R28EIV'
M0W3 KA<T-9 =*]5&4XKG]5.AC[YKO\Y?R/)),7)9%1E3%%T_5=/X+T5>E@ON
M8QQXPH<T(FI+(9" 6-(8AGZ,(E_X(>=6V70'23$WAM0IB)016&HI 03%6N[V
M1T]J1$N@'6U*04N2'#1*AC0Y-O9C$V4-;J, :#18%X2HE;@"&S5 \W1KA=>J
M..3*2Y!TQ9:#9)B6+R^!Z8 Q+VILD)LZJS)EF2J#M]1I_O-56P<HYGZ42 ;]
M*/05)>(0IG4J0)J2 %%%D<0HMKROD[DQ7BLFJ#9R@L?>2BOF>!IYK"]&:727
M=0/0EHAG2M&8 V3ELKX8J,E\UB>^*%>7=LY <<9[??S=*=W7O=+O^:_[G[7C
M/EWV_,VJRJKGS^(NTRG85Y4.E%E(X0>8)@PR*A7O^2R!6*>:0HP2X8E4QQR:
M\-ZI#N;&>8V,8",DT%*:S>>3(/:3G0MH1B8Z2U2,Y^PYU8]83:5@?[S+O_ZD
M7FT,)O67C9UTLL%))O$Y=;H)?/:Y89N]3Z32@7#MF:<R3_PHCCP8H2"%*,02
MXI@%D'F1\'V$F+2KD+K3^MRF;2N<W;9K%R^S[=1@%$:>H:U<Y\_,K;<]1S5V
MM)W9;7O2;<I1M?:W'\<?&KJT7G.NAKQ\I?YZ4]SFWU:+((R0\/P8$A+$$$4R
M@#16NXH8QTD:$)RR0-BMK@=]S&VFMDM)*^<5T)+JK!U:5MME]A!0TY7V(IBF
M66SM$!JPY)[$X()5][#-B1?>DTH=KKVG'QV2SS5_>-!'7V3Y(5N*LLI7HCT>
M*Z^KMUE15ILGOI"E6"#"/$P0@EAHPQI+G6^$2AB%^D8G#X*4F^>^L^U];J2P
MD0X\= IT>2A+0"H@M0XZ#KM[K"2FX1;#AL? /S$FZ"-3S!;>:]F[&(827%>@
M%A]L/?9E9+QM,K&.B/M4V5<'?>_.\JT.!+ _QZIMHQ/F51VH[VXNU:&-#-O+
MU0D)-N47?9&FS*<4)M0+FBN?.(A2R"6CD>\1/XF-#,7CS<]M.6BD&US&<@\[
MLXW=<$1&YFIS,*RW=L=U=K2WVVM\TLW=<<7V=W<GGAI8.ZI+)?*FN1^V^?ZX
M)Z(T4/L[ZND W9BJN2O4+,8\9*$(I8R2R*J U*F>YC:--RERVCMSY9\LZTB=
MQ-1L3CM!:N3IO0&I$W*4J7X6"E>UI4[V,VV!J7/J'E29.OO"!0$X]_E2O5&^
M^<=3G>UR0 X9D=#0"T.]]'/%(1PE,$6>@"BD21BF,N54VJ0 <B.6%>%,D/FG
MOMEVJD9473^JW-+[?_PK#OSD?P)1ZS\@8N?R84V3P*-2"DA)JDN$2C6L*6*0
MI"@@Q L\G,A%<S/Y2T6*:JZ#NR_B>$/\L[C+5G7(/"7J%Z9'[8['#0N*.<<)
M#")?34>)":0TY#"2R ]PF&(1!>VXO5GQ>8]:)^"8#DW^T@-F9B],/P0C&Q?;
M"OT;:%2:19XMMTB[#*Z[7*CIH^V< 7DT_,Y=ZW8F5%E4.D5X]O#TT![1B@@%
M<8KT^5BB;)^$I&H3Y2,81K$G(\&I[QL%X1VT/+>=4RN<&54>XM3/=A=I/S)A
MM7(Y/,8^J6T?::B7M@A#_6M#%H?M33+?3ZK13=G3#PS;N&RB:W45J>M5_1_-
M 5_)LG%ZOB)%\:RF>1V,NTB5M>JS)(1A0'R(/.DI4U8P* 4C0930!)/ QLMA
MV?_<9O!63#I3@ML9/;;8FUDW(R(Z,BML@5G7K=,[N?HO6])?=86(W!DI P%S
M9(W8]CZIV3$0FGW[8F@S;DH:+0(I0A(+!(/4B_0V+M8WGF(8<1YP)JA'N)5G
M=K^#N9'2Q^.>D<N*$@VL/C0C>CFV2YI^2W0*H)$*"+ULI:!3A'#RN:'>5U+5
MU];K&Y=DI0]G/^5EG<UJ?98@<.C%)!4PH"R!R ]BB&,1PS@.HC22,?-2R]N.
MYSN=&S.L96[O(S=2@T[LP4>Q1@-@ZIQQ"^OHI'(QH@.\*N80.?.9&'0YL4?$
M'(1#?X?%NT/#@-\\B.).K2&_%/FWZKZM^;J(L$PQCGSH!]JE[*=):XL0S^.4
M*BHRVS^=Z6=NQ-,&NW:R@D;8KA*N;4#P<6C[^<4A8"-3RD"L!H0&]R)Q07CP
M\78G#A'N5>XP3+C_\<$58A[R56UW?B+%35'S3G.K^9,HZ@P["RK])$ED"F,:
M,+4Y27R8,D] FH@X"0,_H-@J28U!GW,CA^V4"U?@D13@JQ87_)"M -=5RXM2
MYVT&I1;^1^LJ+V>'P,PP<0SLR"328OJEP50)K*\6-"(W^11T=H4FMYG3LBJF
M$+DKE7*VQZG+GYA"<*2DB?&K ZXNW"P?29D59'6]XM>?;ZX__.)?WQ6BMH/:
M P6F]D,1%A'T,?4AHK':(@F40HRIAYG/A-HU&5]6.-_?W'AH+7'M>50R0RTT
M6$MM$1AO '8_ZXP X<B,LT'O6J,'/H,;]><'L(W@D%R_!E!:W"IP"^E$]PA.
M?)BD$]S5C0%S<'KO"!@T,]VM '.==NX!6+PVW#;,JN9BP8KK;(G*^!1J*RK*
MUUG)EGGY5(BU[X0%08Q\M6.L/5B(J[_1) B@[\62)F&4A-BJYJE5[W/CZ2WA
MFS.B;?'!1O[![BR[L3$W'T=!? )#TA78@PQ*:] <FI;F?4]N9%K#<LS<M&]D
M&-F])5E1&[*;ELM-(E!&2,IP$BIRPR%$@B:0<B^"*2(>%V% 1&J4?,:HM[F1
MF1:VW9%]$$3+^F"?XJ(?7S."<H;:R(2T!=B6I."W41*G&H'BB'#Z^YJ48(S4
MWB<4LY<&[%RO.:]=\V2YSB[]6GP5R_Q13Y7/XNYIJ8?Q6=&8OI)9KF]NEMW5
MS85D24QI%$!.4D4Q/J*0>B2 J8>]($YC*BVNX5\NS]Q(:*,1*-;)ZOE&)_73
M3JGF?H56:W.GN5Q?:K;8USD858,M]+1C-3+U;0W3IJ; ECI@HT^]":\UVES]
M+]=W_Z<=)HOM^;3#-='VW=GL<K7/=X=RKQ_ 03?3^0G<8;+C1W#8[("5\_9;
M?GN?/Y7JJ[K]IAI[OEGI8MGJ;]E7H:NDM@XT&G*$PT1"Z24(HC#E, U$#*4(
MA4B(("@RBHVQZ71N:Z#Z?GVPEA-H02UHTA1I@R5K!/Q&7I>4Q* 3&30R R7T
M'II#G+^FL%HL,2/ .]$ZHF&N.IBK!F:=429;P_RHGG>U2%CBU+L2F+8U'=U;
M:K?#Z;;OVD<0W19$7[[Z\OQ \^5"AHA0%#,%K-JR( \12$2:PBA(XX"+&%&:
MFL8,[;0\-PINA0.-=.910;MP]5/L12",S:-F^EM%^AS5=5!LSVY+DT7S'%5@
M.W[G^ -#P_;>*@/LXU.]J(0H"<,$"1@D(H6("0%3D28P)CPFC."$2*-#EV.-
MSVWJM4%G6D#02&@;E+<%W/D9> D<(T]""R0&A-P=JGQ!G-U68Q,'UQVJ<1A1
M=^298:<'^Z63-O[%C8^;4QZD$4,P(B%1.QB!(,:8P0BE(1$H)1ZV.D,PZ'-N
M4_C"$FXF*)N=)#C&;N3Y?EB);?M0<Y13!0N ')TMF/0XZ0F#!03[YPPVKPX\
MKCQ=MNWZ02=$^.]ZI]?FD/J;(,5;]3DNB*\,!A93&.M2DRCA!%(_2*'GRR 4
M5,%DEK?@,C'F1DOJ6TPL3S.'P6]XS#DZJ&.??_:5D;RJT\O55ZBWM;D"6A&@
M-7%X-GH1DJX.38<),>UIZD5 '1RS7M;:T&BUIIKO7[/J_M536>4/HGB?$9HM
ME:&G[\PVE_(7"8D2RF4,>1)A18'"@\0/)(R9%Q 6AH'PC5P5EOW.C?->"RF4
M8!P4XJM8Z>*%*U'?$&SE!8]-6AW;L#2S03 CPA&@'9GY.HG!MTS?AVIEO@)K
MJ:_ 1FZ706A60#D+/S/K=>+ ,RLH#D/.[%Z_(*>VON?_[N&QR+\V\51-+=48
M$930,(68I6J7Z/$(4A9S2+PT)3[!41(9A8&<[VINC+26%&1;H@Y(N'T<6#/*
M<0/7R"RS06I;2N=E9L]CX3)!]_&.ID_6W:OPT<3=_6\,S!>A[U+]K!KG^IZG
M,I-JB^FZ*-1W4/?R\_/FD?8<OJX[VR7'*ZNB/O K;ZI[4=S>D]7-HVY"24?4
M3]^MFOJU"RI\'$8^@4RG>T5"!(IY2*#^&4<)CV08JQWA5U'0W#CKQ$2BVTS(
M;07&FY>U?,JDTK="ZYN@I>55T,E&W8P,YSB2(U-KK0^L%0+;2H,MK0%]!MO/
MM9IWQ;[;M#U;VH-:?5 I_4$+@"9K#0%0GTH#@L/D&Q,/FZL$'E.)/6T2D(D'
MXR"1R-3]7YKDL;Y=_.LJJ\K/7WYM8V?"-!9<F;^0IE0M4HPQB#FAZAN*(@\Q
M(G%$AZ5T/-+;W.SBK9R#M;2@%A?\H 2V75_Z439;%)QA-S*3]\(V0G52(UR<
M9V0\UM<+Y5_L4?MTML6^EP;Z 8_F;SQR\V.!F(RHQP)(N5"L$OL)Q)2%D*>2
MB1 './%"*T^@:<]S8Y@/^4H\@P=2_%U4RB!9,[ZE[\\8>$/OWQAPCNW_.YT4
M]NBE,(<N0%NT7#D!C?N=U@UH"\>!(]"Z@0'![^\SID] ]I-%""H2&B ,U=X<
M*7/'1Y $,8,))X$46*9!8!0ITM/'W"BHE7)0)I,3*/:SC"-LQO;T[<,R)$+]
M!#X6 >F7XS11_'F'E_.\(_T(]$:6GWAUND#R?MEWXL;//#K,(OM4Y$P(7KY5
M8M7G*SJ;L4ZT_9A59+G OOIM$'O0QVI?ARAGD(:(0P\K.\SS2. C;&.&]7<W
M-^+KI 5ZT(#:8M=WZ_1!K'RJ='Q7D3^3994)2VOL#.AF)I@[*$?FR5T4MT0%
MK:SN#"TS3!Q95V<ZF]2D,E-\WXXR?&MHV"TK] G,:]'\]]WJFK'\21EJG\BS
MSI>^$(C0F&*=K)+H 'G)],$J@HPK(\I/O4#:!;R=[7%N_-*)IV_H:OEL(V[/
M 6Q&)$YA&YE+.EG!#YVT/VHO_1K(3V> '!!K:PB.LTC;<_U-'&=KJ/YAE*WI
MBP.V9G_)RJQ8D=M[49!'\51EK%3]M:9SBK&7B#B"H1125T(-(56&"_2H)+['
MO(CZ1IZCLSW-C4U:6<&VL'49O]-VMB6T!KLV5X"-S".GL1JRB>L%S6(KYPJ\
MB39T SXXNXV="1Z]V[O>!J;;Y)GHL;/5,WIA8 7ZXHZLVB!?9?.5^3+CS;'C
MBG]27T?WV6S5-EC7.]C.[+;B7[*[528S1E95R^UUP<=EIG/ ;2[]A&&"&6&*
MC]-$ET\*0IBF'H%ADO)(2LIE9+6%G%J!N='\MOZU.WM+#;#1 W2*V!F5DW\>
M9C;JG =]Y*5J6_4KL*-\/?S;ZN]6D=D@L'TGS>"3&>G>VDL-HB/3?'+Q)[7T
M7VIP]C<.+R;'@'W(.MM2&YOSAA0KP1=IZ'$A"8<D"O01$5)_"R6&4<S4YH1X
MF!!DO ,YWL?<%J6UE%VR,0OK^02*!IN-R[$9F;LWL'1QB(V(EZ-CL:NX'*6)
M]A,''Q$0M:BNMA/]0/1N)$Z\.MT6HE_VG<W#F4>';1M>"UI]$>RIR/1QQY_%
MDM_F'TBE__V\/GC?ND06,DP0\R)(?!E %$@$28(Q1-P3@8@\BF*KJ$#+_N?&
MC^_SU1U4'3V ;/55C4Y[*43KH<N&/K2:;$>BV-GMMN-C9G:/B/K(S*LE!QO1
M&ZAAE<,/1Z >Y^+?0/ <6:NVO4]J; Z$9M]6'-K,T .M]<Q]M])=*QOS0QV7
MI_W934CV1AH=GR2*BF2K-L'4Z;0H.$J2$"N:3$/,(")>##%5U)E0CV-/XB2U
M*RT[EJ!S(]4M/6U/SD8:2=,#MY<?G]'/Z=8JZO.YFHVUXV&C9G<59Z,H^*$.
MSFQT!5TRNT;;'Z?(JC/NJ#@[(!Q)S(G/%<<%^_ X<N3^ABTIVQDW;N1^/HX%
MCDD4QQC!2%\Z1SC4EVP""7T_8;'GXY2'5EG)^KN;&[UO2PM$DX_$CN?/P&O&
MUNY &YES=_#*Y4%R'X>WS\TP<<1X9SJ;E+?,%-]G'\.W!J<W%.HSJCZ1C'\4
MU<(G'D)1ZBL;,N(Z[2B!*0M#]8>,?>&Q@)G%/YQH?VXLT8D''I5\UBD+=Y S
MM=X&XS&ZT=5"H473J;S8\JFVH=J ONR_FY1?]4-7X.91%*0^][EF5?8UZXUC
M'9*D\!A,[A(2[K0^=?+!8ZH=231X]+%ATUQ[\=18E5TMWY])F;$%#X@,U?36
M%@*&*. 1Q"S D# 4!D(R]<E8':X?[65N4[X6RDEY[^.@FO' Q5"-S :=?)M*
MW5>@EM'='.^%P-%,/]['I/.]5\W]6=__\-"45,I0$&N^KA/;K!-?=85>7C_5
MV?IN%>YB(0..?1ISZ <Z<PP17%$"8S"*PM3#$0E]9N5^MY9@;IRAOJO8-EV5
M+>AFO#$JE"-S2B/[MNE0B[^30Z_* 16M"5*G#:V5<)GY:B!^SA)BV?8_<9ZL
M@? <IL\:VM#@'*'Z<CO3FZ1WJT]%?J>^W#8_7$HBFB9^#"/""$0)HY @[1()
MO)AA@A-A1V<]?<V-N+9%U:[4QU98Z]R?)\$UHRU'D(U,4/MH=7(ZS[]G (>[
M3)XG>YHZ>^<YE8]D[#S[RH"XJR_L7O"GI;B1NV=^.Q[<C7MW\^/;^EH4"A-=
M&=J'D<<#B'0&SY3& 51[IC#E,O'"R#P^ZS)9YL8VG3;@1C;!";<YZ#3:/JJY
MWCW+V?K-;[5>-K<G+AS-?OJ:>(Q&IK??X?!8!*I--TP3!;2MARN7X'XOU >4
MFT'1YYX/F^':_,95Y)L;9'LCY"[L8KI(.C=8[$3<.6IRF-U\JLM7;:07\=,H
MC0B&01#J)+*!A!CILB*)'P@<)\(+K6SG,_W-;D6[SXL*[(?>V5G/YR#VPC!B
M,N*0,PTQ9PR2D(00DR0.O5CZ/O(655Z1Y?00KWL=&6*CZ,9K_E]/I<[\H#-:
M.AX$LVV,0VA'7NL-(AC;<\4Z':X^T:%"YH4 U\ME_HTH)@3JG^!5(7A6@?>Y
MW@6]<AWD:(BGH[W0N=XFW0\9JKZ_)S)]S6XU*(MJ\5D\JH_OGFSE"'JEK[V(
MXI$4U?-'];&]SG45\07WPR"DD0>3.-5I?=3?:$(9]*67>#ZG:>H;!998]3JW
ME6%;2J#%-.,C.Z3[66DT_$9WL^Q!!WYK9'00CS<(DSY^40UN<8OZUX97[/J:
MA%T&J=]QS+"7!WA@;I:/I,P*LMI/7(>0+Q-!J2(5XJL_T@02D@K(4)+&2<P0
MEI&Q;^54+W-CDK6<@U(DGL32P+/A J&1N>((.$-R;)Q$R<+!X *MB5P'&]2<
MITL\AT+O-O_DR]-MX,_)O[,U/_OPP!(P.C6VKBVCV*6)'EZ@U$O2($Y@%$L$
M41@PB./8AXG$/.2Q3&D<V6P"#[N8V[[O5O>ABV_DW^X%X>#3/2D>U*,Z7PE9
M=OETRBT]_L>_XL!/_B<0M3Z6]5<.(3?;\ET&Y-@>W2WA_JV[$W%=-:GX:F^@
MVD!_(FXW;:<1<54NY+"#:0M[G%3PH 3'Z2>'I[C?2TR]R:C?)J[>_<'6DVK"
M-"&;K[/R,2_)\I<B?WI4;^BK![E.8/ D>'LDGZ_*!8JBT _2"+*88<4YA$ :
M1 *F"*G/C?E1%"6+Q[H&R)=*67^&I^,3JF S%?<5&6]6_OSFEW<?/[[[^ NX
M>0L^O?G\[N:U?;[]R;Z"6*T\'I+*T@Z%-KQI" G%GIJ6:>Q[7N*'PF^_@C<K
M_L_P#71JC/<%O/GX^G<Q]F9+X%Q'<VPWA5+DZDBYAZWR,\TC^@!N[X>[;ZPQ
M !T(H$:A?G,;![ !PFW]B*F'SV$)BLE$G[R*Q=2#<JP0QN0R#$TT+_0-G;:N
M>'=H@QGQ8^('4.K4\B@((YCZ5$+L4_7S2(C8YW;YY8_T,C=W42MD=Z?1.GG\
M,2#-UH&+X1F9L#MD6@%'.*_J1<!98OAC?4R<#[Y'S<,T\'T/SZU&[MN\D"+3
MY1?*OXKL[EX1V_5715)WHBYZ^)I48IW[8X&)ST60"!@*G7P(IS%,:9V5*.0L
MQC1-/*L4\_-0:VZ$ULK>5M>]]%+6/#!^\3*\8WT08SNT)BO2NP70%>@@ BU&
M30E?H%$RR:DUHSJ^0\9]]E5^K93Z)ZD!/&0@IZL0/$@Z.UN BVSQ1NTCM!QJ
M&2+ZEKE0#9/.:&4\EHSK:ST!IA")A.F%.=".J\B/&26((K/Z]N>ZLB'(:>K1
M-]*"+7$U69&S%J\=POV+F$O41EY6AL)E3.RF6!RAVE*P/][E7W]2330LJ_ZR
M(=>S#4]"=Z;J=01D_/RP[<';;*7LQ?>J3;Z?#N6:L:>'IR71A+25-T69\MSS
M TF@C".F3/D@A#3U4LA1'$O!$LD3:6/*VXLP-[-[2TRP+:>=N3U@*,Q,XW$!
M'IEO&N%A+?UA)J4K8(V]M84Y'#Y'UN   2:UW(8#M&]E7="2@ZSQGP43V5=]
MUO_KH[+MV'TFOM:VW8W\I,/X;K_EURO^-BMT*IDJ4[]XK<P3)6GSVSKU $(L
MX:G0]=%U*;V02)@*&>JKTI)321A"1I<\QA)P;M1YF&J\6"L)GAYU:8V-FOKZ
MUJ-6!53?\OK$1VI=U:NULH!K;>N[V<U#O?D.IOD>^AEZ#J,\,G\?9M[?Z >T
M@F!+0WV=LM8"*"7KRY.UFJ#5$]2*JE6@>V@& WQ!_O^)!_K%B@<XGM%C52%P
M.!Q6)0Q<]/MR]0\<HM9;/,%E/Z[JZ*YSLK1Y_:YI6>D=VB)F"2$\11!%.NM3
MR%*(/:J- @_Y*(EP*M++"NJ>ZGINZ_NK>^T@JW-/Y^M<1:2VZ.KIOFP3V62B
M_-.E57=/#H?9-FD<D$=>7D_4X=WDA6I%![]UPCO-U&V+V&C%>4]V_,)5>L\!
M<KY<[]D6W#M^MO97[5GT)K=:B#T98AE#@7P*D4[<DB82P5"P)/93+J6TJI$P
M4(ZY\9Q]6KNA W"YS\<1K"_I^+FJ(U/8OM-GG$1W%V(Y@1>H3XK9N((,H++Q
M!YDT-XP:/RBK\[G)$O+V:<7+]GZ;"(F/$X:@8"B&RHJ3,$5IJOY),4YC&4O/
M*D3N>#=S([9:RC8ICK(LUL>8=F1W E(S+KL<J+%]'#5&C82@%O'\Q4IK%NI'
MP1')G.AD4@[I5W2?(LX\/< M_+IXNOM 5D]2&5E/A3*\WA)6Y]IL/UJ?^$3A
MEL*8RPBBE(20>*$'0YIB$@1A@IC1^9=)9W-C RTNV)$7= );^.'.(6S@-'6(
MV\CDT /9D.O7Y["S\$<ZQ' BWV*-Y<,.EK*5V957T!"47@_?N3:F\]89:K/C
M>3-]9YAQ]5GH<DZ"=^G9NW05/(D"QC@4/M/IA!6]IC3P82IHQ(3/:1!9!14<
M[V9N=+I]>/U:R(QEAO%&9] TLZLNQVADZNP$!.L2"N[-JGX0')E5)SJ9U*SJ
M5W3?K#KS],#2*0^/R_Q9B"^B^)HQ<3RF\F->IZX3O Z?+.O<!MN_UQG6/N;5
MWX0^$LCO5CKM6GUYO(VG7,0LC&3HJXU9%$NU3Z,!I"2(H,2$^LA+4NQ9Y5F<
M1.JY,=.OJV(M)W@L!*S(=\"VP\@'%8*;Y@LPH[_9C>O(;'HTT'\3P%S77FYT
M[>+_&QVNZJ2&ZK<5>!;U\7VK9YWW\,GEI;!)A\1579Q)9)ZVSLZ4PW!0MV?2
MS@?X!VZ_Y;?W^5-)5ORMFIQ=@#]3<RC[*CZI.;?UQ.U]5E1"K,X\]4W]^/EF
M)8X\=KWB[U;\B=63M+X2T%EY-(JI3P,!?1[I]/E^"&G ?9WW"!.1ACS!1@[)
M66DUMX50]88V%Z%:#8!6X0H$GA^>_EW@'_]=?>Z]4;ZY(&7H3YW54)GX:>8B
MZXS681W:UND"-"@G/I.=YSIHC)ZM 0(*H1-/7Q_[ (<XH^8RNC9>K[G(/$/W
MFOZ*JNXKDOK+;/+#@6S]_3SJ[Z?:?J[JOLSCS^ZT635?I@X.//ZT?BC;?)EW
M-5ZN7'MS&_E>'^)LA)W.63D;E8]Y16<GW- *ELJ4UM;QPF<L3A'G,$J\6"<(
M#B#U*(.>T,?9@OA"5ZPU3Y.Y;MG*@ILJ.Z9MR<D.)3-7PB#=1S8SVH*06BJ7
M-1_W%'56R[%K=^(:C7OJ'-9>W']@P(;QE<[#0?,F?9.:V._5MG:UE16\7 >J
M"JHKQA,?!EB?@D0!A30A*?03+&(OX913SWA'9]SMW+9<.X+7QFHK^B9Q=6D2
MSWK)2!AL;4;!=V12F .T%K;Z*!!/9$SO0MW$NC=0KQ.).[-LK7'J-3W-6YO.
M-K36<,=XLW][:.G<AX=\53L:VXTI"](TQBB & D,$5>,C@75_U1<'O- V5U&
MC'ZRA_F1MQ80U!+:EL;=!\_,^+H(DM'Y=H/&"(?7)U5W5O)VO_V)"]V>4.^P
MO.VI!R_<)=5U 6_%]^IG)=??%X3[A <^@C(*E'V&8Z(3//OZ:%FF02#]1!H5
MK#W3S]SF]';YS%KD-OM"O:J]W]S@:OY=/]"[[;#"W'('-AS)Z?9C;?%7H,4$
MM9P..>$,$JXW;'N]O,SV[;BJ)S=S)QZ?.,'FQR?-5#>R_FUY_95D2RW7V[RH
M_3T+/R!4DH3!@"98A\0ED$8L@C*)9:1$$5X23I(R\XR@<V.K=LVMRYU<-8DO
M@6I?%%^;.HQ963[511EUCLSZU^54B3'/#;D9U\UA($<F2P?)*QME]9+5J O6
M^M9?0:WQ#-)0&H[)2R>6/"?F[R-5I"'8SI(_FO8WM/85J>KNFP+O'D_B./4B
M&!!EH2*4*N,T\5*U?&#,/ ]3$AG5$CW>_-Q8?BU=:TP9^JI.8&=(O(,1&9LN
MC<$84*+JF,[.RE/M-#YQ::ICBAV6I3KZU-QRL?^E#H9[M_I45^4YGU.;QJE0
M]F4 $\DC77<XAI@&$4P3972&- Y8/)-T[)::S8VF&O%GGH[=]NL9V4Q]R6]B
M_G:M85+V]L-3WUV#TC]39O:!X__2-K1SO7X?1O=8PSE=BO:A @YU/I>E$.NT
M/[77ZK-8B6]D>2N*AP6/_9"D,8<1U[4FHP1!G'(*P]@3OB!AF$ABYX3N[6]N
M*^HFM=6R]C07C:A ]?U@ZW'N!]K4\^P,OM$]T%K2JZWD8*U/NA47W/9!., 1
M;02,,X=T?V\3.Z:-5#]T4)N]-B &J3O"N9%_%DM^FW\@^FYW]?Q%,/W?3)37
M*]ZDT= ;G<V/WV<K\4YM@<J%#&,N>!*HG8((U9Y!,D@\*F$B II$-&98FN>]
MN%R>N?'2^I#L1@*M$[C-0:<5V,A?!]UL%-O^S6]:-U K9Q-YXV!H^YGN!09L
M;#/\=SQ6%N%3TX[91'%5VX?1]WKLJAP\=&-7;D9(GT4_;,9N\QM705?NT.V-
MQG+0S71A6NXPV8G?<MBL?>6DU^UW_;^?2*$6DN7S9_&8%]7""^(PC1()::03
M_*>I!RD/"42<10'%482Q,%D/>_J8VQK7B0G6<H)&4/,J2:?0[%^"'&$T\K)B
M#X]55:0S  PJB'2JS<EJ(9U1:KL,TKE'AVVWFU"FMIK2.D@9TUA(F7+HDTA'
MXOL(4A]+&&$>!S%*O22V2G-[M)>Y3>]6O#8_MV4^[N,XFNVA+T9GY(G=%1OJ
M !HCF78O!HXVR<?[F'1KW*OF_H:X_^$!V^ N6/'Y"]'6Q-LG77?Q<_Y,EMI:
M6*!0B,23"<1)B'1J1PP)DA+BV&.,1E3Z062\Q>WO:VYS?RTM*$23D*S2%W>5
MX4P:6UO6\H.B4\!BUW,&=8/=ISLLQ_:Q=8)>@2\M<(VPX+-[X"RV@NX G&B;
M=PF0=OLX,VAZ]VAGFIAN_V6FR\[>RO"5 63;GK&4-[+V9-[G2_[NX;'(F[HM
MY4=1W<A;L2*K:NO'U\ME_DV'9Y:+D",O"GD( ZE+J03,AX0J7HY3+E-/4@\3
MHP!8%\+,C:X[=>I8QF6G$<BV5+H"*U$76*IJM;9_!\A:,0LVNG0\#7A^PE$:
M>2%8#]!->V>B'I]M98#21O^VT6?[5^#Z)8;'8C69<)@F6F[6PZ7FR_'I9#2;
M7/D6'0'<NVA=VL=TJYHC-':6/5=M#G,Z[)[QK9?@CPJ,MF X#3B72#"8"L8A
M2H( DH!22,(X\OTD#"FS<D"<[7%N*UQSCVRK/MAZ/6L%!MKY8UUE^3SR9BX+
MIWB.O!8='/AO&=<;@=VY,HRQ<>36.-_?I"X.8_7WW1WF+PZPQF^*.[)J"^9<
MK_B7[&Z5R8PI@KMF3*=Q5?U^RI<94U.M"8H7J?"]A#&8H)CK;"0A3&-)H4\P
MY2)DB"1&!QS#NI\;'VTK4!\,;ZD -CJ 3@F[>PD#A\C I!X5^+&):XZ86]C)
MHV(_D66\,P;Z4+W<&@.R&8/'5@]7)O!@['J-7OM6IS-S!VN\8]@.;\5N42F+
M:O%9A]9>?\_*A2Y^AB(6P)#Y7->])Q SCT+) \'"E'K2,[I\MM/JW)8 ?1DH
M*RL%YA)\4$OT4U'O"LS89A>O?N(>C,+(?'P" /";EM/!6=A1O?N,1/7"EH&H
M_K4Q#G?;FF06'Q6_FYS'?WG!F?4U^\=35F9ZGK_.'TBV6O@HI0@%&,:(A\I@
M2WU(D3+8$%'&&L7*FD-6D>''NYG;K*RE!%MB#CBW/L32XN#Z(H2F.+G>!@?\
MULCH^N3Z) @NCZX/.YG^[/JDHD</KT\_/6 +UYS*/'^Z)\4#:7-DX2!F1$]R
MM0*G$-$PA#3U8IBH35H0!@GW_<!XDW:D@[G-]E9$T,AH8>@? \]@^W0A)"-/
M[UTTAJ1P/P:+Q0[G0G@FVL,8?C1V&Y0>U7NW(,?>FVZ3T2/USC:B[SDWE?^V
MBM^UM>\6@M H%IZ$+$G5+D(J4X9*AF"0,%T"D'HB99=4 3SL<F[TMET1D+NH
M"'@$93/3QBUV8_/@0:7 'X[45CQ]X?[BLH&GT1FIA."1#E^TG.!I ,Z5%NQY
M<^#NJ/%SE)\%$]E7[>+X**HVB' A AI2*ACDTH\@"G@$->? ($(D382/>6"5
MD+6OLQF22RTK*-;"6NZ5^I UW#$YPFOL?5,'U4;.*T"D&J5-<$8=>_.J$#RK
MP/N\W,0'.]Q:&:#E:H/5U]6TVRP#I0\V6R;O#,S:L[Y\]#9;995XGWW5R0 J
M];EDJI\F1KDY&B!,^H2G,>0$1=KM0B&.>0@]/X[\- IEBJWL%_.NYT8UVS<L
M&]E!+3S82-\ED1V6O\M\4,QX:1RHQ_;';MV%;,2&0U&V3^]B#9BK_"OF'4^;
M(,4:D(,,)O8M7)@YL$E]HO.EY"L=]E2?321A@I&7,DB])O1(J%V8=B-'B8P0
M4[\+AR42/-;;W(BK3:^T$?+<X<8 @ T9R15L(Y.0-6+#<Q#V(>$Z)>'1OEXF
M0V&?VB<3%O:^-(PVUAF.ML[^M,6ES"RUD6N=ATD0ARR@ 22QYT'$J( IC=4_
M$TQ\YB<!\JW*KYMT.C<2V:13N]H^)RUUJIU6<#L^,4+>C%9<XSDRNVQ#N99R
MA%(:-K XHAJC+B=E'!L0]HG'ZMV)\Z>V>=S>?!<%RTIM0.TE<6M_(SX5&1.+
ME/F2AT$$P\1C$(5A#"E&",8RX%',4IZ&5N?H$\D]-Q;L9(5=PLE.6E"+JQ-3
M-HDNK\"6AB^;*]7R2S&TY.8W_F-O3"_/<[K.9+JE_9$DIKO?U RREPX;LY?.
M36HI]>\C\^BPH7"65W1@]R.MC>59,1^SID!>>2+3Z2[U!:D?^A&7D/E"V?G8
M"R$E 5=_$YBH_\61, H\>2D%YK9:OM)'"LOE5,G"77\.CE;"%QSD&2R)I?F:
MN(:A-\7WBZV.(XWC5,ND:_'GM5Z.-#C6"^=8<@Q;0=^M%,V+LGJW8OF#:EE+
M+#[FJ[R[E?=15 O$HX!%A$)?^CY$*2602I*JOP41\Q$E/K$*'S#I=&XK52<S
M^$$T\OZH.$B+7]_0M5NGC$ W6UM<0SGR>K!&L9$7_-!*_&-])W<M])5.$^&.
MN&U <D2V1EU.2I V(.R3FM6[PY.-OLU*1I9_$Z1XJWY2+ECD)Q'A&/(8"8C\
M)($8>3[T<,AY'&'*(Z/,9#U]S(UFUMDT&SF!%A34DMIG&]V'LY]1'($T,H$,
MP&=0NM$3"%R4;G2_S<G3C9Y0ZEBZT5./#KC T=4#;.V;V[S.[K](!?W_V7O7
MY<9Q+4WT51 Q)V:J(HP^! F20/<OIS.SRGNRTGF<KMW343\4N#&MWK+D+<E9
MZ?WT _ B43<*H ":%7&B+V4[26*M#^2'A85UB2*2IA#A3)L2L:(F>3*"*F$L
M(C(F^N_6.1S'QQC;Q[WMSKFHY#3E!LM6'@ZY"R?@[/ZX/8$4^..N\;DKFCV?
M*5%_[P<?A_2.RW$:*,/C]/OD*Q^]&XK.C(\3MPZ7]-$M^T[>QYE+>Y#> _N'
MDJQ*)!'JI<P>7OUNXIMD&:RPNBNNG_3F3C!C4RV?%TL3"EZ?::<TIHC)!/(\
MUW9/HC==)$LRJ'DQ0@+G<4JLRB!=+,G8"+32!7S2^UYM@(+K;TOED(Q^^<18
MD.Q0< >FXAKI/3U I0BH-#%$7>L"VLKTR<B[:%H<N'VHZ1EH!;":IL7Q:?*U
M1OB M',EN6B X=8;'SCLK$I>'MC/+6CR"-CJ\<MR\7TJE7SW^OO*!.5N:G5=
MB_7T>]6#I"EZK^(XBP3CD*2,Z,UZG$*FGPTSIN),%CDEC+@X"=U%&-MJ=7/]
M]5?P\=/=?WX%'^_O?@-W7S[<7S_<?OX%7-\\W/[]]N'VPU?'?@,]YL7.CQ@6
M[=#[!K4&1GK0B&].E'XR&H#I_.=6Z[^M%D&Z&?0'T9/7L8< @_H@^P.T[Y&\
MX$D79@]\VC0ERQ.4D50Q2+,XAS@N!*0H*[35GE*:(R0(<>LG?C#$V!AM(V&/
M5G =0%H>HU\$3^B#;C=D^F<#'"CO.P7@T[ =U,XK>#+8__#*@2-LS_90_KR8
M?R_;*%<.ADF6X9PSSJ#$7#,&%A&D$6-0I'&J[:=(R-2-,8:2?'1$5(:+\#)<
MY+D.%V%&L3*.J(P=6@T5/>O\%D1QGN24%Q#E2$%,2%F]*(<1RG&1HECR!$^>
MRY-__:XOUW_A=V%?BW!OQ#OU;3HWI17,=K<:]J_P+J!<"59DN&[W(44*25[$
M,)64(1QQ)#0C5.I\F,N__)O0Z!#N/= C_+7> $OC9XQS&MJFNCR>OD[3;*D/
M2OW!6@.PC2S<8*!_+%$804A]WXE[ZZ!Z9[G'%2;H>SJ\!=;W%J"?4?Q>\?6V
MI?!N!^)-UEM3!2<12:YD&D%$4J17L1Q#&E,.$\E0E,4LH:E3WPZ7P<=GFBZ6
M:ZA'>@+3<D+J)-A?]]IV7X%MEJ?;VN0T-7;+2RC  Z\01NQ6@_H*9+A>P-^.
M@!R@4E$?V#SQL]/0@U)L'U#V6;+7,WH>=;3"&'?B&R<Y+XB*]18M(DD$L<F-
M)8I(B%2NDDR)+")LLEZLV<SR1./42$X4MADOX*FB&0,L2D.I"G)V/*4X":GE
M880/H$*?.;1D/(AF]GBD< X*7R<')\<9]H#@G+H'YP!G;[BPZL>[+=_\.M4#
M+<7CZR?U7:-05@TB>4HR'D.,3&:$?FL@%8A"3'"6\2S/8V45H>PV[-A,GNT:
M"S;"EEU3/E__O6?)CV[8[6C$/YB!.:4+1^_UA=S0\5W]HWO0MZG_807$R0H@
M=G?W9*/3E=%^62Y6JXG,BI@5VD#AF&@>8C$V&5HQC J:IT(D6+'"B8?.##@V
M!BJ% C=LN7PMS_F?3%U,1^HYA[$EZ7A$+C3==!9/O *EO!X)QQ(97U1S;KAA
M2<92^0-ZL;W/L8_5^GDYN;F>1)HX,DX$C!$S=<M0#!G!!-(TSV*91E$1665V
MUL\;&RW<L-FT6"SG4\N>&0TLW9]Z#V4#?\DWUY]N/][=?[Z]]M".:E>[CHPG
M<V7U)9J?6DVHZB<,TWYJ5]Q-XZF]/_OH6'QOLK#OBM]7U0<X(1F*,$<8IESH
M13<FIE4HCV"N(D%HIO]-.!4^[AQM;)]6*1Y<%/!EI0 K">F2GL3[V-HMMMX0
M"_Q]'O0BWJ#W^ZI>;T,U(CX!2I FQ/MCO6$#XA-J=S<?/G53[XX,38N'\JC&
MG/<LU:.:K_1J7ODJFOR%0A1892G$4MOL6!;$9/XDL$B0PIC)7" G+X+UR&,C
ME7;[DNJ<=D?TLN& <_,&RTFP8YP@T 9FG^N[FUMPO5XOI_QE758;7"_ %U:V
MD_=?4]09(7^M'"S'';JO@QL<1YH\.#Z@1[KBKXOE]%^+^8-^/GLN4TU6MTNE
MWR+Y_OJF8:D\99C1 F8DDA!3DY5(BQ1FA<R2E.1"8?NL1(L!QT9.M<B@+3.H
MA09::H=L-QNXN_DH!(B!::@;/W -;OHD#EJ]N?;Y@9XA'2@-\-RKZ2O5SP&=
MSHP^F^<,E[CGH-5.?I[+?3TX^=.4\>ELNGZ]5R7[/RST2%]9V2GC9?VR5%6W
M0M/17/U8O]/J_&.28IX31B(8\YCH+2DGD,49@930-!(9+J)$67-T#P'&QMD;
M%4"M@S%]]"H*C!IE YE2$;#1Q(%Y^LR/!:D'1CTPR1\"_K PM%0!?G<(./C#
MJ %*/5QXOP_Z#NM X%D8:%UPG@U/Z\0%Z'6N&WV>.]PZ<H'6.^O*)<_I7WSM
M8<GF5<_N>_6\6*XG0B01DFD""U/F&&>17DLH26%:%'HYH2RAU.ILH&N0L:T7
MF_)B6T%!):E[^;4#0+O)WQ=,@0F^!T*]"K"=@N"B"FP'#QV\!-LIM8[58#MY
MK?M'_DEC/OORN)BK.NN$I3@6,N(F=YD;OV,&N=*&HL"9DA*C../8]N/>?_C8
M/NI2/E *>"Z]XSQPYS_B2^ (;9W9(^'TT9Y2N=?'>O"PP3[24VJT/\Z3UUS:
M9_5X8LC7M5[=ZP2/NJ;!:]D,<6O5(I1E$4\QC%*&(%9ZQ>9)6L \RV-$8A+G
MJ5M/@HM%&AL!?'UY>F)ZKUZ&N12+Y5.51L;XXF4-2G6:5+"^_5A[3Y[=J<.P
M4Q*8A(ZFZVWSGYJ"_U=-M9;7NHTKL-DH7M#1]5)HO7=Z[2W0&W6 O13 TYUA
M+W[RA>$?U3&+.7V<")4C0G&A]T(LUX83RB%/4PFC3"&9IRC/8N22%')D#"?Z
M'" =9!N],',^?ST&H1WG70A,8!*[.\C], )Z3/SH4-]W[$9KA+>)V#A4\62<
MQI%+PQA>)]9K3@I4F"V35'$$,=<<0%,IM=F%"Y%GJ=XW29_&UE_)P'HM*TV:
M7.45N'M9K]9L+IV;OO:<%S]VU%_?=AJ%S30*.^FO8!OYM8>\VD"E)_KW9ZW3
M?/W;=*96:[WEK5^Y>R64B4B?T+Q /(\(5%FAV9"A"#)&M3&D#2$:<:;RU*IG
MK,U@8^.\6ESPU,B[*42UK"5V.,TZ![3%N:%'^ *36(/<1M0-E=W[1\[AS,\C
M@@.=[YU_!WU%?EABTWEZ=^X9PYW466JS<RIG>T_?@LM_7@MALM:TQ?1%#Z1_
M%%6_N"^+V52\5O]_:_ 0B5 698G>>$8<8EI@2!)*(<]QQ+&INT*M'/A]!1@;
M'9MY,,;01@>PJX1KG67'Z;"S/T."')BTM>BGP;T"E>#@C_J_0<S.ONAY*Z[L
M./S I97[@7-86+GG<WJ8E_M<NIID(HJ3(I.093F#.,E-D<\TA:FB-#:1;"J+
M)]_5DB^L3,J# 5P^J/8PX;ZKW_:7;I<0M$, +0S%BT )S#(')N%E:#@8?Q>A
M,I"Y=_BN^#+O3FK?:= =WC6<"7=2XAVC[?15?=OEBJ7)%'NOJO_>SK\LU3.;
MRO>J4,NEDG7UF>MYE:Q196I/(E(4(DHX)%1S&V8YACR.4I@1)C&*4FVQ)9.Y
M^F:BO>S,M7Z"6+W3M'JGV^*$>Z5KJ4'=5'=5ECNI*D^)JKQ7K^32GO-D9\4%
MQ'ZH+KR5X."G1H6?RX;J]5S4XI=3467A77=/08^&O)<@Z*U%;R\A!F[:>PE0
MAVU\+WI:/\K<:U[>M-HK79BKUC'!^^GL15_V?KH2L\7J95F5]M^TL1%)S%0>
M)[#(BAAB3C+(,TPAS5BL>**X2ISVNW[$&MLNN-$*LDJMNO@U>*EZX0#!9L+D
M$CH?RWB:13N"'7YN A-NHQ"H-0+;SIV54NWS,N,%U>PPG4VK,*40G8K\(NR)
MD#T)-2A!^P5RG[ ]/[T?@=\LGI[J8)N#@2<)%HC01&I35INW.$42TB07,*4B
M1DH5>8R<.IIT#38VLJUD!2LC[%7#M(O6A]R[^T GY'8<Z@O(P,Q88_BUPK"2
M],HJ>L"9\VP0\<1DG4,-RD\V2N^SCM4]_;CDR])4:UV_?M$OP5J;F::H_7-5
M]?Y!/[$L[DEQK)#B&60RUI8>DP0RE@@HH@+GDF<IXD[QS!9CCHU9/BWFW^JZ
M? \[5?G.50'M#;H=J7B&,C"W]$;1F5H<</'$,#8C#DHT#A#L\XW+K3U+,<G_
M?JD;,9C>[I5YK3ZK]3:<\&'AVEB59PE)\YC %)O:SU&F()680Y62*&$X(8HY
M-;T((>38B*VEH\G$7S9:@KG^*DUTL?FK^5F8=J[%;/$G,*\:V)9:9QL='0M!
MA7@%[%CSK2<V,,WNS>E&06#:\NY$1YM_'D.?WI 3XJN:50@1ARU\%1#D@QI9
M(<?J?5*D1WY@/VJ?ZCLU5\5T/<$L423G.8Q(H5>-E&D[EVIC-R9(L3A.<5$X
MU?H[,<[8B+_F@37[T1SU.!_H'(73^L3F4I#"'\D8?+2(F^.7GVHI/2:5G,'!
MW\'*T5&&/CGI4O7(T4CGY8[EM9?KR5?US1#2+VKQ;<F>'Z>"S=XOGMAT/DGC
M2/%$YC!!J8!8X@QR3F(8<YIEE!>"YM2JZ';7*&,C@+:$X(]*1LM];#>:W0S@
M#:/ W[\;//;%O&W4[_KL]0-:G[S^K57FN_/9PQ3_ME%O4Q+<ZN)+L\EN%C/]
M#PMC57Q7K=2<E=[8?M;:G/CGLM:'V=LLYJLR?V-"25(@)114"&F6(,H4!<8(
MDBA*&4,I8FX]%?V+.#:*:30TA:UV=&RG2*W M6FHLZ?F3DO9MJ)U'I6CQRW
MZV!GZ+SM) <_*S@U8R92I?U[J\?O[DWG9O."5#C?@'M/D_,FX!NET/D&^'1Z
MG?>1^AZ6U&$YY5',%[:\6WY=FYB\LLG4%[4L3V<F,6,4)8I"FBH,,4XS2$2:
MP"1)A$IHDN;4Z0C6;MBQD?]&ZN8\]IDMP?>REYHYAI5FSI8KTQ>^.I)U/)&U
MG O;8Q3?" =FWBVX]4&MEEF_RJ"2NFY9I^6N#G!]GJNX .7M:,5JT(%/5UR
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MSXIRK2*O+_B\F"]WBLI_VJ2."QS%+$4Q1#+'$+,\UIM-',."T53$.4Y)YG1
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M/6DXG[B39CON;K<[>_;^G;&5MNS*6HN?IG-UNU9/JPG2QE>B\A3&*,L@9J*
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MG\=@8;?Q!P\A[@7/L<#B?@_J6>5@FZ^_S7G85(F+121QD0F(."9F^XDA%:*
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M+ B4+(DHQG$JW:*/SHPW.BYI]2>OVUSJG]IM,)L PT(METKV(ITS4V#)./Z
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M7>57F+233>LNX>0.N*^$122W*WR[MAQK:&NY R7X5K.@6O0R!FC=PL =8X?
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MP/B[)DR\FA9?%P69O5TNGKYJBGW3W'HUG3\)7M%M+.:;O9NIDZV,0@G2*"<
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MU(3\7,:Z VD.9$P3SI.8IM0IN\-BSJ$Y[^O3K=Y"?".TFZFR =O.1GF&L*]
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M_2U9LA/E4RR-K"1[YJ87#@6I)V2WTMV4I?WKI] DQ6.3?<#;+R@[R[%)BFH
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MO!JGE.)@CV([";*#2.K5-,3IR?K,))=^G;K\87Y"0E]6]W[UY:MH4N(R,1U
M$;[KS62D8S1XL-:ATYHLX8,UK_8!R+9S&S?"&OQ)?A 5=6!YKJWK]L6&U5A\
MMF1#54@UNRU +%*"TD*G5%*,<D"P=?5L/XSV-T/L$%5T *K+Y[HWX4M]J[N\
MWS)9!285;3U9:R#[F,&7@A",RA076&-2ZX#^_IET Z:#]+SAC?0 H?<!G<49
MC7I'1A,49*)E=%!T]*!*H(7XFK=9O$Q:"<O20\R7/=%S_V3&/>R& U #T7>
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M>588_4LW#QRN1A\W_7\(@.PIV0[,"44K5\9U*[*!MV00L_9@,Z]D QD@TD:
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M:@U?QL@+0#H#?.MCL<W,M[-W3RI7=025/B$@G]M[IPIGZ!@(;B*%T%J"-[I
M5A%+,MRJYND6.TUPW&-X# 3M">+=U=DO5B_$>9=2$T1$PWF!@#E1G&U)I-X*
MD.2;>)]4#+QUJ+KC%,<][OO%:Q.5=H#8>PK.71:;N^J?8Z3U4C(P,I WE5!
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M:=".]P;ED+H:&X<_GU7WYW5Y,5VNIK.T^N%LEFO]"2,S&G+&F=;QO Q@+.A
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M9XQ7>V+Y_6;UZZV1?; FR0ADAT,=.%_ AVR ^UAT= ZU;=T<;W/J]KH%OLF
M_#N>YX_#KV%9/_[V,@]K9IWM:*V,/FH.+*18!S J$I&7H*,QFC%CBDG/X;@!
M'>,>K0<"TIWKY2/JJ8-[GNNN%V]65U?7I7F<G.+ZI@96, [*\PQ>DYM<A+#,
MB2R%;7T'_0@IXR#NZ% 8VNNE WBMLF-HY2JH#SC_-DW3V:=;O59NN%O4$M'%
MPS^ZJH273*T2L&2=Y*Z8T+4'0@(NA!':ER1*:S>[)?WC'IU- '6_U'LL[7:
M[&I_;C;\97D,#X(74SAH*\FQC]I"#%'6[L4Q%QWH.ZT1^A =(]=ZCX:*'T*E
M/574 <Q>420Y+5/ZM2HH"OB&Q?2J.MF;;(OF#%3&.HU':O"1OM0A%Q.%1-7^
M8>]Q<L9-.>D&=*T4-G;2RLZ^S]OK)%ARP+.7W(-U-0G6"-IJ.B!$DU!YA2F[
M>-B0Y>U6Q6_-P3F6$SF& CLX*Q_C\RIGVFO#O*20T*LZ:Q6S &>),<$H'M1"
M)'0;#9_<XKQ\AJ13C&UVA,=P.%V-^*B]$N5=/^,N9[=>0_^8S3$-GV;3_\7\
M-S(S5ZS:PDM27('V2&*L.2(N.P$%A<,24";,&QV3^]%QBD?D?E@\MO+&-ND[
ML/IV6%QOR82LIELC"!'K  $IP4GE(5E4"05S$C<;6K@?'>/DM9XB3G=5WK[)
M%!\/%&3?9?IUF,[_$<XO\(9%Z:1P&G3.NK9A)^_:,@&,.Y8,2LE-ZS*5;>@;
M)Y&V!UM_,"UV['/6BL%+CE#S$F42-3^O]DSQ"#[4+YE7!@LK@K4N 7F>JG'2
M<'M 8V.-G:CS>8O;Y%,,D1P7$6J#62T2A%)X'9(;LC1&N?LEZFW]SRU!V3R)
M]Q1-^QXJ/%$O]/;V--J7S"7$Y%<E^1)"?;>05J:2,!89-FN N3<IX^3QGB)@
M]U#AB;FCM[@TSC'IM0=MHJ7-F#C)-F2P6I'<0PC*M.ZSL"6)XZ0!]^ &'%*7
M)Y!2MPRS3U,2ZZK=R>)*%T.Y_Y.]LN:V7:1U8MQ>3#;*??O;,.0_I^?G!.8?
MEITNTOFPN)CC==92DDHI7B2@J.-O,=,)Z0AJP6>&PF<E[INVO4^,K0AL-R3I
M]70V7>+;.O3W_K+KAP_-I>>%98C!>U!91/ E%-"E)!%3DBZV+C';G+IQ7]@/
MAZG'AQ<UU5<'@?N*]+/T/Q?3Q:J:8)T,DS%YH2C<$S7P$W48I=$!@D;N3,DI
MV=8&^R$Z>AE:U%;G]^O$]E5 AR"ZS!^('IDPF "]IG#,HZ'-Y@LX+:O3FXFY
MULF3#U,R<A/_O37\#&1V$/?8T>]OP[<P7TZOLI%D0G18&X,)1G$0BX4VD$"0
M*$-MXI4+;M8#Y.[G]J7W7=0TM)%9!V?$$X?H3]]_#?\]S%^=A\6Z83P+*#&+
M -*3E58<0RT,"J"== RYH BG=8;"%N3U,N;HH&;I4.KJ&XDWC/T6ON#EAM48
M-<IB@3:6 /(A2:"UHH);F63@V7/>NF1Y2Q)'3ZD^#%0VA^3>>NL EK^'9<V]
MO#S=,_D!6M4V3E(&4+:.6K6,]J[E7%IR'4QIW3#W#@'=0FI_5=\OD]]9[AV
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M1;O1Y=\FR!GSD-E#6??5O8/D1E;XK^&OZ9>++Y>$HPA,A)S 6HZ@G"\0LRW
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M&.@J['J7+UQ"*C_]?2AW,^OL3U!+ P04    " !+@$96T6T3FPH(  #R)0
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MIKETI)4VO5=-_^^46FHQ3Z6:]7X<RA0LNX$IN],ISWZL6@Q)S8*1<1"T\D]
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M6^_RF4^0RM_P-93_+NO\OU!+ P04    " !+@$96R](B6.$$  "P$   &
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MIYA+.<VX2<S^&^P2L_>*$F<F8@X#> (&] FQQ__'SR]>OZ-((X57?(7@#5M
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M*$WB)!N+,1;AP-PZWI0R33I:7G2\X37"H6 Q#N)%2/8"@E@#F44U-H%"*NV
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MMW34P^Z+O8<?=G^W^^;EJY6&_84V@C<#]CN=BNB?/QW\5#H2NN%VN[#)V.4
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M7],F66*@X"C/<U5]JN 6N3-3-X6#@^9P\(ONJ\.5ZN>:DY:W635N;%^OM4J
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MURW,:;/-VDU*:3;-UR]T OM)Y/63)$[6J_8\ @$\]J0;EVR,X704:Q2P5MF
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M,)]'2N(O3\\PJ0A$$R?826S>QXSD8((5;FF,:C"LY)9P;V*4V F5EDF,7N?
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M#=Q3_FJ?1KAP>ZUFP^FW!H-6Y]QI=;(!X<G.X%--?U#CR<$[&Y>7"&:A7S?
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M7T9*P%)XM&WWG.49#.">G?'% [^?P@%W:\Q?;]_S43-AR(.=[D>D))Q+XVR
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MA(43M9_,H599%PXC:-@4 >;49TRJC&(-:3WR.!%(8XC7Z+GY#?5+"GTE!-5
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MUK<=3<^_44<$]C=E53":E9,F T>8D^AS,@-@K4L,TZV-G2[#(P'RS_A >F<
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MTXM0<W>,[NQ[9!K\M$^[X?DWT=V@@=%<G-'M87"C_/INJ?A^(J8S3&*#3Q8
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M0[WAWN(4/[LO #773% D.518?>9"+OM,V95O6GE'KJ0<1@; 'U7>&D2L2QX
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M+GWCQ>8C83)Z9W![3 Q:R(. "(648@@BZ7!>?"85Q7YMEN'=@CRE2TL+X?K
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M\9*D,J4E<KLJ"#(*'XW)>>Z8)%XI+2-(M2DV)((380HG&(-+E>>([-?Q11;
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M[Z\'!XP]\W8>UKY(_.G^2?PWM'//)V22O,&LXG2%/$#W0\7N8=779U35#L#
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M,C,Q+FAT;5!+ 0(4 Q0    ( $N 1E:6P8_W+Q(  +7#   1
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M>#,R,2YH=&U02P$"% ,4    " !+@$96H@[J&[($   :#P  &
M    @ &M; , 87)W<BTR,#(R,3(S,7AE>'@S,C(N:'1M4$L! A0#%     @
M2X!&5C\O]H&NE@  A'@%  X              ( !E7$# &5X:&EB:70Q,#$N
M:'1M4$L! A0#%     @ 2X!&5F8"?C4/70  A38"  T              ( !
G;P@$ &5X:&EB:70S,BYH=&U02P4&      P #  9 P  J64$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
